,id,ticker,title,category,content,date,provider,url,article_id
219616,441132,PFE,Is Pfizer Stock a Buy ,news,"Last Tuesday  pharmaceutical titan Pfizer  NYSE PFE  reported its 2019 fourth quarter earnings  This underwhelming Q4 report    in conjunction with the downturn in the broader markets due to the coronavirus threat    have caused the drugmaker s shares to dip by nearly 7  so far this week 
While Pfizer s year end results were certainly nothing to write home about  it s still fairly rare for a megacap pharma company to fall by high single digits in just a matter of two trading sessions  Should investors take advantage of this profound weakness  or is this hefty sell off justified  Let s break down Pfizer s near term prospects to find out  

Pfizer s transformation might be a buying opportunity
Going forward  Pfizer s biopharma unit will be the foundation of its success or failure  The drugmaker  after all  is slated to spin off its flagging Upjohn generic drug business with Mylan by mid year 
What s on the near term horizon for Pfizer s all important biopharma business  Since announcing the planned merger between Mylan and Upjohn  Pfizer has repeatedly stated that its remaining biopharma unit should post exceptional top line growth in the area of 6  per year  on average  for the next five years  The company s long term revenue forecast is predicated upon the continued success of existing growth products such as Ibrance  Xtandi  Eliquis  Xeljanz  and Vyndaqel  as well as the future commercial success of a suite of next generation products currently under development 
Fleshing out this point  Pfizer stated during its Q4 conference call that the company is on track to make major strides across several key therapeutic areas such as dermatitis  hemophilia  cancer  and vaccines  among many others  over the next year or so  As a direct result  the company revealed that it plans on boosting its already rich dividend program over the course of 2020 and investing in additional business development opportunities to further strengthen its biopharma unit 
In the same breath  management also announced that the company probably won t make any further share repurchases during calendar year 2020  That s a major departure from the company s former policy of beefing up its bottom line through massive share buybacks nearly every quarter 
Verdict
As things stand now  Pfizer arguably already has the assets in place to achieve a respectable 6  compound annual growth rate for its top line over the forecast period    that is  once the Upjohn Mylan merger becomes official later this year  In fact  that s not really a major risk factor  given the company s proven track record as a top notch innovator and commercial powerhouse  Things start to get truly interesting from a value creation standpoint when you consider Pfizer s stated interest in pursing additional mergers and acquisitions  M A  to solidify its core biopharma business 
The obvious problem  though  is that Pfizer has a poor track record when it comes to the M A scene  For example  its  14 billion buyout of Medivation still looks questionable almost four years later  and the drugmaker also paid a rather steep price for cancer specialist Array Biopharma Inc  in 2019  So  there s no guarantee that will be able to readily boost its top line by acquiring late  or commercial stage assets    at least not at an acceptable price tag  And that s probably the main reason investors have largely kept their distance from this top biopharma stock over the past 12 months 
In the final analysis  though  there s still a strong case to be made that Pfizer s stock does indeed deserve a spot in almost any growth or income oriented portfolio  The next stage of the company s life cycle promises to be far more lucrative for investors than the prior decade  Pfizer  after all  finally has a viable growth engine in place thanks to its successful pivot to oncology as a main source of growth  That means management won t have to repeatedly lean on financial engineering tactics    such as massive share buybacks    to impress the market  At some point  the drugmaker s healthy top line growth will shine through ",2020-01-30,The Motley Fool,https://invst.ly/pozzt,2071841
219617,441133,PFE,5 Reasons Pfizer Is Big Pharma s Top Dividend Stock to Buy Right Now,news,"Pfizer  NYSE PFE  recently reported fourth quarter earnings that missed expectations on the top and bottom line  As a result  a jumpy stock market knocked a few percentage points off the stock price 
Despite missing consensus forecasts  Pfizer stock looks like a perfect fit for dividend portfolios  Here are five of the most important reasons to buy this pharma stock on the dip 

1  The price is right
The average stock in the S P 500 trades at 19 3 times forward estimates at the moment  Since announcing fourth quarter earnings  shares of Pfizer have fallen to just 13 7 times the low end of the company s 2020 adjusted earnings forecast  
Right now  the average dividend paying stock in the S P 500 index offers a measly 1 8  dividend yield  Pfizer shares pay out more than double the benchmark average with a 3 9  yield at the moment 
2  A 2 for 1 deal
Around the middle of 2020  Pfizer shareholders will end up owning two very different drugmakers  both of which will continue distributing profits to shareholders  The Pfizer that remains will develop new drugs and sell them until they lose patent protected market exclusivity  
Pfizer s post exclusivity pharmaceutical segment  UpJohn will merge with Mylan  NASDAQ MYL  to form a new company called Viatris  Pfizer shareholders will own 57  of Viatris and receive a significant dividend from the new company  Once the deal completes  Viatris is expected to generate free cash flow at a rate of  4 billion annually and rise from there 

3  Steady Viatris profits
According to Pfizer  dividends from Viatris plus dividends from the Pfizer that remains will fall in line with the amount investors receive from their shares at the moment  Sales of popular brands generally plunge once they have to fight generic competition  but Viatris will have a diverse line of products and geography on its side  The combined entity will market around 3 000 brands and molecules in 165 countries around the globe 
In 2020  Viatris is expected to generate pro forma earnings before interest  taxes  depreciation  and amortization between  7 5 billion and  8 billion from revenue expected to reach between  19 billion and  20 billion  There s a lot of operational overlap between UpJohn and Mylan  and the pair expect to squeeze out synergies that reach  1 billion annually by 2023  
Of course  Viatris isn t simply expecting growth from synergies alone  Potential new generic versions of popular drugs losing exclusivity could add around  3 billion in annual revenue to Viatris  top line by 2023  
4  Rapid growth from the Pfizer that remains
While Viatris delivers a dividend powered by fairly steady profits  the company that remains could deliver a payout that grows at a hair raising pace for years to come  That s because Pfizer s enormous drug development pipeline is going to get much bigger in the years ahead 
In 2019  Pfizer used  8 9 billion to repurchase shares and spent  8 7 billion on research and development expenses  In 2020  the company will continue spending more than  8 billion on R D  but share repurchases will take a backseat to pint sized acquisitions and licensing of new drug candidates in the middle stages of their development timelines  
This year  Pfizer anticipates sharing proof of concept data from 15 potential new drugs and we should also get to see pivotal data from five key studies  With enough financial firepower to sign a dozen significant deals per year  Pfizer s annual pipeline presentations are going to get much longer in the years to come 

5  No more cliffs
Pfizer and big pharma in general make dividend investors extremely nervous because they ve seen the loss of market exclusivity for one or two key products at a time send total revenue plummeting in the past 
The Pfizer that remains will produce lumpier earnings results than Viatris from one year to the next  but steadier than shareholders experienced over the past decade  Rather than trying to offset losses for huge blockbusters with giant mergers  CEO Albert Bourla is thinking much further ahead by stocking the company s pipeline with promising assets in mid stage clinical testing 
Hold tight with both hands
It may seem hard to believe  but Zoetis  the animal health business Pfizer spun off in 2013  has outperformed its parent by a mile  Investors that have held on since the spinoff have seen their Zoetis shares deliver a 343  total return and their Pfizer shares deliver 68  over the same time frame  
Shares of Pfizer at recent prices would make a great addition to a dividend portfolio but investors will want to hold on tight to shares of both companies they ll end up owning for the long term ",2020-01-31,The Motley Fool,https://invst.ly/ppfld,2072914
219618,441134,PFE,Pfizer s Biosimilar Ruxience Gets EU Regulatory Backing,news,"The European Medicines Agency s Committee for Medicinal Products for Human Use  CHMP  on Friday recommended that the European Commission approve Pfizer s  NYSE PFE  drug Ruxience  a biosimilar to MabThera  which to Roche  OTC RHHBY  and Biogen  NASDAQ BIIB  sell in the U S  as Rituxan 
CHMP s positive opinion was based on a clinical trial  dubbed Reflections B3281006  which compared Ruxience to the branded biologic drug MabThera in patients with a specific type of follicular lymphoma  Both drugs produced similar overall response rates 
Biologics are large molecule drugs that are produced using living organisms  as opposed to via chemical processes like conventional  small molecule medications  This difference in how they re manufactured means that while another company may be able to develop a biologic that does essentially the same thing as a previously approved drug  that new version    the biosimilar    will not be not quite the same as the original    thus the  similar  in the name 

While Pfizer is better known for its branded drugs  the pharmaceutical company has jumped on the biosimilar bandwagon  it has already developed four other oncology biosimilars that are available in Europe  The company sold  911 million worth of biosimilar drugs last year  with those revenues split almost equally between the U S  and the rest of the world  Pfizer has also gotten a taste of its own medicine on this front  Sales of its anti inflammatory biologic Enbrel were down 18  in the fourth quarter due to biosimilar competition  When Pfizer hives off its Upjohn generic drug unit later this year  its biosimilars will stay with the branded drug division 
Before Pfizer can start selling Ruxience in the EU  CHMP s positive opinion will need to be finalized by the European Commission  That decision is expected to be handed down in the first half of this year ",2020-01-31,The Motley Fool,https://invst.ly/ppley,2073421
219620,441136,PFE,Should Investors Buy Pfizer on the Dip ,news,"Pfizer  NYSE PFE  still hasn t recovered from the fall the stock took back in late July  when analysts downgraded the stock after a disappointing earnings result and forecast  affected by the company s decision to exit its Upjohn business  Although the stock has been rallying in the months since then  over the past six months  it s up just 4  and nowhere near the S P 500 s returns of 16  during that time  Pfizer has also been struggling in recent days as it released its fourth quarter results on Jan  28  which didn t inspire much enthusiasm from investors 
However  let s take a look at whether the underperforming stock is likely to rally  or if more red is in its future 
The big concern for investors  growth
There are many question marks surrounding how Pfizer will do post Upjohn  and right now  investors aren t convinced that the company will do well    at least not yet  It disappointed investors in Q4  with sales down from the prior year quarter while earnings missed expectations  However  the company did indicate that it expects the new look Pfizer to achieve operational revenue growth of 8  for 2020 
Over the longer term  spinning off the Upjohn business  which features off patent medicine  could be a way for Pfizer to focus on higher growth products that can generate more revenue for the company  However  it s still unclear how all of that will pan out and just how much additional growth the company will generate  For now  it looks as though investors need some convincing of that given their lack of enthusiasm thus far 

With Pfizer also combining its consumer healthcare business with GlaxoSmithKline  it s difficult for Pfizer investors to gauge just how strong the company will be once all the dust settles from these moves 
Still  what s encouraging is that many of Pfizer s biopharma products saw strong growth in 2019  Ibrance  Eliquis  Vyndaqel  Xtandi  and Xeljanz all generated more than 20  sales growth operationally during the year  contributing a combined  12 7 billion  That s more than one quarter of the company s revenue for the year  which totaled  51 8 billion  With those drugs playing such a big role and already achieving such strong growth  there s reason to be optimistic that Pfizer may not be in as much trouble as its share price suggests 
Dividend is a consolation for impatient investors
For companies that may take a while to achieve longer term growth  a dividend can go a long way in appeasing investors who may otherwise not be willing to wait  Currently  Pfizer pays investors a dividend yield of 4  per year  What s even better is that the company recently raised its quarterly payments from  0 36 to  0 38  Pfizer s strong track record of not just paying dividends but increasing them can give investors an added incentive to buy and hold the stock for multiple years  
The company s dividend payments have more than doubled from 2010 when Pfizer was paying its shareholders  0 18 every quarter 
Is the price right 
Pfizer has a good dividend as well as products that are generating solid growth for the company  The last factor to consider in the decision making process is whether it s well priced  Trading at 13 times earnings and a forward price to earnings ratio of just 12  Pfizer is attractive given that the company hasn t run out of growth options just yet  Its PEG ratio of 1 4 also suggests that given the growth analysts are expecting from the stock  it s not that expensive  
Investors typically discount a stock when there s some risk or uncertainty involved  and that looks to be what s happening with Pfizer 

PFE P E Ratio data by YCharts 
Although the stock has traded at lower multiples in the past  its current price suggests the stock is likely undervalued  especially if it becomes a better growth stock as a result of the Upjohn spinoff  For long term investors who are looking for more than just growth  Pfizer is an excellent option  The healthcare stock could be a great buy for many years ",2020-02-06,The Motley Fool,https://invst.ly/ps1gl,2078167
219621,441137,PFE,Better Buy  Pfizer vs  AbbVie,news,"Pfizer  NYSE PFE  and AbbVie  NYSE ABBV  are both top notch dividend stocks  At current levels  Pfizer s shares sport a ginormous yield of 3 99   AbbVie  on the other hand  is the home of one of the industry s most generous payouts  with a forward looking annualized yield of 5 11  
Nonetheless  these two elite income stocks have been headed in drastically different directions over the past half year  While AbbVie s shares have produced total returns on capital of 48   when including dividends  over the last six months  Pfizer s stock has generated a far more modest return on capital of only 6  during the same period  
The central issue behind this stark divergence is that Pfizer and AbbVie have taken markedly different approaches toward solving the same problem  namely  the loss of exclusivity for key revenue generators 
Pfizer  for its part  has decided that it needs to slim down by carving out its legacy products business in a planned merger with generic drug giant Mylan  AbbVie  by contrast  intends on bulking up through a merger with Botox maker Allergan  This mega merger is designed to lower the importance of the biotech s top selling anti inflammatory medication Humira  as the drug starts to face biosimilar competition in earnest    

Which of these two blue chip dividend stocks is the better buy as things stand now  Let s check out how Pfizer and AbbVie stack up on several key fronts  
The case for Pfizer
Pfizer s overarching goal is to become a growth oriented biopharma with keen interests in immunology  oncology  rare diseases  and vaccines  By doing so  it expects to post high single digit top line growth for at least the next five years  That kind of revenue growth won t exactly wow anyone on Wall Street  but it is a welcome change from the company s anemic top line growth over the past decade 
Truth be told  Pfizer s previous decade was really all about financial engineering  huge amounts of share buybacks   rather than solid revenue growth spurred by innovative new products  Pfizer s new lineup of growth products  which includes Ibrance  Xtandi  Eliquis  Xeljanz  and Vyndaqel  should be sufficient to effectively close this dark chapter in the company s history  
But there is a major element of the unknown with Pfizer at the moment  It s no secret that the company is gearing up to pursue one or more bolt on acquisitions in order to flesh out its pipeline and product portfolio  The good news is that the biopharma landscape is an especially target rich environment right now  That being said  Pfizer has been one of the worst companies when it comes to creating value from mergers and acquisitions  M As   So there s no telling how the company s next bout of M A will ultimately pan out   
The case for AbbVie
Even though Humira s sales have been rapidly declining overseas  AbbVie s top line has only continued to tick higher in recent quarters  In the fourth quarter of 2019  for instance  the biotech s revenue rose by a solid 5  compared with the same period a year ago  While Humira s U S  sales did play a big part in this healthy year over year rise in revenue  the drugmaker s newer immunology medicines  Rinvoq and Skyrizi  and its blood cancer franchise consisting of Imbruvica and Venclexta loomed large as well  Skyrizi  in particular  absolutely crushed Wall Street s forecast for the three month period  beating the consensus sales estimate by a whopping 51 3   
What s on tap for AbbVie for the remainder of the year  The seminal event will undoubtedly be AbbVie s forthcoming tie up with Allergan  which is set to close before the end of the first quarter of 2020  This transformational deal will immediately benefit AbbVie s top line  diversify its product portfolio  and perhaps result in another sizable increase to the drugmaker s dividend 
Having said that  there s also a good chance that the combined AbbVie Allergan entity will decide to put some of its noncore assets up for sale in the near future  That s not uncommon upon the closing of a biopharma mega merger  but it does add another moving part to an already complex investing thesis    
Which stock is the better buy 
All things considered  AbbVie appears to have a solid leg up on Pfizer  AbbVie sports a stronger near term growth outlook  a richer dividend  and a broader array of high growth products  Pfizer  on the other hand  still needs to round out its pipeline and product portfolios    a process that could take a few years to complete ",2020-02-11,The Motley Fool,https://invst.ly/ptsah,2081724
219622,441138,PFE,Pfizer axes license agreement with GlycoMimetics,news,"In the wake of a failed late stage study evaluating rivipansel for the treatment of vaso occlusive crisis in sickle cell disease patients  Pfizer  PFE  0 4   has notified licensor GlycoMimetics  GLYC  1 7   that it will terminate their 2011 agreement 
GLYC will regain all rights to respective assets and will incur no termination penalties related to the end of the partnership ",2020-02-11,Seeking Alpha,https://invst.ly/ptvt8,2082067
219623,441139,PFE,U S  stocks higher at close of trade  Dow Jones Industrial Average up 0 94 ,news,"Investing com   U S  stocks were higher after the close on Wednesday  as gains in the Oil   Gas  Technology and Consumer Services sectors led shares higher 
At the close in NYSE  the Dow Jones Industrial Average added 0 94  to hit a new all time high  while the S P 500 index added 0 65   and the NASDAQ Composite index gained 0 90  
The best performers of the session on the Dow Jones Industrial Average were UnitedHealth Group Incorporated  NYSE UNH   which rose 4 36  or 12 69 points to trade at 303 48 at the close  Meanwhile   Nike  Inc  NYSE NKE  added 2 98  or 2 98 points to end at 103 00 and Walgreens Boots Alliance Inc  NASDAQ WBA  was up 2 79  or 1 48 points to 54 47 in late trade 
The worst performers of the session were Merck   Company Inc  NYSE MRK   which fell 2 35  or 2 00 points to trade at 83 25 at the close  The Travelers Companies Inc  NYSE TRV  declined 1 22  or 1 67 points to end at 135 71 and  Pfizer  Inc  NYSE PFE  was down 0 92  or 0 35 points to 37 74 
The top performers on the S P 500 were Interpublic Group of Companies Inc  NYSE IPG  which rose 7 44  to 24 98  Anthem Inc  NYSE ANTM  which was up 5 75  to settle at 296 00 and  Nektar Therapeutics   NASDAQ NKTR  which gained 4 80  to close at 23 48 
The worst performers were  Western Union  Company  NYSE WU  which was down 7 47  to 26 13 in late trade   ABIOMED  Inc  NASDAQ ABMD  which lost 5 05  to settle at 166 94 and Amcor  NYSE AMCR  which was down 4 56  to 10 47 at the close 
The top performers on the NASDAQ Composite were  Gemphire Therapeutics Inc   NASDAQ NRBO  which rose 104 08  to 30 00   Canaan Inc   NASDAQ CAN  which was up 82 73  to settle at 8 04 and Titan Pharmaceuticals Inc  NASDAQ TTNP  which gained 27 19  to close at 0 2900 
The worst performers were  Zosano Pharma Corp   NASDAQ ZSAN  which was down 48 44  to 0 531 in late trade  Polarityte Inc  NASDAQ PTE  which lost 47 17  to settle at 1 68 and Lianluo Smart Ltd  NASDAQ LLIT  which was down 44 00  to 0 7392 at the close 
Rising stocks outnumbered declining ones on the New York Stock Exchange by 1784 to 996 and 102 ended unchanged  on the Nasdaq Stock Exchange  1596 rose and 1017 declined  while 92 ended unchanged 
Shares in Interpublic Group of Companies Inc  NYSE IPG  rose to 52 week highs  rising 7 44  or 1 73 to 24 98  Shares in UnitedHealth Group Incorporated  NYSE UNH  rose to all time highs  gaining 4 36  or 12 69 to 303 48  Shares in Zosano Pharma Corp  NASDAQ ZSAN  fell to all time lows  losing 48 44  or 0 499 to 0 531  Shares in Polarityte Inc  NASDAQ PTE  fell to 5 year lows  losing 47 17  or 1 50 to 1 68  
The CBOE Volatility Index  which measures the implied volatility of S P 500 options  was down 9 49  to 13 74 
Gold Futures for April delivery was down 0 06  or 1 00 to  1569 10 a troy ounce  Elsewhere in commodities trading  Crude oil for delivery in March rose 3 50  or 1 75 to hit  51 69 a barrel  while the April Brent oil contract rose 0 16  or 0 09 to trade at  56 28 a barrel 
EUR USD was up 0 03  to 1 0875  while USD JPY rose 0 00  to 110 08 
The US Dollar Index Futures was up 0 29  at 98 882 ",2020-02-13,Investing.com,https://www.investing.com/news/stock-market-news/us-stocks-higher-at-close-of-trade-dow-jones-industrial-average-up-094-2083433,2083433
219633,441149,PFE,Glaxo  GSK  Misses Earnings   Revenue Estimates In Q4,opinion,GlaxoSmithKline plc   NYSE GSK    one of the largest health care companies  reshaped its business following the March 2015 completion of the three part  inter conditional transaction with Novartis related to its Consumer Healthcare  Vaccines and Oncology businesses  Under the deal  Glaxo sold its oncology assets to Novartis and acquired Novartis  Vaccines business  excluding influenza vaccines   Glaxo has created a joint venture   JV   with Pfizer  NYSE PFE  earlier in 2019  thereby combining their consumer healthcare unit Following the completion of the deal  the UK based company now focuses on its three core businesses   Pharmaceuticals  respiratory  HIV   Vaccines  pediatric  adolescent  adult  and travel vaccines  and Consumer Healthcare  wellness  oral health  nutrition and skin health products   However  Glaxo is currently focusing on its core assets and divesting non core assets Meanwhile  like many of its peers  Glaxo is facing challenges in the form of stiff competition  genericization and pricing pressure  In this scenario  investor focus remains on late stage pipeline candidates and their commercial potential  restructuring and cost cutting initiatives and performance of new products apart from the usual top and bottom line numbers Glaxo s performance has been impressive so far  with the company s earnings beating expectations in each of the trailing four quarters  Overall  the company has delivered an average positive surprise of 17 23  Currently  Glaxo has a Zacks Rank  3  Hold   but that could definitely change following the company s earnings report which was just released  We have highlighted some of the key stats from this just revealed announcement below Earnings Miss  Glaxo reported core earnings of 65 cents per American depositary share in the fourth quarter of 2019  which missed our consensus estimate of 68 cents  Core earnings declined 16  year over year at constant exchange rate   CER   Revenues Miss  Revenues were up 11  year over year at CER to  11 57 billion   8 9 billion    Revenues also missed the Zacks Consensus Estimate of  11 77 billion Key Stats  Glaxo initiated a two year program to split itself into two standalone entities   a biopharma company and a consumer healthcare company  The program is expected to cost  2 4 billion with separation of Consumer Healthcare JV is expected to cost the company additonal one time charge of  600 700 million   Sales in Vaccines segment surged 21  at CER while Consumer Healthcare sales increased 37   Pharmaceuticals sales were down 4  at CER  The Respiratory segment increased 9  at CER  HIV product sales remained flat at CER  Growth in Respiratory segment was completely offset by decline in sales of Established Pharmaceuticals segment 2020 Guidance  Glaxo expects adjusted EPS to decline 1  to 4  at CER  year over year  in 2020 Share Price Impact  Shares fell almost 1  in pre market trading Check back later for our full write up on GSK earnings report later Biggest Tech Breakthrough in a GenerationBe among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity  Current technology will soon be outdated and replaced by these new devices  In the process  it s expected to create 22 million jobs and generate  12 3 trillion in activity A select few stocks could skyrocket the most as rollout accelerates for this new tech  Early investors could see gains similar to buying Microsoft  NASDAQ MSFT  in the 1990s  Zacks  just released special report reveals 8 stocks to watch  The report is only available for a limited time ,2020-02-04,Zacks Investment Research,https://www.investing.com/analysis/glaxo-gsk-misses-earnings--revenue-estimates-in-q4-200504722,200504722
219634,441150,PFE,Novo Nordisk  NVO  Q4 Earnings Match Estimates  Revenues Beat,opinion,Novo Nordisk  CSE NOVOb  A S   NYSE NVO   reported fourth quarter 2019 earnings of 55 cents per American Depositary Receipt  ADR   matching the Zacks Consensus Estimate and increasing 5  in DKK from the year ago quarter Revenues grew 9  year over year in DKK  up 6  at constant exchange rate  CER   to  4 86 billion  Revenues   beat the Zacks Consensus Estimate of  4 83 billion In the past year  Novo Nordisk s shares have rallied 26 5   outperforming the  s growth of 11 7   All growth rates mentioned below are on a year over year basis Quarter in DetailNovo Nordisk operates in two segments   Diabetes and Obesity care  and Biopharmaceuticals The Diabetes and Obesity Care segment sales grew 7  at CER  Sales of insulin decreased 4  at CER to DKK 14 907 million  Sales of long acting insulin  Tresiba  Xultophy and Levemir  declined 9  to DKK 5 102 million Sales at the Biopharmaceuticals segment rose 2  at CER to DKK 5 087 million  Hemophilia sales were up 1  to DKK 2 554 million Ozempic had a strong launch and recorded sales of DKK 4 365 million in the quarter Research and development  R D  expenses declined 5  at CER  owing to the priority review voucher for Rybelsus in the fourth quarter of 2018 Administrative costs decreased 3  at CER from the year ago period Sales and distribution costs ascended 8  at CER  owing to resource allocation to the growth markets  promotional activities for Saxenda  launch activities for Ozempic and prelaunch activities for Tresiba in China Full Year 2019 UpdateThe company recorded earnings of  2 46 for 2019  up 3  in DKK The company recorded sales of  18 3 billion  up 9  in DKK and 6  at CEROther UpdatesIn January 2020  Ozempic was approved in the United States for cardiovascular  CV  risk reduction in people with Type II diabetes and established cardiovascular diseases  Rybelsus  label in the United States was updated with additional information from the PIONEER 6 CV outcomes study  In the same month  Rybelsus was recommended for approval for the treatment of adults with Type II diabetes by the European regulatory authorities 2020 OutlookNovo Nordisk expects 3 6  sales growth at CER for 2020  This reflects a strong performance for the GLP 1 based diabetes care products Ozempic  Victoza and Rybelsus  the obesity care product Saxenda  the portfolio of new generation insulin and the contribution from biopharm products Esperoct  Refixia and NovoEight However  this is expected to be partly offset by intensifying global competition within the Diabetes Care and Biopharmaceuticals segments  especially for hemophilia inhibitor Persistent pricing pressure within Diabetes Care  especially in the United States  might also negatively impact sales Our TakeContinued growth from Victoza and Tresiba  the strong launch of Ozempic and higher contributions from Saxenda should offset the impact of lower realized prices in the United States  loss of exclusivity for products in hormone replacement therapy and stiff rivalry within diabetes and biopharmaceuticals markets  Novo Nordisk A S Price  Consensus and EPS Surprise    Zacks Rank   Stocks to ConsiderNovo Nordisk currently has a Zacks Rank  4  Sell  A few better ranked stocks from the healthcare space are Pfizer  Inc    NYSE PFE    Sanofi   NASDAQ SNY   and Roche Holding  SIX ROG  AG   OTC RHHBY    While Pfizer sports a Zacks Rank  1  Strong Buy   Sanofi and Roche carry a Zacks Rank  2  Buy   You can see  Pfizer s earnings per share estimates have moved up from  2 62 to  2 77 for 2020 and from  2 73 to  2 81 for 2021 in the past 90 days  The company delivered a positive earnings surprise of 7 46   on average  in three of the last four quarters Sanofi s earnings per share estimates have moved up from  3 26 to  3 29 for 2019 and from  3 45 to  3 49 for 2020 in the past 60 days  The company delivered a positive earnings surprise of 8 25   on average  in the last four quarters Roche s earnings per share estimates have increased from  2 61 to  2 66 for 2020 and from  2 82 to  2 85 for 2021 in the past 60 days Biggest Tech Breakthrough in a Generation Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity  Current technology will soon be outdated and replaced by these new devices  In the process  it s expected to create 22 million jobs and generate  12 3 trillion in activity  A select few stocks could skyrocket the most as rollout accelerates for this new tech  Early investors could see gains similar to buying Microsoft  NASDAQ MSFT  in the 1990s  Zacks  just released special report reveals 8 stocks to watch  The report is only available for a limited time ,2020-02-04,Zacks Investment Research,https://www.investing.com/analysis/novo-nordisk-nvo-q4-earnings-match-estimates-revenues-beat-200504864,200504864
219635,441151,PFE,Blueprint Medicines  NDA For Avapritinib Gets Extended Review,opinion,"Blueprint Medicines Corporation   NASDAQ BPMC   announced that the FDA has extended the review period of a new drug application   NDA   for its lead pipeline candidate  avapritinib  by three months  The NDA is seeking accelerated approval for avapritinib  an inhibitor of KIT and PDGFRA proteins  as a treatment for fourth line gastrointestinal stromal tumors   GIST   As a result  the regulatory body will now announce its decision by May 14  2020 instead of the previously anticipated date in February 2019  The extension of the review period is due to requested submission of additional data on the candidate by the FDA Shares of Blueprint Medicines fell 5 4  on Feb 6  following the announcement  The company s shares have declined 15 5  in the past year compared with the  s decrease of 0 1  The company submitted the NDA in June 2019 to the FDA  seeking accelerated approval for avapritinib for treating PDGFRA Exon 18 mutant GIST and fourth line GIST  The NDA was accepted and granted priority review by the regulatory authority in August  The NDA included data from the registration enabling NAVIGATOR study  which showed that patients with PDGFRA Exon 18 mutant GIST achieved an objective response rate   ORR   of 86  while the median duration of response   DOR   was not reached  Meanwhile  patients with fourth line GIST had an ORR of 22  while the median DOR was 10 2 months In October 2019  the FDA informed Blueprint Medicines that it intends to split the NDA into two separate NDAs  each for PDGFRA Exon 18 mutant GIST and fourth line GIST The candidate was approved for treating PDGFRA Exon 18 mutant GIST last month under the tradename of Ayvakit  However  for approval in fourth line GIST the regulatory body requested the company to submit data from ongoing phase III VOYAGER study  evaluating avapritinib in third and fourth line GIST patients  The company expects to report top line data from the study early in the second quarter of 2020  Avapritinib is also under review in Europe for both PDGFRA Exon 18 mutant GIST and fourth line GIST indications The phase III VOYAGER program is evaluating the safety and efficacy of avapritinib compared with Bayer s   OTC BAYRY   Stivarga  regorafenib  in patients with the third or fourth line GIST  The company also plans to initiate a global phase III precision medicine study  COMPASS 2L  to evaluate the safety and efficacy of avapritinib compared to Pfizer s   NYSE PFE   Sutent  sunitinib  for treating second line GIST patients with pre specified disease genotypes in 2020  It plans to submit a label expansion application to seek approval for avapritinib as a treatment for third line GIST in the second half of 2020 Other than GIST  Blueprint Medicines is pursuing a broad clinical development program for avapritinib across the advanced  indolent and smoldering forms of systemic mastocytosis   SM    Avapritinib is currently being evaluated in two studies  namely the phase I EXPLORER clinical study and the registration enabling phase II PATHFINDER study for advanced SM  The company plans to submit a regulatory application seeking label expansion of avapritinib to include patients with advanced SM indication in the first quarter of 2020 Apart from avapritinib  Blueprint Medicines has several pipeline candidates in early developmental stages  Notably  Blueprint Medicines presently has no approved product in its portfolio  Thus  approval of avapritinib will lower the company s heavy dependence on its partners for revenue generation  The company is currently in partnership with Roche   OTC RHHBY   and CStone Pharmaceuticals for the development and commercialization of its pipeline candidates Blueprint Medicines Corporation Price
    Zacks RankBlueprint Medicines currently has a Zacks Rank  3  Hold   You can see  Just Released  Zacks  7 Best Stocks for TodayExperts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 7  per year These 7 were selected because of their superior potential for immediate breakout ",2020-02-06,Zacks Investment Research,https://www.investing.com/analysis/blueprint-medicines-nda-for-avapritinib-gets-extended-review-200505794,200505794
219636,441152,PFE,Pfizer s Xtandi Improves OS Rate In Prostate Cancer Study,opinion,Pfizer Inc    NYSE PFE   and Japanese partner Astellas announced overall survival  OS  data from a late stage study evaluating the combo of Xtandi  enzalutamide  plus androgen deprivation therapy  ADT  in men with non metastatic castration resistant prostate cancer  nmCRPC  Data from the phase III PROSPER study showed that treatment with Xtandi plus ADT led to a statistically significant improvement in OS  a key secondary endpoint  in men with nmCRPC compared to placebo plus ADT Shares of Pfizer have declined 8 7  in the past year against the  increase of 13 3  We remind investors that in July 2018  the FDA granted approval to Xtandi for treating the non metastatic CRPC patient population based on metastasis free survival  MFS  data from the PROSPER study  MFS was the first primary endpoint of the study while OS was its key secondary endpoint Meanwhile  in December 2019  the regulatory body approved Xtandi to treat men with metastatic castration sensitive prostate cancer  mCSPC   The sNDA was based on data from the phase III ARCHES study Following this nod  Xtandi is now approved for three indications in advanced prostate cancer  namely non metastatic and metastatic CRPC and mCSPC Notably  Xtandi was added to Pfizer s portfolio with the acquisition of Medivation in September 2016  While Pfizer sells Xtandi in the United States in partnership with Astellas  the latter owns the drug s marketing rights outside the U S  markets  Pfizer recorded Xtandi alliance revenues worth  838 million in 2019  reflecting an increase of 20  year over year The label expansion of Xtandi allows it to treat a broader prostate cancer patient population and drive growth for Pfizer  However  the medicine faces competition from Johnson   Johnson s   NYSE JNJ   new prostate cancer drug Erleada and the generic versions of its product Zytiga Zacks Rank   Other Key PicksPfizer currently sports a Zacks Rank  1  Strong Buy   Other stocks worth considering in the pharma biotech sector include Novartis AG   NYSE NVS   and Vertex Pharmaceuticals Incorporated   NASDAQ VRTX    both carrying a Zacks Rank  2  Buy  You can see  Novartis  earnings estimates have moved 0 4  north for 2020 over the past 60 days  The stock has rallied 10 6  in the past year Vertex s earnings estimates have been revised 13 5  upward for 2020 over the past 60 days  The stock has jumped 33 7  in the past year Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2019  while the S P 500 gained and impressive  53 6   five of our strategies returned  65 8    97 1    118 0    175 7  and even  186 7  This outperformance has not just been a recent phenomenon  From 2000   2019  while the S P averaged  6 0  per year  our top strategies averaged up to  54 7  per year ,2020-02-11,Zacks Investment Research,https://www.investing.com/analysis/pfizers-xtandi-improves-os-rate-in-prostate-cancer-study-200506892,200506892
219637,441153,PFE,Pfizer s Q4 Results  2020 Guidance Leave Investors Cold,news,"Pharmaceutical giant Pfizer  NYSE PFE  reported fourth quarter results Tuesday that beat expectations for revenue  but missed on the bottom line  That miss  combined with weak profit guidance  helped propel shares lower  The stock was trading down by more than 5  as of 3 p m 
Revenue  which was diminished by the spinoff of its consumer healthcare business in the third quarter  fell 9  to  12 69 billion  but that was better than the analysts  consensus estimate of  12 61 billion  Excluding the impact of the divestiture  revenue grew 2  operationally  Adjusted earnings per share fell 13  to  0 55  compared with analysts  consensus forecast of  0 57 

Pfizer is in the process of spinning off its Upjohn unit  which will be combined with Mylan  NASDAQ MYL  to form a new company to be named Viatris  Mylan s shares were actually up 3  in late afternoon trading 
A large share of the quarter s declines came from the recent arrival on the market of generic competition for Lyrica  a drug that will be part of the spinoff  After multiple generic companies launched their versions  Lyrica sales plummeted 67  in the quarter  But operational revenues increased by 9  for Pfizer s biopharma business  which will be the part of the company that remains after the Upjohn spinoff 
Pfizer s guidance for 2020 was complicated by all the moving pieces  but its earnings forecast for the full company as it exists today was not entirely to the market s liking  Management expects earnings per share to land in the  2 82 to  2 92 range  the midpoint of which was below analyst s consensus expectation of  2 90 
Investors may also have been disappointed by the revenues from two of the company s blockbuster biopharma drugs  Ibrance  sales of which were flat from Q3 despite 25  growth year over year  and Xeljanz  which had a sequential sales gain of only about 1   Management expressed confidence that sales of those two drugs would return to growth  and was optimistic about the pipeline developments it expects this year ",2020-01-28,The Motley Fool,https://invst.ly/po1f7,2069794
219638,441154,PFE,Why Pfizer s Shares Sank Today,news,"What happened
Shares of Pfizer  NYSE PFE  were sinking by 5 4  as of 3 05 p m  EST on Tuesday after the big drugmaker announced its 2019 fourth quarter and full year earnings results before the market open  Pfizer reported Q4 revenue of  12 7 billion  down 9  year over year  The company s adjusted earnings also dropped to  3 1 billion  or  0 55 per share  from  3 75 billion  or  0 63 per share  in the prior year period 
Pfizer also provided full year 2020 guidance  projecting revenue between  48 5 billion and  50 5 billion with adjusted diluted earnings per share between  2 82 and  2 92  Both ranges were below consensus Wall Street estimates 

So what
Investors were understandably disappointed with the Q4 update  especially with the company s guidance  However  the big picture arguably looks better than in recent years 
Pfizer s main problem right now is the declining sales for blockbuster nerve pain drug Lyrica in the face of new generic competition  Lyrica is part of the company s Upjohn unit  which Pfizer plans to spin off and merge with Mylan into a new company  
While this move isn t a perfect solution  it will enable the  new  Pfizer to achieve much stronger growth than the company has been delivering  Pfizer projects that sales for the company remaining after the spinoff of Upjohn will increase by 8  year over year in 2020 
Now what
The smartest thing for investors to do with pharmaceutical stocks is to focus on the prospects of their current drugs and pipeline candidates instead of the performance from one quarter  After the Upjohn Mylan transaction is complete  Pfizer will have multiple growth drivers  notably including Eliquis  Ibrance  Vyndaqel  and Xeljanz  without any major anchors weighing it down  as is the case now with Lyrica 
In addition  Pfizer s pipeline includes plenty of promising candidates  Keep your eyes especially on the company s 20 valent pneumococcal conjugate vaccine PF 06482077  Pfizer plans to report results from three phase 3 clinical studies for the vaccine in the first half of this year ",2020-01-28,The Motley Fool,https://invst.ly/po1f5,2069793
219639,441155,PFE,Pfizer Inc  PFE  Q4 2019 Earnings Call Transcript,news,"Pfizer Inc  NYSE PFE Q4 2019 Earnings CallJan 28  2020  10 00 a m  ETContents 

Prepared Remarks
Questions and Answers
Call Participants

Prepared Remarks 
OperatorGood day  everyone  and welcome to Pfizer s Fourth Quarter 2019 Earnings Conference Call  Today s call is being recorded  At this time  I would like to turn the call over to Mr  Chuck Triano  Senior Vice President of Investor Relations  Please go ahead  sir Chuck Triano    Senior Vice President  Investor RelationsGood morning  and thank you for joining us today to review Pfizer s fourth quarter and full year 2019 performance and 2020 financial guidance I m joined today by our CEO and Chairman  Albert Bourla  Frank D Amelio  our CFO  Mikael Dolsten  President of Worldwide Research and Development  Angela Hwang  Group President  Pfizer Biopharmaceuticals Group  John Young  our Chief Business Officer  and Doug Lankler  General Counsel The slides that will be presented on this call were posted to our website earlier this morning and are available at   You will see here that slide 3 covers our legal disclosures Albert and Frank will now make prepared remarks and then we will move to a question and answer session With that  I will now turn the call over to Albert Bourla  Albert Albert Bourla    Chairman and Chief Executive OfficerThank you  Chuck  and good morning  everyone This morning I will speak about our performance for the year  the continued advancement of our pipeline and the steps we are taking to position Pfizer for accelerated growth following the expected separation of Upjohn from Pfizer later this year  Frank will then provide details regarding our fourth quarter performance and our 2020 financial guidance 2019 was a productive and transformational year for Pfizer  We generated solid full year financial results  These results were highlighted by exceptional 8  operational revenue growth for the year and 9  in the fourth quarter for our Biopharma business  which will become the new Pfizer  following the expected separation of Upjohn Once again  our Biopharmaceutical Group s outstanding growth was driven primarily by the continued strong performance from all our key growth drivers  This include Ibrance  Xtandi  Eliquis  Xeljanz  Vyndaqel  among others  Biopharma also generated 14  operational growth in emerging markets in 2019  I would point out that Biopharma s 2019 growth came from volume increases  not pricing  In fact  pricing had a negative 2  impact in Biopharma s results For full year 2019  global Ibrance revenues increased 23  operationally to become a nearly  5 billion a year product  In the US  Ibrance realized robust growth and retained its strong leadership position in the syndicate class with a nearly 90  surge  Ibrance performance outside of the US was also very strong and we still see significant opportunities in countries where the use of CDK inhibitors has not yet reached the levels seen in the US  Overall  Ibrance is approved in more than 90 countries  It s the number one prescribed CDK4 6 inhibitor globally and has reached more than 250 000 patients For Xtandi  alliance revenues in the US were up 20  for the full year and when combined with our royalty income on ex US sales  totaled nearly  1 2 billion in 2019  Xtandi is the leading branded novel hormone therapy in an increasingly competitive but growing class  with 37  market share in total prescriptions  Their vast year over year growth was due to continued uptake of the non metastatic castration resistant prostate cancer indication as well as prescriber confidence and the recognition of Xtandi s strong data across CRPC  With the recent launch of our Xtandi indication in metastatic castration  sensitive prostate cancer in the US  Xtandi is now the first and only oral treatment approved by the FDA in three distinct types of prostate cancer Eliquis continued to perform well  Pfizer s sale in the global revenues was up 26  operationally to  4 2 billion  This growth was driven primarily by continued increased adoption in non valvular atrial fibrillation as well as oral anticoagulant market share gains  Eliquis is now the oral anticoagulant leader in 12 markets across the globe Xeljanz had a strong performance  with global revenues increasing 29  operationally to  2 2 billion  We are very pleased with the continued positive uptake across all indications  rheumatoid arthritis  psoriatic arthritis and ulcerative colitis  and we continue to launch psoriatic arthritis and ulcerative colitis into new markets Looking at our rare disease business  Vyndaqel continues to ramp up nicely in the US  following the May 2019 approval and launch for the treatment of ATTR cardiomyopathy  Overall  this first of its kind medicine contributed  473 million in revenue in 2019  Our disease awareness efforts helped drive the diagnosis rates to 9  by the end of the fourth quarter compared with 1  prior to launch  As such  at the end of 2019 more than 9 000 patients have been diagnosed  more than 5 500 patients had received a prescription for Vyndaqel and more than 3 000 patients had received the drug  These numbers do not include approximately 100 patients who are still in the early access program Global Prevenar 13 revenues were up 3  operationally to  5 8 billion  The US CDC also published its updated recommendation for immunocompetent adults aged 65 and older to shared  Phonetic  clinical decision making in the November morbidity and mortality weekly report  highlighting that a patient can serve a decision to vaccinate with PCV13 with a physician  physician s assistant  nurse practitioner or pharmacist Looking at our sterile injectables portfolio  our focus on manufacturing recovery is taking shape and beginning to have a positive impact on the top line in the US  We have made solid progress with remediation and modernization and expect continued improvement throughout 2020  Of note  while global revenue from our sterile injectables portfolio declined 1  operationally for the full year  it increased 5  operationally during the fourth quarter  Additionally  more than 80  of our injectables portfolio is in stock today and we anticipate this percentage will continue to increase in 2020 Our global biosimilars portfolio grew 22  operationally to  911 million for the full year  This was driven largely by 70  growth in the US  thanks to the launch of Retacrit and a gradual uptake of Inflectra  The growth in the US was partially offset by decline in international markets  driven mainly by Inflectra  We expect an additional contribution from biosimilars in 2020 with the launch of free oncology monoclonal antibody biosimilars  Last week  we announced the launches of Zirabev and Ruxience in the US market and next month we expect to launch Trazimera  All three products will be available at a substantially discounted price compared with their originator products Full year revenues for our Upjohn business were down 16  operationally to  10 2 billion  The key headwind during the year was the advent of generic competition on Lyrica in the US  which was partially offset by 7  operational growth in China  The growth in China was driven primarily by Viagra and Celebrex as well as Lipitor in non reimbursed channels  which constitute significant market share in China  We are making good progress with a pre integration planning for Upjohn s proposed combination with Mylan  which remains on track for mid 2020 In December  we announced that former Pfizer Chairman  Ian Read  and current Pfizer Director  James Kilts  will join the Viatris  board of directors upon completion of the transaction  We are also working closely with our counterparts of Mylan on the CFO selection process  We expect to announce the appointments of both the CFO and the third Director by the end of this quarter  We have great confidence in Viatris which will combine Upjohn s strong commercial capabilities and iconic brands with Mylan s terrific pipeline Turning now to R D  We remain very pleased with the progress we are making with our pipeline  We are expecting key clinical results in 2020  several of which have the potential to make this an exciting year for patients hoping for new treatment options  We anticipate sharing data from up to 15 proof of concept readouts with contributions from all our therapeutic areas as well as up to 10 pivotal study starts and five key pivotal study readouts I will now highlight some of those expected events  We continue to expect our two event driven Ibrance early breast cancer programs PENELOPE B and PALLAS to read out in late 2020 and early 2021 respectively  If successful  and following regulatory approval  these programs could double the number of patients eligible to benefit from Ibrance  The Phase 2 open label  single arm ANCHOR CRC study evaluating the efficacy and safety of the combination of Braftovi and Mektovi and cetuximab in patients with previously untreated BRAF V600E mutant metastatic colorectal cancer is currently ongoing  Results from the study will be submitted for presentation at a medical congress in the second half of 2020 For abrocitinib  our investigational JAK1 inhibitor for the treatment of moderate to severe atopic dermatitis  we look forward to sharing top line findings from the Phase 3 JADE COMPARE trial in the coming months  Pending successful conclusion of the core Phase 3 studies  regulatory submission in the US is projected for the third quarter of 2020  with subsequent markets following later in the year  This study is designed to assess the efficacy and safety of abrocitinib or dupilumab placebo in adults on background medicated topical therapy with moderate to severe atopic dermatitis  The study also has a key secondary endpoint but it is designed to assess the effect on each severity of abrocitinib compared with dupilumab in adults with moderate to severe atopic dermatitis on background topical therapy There are up to five proof of concept readouts expected in 2020 from our industry leading immunokinase pipeline  Our hope is to advance several of these into Phase 3 trials  This include TYK2 JAK1 with potential POC readouts for psoriatic arthritis and for a topical formulation for psoriasis and atopic dermatitis as well as an oral JAK3 TEC for vitiligo and oral TYK2 for psoriasis  This is a great example of our unique strategy to purposefully match a molecule to a disease where we think it has the potential to make the most difference as well as a formulation that we believe has the potential to treat milder forms of disease Our gene therapy platform is advancing with promising Phase 1 2 hemophilia A data  but is expected to support the Phase 3 start this year  This would be our second gene therapy pivotal study following the ongoing hemophilia B Phase 3 study  In addition  our DMD gene therapy program is gathering additional robust patient data  building on the progress we served at the current project muscular dystrophy conference last June  We are preparing for an expected POC in the first half of 2020 and the Phase 3 pivotal study start in second half of this year We look forward to successfully completing the Phase 3 studies for our investigational 20 valent pneumococcal conjugate vaccine candidate in adults and remain on track to submit the Biologics License Application to the FDA by the end of this year  Pfizer s candidate represents a potential significant advancement compared with the potential 15 valent  If successful in Phase 3 and approved  the five additional serotypes may provide coverage against approximately 33  more strains that cause invasive pneumococcal disease in adults and 42  more strains causing the disease in infants in the United States For our maternal vaccine for respiratory syncytial virus  RSV  we are preparing for an expected POC in the second quarter of 2020  followed by potentially swift progression to Phase 3 We look forward to sharing more updates on our pipeline during our upcoming Investor Day on March 31 In summary  we finished 2019 with strong momentum and we look forward to continuing that momentum in 2020  During the year we generated a solid financial performance  further advanced our strong R D pipeline and took bold actions to reshape Pfizer into an innovation powerhouse that will build on our legacy of delivering breakthroughs that change patients  lives Now I will turn it over to Frank to provide details on the quarter and our outlook for the remainder of 2020  Frank Frank D Amelio    Chief Financial Officer and Executive Vice President  Global Supply and Business OperationsThanks  Albert  Good day  everyone Now moving on to the financials Fourth quarter 2019 revenues were  12 7 billion  down 8  operationally versus the year ago quarter  Excluding the impact of the Consumer Healthcare business  revenue was down 1  operationally  Our Biopharmaceuticals Group business revenues were  10 5 billion  up 9  operationally versus the year ago quarter  with strong operational growth in Ibrance  Eliquis  Xeljanz and Vyndaqel and a second straight quarter of operational growth for our hospital business  including our sterile injectables Revenues for our Upjohn business in the fourth quarter decreased 32  operationally to  2 2 billion  with the primary year over year impact again being generic competition for Lyrica in the US that began in July of 2019  Excluding the unfavorable impact of Lyrica in the US and other recent product losses of exclusivity  fourth quarter 2019 revenues for Upjohn declined 6  operationally  I know Upjohn s business in China has been an area of focus  and fourth quarter revenues for Upjohn declined 1  operationally  We saw the expected revenue declines for Lipitor and Norvasc in provinces where the volume based procurement program has been implemented  and these declines were mostly offset by operational growth from products not impacted by the VBP program including Celebrex and Viagra Adjusted cost of sales as a percentage of revenue was favorably impacted by the July completion of the Consumer Healthcare joint venture transaction with GSK  partially offset by the negative impact of foreign exchange and the Lyrica loss of exclusivity In the fourth quarter we recorded a  0 06 loss per share on a GAAP basis  which was primarily due to a  2 6 billion asset impairment charge for Eucrisa and restructuring  purchase accounting and legal charges  Adjusted diluted EPS for the fourth quarter was  0 55 versus  0 63 in the year ago quarter  The decrease was primarily due to lower revenues  again  mainly due to the Lyrica LOE in the US and higher operating expenses I want to point out that diluted weighted average shares outstanding declined by 281 million shares compared to the year ago quarter  reflecting the impact of shares repurchased during 2018 and 2019 and partially offset by dilution related to share based employee compensation programs  Finally  foreign exchange had a negative impact of  158 million or 1  on fourth quarter 2019 revenues and a  0 03 negative impact on adjusted diluted EPS compared to the year ago quarter As you can see on the chart  our 9  operational growth in the Biopharma business was driven by strong performance by Ibrance  Eliquis  Xeljanz  Xtandi  Vyndaqel and Inlyta Moving on to 2019 financial guidance  As you can see on the chart  we met or exceeded all components of our 2019 financial guidance Now I want to highlight how our 2020 guidance compares to 2019 revenue and adjusted diluted EPS  Starting on the left side of the slide  our 2019 results reflect partial year contributions from the Consumer Healthcare business segment which we deconsolidated in the third quarter of 2019  Excluding  2 1 billion in revenues generated from the Consumer Healthcare business segment  total Company 2019 revenues were  49 7 billion and 2019 adjusted diluted EPS is  2 95 For 2020  the adjusted diluted EPS guidance range reflects Pfizer s share of the Consumer Healthcare joint venture s earnings that were generated in fourth quarter 2019 and will be reported in the first quarter 2020 along with Pfizer s share of the JV s anticipated earnings for the first three quarters of 2020  As you can see  the midpoint of our 2020 guidance range for revenues implies comparable performance to 2019 revenues after excluding the partial year contribution from Consumer Healthcare as well as an anticipated  200 million favorable impact from foreign exchange based on mid January 2020 rates compared to last year  Despite an anticipated  2 4 billion in LOE headwinds in 2020  we expect the midpoint of the revenue range to remain flat operationally  excluding Consumer Healthcare Now let s go through the full details of our 2020 financial guidance for total Company  As we ve said  we are expecting the close of the transaction between our Upjohn business and Mylan to be completed in mid 2020  So we are providing three sets of guidance  First  total Company  which reflects our current construct of the Biopharma and Upjohn businesses and excludes any impact from the pending Upjohn combination with Mylan  second  New Pfizer  which is a full year pro forma view that reflects the impact of the pending fee interest transaction by removing Upjohn and including  12 billion in cash proceeds from Upjohn to New Pfizer and other transaction related factors such as transitional service agreement revenue  and third  Upjohn as a stand alone business  All of these scenarios are based on a full year of revenues and expenses in 2020 Beginning with total Company  2020 revenue guidance of  48 5 billion to  50 5 billion reflects anticipated continued strong momentum in our Biopharma business  primarily offset by the continued negative impact of product losses of exclusivity in our Upjohn business  primarily Lyrica in the US Moving on to other elements of our 2020 financial guidance for total Company  compared with 2019 actual results  the midpoints of these ranges imply higher adjusted cost of sales as a percentage of revenues due to the continued impact from the Lyrica LOE  higher adjusted R D expenses and higher adjusted other income which reflects earnings from the Consumer Healthcare joint venture and lower adjusted SI A expenses and adjusted diluted EPS In 2020  financial guidance for adjusted EPS assumes no new share repurchases and we will focus instead on increasing the dividend and investing in the business during this period of growth  As a result  our guidance for adjusted diluted EPS assumes diluted weighted average shares outstanding of approximately 5 65 billion shares  which is approximately the same as 2019 Moving on to financial guidance for New Pfizer for the full year 2020  we now anticipate full year 2020 revenues between  40 7 billion and  42 3 billion  with the midpoint of the guidance range representing 8  operational growth as compared to 2019 Biopharma revenues  excluding Meridian and Mylan Japan and an improvement from our initial July targets  This guidance range excludes  600 million of contributions from Meridian  a Pfizer subsidiary and manufacturer of EpiPen and other autoinjector products as well as from the strategic collaboration with Mylan in Japan for the development  manufacturing and marketing of generic medicines  Due to an organization realignment  both of these assets have shifted to Upjohn effective at the start of 2020  Both Meridian and Mylan Japan will be reported in Pfizer s Upjohn business beginning in first quarter 2020 We now anticipate full year 2020 adjusted IBT as a percentage of revenue of approximately 37   also an improvement from July  We anticipate the midpoint of the guidance range for adjusted diluted EPS to be  2 30  The operating cash flow guidance range remains approximately  11 billion to  12 billion  This EPS guidance reflects the  12 billion cash that Pfizer will receive upon the close of the combination of Upjohn with Mylan  which will be used to pay down debt during 2020 As you can see  the midpoints for New Pfizer s 2020 revenue and adjusted IBT margin guidance have improved materially since our preliminary 2020 projections were presented in July in conjunction with the announcement of the proposed Mylan and Upjohn combination  We have provided a bridge from our initial July targets to this current guidance on the bottom of the chart for clarity  Upon the close of the Mylan Upjohn combination  and once we become New Pfizer  you can expect the same level of detail in our 2020 guidance that we provided today for total Company Moving on to 2020 financial guidance for Upjohn for the full year 2020  we anticipate revenues of  8 billion to  8 5 billion  reflecting the continued negative impact of losses of exclusivity for products such as Lyrica in the US  which began facing multi source generic competition in July 2019 and the expansion of the volume based procurement program in China and reflecting the inclusion of revenues and expenses associated with Meridian and Mylan Japan We anticipate full year 2020 adjusted EBITDA for the Upjohn business of  3 8 billion to  4 2 billion  Other than the inclusion of revenues and expenses associated with Meridian and Mylan Japan  there are no operational changes to Upjohn s 2020 financial guidance compared with preliminary financial targets provided in July of 2019  Again  we have provided a bridge from our initial July targets to this current guidance at the bottom of the chart Moving on to key takeaways regarding 2019  We delivered a strong fourth quarter with our Biopharma business growing 9  operationally  which represents our go forward business after the pending combination of Upjohn and Mylan  We provided 2020 guidance ranges for total Company  New Pfizer and Upjohn  Importantly  we are projecting strong organic revenue growth for New Pfizer in 2020  We accomplished key product and pipeline milestones since our previous quarterly update  And we returned  16 9 billion to shareholders in 2019 through a combination of dividends and share repurchases Looking ahead  we remain committed to delivering attractive shareholder returns in 2020 and beyond Now I ll turn it back to Chuck Chuck Triano    Senior Vice President  Investor RelationsThanks  Frank and Albert for those remarks  At this time  operator  can we please poll for questions Questions and Answers Operator Operator Instructions  Your first question comes from Randall Stanicky from RBC Capital Markets Randall Stanicky    RBC Capital Markets    AnalystGreat  Thanks  guys for the questions  I have two  one for Albert and one for Angela  Albert  a couple of weeks ago  you called out  4 5 billion in enabling costs in SI A with an opportunity to simplify  So how do we    how do we think about the cost savings opportunity after you close Upjohn in terms of  number one  how much incremental cost savings do you see beyond what is built into the 37  margin  And then number two  how much of that could hit back half 2020 versus 2021  And then I have a follow up after that for Angela Albert Bourla    Chairman and Chief Executive OfficerOkay  I think you should    how can he ask the question to Angela now Chuck Triano    Senior Vice President  Investor RelationsHe can get back Albert Bourla    Chairman and Chief Executive OfficerHe can get back  Okay  All right  So  indeed we have this year approximately  14 3 billion of SI A and I will ask Frank to run the numbers in more details  And as I said  for the half approximately is what we call enabling functions  These are functions like finance  legal  HR  facilities  that they are facilitating and enabling the core functions of our business to perform core functions  I mean  R D that is discovering the products  manufacturing  that is making them happen and commercial  that is making them available to the patients We do believe that this  for the half billions  and actually approximately 10 000 people  can be improved  And we have plans to do so  In the current guidance  and I will ask Frank to comment  there is a part  a small part of that  cost opportunity  saving already incorporated  And in 2021 it will be a much bigger part  So  Frank Frank D Amelio    Chief Financial Officer and Executive Vice President  Global Supply and Business OperationsSo Randall  just let me run the numbers  which is if you look at 2019 actual SI A  for example  we spent about  14 billion as a company  Obviously  that  4 5 billion that Albert alluded to in that  14 billion  If you look at our 2020 guidance for SI A  the range is  12 billion to  13 billion  midpoint  12 5 billion   12 5 billion from  14 billion is a decline of  1 5 billion  Now  roughly half of that is consumer  Because  we went from consolidating Consumer to equity accounting on Consumer once the deal closed in July 31 of 2019 The remaining half is really operational savings across the Company  including part of the    including some of the  4 5 billion that Albert alluded to  And that obviously helped contribute to the IBT as a percentage of revenue improving from 35     from the mid 30s to 37   And then to Albert s point  obviously what we re doing now is working on further improvements that would obviously positively impact the SI A and that was floated upon Chuck Triano    Senior Vice President  Investor RelationsGreat  Thanks  Albert and Frank  Next question  please OperatorYour next question comes from Chris Schott from JPMorgan Chris Schott    JPMorgan    AnalystGreat  thanks very much for the question  Just had three  quick product ones  The first was on Vyndaqel  It seems like a nice step up in all your patient metrics  seems like all those basically doubled or tripled from 3Q  Can you help bridge those figures with the sequential sales ramp we saw which wasn t quite as dramatic The second question was on Ibrance  Just elaboration there in terms of what drove the revised timelines for PALLAS  and have you taken another interim look at the data at this point  And then finally on tanezumab  just an update in terms of what the status and outlook is for that product at this point  Thanks so much Albert Bourla    Chairman and Chief Executive OfficerVery good  Thank you very much  I will ask Angela to address the Vyndaqel and tanezumab questions and then I will say a few words about Ibrance and maybe I will ask Mikael to chime in  Please Angela Hwang    Group President  Pfizer Biopharmaceuticals GroupYeah  So  thanks for the question  And certainly  we are pleased with the increased diagnosis  prescription  as well as the numbers of patients that are receiving Vyndaqel  As you said  our diagnosis now is up to about 9   the ability for patients to receive prescriptions up to about 64  of those that are diagnosed and those that are receiving medications are around 35  of those that are diagnosed and every quarter since we ve been reporting this  we ve been seeing some nice increases  So we re certainly pleased with that I think in terms of just the sort of the commensurate alignment with the actual net sales numbers  I think that there are obviously there    every single day this is a dynamic situation and the number and the proportion of patients  whether they are Medicare and commercial lives  those are changing  And so the gross to nets of those are going to affect  I think  what you see on a net sales basis  So I think that  we are watching and really focused on driving diagnosis and ensuring that as many patients can get on these drugs as possible  and we re starting to see some really nice pickup  But I think that is still a very dynamic situation because we re really relatively new in this process  So we ll continue to monitor and should expect to see some quarter to quarter changes in terms of net sales Albert Bourla    Chairman and Chief Executive OfficerAnd obviously the new patients are contributing disproportionately because they are in fewer months of treatment in terms of sales Angela Hwang    Group President  Pfizer Biopharmaceuticals GroupRight  And then your second question was on tanezumab  So we re really pleased that in December of 2019  we completed our US submission of tanezumab  and we are also pursuing regulatory submissions in the EU and in Japan  This submission was done in close collaboration with the FDA  and it includes the 2 5 milligram in moderate to severe osteoarthritis patients  So  at this moment in time we re awaiting acceptance of this filing  But we see significant potential of tanezumab in osteoarthritis  So we re really excited about this filing  particularly because we re in a time where non opioid solutions are very  very much needed for these patients If you look at the market potential  today  there are about 27 million Americans that suffer from osteoarthritis and 11 million of those have moderate to severe OA  80  of those 11 million people have tried and failed three or more analgesics  So that tells us that there is just a huge amount of unmet need in this patient population  Patients are cycling through a number of pain medications and there just is an incredible need for new options and this is where we think tanezumab can really fill an unmet need  It has the potential to become the first in class non opioid treatment for these patients and we eagerly await the acceptance of this file from the FDA Albert Bourla    Chairman and Chief Executive OfficerThank you  Now let me address the question on Ibrance  The expected completion of the study slipped a little bit    a few weeks  actually  It was at the end of the  19    excuse me  at the end of  20  and now it s moved into the very beginning of  21  The only reason of this is that the events are not coming at the pace that we had forecasted and expected  So  in other means  people are not progressing into their disease  I don t think we can draw any conclusions if that means a good news or bad news  I think it s just facts of the data  We don t know if the people aren t progressing equally in the two arms or they aren t progressing in the treatment arm  That remains to be seen when we unblind the date As regards to your question  if there was an interim analysis  there was not an interim analysis  So we haven t seen an interim analysis  There will be an interim analysis  but we do not expect that    the most likely scenario is that the study will continue when this interim analysis comes  The study was designed to come to full completion  and the criteria that we have set to start for efficacy in the interim study are very  very high  So it s not impossible that this will happen  but most likely scenario  it is that as we had planned that the study will come to completion at the end of it  this is what will happen We are very    we still remain very  very encouraged and optimistic about Ibrance  Of course  it s a Phase 3  You never know what it would be  But all the science behind it is supporting that we could have a positive outcome  And I will ask actually Mikael to make few comments on the science and what does this mean Mikael Dolsten    Chief Scientific Officer and President  Worldwide Research  Development and MedicalI ll just punctuate a few things that Albert described so well  Four aspect of why we are very excited and optimistic about the science and clinical data to predict a potential positive outcome for the discussed PALLAS study  As you know  first of all that the CDK4 6 inhibitor Ibrance converge with SGN receptor drives to stop cancer cells or breast cancer cells to divide  We have shown that in the PALOMA 2 and 3 studies  and more recently we reported that we could reproduce data direction in real world evidence  based on real world data from Flatiron and other databases    and this is noteworthy including also overall survival data    again showing  in medical practice  the importance of these drugs Three  the PALLAS study that looked at the ability of palbociclib  Ibrance to stop dividing of SGN receptor positive breast cancer showed that this mechanism was very well operating in a powerful way  And finally  let me remind you that other agents that act on SGN receptor positive breast cancers and converge with the palbociclib such as tamoxifen and aromatase inhibitors all were initially developed in metastatic cancer and did very well in adjuvant treatment in early breast cancer So these four observations and others makes us continue to be excited and very optimistic  And as Albert alluded to  a relatively small change in projected trial is based on the trial that actually started four and a half years ago  and it is quite common that in the final 12 months or so  minor changes in enrollment rate and process planning for study reports can affect a trial  But with all of this  you can hear we remain encouraged  enthusiastic about what Ibrance can offer for adjuvant treatment of breast cancer Chuck Triano    Senior Vice President  Investor RelationsRight  Thanks for the helpful context  Michael  Next question  please OperatorYour next question comes from Terence Flynn from Goldman Sachs Terence C  Flynn    Goldman Sachs    AnalystHi  thanks for taking the questions  Maybe just two product ones for me  I was wondering if you can talk about Ibrance s rest of world dynamics  any specific headwinds this quarter and how to think about the trajectory into end of this year  And then for Xeljanz  I was wondering if you can give us a split of sales by indication and if you re seeing any impact in RA from the launch of AbbVie s Rinvoq on either share price  Thank you Albert Bourla    Chairman and Chief Executive OfficerThank you very  very much  So  Angela Angela Hwang    Group President  Pfizer Biopharmaceuticals GroupSure  So first of all on Ibrance  We continue to see good growth and strong growth ex US  But probably two factors that are tempering the net sales  as you saw in Q4  The first is pricing  and that continues to be something that we work hard at  especially in EU to gain access for our products in Europe And the second is class growth  So  if you look at the class growth of the CDK class through the quarters  that has increased  but over the last quarter it has tempered  and it s sort of sitting at around a 35  CDK class growth right now    class share  But within that  the Ibrance still has a very  very high product share  in the 80s  So I think it s pointing out to us the fact that there is still opportunity for us to grow and that growing the CDK class is going to be an area of our tremendous focus for us  ex US in 2020 and beyond Your second question was around Xeljanz  And so Xeljanz again  we continue to see excellent growth in Xeljanz  In fact  despite the fact that you only see this sort of 1  net sales growth in Q4  I ll point out that globally  full year  we had 29  growth of Xeljanz which is one of the highest of all of our core brands here at Pfizer in our entire portfolio  Q4  we saw 23  prescription growth  and this prescription growth was driven by extremely strong performance in rheumatoid arthritis  which really was not impacted by the label changes  And we still continue to see strong growth in ulcerative colitis even though here was the biggest label change and so physicians that have to adjust the way that they were prescribing Xeljanz But we expect this growth to continue because we have excellent momentum and confidence in prescribing from our physicians  We have significant unmet need  And we have greatly improved access  And this access is in fact what drove the 1  net sales in Q4  There was a    in Q4 of  18  we saw an inventory build at the end of the year  which didn t happen in Q4  19  So that was one of the reasons that affected our Q4 performance in  19 and then also and more importantly  throughout the course of 2019  we gained significant access In fact  we added 59 million incremental lives through contracting  and it s because of the timing of when these contracts were signed or renewed that drove the subsequent impacts of rebates  and this sort of came to a head and sort of disproportionately affected us in Q4 of   19  So I think stepping back  we re really pleased with the access that we do have in Xeljanz since it was launched eight years ago  This is the most favorable access situation that we ve ever had  which is very important when it comes to our ability to compete with Rinvoq You asked a question around Rinvoq  Just to sort of put into perspective  I think that we are excited about having another competitor help drive the growth of the JAK class in all of our indications  That being said  Xeljanz still enjoys a leading market share  especially in RA  where we have more than 15  of the market share of the entire class Chuck Triano    Senior Vice President  Investor RelationsRight  Thank you very much  Angela  Next question please OperatorYour next question comes from Umer Raffat from Evercore Umer Raffat    Evercore ISI    AnalystHi  thanks so much for taking my question  First  Albert  if I may  what are you hearing on a possible upcoming rule on IPI  There s a lot of press that companies have been notified by White House  I was curious what you know about it and if there s something we should be very concerned about Mikael  two quick ones  one quick one for you on the DMD gene therapy for a minute  You mentioned there is a proof of concept coming  My question is  have there been additional protocol driven pauses in enrollment and I asked because recall when the first SAE and acute kidney injury happened  the trial was paused and I m curious  has anything like that happened again And then finally  Frank  maybe just quickly on SI A line  I know it s a little higher than consensus  but technically year over year versus 4Q  18  it wasn t that much higher  but I also realized 4Q  18 had some Consumer  Maybe if you could just tell us about your holiday party  Thank you very much Albert Bourla    Chairman and Chief Executive OfficerAll right  so let me start with the IPI  We have not received any notification on that  So there is no news from our side other than what we read on the newspaper  So  Mikael Mikael Dolsten    Chief Scientific Officer and President  Worldwide Research  Development and MedicalYeah  Just to remind you we shared at the PPMD conference mid of last year update on six patients dosed with our DMD gene therapy that showed encouraging data on expression new muscle fibers amount to micro dystrophin and on some of the patients we had also an opportunity to report the encouraging trends on functional outcomes  We have dosed additional patients since then And we continue to garner experience on efficacy  safety and clinical management that are incorporated in the procedures  how we manage these patients going forward  We plan to conclude Phase 2 this spring  And based on current data and insights we are planning to start Phase 3  of course pending regulatory dialogs later this year  as indicated in Albert s opening remarks Albert Bourla    Chairman and Chief Executive OfficerAll right  Frank  Maybe you want to tell us about the holiday party I was not invited to Frank D Amelio    Chief Financial Officer and Executive Vice President  Global Supply and Business OperationsSure  Yes  I wasn t invited either  So I m busy since the party  Well  let me run the numbers  and I ll explain what happened  So for the quarter SI A all in was about  4 1 billion  It was up about 4  operationally   100 million  give or take from the prior year quarter  What really drove that was increased investment behind some of our brands  some of our oncology products  some of our launch products like Vyndaqel and some increased investments in emerging markets  but it was really investment in terms of supporting our brands Albert Bourla    Chairman and Chief Executive OfficerYeah  Thank you  Mikael  And just to make a comment  we are very  very diligent in the way that we allocate capital  And we are    when we have opportunities to put in promotional money  so we can have a very strong start  we do it  And we spend those money usually by being very diligent in the way that we control the indirect expense  I have been very clear but direct with indirect is a very clear distinction in our mind  So when it comes to things that they are overheads and things that they are not affecting directly the business results  we are very  very tough  And when it comes to areas that the investments can affect business results  we are creative and generous  So that s what we associate Umer Raffat    Evercore ISI    AnalystAnd these are clearly direct expense spend Albert Bourla    Chairman and Chief Executive OfficerAnd these are all direct expense spends  And the same  by the way  although you didn t ask  comes to R D  Right now  we are increasing R D investments  but we are increasing R D investments only for programs  only for projects  We are not increasing for infrastructure  we are not increasing for research centers  At large  we maintain a very strong presence there and we keep that very strong  But what is driving the increased R D  it is more Phase 3 or Phase 2 studies  It s very clear Chuck Triano    Senior Vice President  Investor RelationsRight  Thank you  Next question please  operator OperatorYour next question comes from David Risinger from Morgan Stanley David Reed Risinger    Morgan Stanley    AnalystYes  Thanks very much  So I have three questions  please  First  Albert  could you discuss why Pfizer decided not to repurchase shares in 2020  And then maybe  Frank  you can comment on how we should think about the EPS implications when we consider your guidance relative to consensus  which had assumed some share repurchase Second  regarding the opportunity to rationalize the  4 5 billion in costs  could you just give us a sense for what percentage reduction is reasonable to assume a few years out  I was guessing maybe 20   But I just don t know what s reasonable  And then third  regarding the transfer of  600 million in revenue to Upjohn  does that change the economics that Pfizer will receive as part of the exit to Mylan  Thank you Albert Bourla    Chairman and Chief Executive OfficerYes  I think basically all questions can be answered by Frank  I would just make some introductory comments  The reason why in our capital allocation we are allocating right now money to increase the dividend and also to invest in our business  all the opex to modernize our facilities    all the capex to modernize our facilities  The reason why we don t do right now share repurchase is because we want to make sure that we maintain very strong firepower to invest in the business The past was a very different Pfizer  The past of the last decade had to deal with declining of revenues  constant declining of revenues  And we had to do what we had to do  even if that was financing visionary  We couldn t invest them and create higher value  Now is a very different situation  We are a very different company  The Company is going to have best in class top line growth  revenue story starting from now  from the separation of Upjohn in the middle of the year    from the expected separation of Upjohn in the middle of the year  And we do not need  We can organically grow EPS  As you can see  all our projections on EPS this year are organically  Indecipherable  but we can use the capital to invest in good Phase 2  Phase 3 assets that will build our pipeline  So this is the strategy behind it Now let me ask Frank to run the numbers Frank D Amelio    Chief Financial Officer and Executive Vice President  Global Supply and Business OperationsSo  David all I ll do is I don t want to duplicate anything Albert said  I ll just add a couple of things on the share repurchases  One  we also announced a dividend increase in December  So obviously we continue to deploy capital in the area of dividends  which we think is important to our investment thesis  And that s something obviously as we go forward we ll continue to look at  and then obviously our 2020 guidance assumes no repurchases  So when you look at the improvement which is material in terms of the midpoint versus what we did back in July  none of that is coming from share repurchases Now let me answer your other couple of questions  On the  600 million transfer to Upjohn and does that change any of the economics  Let me kind of    let me give some context on this  which is  one  nothing has been decided yet  We are still in negotiations with Mylan on those two businesses and whether or not they will transfer the Viatris upon close  By the way  if we don t come to an agreement  those businesses would remain with New Pfizer  And so  we re still in negotiations  And so in terms of the economics  I d say  more to come  still to be determined and if and when we complete that obviously  I ll be in a better position to answer that On the  4 5 billion of indirect spend and directionally what do we think we can do there  I don t want to give a specific percentage because we re still working our way through the process  But I think I alluded to this earlier  which is  we ve already made some nice headway  I think we can make additional headway  That additional headway would show up in SI A  and obviously our intent would be for that to show up in the IBT as a percentage of revenue line  So that s what we re working to do  Our intent is to improve upon those numbers  And  as we work our way through the process and as we have more to report  we ll make sure we do so Albert Bourla    Chairman and Chief Executive OfficerThank you  Frank  Just a comment on the reasons why we transfer those business to Upjohn  Both on these businesses  first of all  they fit more under Upjohn in terms of the dynamics that they have so they can be managed much better  And secondly  I think they fit very nicely with Mylan because  one  it is the EpiPen predominantly business that Mylan is    but right now it s shared between the Mylan  we are providing for them And the second  it is  say  a partnership that we have with Mylan that was established years back and with generic  Indecipherable   So both of them fit much better in Viatris and that s the reason why we separated them  And also that will allow you to have  in case that this happens  a much more cleaner view of a growth trajectory of the Company because now you know exactly what will be the P L of the remaining company Chuck Triano    Senior Vice President  Investor RelationsThank you  Next question  please  operator OperatorYour next question comes from Louise Chen from Cantor Louise Alesandra Chen    Cantor Fitzgerald    AnalystHi  thanks for taking my questions here  So I had a few  My first question is  is the 6     approximately 6  five year sales CAGR for stand alone Pfizer  the New Pfizer still hold  Second question I had is  how much of a priority is M A for you under the New Pfizer and what kind of size of deals or types of deals are you most interested in  And last question I have is on the PCV dataset that s coming through  You and a competitor also have a whole set of PCV data  I m just curious how you see that landscape evolving over time  Thank you Albert Bourla    Chairman and Chief Executive OfficerYeah  Thank you very  very much Louise  Let me start with the 6  CAGR  if it still holds  absolutely  It s still holds  Actually  as you can see  if anything else  this business what we are projecting five years CAGR  all the way to  25 actually CAGR  of 6   This year performed at 8   9  for the quarter and we are projecting 8  for 2020  So  definitely we are on good  let s say  way to achieve that As regards the M A  yes  the M A is a very important part of our strategy  and as I just alluded before  this is why also we are not diluting our firepower with stock purchases right now because we do believe that we can create significant value with the right strategic move Now  we never say never to anything  But strategically we have made very clear that we are not interested in for a big M A that will have cost synergies as value driver because  first of all  that would be like diluting our top line growth  I don t think there are many companies that they can have this type of growth trajectory that we have in the next few years Second  it could be disruptive because having a big M A means that the thousands of people will have to work on integrations rather than supporting all these products that we just saw that are growing in 20s and 30s and also all this pipeline that is coming up  So we never say never  but this is not our strategy  Our strategy for M A  it is to be able to have Phase 2  Phase 3 programs ready    Phase 2  Phase 3  which could become potential medicines in the period  25   26   27   28  so that we can augment our internal pipeline and be able that we maintain this 6  growth for the long term  actually for the very  very long term because it s right now five years  I would say  is the long term And the other thing that I want to emphasize  it is that the 6  CAGR  it is risk adjusted  I repeat  it is risk adjusted  That means that in our projections  we are adjusting all the non read studies right now appropriate  Now  if all the Phase 3 goals in the right way and they are all successful  it s not going to be 6   It is going to be double digits  12  13   14   15   Now  if everything fails  also will not be 6   will be very low But these statistics works and the studies    and let s say at 50  more or less are successful  that means that we will achieve 6   That s why I want to emphasize that there is no binary event in our projections  Binary event would be if the 6  was dependent on two or three major results  that if they could go one way or another could affect  Right now  they are dependent on 15  16  17 blockbusters and then many other that are much smaller So then  Frank  maybe something to add on that before I ask Mikael to comment on specific data Frank D Amelio    Chief Financial Officer and Executive Vice President  Global Supply and Business OperationsAnd Louise  the only thing I wanted to add just to punctuate everything Albert said is    and why are we focusing on Phase 2b  Phase 3  is because the LOEs really start to kick in 2007  So if you think about we re in January of 2020  we literally have 8 years to work our way through this problem  And by the way  given that kind of a timeframe  given the breadth and strength of our pipeline  given our balance sheet  our capacity  obviously  we feel confident we will be able to solve it Albert Bourla    Chairman and Chief Executive OfficerMikael Mikael Dolsten    Chief Scientific Officer and President  Worldwide Research  Development and MedicalYeah  I m pleased that you asked about our  Indecipherable  next generation  So as you know  we have adult and pediatric studies ongoing  The adult study has been given breakthrough designation on 28 September based on our encouraging Phase 2 data  and we expect very soon to report Phase 3 outcome of the adult PCV20 trial  And obviously  we are optimistic about that outcome based on the Phase 2 and the breakthrough designation On the pediatric  we have now accumulated further  Indecipherable  dose data of the PCV20 Phase 2 study  These data from the  Indecipherable  further substantiate the positive data reported in the press release of the  Indecipherable  and we expect initiation of Phase 3 soon for the infant vaccine pending discussions with regulators  The full dataset will be presented at the major vaccine related conference likely mid of this year Now  Albert commented also in his introduction very nicely on the improved relative coverage of the PCV20 from us versus a potential competitor 15 valent  And he mentioned 33  better coverage for adults and 42  better coverage in the US for infants  obviously very important significant better coverage  I just wanted to punctuate when you look in the top European market similar improved coverage in adults is actually 62 to 100   in infants 80 to 200   This is all for invasive pneumococcal disease Also in US  we have analyzed for community acquired pneumonia where we see substantial data coverage for the 20 versus a potential 15 valent  So all in all  you can see  we look forward to data sets advancing the program and think it would be the premier 20 valent and premier pneumococcal vaccine for patients Albert Bourla    Chairman and Chief Executive OfficerThank you Chuck Triano    Senior Vice President  Investor RelationsThank you  Next question please  operator OperatorYour next question comes from Steve Scala from Cowen Stephen Michael Scala    Cowen and Company    AnalystThank you  I have a few questions  An increase in the dividend was mentioned twice  but it sounds as though Upjohn will be  spun not split  in which case the dividend will be reduced  So I m wondering if you could clarify the dividend comment and I assume the 2020 EPS guidance implies a spin  not a split  Secondly on the abrocitinib versus dupixent study  given the fact that it is completed  Mikael  I m wondering if the data met the very positive portrayal you provided on the Q3 call which included superior itch relief to dupixent  And then lastly  will the proof of concept DMD data be presented at the March 31 meeting  Thank you very much Albert Bourla    Chairman and Chief Executive OfficerWell  thank you very much  Steve  Very good question  So  Frank why don t you clarify once more the dividend Frank D Amelio    Chief Financial Officer and Executive Vice President  Global Supply and Business OperationsSure  So  Steve  in terms of the guidance  you are right  it assumes a spin  not a split  And then in terms of the dividend  you said    I think you said in your question  it d be a reduction  I don t see it that way  What we ve said is the sum of Viatris dividend and our dividend would equal the current dividend that a Pfizer shoulder receives today  So I don t see a reduction in the dividend  The dividend income will be kept whole  I think we ve been very clear about that all along Albert Bourla    Chairman and Chief Executive OfficerAnd we ll continue growing  maybe not at the same pace  which we do right now  it s  0 02 per quarter  but we ll continue growing Frank D Amelio    Chief Financial Officer and Executive Vice President  Global Supply and Business OperationsRight  And Steve I can quickly run the numbers for you if you d like  just    so what do you think  What Viatris has said  is their first full year of about  4 billion of free cash flow  they d pay about 25  of that in the dividends  so that s 1  Phonetic  billion  Total Viatris will have about 1 2 billion shares  you put the 1 billion over 1 2 billion shares  it s about  0 83  The exchange ratio is about 1 2  Phonetic   You put a 100 shares of Pfizer  you get 12 shares of Viatris assuming a spin that s roughly  10 a share  We would reduce our dividend on an annual basis by that  10 but some of our dividend plus that  10   Albert Bourla    Chairman and Chief Executive Officer 0 10 Frank D Amelio    Chief Financial Officer and Executive Vice President  Global Supply and Business Operations 0 10  I m sorry  yeah  thank you  would equal what Pfizer s only gets today  And my thing it s  10 not  0 10 Albert Bourla    Chairman and Chief Executive OfficerOkay Stephen Michael Scala    Cowen and Company    AnalystAbrocitinib Mikael Dolsten    Chief Scientific Officer and President  Worldwide Research  Development and MedicalYes  So  thank you for your interest in abrocitinib  And we believe that it s going to be a new drug class for such a prevalent disease that affects tens of millions of Americans  atopic dermatitis and where an oral alternative seems to be a real patient and physician preference  We will soon report out the data from the important COMPARE study So I haven t actually seen the data  so I can only punctuate a little bit what we discussed at earlier investor meetings that the historical comparison between abrocitinib and Dupixent suggest that we should expect to see similar or better impact on clearing skin  And particularly as Albert alluded to in his introduction  there is an important key secondary endpoint looking at itch relief starting with a readout already of two weeks and then following the study through the 12 to 16 weeks And the historical data suggests that we should be very optimistic about abrocitinib outperforming biological such as Dupixent on itch relief at earlier time points and provide the potential benefit of early onset of relief for disease  Now  we have to wait for the data to be able to obviously be absolutely confident in that outcome  but this is what I believe and look forward very much to see the data come shortly Albert Bourla    Chairman and Chief Executive OfficerAnd on the DMD question Mikael Dolsten    Chief Scientific Officer and President  Worldwide Research  Development and MedicalYeah  We are finalizing I think the program for the R D Day  So I can t be absolutely promise you  but I think it s likely that such an interesting program as the DMD gene therapy will be one of the potential agenda items  And obviously we would like to then share updates from increased number of patients over a longer time period  So please welcome and take a front row seat Albert Bourla    Chairman and Chief Executive OfficerThank you very much  both  And by the way  Frank  as always was right  It is  10 for 20 shares of Mylan Chuck Triano    Senior Vice President  Investor RelationsAll right  Move on to our next question  please OperatorYour next question comes from Geoff Meacham from Bank of America Geoff Meacham    Bank of America    AnalystGood morning  guys  Thanks so much for the question  Just have a couple  Mikael  the gene therapy platform with the advancement of hemophilia A and B  as well as DMD into Phase 3  what s the capacity to add additional indications to the portfolio  I mean  you guys have been successful partnering  but at this point it does seem like you could expand the platform organically in a material way And then for Angela on Xtandi  I just wanted to get your perspective on the inroads you ve made in M0 prostate patients and where do you think could represent a tipping point commercially  especially given that generic Zytiga available in the US  Thank you Albert Bourla    Chairman and Chief Executive OfficerMikael Mikael Dolsten    Chief Scientific Officer and President  Worldwide Research  Development and MedicalYes  So  Geoff  you are showing  Indecipherable  for the gene therapy platform and what is particularly I think a strategic advantage for us is the end to end capability from discovery  clinical  manufacturing and of course that capability is also linked to important external partners that gives us capacity to advance increasing number of internal as well as partner programs  And we have an option for the Vivet Wilson disease program that could in a relatively near term future be available for clinical studies  And we expect from internal and external initiative to aspire to about bringing one new gene therapy into the clinic every year or so for the next period to come  And we think that should build up a very comprehensive gene therapy portfolio The three programs you alluded to are of course the frontier for us with factor IX that we hope to be the first company bringing that over the finish line in Phase 3 now and to start additional two Phase 3s for hemae  Phonetic  where we think we have a best in class profile so far  And then we already spoke about the NDA  Phonetic  Albert Bourla    Chairman and Chief Executive OfficerThank you very much  Angela Angela Hwang    Group President  Pfizer Biopharmaceuticals GroupSure  So  in terms of the M0  the non metastatic CRPC  I mean  what we re seeing here is just tremendous growth and tremendous performance  Just broadly speaking in terms of Xtandi  we had a great quarter  right  We grew 29   and this was driven by two things  One was actually demand across both metastatic as well as non metastatic  but also what we saw was the continued expansion of the actual class  the novel hormone therapies  And in this class Xtandi has the lion s share  We have about 35  share right now So first of all  to answer your question vis a vis generic Zytiga  we really don t see a competition from a generic versus brand in this instance  I think the competition    Zytiga is really among generic Zytiga versus branded Zytiga  whereas what we re seeing here is a clear uptick in Xtandi and specifically from the prostate trial in this M0 population as you say  we are continuing to see  As I ve talked about in all the previous quarters  really  really significant and very confident and uptake in urology prescribing  And we do believe that this is underpinning the growth of our non metastatic population  And the fact that these are patients also earlier in their disease is helpful in driving our growth in this population I also mentioned that just from a market share perspective  though the non metastatic  the M0 population has Xtandi  Erleada as well as Nubeqa  Xtandi by far and away has the leading market share in this segment and has been from the time that it was launched Chuck Triano    Senior Vice President  Investor RelationsGreat  Thank you  Angela  Next question  please  operator OperatorYour next question comes from Tim Anderson from Wolfe Research Tim Anderson    Wolfe Research    AnalystThank you  A couple of questions  One is on Prevenar in China  So sales have been ramping up there  but the regulatory authorities recently approved a domestically produced 13 valent product and the CEO of that company suggest they have capacity that s in the 10s of millions of doses  and who knows if that s true or not  But I m wondering if you can give some perspective on how you see competitive dynamics in a situation like this going forward  not only in China  where a domestic producer could potentially benefit from favoritism but also if that company were to take their product into other markets outside of China at a different price point  I think a lot of investors assume vaccines are durable forever  but I m wondering if this sort of thing could be disruptive and how you take the sort of potential competition into your forecast Second question is on M A  So any M A that you may engage with in 2020  Should we assume at least during this first six month window while you still have Upjohn that that is probably put on hold  And then last question on Vyndaqel  Might there be a low hanging fruit phenomenon where we see initial nice uptake  but then it kind of flattens out suddenly  Or do you expect this will be continued strong linear growth Albert Bourla    Chairman and Chief Executive OfficerThank you very much  I will give a quick answer to your M A question  Tim  and then Angela can deal with Prevenar China growth  On M A  no  the answer is no  absolutely not  We are very actively looking to invest capital on value creation opportunities  And then I assume that we will have several of them in the first half of 2020 before the close of the deal  Again  across the lines that I have described  you know exactly what we re doing  We want to make sure that we sustain the growth beyond 2027 when the alloys will have some impact Angela  what about Prevenar China Angela Hwang    Group President  Pfizer Biopharmaceuticals GroupSure  So we have acknowledge that there is a new competitor in the form of Volvax  Phonetic  in PCV13  However  I want to recognize that there are some differences here  Though it is a 13 valent vaccine  Volvax s vaccine is made with a different conjugate  And this conjugate technology being an older technology  so quite different from what we see in PCV13  That being said  it is a competitor However  if you sort of step back and look at the opportunity that we have in pneumococcal vaccinations  there are approximately 14 million new births every year in China and today only over maybe 1  of those infants are being vaccinated  So regardless of the volumes that Volvax might have available  I think the opportunity between us is just much larger than that  And we have a tremendous amount of untapped potential in the marketplace and we are confident that with the quality  the reliability  as well as the tremendous experience that Pfizer has had globally with PCV13 but also the tremendous success that we ve had in China  specifically for PCV13 that our growth will continue  And this is what we expect We have a very robust footprint  As you know  the vaccines    and it will be the same for Volvax  PCV13  This is an out of pocket market and it will be the same for the both of us  So this is where we ll be competing  which is why having a robust promotional engine and having a footprint of representatives that can really be available to support patients and caregivers at the points of vaccinations is really important  And I think in this regard  we have demonstrated great expertise and ability to grow this market So that s how we see it  We acknowledge the competition  but we continue to see tremendous potential Albert Bourla    Chairman and Chief Executive OfficerWhat about Vyndaqel Angela Hwang    Group President  Pfizer Biopharmaceuticals GroupAll right  So in terms of Vyndaqel  so yes  of course  in the year of launch one might expect to see a little bit of a bolus  a number of patients who have been identified and are awaiting diagnosis and treatment  That being said  we are confident of what we    we re confident about what we ve learned in the marketplace  in our first year of launch  We are confident that we have the right set of tools for helping to physicians to suspect the patients that might have ATTR CM  We have mobilized education around using non invasive methods like scintigraphy to diagnose patients  And we have also mobilized a patient support hub to help patients receive their medications So I think doing more of that as well as continuing to think about new methods to help diagnose and treat patients such as using artificial intelligence and increased number of tools  all of that will continue to support our ability to drive the important and rapid diagnosis of patients as well as their treatment Chuck Triano    Senior Vice President  Investor RelationsGreat  Thank you  Next question  please OperatorYour next question comes from Andrew Baum from Citi Andrew Baum    Citi    AnalystThank you  Couple of questions  please  Firstly on your pending oncology biosimilars rollout in the US  Given the challenges to start with biosimilar penetration  could you talk to your expectations  particularly with these three drugs  there should be an economic incentive for payers given the pass through  But yes  those issues in patients already on an established  Indecipherable  biosimilar to switch    and it s a brand to switch to biosimilar  So if you could give us some kind of sense of how much penetration and how quickly you may expect  that would be super helpful And then second  in terms of tafamidis  Angela  you tried to give some penetration figures at the beginning which I was struggling to keep up with and writedown  But just more broadly  could you outline how large you think the untapped patient population really is here and how far Pfizer is along in establishing that market  Many thanks Albert Bourla    Chairman and Chief Executive OfficerAngela  a lot of questions for you today  Please go ahead Angela Hwang    Group President  Pfizer Biopharmaceuticals GroupOkay  Sure  All right  So I think firstly we see the dynamics in oncology biosimilar as being very different from that of the    what we saw for inflammation in the form of Inflectra  So to your point about how will the dynamics change here and how quickly can payers as well as providers capture their savings is going to be much quicker  This is    the use of oncology biosimilars are much more rapid  right  You see more patients cycling through  treatment times are much shorter  So that s going to enable payers them providers to capture savings much more quickly  which is a very different dynamic that you see in Inflectra where it s a chronic treatment and patients are on their treatment for a very long time  So I think that s one big difference The second is that there is already some    we already have some precedents  We saw this with Retacrit  where after a year of being in the market  Indecipherable  supportive care in oncology  We already have 20  market share  This is still a far cry from what we see in Europe where there is much more rapid uptake  But I think that s  it s a signal  an indicator of the differences you see in the various biosimilar markets And we also have some early signals from competitor biosimilars that have already some good market share in oncology biosimilars  So I think that we have some good indicators that this is going to be different  I think the benefit that we see here is that we have a portfolio of three oncology biosimilars  all coming out around the similar time like around now  And I think what we have    we have a robust pricing strategy discount to the WACC  Phonetic  of the originator as well as I think strong relationships and networks built with both providers and payers that give us confidence that this will be an area of high growth for Pfizer Albert Bourla    Chairman and Chief Executive OfficerThank you  Angela Angela Hwang    Group President  Pfizer Biopharmaceuticals GroupAnd then your question was around tafamidis  So can you just repeat that again Andrew Baum    Citi    AnalystThe untapped population  Indecipherable  Angela Hwang    Group President  Pfizer Biopharmaceuticals GroupSo  as we have said in previous calls  we do believe that this is a rare disease and that in the US  there will be about 100 000 patients in total  Globally  500 000  but in the US  100 000  To date  we have diagnosed 9 000 patients  So that leads us to 9  of the population that we have diagnosed So while this may feel like very significant progress on the time that we have launched  and it is  I think you can also see that we have a long  long way to go to finding all 100 000 of these patients  And what I spoke earlier about in terms of the education  in terms of how to suspect the disease  how you diagnose the disease and then very quickly gaining access so our patients can benefit from treatment of the disease  These are all three levers that we are intensely focused on Chuck Triano    Senior Vice President  Investor RelationsGreat  Thank you  Next question  please OperatorYour next question comes from Navin Jacob from UBS Navin Jacob    UBS    AnalystHello  Thanks for taking my questions  A couple if I may  Just on biosimilars following up with Angela  Your comment about strong growth continuing on for the biosimilar  So I m wondering if you could give any color around how we should think about the trajectory over the next couple of years  Is this a doubling or tripling of that now almost  1 billion business  And then also  would love to understand how you re thinking about the tail of each of the individual assets  Are you seeing    should we be thinking of this as a ramp that goes up for a few years and then eventually starts tailing off like other generics  Or do you see this stabilizing and having a sustainable tail And then just on Vyndaqel  you received a positive CHMP opinion in the EU in December  Given that Vyndaqel is already approved in the polyneuropathy indication  wondering how we should be thinking about the price with the addition of the cardiomyopathy indication  Is there any chance for moving that around  And then how we think about the ramp in the EU  relative to the US  Thank you so much Angela Hwang    Group President  Pfizer Biopharmaceuticals GroupSure  So  I ll start with the last one first  So you re right  we just received EU approval for Vyndaqel  And as you know  there is quite a time lag between approval and then reimbursement in each of the countries  So all I can say is  right now we are in active negotiations with the countries in terms of determining the price of Vyndaqel as well as its reimbursement  You referred to the fact that we already have the 20 milligram of peripheral polyneuropathy in Europe and we recognize that That being said  we have    first of all  ATTR CM is a completely different indication  The trials that were conducted as well as the significant mortality benefits that were demonstrated in our clinical trials in ATTR CM are completely different  and we have the clinical data to demonstrate the great patient benefits that we have in ATTR CM  And so that s the basis of our discussions with each of the countries in Europe for reimbursement Your second question was around Vyndaqel growth and sort of the pace of it  I think the way to think about it is the following  We have through analogs seen that only 30  to 50  of all rare diseases are ever diagnosed  But of course  we believe that based on the mortality data that we have and the patient benefit that can be derived that it is critical that we meet that or at beat that  And so that s what we are intensely focused on  We have 10  of our patients    or with 9  in the US are diagnosed today  we have a long way to go and that s what we need to do Your last question Navin Jacob    UBS    AnalystWas the rhythm on the biosimilars  We ve had strong growth  22  this year for the year  What can we expect going forward Angela Hwang    Group President  Pfizer Biopharmaceuticals GroupThat s right  So I think in terms of the biosimilars  again  this is an area of growth that we can anticipate  We have three biosimilars now in oncology  plus the two that we have been supportive care  And so we look forward to this being a significant growth contributor to oncology portfolio  not just from a growth percentage perspective  but also from a revenue base perspective Chuck Triano    Senior Vice President  Investor RelationsRight Mikael Dolsten    Chief Scientific Officer and President  Worldwide Research  Development and MedicalI just would    yeah  I just wanted to add that Vyndaqel polyneuropathy has a positive EU recommendation  So we expect approval to come soon  And you know that links very nicely to really helpful outline you did  Angela Angela Hwang    Group President  Pfizer Biopharmaceuticals GroupThanks  Mikael Chuck Triano    Senior Vice President  Investor RelationsGreat  And if we can take our last question please  operator OperatorYour final question comes from the line of Mani Foroohar from SVB Leerink Mani Foroohar    SVB Leerink    AnalystHey  guys  thanks for taking my question  A couple of little ones on the Rare Disease side  In terms of tafamidis  we saw pretty attractive growth OUS including some markets that don t necessarily have the cardiomyopathy indication yet   Indecipherable  some follow on benefit in polyneuropathy from the increased promotional efforts in cardiomyopathy in Europe and elsewhere As a second question  given the expansion of patient opportunity into polyneuropathy in the US  how do you think about the opportunity to pursue a supplemental NDA or similar strategy in the US based on the real world evidence guidelines laid out previously by the FDA or would that require a separate study  And then finally on the gene therapy side  obviously pretty interesting data in hemophilia at ASH  moving forward in a couple of Phase 3s now  How do you think about that market in a universe where you have multiple therapies within curative intent in gene therapy alongside a number of fairly robust chronic therapies  Who are the patients who should receive an irreversible intervention in terms of gene therapy and who do you think that are more appropriate for chronic therapy such as  Indecipherable  Thank you Albert Bourla    Chairman and Chief Executive OfficerYeah  I think I will ask Mikael to start with gene therapy and  Indecipherable  follow this great assets that we have and how they fit together  Mikael Mikael Dolsten    Chief Scientific Officer and President  Worldwide Research  Development and MedicalYeah  Thank you very much  What I think is unique in our hemophilia portfolio  first  of course  we have a legacy of being one of the pioneers four intravenous delivery of factor VIII and factor IX  So we have a platform and experience on the business and R D side  And  as you so nicely alluded to  we also shared with our partner Sangamo some very much best in class data recently on the factor VIII gene therapy  Our current portfolio has factor VIII and factor IX gene therapy plus our TFPI antibody that has  like Hemlibra  an opportunity to provide subcute alternative but actually TFPI can be applicable for both factor VIII and factor IX deficiency So  the way we see it develop is that    I think physicians will look at gene therapies that have durability and good tolerability  and that has really been the hallmark for the strategies when we developed factor VIII and factor IX best in class profile because there are alternatives for these patients  So once they see the data for drugs    treatments that are approved that have durability and really good outcomes  which I think has been so far what we have seen with our gene therapies  those will be the one that can be adopted because there are alternatives that have less convenience but will at least until strong data is available be used For patients that are early in the disease diagnosed at earlier age  I think this would be a very important treatment as it saves them from the breakthrough bleedings that occur on lifelong treatment with infused factor VIII  Phonetic  and particularly for patients that are at early age that are very physically active it is important to have a solution for cure  So I think this will be a tremendous important patient populations  But availability of subcutaneous agents will supplement them and also allow for patients that may have antibodies to gene therapies to use them until a sufficient number of gene therapies available that there is always one for each patient And finally  us bringing together  I think what s unique with us is the entire portfolio that can address these patients  and we look really much forward to the year around 2021 and  22 when we see this portfolio coming into registration phase  I think that was the main piece here Albert Bourla    Chairman and Chief Executive OfficerYeah  And then  Angela  maybe on Vyndaqel  we have seen some uptick in markets that cardiomyopathy was not approved  what s going on there and about supplemental filing on polyneuropathy Angela Hwang    Group President  Pfizer Biopharmaceuticals GroupYeah  In terms of polyneuropathy in the US  this is something that we re continuing to explore with the FDA  So   Albert Bourla    Chairman and Chief Executive OfficerNo  this is  Speech Overlap  made yet  but we are in discussions Angela Hwang    Group President  Pfizer Biopharmaceuticals GroupThat s right  exactly  And then in terms of the upticks in polyneuropathy  I mean  I m not sure that it s a cardiomyopathy effect  As you know  we are improved  It s an approved indication for us ex US  So  we continue to actively promote it and it s probably as a result of those activities Albert Bourla    Chairman and Chief Executive OfficerYeah  We will have  as we said  approval for that indication  and this is one I would think we will see material impact on Vyndaqel in cardiomyopathy in these patients who are not right now    we are just promoting  of course  The indications that we have registered over there  so we don t do anything outside that All right  I think this concludes more or less our call  Just I wanted to make some comments because really  I feel that we have at an exciting point in Pfizer s history  And if you take a big picture view over the last decade  we have changed and refocused our approach to R D  we have improved dramatically its productivity and we have developed the best pipeline we ever had and one of the best I believe in the industry  If you ve seen 2019  it was a year that we took deliberate and forceful steps to strengthen each one of our businesses and eventually shred  Phonetic  the current Pfizer into a new  smaller  high growth profile enterprise that will remain powerhousing marketing but also has been converted to the powerhouse of science Following the expected close of the Upjohn and Mylan transaction later this year  of course  we will be a very different company  And we will focus on continuing to execute our strategy  This includes we will continue the commercial momentum and preparing our new product launches  You have all asked a lot of questions about those products that keep surprising with their growth profile  And also you ve seen that we are taking seriously and we are investing in new launches We are continually advancing our internal pipeline and we ll augment it with mid stage R D programs through targeted bolt on business development opportunities  As I referenced before  we should continue seeing these type of activities in the first and second half of this year  Of course  we are working very intensively to set up Upjohn to be in a strong position when it combines with Mylan to become  Indecipherable  and create a formidable company  And of course  we will continue leading the conversation in Washington as we work to address the affordability challenge facing patients  These are the areas that we are focusing for next year Once again  we look forward to sharing more pipeline updates during our Investor Day on March 31  Have a great rest of your day Operator Operator Closing Remarks Duration  88 minutesCall participants Chuck Triano    Senior Vice President  Investor RelationsAlbert Bourla    Chairman and Chief Executive OfficerFrank D Amelio    Chief Financial Officer and Executive Vice President  Global Supply and Business OperationsAngela Hwang    Group President  Pfizer Biopharmaceuticals GroupMikael Dolsten    Chief Scientific Officer and President  Worldwide Research  Development and MedicalRandall Stanicky    RBC Capital Markets    AnalystChris Schott    JPMorgan    AnalystTerence C  Flynn    Goldman Sachs    AnalystUmer Raffat    Evercore ISI    AnalystDavid Reed Risinger    Morgan Stanley    AnalystLouise Alesandra Chen    Cantor Fitzgerald    AnalystStephen Michael Scala    Cowen and Company    AnalystGeoff Meacham    Bank of America    AnalystTim Anderson    Wolfe Research    AnalystAndrew Baum    Citi    AnalystNavin Jacob    UBS    AnalystMani Foroohar    SVB Leerink    Analyst
More PFE analysis
All earnings call transcripts",2020-01-28,The Motley Fool,https://invst.ly/po4-i,2070048
219640,441156,PFE,3M  McCormick  and Pfizer,news,"In this episode of MarketFoolery  Mac Greer talks with Fool analyst Emily Flippen about some market news  McCormick  NYSE MKC   3M  NYSE MMM   and Pfizer  NYSE PFE  all fell on earnings  Emily explains some of the context behind the companies and their drops    McCormick s acquisitions and growth  3M s one time fees  Pfizer s new plan  and more    and how attractive they look going forward  Also  Emily shares her take on the U S  China trade war phase one deal and what investors might expect in the next few quarters  some things to keep in mind regarding the coronavirus and its potential impact on the Chinese economy  and more 
To catch full episodes of all The Motley Fool s free podcasts  check out our podcast center  To get started investing  check out our quick start guide to investing in stocks  A full transcript follows the video 


This video was recorded on Jan  28  2020 
Mac Greer  It s Tuesday  January 28th  Welcome to MarketFoolery  I m Mac Greer  and I am joined in studio by Motley Fool analyst Emily Flippen  Emily  how are you doing today 
Emily Flippen  I m all right  How about yourself 
Greer  I m doing good  I m doing good  Now  in a minute  as our resident expert  as a student of China    do you like when I always just kind of build your credentials up 
Flippen   laughs  I love it 
Greer  Well  I m going to have to ask you about the coronavirus 
Flippen  Of course 
Greer  Chris and Jason talked about it on yesterday s MarketFoolery  and I certainly want to talk to you about it in a few minutes  But I want to kick things off with some earnings stories  And let s begin with McCormick  the spice maker  And really a dang good stock over the last few years  but not so much today  Shares slipping a bit after McCormick reported lower than expected earnings  What is going on here 
Flippen  Well  not only did McCormick miss on their revenue and earnings  but they gave weak guidance for 2020  Net income was actually down  0 01 year over year on flat revenue  So  I think all in all    I mean  McCormick s never been a high flying stock  but it was a worse quarter than what was expected  But you need to put it in context  For instance  McCormick prior to this earnings was up 40  over the past year alone  And that is foiled against the market s 25   but still  that s 15   20  over the market  which is extremely impressive for a company that has only grown revenue in the low single digits for a long time now 
Greer  That s a lot of Old Bay 
Flippen  It s a lot of Old Bay  And it might not be a high flying company  but in constant currency terms  the company actually grew sales 3   So  there were some headwinds in there that were a little bit out of their control  I think all in all  McCormick  ultimately what you re seeing is a strong  stable  dividend paying company that has just been on a tear  and needs a little bit of a pullback  if you ask me 
Greer  And speaking of being on a tear  I think a lot of us  when we think McCormick  we think spices  But in recent years  they ve gone on a bit of a buying spree where they bought food companies and food brands like Frank s Red Hot  French s  When I think mustard  I think French s  So  it s not just a spice maker anymore 
Flippen  Yeah  look  I have a bottle of Frank s Red Hot in my fridge constantly  I put that stuff on everything  to stick with their tag line there  So  McCormick is smart  because they re always looking forward and thinking  OK  well  if we see any softness in the spice market    last year  there was some softness on the food service side of their spice division  So  yeah  when they see opportunities to acquire different brands  then they do that  And it s smart because it diversifies their revenue stream a little bit  And Frank s Red Hot is great 
Greer  Do you have a favorite spice 
Flippen  I like McCormick s premixed spices  I know it s a cop out 
Greer  In the little paper bags 
Flippen  In the little paper bags  I know  I know  When I go home  I already have all those spices in my cabinet somewhere  But there s something so nice about just getting a little bag  putting it on the chicken  putting it on whatever  and then baking it and making it all easy enough 
Greer  I think there s no crime in that  I think you should just own it  You know what I love  And I m such a late adopter  I feel like I came across this maybe 10  15 years ago  but I m such a huge fan of sea salt  And I know salt  I know the world   
Flippen  What s the difference 
Greer  I don t know  it just feels kind of chunkier  I don t know  it feels better  Now  I know the tide has been turning against salt for a while  And I know that too much salt  not a great thing  So  hold your emails  But  love me some sea salt  So  back to the stock  The stock has more than doubled over the last five years  Are you still bullish on McCormick going forward 
Flippen  I am  Their cash flow from operations were up 15  year over year  And in November  they authorized their 34th consecutive quarter of dividend increases  I think today s reaction might be a little bit of a needed pullback for the stock itself  but in terms of it as an investment  especially if you re looking for a dividend  it s a low dividend at about a 1 5  yield  but it s a good  stable player that generates a lot of cash flow 
Greer  And let s move on to 3M  Shares of 3M down around 4  on earnings  3M also announcing that it is laying off 1 500 employees  That works out to around 1 5  of its workforce  Emily  what do you think 
Flippen  3M had an interesting quarter  Their sales slightly missed  Their earnings missed big  They posted a gap EPS of  1 66 versus  2 10 expected  So  a big miss there  But there was a  0 49 headwind associated with  as you mentioned  the restructuring charges with that layoff of 1 500 people  a huge number of people  as well as litigation costs that don t expect to reoccur  So  on the bright side  it seems like they have some room for operational improvements throughout 2020  In fact  in 2020  they guided that the bottom line should rise more in the range of 2  to 7  thanks to those job cuts  It s never really a good thing you want to see with a company that needs to raise that income by laying off a huge number of people like this  But at the same time  they really do need to return to growth in 2020  Their sales were down 2  year over year 
Greer  And let s talk about another potential catalyst  Because back in October of 2018  3M first warned that trade tensions with China would be a problem  Now  last week  we talked about phase one of the trade deal with China  We ve got that now locked in  So  could that be a catalyst  I mean  it seems like things are getting better  and that can only help 3M  right 
Flippen  Every single time I think things are getting better the trade war  I need to knock on wood  because it seems like you take a step forward then two steps back  I really think it s too early to say whether or not we re going to see any further improvements in the trade war than the phase one deal  The phase one deal was the low hanging fruit  There s a lot of very nitty gritty details there that need to be worked out  And unfortunately  the safety and industrial segment for 3M is their largest revenue segment  and that s the most affected by the trade war 
Greer  Exit question  10 years from now  will there still be Post it Notes 
Flippen  100   just because David Gardner will still be in the world and he ll still be buying those Post it Notes 
Greer  I love it  you re bullish on Post it Notes 
Flippen  I m bullish on Post it Notes 
Greer  I love Post it Notes  but I m not sure with millennials    I mean  you  as a millennial  I feel like it s all gone digital  So  I m not sure  Five years from now  maybe so  10 years from now  I think there s going to start to be a backlash against Post it Notes because of the waste  And I love Post it Notes 
Flippen  I also love Post it Notes  If you go into my workspace at my home  I have Post it Notes all over the place  I will admit  it s maybe not the most environmentally friendly thing I do 
Greer  Well  let s move on to Pfizer  Shares of Pfizer falling on earnings  down around 4   Emily  what is going on with Pfizer 
Flippen  Ultimately  the big story with Pfizer is that they were not helped by the loss of patent exclusivity for Lyrica  That s Pfizer s drug used to treat pain from fibromyalgia and other nervous system diseases  That s a mouthful  It s essentially to say that  yeah  Lyrica lost two thirds of its revenue over the past year because of the loss of this patent  which has really impacted Pfizer s bottom line  They missed on earnings  And that was actually a 13  decrease year over year in earnings  But  Pfizer s looking up for 2020  They re actually spinning off one of their divisions  Upjohn selling it to Mylan  and they re forming what they call a new Pfizer  which is a new and improved  smaller  lean  innovative machine 
Greer  A new Pfizer  I hope that works out better than the whole New Coke thing 
Flippen  I hope so  too 
Greer  Back to back to the loss of exclusivity  When you re looking at a drug maker like Pfizer  it s really all about the pipeline  right  for investors  and their ability to replenish that pipeline as they lose exclusivity 
Flippen  Exactly  And you have to recognize that Pfizer and other companies like this are always going to be very lumpy  They tend to have really great quarters  and then really bad quarters  It depends a lot on that patent process  I presume that new Pfizer s focus will be on biopharma  They have a lot of great products coming out in that division  as well as bringing their existing products into emerging markets  But the CEO  Albert Borella said that  quote   The company will be a smaller  science based company with a singular focus on innovation   So  hopefully  moving forward  that means that they re focusing on their core products that they see their ability to scale 
Greer  And as we wrap up  Emily  as I mentioned  I want to ask you about the coronavirus  Now  Chris and Jason talked about it on yesterday s show  We re seeing a lot of stocks getting hurt  Travel stocks  especially  and gaming stocks  like Wynn really falling  because of the coronavirus story  Now  Chris talked about how it s an opportunity to see how companies communicate  and to see how transparent and how forthcoming some of these companies are  We ve seen Starbucks and Disney both make statements and close    to see how companies communicate  As you watch this coronavirus story unfold  what are you watching  What s your big question 
Flippen  I think Chris hit the nail on the head with watching how these companies communicate  I will just add a grain of salt there  which is to say  what they re operating off of is limited information  And they re usually getting that information from the horse s mouth itself  which is the Chinese government  It s not the most reliable source of information  So  even though you can have companies that are trying their best to be as transparent as possible with what they know about the impact of this disease  if anybody is being over communicative  it s probably going to give investors a feeling of false hope  right  Nobody really knows where this is going to develop  Nobody can really tell the impact of it 
What I ll be watching is seeing how this affects the general Chinese economy over the next quarter  Chinese stocks have been beaten down because of the trade war issues associated with our different governments  And this definitely does not help what I had initially hoped in 2020 would be a secular rotation back into Chinese companies  So  we need to make sure that this doesn t impact the Chinese economy too much  or these Chinese companies can continue to stay hit down 
Greer  And as we wrap up  the desert island question  You re on a desert island for the next five years  and for some reason  well  you re going to buy a stock  You have to buy one of these three stocks  McCormick  3M  or Pfizer 
Flippen  That s such an easy question to me  For me  that s McCormick  100  
Greer  Wow  didn t even hesitate 
Flippen  I really don t need to  When I look off into the future five  10 years from now  I see McCormick still being around  They re really the leader in their space  I think they re well managed  They re not the biggest dividend player    all of these companies are dividend payers  by the way    but  they do pay a steady dividend  They have strong cash flows  Look  any company that acquires Frank s Red Hot is good in my book 
Greer  I like that  And they have the premade spice packs  You don t have to do anything  You just tear the thing up  Yeah  I love that  too 
Well  as always  people on the show may have interest in the stocks they talk about  and The Motley Fool may have formal recommendations for or against  so don t buy or sell stocks based solely What you hear  Emily Flippen  thanks for joining me 
Flippen  Thanks for having me 
Greer  That s it for this edition of MarketFoolery  This show is mixed by Dan Boyd  I m Mac Greer  Thanks for listening and we will see you tomorrow ",2020-01-29,The Motley Fool,https://invst.ly/poius,2070859
219641,441157,PFE,Pfizer shares still soft after Q4 miss,news,"Pfizer  PFE  1 2   remains in the red after yesterday s Q4 report that came in below expectations  Share have sold off 6  since  Sell siders weigh in 
Cantor s Louis Chen  Overweight  53   Earnings miss and concerns about the company s growth prospects are overdone  Confident that it will achieve its five year CAGR of  6  in revenue  Solid execution and innovation will drive sales growth 
Goldman s Terence Flynn  Weakness in shares probably driven by headwinds to key franchises like Ibrance  extension of late stage data readout on Ibrance in an adjuvant setting  Key data readouts this year are a key to building investor confidence that its R D productivity can deliver new drugs to replace those that will lose patent protection in 2026 and beyond 
JPMorgan s Chris Schott  Neutral  37   6  CAGR in revenue target looks achievable  Not enough in the company s update to support a further upside in valuation  however ",2020-01-29,Seeking Alpha,https://invst.ly/pojn1,2070920
219648,441164,PFE,Is A Disappointment In Store For Glaxo s  GSK  Q4 Earnings ,opinion,"GlaxoSmithKline plc   NYSE GSK   is scheduled to report fourth quarter 2019 results on Feb 5  before market open  In the last reported quarter  the company delivered a positive surprise of 14 46  Shares of Glaxo have outperformed the  in the past year  The stock has returned 19 6  compared with the industry s increase of 10 2  Glaxo s earnings performance has been impressive so far  The company s earnings surpassed estimates in each of the trailing four quarters by 17 23   on average Factors to ConsiderStrong demand for its shingles vaccine Shingrix and respiratory drugs is likely to have driven sales of Glaxo s Pharmaceuticals segment  However  rising competition in the HIV segment  especially for three drug regimens  might have hurt sales The growth trend in sales of the Respiratory category is likely to have continued in the fourth quarter on the back of strong demand for Trelegy Ellipta and Nucala  Label expansion of Nucala to include children aged six years or older with severe eosinophilic asthma in September might have boosted the drug s sales in the quarter  However  older respiratory drugs   Advair and Relvar Breo Ellipta   facing competitive and pricing pressure are likely to have unfavorably impacted Glaxo s sales in the soon to be reported quarter The Vaccines segment is likely to have benefited from the sustained uptake of Shingrix  Moreover  sales of meningitis vaccine Bexsero  acquired from Novartis AG   NYSE NVS    have demonstrated growth in the previous three quarters  The trend is likely to have continued in the fourth quarter  However  Menveo sales slightly declined in the prior quarter  Demand for these vaccines fluctuates every season and therefore  sales may vary Sales growth of Glaxo s Benlysta were at record levels in the third quarter  During the fourth quarter  the drug s label was expanded to include children aged five years or older with lupus in Europe  which may have boosted sales in the quarter  Oncology sales  solely from Zejula  are also likely to have witnessed growth Meanwhile  the competitive environment and the shift in the portfolio toward two drug regimens have likely hurt sales of three drug regimens   Tivicay and Triumeq   and older HIV drugs  However  the strong growth trend witnessed in two drug regimens  Juluca and Dovato  might have helped the company to partially offset some of the losses in sales of three drug regimens Glaxo formed a joint venture with Pfizer   NYSE PFE   in August to create the world s largest consumer healthcare business  While Glaxo owns a controlling stake of 68  in the JV  Pfizer owns 32   In the Consumer Healthcare segment  sales are likely to have been driven by Oral health products and Pfizer s legacy products Earnings WhispersOur proven model does not conclusively show that Glaxo will beat on earnings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to be able to beat estimates  Unfortunately  that is not the case here  as you will see below Earnings ESP  Earnings ESP  which represents the difference between the Most Accurate Estimate  69 cents  and the Zacks Consensus Estimate  70 cents   stands at  1 55   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Glaxo currently has a Zacks Rank  3 GlaxoSmithKline plc Price and Consensus
    A Stock to ConsiderHere is a large drug biotech stock you may want to consider  as our model shows that it has the right combination of elements to post an earnings beat this season Regeneron Pharmaceuticals  Inc    NASDAQ REGN   has an Earnings ESP of  5 39  and a Zacks Rank  3  The company is scheduled to release fourth quarter results on Feb 6  You can see  Free  Zacks  Single Best Stock Set to DoubleToday you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ",2020-02-02,Zacks Investment Research,https://www.investing.com/analysis/is-a-disappointment-in-store-for-glaxos-gsk-q4-earnings-200503988,200503988
219649,441165,PFE,Pfizer posts 9  fall in fourth quarter revenue,news,Pfizer on Tuesday reported lower than expected quarterly profit and a decline in revenue The company s total revenue fell 9  to  12 69 billion in the fourth quarter  with Lyrica sales sinking 68  to  433 million due to competition from generic drugs Revenue was also lower in the absence of any sales from the separated consumer health business ,2020-01-28,CNBC,https://invst.ly/pnuuf,2069287
219650,441166,PFE,Pfizer Stock Falls 3 ,news,"Investing com    Pfizer   NYSE PFE  Stock fell by 3 06  to trade at  38 92 by 09 36  14 36 GMT  on Tuesday on the NYSE exchange 
The volume of Pfizer shares traded since the start of the session was 5 19M  Pfizer has traded in a range of  38 87 to  39 44 on the day 
The stock has traded at  40 9700 at its highest and  38 9200 at its lowest during the past seven days ",2020-01-28,Investing.com,https://www.investing.com/news/stock-market-news/pfizer-stock-falls-3-2069447,2069447
219651,441167,PFE,How Far Will Pfizer Stock Slump ,news,"When Pfizer Inc   NYSE  PFE  released its fourth quarter earnings report before the opening bell Tuesday  the pharmaceutical giant said that it had  0 55 in earnings per share  EPS  and  12 7 billion in revenue  That compared with consensus estimates of  0 57 in EPS and  12 61 billion in revenue  as well as the  0 64 per share and  13 98 billion posted in the same period of last year In terms of the breakdown  Biopharma revenues totaled  10 5 billion  up 9  operationally  primarily driven by Eliquis  Vyndaqel Vyndamax  Ibrance  Inlyta and Prevenar Upjohn revenues were down 32  on an operational basis to  2 2 billion  This move was primarily driven by the expected significant volume declines for Lyrica in the United States due to multisource generic competition that began in July 2019  Excluding the unfavorable impact of Lyrica in the United States and other recent product losses of exclusivity  fourth quarter 2019 revenues for Upjohn declined 6  operationally div connatix margin bottom  1 5em   div connatix img  margin  unset  Looking ahead to the 2020 fiscal full year  the company expects to see EPS in the range of  2 82 to  2 92 and revenue between  48 5 billion and  50 5 billion  The consensus estimates call for  2 90 in EPS and  49 52 billion in revenue for the full year Dr  Albert Bourla  Pfizer s board chair and chief executive  commented 2019 was a busy year  highlighted by solid financial performance  shareholder friendly capital allocation  the strengthening of our pipeline as well as the formation of the Consumer Healthcare JV with GSK  We also announced a definitive agreement to combine Upjohn and Mylan to create a new global pharmaceutical company  Viatris  marking an important milestone in Pfizer s evolution toward becoming a more focused  global leader in innovative medicines Short sellers seemed to be taking a wait and see approach to Pfizer in the most recently reported period  but it remains one of the most shorted Dow Jones industrials Shares of Pfizer were traded down over 3  on Tuesday  at  38 76 in a 52 week range of  33 97 to  44 56  The consensus price target is  42 33  
By Chris Lange",2020-01-28,247wallst,https://invst.ly/pnyp-,2069537
219652,441168,PFE,The 3 Most Important Things to Know About Pfizer s Q4 Earnings Results,news,"Everyone who follows Pfizer  NYSE PFE  expected that 2019 would be a challenging year for the big drugmaker  And it was  The company s blockbuster nerve pain drug Lyrica faced generic competition  with sales quickly plummeting  Pfizer s share price fell 10  last year  while the S P 500 index soared 29  
Pfizer announced its fourth quarter results before the market opened on Tuesday  Here are the three most important things to know about the company s Q4 update  

1  Overall revenue declined  but there are some bright spots
Pfizer s revenue in the fourth quarter fell by 9  year over year to  12 7 billion  There was one major culprit behind the decline  Sales for Lyrica plunged 67   from  1 32 billion in the prior year period to  433 million in the fourth quarter of 2019  Pfizer also reported sales declines for several other drugs  most notably Enbrel  which saw sales fall 21  year over year to  414 million 
But there were some bright spots with Pfizer s Q4 revenue  It topped the consensus analysts  estimate of  12 6 billion  And while overall revenue fell  sales for Pfizer s biopharma segment increased by 7  on a reported basis and 9  operationally to over  10 5 billion 
Sales for the company s top selling product  pneumococcal vaccine Prevnar 13  rose 4  year over year to  1 58 billion  The most impressive growth  though  came from rare disease drug Vyndaqel  with sales skyrocketing from  39 million in the prior year period to  213 million in Q4  Pfizer s top blockbusters also delivered strong growth  Sales for blood thinner Eliquis soared 21  to nearly  1 1 billion  with sales for breast cancer drug Ibrance jumping 13  to  1 28 billion 
2  Earnings were a little below expectations 
With Pfizer s revenue sliding  it came as no surprise that earnings would fall as well  Pfizer reported a net loss of  337 million  or  0 06 per share  based on generally accepted accounting principles  GAAP   The company posted a GAAP net loss of  394 million  or  0 07 per share  in the prior year period 
Pfizer announced adjusted income of  3 1 billion  or  0 55 per share  This was well below the adjusted income of  3 75 billion  or  0 63 per share  posted in the same period in 2018 
CFO Frank D Amelio said that full year results for 2019  met or exceeded all components of our financial guidance   He was right  However  the company didn t quite meet Wall Street s expectations of adjusted earnings per share of  0 57 
3  Complicated guidance
Pfizer provided three different outlooks for full year 2020  Why such complicated guidance  The company plans to spin off its Upjohn unit and merge it with Mylan  Because of this pending transaction  Pfizer gave full year 2020 guidance for the full company as it stands now  for the  new  Pfizer that will remain after the deal is finalized  and for Upjohn by itself 
For the full company  Pfizer projects full year 2020 revenue will be between  48 5 billion and  50 5 billion with adjusted diluted EPS of  2 82 to  2 92  This guidance reflects low single digit percentage declines on both the top and bottom lines 
The picture looks much better for the  new  Pfizer that will emerge after Upjohn is spun off  It expects full year revenue between  40 7 billion and  42 3 billion for the new company  reflecting 8  year over year operational growth at the midpoint of the range  Adjusted diluted EPS is projected to come in between  2 25 and  2 35 
Pfizer expects that full year 2020 revenue for Upjohn will be between  8 billion and  8 5 billion  The midpoint of this range reflects a 23  year over year operational decline  Pfizer didn t provide adjusted EPS guidance for Upjohn  but the company projects that Upjohn s adjusted EBITDA for full year 2020 will fall between  3 8 billion and  4 2 billion 
Looking ahead
As is the case with any pharmaceutical stock  Pfizer s future rests on its pipeline  The company has several important milestones on the way this year for investors to watch 
CEO Albert Bourla said that the company expects to report pivotal top line results in the first half of 2020 for abrocitinib in treating atopic dermatitis  for three late stage studies of 20 valent pneumococcal conjugate vaccine PF 06482077  and for Xeljanz in treating ankylosing spondylitis  Even more late stage results should be on the way in the second half of the year  as well as results from earlier stage clinical studies throughout 2020 
Bourla also said   2020 is expected to be an exciting year for Pfizer with the close of the Upjohn Mylan transaction anticipated by midyear  leaving New Pfizer positioned to deliver revenue and adjusted diluted EPS growth that is expected to be among the industry leaders  New Pfizer will be a smaller  science based company with a singular focus on innovation  while also continuing to allocate significant capital directly to shareholders  primarily through dividends  
Current shareholders will probably like the prospects of stronger revenue and earnings growth  But they ll especially like that the company intends to keep the solid dividends flowing ",2020-01-28,The Motley Fool,https://invst.ly/pnywd,2069553
219653,441169,PFE,Pfizer launches three biosimilars priced for market penetration,news,"Pfizer  PFE  3 7   is launching three biosimilars in the U S  priced aggressively to capture market share 
Zirabev  bevacizumab bvzr   a biosimilar to Roche s  OTCQX RHHBY  0 7   Avastin  was launched on December 31  2019  at a wholesale acquisition cost  WAC  of  61 34 per 10 mg  a 23  discount compared to the WAC of the branded product 
Ruxience  rituximab pvvr   a biosimilar to Roche s Rituxan  was launched today at a WAC of  71 68 per 10 mg  a 24  discount versus the branded version 
Trazimera  trastuzumab qyyp   a biosimilar to Roche s Herceptin  will be available on February 15 at a WAC of  80 74 per 10 mg  a 22  discount versus the branded product 
The WAC of each product does not include discounts to payers  providers  distributors and other purchasing organizations 
Shares are down on the company s Q4 miss ",2020-01-28,Seeking Alpha,https://invst.ly/pnzeu,2069583
219659,441175,PFE,Pfizer EPS misses by  0 03  misses on revenue,news,"Pfizer  NYSE PFE   Q4 Non GAAP EPS of  0 55 misses by  0 03  GAAP EPS of   0 06 misses by  0 59 
Revenue of  12 69B   9 2  Y Y  misses by  40M 
Shares  1 27  PM 
Press Release",2020-01-28,Seeking Alpha,https://invst.ly/pnum2,2069203
219662,441178,PFE,Pfizer misses Q4 consensus,news,"Pfizer  PFE  Q4 results  Revenues   12 688M   9 2    Biopharma   10 532M   7 3    Upjohn   2 156M   32 2   
Internal Medicine   2 365M   1    Oncology   2 466M   24    Vaccines   1 708M   5    Hospital   2 056M   2    Inflammation   Immunology   1 251M   4    Rare Disease   686M   22   
Key Product Sales  Ibrance   1 283M   13    Eliquis   1 099M   21    Prevnar 13 Prevenar 13    1 579M   4    Xeljanz   607M   10    Enbrel   414M   21    Lyrica   433M   67    Lipitor   468M   11    Norvasc   215M   14    Sutent   231M   12    Xtandi alliance revenues   244M   26   
Net loss    337M    14 5    loss share    0 06    14 3    non GAAP Net Income   3 108M   17 1    non GAAP EPS   0 55   12 7   
2020 Guidance  Revenues   48 5B   50 5B vs  estimates for  49 6B  non GAAP EPS   2 82   2 92 vs  estimates for  2 90 
Shares are down 1  premarket 
Previously  Pfizer EPS misses by  0 03  misses on revenue",2020-01-28,Seeking Alpha,https://invst.ly/pnuxo,2069222
219663,441179,PFE,Pfizer s stock falls after profit misses expectations  while revenue was in line,news,"Shares of Pfizer Inc  

                            
                            
                                  
      
      
      
      
      
      
      
                                  
                                    PFE   1 29 

                            
                                  
      
      
      
      
      
      
      
                                         fell 0 9  in premarket trading Tuesday  after the drug maker reported a fourth quarter profit that missed expectations  while revenue rose in line with forecasts  The company reported a net loss that narrowed to  337 million  or 6 cents a share  from  394 million  or 7 cents a share  in the year ago period  Excluding non recurring items  adjusted earnings per share fell to 55 cents from 63 cents  below the FactSet consensus of 58 cents  Sales fell 9  to  12 69 billion to match the FactSet consensus  as biopharma sales rose 7  to  10 53 billion and Upjohn sales dropped 32  to  2 16 billion  For 2020  Pfizer expects adjusted EPS to be  2 82 to  2 92  surrounding the FactSet consensus of  2 90  and revenue of  48 5 billion to  50 5 billion  compared with expectations of  49 6 billion  The stock has rallied 7 7  over the past three months through Monday  while the Dow Jones Industrial Average 

                            
                            
                                  
      
      
      
      
      
      
      
                                  
                                    DJIA   0 38 

                            
                                  
      
      
      
      
      
      
      
                                         has gained 5 3  




  div gpt ad 1569967089584 0   div   iframe   width  100   important   min width  300px  max width  800px   ",2020-01-28,MarketWatch,https://invst.ly/pnux-,2069226
219666,441182,PFE,Pfizer to offer generic Viagra through digital health clinic,news,"Pfizer  NYSE PFE  subsidiary Greenstone inks a supply agreement with Roman  a digital healthcare clinic for men  to offer its authorized generic version of Viagra  sildenafil citrate  to Roman members 
The product will be manufactured in Europe in the same facilities that make branded Viagra ",2020-01-23,Seeking Alpha,https://invst.ly/plvc0,2065919
219667,441183,PFE,Pfizer to Market Viagra Through Roman s Telehealth Service,news,"Pfizer  NYSE PFE  will provide patients of Roman  a men s health subsidiary of the privately held digital health company Ro  with the only Pfizer authorized generic version of Viagra  a blockbuster erectile dysfunction treatment 

Under the deal  Pfizer s U S  generic subsidiary  Greenstone  will provide generic Viagra to Roman patients following a telehealth consultation with one of Roman s licensed physicians  This is the first time that Greenstone is collaborating with a direct to patient health company 
Viagra won Food and Drug Administration approval in 1998 and it grew into one of the world s best selling medications  with global sales in excess of  2 billion at their peak in 2012  Generic drugmakers  including Teva Pharmaceutical  NYSE TEVA  and Mylan  NASDAQ MYL  have been marketing generic versions of the drug since 2018  but Greenstone is the only manufacturer authorized to produce pills in the same plant as Pfizer s brand name drug  In Q3  2019  Pfizer reported global Viagra revenue of  120 million  including  20 million in the United States  
The agreement is significant because men are 24  less likely to go to a doctor over a one year period than women and according to the companies  only one quarter of the 30 million American men experiencing ED are getting treatment  By providing access to generic Viagra through an online doctor s visit  the companies hope to break down barriers preventing men from consulting with their doctor about ED  while also ensuring patients receive a high quality product  as Viagra is one of the most counterfeited drugs in the world ",2020-01-23,The Motley Fool,https://invst.ly/ply-x,2066207
219681,441197,PFE,Exact Sciences Rides On Cologuard  Eyes Merger Synergies,opinion,On Jan 7 2020  we initiated coverage on Exact Sciences Corporation   NASDAQ EXAS    While we are impressed with the company s steady top line performance  its overdependence on a single brand may be worrisome  The stock currently carries a Zacks Rank  2  Buy  Exact Sciences is a molecular diagnostics company focusing on the early detection and prevention of some of the deadliest forms of cancer  Over the past year  the stock has outperformed its   soaring 51 8   While the industry has risen 10 6  Exact Sciences exhibited a stellar performance with better than expected earnings results in the third quarter of 2019  The company demonstrated strength across its entire business  driven by encouraging performances in its Cologuard business  It is also progressing well in terms of fulfilling its three priorities of 2019  which are strengthening its partnership with Pfizer  NYSE PFE   enhancing Cologuard and advancing its pipeline of blood based cancer diagnostic tests Exact Sciences Corporation Price   In this regard  the company is confident about capturing at least 40  of the U S  colorectal cancer screening market  showing a sharp rise from about 5  now  This is possible on the back of strong sales teams  alliance with Pfizer  an innovative marketing campaign and deep payer relationships providing a powerful commercial organizational support to Cologuard s growth  Pfizer tie up has been valuable in driving Cologuard s adoption We are currently looking forward to Exact Science s recently closed merger with advanced molecular diagnostics company Genomic Health  which combined two of the strongest brands in cancer diagnostics  namely Cologuard and OncotypeDX  thus bolstering growth On an adjusted basis  the combined entity is projected to generate revenues of  1 6 billion and a gross profit of  1 2 billion in 2020  Annualized cost synergies of approximately  25 million are expected within the third year from the completion date of the deal  primarily via reduction of public company costs and purchase optimization On the flip side  escalating expenses are putting pressure on the company s operating margin  Excessive reliance on Cologuard and competitive headwinds persist as major downsides Other Stocks Worth a LookA few other top ranked stocks from the broader medical space are Haemonetics Corporation   NYSE HAE    West Pharmaceutical Services   NYSE WST   and Omnicell   NASDAQ OMCL    While Haemonetics sports a Zacks Rank  1  Strong Buy   the other two carry the same top Zacks Rank as Exact Sciences  You can see Haemonetics has an estimated long term earnings growth rate of 13 5  West Pharmaceutical Services has an anticipated long term earnings growth rate of 14  Omnicell has a long term earnings growth rate of 12 5  Just Released  Zacks  7 Best Stocks for TodayExperts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 6  per year These 7 were selected because of their superior potential for immediate breakout ,2020-01-06,Zacks Investment Research,https://www.investing.com/analysis/exact-sciences-rides-on-cologuard-eyes-merger-synergies-200496964,200496964
219682,441198,PFE,Is Pfizer  PFE  Stock Outpacing Its Medical Peers This Year ,opinion,"Investors focused on the Medical space have likely heard of Pfizer  PFE   but is the stock performing well in comparison to the rest of its sector peers  A quick glance at the company s year to date performance in comparison to the rest of the Medical sector should help us answer this question 
Pfizer is a member of our Medical group  which includes 908 different companies and currently sits at  2 in the Zacks Sector Rank  The Zacks Sector Rank considers 16 different sector groups  The average Zacks Rank of the individual stocks within the groups is measured  and the sectors are listed from best to worst 
The Zacks Rank is a successful stock picking model that emphasizes earnings estimates and estimate revisions  The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months  PFE is currently sporting a Zacks Rank of  1  Strong Buy  
Within the past quarter  the Zacks Consensus Estimate for PFE s full year earnings has moved 1 50  higher  This signals that analyst sentiment is improving and the stock s earnings outlook is more positive 
Our latest available data shows that PFE has returned about 0 79  since the start of the calendar year  Meanwhile  stocks in the Medical group have gained about 0 76  on average  This shows that Pfizer is outperforming its peers so far this year 
Looking more specifically  PFE belongs to the Large Cap Pharmaceuticals industry  which includes 14 individual stocks and currently sits at  48 in the Zacks Industry Rank  Stocks in this group have gained about 0 45  so far this year  so PFE is performing better this group in terms of year to date returns 
PFE will likely be looking to continue its solid performance  so investors interested in Medical stocks should continue to pay close attention to the company ",2020-01-12,Zacks Investment Research,https://www.investing.com/analysis/is-pfizer-pfe-stock-outpacing-its-medical-peers-this-year-200498382,200498382
219683,441199,PFE,Is Pfizer s Stock a Buy ,news,"Pfizer  NYSE PFE  is one of the top pharmaceutical companies in the world  With more than  50 billion in annual sales and profits of more than  16 billion over the trailing twelve months  the company offers investors a great deal of stability  The problem is that its business has shown minimal growth in recent years  While its dividend may attract investors looking for recurring income  it may be a struggle to find another reason to buy shares of Pfizer today  However  recent developments could make the company much more investable in the near future 
Changes to the business could improve its growth rate
There are two big moves the company is making that will change how the stock looks and that should improve its growth rate as well 
The first is the spinoff of its Upjohn division  which encompasses the company s off patent medicine  The division will merge with another drug manufacturer  Mylan  Upjohn contributed  8 1 billion to the company s top line over the past nine months  or one fifth of the  39 1 billion in sales that Pfizer earned over that time  but that s down 13  from the  9 3 billion that the segment generated over the prior year period  Spinning off the business will allow Pfizer to focus on products that are exhibiting more growth  like breast cancer drug Ibrance  which has seen its sales rise 23  year to date  Eliquis  which treats blood clots  has also seen impressive year over year sales growth of 24  

Another change for Pfizer comes with its consumer healthcare business combining forces with GlaxoSmithKline in a joint venture  effective Jul  31  2019  It isn t a big segment of Pfizer s business  as its 2018 sales from consumer healthcare totaled just  3 6 billion  which is a relatively small chunk of the  53 6 billion in revenue it generated during the year  It didn t show much growth  either  rising just 3 8  from the prior year  
By shifting its focus onto products that are core to its business and that have been exhibiting more growth  Pfizer s stock becomes more valuable in the process  While sales for Pfizer will look smaller  its growth rate may actually improve  Revenue in the third quarter was down 4 6   while year to date totals are down around 1 5  
But will it be enough to attract growth investors 
Although Pfizer will be cutting some low performing segments out of the stock s financial results  what s left may still not be enough to make the company an attractive buy from a growth perspective  In Q3  the company s biopharma segment  which accounts for 80  of its top line  was up just 7 3  from the prior year quarter  while year to date figures show even less impressive growth   4 1   Aside from its oncology products  where sales were up 28  in Q3  there aren t a whole lot of reasons for growth investors to get excited 
That makes Pfizer primarily a buy for those investors who are looking for a recurring payout and a bit of stability as well  The low volatility stock currently pays its shareholders a quarterly dividend of  0 38  The company recently hiked its dividend payments from  0 36 and the dividend yield is now up to 3 9   well above the 1 85  that the S P 500 averages  While it s not a Dividend Aristocrat  Pfizer has been raising its payouts consistently since 2010 
Is the stock a buy 
If you re looking for a solid dividend stock to buy and hold  Pfizer could be a good option for your portfolio  And with better prospects for growth moving forward  the stock may perform better than it has over the past five years    rising just 18   far below the S P 500  which is up 62  over the same period 
But with higher yielding dividend stocks out there and better options available for growth  there isn t an overly compelling reason to buy Pfizer today  especially with all the changes that the company is undergoing  Until Pfizer can show some strong  sustainable growth  investors may want to look elsewhere  at other healthcare stocks to invest in ",2020-01-14,The Motley Fool,https://invst.ly/phtb6,2058798
219684,441200,PFE,Why Pfizer Stock Fell 10 2  in 2019,news,"What happened
Pharmaceutical mega titan Pfizer  NYSE PFE  lost an eye catching 10 2  of its value over the course of 2019  according to data from S P Global Market Intelligence  Investors avoided this top drugmaker last year for two major reasons 
First  the drugmaker s decision to spin off its generic drug business  known as Upjohn  and merge it with Mylan  was not a big hit with Wall Street  Although this strategic move will remove a key overhang in the form of ongoing patent losses  it will also significantly reduce the company s free cash flow  lessening its firepower for value creating business development transactions 
Second  Pfizer s top selling pain medication  Lyrica  officially began facing generic competition in the middle of 2019  Unsurprisingly  its sales plummeted during the third quarter   

So what
Wall Street rarely likes major shake ups  especially when they are undertaken by industry stalwarts like Pfizer  Pfizer  however  clearly needed to change course  Despite the drugmaker s successful pivot to oncology as a main growth driver  it simply hasn t been able to generate healthy levels of top line growth on a consistent basis due to an avalanche of patent expiries  The spin off of its generic drug business should immediately remedy that fundamental problem  In fact  management expects the company s revenues to rise by an average of 6  annually for the period from 2021 through 2025     
Now what
Is Pfizer s stock worth buying after last year s double digit pullback  The answer is a resounding yes  The fact of the matter is that this pharmaceutical giant should be a far more compelling growth play than it has been in years past  thanks to management s decision to finally execute a much needed split ",2020-01-16,The Motley Fool,https://invst.ly/piw9x,2061180
219696,441212,PFE,Is Pfizer Raising Drug Prices Too Much in 2020 ,news,"Ahead of election years  the cost and future of health care has become one of the top debates for better than two decades now  Most politicians say that they want to lower prescription drug costs  The only problem is that it never really seems to happen on a measurable basis  A study from Rx Savings Solutions showed that pharmaceutical companies have issued price hikes on hundreds of drugs for 2020  While the average price increase of 5 8  was less than the average price hike of just over 6  seen a year earlier  some companies are targeting higher price hikes than others Pfizer Inc   NYSE  PFE   which saw its stock lose 10  in 2019 versus the 28  gain for the S P 500  appears to be among the companies with the largest price hikes for prescription drugs in 2020  The data are from outside sources  and investors and consumers should keep in mind that some price hikes on the list prices may not be true price hikes after considering rebates and or other discounts Pfizer was shown to have raised prices by more than 9  on over 40 pharmaceutical products for 2020  Pfizer was also shown to have price hikes of about 5 6  on about 27  of the drugs it sells in the United States  and prices were higher in 2020 on more than 90 drugs div connatix margin bottom  1 5em   div connatix img  margin  unset  The WSJ reported that nearly half of the drugs with price hikes were classified as sterile injection drugs which are typically administered in hospitals and in medical clinics  with the majority being a hike of less than  1 00 per product dose A further executive summary of the CPI RX from the White House in October 2019 showed that  as of August 2019  the annualized price change in drug prices had been  0 7  from a year earlier  The White House document also warned that there is no formal way of tracking net net drug price changes due to the complexities and variables  It said The most informative measure of prescription drug prices would be based on net prices and would reflect all discounts and rebates  However  due to the difficulty in obtaining information on rebates  no such measure exists Heparin products  which are blood thinners  were shown to have price hikes of 15   and that is after a 50  increase in the costs of its raw materials and expanded capacity to meet demand  The African swine flu in China was shown to have a hand in the cost of materials as the drug is derived from pig products  although Pfizer s U S  heparin supply is not shown to be sourced from China In a prior blog post  Rx Savings Solutions discussed the Consumer Price Index Prescription Drug Index  CPI Rx  as an overall inflation measurement of drug prices  Unfortunately  this is only a partial guide as the CPI Rx is shown to not include specialty drugs and that the CPI Rx also does not accurately measure what insurers pay  These so called list prices on drugs also do not take into consideration rebates and discounts and the group showed that some pharmaceutical companies are claiming that their prices are lower An opinion piece from NBC showed that Big Pharma greed is to blame for the industry s price hikes  and that the status quo is unhealthy for anyone except pharmaceutical company executives In the case of Pfizer  the company was shown to have its price hikes offset by higher rebates paid to insurance companies and to sales organizations  Pfizer has come under fire from President Trump back in 2018 after raising prices at that time  and the company ended up rolling back those price hikes before reinstating them Pfizer s loss of 10  in 2019 was versus a 19  gain for rival Merck and was versus a 25  gain for the SPDR S P Pharmaceuticals ETF  XPH   As of the start of 2020  Pfizer s Refinitiv consensus analyst target price of  41 91 implied a total return projection of 10 9  after taking its 3 9  dividend yield into consideration  That said  the 10  drop in 2019 was after a 20 5  gain in 2018 and the consensus data a year ago had been calling for upside of about 7 1  
By Jon C  Ogg",2020-01-02,247wallst,https://invst.ly/pcm29,2051517
219697,441213,PFE,Why Pfizer Is My Drug Stock of Choice,news,"With the market at all time highs and a  risk on  mentality perhaps more common than not  the pharmaceutical space might not seem like the most opportune sector in which to be on the prowl  However  there is a name in the industry that I sense deserves more than a passing glance  and that s Pfizer  NYSE PFE  
What makes the drug giant worth a gander  A couple of things stand out 

Expectations are low  but the future is promising
A quick look at consensus analyst figures shows that investors aren t expecting anything extraordinary on the earnings front in the near future  In fact  analysts are calling for the company to earn  2 97 per share this year  down 1  from the prior year  and that trend is set to continue with expected 2020 earnings down another 8  
I know what you re thinking    that s hardly inspiring  But I m still upbeat when it comes to Pfizer s future earnings potential  especially given its development pipeline and storied history of blockbuster products 
As far as its current drug pipeline is concerned  as of Oct  29th  it had 96 products in varying stages of development  And of that number  there were 37 and 24 products in Phase II and or Phase III trials  respectively  some of which may bear fruit in the not too distant future  For example  Abrocitinib is a Phase III product for atopic dermatitis  or what s more commonly known as eczema  The company noted in its third quarter earnings release 

In October 2019  Pfizer announced complete results from a Phase 3  12 week  pivotal study  JADE MONO 1  in patients aged 12 and older with moderate to severe atopic dermatitis  AD   Abrocitinib  an investigational oral Janus kinase 1  JAK1  inhibitor  met all the co primary and key secondary endpoints  which were related to skin clearance and itch relief compared to placebo 

For a condition that s estimated to affect as many as 10  of adults and 20  of children worldwide  this is just one example of the significant markets Pfizer can serve with the products in its pipeline  For a company that generated over  53 billion in revenue in the trailing 12 month period  that s got my attention 
So what is the company s cache of products worth 
Given the competitive landscape and the fact there are always unexpected costs and risks when advancing products through clinical trials  it s hard to quantify  However  my ears perked up when the company declared earlier in the year that there could be as many as 15 potential billion dollar drugs it says could win approval within the next five years 
Another thing worth mentioning
As of Oct  29  Pfizer had some 42 oncology cancer products in its pipeline  This is important  because as one might surmise  cancer is a serious health concern  And just to put some perspective on how much cancer affects our every day lives  more than 600 000 people in the United States alone were expected to die from the disease in 2018  according to the National Cancer Institute  And more than 1 7 million cases were expected to be diagnosed  In short  Pfizer is in a good place to help in the fight against this disease for years to come 
Also investors should remember that Pfizer has a strong track record  Ever heard of Lipitor  Xanax  Dilantin  Viagra  or Zoloft  They all fall under the Pfizer product umbrella  not to mention everyday consumer products like ChapStick  Centrum  and Advil  All are part of the company s arsenal 
In nutshell  Pfizer has a history of managing blockbuster products  and I d wager that a respectable number of those 96 products in development could ultimately end up being household names as well 
The dividend provides a bit of a cushion
To be clear  Pfizer s dividend isn t some massive  double digit behemoth  But the stock does sport a generous yield approaching 4  as of this writing  Also  I d be remiss if I didn t point out that the company has impressively grown its dividend since 2010 

Data by YCharts 
Now  as the old saying goes  past performance is not necessarily indicative of future results  and Pfizer s payouts will change shape following the expected Upjohn and Mylan combination  But I d argue that the track record is still impressive given the economic backdrop  particularly in the early part of the decade and the capital intensive nature of the pharmaceutical business in general  A quick look at the company s cash flows also leaves me optimistic that it has flexibility to keep rewarding shareholders going forward 
Pfizer isn t expected to grow leaps and bounds in the near term    that much is clear  But it does have a strong existing portfolio of big names  plus a sizable pipeline of products that will drive the company s growth over the next decade  With a solid dividend yield that can also serve as a cushion should the broad market experience a pullback  which is not beyond the realm of possibility given its trajectory over the last 12 months  ignore Pfizer at your own risk ",2020-01-10,The Motley Fool,https://invst.ly/pgft4,2056891
219711,441227,PFE,Epizyme  EPZM  Shares Soar On Lead Candidate s Progress,opinion,Shares of Epizyme Inc    NASDAQ EPZM   have soared 246 2  year to date compared with the  s growth of 10 3    The company s lead pipeline candidate is tazemetostat  a first in class EZH2 inhibitor  which is currently being evaluated for the treatment of solid tumors and hematological malignancies as a monotherapy  and to treat relapsed and front line diseases as a combination therapy In December  the Oncologic Drugs Advisory Committee  ODAC  of the FDA unanimously voted  11 0  in favor of the benefit risk profile of tazemetostat as a treatment for patients with metastatic or locally advanced epithelioid sarcoma  ES  that is not eligible for curative surgery  ES is a rare and serious soft tissue sarcoma  STS   with a high rate of local recurrence and distant metastasis The committee s positive vote gives a positive signal to the candidate  The new drug application  NDA  for tazemetostat is currently under Priority Review with the FDA  with an action date of Jan 23  2020  The NDA was supported by data from the ongoing phase II study in patients with molecularly defined solid tumors  The company is confident that the comprehensive clinical data package for ES  which it has submitted  will support tazemetostat s approval If approved  tazemetostat will be the first treatment for patients with ES  This is expected to significantly benefit the company  It will also be the first commercial product for Epizyme  which will enable it to realize sales  This should boost the company s growth prospects Tazemetostat is being evaluated in multiple indications Notably  the company also submitted an NDA to the FDA in December for accelerated approval of the drug for the treatment of patients with relapsed or refractory follicular lymphoma  FL   both with or without EZH2 activating mutations  who have received at least two prior lines of systemic therapy  The submission is based primarily on updated phase II efficacy and safety data on tazemetostat in this patient population To support the full approval of tazemetostat for FL  Epizyme is conducting a single  global  randomized  adaptive study  The company is evaluating the chemo free combination of Roche s   OTC RHHBY   Rituxan and Revlimid with tazemetostat compared to the combo with placebo in patients with relapsed or refractory FL  The study is expected to enroll 500 FL patients  stratified based on their EZH2 mutation status Moreover  the company is exploring tazemetostat to increase the clinical activity of immuno oncology therapies by combining with an anti PD 1 or PDL 1 agent  Under its collaboration with Roche  Epizyme is evaluating tazemetostat in a combination with anti PD L1 cancer immunotherapy  Tecentriq  for the treatment of patients with relapsed or refractory diffuse large B cell lymphoma  DLBCL  to determine the recommended phase II dose and advance into the expansion portion of the study In addition  the European Commission granted orphan drug designation to tazemetostat for the treatment of patients with FL  DLBCL and malignant mesothelioma The potential approval of tazmetostat will significantly boost Epizyme s growth prospects Epizyme also aims at completing IND enabling studies on EZM8266  its G9a inhibitor designed to treat patients with sickle cell disease  SCD   It is on track to begin the clinical development of the candidate soon  with a dose finding and safety study Epizyme s proprietary product platform is used to create small molecule inhibitors of a class of enzymes known as histone methyltransferases  HMTs   However  the company faces competition from the likes of Glaxo  Novartis   NYSE NVS    Pfizer   NYSE PFE   and Constellation  which are developing new epigenetic treatments for cancer targeting HMTs Epizyme currently carries a Zacks Rank  2  Buy   You can see  Epizyme  Inc  Price    5 Stocks Set o DoubleEach was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ,2019-12-25,Zacks Investment Research,https://www.investing.com/analysis/epizyme-epzm-shares-soar-on-lead-candidates-progress-200494945,200494945
219712,441228,PFE,Novartis s  90 million Swiss factory to help solve cell therapy bottleneck,news,"By John Miller
ZURICH  Reuters    Swiss drugmaker Novartis s  S NOVN  new  90 million cell and gene therapy factory in northern Switzerland is on track to begin commercial production of treatments  including Kymriah for cancer and Zolgensma for spinal muscular atrophy  in 2020 
The new gene and cell therapy factory  expected to employ 450 people  will allow the drugmaker to make its Kymriah treatment for European patients without first having to fly their immune cells across the Atlantic Ocean 
The Swiss factory  as well as a separate French site also being expanded  are central to Novartis s plans to transform Kymriah from a modest  250 million per year seller into a  1 billion blockbuster as European demand rises 
 We have already started to produce clinical batches at both sites and are on track to begin producing commercial product in 2020    Novartis  said 
Basel based Novartis sees cell and gene therapies eventually contributing about 15  of its revenue 
T cells currently harvested from Europeans getting the  400 000 per patient Kymriah blood cancer therapy currently must be sent to a U S  laboratory for re engineering  Analysts have called the lack of manufacturing capacity a  major bottleneck  
Novartis is investing some  500 million in new facilities around the world to address production bottlenecks and drug companies including Novartis   Pfizer   N PFE  and others  have plans to spend  2 billion building out gene and cell therapy manufacturing after rapid expansion into these treatments 
Novartis will also make Zolgensma at the Swiss and French factories  a  2 1 million per patient spinal muscular atrophy gene therapy awaiting European and Japanese approval 
Kymriah s global rollout in 20 countries  plus Novartis s efforts to expand the therapy s indications  make adding commercial production a priority  including in China and Japan 
Kymriah s 2018 approval was hailed as a breakthrough as a last ditch treatment for acute lymphoblastic leukemia and diffuse large B cell lymphoma  T cells are extracted from patients  modified to attack their cancer  then re infused in the hope they work where other treatments failed 
But its complex production  tailor made for each patient  poses logistical challenges compared to off the shelf treatments  especially in Europe where Novartis lacked commercial manufacturing 
 The key factor in bringing local manufacturing to each region is to make Kymriah available as quickly as possible   Novartis said ",2019-11-28,Reuters,https://www.investing.com/news/stock-market-news/novartiss-90-million-swiss-factory-to-help-solve-cell-therapy-bottleneck-2030168,2030168
219723,441239,PFE,J J s Remicade losing ground in Quebec health plan despite court victory,news,By Allison Martell and Allison Lampert TORONTO MONTREAL  Reuters    Johnson   Johnson s Remicade  a blockbuster drug that treats autoimmune disorders  has steadily lost market share among patients enrolled in the Canadian province of Quebec s public drug program  even after a court ruling reinstated full coverage in January  a Reuters analysis of government data shows  The plan s administrator stopped covering Remicade  J J  NYSE JNJ  unit Janssen s version of the drug infliximab  for some new patients in February 2017  in favor of cheap near copies called biosimilars  mainly  Pfizer   NYSE PFE  Inc s version of infliximab  called Inflectra  In January  a Quebec court ordered it to resume coverage  Remicade s eroding market share underscores a gradual shift underway in Canada  where biosimilars have been slowly catching on with doctors and patients  The drug is under pressure elsewhere   in the third quarter  total global sales fell 17 6   Canadian governments have sought to boost the use of biosimilars as they try to bring down drug costs   In case of infliximab  biosimilars  market share rose to 11 4  in January 2019  from 0 7  in February 2017  according to Reuters analysis of data provided by the Quebec plan s administrator  the R gie de l assurance maladie du Qu bec  RAMQ    For a graphic on Biosimilars gaining market share in Quebec plan   Resuming coverage of Remicade  as the court ordered  did not reverse Pfizer s gains  By August 2019  13 4  of 2 164 patients were on the biosimilar  a single patient on Merck   Co Inc s biosimilar  Renflexis  with the rest on Pfizer s biosimilar  That left some 86 6  of the market to J J  down from nearly 100   About 3 7 million people are enrolled in the plan  Though Canada has about 2  of global drug sales  it had 16  of Remicade sales in 2017  about C 1 billion   755 8 million   according to the country s Competition Bureau  Janssen said Remicade s re listing was part of its  commitment to preserve patient and physician choice    We strongly believe the use of biosimilars in Canada should be based on what physicians determine is in the best interest of their patients rather than being driven by efforts that restrict treatment choice in any way   the company said in a statement  Janssen said it is proposing agreements with Canadian governments to  provide the cost savings being sought    TOO LATE   Louis Bessette  a rheumatologist and professor at Universit  Laval in Quebec  said doctors in Quebec have gained more experience with biosimilars  and the court ruling did not change his prescribing choices    We prescribe them more and more   he said of biosimilars   I think for Janssen it was too late  and there s no coming back    But Bessette noted that overall  patients are generally unwilling to switch to biosimilars  Those patients look to be the new frontier for Canadian governments  In May  the province of British Columbia said it would require thousands of patients on its public drug plan to switch to biosimilars  Health Canada says biosimilars are just as safe and effective  but some drugmakers and patient groups have pushed back   So far  Quebec has no switching policy  And Pfizer remains frustrated with slow biosimilar uptake in Canada    This slow uptake undermines the potential value that biosimilars can offer and the savings they can bring to the health care system   Pfizer said in a statement   Pfizer said its internal data shows a recent decline in the number of new patients prescribed Inflectra  which the company attributes to the January court ruling  Comparing March to September 2019 to March 2017 to February 2019  they said  new enrollments dropped 30    The RAMQ data obtained by Reuters shows that growth prescriptions for Inflectra and Remicade leveled off in early 2018  It is not clear what is behind this trend  which predates the court ruling   One possible explanation is competition from new drugs  Waqqas Afif  a gastroenterologist at McGill University Health Center in Montreal  said doctors are prescribing Takeda Pharmaceutical Co Ltd s Entyvio and Janssen s Stelara to some patients instead of infliximab  Quebec s health ministry said in a statement it is working on a biosimilar policy but declined to go into detail on the options it is considering ,2019-11-13,Reuters,https://www.investing.com/news/stock-market-news/jjs-remicade-losing-ground-in-quebec-health-plan-despite-court-victory-2019475,2019475
219733,441249,PFE,Iterum Down As Sulopenem Antibiotic Fails In Phase III Study,opinion,"Shares of Iterum Therapeutics plc   NASDAQ ITRM   crashed 35 7  on Dec 11  following the announcement of disappointing data from a phase III study evaluating its antibiotic candidate  sulopenem  The company s shares have decreased 37 8  so far this year against the  s increase of 11 1  The late stage study was evaluating oral and intravenous administration of the candidate in patients with complicated intra abdominal infections  cIAI  compared to Merck s  MRK  Invanz  ertapenem for injection   Data from the study showed that the candidate failed to meet the primary endpoint on non inferiority of clinical response to Invanz as measured on day 28 in the micro MITT population Detailed data showed that 85 5  of the micro MITT patient population achieved a clinical response upon treatment with sulopenem compared to 90 2  for Invanz  The median difference in clinical response was  4 7  for sulopenem  We note that the FDA requires that the lower limit of the difference in the actual outcome rates be   10  to support non inferiority  However  the highest difference in outcomes was measured to be  10 3   Although the study missed the primary endpoint by a very small margin  it will not be able to support an approval for sulopenem as a treatment for patients with cIAI However  Iterum stated in its release that imputing an outcome for the patients with missing data and the secondary supporting analyses demonstrate potential of the candidate in treating multi drug resistant infections Please note that Iterum in licensed sulopenem from Pfizer   NYSE PFE   in 2015 Apart from cIAI  the company is also developing sulopenem for the treatment of complicated and uncomplicated urinary tract infections   UTI    and complicated intra abdominal infections  Separate phase III studies are evaluating the candidate in patients with either complicated or uncomplicated UTI  Data from these studies are expected in the first quarter of 2020  A new drug application seeking approval for sulopenem as a treatment for complicated and uncomplicated UTI is planned to be filed with the FDA in the first half of 2020  following a positive data readout  However  any setback in the UTI phase III studies will bring the share price down further We note that several other pharma biotech companies are also developing candidates targeting UTI patients  including gepotidacin from GlaxoSmithKline   NYSE GSK    tebipenem pivoxil from Spero Therapeutics  Inc    NASDAQ SPRO    delafloxacin from Melinta Therapeutics  Inc   among others  Successful development of these candidates will increase competition for the company  if sulopenem is approved for treating UTI Iterum Therapeutics PLC Price
    Zacks RankIterum currently carries a Zacks Rank  3  Hold   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-12-11,Zacks Investment Research,https://www.investing.com/analysis/iterum-down-as-sulopenem-antibiotic-fails-in-phase-iii-study-200492141,200492141
219734,441250,PFE,Pfizer Rises 3 ,news,"Investing com    Pfizer   NYSE PFE  rose by 3 09  to trade at  38 42 by 09 33  13 33 GMT  on Tuesday on the NYSE exchange 
The volume of Pfizer shares traded since the start of the session was 2 07M  Pfizer has traded in a range of  37 99 to  38 42 on the day 
The stock has traded at  38 4200 at its highest and  36 2200 at its lowest during the past seven days ",2019-10-29,Investing.com,https://www.investing.com/news/stock-market-news/pfizer-rises-3-2006570,2006570
219735,441251,PFE,Ex FDA chief Gottlieb sees investment opportunity in  unloved  antibiotics,news,"By Rebecca Spalding
NEW YORK  Reuters    As a private investor  former U S  Food and Drug Administration Commissioner Scott Gottlieb is focused on an area where few have found success in recent years  developing new antibiotics 
Since leaving the FDA in April  Gottlieb has revealed little about what types of investments he would make in his new role at New Enterprise Associates  one of the country s largest venture capital firms where he worked prior to his time in government 
But in an interview  Gottlieb said he intends to use his expertise to back therapeutic areas that other healthcare investors have overlooked due to concerns over how the treatments are paid for 
Near the top of his list are companies researching new kinds of antibiotics  an issue he advocated for while at the FDA 
 I m very interested in finding opportunities in the anti infective space  particularly around multi drug resistant organisms   Gottlieb said in an interview   Anti infectives have been unloved for a very long time  There s a huge clinical need  
In many ways  it s a contrarian bet  Global health officials have repeatedly warned about the rise of bacteria and other microbes that are resistant to most available drugs  raising the specter of untreatable infectious diseases that could spread rapidly 
But few large drugmakers are researching new medicines that can combat these so called  superbugs  because the economics often work against them  Drugmakers earn more revenue the more drugs they sell  However  antibiotics are more effective the less they are used 
Last year  pharmaceutical giant  Novartis  AG  S NOVN  said it would abandon its antibiotic research  following similar moves made by peers AstraZeneca Plc  L AZN  and Sanofi SA  PA SASY  
 Pfizer  Inc  N PFE   whose board Gottlieb joined in June after leaving government  is one of the few remaining large players still in the space along with GlaxoSmithKline Plc  L GSK   which this week begun late stage testing of an experimental antibiotic in patients with urinary tract infections and gonorrhea 
Smaller players  meanwhile  have struggled to find financing  Achaogen Inc said earlier this year that it would file for bankruptcy despite having brought a novel antibiotic through FDA approval  Tetraphase Pharmaceuticals  Inc  O TTPH  plummeted earlier this month after it gave a disappointing sales forecast for its antibiotic treatment 
Gottlieb said the sector s low valuations create an opportunity to roll up therapies into a larger company focused on making antibiotics 
 After the Achaogen episode  a lot of valuations have been driven down quite dramatically  I think there s an opportunity to try to find some existing assets and maybe build a company around those assets   he said 
 That s what I think I d be interested in doing   Gottlieb said   There are other investors that are interested in this as well  I think the capital is out there to do that  
While at the FDA  Gottlieb advocated finding new ways to pay for antibiotics  such as a licensing model that would charge hospitals upfront for access to new kinds of anti infective drugs rather than paying for them on a per unit basis 
In the past  Gottlieb was criticized over potential conflicts of interest between his government and private sector work  including an investment in Kure Corp  a privately held vaping company  Gottlieb promised to divest that interest prior to joining the FDA  where he assumed oversight of the burgeoning e cigarette market ",2019-10-29,Reuters,https://www.investing.com/news/stock-market-news/exfda-chief-gottlieb-sees-investment-opportunity-in-unloved-antibiotics-2007065,2007065
219744,441260,PFE,Why Is Pfizer  PFE  Up 0 4  Since Last Earnings Report ,opinion,"It has been about a month since the last earnings report for Pfizer  PFE   Shares have added about 0 4  in that time frame  underperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Pfizer due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important catalysts  Pfizer Q3 Earnings   Sales Beat  Ups EPS ViewPfizer beat estimates for both earnings and sales in the third quarter while raising its guidance for earnings and tightening the same for revenues Third quarter 2019 adjusted earnings per share of 75 cents beat the Zacks Consensus Estimate of 63 cents  Earnings declined 2  year over year due to lower revenues and higher taxes  which offset the impact of lower costs in the quarter  Currency changes had a negative impact of 2 cents per share on adjusted earnings Revenues of  12 68 billion beat the Zacks Consensus Estimate of  12 15 billion  Revenues declined 5  from the year ago quarter on a reported basis  On an operational basis  excluding the 2  negative impact of currency  revenues declined 3  year over year as higher sales of some key brands in Pfizer s Biopharmaceuticals group was offset by a decline of revenues in the Upjohn segment  The segment was hurt mainly by the loss of Lyrica exclusivity in July 2019 in the United States Excluding the spin off of the Consumer Healthcare unit  third quarter revenues were flat operationally International revenues declined 2  to  6 83 billion  However  on an operational basis  international sales rose 2  in the quarter  U S  revenues declined 8  to  5 85 billion Adjusted selling  informational and administrative  SI A  expenses declined 7   operationally  in the quarter to  3 2 billion  Adjusted R D expenses declined 2  to  1 94 billion Segment DiscussionPfizer Biopharma sales grew 7  on a reported basis  up 9  an operational basis  from the year ago period to  10 1 billion driven by volume growth  Higher sales of brands like Eliquis  Ibrance  Inlyta and Xeljanz  and a strong emerging markets performance  up 15   drove this segment s sales growth  Weaker sales of Prevnar 13 Prevenar 13 and Enbrel internationally offset the increase Within the Biopharma group  Oncology revenues increased 30   on an operational basis  to  2 35 billion  Vaccine revenues declined 1  to  1 81 billion  Internal Medicine rose 3  to  2 21 billion  The Inflammation   Immunology franchise rose 6  to  1 23 billion  The portfolio of Rare Disease rose 16  to  601 million  The newly added Hospital sub segment s sales rose 6  to  1 92 billion Pfizer s Upjohn group s sales declined 28   down 26  on an operational basis  to  2 2 billion mainly due to U S  loss of exclusivity of Lyrica in July 2019  Excluding the unfavorable impact of Lyrica in the United States  Upjohn sales declined 6  operationally as continued generic competition for certain off patent products offset sales growth in China Revenues from the Consumer Healthcare unit declined 55   54  on an operational basis  to  377 million as a result of the completion of the JV transaction with Glaxo  Consumer Healthcare s third quarter revenues reflect only one month of domestic operations and two months of international operations Performance of Key DrugsIbrance revenues rose 27  year over year to  1 28 billion on continued strong uptake in international markets and consistent growth in the United States Xeljanz sales rose 40  to  599 million driven by continued growth in rheumatoid arthritis  RA  revenues and contributions from the drug s 2018 launches for psoriatic arthritis and ulcerative colitis in the United States and only ulcerative colitis indication in certain developed markets In July  Xeljanz s prescribing information in the United States was updated by the FDA to include two additional boxed warnings as well as changes to the indication and dosing for UC following review of a post marketing study  Regarding this update  Pfizer mentioned on the call that it was not sure how the label update will affect prescribing trends of the drug in the future quarters Inlyta revenues increased 98  to  139 million driven mainly by 240  growth in the United States  U S  sales gained from increased uptake resulting from recent FDA approvals for the combination of Inlyta plus Bavencio and Inlyta plus Keytruda in first line treatment of advanced renal cell carcinoma patients Global Prevnar 13 Prevenar 13 revenues declined 3  to  1 60 billion  Prevnar 13 revenues declined 7  in the United States  reflecting decreased government purchases for the pediatric indication and continued decline in revenues for the adult indication  Prevenar 13 revenues rose 7  in international markets Meanwhile  owing to some unfavorable revisions in ACIP s pneumococcal vaccination guidelines for Prevnar 13 in adults in the United States  there may be some decline in demand for Prevnar  which can hurt sales in the future quarters Enbrel revenues declined 19  to  415 million in key European markets due to continued biosimilar competition Xalkori sales rose 5  to  130 million  Sutent sales declined 7  to  224 million  Eliquis alliance revenues and direct sales rose 20  to  1 03 billion  Chantix sales rose 7  to  276 million in the quarter  Xtandi recorded alliance revenues of  225 million in the quarter  up 25  year over year Importantly  new drug Vyndaqel  which was launched in the United States in May 2019 for the treatment of the transthyretin amyloid cardiomyopathy  recorded sales of  156 million in the quarter with  79 million in the United States Total biosimilar revenues were  236 million  up 22  year over year  Inflectra  Remsima recorded sales of  155 million globally  down 5  year over year  New biosimilar product  Retacrit  a biosimilar of Epogen and Procrit  is off to a good start in the United States  recording  64 million of revenues in the third quarter of 2019 versus  30 million in the second quarter In sterile injectables  global revenues increased 3  operationally and U S  revenues increased 1  operationally as Pfizer s manufacturing recovery efforts start taking shape In the Upjohn segment  sales of key drug Lyrica declined 57  to  527 million due to multi source generic competition that began in July 2019  Viagra sales declined 11  to  120 million due to generic competition that began in December 2017 2019 GuidancePfizer raised its previously issued 2019 guidance for earnings while tightening its range for revenues  Expectations for better operational growth were offset by more onerous currency headwinds than guided previously  Foreign exchange is expected to have an unfavorable impact of  1 4 billion on revenues and 10 cents on adjusted EPS for the year  which indicates more onerous negative impact than guided previously Revenues are expected in the range of  51 2 billion to  52 2 billion compared with  50 5 billion to  52 5 billion expected previously  Adjusted earnings per share are expected in the range of  2 94  3 00 versus the previous expectation of  2 76  2 86 Research and development expense is expected in the range of  7 7  8 1 billion versus  7 9  8 3 billion while SI A spending is projected in the range of  13 5  14 0 billion versus  13 0  14 0 billion expected earlier  Adjusted tax rate is still expected to be approximately 16  in 2019 
How Have Estimates Been Moving Since Then 
It turns out  estimates review have trended upward during the past month  The consensus estimate has shifted 8 18  due to these changes 
VGM Scores
Currently  Pfizer has a poor Growth Score of F  however its Momentum Score is doing a lot better with an A  Charting a somewhat similar path  the stock was allocated a grade of B on the value side  putting it in the second quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of C  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been trending upward for the stock  and the magnitude of these revisions looks promising  It comes with little surprise Pfizer has a Zacks Rank  2  Buy   We expect an above average return from the stock in the next few months ",2019-11-27,Zacks Investment Research,https://www.investing.com/analysis/why-is-pfizer-pfe-up-04-since-last-earnings-report-200488699,200488699
219745,441261,PFE,Italy business leaders urge government to restore investment scheme,news,"By Valentina Za and Giancarlo Navach
CERNOBBIO  Italy  Reuters    Italian business leaders called on the country s new government on Friday to restore incentives for investment and to support economic growth  while keeping public finances in check 
The country s economy flirted with recession under the previous ruling coalition  which collapsed last month after infighting and repeated confrontations with Brussels over increased budget spending 
Business leaders gathered on the shores of Lake Como for the annual Ambrosetti forum were cautiously hopeful that conditions could improve under the new coalition between the center left Democratic Party  PD  and anti establishment 5 Star Movement 
 This government will definitely do more than the previous one  that s not at all hard   said Alberto Bombassei  chairman of brake maker Brembo  urging the executive to unblock public works 
Italy s investment spending is equivalent to 2  of gross domestic product  a third less than at the start of the decade  Private investments are also below pre crisis levels having shrunk by 30  between 2007 and 2013  according to the Bank of Italy 
Businesses said they hoped for a new version of an incentive scheme for investment and innovation introduced by the former center left government  which was phased out by the recently collapsed coalition in order to raise money to send people into early retirement and provide a basic income for the poor 
 The government needs to pay closer attention to both foreign and domestic investments in the country   said Claudio Brandolino  chief financial officer at the Italian arm of French IT services firm Atos 
 The Industry 4 0 package was a good starting point   he said in reference to the center left s incentive scheme 
The PD 5 Star coalition  however  has little room for maneuver  It must cut spending or find alternative revenues for 23 billion euros to defray a scheduled sales tax increase next year  which businessmen in Cernobbio said had to be avoided at all costs 
It has promised the 2020 budget  a draft of which must be presented to Brussels by mid October  will be expansionary without jeopardizing public finances 
Fiscal discipline is necessary to keep the cost of refinancing Italy s 2 3 trillion euro public debt near the record lows it hit this week when markets welcomed the new pro European government 
 The fall in  bond yield  spreads is a positive sign  but public debt must be reined in   said Andrea Costantini  vice president of Agrati Group  a family owned maker of fastening systems for the automotive sector based north of Milan 
With a question mark hanging over how workable a coalition comprising two former bitter enemies will turn out to be  the desire for political stability topped some people s wish list 
 Political stability is the key element for foreign investments  even more than incentives which you could not otherwise be sure are there to stay    Pfizer   NYSE PFE  Italia CEO Massimo Visentin said ",2019-09-06,Reuters,https://www.investing.com/news/economic-indicators/italy-business-leaders-urge-government-to-restore-investment-scheme-1972504,1972504
219763,441279,PFE,Pfizer Falls 3 ,news,"Investing com    Pfizer   NYSE PFE  fell by 3 04  to trade at  36 83 by 12 56  16 56 GMT  on Monday on the NYSE exchange 
The volume of Pfizer shares traded since the start of the session was 18 07M  Pfizer has traded in a range of  36 84 to  37 82 on the day 
The stock has traded at  43 1700 at its highest and  36 8300 at its lowest during the past seven days ",2019-08-05,Investing.com,https://www.investing.com/news/stock-market-news/pfizer-falls-3-1945814,1945814
219764,441280,PFE,Pfizer Falls 3 ,news,"Investing com    Pfizer   NYSE PFE  fell by 3 05  to trade at  35 24 by 13 00  17 00 GMT  on Monday on the NYSE exchange 
The volume of Pfizer shares traded since the start of the session was 15 08M  Pfizer has traded in a range of  35 22 to  36 32 on the day 
The stock has traded at  38 5400 at its highest and  35 2300 at its lowest during the past seven days ",2019-08-12,Investing.com,https://www.investing.com/news/stock-market-news/pfizer-falls-3-1952854,1952854
219771,441287,PFE,Pfizer Falls 3 ,news,"Investing com    Pfizer   NYSE PFE  fell by 3 02  to trade at  41 78 by 15 09  19 09 GMT  on Monday on the NYSE exchange 
The volume of Pfizer shares traded since the start of the session was 43 48M  Pfizer has traded in a range of  41 75 to  43 00 on the day 
The stock has traded at  43 2300 at its highest and  41 7500 at its lowest during the past seven days ",2019-07-29,Investing.com,https://www.investing.com/news/stock-market-news/pfizer-falls-3-1937975,1937975
219772,441288,PFE,Pfizer Falls 7 ,news,"Investing com    Pfizer   NYSE PFE  fell by 6 61  to trade at  38 70 by 15 10  19 10 GMT  on Tuesday on the NYSE exchange 
The volume of Pfizer shares traded since the start of the session was 75 00M  Pfizer has traded in a range of  38 64 to  40 20 on the day 
The stock has traded at  43 2300 at its highest and  38 6300 at its lowest during the past seven days ",2019-07-30,Investing.com,https://www.investing.com/news/stock-market-news/pfizer-falls-7-1939402,1939402
219776,441292,PFE,Glaxo  GSK  Beats Earnings   Revenue Estimates In Q3,opinion,GlaxoSmithKline plc   NYSE GSK    one of the largest health care companies  reshaped its business following the March 2015 completion of the three part  inter conditional transaction with Novartis related to its Consumer Healthcare  Vaccines and Oncology businesses  Under the deal  Glaxo sold its oncology assets to Novartis and acquired Novartis  Vaccines business  excluding influenza vaccines   Glaxo has created a joint venture   JV   with Pfizer  NYSE PFE  earlier in 2019  thereby combining their consumer healthcare unit Following the completion of the deal  the UK based company now focuses on its three core businesses   Pharmaceuticals  respiratory  HIV   Vaccines  pediatric  adolescent  adult  and travel vaccines  and Consumer Healthcare  wellness  oral health  nutrition and skin health products   However  Glaxo is currently focusing on its core assets and divesting non core assets Meanwhile  like many of its peers  Glaxo is facing challenges in the form of stiff competition  genericization and pricing pressure  In this scenario  investor focus remains on late stage pipeline candidates and their commercial potential  restructuring and cost cutting initiatives and performance of new products apart from the usual top and bottom line numbers Glaxo s performance has been mixed so far  with the company s earnings beating expectations thrice in the trailing four quarters while missed once  Overall  the company has delivered an average positive surprise of 12 74  Currently  Glaxo has a Zacks Rank  2  Buy   but that could definitely change following the company s earnings report which was just released  We have highlighted some of the key stats from this just revealed announcement below Earnings Beat  Glaxo reported core earnings of 95 cents per American depositary share in the third quarter of 2019  which beat our consensus estimate of 83 cents  The company s focus on cost control initiative has boosted margins Revenues Beat  Revenues were up 11  year over year at constant exchange rate   CER   to  11 56 billion   9 4 billion    Revenues beat the Zacks Consensus Estimate of  11 34 billion Key Stats  Sales in Vaccines segment surged 15  at CER while Consumer Healthcare sales increased 25   Pharmaceuticals sales were up 3  at CER   The Respiratory segment increased 19  at CER  HIV product sales remained flat at CER 2019 Guidance  Glaxo provided an improved earnings guidance for 2019  Adjusted EPS is expected to remain flat at CER  previously decline by 3 5   in 2019  The new guidance reflects improvement in operating performance  increased investment in R D and priority assets and expected lower effective tax rate Share Price Impact  Shares rose almost 2 4  in pre market trading Check back later for our full write up on GSK earnings report later Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-10-30,Zacks Investment Research,https://www.investing.com/analysis/glaxo-gsk-beats-earnings--revenue-estimates-in-q3-200480016,200480016
219782,441298,PFE,PFE Vs  NVO  Which Stock Is The Better Value Option ,opinion,"Investors interested in Large Cap Pharmaceuticals stocks are likely familiar with Pfizer  PFE  and Novo Nordisk  CSE NOVOb   NVO   But which of these two companies is the best option for those looking for undervalued stocks  Let s take a closer look 
The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system  The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends  while our Style Scores work to grade companies based on specific traits 
Pfizer and Novo Nordisk are sporting Zacks Ranks of  2  Buy  and  3  Hold   respectively  right now  This means that PFE s earnings estimate revision activity has been more impressive  so investors should feel comfortable with its improving analyst outlook  But this is only part of the picture for value investors 
Value investors analyze a variety of traditional  tried and true metrics to help find companies that they believe are undervalued at their current share price levels 
Our Value category highlights undervalued companies by looking at a variety of key metrics  including the popular P E ratio  as well as the P S ratio  earnings yield  cash flow per share  and a variety of other fundamentals that have been used by value investors for years 
PFE currently has a forward P E ratio of 12 92  while NVO has a forward P E of 21 52  We also note that PFE has a PEG ratio of 2 15  This figure is similar to the commonly used P E ratio  with the PEG ratio also factoring in a company s expected earnings growth rate  NVO currently has a PEG ratio of 2 19 
Another notable valuation metric for PFE is its P B ratio of 3 37  The P B ratio pits a stock s market value against its book value  which is defined as total assets minus total liabilities  For comparison  NVO has a P B of 16 02 
Based on these metrics and many more  PFE holds a Value grade of B  while NVO has a Value grade of C 
PFE is currently sporting an improving earnings outlook  which makes it stick out in our Zacks Rank model  And  based on the above valuation metrics  we feel that PFE is likely the superior value option right now ",2019-10-16,Zacks Investment Research,https://www.investing.com/analysis/pfe-vs-nvo-which-stock-is-the-better-value-option-200474525,200474525
219783,441299,PFE,Pfizer names former FDA chief Scott Gottlieb to its board,news, Reuters     Pfizer  Inc  N PFE  said on Thursday it has named former U S  Food and Drug Administration Commissioner Scott Gottlieb to its board of directors  effective immediately  Gottlieb stepped down abruptly as the FDA chief in March this year  a role he had held since May 2017  He was well regarded by public health advocates and won bipartisan support for his efforts  to curb use of flavored e cigarettes by youths   Unlike his predecessors  who said drug pricing was not the purview of the FDA  Gottlieb waded into the intensifying debate about the high cost of medicines for U S  consumers and had the agency actively looking into possible solutions  Gottlieb ran into fierce opposition from anti regulation groups such as Americans for Tax Reform and former FDA officials  who said the agency s regulatory efforts would destroy thousands of jobs  Pfizer has also appointed Gottlieb to the board s regulatory and compliance as well as the science and technology committees ,2019-06-27,Reuters,https://www.investing.com/news/stock-market-news/pfizer-names-former-fda-chief-scott-gottlieb-to-its-board-1910037,1910037
219784,441300,PFE,Senator Warren asks former FDA chief Gottlieb to resign from Pfizer board,news," Reuters    U S  Senator Elizabeth Warren urged former U S  Food and Drug Administration Commissioner Scott Gottlieb to immediately step down from  Pfizer  Inc s  N PFE  board  three months after his departure from the health regulator 
In a letter to Gottlieb  Warren  who is seeking the Democratic nomination for the 2020 presidential election  said  this kind of revolving door influence peddling smacks of corruption  
Gottlieb  who won bipartisan support for his efforts to curb use of flavored e cigarettes by youths  stepped down from the FDA in April  a role he had held since May 2017 
He was named to Pfizer s board last Thursday and was added to the board s regulatory and compliance as well as the science and technology committees 
Warren added that such moves could make Americans cynical and distrustful about whether high level officials from President Donald Trump s administration are working for the people or for future corporate employers 
Gottlieb said in a tweet on Tuesday that he had a productive relationship with Warren while he was at the FDA and would respond to her letter privately 
When asked to comment on Senator Warren s letter  Pfizer pointed Reuters to the company s announcement on Thursday ",2019-07-02,Reuters,https://www.investing.com/news/stock-market-news/senator-warren-asks-former-fda-chief-gottlieb-to-resign-from-pfizer-board-1913741,1913741
219785,441301,PFE,Pfizer Falls 3 ,news,"Investing com    Pfizer   NYSE PFE  fell by 3 13  to trade at  42 66 by 10 18  14 18 GMT  on Thursday on the NYSE exchange 
The volume of Pfizer shares traded since the start of the session was 4 35M  Pfizer has traded in a range of  42 68 to  43 56 on the day 
The stock has traded at  44 5600 at its highest and  42 6600 at its lowest during the past seven days ",2019-07-11,Investing.com,https://www.investing.com/news/stock-market-news/pfizer-falls-3-1921054,1921054
219796,441312,PFE,Hutchison China MediTech  Surufatinib NETs Solid Data At ESMO,opinion,"Hutchison China MediTech  Ltd  NASDAQ HCM  presented robust SANET ep Phase III China data at ESMO 2019 on surufatinib in non pancreatic neuroendocrine tumors  NET   The data support a China NDA submission  imminent   with surufatinib likely to be the first of HCM s non partnered assets to reach the market  late 2020   NET tumors are highly prevalent  fragmented in primary origin and are an unmet medical need  Surufatinib could be the first universal drug to treat NET in all patients regardless of tumor subtype  the SANET p Phase III data in  pancreatic NET H120   is critical to widening its market potential  The global  US and Europe  registration Phase III study is planned for H120  CK Hutchison Holdings  CKHH  reduced its holding by 1 3  to below 50   49 9    We see this as a significant positive as it removes the significant overhang on the shares  We value HCM at  5 7bn 




Surufatinib solid data in non pancreatic NET
Positive Phase III surufatinib data unveiled at the interim analysis of SANET ep  advanced extra pancreatic NET  led to trial cessation  as recommended by IDMC  a year ahead of schedule  Surufatinib met superiority criteria in meeting its primary endpoint of progression free survival  PFS   9 2 months vs placebo 3 8 months  HR 0 334  p
NET and BTC represents   1bn global opportunity
We continue to forecast global peak sales for surufatinib of  953m across the NET and biliary tract cancer  BTC  indications  We now forecast China launch in late 2020  previously 2021  due to clearer regulatory timelines and US EU launch in 2024  HCM has accelerated global  ex China  development of its non partnered assets  fruquintinib  surufatinib  HMPL 523 and HMPL 689  as evidenced by a leap in R D expense in 2018 19  In the rapidly changing landscape that is oncology  timeliness is critical and investment in surufatinib is coming to fruition 
Valuation   5 7bn or  42 78 ADS
We value HCM at  5 7bn   42 78 ADS  vs  5 7bn   42 62 ADS  previously  We now forecast surufatinib launch in China in late 2020  previously early 2021  based on an October 2019 China NDA submission  We have increased 2020 R D expenses and rolled forward our model in time 
ADR share price performance




Business description
Hutchison China MediTech is an innovative China based biopharmaceutical company targeting the global market for novel  highly selective oral oncology and immunology drugs  Its established commercial platform business continues to expand its outreach 
Portfolio rapidly advancing
HCM continues to make rapid progress towards its goal of becoming an international biotech company with a marketed portfolio of innovative drugs  Of its late stage pipeline  surufatinib  savolitinib and fruquintinib are in pole position to ensure HCM s goal is reached in the medium term  Surufatinib has made significant strides this year  the Phase III SANET ep trial cessation one year ahead of schedule due to overwhelming positive efficacy in advanced stage non pancreatic NET means the drug could launch in China in late 2020  If the global Phase III trial  US and Europe due to initiate in H1 20  results are consistent with data seen in Chinese patients to date  this would pave the way for surufatinib to be the first universal small molecule drug treatment for NET 
NET  Fragmented but highly prevalent disease
Data from Frost   Sullivan indicate the global NET market in 2018 was worth approximately  5 8bn and is expected to grow to  21 2bn by 2030  NET cancers arise out of cells of the endocrine and nervous systems  predominately the digestive and respiratory tracts  NETs can be aggressive or indolent in nature  the latter meaning that patients can survive longer in the course of disease than certain solid tumors  NETs are typically classified as pancreatic NETs or extra pancreatic NETs  a catch all for a tumor that does not arise out the pancreas  and commonly include lung NETs and gastrointestinal  GI  NETs  NETs can be functional   40  of patients  or non functional depending on whether the hormones produced by the tumor lead to symptoms  functional NET  
In China there is significant market opportunity with reported incidence of NET in 2018 of approximately 67 600  While the current prevalence of NET in the US is  150 000 patients  incidence of  19 000 new cases per year   current treatment modalities are typically limited to subsets of NET with only Afinitor approved for a broad range of NETs  pancreatic  GI and lung  
SANET ep supports broad use in non pancreatic NET
Surufatinib s China Phase III program consists of two studies evaluating the drug  vs placebo  in pancreatic NET  SANET p  planned n 195  and non pancreatic NET  SANET ep  actual n 198   thus covering all NET patient types  In June 2019  HCM announced the independent data monitoring committee had recommended stopping the Phase III SANET ep early following positive interim data  This was based on the trial meeting its primary endpoint of PFS and the trial was unblinded a year ahead of schedule  Upon unblinding  patients on placebo had the opportunity to cross over to the surufatinib arm  Surufatinib met primary endpoints and significantly improved investigator assessed PFS  PFS 9 2 months vs placebo 3 8 months  HR 0 334  p




Eligibility criteria for the study included well differentiated extrapancreatic  ep  NET pathological grade 1 or 2 with advanced disease  patients with prior use of VEGF VEGFR inhibitors were excluded  Around 69  of patients on surufatinib had received prior systemic anti tumor therapy  chemotherapy  somatostatin analogues  everolimus  vs 64  on placebo 
Safety was in line with previous data  hypertension  64 3  on drug vs 26 5  on placebo  and proteinuria  70 5  on drug vs 52 9  on placebo   while the most common adverse events were medically manageable  Given surufatinib inhibits three different targets  vascular endothelial growth factors  VEGFRs  fibroblast growth factor receptor 1  FGFR1  and colony stimulating factor 1 receptor  CSF 1R  at therapeutic dosing  its tolerability with combination therapies is an important factor  However  median exposure days on surufatinib  217 days  and placebo  146 days  suggests discontinuation rates were largely due to disease progression rather than tolerability issues 
At ESMO 2019 HCM reported preliminary results of the global Phase Ib study of surufatinib in US solid tumor patients   HCM initiated the US Phase Ib II study in P NET and BTC in July 2018  The two part study design including dose escalation and dose expansion assessed safety and tolerability  It confirmed a safety and PK  pharmacokinetic  profile consistent with studies in China patients  Importantly  surufatinib showed early signs of utility  two partial responses  n 15 pNET patients  in heavily pre treated patients with some receiving up to eight different lines of therapy  The maximum tolerated dose recommended Phase II dose was established as 300mg daily for global development 
Global development plans closely follow China
HCM is building its China oncology commercial team ahead of surufatinib launch  with the intention to have full coverage of China in preparation for launch late 2020  NET will be surufatinib s first  potential  approved indication  Non pancreatic NET is estimated by HCM to represent  80  of NET cases in China  SANET p Phase III data  pancreatic NET H1 20  is critical to widening its market potential to an additional 10 20  of patients  Based on the SANET ep data  of the Chinese patients with advanced disease  prior to enrolment around 40  had received treatment with chemotherapy  30  with a somatostatin analogue and c 10  with everolimus  on the strength of the data presented we believe that surufatinib could provide a universal treatment for NET  particularly if SANET p provides a similar benefit to patients with pancreatic NET  reduction in risk of disease progression   Pricing strategies in China will be important given competitor NRDL reference pricing of  2 007 per month for Sutent and  1 320 per month for Affinitor 
HCM plans to investigate surufatinib in other solid tumors both as monotherapy and in combination therapy with a PD 1 focus  HCM has multiple PD 1 collaborations in place  the Tuoyi  Junshi collaboration  dose expansion study in multiple tumor types is anticipated to start in Q419 
Following encouraging proof of concept data from the Phase II study in BTC  a pivotal open label Phase IIb III trial  NCT03873532  in China initiated in 2019  Interim data on the first 80 patients recruited into this trial are expected mid 2020  BTC represents a high unmet need due to limited treatment options and an increasing patient population 
Surufatinib s global registration clinical trial is in planning stage  The end of Phase II meeting with the FDA is expected in Q419  with US and Europe Phase II III estimated to start in H1 20 
Competitive landscape in NET
To date no targeted therapies have been approved across the broad NET population  Although progress has been made in the treatment of NETs  most approved treatments are for subsets of NET  dependent on the primary site of NET  stage and grade  Treatment options include surgery where possible and long term systemic treatment to treat symptoms and suppress tumor growth include somatostatin inhibitors such as Novartis s Sandostatin LAR  octreotide  and Lutathera  177Lu Affinitor   which slow the hormonal production driving the formation of NETs  ex lung   Approved drugs include somatostatin inhibitors  Afinitor  an mTOR inhibitor  and sunitinib  a tyrosine kinase inhibitor  Exhibit 2 highlights the different treatment options by NET subtype available in the US  In China  the Afinitor label has now been expanded to include the same NET indications as its USA label  pancreatic  GI and lung  




The treatment landscape is fragmented  for example Lanreotide data  CLARINET  supports use in pNET  and GI NET  while Sutent  sunitinib  data support its use in pNET only  Targeting aberrant angiogenic VEGF signalling has been proven with Sutent in treating pancreatic NETs  demonstrating a 5 9 month improvement in mPFS vs placebo  HR 0 42  p
Surufatinib multiple modes of action in cancer
Surufatinib is an oral angio immunokinase inhibitor that targets VEGF1  2 and 3  FGFR1 and CSF 1R kinases  During the last decade modalities of cancer treatment that involve targeted therapy  addressing cancer specific mutations   harnessing the power of the immune system and cancer cell blood supply to treat the tumor microenvironment are additional armaments to traditional chemotherapy and surgical treatment options  As such combination therapies evaluating drugs with multiple mechanism of action are approved  eg EGFR inhibitor plus PD 1 inhibition  or undergoing late stage testing in a multitude of cancer  Surufatinib is a small molecule therapeutic protein that addresses three distinct kinases and thus multiple different regulatory processes that enable cancer proliferation 
Anti angiogenesis via VEGF receptor and FGFR inhibition  VEGF inhibition is a well known mechanism of action  with leading antibody Avastin  FY18 sales   7 0bn  approved for over 30 tumor types in its decade on the market  FGFRs are transmembrane receptor tyrosine kinases that mediate cell differentiation  migration and survival  genetic aberrations to FGFRs can lead to a gain in function and have been implicated in the progression of a range of cancers 
CSF 1R is a cell surface protein that acts as the receptor for the cytokine CSF1  which controls macrophage  a type of white blood cell  function  Inhibition of CSF 1R limits the production of pro tumor macrophages  which  among other functions  is believed to aid in angiogenesis  tumor cell invasion and evasion of the immune system  CSF 1R activity  which is very novel and potentially important for PD 1 combinations as there may be synergy  both act by activating the immune system against the cancer   may differentiate it from competitor PD 1 PD L1 inhibitor combination studies with axitinib   Pfizer   NYSE PFE   or lenvatinib 
Surufatinib s three in one profile bodes well for current and evolving treatment paradigms in oncology where immunomodulatory drugs such as checkpoint inhibitors are being used in earlier lines of therapy 
Valuation
We value HCM at  5 7bn   42 78 ADS  vs  5 7bn   42 62 ADS  previously  We now forecast surufatinib is launched in China in late 2020  previously early 2021   We have increased 2020 R D expenses and rolled our model forward in time  We use a risk adjusted net present value  NPV  method to discount future cash flows for the innovation platform  savolitinib  fruquintinib  surufatinib  epitinib  HMPL 523 and HMPL 689   valuation of  4 131 4m   We use earnings based multiples for HCM s commercial platform  subsidiaries and JVs   Applying a 20 4x multiple on our forecast 2019 net attributable profit  equity in earnings of equity investees  net of tax  for the JVs of  39 2m yields a valuation of  800 4m  Exhibit 3  




CKHH offering removes a significant overhang on the shares




In June 2019  major shareholder CKHH completed an offering of some of its ADSs  which reduced its holding in HCM to 51 15   from 60 2  previously   CKHH recently announced it had reduced its holding by 1 3  to below 50   49 9    This will enable CKHH to deconsolidate HCM from its accounts  CKHH remains committed to its investment in HCM and has no plans in the near future to reduce its holdings further  We see this as a positive for HCM as it removes a significant overhang on the shares  We note that this latest offering has had no effect on the number of shares in issue and does not dilute any current shareholders ",2019-10-10,Edison,https://www.investing.com/analysis/hutchison-china-meditech-surufatinib-nets-solid-data-at-esmo-200472178,200472178
219797,441313,PFE,Alteryx Highlighted As Zacks Bull Of The Day,opinion,For Immediate ReleaseChicago  IL   October 11  2019    Alteryx   NYSE AYX   as the Bull of the Day Here is a synopsis of all four stocks  Alteryx is the  7 billion big data analytics engine that serves customers across dozens of industries from Audi and Barclays  LON BARC  to Pfizer  NYSE PFE  and Unilever  LON ULVR  Since I bought Alteryx for my TAZR Trader portfolio in late May  I ve produced several research articles and video reports on this amazing big data  analytics engine  And since Alteryx just delivered another strong beat and raise quarter  which will keep it a Zacks  1 Rank  Strong Buy   it s time to recap the investment thesis and the opportunities ahead for the company  Here s what I told my members on July 31 after the AYX Q2 report   TAZR TradersRight now  let s get to our all star earnings player  Alteryx We got a beat and raise  though Q3 EPS could be softer than expected as the full year powers through to 47 cents vs consensus of 43c Alteryx delivered Q2 EPS of  0 01 vs expectations of a 6 cent loss Even better  revs came in over 7  higher than consensus at  82M vs  76 5M The slight  wince  on the guide was management seeing Q3 EPS 6c 9c vs  consensus 13c  But as noted above  the full year guide is a range of 44c 50c And the revenue guidance still maintained an upward trajectory with Q3 seeing  88 91 million vs  consensus  87 5M Full year rev guide is for  370 375 million vs  consensus of  360M  representing a blistering 83  annual growth in sales Key highlights of the business expansion     Added 305 new customers in Q2 to hit 5 278 customers  a 34  increase from Q2 2018   Achieved a dollar based net expansion rate  annual contract value based  of 133    Large contract momentum persists with a 50   increase in deals over  250 000   Doubling of contracts deals over  1 000 000   Our forward momentum continued in the second quarter highlighted by revenue growth of 59  year over year and net expansion rates of over 130  driven by both strong market tailwinds and solid execution   said Dean Stoecker  CEO of Alteryx  Inc   We continue to be humbled and amazed by the innovative ways our customers are leveraging the Alteryx platform to transform their business in remarkable ways   end of TAZR notes from July 31 That last sentence from Dean Stoecker is a key ingredient of Alteryx success  I learned this when I was studying the company platform and customers in early June during their annual user conference Inspire in Nashville Media ContactZacks Investment Research800 767 3771 ext  9339Zacks com provides investment resources and informs you of these resources  which you may choose to use in making your own investment decisions  Zacks is providing information on this resource to you subject to the Zacks  Terms and Conditions of Service  disclaimer   Past performance is no guarantee of future results  Inherent in any investment is the potential for loss This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-10-10,Zacks Investment Research,https://www.investing.com/analysis/alteryx-highlighted-as-zacks-bull-of-the-day-200472795,200472795
219798,441314,PFE,Germany s Stada buys six of GSK s consumer brands  eyes further deals,news,"FRANKFURT  Reuters    Private equity backed generic drugmaker Stada said on Friday it would buy six consumer healthcare products from British drugmaker GlaxoSmithKline to bolster its presence in Europe   The price tag for the mainly Europe focused brand portfolio  which include itch relief cream Eurax  antiseptic cream Savlon and Tixylix cough liquids  was in the high double digit million pound range  according to a person close to the deal  Stada declined to comment on the price  GSK is streamlining its product offering as it prepares to fold its consumer business into a joint venture with  Pfizer   NYSE PFE  by the second half of this year  creating a market leader that will primarily look to the United States and China for growth  Stada CEO Peter Goldschmidt said the company  which will fold the brands into its British Thornton   Ross unit  would bring to bear its knowledge of complex European healthcare markets that some global players are lacking  also with a view to future deals or alliances   We have a strong presence in almost all the European countries  there are not many companies where that is the case  For companies in  say  the United States  India or China that are looking for a European partner we are the go to partner   the CEO told Reuters  
The German company  majority owned by buyout firms Bain and Cinven since 2017  reported adjusted earnings before interest  taxes  depreciation and amortization  EBITDA  of just over 500 million euros last year on sales of 2 3 billion euros ",2019-06-07,Reuters,https://www.investing.com/news/stock-market-news/germanys-stada-buys-six-of-gsks-consumer-brands-eyes-further-deals-1891316,1891316
219801,441317,PFE,Zoetis Appoints Kristin Peck As New CEO  Alaix To Retire,opinion,Zoetis Inc    NYSE ZTS   announced that Kristin Peck will succeed Juan Ram n Alaix as the chief executive officer  CEO   effective Jan 1  2020  as the latter will retire by the end of the year Alaix has been Zoetis  CEO since its formation in 2012 and will continue to act as an advisor on the leadership transition through Dec 31  2020 Currently  Peck is the executive vice president and group president of U S  Operations  Business Development and Strategy  She too has been a member of the executive leadership team since the company s formation and has played a key role in its growth trajectory  She previously served as Pfizer s   NYSE PFE   executive vice president of Worldwide Business Development and Innovation  as part of the company s Executive Leadership Team It remains to be seen how this transition impacts the business Zoetis is a leader in the animal health business with a wide portfolio  The company s performance has been stellar in the year so far  backed by growth in new parasiticide products and vaccines  a solid dermatology portfolio  and the addition of Abaxis  diagnostics platform  Livestock product sales too returned to growth in the second quarter Key dermatology products like Apoquel and Cytopoint  new products such as Simparica and Stronghold Plus  and increased medicalization rates in key international markets should propel further growth  Notably  the European Commission  EC  recently granted marketing authorization to Simparica Trio  sarolaner moxidectin pyrantel  chewable tablets  a once monthly triple combination antiparasitic medication for dogs with or at risk from mixed external and internal parasitic infestations  The approval should strengthen the company s market leading parasiticide portfolio for companion animals Per Zoetis  the global canine parasiticides market is worth more than  4 billion and the largest therapeutic category in medicines for dogs The FDA earlier approved ProHeart 12  moxidectin   the industry s only once yearly injection to prevent heartworm disease in dogs aged 12 months or older  Zoetis expanded its Fostera swine vaccine franchise in the second quarter with approvals of different formulations in new geographies  These should boost further growth Meanwhile  the animal health business has been in focus  Elanco Animal Health   NYSE ELAN   recently inked a definitive agreement to acquire Bayer s   OTC BAYRY   Animal Health business for  7 6 billion Just Released  Zacks  7 Best Stocks for TodayExperts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 6  per year These 7 were selected because of their superior potential for immediate breakout ,2019-10-06,Zacks Investment Research,https://www.investing.com/analysis/zoetis-appoints-kristin-peck-as-new-ceo-alaix-to-retire-200471089,200471089
219802,441318,PFE,Pfizer  PFE  Stock Moves  1 1   What You Should Know,opinion,"Pfizer  PFE  closed the most recent trading day at  35 44  moving  1 1  from the previous trading session  This change was narrower than the S P 500 s 1 56  loss on the day  Elsewhere  the Dow lost 1 19   while the tech heavy Nasdaq lost 1 67  
Heading into today  shares of the drugmaker had lost 2 72  over the past month  outpacing the Medical sector s loss of 3 6  and lagging the S P 500 s loss of 1 22  in that time 
PFE will be looking to display strength as it nears its next earnings release  which is expected to be October 29  2019  The company is expected to report EPS of  0 63  down 19 23  from the prior year quarter  Our most recent consensus estimate is calling for quarterly revenue of  12 22 billion  down 8 07  from the year ago period 
For the full year  our Zacks Consensus Estimates are projecting earnings of  2 81 per share and revenue of  50 98 billion  which would represent changes of  6 33  and  4 97   respectively  from the prior year 
Investors might also notice recent changes to analyst estimates for PFE  These recent revisions tend to reflect the evolving nature of short term business trends  As such  positive estimate revisions reflect analyst optimism about the company s business and profitability 
Research indicates that these estimate revisions are directly correlated with near term share price momentum  To benefit from this  we have developed the Zacks Rank  a proprietary model which takes these estimate changes into account and provides an actionable rating system 
The Zacks Rank system ranges from  1  Strong Buy  to  5  Strong Sell   It has a remarkable  outside audited track record of success  with  1 stocks delivering an average annual return of  25  since 1988  The Zacks Consensus EPS estimate has moved 0 12  higher within the past month  PFE currently has a Zacks Rank of  1  Strong Buy  
Digging into valuation  PFE currently has a Forward P E ratio of 12 74  This valuation marks a discount compared to its industry s average Forward P E of 14 44 
Investors should also note that PFE has a PEG ratio of 2 85 right now  The PEG ratio is similar to the widely used P E ratio  but this metric also takes the company s expected earnings growth rate into account  Large Cap Pharmaceuticals stocks are  on average  holding a PEG ratio of 2 11 based on yesterday s closing prices 
The Large Cap Pharmaceuticals industry is part of the Medical sector  This industry currently has a Zacks Industry Rank of 35  which puts it in the top 14  of all 250  industries 
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
You can find more information on all of these metrics  and much more  on Zacks com ",2019-10-08,Zacks Investment Research,https://www.investing.com/analysis/pfizer-pfe-stock-moves-11-what-you-should-know-200471632,200471632
219803,441319,PFE,Pfizer Executive  Technology Is  Basically Good Enough  to Ramp Up Production Blockchains,news,"A  Pfizer   NYSE PFE  executive has challenged existing theories about slow rates of blockchain adoption   telling the Consensus conference on May 14 that the technology is  basically good enough to have more production blockchains than we have today  
Ken Nessel  senior director of business technology at the pharmaceutical giant  made his comments during the second day of the conference in New York City  He joined AstraZeneca s Kate Gofman for an event called From Bench to Bedside  Blockchains and the Future of Clinical Research ",2019-05-14,Cointelegraph,https://www.investing.com/news/cryptocurrency-news/pfizer-executive-technology-is-basically-good-enough-to-ramp-up-production-blockchains-1867817,1867817
219812,441328,PFE,Exact Sciences Gets FDA Nod For Label Expansion Of Cologuard ,opinion,"Exact Sciences Corp    NASDAQ EXAS   announced that the FDA has approved a label expansion of its noninvasive colorectal cancer screening test  Cologuard The test can now be used in eligible average risk individuals aged 45 years or older  expanding on its previous indication for 50 years or older As a result of the broader label  approximately 19 million average risk people in the United States from the age group of 45 49 years can now access a new  sensitive  at home  stool based screening test Cologuard is a stool DNA based colorectal cancer screening test for average risk individuals  The test uses a biomarker panel  which analyzes a person s stool sample for 10 DNA markers  as well as blood in the stool We note that the FDA approved Cologuard for the first time in August 2014   Colorectal cancer is the second deadliest cancer in the United States and an early screening will go a long way in better management of the disease Given the widespread prevalence of colorectal cancer among Americans under 50 years  the expanded label bodes well for molecular diagnostics company  Exact Sciences  Notably  in May 2018  the American Cancer Society  ACS  updated its colorectal cancer screening guidelines to include people between 45 years and 49 years  while the prior ACS recommendation called for screening to begin at age 50 The news of the approval boosted the company s stock price  which eventually retraced by the end of the day Exact Sciences Corporation Price
    In July  Exact Sciences announced that it will acquire Genomic Health  Inc    NASDAQ GHDX   for  2 8 billion  thereby creating a leading global cancer diagnostics company  The combined company will offer two of the strongest and fastest growing brands in cancer diagnostics   Cologuard and Oncotype DX We remind investors that Exact Sciences also has a promotion agreement with Pfizer  Inc    NYSE PFE    whereby the latter will promote Cologuard and provide certain sales  marketing  analytical and other commercial operations support services Meanwhile  Guardant Health  Inc    NASDAQ GH   is evaluating LUNAR RUO assay to identify early stage colorectal cancer patients with post operative molecular residual disease  who may benefit from adjuvant therapy Exact Sciences currently carries a Zacks Rank  2  Buy   You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-09-23,Zacks Investment Research,https://www.investing.com/analysis/exact-sciences-gets-fda-nod-for-label-expansion-of-cologuard-200467475,200467475
219813,441329,PFE,Protalix Completes Enrollment In Third Fabry Disease Study,opinion,"Protalix BioTherapeutics  Inc    NYSE PLX   announced that it has completed enrollment in the third phase III study  evaluating its pipeline candidate   PRX 102  pegunigalsidase alfa    for the treatment of Fabry disease  a rare inherited genetic lysosomal disorder 
The BALANCE study is designed to evaluate the safety and efficacy of PRX 102 compared to Fabrazyme  agalsidase beta  on renal function in Fabry patients with progressing kidney disease previously treated with agalsidase beta 
Fabrazyme  currently marketed by Sanofi   NASDAQ SNY    is already approved for treating Fabry disease  Replagal too won the nod for addressing the same 
Shares of Protalix have slumped 33 5  so far this year compared with the  decline of 3 2  

 
BALANCE is the third phase III study on PRX 102  The first two studies   BRIDGE and BRIGHT   are both fully enrolled and ongoing 
Along with the press release  the company said it plans to submit a biologics license application  BLA  to the FDA under an accelerated approval pathway for PRX 102 in the first quarter of 2020  The BLA will be supported by results from the completed phase I II studies of PRX 102 and the ongoing phase III BRIDGE clinical study 
Notably  in January 2018  the FDA granted a Fast Track designation to the candidate for the treatment of Fabry disease 
We would like to remind investors that Protalix has a single marketed drug  Elelyso  approved for treating Gaucher disease  The drug is marketed by Pfizer Inc    NYSE PFE   in the United States as part of an exclusive license and supply agreement 
The company is also developing OPRX 106 as an orally delivered anti inflammatory treatment  In 2018  it delivered positive results from the phase II OPRX 106 study for the treatment of ulcerative colitis Protalix BioTherapeutics  Inc  Price

    
Zacks Rank   A Stock to Consider
Currently  Protalix is a Zacks Rank  3  Hold  stock 
A better ranked stock in the biotech sector is Acorda Therapeutics Inc    NASDAQ ACOR    carrying a Zacks Rank  1  Strong Buy   at present  You can see  
Acorda s loss per share estimates for the current year narrowed from  3 51 to  2 74 over the past 60 days  The company recorded a positive earnings surprise in the preceding four quarters  the average beat being 69 68      
5 Stocks Set to Double 
Each was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth  Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ",2019-09-25,Zacks Investment Research,https://www.investing.com/analysis/protalix-completes-enrollment-in-third-fabry-disease-study-200468087,200468087
219814,441330,PFE,Pfizer posts earnings beat  raises 2019 profit forecast,news,By Tamara Mathias  Reuters     Pfizer  Inc  NYSE PFE  on Tuesday beat Wall Street estimates for quarterly profit and slightly raised its earnings forecast for the year  as the largest U S  drugmaker reined in costs and recorded higher sales of cancer drug Ibrance and pneumonia vaccine Prevnar  Shares of the company rose 1 percent to  39 98 in trading before the bell  To push growth and reduce bureaucracy  Chief Executive Officer Albert Bourla has ordered a reorganisation of Pfizer into three businesses since taking over in January  Analysts are impatiently awaiting the changes that will spur growth for the company in the next few years  Pfizer expects mid single digit operational revenue growth from post 2020 through 2025  said Bourla  Meanwhile  the company is relying on its growth drivers such as Ibrance and Prevnar   Ibrance brought in sales of  1 13 billion during the quarter  up 21 4 percent from a year earlier  just ahead of analysts  estimates of  1 12 billion  Prevnar raked in  1 49 billion  beating the average estimate of  1 39 billion    Overall we think these results are good enough given the pressure the stock has felt in recent weeks  but probably do not do much to change the fundamental debates around the stock    Credit Suisse   SIX CSGN  analyst Vamil Divan said  Pfizer is under pressure as one of its biggest drugs  Lyrica  faces generic competition  The company  therefore  has been investing in cancer treatments and gene therapies  and expects to gain approval for a new heart drug  touted as a potential blockbuster  later this year  It has also signed a joint venture agreement with Britain s GlaxoSmithKline Plc to form the world s biggest consumer health business  with brands such as Advil and Chapstick  by the second half of the year  Pfizer pushed its 2019 adjusted earnings per share forecast marginally higher to between  2 83 and  2 93   from a prior estimate of  2 82 to  2 92  It also reiterated its full year revenue target of  52 billion to  54 billion   Excluding special items  the company earned 85 cents per share  beating analysts  estimate of 75 cents  Net income rose 9 percent to  3 88 billion  or 68 cents per share  in the first quarter  Revenue rose 1 6 percent to  13 12 billion  ahead of estimates of  12 99 billion ,2019-04-30,Reuters,https://www.investing.com/news/stock-market-news/pfizer-posts-9-percent-rise-in-firstquarter-profit-1850461,1850461
219815,441331,PFE,Pfizer Rises 3 ,news,"Investing com    Pfizer   NYSE PFE  rose by 3 01  to trade at  40 79 by 11 40  15 40 GMT  on Tuesday on the NYSE exchange 
The volume of Pfizer shares traded since the start of the session was 10 43M  Pfizer has traded in a range of  39 80 to  40 80 on the day 
The stock has traded at  40 8000 at its highest and  38 8100 at its lowest during the past seven days ",2019-04-30,Investing.com,https://www.investing.com/news/stock-market-news/pfizer-rises-3-1850910,1850910
219825,441341,PFE,Pfizer  PFE  Stock Moves  0 24   What You Should Know,opinion,"Pfizer  PFE  closed at  36 82 in the latest trading session  marking a  0 24  move from the prior day  This change was narrower than the S P 500 s daily loss of 0 31   At the same time  the Dow lost 0 52   and the tech heavy Nasdaq lost 0 28  
Prior to today s trading  shares of the drugmaker had gained 7 05  over the past month  This has outpaced the Medical sector s loss of 0 98  and the S P 500 s gain of 2 92  in that time 
PFE will be looking to display strength as it nears its next earnings release  On that day  PFE is projected to report earnings of  0 62 per share  which would represent a year over year decline of 20 19   Our most recent consensus estimate is calling for quarterly revenue of  12 22 billion  down 8 07  from the year ago period 
PFE s full year Zacks Consensus Estimates are calling for earnings of  2 81 per share and revenue of  50 98 billion  These results would represent year over year changes of  6 39  and  4 97   respectively 
Investors might also notice recent changes to analyst estimates for PFE  Recent revisions tend to reflect the latest near term business trends  As a result  we can interpret positive estimate revisions as a good sign for the company s business outlook 
Based on our research  we believe these estimate revisions are directly related to near team stock moves  Investors can capitalize on this by using the Zacks Rank  This model considers these estimate changes and provides a simple  actionable rating system 
The Zacks Rank system ranges from  1  Strong Buy  to  5  Strong Sell   It has a remarkable  outside audited track record of success  with  1 stocks delivering an average annual return of  25  since 1988  Within the past 30 days  our consensus EPS projection has moved 0 3  higher  PFE currently has a Zacks Rank of  4  Sell  
Digging into valuation  PFE currently has a Forward P E ratio of 13 14  This represents a discount compared to its industry s average Forward P E of 13 83 
Also  we should mention that PFE has a PEG ratio of 2 94  The PEG ratio is similar to the widely used P E ratio  but this metric also takes the company s expected earnings growth rate into account  The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 1 99 as of yesterday s close 
The Large Cap Pharmaceuticals industry is part of the Medical sector  This industry currently has a Zacks Industry Rank of 35  which puts it in the top 14  of all 250  industries 
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Be sure to follow all of these stock moving metrics  and many more  on Zacks com ",2019-09-16,Zacks Investment Research,https://www.investing.com/analysis/pfizer-pfe-stock-moves-024-what-you-should-know-200465124,200465124
219826,441342,PFE,Transgene  PHOCUS Turns To Earlier Stage Assets,opinion,"The recent failure of the Phase III PHOCUS trial is disappointing but we do not feel is critical to Transgene s  PA TRNG  future  The company s potential pipeline combined with ICIs remains the key driver of long term value  Focus now turns to the rest of the pipeline  particularly the expected readout by year end of the Phase II trial of TG4010   nivolumab in first line non small cell lung cancer  NSCLC   Early stage development continues with the announcement of the Invir IO collaboration with AstraZeneca  AZN  and the advancement of the first product candidate  TG4050  from the company s myvac platform into the clinic  initiating clinical trials in H219   We value  Transgene  at  287m   3 45 share  vs  312m   5 02 share  previously 




Pexa Vec fails Phase III futility analysis
The PHOCUS Phase III trial has been terminated based on the recommendation of the Independent Data Monitoring Committee  IMDC  following a planned interim futility analysis  The IMDC believed the trial was unlikely to meet its primary endpoint of a statistical increase in overall survival  OS  over the control arm  The trial had enrolled 190 patients at time of completion  Patients in the PHOCUS trial were randomised to one of two treatment arms where they received Pexa Vec   sorafenib  Nexavar  or sorafenib alone  Following a review of the full data set and interactions with clinicians  Transgene has also decided to halt the ongoing Pexa Vec   nivolumab Phase II trial 
Expansive pipeline offers opportunities
Transgene has four ongoing studies with two new products  TG4050 and anti CTLA 4 oncolytic virus  expected to enter the clinic in the next 12 months  Efficacy data from the Phase II TG4010   nivolumab  chemotherapy  trial in first line NSCLC will be central to determining Transgene s long term immune oncology  IO  strategy  data due in H219   Transgene continues to progress its technology  notably  in H119 it announced a partnership with AZN to develop five novel armed oncolytic viruses   10m upfront  potential future milestones and royalties  
Valuation   287m   3 45 share 
We value Transgene at  287m   3 45 share  vs  312m   5 02 share  previously  based on a risk adjusted NPV model of TG4010  TG4001  TG1050 and TG6002  The decrease in value is driven by the removal of Pexa Vec from our valuation  This has been offset by the gross  48 7m capital raise and  10m upfront from the AZN deal  We have updated our R D cost assumptions across assets  rolled forward our model and updated for FX 
Share price performance
Business description
Transgene is a French drug discovery and development company focused on the treatment of cancer and infectious diseases with immunotherapies  Its products are TG4010  TG4001  TG1050  TG6002 and TG4050 
Investment summary
Company description  Immunotherapy platform
Transgene is a drug discovery and development company that develops viral vector based immunotherapies for the treatment of cancers and infections  It has two platforms  therapeutic vaccines and oncolytic viruses  Its lead clinical stage programme is TG4010  Therapeutic vaccine TG4010 is being trialled in combination with PD 1 ICIs in first line non squamous NSCLC  Transgene s other clinical candidates are TG4001 in head and neck cancer  TG1050 in hepatitis B  TG6002 in glioblastoma and Pexa Vec   nivolumab  in hepatocellular carcinoma  HCC   Early stage development continues with its Invir IO  anti CTLA 4  and myvac platforms  TG4050   Transgene is based near Strasbourg  France  and was founded in 1979  It was listed on the Nouveau March   now Euronext  in 1998  Transgene is 60  owned by Institut M rieux 
Valuation  rNPV of  287m   3 45 share 
We value Transgene at  287m   3 45 share  vs  312m previously   5 02 share   based on a risk adjusted NPV model of TG4010  TG4001  TG1050  Pexa Vec and TG6002  The decrease in value is driven by the removal of Pexa Vec from our valuation  This decrease has been offset by the gross  48 7m capital raise  assumed net  47m  and  10m upfront from the AZN deal  We have updated our R D cost assumptions across assets  rolled forward our model and updated for FX  Our valuation includes the prospects for TG4010 in NSCLC in the US and Europe  combined peak potential sales of c  2 5bn   TG1050 for hepatitis B in the US and Europe  peak potential sales of c  2 0bn across both regions   and TG4001 for oesophageal cancer in the US and Europe  peak potential sales of c  200m across both regions   Due to a shift in strategy we no longer value TG6002 for glioblastoma and instead now value its potential in colorectal cancer in the US and Europe  peak potential sales of c  800m across both regions   We do not currently include TG4050 or the Invir IO anti CTLA 4 oncolytic virus in our model but will reassess on the start of clinical trials 
Financials   48 7m capital raise enables cash reach into 2021
Transgene reported cash and equivalents of  12 8m at 30 June 2019  vs  16 9m at 31 December 2018   This does not include the post period gross capital raise of  48 7m and the  10m upfront from signing the AZN deal  Net cash burn in H119 was  4 1m vs  8 3m in H119 and the company expects this to be around  20m in FY19  we forecast  20 4m   Transgene has secured a  20m revolving credit facility with Natixis  The credit facility has a 30 month term and Transgene will be able to draw and repay the facility at its discretion  Transgene has used its shares in Tasly Biopharmaceuticals as collateral  We forecast a decrease in 2019 R D based on a reduction in the number of clinical trials year on year while we expect 2019 G A expenses to be largely in line with 2018  We forecast a cash reach into 2021 based on the capital raise and AZN upfront alone with no draw down of the Natixis credit facility 
Sensitivities  ICI combinations may not be conclusive
Transgene is subject to the usual risks associated with drug development  including clinical development delays or failures  regulatory risks  competitor successes  partnering setbacks and financing and commercial risks  The key sensitivities relate to the results of the ICI combination studies of TG4010 and TG4001  The outcome of the TG4010 combination studies in particular will have an impact on its partnership and or the financing prospects for the programme  First results from these trials will be available later this year  We note that the ICI combination trials are small  open label and non controlled  therefore  it is not possible to ascertain the magnitude of the effect of each product separately and assess the actual synergistic effect 
Broad pipeline of assets limits PHOCUS impact
Partner Sillajen has stopped the Phase III PHOCUS trial of Pexa Vec in patients with advanced HCC  hepatocellular carcinoma  after planned interim futility analysis determined the therapy was unlikely to meet its primary endpoint  While the failure is disappointing  we do not feel it is critical to Transgene s future  The potential of the company s pipeline in combination with ICIs  particularly in relation to expanding the eligible patient population who respond to ICIs  remains the key driver of long term value  As such  multiple combination readouts before year end will be more telling of the strategic potential of its assets  notably the data from the Phase II TG4010   nivolumab   chemotherapy  trial in first line NSCLC 
In addition to clinical assets  Transgene continues to rapidly advance its next generation platforms  Invir IO and myvac   The first product candidate  TG4050  from the company s myvac platform is expected to enter the clinic by year end  while the collaboration with BioInvent aims to have its anti CTLA 4 oncolytic virus enter the clinic in Q120 
Global pharmaceutical companies continue to recognise the need to develop the next generation of immunotherapies  This was evidenced by the announcement earlier in the year of the collaboration with AZN to develop five novel armed oncolytic immunotherapies   10m upfront  potential future milestones and royalties   This partnership provides external validation of Transgene s oncolytic virus expertise and in the long term could be a significant contributor of revenue to the company 




Pexa Vec  End of the line
Pexa Vec is an oncolytic virus that targets fast dividing cells with an active EGFR Ras signalling pathway that is believed to cause cells to lyse and stimulate a T cell immune response  Transgene s partner Sillajen has stopped the Phase III PHOCUS trial of Pexa Vec in patients with advanced HCC after a planned interim futility analysis determined the therapy was unlikely to meet its primary endpoint 
The PHOCUS study was an international randomised  1 1  open label study comparing Pexa Vec followed by Bayer s sorafenib  anti BRAF VEGFR PDGFR tyrosine kinase inhibitor  versus sorafenib alone in patients with advanced HCC who have not received prior systemic therapy  n 600   Pexa Vec was administered as three bi weekly intratumoural injections at day one and weeks two and four  followed by sorafenib at week six  the comparator arm received sorafenib 400mg twice daily starting on day one  The primary endpoint was OS  secondary endpoints include time to progression  progression free survival  PFS   overall response rate  ORR  and disease control rate  DCR   SillaJen had responsibility for conducting and funding the study and retains rights outside Europe  China and South Korea  Transgene retains development and commercialisation rights in Europe  Lee Pharma retains China rights and Green Cross Pharma has South Korea rights 
The trial was ceased based on the recommendation of the IMDC  The IMDC believed the trial was unlikely to meet its primary endpoint of a statistical increase in OS over the control arm  The trial had enrolled 190 patients at the time of completion  Patients in the PHOCUS trial were randomised to one of two treatment arms where they received Pexa Vec   sorafenib  Nexavar  or sorafenib alone 
Following the failure of the Phase III PHOCUS trial  analysis of the data and conversations with physicians in the field  Transgene has decided to cease the Pexa Vec   nivolumab  Opdivo  Phase II trial  We believe recent struggles for ICIs in HCC  as shown by the failure of the second line Phase III KEYNOTE 240 trial  following accelerated approval of Keytruda in this setting based on Phase II KEYNOTE 224 results  and the first line Phase III Checkmate 459 trial  will also have been factored into the reasoning for the cessation of the trial  particularly as the standard of care  SOC  for HCC continues to evolve rapidly  with recent approvals for tyrosine kinase inhibitor lenvatinib  first line HCC  and cabozantinib  second line HCC  
At this time we do not expect Pexa Vec to be utilised in any new clinical trials 
TG4010  Important data readout approaches
Initial data from the Phase II  NCT03353675  in first line patients testing a triple combination of TG4010  Opdivo  nivolumab  Bristol Myers Squib  and chemotherapy are expected to readout by year end  The trial is a single arm EU US study and is anticipated to enrol 39 patients  without EGFR mutations or ALK rearrangements  who express low or undetectable levels of PD L1  The primary endpoint is an objective response rate and Transgene is funding the study with Bristol Myers Squib supplying Opdivo  For patients without a driver mutation  EGFR  MEK etc  the standard of care has quickly become chemotherapy plus Keytruda  irrespective of PD L1 status  The first line setting could be a significant opportunity for Transgene if TG4010 in combination with a PD  L 1 ICI is proven to be more effective than PD  L 1 ICI monotherapy treatment in low PD L1 expressing patients 
First line NSCLC treatment is now dominated by PD  L 1 approvals  notably Keytruda plus chemotherapy and Tecentriq plus Avastin plus chemotherapy  Transgene s first line TG4010 NSCLC trial will need to demonstrate a comparable or improved ORR  Keytruda combo ORR  48   95  CI  43 45  and Tecentriq triple combo ORR  55   95  CI  49 60   in similar patient populations to be considered for future development  Since the commercial launch of Keytruda  Merck  and Opdivo  Bristol Myers Squib  in melanoma in 2014  PD  L 1 ICIs have become the standard of care in many cancers  FY18 sales of Opdivo and Keytruda were  6 7bn and  7 2bn respectively  




Transgene believes its therapeutic vaccine TG4010  a modified vaccinia Ankara  MVA  virus that expresses MUC1 antigen and interleukin 2  IL 2   could prove beneficial in combination with PD  L 1 ICIs  TG4010 is believed to induce a specific T cell response to target MUC1 expressing cancer cells that when used in combination with a PD  L 1 ICI removes inhibitory effects on the T cell  Along with the MUC1 T cell stimulation  IL 2 enables the differentiation of T cells into effector and memory T cells  which could enhance the response against the MUC1 expressing cancer cells 
TG4010 has previously been tested in combination with chemotherapy  Data from the Phase IIb TIME trial compared chemotherapy plus TG4010 to chemotherapy plus placebo in patients with advanced NSCLC  n 222   For the total population  squamous and non squamous NSCLC   patients receiving TG4010 benefited compared to the placebo arm  ORR  39 6  vs 28 8   duration of response  30 1 vs 18 7 weeks   In non squamous NSCLC patients  the ORR was 40   n 98  in the experimental arm compared with 28  in the control arm  with median duration of response of 41 and 18 weeks respectively  Median PFS in non squamous NSCLC patients was 5 8 months  95  CI  5 5 7 2  vs 5 0 months  95  CI  4 2 5 8  for the control  The median OS in non squamous NSCLC patients was 14 6 months  95  CI  11 1 20 4  vs 10 8 months  95  CI  9 5 14 5  for the control  In a post hoc analysis of all non squamous NSCLC patients  there was a similar level of PFS and OS benefit in the 97 patients with low levels of PD  L 1 expression  
Rest of pipeline still on track for inflection points
Transgene has a range of other product candidates in the clinic with multiple readouts anticipated in the next 12 months  Transgene forecasts readouts for TG6002 in colorectal cancer  administered intravenously  and TG4001 in HPV   human papilloma virus  cancers including oropharyngeal  in combination with PD L1 inhibitor avelumab  in H219 and H1120 respectively  Additionally  Transgene will present Phase Ib trial data at ESMO 2019  27 September to 1 October  for TG4001  Beyond these  new trials are expected to initiate by year end with TG4050 tested in patients with HPV  head and neck ovarian cancers and TG6002 tested in patients with colorectal cancer and liver metastasis  intrahepatic arterial administration  
TG4001  Potential in HPV positive HNSCC
TG4001 is a therapeutic vaccine based on an MVA vector engineered to express HPV 16 antigens E6 and E7 with adjuvant IL 2  In collaboration with  Pfizer   NYSE PFE  and Merck  Transgene is running a Phase Ib II study in second line HPV positive head and neck squamous cell carcinoma  HNSCC  combining TG4001 and the anti PD L1 antibody avelumab  The trial is funded by Transgene  while Pfizer and Merck will provide avelumab  Pfizer and Merck do not have exclusive rights to the data or TG4001  both of which remain Transgene s  Patient enrolment is ongoing with 52 patients expected to be treated  The study is split into two parts  in the Phase Ib component nine patients were tested at increasing doses of TG4001 in combination with a fixed dose of avelumab 
Transgene will present Phase Ib trial data at ESMO 2019 and plans to host a press conference on 3 October to further detail the findings  The published ESMO abstract highlights the treatment of nine patients with oropharyngeal  five   anal  two   cervical  one  or vaginal  one  cancer  Patients had refractory or metastatic cancers and had received at least two prior treatment regimens  Three patients received a low dose  5x106 plaque forming units  pfu   of TG4001 and the other five a high dose  5 x107 pfu   TG4001 was administered SC weekly for six weeks  every two weeks up to M6  and every 12 weeks thereafter  All patients additionally received avelumab at 10mg kg every two weeks  No dose limiting toxicities or serious adverse events were observed  Three out of the nine patients had a partial response  Phenotypic and gene findings supported the idea of a shift in tumours from a  cold  state to an immunologically  hot  state 
In the expansion cohort  Phase II   40 patients with HPV positive HNSCC are being enrolled into a single arm cohort  Patients will receive the highest dose tested in the Phase Ib component of the trial  The primary outcome of the Phase II part will be efficacy as measured by ORR  Interim results are expected in H120  Details of the financial terms  IP rights or other aspects of the agreement between the three parties have not been disclosed 
TG1050  Phase I complete in hepatitis B
TG1050 is a therapeutic vaccine for the treatment of chronic hepatitis B that expresses three antigens of the hepatitis B virus  HBV   Transgene presented Phase I data  NCT02428400  for TG1050 at the AASLD 2018 liver meeting  Data were presented on the safety and immunogenicity of either single or multiple injections of TG1050 at various dose levels  The 48 patients were split into single  n 12  or multiple injections  n 36  cohorts  Patients in each cohort were then randomised across three dose levels  109  1010 and 1011 virus particles  and randomised in each dose level 3 1 to either receive treatment or placebo 
There were no serious adverse events  AE  reported and all AEs were grade 1 or 2 except one grade 3  which was not related to treatment  Immune responses to the HBV antigens that TG1050 encodes for were monitored  Exhibit 3   Detectable responses occurred at the higher doses  1010 and 1011 virus particles  in both the single injection  SD  cohort and the multiple injection  MD  cohort against the three antigens vectorised by TG1050  The intermediate dose  1010 vp  was immunogenic in c 70  of patients 




Additionally  at the 2018 AASLD liver meeting Transgene presented preclinical data on the combination of TG1050 with a range of immunomodulators  TLR9 agonist  PDE5 inhibitor  and direct acting antivirals  siRNA  capsid inhibitor  entecavir   Combinations with the TLR9 agonist  PDE5 inhibitor and the siRNA led to improvements in antiviral effects 
Next generation viral vector in TG6002
TG6002 is a viral vector derived from vaccinia virus expressing the FCU1 gene  The FCU1 gene encodes a protein that catalyses the transformation of the nontoxic pro drug flucytosine into 5 FU and 5 fluorouridine monophosphate  a widely used chemotherapy  Its expression is restricted to tumours  thereby reducing toxicity to normal tissues  The company has conducted numerous in vitro and in vivo experiments to establish its mechanism of action 
TG6002 is involved in a Transgene sponsored Phase I II trial in advanced gastrointestinal adenocarcinoma  colon cancer  and the first patient was dosed  via IV  in October 2018  The trial  NCT03724071  is enrolling 50 patients who have failed  or are intolerable to  standard therapeutic options  Initial data are expected by year end 
Additionally  Transgene is preparing a new Phase I II study in patients with advanced gastrointestinal adenocarcinoma  colon cancer  with liver metastasis who will be dosed by intrahepatic arterial administration  The first patient is expected to be enrolled by year end  Transgene also expects to take TG6002 into a new indication in 2020 
We note the Phase I II trial in glioblastoma with Assistance Publique H pitaux de Paris  principal investigator Professor Delattre  and support from French National Cancer Institute is still enrolling patients  However  it no longer forms a core part of Transgene s strategy  No safety issues have been found to date  according to clinicaltrial gov the completion of the trial is expected in 2021 
Evolving partnerships and platforms
Transgene continues to advance its partnerships and early stage technologies  Notable in 2019 was the announcement of a partnership with AZN to develop oncolytic viruses using Transgene s Invir IO platform  Although early  the partnership could generate significant value for Transgene in the long run  More advanced is Transgene s partnership with Tasly Biopharmaceuticals  which was formed in summer 2018  Tasly paid Transgene  48m in shares and has gained Greater China rights to T601 and T101  The Invir IO collaboration with BioInvent has been expanded to include the development of anti CTLA 4 antibody armed oncolytic vaccinia virus  expected in the clinic in H120   The first product candidate  TG4050  from the company s myvac platform is expected to enter clinical trials later this year 
AZN partnership major validation of Invir IO platform
Global pharmaceutical companies continue to recognise the need to develop the next generation of immunotherapies  This was evidenced by the announcement earlier in the year of the collaboration with AZN to develop five novel armed oncolytic immunotherapies based on Transgene s novel vaccinia virus double deleted backbone  Invir IO platform   Transgene received  10m upfront and is eligible for additional pre clinical milestones of up to  3m  If AZN decides to exercise an option on any of the candidates  Transgene will receive an option payment in addition to eligibility for development and commercial milestones  plus royalties on any future sales 
Transgene is responsible for the design and engineering of the oncolytic virus and for in vitro pre clinical development  AZN will select the genes to be encoded within the viruses and will be responsible for further in vivo pre clinical development  If AZN decides to take up the option on a virus it will then be responsible for clinical development and commercialisation  This partnership provides external validation of Transgene s oncolytic virus expertise and in the long term could be a significant contributor of revenue to the company  We do not currently value the AZN partnership due to its early nature but will reassess this once assets enter the clinic 
Tasly Biopharmaceuticals  Hong Kong IPO still expected
In July 2018  Transgene sold the greater China rights for T601  TG6002  and T101  TG1050  to Tasly Biopharmaceuticals  This was an expansion of a previous partnership formed in 2010 that was based on the development of T601 and T101  Transgene received approximately 2 53  of the outstanding capital of Tasly Biopharmaceuticals  which was valued at  48m  However  the valuation of this holding could decrease or increase depending on future funding events  Tasly has filed its prospectus with the Hong Kong Stock Exchange and we expect it to aim complete the IPO as soon as possible  although we note local political unrest could halt or delay any planned filing  Transgene has a 12 month post IPO lock up on its shares in Tasly Biopharmaceuticals 
In China T101 has completed a Phase I trial of T101 for treating chronic HBV infection  T101 is a viral vector that expresses the same suite of HBV antigens as TG1050  The trial is a randomised  double blind  placebo controlled study that enrolled 36 patients who are on antiviral therapy  According to Tasly the trial  produced satisfying results in safety  tolerability and immunogenicity  with both single and multiple injections well tolerated and producing no serious AEs  The trial demonstrated that T101 could stimulate an HBV specific T cell response when injected subcutaneously generated antiviral activity  Future development plans are unclear at this time 
T601 is an oncolytic virus that expresses the same FCU1 gene as TG6002  Tasly submitted an IND application to the China authorities  National Medical Products Administration  in April 2018 and it was approved in April 2019  Under the IND application  Tasly has agreed to commence a clinical trial in advanced malignant solid tumours of the digestive tract  The company expects a Phase I trial to initiate in H219 and plans to enrol 45 60 patients 
Invir IO and myvac  Deals demonstrate value
Transgene s early stage technology platforms Invir IO and myvac are coming to a critical juncture in the next 12 months as they enter the clinic  For myvac  Transgene has announced its plans to start clinical development  partnership with NEC Corporation  for new asset TG4050 by year end  TG4050 is based on Transgene s personalised immunotherapy platform  myvac  and NEC s neoantigen prediction system  Transgene will initiate two clinical studies in H219 focusing on second line  following surgery and chemo  ovarian cancer and second line  following surgery and radiation therapy  head and neck cancer patients  The trials are jointly funded by both parties 
In additional support of the industrialisation of the myvac platform  the NEOVIVA project was awarded a  5 2m grant from Bpifrance s  Investments for the Future  programme  Transgene will receive  2 6m of the grant  The NEOVIVA project is across four companies and aims to develop and validate manufacturing approaches for individualised therapies  The two TG4050 trials will provide proof of concept for the myvac platform 
In 2017  Transgene launched its Invir IO technology platform  The technology aims to use the cancer cell killing capability of oncolytic viruses in combination with the ability of the viruses to insert relevant genes into cancer cells to express other anti cancer compounds  The technology is based around high capacity vaccinia viruses  which are engineered to express a range of anti cancer drugs such as ICIs  enzymes  ligands  chemokines and cytokines  Transgene is developing both its own internal proprietary product candidates and partnered candidates  most notably with AZN and BioInvent 
The BioInvent collaboration is focused on new  unspecified multifunctional oncolytic viruses for the treatment of solid tumours  Transgene will provide its oncolytic virus expertise and technology  Invir IO   while BioInvent will provide its antibody capabilities  including novel antibody sequences  Costs  revenue and royalties will be split 50 50  The first product will look to vectorise BioInvent s anti CTLA 4 antibodies for use in cancers  R D costs  in addition to revenues and royalties from any candidates produced  will be shared 50 50  Transgene has 10 wholly owned preclinical candidates based on its Invir IO platform and anticipates the first product candidate will enter the clinic in H120 
Sensitivities
Transgene is subject to the usual risks associated with drug development  including clinical development delays or failures  regulatory risks  competitor successes  partnering setbacks and financing and commercial risks  The key sensitivities relate to the results of the ICI combination studies of TG4010 and TG4001  The outcome of the TG4010 combination studies in particular will have an impact on its partnership and or the financing prospects for the programme  First results from these trials will be available later this year  We note that the ICI combination trials are small  open label and non controlled  therefore  it is not possible to ascertain the magnitude of the effect of each product separately and assess the actual synergistic effect 
Financials   48 7m capital raise boosts cash reach
Transgene reported revenue for H119 of  4 9m  vs  3 5m in H118   which consisted of  3 1m in government financing for research expenditure and  1 5m in collaboration and licensing income  Net cash burn in H119 was  4 1m vs  8 3m in H119 and the company expects this to be around  20m for the full year  we forecast  20 4m  
Transgene reported cash and equivalents of  12 8m at 30 June 2019  vs  16 9m at 31 December 2018   This does not include the post period gross capital raise of  48 7m and the  10m upfront from signing the AZN deal 
Transgene has secured a  20m revolving credit facility with Natixis  The credit facility has a 30 month term and Transgene will be able to draw and repay the facility at its discretion  Transgene has used its shares  27 4m  in Tasly Biopharmaceuticals as collateral  We forecast a decrease in 2019 R D  to  23 3m  based on a reduction in the number of clinical trials y o y as numerous trials were completed or terminated in 2018  TG4010 in second line NSCLC  TG1050 in hepatitis B and Pexa Vec in HCC  breast and solid tumours   We forecast 2019 G A expenses   7 1m  to be largely in line with 2018  We forecast a cash reach into 2021 based on the capital raise and AZN upfront alone with no draw down of the Natixis credit facility 
Valuation   287m   3 45 share 
We value Transgene at  287m   3 45 share  vs  312m   5 02 share  previously  based on a risk adjusted NPV model of TG4010  TG4001  TG1050 and TG6002  The decrease in value is driven by the removal of Pexa Vec from our valuation  This has been offset by the gross  48 7m capital raise  assumed net  47m  and  10m upfront from the AZN deal  However  we note that on a per share basis our valuation has lowered significantly as a result of the dilution from the  48 7m capital raise  We have updated our R D cost assumptions across assets  rolled forward our model and updated for FX  Our valuation includes the prospects for TG4010 in NSCLC in the US and Europe  combined peak potential sales of c  2 5bn   TG1050 for hepatitis B in the US and Europe  peak potential sales of c  2 0bn across both regions   and TG4001 for oesophageal cancer in the US and Europe  peak potential sales of c  200m across both regions   Due to a shift in strategy we no longer value TG6002 for glioblastoma and instead now value its potential in colorectal cancer in the US and Europe  peak potential sales of c  800m across both regions   We do not currently include TG4050 or the Invir IO anti CTLA 4 oncolytic virus in our model but will reassess on the start of clinical trials
Our key assumptions on TG4010  TG1050  TG6002 and TG4001 are as follows 
TG4010  we model a classical clinical development timeline for the project in NSCLC  There could be considerable upside if the company goes for accelerated filing  and or development is expanded into other cancer indications 
TG1050  our valuation includes the EU and US markets and we have assumed TG1050 will be out licensed on completion of a successful Phase II proof of concept study  We forecast that a partner will fund Phase III trials  registration and commercial launch 
TG6002  we no longer value glioblastoma and our valuation is now based on colorectal cancer patients in the EU and US  For TG6002 we have assumed that TG1050 will be out licensed on completion of a successful Phase I studies  We forecast that a partner will fund Phase II III trials  registration and commercial launch 
TG4001  our valuation is based on HPV positive oesophageal patients in the EU and US who have failed standard therapy ",2019-09-23,Edison,https://www.investing.com/analysis/transgene-phocus-turns-to-earlierstage-assets-200467004,200467004
219827,441343,PFE,Drones to deliver vaccines  blood and drugs across Ghana,news,"By Kate Kelland LONDON  Reuters    Hundreds of drones will begin delivering life saving vaccines  blood and medicines to patients in Ghana this week in the largest scheme of its kind  the global vaccine alliance GAVI said on Wednesday  Medics will place orders by text message when supplies run dry  said GAVI chief executive Seth Berkley  Drones will then fly in from four distribution centers  hover over health posts and drop deliveries using tiny parachutes   The idea is that these four distribution centers can make up to 600 on demand delivery flights a day   Berkley told reporters in a telephone briefing   And that can expand up to 2 000  a day  over time   The aim is for deliveries to arrive within 30 minutes  Berkley added  meaning emergency treatments such anti snake venom or rabies shots could arrive in time to save lives  The project   led by Zipline  a California based robotics company   is designed to deliver to around 2 000 health facilities serving 12 million people across the west African country   It is backed by the non profits GAVI and the Bill   Melinda Gates Foundation  as well as several companies including the parcel delivery firm UPS and the pharmaceutical giant  Pfizer   NYSE PFE   Up to 12 routine and emergency vaccines will be available  including shots for yellow fever  polio  measles  meningitis and tetanus  as well as 148 blood products and other critical medicines  The drones fly autonomously and can carry up to 1 8 kilograms of cargo  GAVI said  
Zipline said a similar but smaller project had made more than 13 000 deliveries of blood products since it was launched in Rwanda in 2016   about a third of them for emergency life saving treatment ",2019-04-24,Reuters,https://www.investing.com/news/world-news/drones-to-deliver-vaccines-blood-and-drugs-across-ghana-1844082,1844082
219828,441344,PFE,Newer drugs fuel AstraZeneca quarterly sales beat,news,By Pushkala Aripaka and Ankur Banerjee  Reuters    AstraZeneca Plc beat first quarter sales and earnings expectations on Friday as the British drugmaker benefited from a push into cancer drugs and emerging markets including China  Newer treatments such as lung cancer drug Tagrisso  now the company s top selling medicine  have helped the drugmaker s return to growth after years of crumbling sales due to patent losses on older drugs   Sales in China have shown explosive growth  more than doubling since 2012  but AstraZeneca executives on Friday said that may not be sustained    The enormous growth you currently see in China  28 percent  probably is not sustainable  but we feel very bullish that the growth will continue to be at a pace of between 15 percent and 20 percent   Ruud Dobber  executive vice president  BioPharma  told Reuters   Shares of the company were down 0 2 percent at 5 878 pence at 1031 GMT   The turnaround in AstraZeneca s fortunes has been powered by a push into cancer treatments led by Chief Executive Pascal Soriot  who saw off a 2014 takeover bid from  Pfizer   NYSE PFE  in part by promising annual sales of  45 billion by 2023   In the first quarter  sales from its oncology unit rose 59 percent to  1 89 billion  accounting for 35 percent of total product sales   The company has moved deeper into cancer therapy market through wide ranging deals  including those for immunotherapy and targeted therapy  Last month  it agreed a multi billion dollar oncology deal with Japan s Daiichi Sankyo Co Ltd  Interactive graphic on AZN s top 10 drugs by sales     We re reaching that point where after years of having to keep faith  we have actually got something tangible to believe in    Hargreaves  Lansdown  LON HRGV  analyst Nicholas Hyett said   AstraZeneca also backed its annual sales and earnings forecast and said it has extensively prepared for UK s anticipated exit from the European Union  even in the event of a no deal exit   The company has already spent more than 40 million pounds   52 million  on Brexit preparations  including stockpiling six weeks  worth of drugs in the UK and four weeks in continental Europe to guard against shortages  AstraZeneca said product sales rose 14 percent at constant currency to  5 47 billion in the quarter  led by its lung cancer drug Tagrisso and respiratory treatment Pulmicort  Interactive graphic on AZN s quarterly oncology sales    China sales increased by 28 percent to  1 24 billion in the quarter  accounting for nearly a quarter of overall product sales  Core earnings came in at 89 cents per share in the quarter  Analysts on average were expecting core earnings of 85 cents per share and product sales of  5 29 billion  according to a company provided consensus of 19 analysts ,2019-04-26,Reuters,https://www.investing.com/news/stock-market-news/newer-drugs-fuel-astrazeneca-quarterly-sales-beat-1847420,1847420
219829,441345,PFE,Pfizer Earnings  Revenue Beat in Q1,news,"Investing com    Pfizer   NYSE PFE  reported first quarter earnings  that Beat analysts  expectations on Tuesday and revenue that topped forecasts 
The firm reported earnings per share of  0 85 on revenue of  13 12B  Analysts polled by Investing com forecast EPS of  0 75 on revenue of  13B  That compared to EPS of  0 77 on revenue of  12 91B in the same period a year earlier  The company had reported EPS of  0 64 on revenue of  13 98B in the previous quarter 

Pfizer follows other major Healthcare sector earnings this month
 On April 16  J J reported first quarter EPS of  2 1 on revenue of  20 02B  compared to forecasts of EPS of  2 04 on revenue of  19 61B 
Novartis ADR earnings Beat analysts  expectations on April 24  with first quarter EPS of  1 21 on revenue of  11 11B  Investing com analysts expected EPS of  1 11 on revenue of  11 09B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2019-04-30,Investing.com,https://www.investing.com/news/stock-market-news/pfizer-earnings-revenue-beat-in-q1-1850405,1850405
219835,441351,PFE,Pfizer Falls 3 ,news,"Investing com    Pfizer   NYSE PFE  fell by 3 02  to trade at  39 69 by 13 51  17 51 GMT  on Wednesday on the NYSE exchange 
The volume of Pfizer shares traded since the start of the session was 22 15M  Pfizer has traded in a range of  39 68 to  40 96 on the day 
The stock has traded at  43 0000 at its highest and  39 6500 at its lowest during the past seven days ",2019-04-17,Investing.com,https://www.investing.com/news/stock-market-news/pfizer-falls-3-1838911,1838911
219843,441359,PFE,Pfizer  PFE  Down 11 5  Since Last Earnings Report  Can It Rebound ,opinion,"A month has gone by since the last earnings report for Pfizer  PFE   Shares have lost about 11 5  in that time frame  underperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is Pfizer due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important catalysts  Pfizer Beats on Q2 Earnings  Misses Sales  Lowers 2019 OutlookPfizer posted mixed results for the second quarter of 2019  While it beat earnings estimates  it fell short of the consensus mark for revenues  The company lowered its guidance for full year earnings and sales Second quarter 2019 adjusted earnings per share of 80 cents beat the Zacks Consensus Estimate of 77 cents  Earnings rose 4  year over year driven by higher revenues on an operational basis  lower cost of sales and reduced share count  Currency changes had a negative impact of 3 cents per share on adjusted earnings Revenues of  13 26 billion missed the Zacks Consensus Estimate of  13 32 billion  Revenues declined 2  from the year ago quarter on a reported basis  On an operational basis  excluding the 4  negative impact of currency  revenues rose 2  year over year as higher sales of some key brands in Pfizer s Biopharmaceuticals group was partially offset by generic biosimilar competition for products that have lost marketing exclusivity and decline of Upjohn revenues in China International revenues declined 4  to  6 93 billion  However  on an operational basis  international sales rose 3  in the quarter  U S  revenues were up 2  to  6 34 billion Adjusted selling  informational and administrative  SI A  expenses rose 2   operationally  in the quarter to  3 46 billion  Adjusted R D expenses rose 3  to  1 83 billion Segment DiscussionIn 2018  Pfizer s reporting segments were Pfizer Innovative Health  IH  and Pfizer Essential Health  EH   Beginning the first quarter of 2019  Pfizer started reporting under three new business units   Pfizer Biopharmaceuticals Group  previous IH unit except Consumer Healthcare   Upjohn  previous EH unit  and Consumer Healthcare Pfizer Biopharma sales grew 2  on a reported basis  up 6  an operational basis  from the year ago period to  9 6 billion  Higher sales of brands like Eliquis  Ibrance and Xeljanz  biosimilars and a strong emerging markets performance  up 12   drove this segment s sales growth  Weaker sales of Prevnar 13 Prevenar 13 and Enbrel internationally and product supply shortages in the hospital business partially offset the increase Within the Biopharma group  Oncology revenues increased 23  to  2 24 billion  Vaccine revenues rose 2  to  1 38 billion  Internal Medicine rose 6  to  2 33 billion  The Inflammation   Immunology franchise rose 5  to  1 22 billion  However  the portfolio of Rare Disease declined 2  to  521 million  The newly added Hospital sub segment s sales declined 4  to  1 91 billion  The Hospital segment comprises Pfizer s global portfolio of sterile injectable and anti infective medicines  In the sterile injectables business  manufacturing supply constraints continue to impact Pfizer s sales Pfizer s Upjohn group s sales declined 11  on reported basis to  2 81 billion  On an operational basis  sales declined 7  in the segment due to lower revenues in China and the United States  China revenues were hurt by volume based procurement reforms that were implemented in March 2019 while in the United States  sales were hurt by lower revenues for Viagra Revenues from the Consumer Healthcare unit declined 3  to  862 million  However  on an operational basis  sales rose 1  as lower sales in the U S  market were offset by higher sales in international markets Performance of Key DrugsIbrance revenues rose 27  year over year to  1 26 billion on continued strong uptake in developed Europe and Japan as well as in certain emerging markets and consistent growth in the United States Xeljanz sales rose 36  to  613 million driven by continued growth in rheumatoid arthritis  RA  revenues and contributions from the drug s recent expansion into psoriatic arthritis and ulcerative colitis in the United States and only ulcerative colitis indication in certain developed markets In July  Xeljanz s prescribing information in the United States was updated by the FDA to include two additional boxed warnings as well as changes to the indication and dosing for UC following review of a post marketing study  Regarding this update  Pfizer mentioned on the call that the label update may have some negative impact on prescribing and hurt sales in the future quarters Global Prevnar 13 Prevenar 13 revenues declined 3  to  1 18 billion  Prevnar 13 revenues declined 10  in the United States  reflecting decreased government purchases for the pediatric indication and continued decline in revenues for the adult indication  Prevenar 13 revenues rose 6  in international markets Meanwhile  due to some unfavorable revisions in ACIP s pneumococcal vaccination guidelines for Prevnar 13 in adults in the United States  Pfizer expects some decline in demand for Prevnar  which can hurt sales in the future quarters Enbrel revenues declined 16  to  420 million in key European markets due to continued biosimilar competition as well as unfavorable timing of government purchases in certain emerging markets Xalkori sales rose 2  to  133 million  Sutent sales declined 4  to  248 million  Inlyta revenues increased 34  to  104 million  Eliquis alliance revenues and direct sales rose 26  to  1 09 billion  Chantix sales rose 1  to  276 million in the quarter  Xtandi recorded alliance revenues of  201 million in the quarter  up 18  year over year Revenues from the biosimilars portfolio grew 20  operationally to  217 million in the quarter  Inflectra recorded sales of  53 million globally  flat year over year  New biosimilar product  Retacrit  a biosimilar of Epogen and Procrit  is off to a good start in the United States  recording  30 million of revenues in the second quarter In the Upjohn segment  sales of key drug Lyrica declined 1  to  1 18 billion reflecting wholesaler destocking ahead of the drug s loss of exclusivity  which began in July  Viagra sales declined 35  to  114 million due to generic competition that began in December 2017 2019 GuidancePfizer lowered its previously issued sales and earnings guidance for 2019 to reflect the formation of the Consumer Healthcare JV with Glaxo and the completion of Array BioPharma and Therachon acquisitions  Other than pending business development activity  incremental negative impact of foreign exchange and unfavorable product developments in case of Prevnar and Xeljanz also contributed to the guidance cut Revenues are expected in the range of  50 5 billion to  52 5 billion compared with  52 0 billion to  54 0 billion expected previously  Adjusted earnings per share are expected in the range of  2 76  2 86 versus the previous expectation of  2 83  2 93 For the remainder of the year  the consumer JV with Glaxo is expected to have a negative impact of 3 cents on adjusted EPS  The Array and Therachon acquisitions will hurt the same by 4 cents per share  Foreign exchange is expected to have a unfavorable impact of  1 2 billion on revenues and 8 cents on adjusted EPS for the year  which represents more onerous negative impact than guided previously Research and development expense is expected in the range of  7 9  8 3 billion versus  7 8  8 3 billion while SI A spending is projected in the range of  13 0  14 0 billion versus  13 5   14 5 billion expected earlier  Adjusted tax rate is still expected to be approximately 16  in 2019  
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates  The consensus estimate has shifted  8 15  due to these changes 
VGM Scores
At this time  Pfizer has a subpar Growth Score of D  however its Momentum Score is doing a lot better with a B  Charting a somewhat similar path  the stock was allocated a grade of C on the value side  putting it in the middle 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of C  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of these revisions indicates a downward shift  It s no surprise Pfizer has a Zacks Rank  5  Strong Sell   We expect a below average return from the stock in the next few months ",2019-08-27,Zacks Investment Research,https://www.investing.com/analysis/pfizer-pfe-down-115-since-last-earnings-report-can-it-rebound-200459353,200459353
219844,441360,PFE,Global Blood Focuses On Lead Candidate Amid Competition,opinion,We issued an updated report on Global Blood Therapeutics  Inc    NASDAQ GBT   on Sep 2 The company s lead product candidate is voxelotor  GBT440   an oral  once daily treatment for sickle cell disease  SCD   SCD is a chronic  inherited blood disorder that affects hemoglobin  The company is evaluating voxelotor in a phase III HOPE study in adult and adolescent patients with SCD  Data from the study  presented in December 2018  demonstrated rapid  robust and sustained improvements in hemoglobin levels and measures of hemolysis  with a favorable safety and tolerability profile for both 1500 mg and 900 mg doses In the second quarter of 2019  the company announced a final agreement with the FDA on the design of the post approval confirmatory study of voxelotor to demonstrate stroke risk reduction benefit of the drug  considering transcranial doppler  TCD  flow velocity as the primary endpoint Shares of the company have gained 12  year to date against the s decline of 1 7    The FDA approved a rolling submission of voxelotor for the potential treatment of SCD  The company expects to submit an NDA in the second half of 2019 In August 2018  the company entered an exclusive worldwide license agreement with drug giant Roche Holding  SIX ROG  AG   OTC RHHBY   for the development and commercialization of inclacumab  a novel  fully human monoclonal antibody against P selectin  as a treatment for vaso occlusive crises   VOC   in patients with SCD However  Global Blood has no approved products in its portfolio yet  The company has only one candidate  voxelotor  which is in late stage studies  If the company is unable to receive regulatory approval for the drug  its business will be significantly affected  as inclacumab is in early stages of development The company is also battling stiff competition  The FDA has accepted Novartis    NYSE NVS   Biologics License Application  BLA  for its investigational sickle cell medicine  crizanlizumab  SEG101   and granted Priority Review to the same  Pfizer   NYSE PFE   is also developing rivipansel for the treatment of VOC in patients with SCD Global Blood currently has a Zacks Rank  3  Hold   You can see Legalizing THIS Could Be Even Bigger than Marijuana Americans spend an estimated  150 billion in this industry every year  more than twice as much as they spend on marijuana Now that 8 states have fully legalized it  with several more states following close behind   Zacks has identified 5 stocks that could soar in response to the powerful demand  One industry insider described the future as  mind blowing    and early investors can still get in ahead of the surge ,2019-09-03,Zacks Investment Research,https://www.investing.com/analysis/global-blood-focuses-on-lead-candidate-amid-competition-200461060,200461060
219856,441372,PFE,Medical R D Alliance Expands Blockchain Project to Include Data Sharing,news,"The Pistoia Alliance has expanded its blockchain project to include data sharing  data identity  and data integrity  according to a press release published on Feb 8 
The Pistoia Alliance is a not for profit organization established in 2007  with representatives from well known pharmaceutical industry companies which include  Pfizer   NYSE PFE   Novartiz  and GSK  The Pistoia Alliance was formed to help integrate new technology to assist in the companies  respective research and development  R D  fields ",2019-02-08,Cointelegraph,https://www.investing.com/news/cryptocurrency-news/medical-rd-alliance-expands-blockchain-project-to-include-data-sharing-1774724,1774724
219857,441373,PFE,Irish drug trial technology firm Teckro wins  25 million injection,news,By Ludwig Burger  Reuters    Ireland s Teckro  which makes software that allows physicians to take part in drug development trials from mobile devices  has won  25 million in financial backing from investors  as it hatches longer term plans for a stock market listing  A fund managed by Bill Maris  the former head of Google s venture capital arm  as well as Founders Fund  an early backer of SpaceX and Airbnb  took part in the latest funding round  it said on Thursday  It will allow Teckro to expand internationally and develop its machine learning based digital platform  which it sells to drugmakers  The drug companies  in turn  make the software available to physicians and nurses involved in the clinical development studies they sponsor   Testing on humans is by far the most expensive part of bringing experimental drugs to market   Those costs are rising as the science behind the drug becomes more complex and Teckro says it can simplify the process by moving some of the paperwork into digital form and by allowing doctors to quickly retrieve information   It s really about providing answers to day to day questions any doctor and nurse may have in the context of a clinical trial in an instant   said co founder and Chief Executive Gary Hughes  The healthcare industry is quickly adopting digital business models  using tools from computer aided molecular drug design to artificial intelligence to analyze patients  treatment history or genetic code   Pharma majors Novartis  GlaxoSmithKline and  Pfizer   NYSE PFE  have created the role of chief digital officer over the past two years  Teckro s system is already used by more than 10 000 healthcare practitioners and its commercial customers include global pharma majors as well as smaller biotech firms  said Hughes  He declined to provide names  The latest round takes Teckro s total funding to  43 million  Hughes declined to say what percentage in the company the investors received in return or what price tag the transaction puts on the entire company  If the administrative hassle of clinical trials can be reduced more community hospitals will eventually be able to participate in them  he added   While Teckro s three founders sold a previous venture  Firecrest  in 2011  Hughes vowed that they have longer term ambitions for Teckro  which was founded in 2015   This time our ambition is to go all the way  An IPO  initial public offering  is potentially out there  We don t have a specific time frame in mind  other than we re thinking long term for Teckro  ,2019-02-14,Reuters,https://www.investing.com/news/technology-news/irish-drug-trial-technology-firm-teckro-wins-25-million-injection-1779332,1779332
219870,441386,PFE,Conatus  CNAT  Beats On Q2 Earnings  Stops Emricasan Studies,opinion,Conatus Pharmaceuticals Inc    NASDAQ CNAT   reported a loss of 2 cents per share in the second quarter of 2019  narrower than the Zacks Consensus Estimate of 12 cents and also the year ago loss of 15 cents Moreover  revenues of  10 8 million rose 22 7  year over year owing to an increase in net cumulative catch up revenues recognized from its partner Novartis   NYSE NVS    Moreover  the top line comprehensively beat the Zacks Consensus Estimate of  7 million Shares of Conatus have plummeted 82 3  so far this year against the  increase of 12 3  Conatus has no approved product in its portfolio at the moment  The revenues generated by the company are all related to its collaboration with Novartis for the worldwide development and commercialization of emricasan  Due to lack of an approved product  the company is totally dependent on emricasan for growth However  following a series of disappointing results from the study on emricasan  Conatus and Novartis have decided to stop planning for the further development of emricasan  Moreover  along with earnings release  Conatus stated that is in discussion with Novartis for winding down the collaboration altogether Emricasan  a caspase inhibitor  was being developed for the treatment of patients with fibrosis or cirrhosis caused by nonalcoholic steatohepatitis  NASH   Conatus acquired the worldwide rights to emricasan from Pfizer   NYSE PFE   in July 2010 Quarter in DetailIn the second quarter  research and development expenses were  8 6 million  down 19 6  from the year ago figure  mainly owing to lower expenses related to emricasan and lower personnel costs General and administrative expenses were  3 1 million  up 19 2  from the year earlier quarter  primarily due to the recognition of severance and noncash stock compensation costs Emricasan FailsIn June  Conatus announced top line results from the phase IIb ENCORE LF study on emricasan for treating patients with decompensated nonalcoholic steatohepatitis  NASH  cirrhosis  The study failed to meet its primary endpoint  Consequently  the company decided to discontinue further development of emricasan in the ENCORE LF study At the same time  Conatus announced outcomes of the phase IIb ENCORE PH program  which evaluated emricasan for a 24 week extension period  Although results were consistent from the initial 24 week treatment period  the study missed predefined objectives Last December  Conatus presented top line data from the ENCORE PH study wherein emricasan demonstrated clinically meaningful treatment effects on the compensated NASH cirrhosis patients  who face the peril of passing to the decompensation state  However  the study failed to attain its primary goal Earlier this March  Conatus announced that the ENCORE NF study  which evaluated emricasan for treating patients with biopsy confirmed NASH and liver fibrosis  could not achieve the primary goal as it lacked the desired effect on earlier stage NASH fibrosis patients Also  in June 2019  Conatus announced that it is planning to explore and evaluate strategic alternatives to add shareholder value  The company appointed Oppenheimer   Co   Inc  an independent investment bank and financial services company as its financial advisor for assistance Conatus also decided to slash its staff headcount by almost 40  as part of its restructuring plan and suspend the development of its preclinical candidate CTS 2090  which was being assessed for treating autoinflammatory diseases As of Jun 30  2019  Conatus had cash  cash equivalents and marketable securities of  28 7 million compared with  33 8 million as of Mar 31  2018  The company expects the current year end balance in the range of  10  15 million Conatus Pharmaceuticals Inc  Price  Consensus and EPS Surprise   Zacks Rank   Key PickConatus carries a Zacks Rank  3  Hold   A better ranked stock in the healthcare sector is BeiGene  Ltd    NASDAQ BGNE    which sports a Zacks Rank  1  Strong Buy   You can see  BeiGene s loss per share estimates have been narrowed 2 7  for 2019 and 2 2  for 2020 over the past 60 days This Could Be the Fastest Way to Grow Wealth in 2019Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ,2019-08-06,Zacks Investment Research,https://www.investing.com/analysis/conatus-cnat-beats-on-q2-earnings-stops-emricasan-studies-200452370,200452370
219871,441387,PFE,Deciphera s GIST Drug Succeeds In Pivotal Study  Stock Up 80 ,opinion,"Deciphera Pharmaceuticals  Inc    NASDAQ DCPH   announced encouraging data from a pivotal phase III study   INVICTUS   evaluating its pipeline candidate  ripretinib  in patients with gastrointestinal stromal tumors   GIST   in fourth or later line setting  Data from the study demonstrated that treatment with ripretinib led to significant reduction in the risk of disease progression or death On the back of this encouraging data  the company announced that it will file a new drug application in the first quarter of 2020  seeking approval of ripretinib in a similar indication Shares of Deciphera skyrocketed almost 80  on Aug 13  following the study data announcement  In fact  the company s shares have rallied 71  so far this year against the  s decline of 2 1   The INVICTUS study evaluated KIT and PDGFR  inhibitor  ripretinib  in GIST patients previously treated with at least Novartis    NYSE NVS   Gleevec  imatinib   Pfizer s   NYSE PFE   Sutent  sunitinib  and Bayer s   OTC BAYRY   Stivagra  regorafenib  Data from the study showed ripretinib met the primary endpoint of progression free survival   PFS    The median progression free survival or PFS was 6 3 months for ripretinib  significantly higher than 1 month for placebo or 85  reduction in risk of disease progression or death  Median overall survival was 15 1 months for ripretinib versus 6 6 months for placebo  Although ripretinib improved objective response rate or ORR   9 4    it was not statistically significant compared to placebo  ORR 0   In a separate press release  Deciphera announced updated data from a phase I study evaluating ripretinib in GIST patients in second  third or fourth line settings  Data showed that treatment with ripretinib led to median PFS of 42 weeks  40 weeks and 30 weeks  and achieved ORR of 30   23  and 15  in second   third  and fourth line setting  respectively  Updated data demonstrates that median PFS was sustained across all arms of the study  Moreover  the data supports ongoing phase III study   INTRIGUE   evaluating ripretinib in second line GIST Deciphera Pharmaceuticals  Inc  Price
    Zacks RankDeciphera currently has a Zacks Rank  3  Hold   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-08-13,Zacks Investment Research,https://www.investing.com/analysis/decipheras-gist-drug-succeeds-in-pivotal-study-stock-up-80-200455116,200455116
219872,441388,PFE,Epizyme  EPZM  Focuses On Developing Lead Drug Tazemetostat,opinion,We issued an updated report on Epizyme Inc    NASDAQ EPZM   on Aug 14 The company s lead pipeline candidate is tazemetostat  a first in class EZH2 inhibitor  which is currently being evaluated for the treatment of solid tumors and hematological malignancies as a monotherapy and to treat relapsed and front line disease as a combination therapy Epizyme s NDA for accelerated approval of tazemetostat for the treatment of patients with metastatic or locally advanced epithelioid sarcoma  ES   who are not eligible for curative surgery  was accepted by the FDA for priority review in July 2019  The FDA is expected to give its decision on Jan 23  2020  If approved  tazemetostat will be the first commercially available EZH2 inhibitor and the first treatment specifically indicated for epithelioid sarcoma patients   A potential approval will significantly boost the growth prospectsThe company also plans to submit an NDA for accelerated approval of tazemetostat in patients with follicular lymphoma  FL   regardless of their EZH2 mutational status  who have been previously treated with two or more systemic therapies  The company expects to submit the NDA for accelerated approval in the fourth quarter of 2019  Epizyme is planning to initiate multiple clinical studies to evaluate tazemetostat in earlier treatment lines of follicular lymphoma  and explore new combinations and potential indications in both FL and solid tumors The company also intends to discover the potential of tazemetostat in earlier lines of FL as combination therapy  It is planning to conduct a confirmatory program with an adaptive study evaluating the combination of tazemetostat and the chemo free treatment regimen  R2   Celgene s   NASDAQ CELG   Revlimid plus Roche s   OTC RHHBY   Rituxan  in the second line or later treatment setting for FL patients  both with and without EZH2 activating mutations  The final design is subject to alignment with the FDA and the company expects to initiate the safety run in portion in the second half of 2019 Epizyme also aims at completing IND enabling studies on EZM8266  its G9a inhibitor designed to treat patients with sickle cell disease  SCD   It is on track to begin clinical development of the candidate in the second half of 2019 with a dose finding and safety study Epizyme s proprietary product platform is used to create small molecule inhibitors of a class of enzymes known as histone methyltransferases  HMTs   However  the company faces competition from companies like Glaxo  Novartis   NYSE NVS    Pfizer  NYSE PFE  and Constellation  which are developing new epigenetic treatments for cancer targeting HMTs Breakout Biotech Stocks with Triple Digit Profit Potential The biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases  Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-08-14,Zacks Investment Research,https://www.investing.com/analysis/epizyme-epzm-focuses-on-developing-lead-drug-tazemetostat-200455494,200455494
219873,441389,PFE,Pfizer Rises 3 ,news,"Investing com    Pfizer   NYSE PFE  rose by 3 01  to trade at  42 46 by 14 49  19 49 GMT  on Thursday on the NYSE exchange 
The volume of Pfizer shares traded since the start of the session was 20 56M  Pfizer has traded in a range of  41 35 to  42 46 on the day 
The stock has traded at  42 4700 at its highest and  39 4700 at its lowest during the past seven days ",2019-01-31,Investing.com,https://www.investing.com/news/stock-market-news/pfizer-rises-3-1765513,1765513
219874,441390,PFE,GSK pays up to  4 2 billion for Merck KGaA cancer immunotherapy,news,"By Ludwig Burger FRANKFURT  Reuters    GlaxoSmithKline bolstered its cancer drug development pipeline on Tuesday  agreeing to pay up to 3 7 billion euros   4 2 billion  to Germany s Merck KGaA for the rights to a next generation immunotherapy  Merck will receive an upfront payment of 300 million euros for the drug   known as M7824  or bintrafusp alfa   and is eligible for potential payments of up to 500 million euros depending on development milestones in lung cancer  the two companies said in statements on Tuesday  Merck could also get up to a further 2 9 billion euros  depending on commercial milestones  for a total deal value of as much as 3 7 billion euros  Merck will book any future U S  sales from the product  while GSK will account for sales from other parts of the world  GSK in December moved to bolster its cancer medicines cabinet with the  5 1 billion purchase of Tesaro   Later that month  it unveiled plans to separate its prescription drugs and vaccines business from its over the counter products unit under a joint venture deal with Pfizer s consumer health division   For GSK  this alliance is a further step in the company s priority to strengthen its pharmaceuticals pipeline   it said  The M7824 drug  a fusion protein that triggers two immune responses to cancer cells  is being tested on 10 tumour types and was recently shown to delay the progression of a certain type of lung cancer for at least 9 5 months in half of the trial participants  Merck has already started a mid stage phase II trial in non small cell lung cancer  comparing M7824 directly with U S  rival Merck   Co s Keytruda  currently seen as the most promising cancer immunotherapy on the market with  7 2 billion in 2018 sales  Keytruda is part of a class of immunotherapies known as checkpoint inhibitors  which are expected to generate well over  20 billion in combined annual revenues over the next few years  Merck KGaA  which has no ownership ties with Merck   Co  is competing in that class with a drug called Bavencio  jointly developed with  Pfizer   NYSE PFE   but analysts expect the drug to play only a minor commercial role  For M7824  Merck combined Bavencio s mode of action with another immune response booster known as TGF beta inhibtion   This combination in a single molecule is unique  We don t know of any other at this time   said Belen Garijo  the head of Merck s healthcare division   Deutsche Bank   DE DBKGn  analysts said the trial against Keytruda was the main study to watch   We expect investors to see the deal as a bold move to build GSK s late stage oncology pipeline  bringing in an asset with very large potential but with substantial risk   they wrote in a note   Merck s shares traded 2 1 percent higher at 1420 GMT  while GSK was up 1 7 percent  both outperforming the 0 7 percent gain in the STOXX Europe 600 Health Care index  
  1   0 8758 euros ",2019-02-05,Reuters,https://www.investing.com/news/stock-market-news/gsk-pays-up-to-42-billion-for-merck-kgaa-cancer-immunotherapy-1769709,1769709
219883,441399,PFE,SNY Vs  PFE  Which Stock Is The Better Value Option ,opinion,"Investors interested in Large Cap Pharmaceuticals stocks are likely familiar with Sanofi  PA SASY   SNY  and Pfizer  PFE   But which of these two stocks is more attractive to value investors  We ll need to take a closer look to find out 
The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system  The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends  while our Style Scores work to grade companies based on specific traits 
Sanofi and Pfizer are sporting Zacks Ranks of  2  Buy  and  5  Strong Sell   respectively  right now  This means that SNY s earnings estimate revision activity has been more impressive  so investors should feel comfortable with its improving analyst outlook  But this is just one piece of the puzzle for value investors 
Value investors are also interested in a number of tried and true valuation metrics that help show when a company is undervalued at its current share price levels 
Our Value category highlights undervalued companies by looking at a variety of key metrics  including the popular P E ratio  as well as the P S ratio  earnings yield  cash flow per share  and a variety of other fundamentals that have been used by value investors for years 
SNY currently has a forward P E ratio of 12 37  while PFE has a forward P E of 13 12  We also note that SNY has a PEG ratio of 1 84  This figure is similar to the commonly used P E ratio  with the PEG ratio also factoring in a company s expected earnings growth rate  PFE currently has a PEG ratio of 2 93 
Another notable valuation metric for SNY is its P B ratio of 1 59  The P B is a method of comparing a stock s market value to its book value  which is defined as total assets minus total liabilities  By comparison  PFE has a P B of 3 47 
Based on these metrics and many more  SNY holds a Value grade of A  while PFE has a Value grade of D 
SNY stands above PFE thanks to its solid earnings outlook  and based on these valuation figures  we also feel that SNY is the superior value option right now ",2019-08-05,Zacks Investment Research,https://www.investing.com/analysis/sny-vs-pfe-which-stock-is-the-better-value-option-200451376,200451376
219884,441400,PFE,Pfizer Shares Slump 2  After Cutting Full Year Revenue Outlook,news,"Investing com   Shares of  Pfizer   NYSE PFE  slumped in premarket trade on Tuesday  after the pharmaceutical giant provided a downbeat revenue outlook for the coming year 
For 2019  the company revised its revenue guidance range to  52 0 billion to  54 0 billion from  53 0 billion to  53 7 billion and lowered its forecast for adjusted EPS to between  2 82 and  2 92   from an earlier range of  2 98 to  3 02  
 We enter 2019 with confidence in the competitive positioning of our businesses  the prospects for our recently launched products and product line extensions  as well as the strength and breadth of our research pipeline   Albert Bourla  Pfizer s chief executive officer  said in a press release 
The lowered forecast represented expectations for an  essentially flat operating performance  this year  with the overall drop being explained by foreign exchange movements and changes in the value of equity investments 
For the current quarter  Pfizer posted earnings per share of 64 cents for the fourth quarter  matching expectations 
Revenue totaled  13 98 billion  above forecasts of  13 96 billion 
Pfizer shares dropped 2 2  in premarket trade to  38 68 
Pfizer follows other major Healthcare sector earnings this month
 On January 22  J J reported fourth quarter EPS of  1 97 on revenue of  20 39B  compared to forecasts of EPS of  1 95 on revenue of  20 2B 
Abbott Labs earnings matched analysts  expectations on January 23  with fourth quarter EPS of  0 81 on revenue of  7 77B  Investing com analysts expected EPS of  0 81 on revenue of  7 81B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2019-01-29,Investing.com,https://www.investing.com/news/stock-market-news/pfizer-earnings-inline-revenue-beats-in-q4-1761210,1761210
219885,441401,PFE,Pfizer Rises 3 ,news,"Investing com    Pfizer   NYSE PFE  rose by 3 05  to trade at  40 66 by 12 20  17 20 GMT  on Tuesday on the NYSE exchange 
The volume of Pfizer shares traded since the start of the session was 21 25M  Pfizer has traded in a range of  39 47 to  40 74 on the day 
The stock has traded at  42 8800 at its highest and  39 4400 at its lowest during the past seven days ",2019-01-29,Investing.com,https://www.investing.com/news/stock-market-news/pfizer-rises-3-1761798,1761798
219887,441403,PFE,Pfizer  PFE  Q2 Earnings Top Estimates,opinion,"Pfizer  PFE  came out with quarterly earnings of  0 80 per share  beating the Zacks Consensus Estimate of  0 77 per share  This compares to earnings of  0 81 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 3 90   A quarter ago  it was expected that this drugmaker would post earnings of  0 77 per share when it actually produced earnings of  0 85  delivering a surprise of 10 39  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
Pfizer  which belongs to the Zacks Large Cap Pharmaceuticals industry  posted revenues of  13 26 billion for the quarter ended June 2019  missing the Zacks Consensus Estimate by 0 44   This compares to year ago revenues of  13 47 billion  The company has topped consensus revenue estimates two times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Pfizer shares have lost about 1 3  since the beginning of the year versus the S P 500 s gain of 20 7  
What s Next for Pfizer 
While Pfizer has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Pfizer was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  0 68 on  12 86 billion in revenues for the coming quarter and  2 88 on  52 86 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Large Cap Pharmaceuticals is currently in the top 14  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-07-29,Zacks Investment Research,https://www.investing.com/analysis/pfizer-pfe-q2-earnings-top-estimates-200446288,200446288
219888,441404,PFE,Aileron up 35  on advancement of ALRN 6924   Ibrance study,news,Thinly traded nano cap Aileron Therapeutics  ALRN  35 1   is up on an 8x surge in volume following its announcement that dosing is underway in an expansion cohort in its Phase 2a clinical trial evaluating lead candidate ALRN 6924  combined with  Pfizer  s  PFE  0 6   IBRANCE  palbociclib   in patients with MDM2 amplified solid tumors The new arm will enroll up to 25 participants  Preliminary data should be available in H2 ALRN 6924 is a cell permeating peptide that mimics the p53 tumor suppressor protein to disrupt its interaction with MDMX and MDM2  two proteins that interfere with its action Palbociclib inhibits two enzymes  CDK4 and CDK6  that play key roles in the cell cycle  Blocking their action interferes with cancer cell proliferation Now read ,2019-01-16,Seeking Alpha,https://www.investing.com/news/stock-market-news/aileron-up-35-on-advancement-of-alrn6924--ibrance-study-1748934,1748934
219889,441405,PFE,GSK Chairman Hampton to step down ahead of split,news,"By Arathy S Nair  Reuters    GlaxoSmithKline Plc  L GSK  Chairman Philip Hampton will step down after more than three and a half years in the role  as Britain s biggest drugmaker prepares to split its business into two  The announcement comes a month after GSK s Chief Executive Emma Walmsley announced her boldest plans yet   to split the company into two businesses    one for prescription drugs and vaccines  the other for over the counter products  Walmsley  who took the helm in 2017  announced in December that GSK and  Pfizer   N PFE  would combine their consumer health businesses in a joint venture with sales of 9 8 billion pounds   12 7 billion   68 percent owned by the British company  in an all equity transaction   Following the announcement of our deal with Pfizer and the intended separation of the new consumer business  I believe this is the right moment to step down and allow a new Chair to oversee this process through to its conclusion over the next few years   Hampton said in a statement  Hampton  aged 65  was paid a sum of 700 000 pounds   900 550   of which he elected to take 25 percent in GSK shares  according to the company s 2017 annual report  He took the top job at GSK at a testing time   just after a profit warning in 2014 due to weak sales of its core respiratory drugs   The Briton was tasked with helping steer the drugmaker back to sustainable growth  Shares of GSK have  however  remained flat after peaking about 17 percent during his tenure  They were little changed in early trading on Monday   GSK  whose consumer products include Sensodyne toothpaste and Panadol painkillers  has lagged rivals in recent years in producing multibillion dollar blockbusters and it largely sat out a spate of dealmaking by rivals under previous CEO Andrew Witty   Seeking to reassure investors of its financial strength  GSK extended its guarantee on the dividend by stating it expected to pay unchanged dividends of 80 pence per share for 2019  Before joining GSK  Hampton was chairman of Royal Bank of Scotland Group Plc  L RBS  and J  Sainsbury  plc  L SBRY    He was parachuted in to help rescue RBS following its 45 billion pounds bailout during the financial crisis and led the bank through a turbulent period of transition  
GSK  which has been looking to buy early stage assets and partner with companies  said it had started the search for a successor ",2019-01-21,Reuters,https://www.investing.com/news/stock-market-news/gsk-chairman-hampton-to-step-down-1752153,1752153
219890,441406,PFE,Pfizer Falls 3 ,news,"Investing com    Pfizer   NYSE PFE  fell by 3 01  to trade at  40 88 by 11 56  16 56 GMT  on Thursday on the NYSE exchange 
The volume of Pfizer shares traded since the start of the session was 12 70M  Pfizer has traded in a range of  40 89 to  41 79 on the day 
The stock has traded at  43 2400 at its highest and  40 8200 at its lowest during the past seven days ",2019-01-24,Investing.com,https://www.investing.com/news/stock-market-news/pfizer-falls-3-1756759,1756759
219897,441413,PFE,Analysts Estimate Pfizer  PFE  To Report A Decline In Earnings  What To Look Out For,opinion,"The market expects Pfizer  PFE  to deliver a year over year decline in earnings on lower revenues when it reports results for the quarter ended June 2019  This widely known consensus outlook is important in assessing the company s earnings picture  but a powerful factor that might influence its near term stock price is how the actual results compare to these estimates 
The earnings report  which is expected to be released on July 30  2019  might help the stock move higher if these key numbers are better than expectations  On the other hand  if they miss  the stock may move lower 
While management s discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations  it s worth having a handicapping insight into the odds of a positive EPS surprise 
Zacks Consensus Estimate
This drugmaker is expected to post quarterly earnings of  0 77 per share in its upcoming report  which represents a year over year change of  4 9  
Revenues are expected to be  13 42 billion  down 0 3  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  This insight is at the core of our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction  
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Pfizer 
For Pfizer  the Most Accurate Estimate is lower than the Zacks Consensus Estimate  suggesting that analysts have recently become bearish on the company s earnings prospects  This has resulted in an Earnings ESP of  2 91  
On the other hand  the stock currently carries a Zacks Rank of  3 
So  this combination makes it difficult to conclusively predict that Pfizer will beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Pfizer would post earnings of  0 77 per share when it actually produced earnings of  0 85  delivering a surprise of  10 39  
Over the last four quarters  the company has beaten consensus EPS estimates four times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Pfizer doesn t appear a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-07-22,Zacks Investment Research,https://www.investing.com/analysis/analysts-estimate-pfizer-pfe-to-report-a-decline-in-earnings-what-to-look-out-for-200443290,200443290
219898,441414,PFE,Can Pfizer s Q2 Earnings Help Boost PFE Stock In A Struggling Pharma Market ,opinion,"Pfizer Inc    NYSE PFE   is set to report its Q2 earnings results on Tuesday  July 30  Investors are hoping the report can boost PFE stock since it is down over 2  YTD 
It is important to note the large cap pharmaceutical market has been struggling as a whole recently  The Large Cap Pharma market is down roughly 1  so far this year  while the S P 500 is up 18  in 2019 

Overview
Headquartered in New York City  Pfizer is one of the world s largest pharmaceutical companies  The company is a component of the so called S P 100 and ranked No  57 on the Fortune 500 list in 2018  Pfizer produces popular over the counter drugs such as Advil and Robitussin  as well as a variety of prescription drugs including Lipitor  Viagra  Xanax  and Zoloft 
Along with some of the most popular drugs on the market  Pfizer boasts a major research and develop leg  as do many pharma companies  Pfizer had 97 drugs in its product pipeline as of April 30  according to its website  Over a third of these drugs are currently in the clinical trial phase  or being registered approved by the FDA 
PFE is trading with a P E of 14 72 at the moment  This is just above the industry average of 14 42  but Pfizer has historically traded below its peers  Although the stock is down YTD  it has gained 7  over the past 3 months  In that same time period  its forward earnings estimates have not increased at the same rate which has caused its P E to increase substantially  Because of this  PFE could potentially be overvalued at its current price of  42 89 

Pfizer also pays a dividend and it has increased its payout by  0 08 annually every year since first announcing its dividend in 2009  PFE s annual dividend is currently  1 44 a share  with a strong 3 4  yield at the moment 
Q2 Outlook   Earnings Trends
In Q2  Pfizer is expected to earn  13 42 billion in revenue  according to our Zacks Consensus Estimates  That number falls 0 31  below the year ago period s revenue of  13 47 billion  Revenue shrinkage is not expected to end after this quarter either  with Q3 revenues projected to sink 4 26   And overall fiscal 2019 sales are expected to fall 1 47  
Looking back  Q1 revenue did pop 2  year over year  primarily driven by growth in key brands and emerging markets  Foreign exchange rates had a significant negative effect on Pfizer s Q1 financials and this problem may persist in Q2 
Meanwhile  Pfizer s adjusted EPS figure is also expected to decline  Current estimates call for EPS of  0 77 in Q2  a 4 94  fall from the same period last year  This expected quarterly decline is part of the reason Pfizer s yearly EPS is predicted to fall 4  from last year 
Bottom Line
Pfizer s growth prospects are not that strong right now  With that said  the company provides income through its solid dividend and PFE stock had tracked the larger market for the better part of a decade  until its recent downturn  In the end  Pfizer is a relatively safe investment given its historical performance and should not be going anywhere anytime soon 
If the firm can post better than expected Q2 earnings it may help it to bounce back from its YTD slump  Additionally  any positive updates regarding the progress of its drugs in development could lift PFE stock 
The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2019-07-24,Zacks Investment Research,https://www.investing.com/analysis/can-pfizers-q2-earnings-help-boost-pfe-stock-in-a-struggling-pharma-market-200444398,200444398
219899,441415,PFE,Pfizer launches pivotal study of alopecia areata candidate,news,Pfizer   NYSE PFE  initiates a Phase 2b 3 clinical trial evaluating Breakthrough Therapy tagged PF 06651600  an oral JAK3 inhibitor  in patients with alopecia areata  an autoimmune disorder characterized by hair loss on the scalp  face or body The primary endpoint of the 660 subject  double blind  placebo controlled study is the proportion of patients achieving a score of 10 or less on a scale called Severity of Alopecia Tool  SALT  at week 24 compared to control  The estimated completion date is June 2021 Related tickers   NASDAQ ACRS  NASDAQ CNCE Now read ,2019-01-03,Seeking Alpha,https://www.investing.com/news/stock-market-news/pfizer-launches-pivotal-study-of-alopecia-areata-candidate-1736304,1736304
219900,441416,PFE,Pfizer Rises 3 ,news,"Investing com    Pfizer   NYSE PFE  rose by 3 01  to trade at  43 30 by 13 05  18 05 GMT  on Friday on the NYSE exchange 
The volume of Pfizer shares traded since the start of the session was 11 92M  Pfizer has traded in a range of  42 26 to  43 33 on the day 
The stock has traded at  43 7300 at its highest and  40 4200 at its lowest during the past seven days ",2019-01-04,Investing.com,https://www.investing.com/news/stock-market-news/pfizer-rises-3-1737862,1737862
219901,441417,PFE,GSK chief Walmsley not finished with business shakeup,news,In an interview with CNBC s Jim Cramer  GlaxoSmithKline  GSK  0 7   CEO Emma Walmsley says there are  tremendous opportunities  to improve operating performance  adding that the company will get  radical  about reshaping its portfolio She is already making significant waves considering last month s Tesaro buy and its joint venture with  Pfizer   PFE  1 3   that will split up GSK s two major businesses Now read ,2019-01-07,Seeking Alpha,https://www.investing.com/news/stock-market-news/gsk-chief-walmsley-not-finished-with-business-shakeup-1739761,1739761
219909,441425,PFE,SNY Or PFE  Which Is The Better Value Stock Right Now ,opinion,"Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Sanofi  PA SASY   SNY  and Pfizer  PFE   But which of these two stocks presents investors with the better value opportunity right now  Let s take a closer look 
Everyone has their own methods for finding great value opportunities  but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank  The proven Zacks Rank emphasizes companies with positive estimate revision trends  and our Style Scores highlight stocks with specific traits 
Right now  Sanofi is sporting a Zacks Rank of  2  Buy   while Pfizer has a Zacks Rank of  3  Hold   Investors should feel comfortable knowing that SNY likely has seen a stronger improvement to its earnings outlook than PFE has recently  However  value investors will care about much more than just this 
Value investors are also interested in a number of tried and true valuation metrics that help show when a company is undervalued at its current share price levels 
The Style Score Value grade factors in a variety of key fundamental metrics  including the popular P E ratio  P S ratio  earnings yield  cash flow per share  and a number of other key stats that are commonly used by value investors 
SNY currently has a forward P E ratio of 13 05  while PFE has a forward P E of 14 91  We also note that SNY has a PEG ratio of 1 89  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  PFE currently has a PEG ratio of 2 49 
Another notable valuation metric for SNY is its P B ratio of 1 52  The P B ratio pits a stock s market value against its book value  which is defined as total assets minus total liabilities  For comparison  PFE has a P B of 4 03 
These are just a few of the metrics contributing to SNY s Value grade of A and PFE s Value grade of C 
SNY has seen stronger estimate revision activity and sports more attractive valuation metrics than PFE  so it seems like value investors will conclude that SNY is the superior option right now ",2019-07-11,Zacks Investment Research,https://www.investing.com/analysis/sny-or-pfe-which-is-the-better-value-stock-right-now-200439253,200439253
219910,441426,PFE,Deciphera launches late stage study of ripretinib in second line GIST,news,Deciphera Pharmaceuticals   NASDAQ DCPH  initiates a Phase 3 clinical trial  INTRIGUE  evaluating DCC 2618  ripretinib   compared to  Pfizer  s  NYSE PFE  SUTENT  sunitinib malate   for the treatment of gastrointestinal stromal tumor  GIST  patients who previously received Novartis   NYSE NVS  GLEEVEC  imatinib mesylate  The primary endpoint is progression free survival  PFS  at month 30  The estimated primary completion date is June 2021 Topline data from another Phase 3  INVICTUS  in fourth line GIST should be available in mid 2019 Now read ,2018-12-20,Seeking Alpha,https://www.investing.com/news/stock-market-news/deciphera-launches-latestage-study-of-ripretinib-in-secondline-gist-1727547,1727547
219911,441427,PFE,Pfizer Falls 3 ,news,"Investing com    Pfizer   NYSE PFE  fell by 3 10  to trade at  40 63 by 12 21  17 21 GMT  on Monday on the NYSE exchange 
The volume of Pfizer shares traded since the start of the session was 12 08M  Pfizer has traded in a range of  40 61 to  41 96 on the day 
The stock has traded at  44 1200 at its highest and  40 6300 at its lowest during the past seven days ",2018-12-24,Investing.com,https://www.investing.com/news/stock-market-news/pfizer-falls-3-1730247,1730247
219912,441428,PFE,Pfizer Rises 3 ,news,"Investing com    Pfizer   NYSE PFE  rose by 3 02  to trade at  41 77 by 15 35  20 35 GMT  on Wednesday on the NYSE exchange 
The volume of Pfizer shares traded since the start of the session was 16 54M  Pfizer has traded in a range of  40 42 to  41 79 on the day 
The stock has traded at  43 9700 at its highest and  40 4200 at its lowest during the past seven days ",2018-12-26,Investing.com,https://www.investing.com/news/stock-market-news/pfizer-rises-3-1731162,1731162
219917,441433,PFE,AFT Pharmaceuticals  A Licensing Deal For Pascomer,opinion,"AFT Pharmaceuticals  ASX AFP  has reported a North American licensing deal for Pascomer  a topical formulation of rapamycin being developed for facial angiofibromas in tuberous sclerosis complex  TSC   to private US based Timber Pharmaceuticals  Timber will fund clinical development and provide AFT with over US 10m in upfront  development and regulatory milestones  as well as over US 10m in sales milestone payments and royalties  An Investigational New Drug Application has been approved by the FDA  The first of two 120 patient clinical studies is expected to start shortly  with results in 2020 

An attractive orphan market
According to the US National Institute of Neurological Disorders and Stroke  TSC affects between 25 000 and 40 000 Americans and one to two million people worldwide  Angiofibromas  which can be highly disfiguring  affect around 80  of patients with TSC  Current therapies are typically surgical  such as chemical peeling  excision and laser surgery 
Evidence of rapamycin efficacy
Oral rapamycin was first approved in 1999 for immunosuppressant use  Initial evidence of its potential efficacy in angiofibromas occurred in a patient who initiated oral rapamycin because of renal transplantation and her facial angiofibromas improve markedly  A review of recent studies indicates that compounded topical formulations of rapamycin have improved lesions in 94  of subjects although there is no topical formulation available commercially 
A low risk development plan for AFT
The licensing agreement with Timber allows AFT to retain some of the upside potential of Pascomer but without having to yield near  to medium term profitability to fund its development  Timber will have full responsibility for R D investment  while AFT will collect high margin royalties if Pascomer is successfully developed 
Valuation  NZ 495m or NZ 5 09 per share
We are maintaining our valuation of NZ 495m or NZ 5 09 per share  To be conservative  we are not including Pascomer development in our estimates due to its early stage but we will revisit this as the programme progresses  Also  the company reiterated its operating profit target is between NZ 9m and NZ 12m for FY20 


Business description
AFT Pharmaceuticals is a specialty pharmaceutical company that operates primarily in Australasia but has product distribution agreements across the globe  The company s product portfolio includes prescription and over the counter drugs to treat a range of conditions and a proprietary nebuliser 
Pascomer for facial angiofibromas in TSC
AFT has announced it has licensed Pascomer  which is being developed for facial angiofibromas in TSC patients  to Timber Pharmaceuticals for over US 10m in upfront  development and regulatory milestones  as well as over US 10m in sales milestone payments and royalties 
TSC is a multisystem  autosomal dominant genetic disorder resulting from a mutation in one of two tumour suppressor genes  TSC1  encoding hamartin  or TSC2  tuberin   TSC is characterised by benign tumours  known as hamartomas  in various organs  most commonly the skin  brain  kidneys  heart and lungs  A hamartoma is composed of an overgrowth of mature cells and tissues  which normally occurs in the affected tissue  TSC affects both sexes and all ethnic groups  affecting as many as 25 000 40 000 individuals in the US and one to two million individuals worldwide  with an estimated prevalence of one in 6 000 newborns according to the US National Institute of Neurological Disorders and Stroke  Angiofibromas  which can be highly disfiguring  affect around 80  of patients with TSC 
Pascomer is a topical version of rapamycin  marketed as Rapamune by Pfizer  NYSE PFE    an immunosuppressant used for prophylaxis of organ rejection in patients receiving kidney transplants  It is also approved for the treatment of lymphangioleiomyomatosis  a progressive disease often associated with TSC that results in lung destruction  Rapamycin is an inhibitor of mammalian target of rapamycin  mTOR   which has many functions in protein synthesis and cell growth and is aberrantly activated in patients with TSC  making it a logical target for development in the treatment of this disease 
Initial evidence of rapamycin s potential efficacy in angiofibromas occurred in a patient who initiated oral rapamycin because of renal transplantation and her facial angiofibromas improve markedly 1 As rapamycin is a potent immunosuppressive  systemic exposure for the sake of improving facial angiofibromas is not ideal and there have been several small studies of topical rapamycin in this indication 
According to one review  94  of the 84 patients treated with a topical rapamycin in various studies showed improvement in their lesions 2 In the one randomised  double blind  placebo controlled study  with 23 subjects  in the review  73  of the subjects who received treatment reported a subjective improvement in their angiofibromas compared to 38  in placebo although the p value was not significant  p 0 18   likely because of the size of the study 3 Importantly  although a variety of different topical formulations were used  rapamycin was detected in only three patients out of the 74 tested for serum rapamycin levels  indicating a lack of systemic exposure  However  one of the issues with the various topical formulations used in these studies is that stability is limited  AFT believes it has developed a formulation using a proprietary dermal delivery technology that would be stable and hence commercially viable 
For intellectual property  there are no unexpired patents related to Rapamune in the FDA Orange Book so AFT appears to be free to operate  We do not know the extent of the patent estate for Pascomer but at the very least it will be eligible for orphan drug exclusivity  which is seven years in the United States and 10 years  worth of data exclusivity in the EU  although we would expect patent coverage to go well beyond that due to the proprietary nature of the formulation  
As part of the agreement  Timber will cover the clinical trial costs associated with clinical development  An Investigational New Drug Application has already been approved by the FDA with the first of two 120 patient clinical studies expected to start shortly in eight centres in the US  the Mayo Clinic   Australia  New Zealand  Spain and the UK  Results are expected in 2020 
Valuation
We are maintaining our valuation of NZ 495m or NZ 5 09 per share as Pascomer development is too early stage to include in our estimates  We will revisit this as the programme progresses 

Financials
We are maintaining our financial estimates as the precise size of the upfront payment is undisclosed  Also  the company has reiterated its operating profit target of between NZ 9m and NZ 12m for FY20 ",2019-07-10,Edison,https://www.investing.com/analysis/aft-pharmaceuticals-a-licensing-deal-for-pascomer-200438320,200438320
219918,441434,PFE,Sangamo Up As Gene Therapy Shows Promise In Hemophilia Study  Revised ,opinion,"Shares of Sangamo Therapeutics  Inc    NASDAQ SGMO   increased 1 1  following the presentation of promising new data from phase I II Alta study evaluating its gene therapy  SB 525  in patients with severe hemophilia A  Sangamo is developing the gene therapy candidate in collaboration with Pfizer   NYSE PFE   The data were presented at the Congress of the International Society on Thrombosis and Haemostasis   ISTH   in Australia Sangamo s shares have gained 0 3  so far this year compared with the  s increase of 3 8   The phase I II study is evaluating four doses of SB 525   9e11 vg kg  2e12 vg kg  1e13 vg kg and 3e13 vg kg  Updated data from the study showed that two patients treated with the highest dosage  3e13 vg kg  achieved normal factor VIII levels  with no bleeding event  which continued for 19 and 24 weeks  Moreover  two new patients enrolled in the highest dosage cohort also demonstrated similar factor VIII activity kinetics consistent with the first two patients at week four and six  The company will soon initiate dosing of the fifth patient in the highest dosage cohort The fact that the highest dose of SB 525 achieved normal factor VIII levels within five to seven weeks probably encouraged investors  However  the sustainability of this level remains to be seen  Data available so far showed that normal levels of factor VIII were sustained for 24 weeks in the highest dose cohort  Moreover  one patient receiving 1e13 vg kg of SB 525 has shown durable factor VIII level for 52 weeks Please note that there are several other pharma biotech companies developing gene therapies for treating hemophilia A  The most advanced gene therapy for hemophilia A treatment in clinical studies is BioMarin s valoctocogene roxaparvovec  BMN 270   Late stage studies are evaluating 6e13 vg kg and 4e13 vg kg doses of the candidate  BioMarin s candidate has also achieved durable factor VIII levels in patients  BioMarin will file regulatory applications seeking approval of valoctocogene roxaparvovec for severe hemophilia A in both the United States and EU in the fourth quarter of 2019  Other companies developing gene therapy candidates for treating hemophilia A include Spark Therapeutics   NASDAQ ONCE   and uniQure   NASDAQ QURE   Although Sangamo is a long way from commercialization of SB 525  the candidate has demonstrated better improvement in factor VIII levels compared to BioMarin s gene therapy candidate  The promising data from the early stage study on SB 525 resulted in a decline in shares of BioMarin and Spark on Jul 8 Please note that Sangamo s SB 525 enjoys regenerative medicine advanced therapy   RMAT   designation for hemophilia A  The RMAT designation includes all benefits of fast track and breakthrough therapy designation programs Sangamo Therapeutics  Inc  Price
    Zacks RankSangamo currently carries a Zacks Rank  3  Hold   You can see   We are reissuing this article to correct a mistake  The original article  issued on July 9  2019  should no longer be relied upon  ",2019-07-11,Zacks Investment Research,https://www.investing.com/analysis/sangamo-up-as-gene-therapy-shows-promise-in-hemophilia-study-revised-200438766,200438766
219919,441435,PFE,Pfizer Falls 3 ,news,"Investing com    Pfizer   NYSE PFE  fell by 3 10  to trade at  43 74 by 11 25  16 25 GMT  on Thursday on the NYSE exchange 
The volume of Pfizer shares traded since the start of the session was 8 95M  Pfizer has traded in a range of  43 69 to  44 73 on the day 
The stock has traded at  46 4500 at its highest and  42 9700 at its lowest during the past seven days ",2018-12-06,Investing.com,https://www.investing.com/news/stock-market-news/pfizer-falls-3-1713499,1713499
219925,441441,PFE,Glaxo s Dovato Wins EU Nod  RA Candidate Enters Phase III,opinion,GlaxoSmithKline plc s   NYSE GSK   HIV subsidiary  ViiV Healthcare  announced that the European Commission has granted a marketing authorization to Dovato  its once daily  single tablet two drug HIV regimen  The approval in the EU is for the treatment of HIV 1 infection in adults adolescent patients  aged above 12 years and weighing minimum 40 kg with no known resistance to integrase inhibitors or lamivudine ViiV Healthcare is majorly owned by Glaxo and Pfizer   NYSE PFE   Dovato is a fixed dose combination of Tivicay  dolutegravir   50 mg  and lamivudine  300 mg  and was approved by the FDA in this April The EU approval was based on data from the GEMINI 1 2 studies  which evaluated more than 1 400 patients with HIV 1 infection  Data from the studies showed that after 48 weeks  treatment with the two drug regimen of Dovato demonstrated non inferior efficacy as compared to a three drug regimen for treatment na ve  HIV 1 patients  This means  a two drug HIV regimen can control the intensity of HIV in treatment na ve patients as effectively as a three drug regimen  thereby exposing the newly diagnosed patients to fewer drugs at the start of their treatment for the first time Following this nod  patients can begin treatment with Dovato as the first once daily two drug regimen knowing that efficacy is non inferior to the standard three drug regimen for the given patient population Shares of Glaxo have rallied 8 1  so far this year  outperforming the rise of 3 7  HIV is a key therapeutic area for Glaxo with successful dolutegravir based regimens  namely Tivicay  Triumeq and Juluca in its portfolio  HIV sales totaled  1 1 billion in the first quarter of 2019  The metric increased 4  at CER on the back of 7  growth in dolutegravir franchise  Triumeq and Tivicay and Juluca   which partly offset lower sales of the established HIV products In a separate press release  Glaxo announced that it has started the phase III program on its anti GM CSF antibody  otilimab for the treatment of patients with moderate to severe rheumatoid arthritis  RA   who do not respond to disease modifying antirheumatic drugs  DMARD  or any such targeted therapies The phase III ContRAst study will also include head to head comparison of otilimab with Pfizer s Xeljanz  tofacitinib  and Regeneron Pharmaceuticals   NASDAQ REGN    Sanofi  PA SASY  s   NASDAQ SNY   Kevzara  sarilumab  across all pivotal studies The primary endpoint of these analyses will assess the proportion of patients achieving the American College of Rheumatology criteria  ACR20  at 12 week treatment compared with placebo The study will be conducted across a broad range of difficult to treat patients  The initiation of the phase III program was based on encouraging data from the phase II BAROQUE study  which showed striking clinical improvements in patients treated with otilimab Zacks RankGlaxo currently carries a Zacks Rank  3  Hold   You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-07-03,Zacks Investment Research,https://www.investing.com/analysis/glaxos-dovato-wins-eu-nod-ra-candidate-enters-phase-iii-200437074,200437074
219926,441442,PFE,A Recession Proof Industry You Probably Haven t Heard Of,opinion,"Recession proof industries are unique 
They sell stuff that people buy no matter what s happening in the economy things like electricity  internet access  toilet paper  and now pet care 
That s right  America is pet obsessed 
Pet ownership is up  Spending on pets is up  In fact  we actually spend more on our pets during a recession 
We ll dig into the details in a moment  and look at three companies in a niche of this recession proof industry that can bolster your portfolio 
Most of Us Own Pets
Around 85 million US families own a pet  according to the National Pet Owners Survey  That s 68  of US households 
This figure has increased around 2  annually since 2011  But spending on those pets has increased almost 7  annually 
Meanwhile  spending on veterinary care is growing especially fast  From 1991 to 2015  it shot from  4 9 billion to  35 billion  For perspective  that s three times faster than US GDP grew over the same period 
And there s more 
Pet care spending even grew during the last two recessions  29  during the 2001 recession and 17  during the 2008 2009 recession 
You can see this in the next chart  
This all points to a solid  recession proof industry 
It means pet care companies enjoy predictable cash flows and sales growth  even during a recession 
It also means stable share prices for stockholders when they re looking for it the most 
The  Dog Mom  Generation There are demographic reasons behind the jump in pets and pet spending 
To start  US household formation is near all time lows  according to Yardeni Research 
The main reason for this  says the Institute for Family Studies  IFS   is that millennials born between 1980 and 2000 are marrying later  And they re turning to pets for companionship 
Millennials make up 25  of the US population  But they own 35  of all pets  making them the largest pet owning cohort in the country 
Aging baby boomers and empty nesters are also big pet fans 
In 2007  only 34  of adults over age 70 owned pets  But by 2016  the year boomers started turning 70  that figure had jumped to 41  
As I write  fewer than half of the country s 75 million baby boomers have reached their 70s  So the  dog mom  generation still has plenty of room to grow 
And these folks are spending a lot on their pets  The Fastest Growing Area in Pet Care Dog owners spend over  1 000 a year on Fido  on average  So companies that cater to these  dog moms  should continue to thrive 
Overall  spending on pets in the US has gone up every year since 1994  And it s grown 4 6  annually over the last 10 years or three times faster than overall consumer spending 
This is good news for pet care companies  And it makes sense that they ve done well  even during the last two recessions 
Pets are  part of the family  now  Their owners skimp on other things before downgrading to cheaper pet food or cutting back on supplies 
This is especially true for the  15 billion pet medication industry  Sure  you might skip your regular dog grooming appointment during a recession  but you re not going skip your pet s medication 
The booming pet medication market is proof positive of that  Pet medication sales are growing twice as fast as overall pet spending 
The pet medication market will be the highest growth area of the pet care industry for the next decade  reports market research firm Packaged Facts  It expects new products for flea and tick prevention as well as itch relief to drive sales 
And we can get a slice of that 
How to Profit from the Pet Health Market Recession is probably not imminent  But it s coming sooner rather than later 
That s why my focus is recession proof dividend paying stocks right now  It will help you add safety and stability to your portfolio and prepare for this recession 
The pet health market is one way to do that 
One of my favorite pet health companies is PetMed Express Inc   NASDAQ PETS    PetMed is a leading  nationwide pet pharmacy  The company markets over 3 000 prescription and non prescription medications for dogs and cats directly to consumers 
PETS pays a hefty 6 7  dividend yield  It also has a low payout ratio  which is critical to dividend stocks  Shares have struggled a bit this year  but that also means they re attractively priced right now and a good way to take advantage of the growing pet health market 
Next on my list is Zoetis Inc   NYSE ZTS   Zoetis used to be the animal health unit of Pfizer  NYSE PFE   The company is the largest manufacturer of anti infectives  vaccines  and other animal health products in the world 
ZTS pays a small 0 6  dividend yield  However  with a 19  payout ratio  there s plenty of room for the company to increase its dividend payout 
Lastly  we have Pets at Home Group PLC  PAHGF   The company operates a network of stores  pet services  and veterinary services in the United Kingdom 
The company pays a high 4 2  dividend yield  At 125   the payout ratio is higher than I would like  But the company has very low debt and strong free cash flow  So it isn t likely to cut the dividend  despite the high payout ratio 
Remember  this recession probably isn t coming tomorrow  But it s still important to buoy your portfolio now 
You want to buy recession proof companies when you can  not when you need to  And now is the perfect time to add some dividend paying pet health companies to your portfolio ",2019-07-05,Robert Ross,https://www.investing.com/analysis/a-recessionproof-industry-you-probably-havent-heard-of-200437193,200437193
219927,441443,PFE,Pfizer sells  523M stake in ICU Medical to C P  Pharmaceuticals,news,"Pfizer   NYSE PFE  has sold out of its holdings of  ICU Medical   NASDAQ ICUI  for about  523M  according to a filing  It sold the stake via private placement to C P  Pharmaceuticals International  The filing shows 2 5M shares sold at an average price of  209 25 as of yesterday 
Previously  WSJ  Pfizer to reverse course  raise prices on 41 drugs  Nov  16 2018  Now read ",2018-11-16,Seeking Alpha,https://www.investing.com/news/stock-market-news/pfizer-sells-523m-stake-in-icu-medical-to-cp-pharmaceuticals-1692465,1692465
219928,441444,PFE,SunTrust  Venclexta could add  1B  for AbbVie,news,"SunTrust says the FDA s new approval of AbbVie s  ABBV  0 2  Venclexta could add  1B  in peak annual sales 
The approval was for first line treatment for elderly patients with acute myeloid leukemia who can t get high doses of chemotherapy  
Pfizer s  PFE  0 7   Daurismo was approved Wednesday and could compete with AbbVie in the leukemia market  but SunTrust thinks ABBV s has the better chance of becoming standard care   based on a broader label   more robust efficacy profile  
Source  Bloomberg First Word 
Previously   Pfizer  s Daurismo combo for elderly adults with AML gets FDA approval  Nov  21 
Previously  Venclexta gets accelerated approval for newly diagnosed AML  Nov  21 
Now read ",2018-11-23,Seeking Alpha,https://www.investing.com/news/stock-market-news/suntrust-venclexta-could-add-1b-for-abbvie-1698902,1698902
219929,441445,PFE,Dar  Bioscience launches thermography study of Sildenafil Cream in women  shares ahead 2 ,news,Thinly traded nano cap Dar  Bioscience  DARE  is up 2  in early trade  albeit on only 110 shares  on the heels of its announcement that enrollment is underway in an investigational study assessing the pharmacodynamics of Sildenafil Cream  3 6  in healthy women  The company is developing the topical product for the potential treatment of female sexual arousal disorder  The study will use thermography technology  specifically a infrared camera  to measure genital temperature  a surrogate for genital blood flow  The results will inform on the design of a Phase 2b study expected to launch in 2019  Sildenafil is the active ingredient in  Pfizer   NYSE PFE  s Viagra  Now read ,2018-11-27,Seeking Alpha,https://www.investing.com/news/stock-market-news/dare-bioscience-launches-thermography-study-of-sildenafil-cream-in-women-shares-ahead-2-1701783,1701783
219930,441446,PFE,Pfizer s Lyrica nabs extra six months of pediatric exclusivity in U S ,news,The FDA has granted an additional six months of pediatric exclusivity to  Pfizer  s  PFE  1 2   LYRICA  pregabalin   extending the period to June 30  2019  The agency based its decision on data from the LYRICA Pediatric Epilepsy Program which was submitted at the FDA s request to evaluate the drug as adjunctive therapy for partial onset seizures in pediatric epilepsy patients Now read ,2018-11-27,Seeking Alpha,https://www.investing.com/news/stock-market-news/pfizers-lyrica-nabs-extra-six-months-of-pediatric-exclusivity-in-us-1702208,1702208
219939,441455,PFE,Takeda CEO confident of investor backing for  62 billion Shire deal,news,"By Ben Hirschler LONDON  Reuters    The boss of Japan s Takeda Pharmaceutical  T 4502  said on Monday he was confident of securing investor backing for its  62 billion acquisition of London listed  Shire   L SHP   despite some shareholders  fears about the resulting debt burden  Buoyed by a strong set of quarterly results last week   helped by strong demand for its existing drugs   Chief Executive Christophe Weber insisted that buying rare diseases specialist Shire was not a defensive move   We are quite satisfied with our current progress at Takeda  Our business is doing well   he told the FT Global Pharmaceutical and Biotechnology conference in London    We don t have to do this Shire acquisition  We just feel it is a way to accelerate our progress and our evolution   Takeda has already gained approval for what would be the biggest ever overseas acquisition by a Japanese company from U S   Japanese and Chinese regulators   but it is still waiting for the nod from European authorities  Crucially  Takeda also needs two thirds support from shareholders  It has set Oct  19 as the record date entitling investors to vote in an extraordinary general meeting  EGM  on the deal  allowing it to hold the meeting within a three month period ending Jan  18  Alternatively  it could set a new record date  Takeda  which has a market value of around  32 billion  has secured a  30 9 billion bridge loan to help finance the Shire acquisition and some investors are concerned as to how well it will cope with debt repayments  Weber  however  said he was confident he had persuaded Takeda shareholders sufficiently for the company to name an EGM date  without specifying exactly when it would be held  The Japanese company struck its agreement to take over Shire in May  a deal that will propel it into the top 10 rankings of global drugmakers by sales  alongside the likes of  Novartis   S NOVN  and  Pfizer   N PFE   It will also increase Takeda s exposure to the U S  drugs market   the world s biggest   which will account for around half of the enlarged group s business  just as President Donald Trump puts a squeeze on drugmakers to cut their prices  Weber said Trump s plans to base the price the government s Medicare program pays for some medications on the lower prices paid in other countries would add to pressure but would not undermine the fundamental attractions of the U S  marketplace   This is still the country where new innovative medicine has the fastest access   there is this willingness to treat patients with the latest medicine   he said  
 My assumption always has been there would be more price pressure in the U S  and we have to deal with it  ",2018-11-05,Reuters,https://www.investing.com/news/stock-market-news/takeda-ceo-confident-of-investor-backing-for-62-billion-shire-deal-1674171,1674171
219940,441456,PFE,Pfizer Rises 3 ,news,"Investing com    Pfizer   NYSE PFE  rose by 3 29  to trade at  44 42 by 10 41  15 41 GMT  on Wednesday on the NYSE exchange 
The volume of Pfizer shares traded since the start of the session was 7 13M  Pfizer has traded in a range of  43 29 to  44 44 on the day 
The stock has traded at  44 4200 at its highest and  41 7800 at its lowest during the past seven days ",2018-11-07,Investing.com,https://www.investing.com/news/stock-market-news/pfizer-rises-3-1678110,1678110
219948,441464,PFE,Pfizer  PFE  Flat As Market Sinks  What You Should Know,opinion,"Pfizer  PFE  closed at  43 76 in the latest trading session  marking no change from the prior day  This move was narrower than the S P 500 s daily loss of 0 95   Elsewhere  the Dow lost 0 67   while the tech heavy Nasdaq lost 1 51  
Prior to today s trading  shares of the drugmaker had gained 4 31  over the past month  This has outpaced the Medical sector s gain of 3 89  and lagged the S P 500 s gain of 4 32  in that time 
Investors will be hoping for strength from PFE as it approaches its next earnings release  The company is expected to report EPS of  0 78  down 3 7  from the prior year quarter  Meanwhile  the Zacks Consensus Estimate for revenue is projecting net sales of  13 42 billion  down 0 31  from the year ago period 
Looking at the full year  our Zacks Consensus Estimates suggest analysts are expecting earnings of  2 88 per share and revenue of  52 86 billion  These totals would mark changes of  4  and  1 46   respectively  from last year 
Any recent changes to analyst estimates for PFE should also be noted by investors  These revisions help to show the ever changing nature of near term business trends  With this in mind  we can consider positive estimate revisions a sign of optimism about the company s business outlook 
Based on our research  we believe these estimate revisions are directly related to near team stock moves  Investors can capitalize on this by using the Zacks Rank  This model considers these estimate changes and provides a simple  actionable rating system 
The Zacks Rank system  which ranges from  1  Strong Buy  to  5  Strong Sell   has an impressive outside audited track record of outperformance  with  1 stocks generating an average annual return of  25  since 1988  Over the past month  the Zacks Consensus EPS estimate has moved 0 12  lower  PFE is currently sporting a Zacks Rank of  3  Hold  
Digging into valuation  PFE currently has a Forward P E ratio of 15 19  Its industry sports an average Forward P E of 14 83  so we one might conclude that PFE is trading at a premium comparatively 
Meanwhile  PFE s PEG ratio is currently 2 54  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 2 12 as of yesterday s close 
The Large Cap Pharmaceuticals industry is part of the Medical sector  This industry currently has a Zacks Industry Rank of 76  which puts it in the top 30  of all 250  industries 
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Make sure to utilize Zacks  Com to follow all of these stock moving metrics  and more  in the coming trading sessions ",2019-06-25,Zacks Investment Research,https://www.investing.com/analysis/pfizer-pfe-flat-as-market-sinks-what-you-should-know-200434639,200434639
219949,441465,PFE,Pfizer cuts revenue forecast as supply snags  dollar strength weigh,news,"By Tamara Mathias and Aakash B  Reuters     Pfizer  Inc  N PFE  on Tuesday reported worse than expected third quarter revenue and lowered the top end of its full year sales forecast as generic competition and drug pricing pressure in the United States hurt its older drugs business  Pfizer said it now expects 2018 revenue of between  53 billion and  53 7 billion  compared with an earlier forecast of  53 billion to  55 billion  Sales of breast cancer medicine Ibrance and rheumatoid arthritis drug Xeljanz  both considered growth drivers for the company  also disappointed in the quarter and shares of the largest U S  drugmaker declined 3 2 percent in premarket trading   Investor attention has been increasingly focused on the company post 2020  with a view toward drugs they hope will be on the market by then  including the non opioid pain treatment tanezumab   Credit Suisse   SIX CSGN  analyst Vamil Divan said  However  shareholders are keen to know how the company plans to bridge the gap until 2020 with products such as Ibrance and Xeljanz underperforming this quarter  he added  Ibrance sales for the quarter of  1 03 billion was below analysts  estimates of about  1 07 billion  according to Refinitiv data  Xeljanz brought in  432 million  also short of estimates of about  476 3 million  Pfizer  which gets just over half of its revenue from outside the United States  said strengthening of the dollar in relation to the euro and certain emerging market currencies led to diminished revenue projections   While we are disappointed by the lowered guidance  we recognize that it was the result of factors unrelated to the company s innovative new product portfolio   Edward Jones analyst Ashtyn Evans said  Supply problems at facilities making Pfizer s sterile injectables  as well as competition from cheaper generic medicines in the United States  hit sales at the company s Essential Health business  Sales from the unit  which Pfizer plans to reorganize into a new division that sells off patent medicines and generic drugs  fell 4 4 percent to  4 83 billion in the quarter  Excluding one time items  Pfizer earned 78 cents per share  topping analysts  average expectations by 3 cents  according to Refinitiv  The company said it benefited from a 13 3 percent tax rate on adjusted income  well below the 23 7 percent it paid last year before the U S  Congress passed a bill that significantly lowered corporate tax rates   Net income rose 45 percent to  4 11 billion in the three months ended Sept  30  
Overall revenue for the quarter edged 1 percent higher to  13 30 billion  Analysts had expected  13 53 billion ",2018-10-30,Reuters,https://www.investing.com/news/stock-market-news/pfizer-thirdquarter-profit-jumps-45-percent-1665348,1665348
219950,441466,PFE,AbbVie rheumatoid arthritis drug succeeds in late stage trial,news,"NEW YORK  Reuters     AbbVie Inc   NYSE ABBV  on Tuesday said its experimental rheumatoid arthritis  RA  treatment showed significant improvement in physical function  pain and quality of life compared with the commonly prescribed generic drug methotrexate in a late stage clinical trial  The U S  drugmaker hopes the drug  upadacitinib  can help replace lost revenue from its top selling RA treatment Humira when it starts to face biosimilar competition in the United States in 2023  AbbVie said it will file applications this years seeking regulatory approval for the medicine  Top line results from the Phase III study were previously announced in June  Upadacitinib belongs to a class of drugs known as JAK inhibitors  which block inflammation causing enzymes called Janus kinases   Pfizer   NYSE PFE  Inc s Xeljanz belongs to the same class of drugs  AbbVie said that after 14 weeks of treatment  69 percent of patients receiving a 30 milligram dose of the drug and 65 percent of patients receiving a 15 mg dose reported improvements in physical function  That compared with improvements reported in 45 percent of patients receiving methotrexate  which is typically the first medicine prescribed for RA patients   It said that 75 percent of patients receiving the 30 mg dose of the drug and 64 percent of patients receiving the lower dose said they had less pain  That compared with 46 percent of patients receiving methotrexate  In addition  73 percent of patients receiving the higher dose of upadacitinib and 65 percent of those who got the lower dose reported quality of life improvements versus 48 percent for methotrexate  
Humira  the world s biggest selling prescription drug with sales expected to reach  20 billion this year  began facing competition from biosimilar versions in Europe last week ",2018-10-31,Reuters,https://www.investing.com/news/general-news/abbvie-rheumatoid-arthritis-drug-succeeds-in-late-stage-trial-1655768,1655768
219954,441470,PFE,Stock Picks  3 Biotechs On The Move,opinion,"Three biotechs  along with recent IPO Pinterest  PINS   are among our four charts to watch today 
G1 Therapeutics Inc   NASDAQ GTHX  jumped  4 75  or 24   to  24 50 on 2 2 million shares Tuesday  The move  on over 5 times its average volume  came on news of encouraging data from the company s phase 2 study of its trilaciclib treatment for metastatic triple negative breast cancer  The stock has next resistance at its May high at  27 90  a move through which could take it to  30 
Iovance Biotherapeutics Inc   NASDAQ IOVA  gained 45 cents to  22 40 on 2 3 million shares  IOVA was among cancer therapy stocks moving on Monday s news that Pfizer Inc   NYSE PFE  will acquire cancer drug maker Array BioPharma Inc  in a deal worth up to  11 4 billion  The stock is near the top of the rising channel it s been in since gapping up a month ago and could see some consolidation before its next move  with a target of  28 
Nektar Therapeutics  NASDAQ NKTR  popped  1 47 to  35 17 on 1 1 million shares Tuesday on no news from the developer of drug candidates for cancer  auto immune disease  and chronic pain  The stock is in a mini base pattern and needs to get through its recent double top at  35 80  A move through there could get it to  38 75 next 
Pinterest Inc   NYSE PINS  rallied 95 cents to  28 80 on 8 7 million shares Tuesday  The move came on no news from the online discovery service  but followed bullish comments and coverage initiation Monday by a Wedbush analyst  After exploding out of its recent IPO and then pulling back  the stock is on the move again  Next target would be the lateral resistance level at about  31 
See Harry s video chart analysis on these stocks 
No holdings 
Harry Boxer is founder of TheTechTrader com  a live trading room featuring his stock picks  technical market analysis  and live chart presentations ",2019-06-19,Harry Boxer,https://www.investing.com/analysis/stock-picks-3-biotechs-on-the-move-200432904,200432904
219955,441471,PFE,Pfizer to cut around 2 percent of jobs through early next year,news,"NEW YORK  Reuters    U S  drugmaker  Pfizer  Inc  N PFE  plans to reduce its global headcount by around 2 percent through voluntary retirements and layoffs this year and early next year  as it looks to streamline its corporate structure and eliminate some managerial roles and responsibilities  Pfizer has around 90 000 employees worldwide   Pfizer spokeswoman Sally Beatty said the job cuts were  about creating a simpler  more efficient structure and not achieving cost savings    The job cuts were originally reported by CNBC  The move follows the announcement earlier this month that Chief Operating Officer Albert Bourla would succeed Ian Read as chief executive in January  The company also added new responsibilities for many of its top managers and hired a new chief digital officer  
Shares of Pfizer were up 1 8 percent at  44 70 in early afternoon trading on the New York Stock Exchange  Its shares are up around 20 percent this year  outperforming the Standard   Poors 500 index  which is up about 4 percent over the same period ",2018-10-17,Reuters,https://www.investing.com/news/stock-market-news/pfizer-to-cut-around-2-percent-of-jobs-through-early-next-year-1648401,1648401
219956,441472,PFE,Pfizer Falls 3 ,news,"Investing com    Pfizer   NYSE PFE  fell by 3 06  to trade at  42 75 by 15 29  19 29 GMT  on Wednesday on the NYSE exchange 
The volume of Pfizer shares traded since the start of the session was 23 80M  Pfizer has traded in a range of  42 74 to  44 29 on the day 
The stock has traded at  44 8300 at its highest and  42 7500 at its lowest during the past seven days ",2018-10-24,Investing.com,https://www.investing.com/news/stock-market-news/pfizer-falls-3-1658265,1658265
219957,441473,PFE,Pfizer Rises 3 ,news,"Investing com    Pfizer   NYSE PFE  rose by 3 11  to trade at  43 80 by 11 21  15 21 GMT  on Thursday on the NYSE exchange 
The volume of Pfizer shares traded since the start of the session was 13 80M  Pfizer has traded in a range of  41 66 to  43 83 on the day 
The stock has traded at  44 8300 at its highest and  41 9000 at its lowest during the past seven days ",2018-10-25,Investing.com,https://www.investing.com/news/stock-market-news/pfizer-rises-3-1659864,1659864
219958,441474,PFE,European shares in tentative rebound after sell off  HSBC shines,news,"By Julien Ponthus LONDON  Reuters    European shares  set for their worst monthly performance since August 2015  opened in positive territory on Monday in a tentative rebound from a sell off which has depressed them to a level not seen since December 2016  At 0957 GMT  the pan European STOXX 600  STOXX  was up 1 percent with most bourses firmly in the black with U S  stock futures turning positive despite worries about China s slowing economy previously weighing on Asian shares   European markets enjoyed a stronger start to the week  despite a sell off in China as investors digested the impact of a trade war with the US on industrial earnings   said Russ Mould  investment director at AJ Bell  The banking sector  SX7P  was the best performing one  up 1 8 percent with HSBC  L HSBA  rising 4 5 percent after Europe s biggest bank by assets posted a higher than expected 28 percent rise in third quarter profit   On the other hand  Spain s state controlled  Bankia   MC BKIA  was down 4 7 percent after posting lower than expected Q3 results   Italian banks shone after rating agency S P kept its credit rating two notches above non investment grade for Italian sovereign bonds   Banco BPM  shares rose 3 3 percent   Ubi Banca   MI UBI  3 percent and Unicredit  MI CRDI  2 5 percent  Milan s FTSE MIB  FTMIB  posted the best regional rise  up 1 2 percent while London s FTSE rose 0 9 percent with investors waiting to learn more about Britain s 2019 budget and what impact it might have on individual companies  Frankfurt s  GDAXI  accelerated its gains to 1 3 percent after a senior party source said German Chancellor Angela Merkel would not seek re election as party chairwoman at a conference in early December   The open of Paris CAC 40  FCHI  resumed after being delayed due to technical issues and was up 0 3 percent   Another strong performing sector was healthcare  SXDP   up 1 7 percent with  Novartis   S NOVN  adding 1 9 percent   
The Swiss group and  Pfizer  Inc  NYSE PFE  PFE N are teaming up to develop treatments for a liver disease many drug companies believe will become a hugely lucrative market  as it is tied to the obesity and diabetes epidemics ",2018-10-29,Reuters,https://www.investing.com/news/stock-market-news/european-shares-in-tentative-rebound-after-selloff-hsbc-shines-1663257,1663257
219966,441482,PFE,Protalix  PLX  Completes Enrollment In Fabry Disease Study,opinion,Protalix BioTherapeutics  Inc    NYSE PLX   announced completion of enrollment in a phase III study  evaluating its pipeline candidate   PRX 102  pegunigalsidase alfa    for the treatment of Fabry disease  a rare inherited genetic lysosomal disorder The phase III BRIGHT study  evaluated the safety  efficacy and pharmacokinetics  PK  of PRX 102 through intravenous  IV  infusions of 2 mg kg  administered once every four weeks to patients  previously treated with an enzyme replacement therapy  ERT    Fabrazyme or Replagal for 12 months  Moreover  the study compared PRX 102 with the current standard of care treatment regimen of infusions every two weeks Fabrazyme  currently marketed by Sanofi   NASDAQ SNY    is already approved for treating Fabry disease  Replagal too won the nod for addressing the same To date  all patients who enrolled in the BRIGHT program  decided to continue treatment under the 4 week dosing regimen in a long term extension study Shares of Protalix have surged 35 8  so far this year  outperforming the  increase of 1 4  Notably  last January  the FDA granted a Fast Track designation to PRX 102 for the treatment of Fabry disease  In early 2019  Protalix had a productive meeting with the FDA to discuss the potential filing of its application for the accelerated approval of PRX 102  Last month  the company announced that it plans to hold a follow up meeting in the second quarter of 2019 to discuss the data and content of the potential filing for an expedited nod We would like to remind investors that Protalix has a single marketed drug  Elelyso  approved for treating Gaucher disease  The drug is marketed by Pfizer Inc    NYSE PFE   in the United States as part of an exclusive license and supply agreement The company is also developing OPRX 106 as an orally delivered anti inflammatory treatment  In 2018  it delivered positive results from its phase II study of OPRX 106 for the treatment of ulcerative colitis Zacks Rank   Key PickProtalix currently has a Zacks Rank  4  Sell  A better ranked stock in the healthcare sector is Acorda Therapeutics  Inc    NASDAQ ACOR    which sports a Zacks Rank  1  Strong Buy   You can see  Acorda s loss per share estimates have been narrowed 6 5  for 2019 and 6 9  for 2020 over the past 60 days Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-06-17,Zacks Investment Research,https://www.investing.com/analysis/protalix-plx-completes-enrollment-in-fabry-disease-study-200432530,200432530
219967,441483,PFE,Pfizer Falls 3 ,news,"Investing com    Pfizer   NYSE PFE  fell by 3  to trade at  43 13 by 11 05  15 05 GMT  on Thursday on the NYSE exchange 
The volume of Pfizer shares traded since the start of the session was 10 35M  Pfizer has traded in a range of  43 01 to  44 49 on the day 
The stock has traded at  45 81 at its highest and  43 06 at its lowest during the past seven days ",2018-10-11,Investing.com,https://www.investing.com/news/stock-market-news/pfizer-falls-3-1640801,1640801
219968,441484,PFE,Pfizer settles New York probe into  deceptive  copay coupons,news,"By Jonathan Stempel NEW YORK  Reuters     Pfizer  Inc  NYSE PFE  on Thursday settled charges by New York s attorney general that it misled consumers in its drug copayment coupon program into thinking they would pay far less to fill prescriptions than they ended up having to shell out  The drugmaker agreed to pay  500 000 in fines and costs  and make more than  200 000 in restitution over the coupons  which can help consumers burdened by health insurance plans that carry high copayments and deductibles  Pfizer s coupons said consumers would  PAY NO MORE THAN   15   20 or  25 for Estring to treat vaginal atrophy  Quillivant XR and Quillichew ER for attention deficit hyperactivity disorder  and Flector patches for acute pain from minor injuries  New York Attorney General Barbara Underwood said this was  deceptive  because Pfizer buried limits on the total savings in the small print  and that thousands of consumers ended up paying much more  Underwood said one woman got a surprise at her pharmacy register when she was required to pay  144 62 for Estring instead of the promised  15 maximum  The settlement resolves claims from 2014 to 2017  and Underwood said the rate at which New York consumers paid more than the advertised maximums went up over time  Pfizer changed the text of its coupons this year to say consumers could  pay as little as  specified amounts  The New York based company acknowledged some of the attorney general s findings but did not admit or deny liability  Pfizer confirmed the settlement  and said reimbursements will go to consumers who used coupons in the last three years  
It refunded  129 62 to the woman who paid  144 62 for Estring after the attorney general s office intervened  according to a footnote in the settlement agreement ",2018-10-11,Reuters,https://www.investing.com/news/stock-market-news/pfizer-settles-new-york-probe-into-deceptive-copay-coupons-1641067,1641067
219975,441491,PFE,With drugs pipeline in focus  Bayer considers job cuts  source,news,"By Ludwig Burger and Patricia Weiss FRANKFURT  Reuters    Bayer  DE BAYGN  is considering job cuts and outsourcing as part of a wide ranging review of drug research and development that will last until at least November  a person familiar with the company told Reuters  The prospect of  very tangible changes  contributed to a decision by key board members to extend the contract of Hartmut Klusik  the 62 year old head of personnel  which was due to expire at the end of the year  the source said  That decision is due to be signed off by the full board in September  The savings that Bayer   the inventor of aspirin and maker of Yasmin birth control pills   could make as part of the overhaul would give it financial wiggle room as it competes with larger rivals to buy the right to promising treatments from biotech firms  Bayer  which is due to release second quarter results on Wednesday  is under pressure from investors to make purchases or do licensing deals that they say are needed to ensure the long term independence of the pharmaceutical division  But any major external expansion is unlikely until after the review is complete  the source said  A company spokesman declined to comment on Klusik  any potential job cuts or outsourcing  An extension of Klusik s contract had been in doubt  two sources familiar with the company said  This is because drug production at Bayer s Leverkusen plant in Germany was found to be substandard by U S  regulators in February and this fell under his remit  Bayer has said it launched the R D review   starting in January when drug development head Joerg Moeller was given additional control over research and discovery in January   to  seamlessly steer  R D activities  A new team  reporting directly to Moeller has just been appointed to help map out the new setup  a third source said  The review will look at whether drug testing services should be outsourced to cheaper contractors  Labor representatives  who are worried about jobs moving outside the company  are involved in the talks  the first source said  WINDOW OF OPPORTUNITY After Bayer s  63 billion acquisition of  Monsanto   NYSE MON   which was concluded on June 7  profits depend equally on farming supplies and pharmaceuticals  Without an upgrade of the drugs pipeline  analysts say the balance could swing in favor of the agriculture unit  Revenues from the drug unit s top products  blood thinner Xarelto and eye drug Eylea  will peak over the next six years   That gives Bayer a window of one two three years to license something in and  if not  to show that something is yet to emerge from its earlier stage pipeline   said Frankfurt based fund manager Markus Manns at Union Investment  who holds Bayer shares  Analysts say a better pipeline is crucial to preserving the independence of a pharma business that ranks 15th place among global peers  with about half the revenues of top three  Novartis NOVN S   Pfizer   NYSE PFE  PFE N and Roche ROG S   If Bayer consisted only of its pharma division they would certainly be an attractive takeover target and would probably not prevail on a standalone basis   said Manns  The sources said that CEO Werner Baumann and Chairman Werner Wenning s push to acquire Monsanto was meant to render Bayer immune to unwanted overtures from larger pharmaceutical rivals  The Bayer spokesman declined to comment  LIMITED FIREPOWER Bayer has said its six most promising experimental treatments had an annual peak sales potential of at least 6 billion euros  CEO Baumann said in May that  with 50 projects in the clinical stage  pharma development was well positioned  Investors have said Bayer s November deal with Loxo Oncology to jointly develop cancer drug larotrectinib  was a step in the right direction   A number of drug development projects fell short recently  including a trial on drug anetumab ravtansine against an asbestos linked type of cancer and a bid to widen the use of prostate cancer drug Xofigo  Other problems are also piling up for CEO Baumann  These include the prospect of years of lawsuits against Monsanto  the order by U S  regulators to fix production problems in Germany and weak sales of consumer healthcare products  For a factbox   
Financial firepower for expansion is limited  Standard   Poor s cut its credit rating to triple B in the wake of the Monsanto deal  Bayer has said it will pay back debt to return to a single A rating ",2018-09-04,Reuters,https://www.investing.com/news/economy-news/with-drugs-pipeline-in-focus-bayer-considers-job-cuts-source-1596533,1596533
219976,441492,PFE,Lilly s Elanco unit expects IPO to raise up to  1 45  billion,news," Reuters    Eli Lilly   Co s Elanco Animal Health unit on Thursday said it expects its initial public offering of 62 9 million shares to raise up to  1 45 billion  The IPO is expected to be priced between  20  23 per share  At the high end of the range  the company would have a valuation of about  8 billion  In July  Lilly said it would take Elanco public  marking the end of a nine month review that weighed options for the unit  Analysts have cited the strong growth of top animal health company  Zoetis Inc   NYSE ZTS  since  Pfizer   NYSE PFE  listed it about five years ago  Zoetis  IPO  raised  2 2 billion and the company currently has a market capitalization of  43 billion  
For the six months ended June 30  Elanco s net income was 9 9 million and the company brought in revenue of  1 5 billion ",2018-09-06,Reuters,https://www.investing.com/news/stock-market-news/lillys-elanco-unit-expects-ipo-to-raise-up-to-145--billion-1600107,1600107
219984,441500,PFE,Exclusive  Pharma sector warns Saudis on German drug curbs,news,"By Noah Barkin and Caroline Copley BERLIN  Reuters    European and U S  pharmaceutical associations have waded into a diplomatic row between Germany and Saudi Arabia  warning that ongoing restrictions on German made drugs could hurt Saudi patients and dampen future investment in the kingdom  In a strongly worded letter to Crown Prince Mohammed bin Salman  a copy of which has been seen by Reuters  the associations highlighted the level of concern in Germany and elsewhere about restrictive procurement measures implemented by Riyadh in response to criticism of its policies   While a human rights row between Canada and Saudi Arabia has dominated headlines in recent weeks  Germany has been embroiled in its own spat with the oil rich kingdom since November  Germany s foreign minister at the time  Sigmar Gabriel  condemned  adventurism  in the Middle East in comments perceived by some as an attack on increasingly assertive Saudi policies  Riyadh dismissed the comments as  shameful  and withdrew its ambassador to Germany  Since then  Chancellor Angela Merkel has tried to ease the tensions  speaking to Prince Mohammed by telephone  But the row has rumbled on and German officials say companies such as Siemens Healthineers  DE SHLG   Bayer  DE BAYGn  and Boehringer Ingelheim are being excluded from public healthcare tenders in Saudi Arabia   For the past six months German healthcare companies have been having trouble doing business in Saudi Arabia   said Oliver Oehms of the German chamber of commerce and industry in Riyadh   It is not a general boycott  but the healthcare sector is clearly suffering   The dilemma for Berlin has been deepened by the Canada Saudi dispute  which was triggered by a tweet from the Canadian foreign minister calling for the release of human rights activists in Saudi Arabia  The kingdom responded by expelling the Canadian ambassador  recalling its own envoy  freezing new trade and investment  suspending flights and ordering Saudi students to leave Canada  Some German politicians have denounced the Saudi reaction  but the government has remained conspicuously quiet for fear of sabotaging its own conciliation efforts   MAJOR NEGATIVE EFFECTS  News that Saudi Arabia was punishing German companies broke in May  But the existence of the letter  dated June 12 and addressed to Prince Mohammed  has not been reported previously     This action could have major negative effects on the sustainable supply of innovative  critically necessary medicines for the treatment of patients in the Kingdom of Saudi Arabia   the letter from the German  VFA   European  EFPIA  and American  PhRMA  pharmaceutical associations reads  It says a decision to exclude German made products from the centralized Saudi procurement process for medical supplies  is likely to significantly dampen industry s perception of Saudi Arabia as a site for future investment in innovative medicines   The associations declined to comment further  but German officials said there had been no response from the Saudis or an improvement in their situation since the letter was sent  The Saudi authorities did not respond immediately to a request for comment  Saudi Arabia is the largest pharmaceuticals market in the Middle East and Africa  with sales of  7 6 billion last year  according to healthcare information company IQVIA  With a growing burden of chronic diseases tied to a more Western lifestyle  Saudi Arabia s overall drugs market is growing at 10 percent a year and the tender sector is expanding by about 30 percent  Neither Bayer nor Boehringer rank among the top 10 drug suppliers in Saudi Arabia  That list is led by  Novartis   S NOVN    Pfizer   N PFE  and local manufacturer Tabuk  according to IQVIA  German exports to Saudi Arabia fell 5 percent in the first half of 2018  They totaled 6 6 billion euros in 2017  with an estimated 15 percent coming from the healthcare sector  AMERICAN HELP Bayer and Boehringer declined to comment  But Siemens Healthineers  which makes X ray and MRI machines as well as diagnostic equipment  acknowledged that its business in Saudi Arabia had been affected and said it had turned to U S  authorities for help in ending the impasse   The decision of the Saudi Arabian government indeed has an impact on our local business   said a spokesman for the Siemens unit  which does not provide a breakdown of its Saudi business   We are working on a solution together with U S  authorities to utilize our global value chain to overcome the restrictions of the Saudi Health Ministry   he added  declining to provide further details  The company employs about 13 000 people in the United States  more than a quarter of its global workforce  and could make the case to American authorities that its U S  operations and jobs will be hit if Saudi restrictions are not lifted  It could also rejig supply routes to send more products from the United States instead of Germany  Johann Wadephul  a senior member of parliament from Merkel s conservative Christian Democrats  CDU   described the row with Saudi Arabia  very damaging    Should there be solidarity with Canada  Yes  But I don t think this should be the focus of German foreign policy in the region   he told Reuters   
 The focus should be on improving relations with Saudi Arabia  Unfortunately  we haven t achieved this so far  ",2018-08-22,Reuters,https://www.investing.com/news/stock-market-news/exclusive-pharma-sector-warns-saudis-on-german-drug-curbs-1583239,1583239
219992,441508,PFE,Pfizer  PFE  Up 2 3  Since Last Earnings Report  Can It Continue ,opinion,"It has been about a month since the last earnings report for Pfizer  PFE   Shares have added about 2 3  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Pfizer due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers  Pfizer Beats on Q1 Earnings   Sales  Raises EPS ViewPfizer beat estimates for first quarter earnings and sales  raised the mid point of its earnings expectations for 2019 by a penny and confirmed its previous guidance for full year salesFirst quarter 2019 adjusted earnings per share of 85 cents beat the Zacks Consensus Estimate of 77 cents  Earnings rose 13  year over year driven by higher sales and reduced share count  Currency changes had a negative impact of 2 cents per share on adjusted earnings Revenues of  13 12 billion beat the Zacks Consensus Estimate of  12 80 billion  Revenues rose 2  from the year ago quarter on a reported basis  Currency fluctuation hurt sales by 4  in the quarter  On an operational basis  excluding the impact of currency  revenues rose 5  year over year driven by higher sales of some key brands in Pfizer s Biopharmaceuticals group  While volumes rose 8   net prices declined 3  in the quarter International revenues rose 5   up 12  an operational basis  to  6 94 billion  U S  revenues however declined 2  to  6 18 billion Adjusted selling  informational and administrative  SI A  expenses rose 3   operationally  in the quarter to  3 31 billion  Adjusted R D expenses declined 2  to  1 69 billion In the quarter  Pfizer re purchased shares worth  8 9 billion comprising  2 1 billion of open market share repurchases and  6 8 billion in accelerated share repurchases per an agreement executed in February 2019  The remaining share authorization at the end of April was  5 3 billion Change in Segment ReportingIn 2018  Pfizer s reporting segments were Pfizer Innovative Health  IH  and Pfizer Essential Health  EH  Beginning the first quarter of 2019  Pfizer is reporting under three new business units   Pfizer Biopharmaceuticals Group  previous IH unit except Consumer Healthcare   Upjohn  previous EH unit  and Consumer Healthcare  However  Pfizer re allocated its biosimilar portfolio and certain legacy established products into the Biopharma group from the previous EH unit  The Biopharma group now includes the Hospital franchise  which comprises Pfizer s global portfolio of sterile injectable and anti infective medicines and also includes revenues from its contract manufacturing operation called Pfizer CentreOne Segment DiscussionPfizer Biopharma sales grew 3  on a reported basis  up 7  an operational basis  from the year ago period to  9 19 billion  Higher sales of Eliquis  Ibrance  Prevnar 13 Prevenar 13 and Xeljanz drove this segment s sales growth  partially offsetting sales in the hospital and rare disease businesses  In the Biopharma group  which accounted for 70  of Pfizer s revenues in the quarter  volumes rose 11  driven by growth in several key brands  emerging markets and biosimilars Within the Biopharma group  Oncology revenues increased 15  to  1 96 billion  Vaccine revenues rose 13  to  1 61 billion  Internal Medicine rose 10  to  2 22 billion  The Inflammation   Immunology franchise rose 8  to  1 04 billion  However  the portfolio of Rare Disease declined 9  to  470 million Newly added Hospital sub segment s sales declined 3  to  1 9 billion Pfizer s Upjohn group s sales declined 1  to  3 08 billion  On an operational basis  sales rose 1  in the segment as strong growth in emerging markets  mainly China  and Japan was offset by decline in developed markets other than Japan due to lower revenues of Viagra authorized generic version of Viagra  Lyrica and Greenstone  Upjohn s authorized generic subsidiary  primarily due to industry wide pricing challenges in the United States Revenues in the Consumer Healthcare unit declined 5   2  on an operational basis  to  858 million due to lower sales in the U S  market  which were partially offset by higher sales in international markets Performance of Key DrugsIbrance revenues rose 25  year over year to  1 13 billion as continued strong uptake in international markets made up for moderating volumes in United States Xeljanz sales rose 34  to  423 million driven by continued growth in rheumatoid arthritis  RA  revenues and contributions from the drug s recent expansion into psoriatic arthritis and ulcerative colitis in the United States and only ulcerative colitis indication in certain developed markets Global Prevnar 13 Prevenar 13 revenues rose 10  to  1 49 billion  Prevnar 13 revenues rose 6  in the United States reflecting increased government purchases for the pediatric indication  which made up for the continued decline in revenues for the adult indication  Prevenar 13 revenues rose 16  in international markets driven by higher revenues in emerging markets Enbrel revenues declined 3  to  451 million in key European markets due to continued biosimilar competition Xalkori sales declined 16  to  123 million primarily due to competitive pressure  Sutent sales declined 6  to  232 million  Eliquis alliance revenues and direct sales rose 36  to  1 01 billion  Chantix sales rose 10  to  273 million in the quarter  Xtandi recorded alliance revenues of  168 million in the quarter  up 6  year over year Revenues from the biosimilars portfolio grew 7  operationally in the quarter  Inflectra recorded sales of  138 million globally  flat year over year In the Upjohn segment  sales of key drug Lyrica declined 1  to  1 19 billion reflecting wholesaler destocking ahead of the drug s anticipated loss of exclusivity  LOE  in June and lower sales in developed Europe due to generic launches  Viagra sales declined 19  to  145 million due to generic competition that began in December 2017 2019 GuidancePfizer maintained its sales guidance for 2019  However  the company raised the mid point of its earnings guidance by a penny as increased expectation for other income due to a milestone payment recorded in the first quarter  was offset by stronger currency headwinds  The guidance includes a full year of revenues and expense contribution from the Consumer Healthcare unit Revenues are still expected in the range of  52 0 billion to  54 0 billion  Adjusted earnings per share are expected in the range of  2 83  2 93 versus the previous expectation of  2 82  2 92 In 2019  Pfizer expects continued strong growth of key product franchises  including Ibrance  Eliquis  Xeljanz and Prevnar However  LOEs are expected to hurt 2019 sales by  2 6 billiion including the expected LOE of key drug Lyrica in the United States in June 2019  Also  currency headwinds are expected to significantly pull down 2019 revenues Research and development expense is expected in the range of  7 8  8 3 billion while SI A spending is projected in the range of  13 5   14 5 billion  Adjusted tax rate is expected to be approximately 16  in 2019 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed an upward trend in fresh estimates 
VGM Scores
Currently  Pfizer has an average Growth Score of C  a grade with the same score on the momentum front  Following the exact same course  the stock was allocated a grade of C on the value side  putting it in the middle 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of C  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been trending upward for the stock  and the magnitude of this revision has been net zero  Notably  Pfizer has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-05-29,Zacks Investment Research,https://www.investing.com/analysis/pfizer-pfe-up-23-since-last-earnings-report-can-it-continue-200426553,200426553
219993,441509,PFE,Blueprint Medicines  NDA For Avapritinib On Track For GIST,opinion,Blueprint Medicines Corporation   NASDAQ BPMC   presented data from the NAVIGATOR study on its lead pipeline candidate  avapritinib  at the annual meeting of American Society of Clinical Oncology  ASCO   held in Chicago The registration enabling NAVIGATOR study evaluated avapritinib for treating patients with PDGFRA Exon 18 mutant gastrointestinal stromal tumors  GIST  and the fourth line GIST on two patient groups  The indications currently have no approved therapies  Data from the program showed that patients with PDGFRA Exon 18 mutant GIST achieved an objective response rate  ORR  of 86  while the median duration of response  DOR  was not reached  Meanwhile  patients with fourth line GIST had an ORR of 22  while the median DOR was 10 2 months Based on the data presented  Blueprint Medicines plans to submit a new drug application  NDA  for avapritinib later this month and subsequently  file a regulatory application in Europe during third quarter 2019 for the given indication Meanwhile  Blueprint Medicines is also investigating avapritinib in other settings for GIST  The phase III VOYAGER program is evaluating the safety and efficacy of avapritinib compared with Bayer s   OTC BAYRY   Stivarga  regorafenib  on patients with the third or fourth line GIST  The company also has an objective to initiate a global phase III precision medicine probe  COMPASS 2L  to evaluate the safety and efficacy of avapritinib as compared to Pfizer s   NYSE PFE   Sutent  sunitinib  for second line GIST patients with pre specified disease genotypes in the second half of 2019 Shares of Blueprint Medicines have soared 57  so far this year versus the  slip of 1 9  We would like to remind investors that other than GIST  Blueprint Medicines is pursuing a broad clinical development investigation on avapritinib across the advanced  indolent and smoldering forms of systemic mastocytosis  SM  Avapritinib is currently being evaluated in two studies  namely the phase I EXPLORER clinical study and the registration enabling phase II PATHFINDER study for advanced SM  The company looks forward to submit an NDA for avapritinib pertaining to the advanced SM indication in the first quarter of 2020 Blueprint Medicines has no approved product in its portfolio at the moment  Thus  an approval of avapritinib will lower the company s heavy dependence on its partners for revenue generation  The company currently has partnership with Roche   OTC RHHBY   and CStone Pharmaceuticals for the development and commercialization of its pipeline candidates Zacks RankBlueprint Medicines currently has a Zacks Rank  3  Hold   You can see  Will you retire a millionaire One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ,2019-06-02,Zacks Investment Research,https://www.investing.com/analysis/blueprint-medicines-nda-for-avapritinib-on-track-for-gist-200427856,200427856
220001,441517,PFE,Ocular s Glaucoma Drug Study Fails To Meet Primary Endpoint ,opinion,"Ocular Therapeutix  Inc    NASDAQ OCUL   announced top line results from the first pivotal phase III study on OTX TP  sustained release travoprost for the reduction of intraocular pressure  IOP  in patients with primary open angle glaucoma or ocular hypertension  The study did not meet the primary endpoint and shares of the company fell 2 6  following the news  In fact  shares of Ocular have declined 15 3  year to date against the  s growth of 4 7  

 
The study enrolled 554 subjects with open angle glaucoma or ocular hypertension in the full analysis set  FAS  population  The primary endpoint of the study was reduction of intraocular pressure  IOP  from baseline on treatment with OTX TP compared with placebo insert treated subjects at nine different time points  three diurnal time points at each of 2  6  and 12 weeks following insertion  
Top line results showed that the study did not achieve its primary endpoint of statistically significant superiority in mean reduction of IOP compared with placebo at all nine time points  However  OTX TP treated subjects did have a statistically significant reduction in IOP from baseline relative to placebo insert at eight of the nine pre specified time points 
OTX TP was generally well tolerated and no ocular serious adverse events were observed Ocular will continue to review the data from the study and will meet the FDA for a discussion before determining the next steps in its clinical development plans 
We remind investors that in March 2019  Aerie Pharmaceuticals  Inc    NASDAQ AERI   received FDA approval for Rocklatan 0 02  0 005  to reduce elevated intraocular pressure  IOP  in patients with open angle glaucoma or ocular hypertension  Rocklatan is a once daily  quadruple action fixed dose combination of Rhopressa  netarsudil  and Pfizer s   NYSE PFE   Xalatan  latanoprost  
Zacks Rank   Stock to Consider
Ocular currently has a Zacks Rank  3  Hold  
A better ranked stock in the same space is Eisai Co    OTC ESALY    carrying a Zacks Rank  1  Strong Buy   You can see  
Eisai s earnings per share estimates have moved up from  1 86 to  1 95 for 2019 and from  1 89 to  2 02 for 2020 in the past 90 days 
Will you retire a millionaire  
One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ",2019-05-21,Zacks Investment Research,https://www.investing.com/analysis/oculars-glaucoma-drug-study-fails-to-meet-primary-endpoint-200423636,200423636
220002,441518,PFE,Pfizer CEO expects Trump to eliminate drug rebates,news,"By Michael Erman and Tamara Mathias  Reuters     Pfizer  Inc  N PFE  Chief Executive Ian Read said on Tuesday he believes the Trump administration intends to stop the practice of allowing rebates on prescription drug purchases  suggesting that U S  drug pricing reforms may focus on middlemen rather than drugmakers   I believe the administration does want to remove rebates  and they consider it a priority   he said in an interview  following similar comments made on Pfizer s conference call to discuss second quarter earnings  The administration has already proposed a rule that would scale back protections currently in place that allow rebates between drug manufacturers and insurers and pharmacy benefits managers  PBMs   Read said he believes the administration wants to get rid of them entirely  These rebates are rarely passed along to U S  patients   Read said Pfizer had discussed the administration s plan for rebates  in broad terms  with Health and Human Services Secretary Alex Azar  The CEO said he does not know how quickly changes to rebate policy could be implemented  U S  President Donald Trump has made lowering prescription drug costs for U S  consumers a top priority  His administration has placed blame on  middlemen  such as PBMs   which administer drug benefits for employers and health plans   and health insurers for driving up drug prices by demanding hefty rebates in exchange for broad access to patients   Read said Pfizer currently receives around 58 percent of its list prices on drugs  suggesting that about 40 percent goes to middlemen  He said ending the rebate system would allow drugmakers to keep price hikes in line with health care inflation  The largest U S  drugmaker retreated from planned price hikes on about 40 of its drugs earlier this month  following criticism from President Trump  Read has spoken with Trump and visited the White House since deferring those price increases  Bowing to intensifying political pressure  several major drugmakers have also announced drug price freezes until the end of the year   Pfizer shares rose  1 09  or 2 8 percent  to  39 68 in afternoon trading  closing in on near 16 year highs  Pfizer on Tuesday also reported better than expected second quarter profit  but trimmed its full year revenue forecast due to the strengthening dollar  Edward Jones analyst Ashtyn Evans said investors were encouraged by management optimism about new drugs and long term growth prospects after prior disappointment that Pfizer had not done a big acquisition   There s more optimism around the internal pipeline and their ability to expand margins long term   she said  Excluding special items  Pfizer earned 81 cents per share  beating analysts  average estimate by 7 cents  according to Thomson Reuters I B E S  Pfizer said it now expects 2018 revenue of between  53 billion and  55 billion  versus its a prior forecast of  53 5 billion to  55 5 billion  It raised both ends of its 2018 adjusted earnings forecast range by 5 cents and now expects  2 95 to  3 05 per share  Second quarter results were helped by higher than expected sales of rheumatoid arthritis drug Xeljanz at  463 million  and by the staying power of its former top seller Lipitor  The off patent cholesterol drug still generated worldwide sales of  521 million  
Total revenue in the quarter rose 4 4 percent to  13 47 billion  ahead of Wall Street expectations of  13 31 billion ",2018-07-31,Reuters,https://www.investing.com/news/stock-market-news/pfizer-profit-rises-26-percent-1552720,1552720
220007,441523,PFE,Pfizer Rises 3 06  With Earnings In Focus,news,Investing com    Pfizer   NYSE PFE  rose by 3 06  to trade at  39 77 by 11 14  15 14 GMT  on Tuesday on the NYSE exchange  up 3 06  on the day  The volume of Pfizer  shares traded since the start of the session was 14 61M Pfizer has traded in a range of  38 21 to  39 78 on the day  The stock has traded at  39 78 at its highest and  37 14 at its lowest during the past seven days ,2018-07-31,Investing.com,https://www.investing.com/news/stock-market-news/pfizer-rises-306-with-earnings-in-focus-1553392,1553392
220009,441525,PFE,Conatus   CNAT  Earnings  Revenues Miss Estimates In Q1,opinion,"Conatus Pharmaceuticals Inc    NASDAQ CNAT   incurred a loss of 14 cents per share in the first quarter of 2019  wider than the Zacks Consensus Estimate of 12 cents but narrower than the year ago quarter s loss of 17 cents 
Revenues came in at  7 million  down 27 8  year over year due to lower reimbursement from partner Novartis   NYSE NVS   for the costs incurred to support the company s development of its lead pipeline candidate  emricasan  Moreover  the top line fell shy of the Zacks Consensus Estimate of  8 million 
Shares of Conatus have plunged 47 9  so far this year  underperforming the  increase of 11 2  

 
Conatus has no approved product in its portfolio at the moment  The revenues generated by the company are all related to its collaboration with Novartis for the worldwide development and commercialization of emricasan 
Quarter in Detail
In the first quarter  research and development expenses were  9 4 million  down 22 3  from the year ago period s figure  mainly on account of lower spending associated with the ongoing ENCORE PH study on emricasan  This was partially offset by higher spending related to ENCORE LF study 
General and administrative expenses were  2 6 million  marginally down from the year earlier quarter s  2 7 million 
Emricasan in Focus
Emricasan  a caspase inhibitor  is being developed for the treatment of patients with fibrosis or cirrhosis caused by nonalcoholic steatohepatitis  NASH   Conatus acquired the worldwide rights to emricasan from Pfizer   NYSE PFE   in July 2010 
The company is currently conducting two ongoing phase IIb ENCORE programs on emricasan for treating fibrosis or cirrhosis induced by NASH  Those are  ENCORE PH  for portal hypertension  and ENCORE LF  for liver function  
Last December  Conatus announced top line results from a phase IIb ENCORE PH  Under the evaluation  emricasan demonstrated clinically meaningful treatment effects on compensated NASH cirrhosis patients  who stand at a risk of passing to the decompensation state  However  the probe failed to meet its primary endpoint  Following a post hoc analysis  emricasan showed a clinically meaningful treatment impact compared with placebo  Additional results are now expected in mid 2019 
Meanwhile  during the first quarter of 2019  Conatus completed enrolling patients in the phase IIb ENCORE LF study  the primary endpoint being event free survival  Top line data from the investigation is anticipated in mid 2019 
Notably  this March  Conatus announced that the ENCORE NF study  which evaluated emricasan for treating patients with biopsy confirmed NASH and liver fibrosis could not achieve the primary goal as it lacked the desired effect on these earlier stage NASH fibrosis patients  Shares of the company significantly dropped back then 
Additionally  in the same month  Conatus announced that it has selected CTS 2090  currently in preclinical development  to move into clinical studies  CTS 2090 is an orally active  potent and highly selective inhibitor of caspase 1  The company plans to submit an investigational new drug  IND  application by the first half of 2020 to begin clinical assessments on the candidate for treating autoinflammatory diseases 
As of Mar 31  2019  Conatus had cash  cash equivalents and marketable securities of  33 8 million compared with  40 7 million as of Dec 31  2018  Conatus expects the 2019 end balance in the range of  10  15 million excluding any potential milestone fee under the Novartis collaboration 
Conatus Pharmaceuticals Inc  Price  Consensus and EPS Surprise
   Zacks Rank   Key Pick
Conatus carries a Zacks Rank  3  Hold   A better ranked stock in the healthcare sector is PDL BioPharma  Inc    NASDAQ PDLI    sporting a Zacks Rank  1  Strong Buy   You can see  
PDL BioPharma s earnings estimates have been revised 100  upward for 2019 and 30  for 2020 over the past 60 days  The stock has rallied 15 5  year to date 
Will you retire a millionaire 
One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ",2019-05-06,Zacks Investment Research,https://www.investing.com/analysis/conatus-cnat-earnings-revenues-miss-estimates-in-q1-200417542,200417542
220010,441526,PFE,Pfizer to split into three units  separates consumer healthcare,news," Reuters     Pfizer  Inc  N PFE  said on Wednesday it would reorganize into three units  separating its consumer healthcare business that the U S  drugmaker has been trying to sell since last year  The news comes a day after the company decided to defer drug price increases for no more than six months  following criticism from U S  President Donald Trump for raising list prices of some medicines  The units would be Innovative Medicines  Established Medicines and Consumer Healthcare  The company is currently split into two units   Innovative Medicines  which includes the consumer business  and Essential Health   This design gives us a sharper focus on diverse patients in diverse markets   Albert Bourla  chief operating officer said   The Innovative Medicines business will now also include biosimilars and a new hospital business unit  and together with the Consumer Healthcare business  will account for about three quarters of the company s revenue  Pfizer s 2017 annual revenue was  52 55 billion  Pfizer said it would still evaluate options for its consumer healthcare business and expects to make a decision in 2018   The company said in October last year that it was considering the sale or spin off of the consumer healthcare business  which is worth about  15 billion  In May  Pfizer said that it had not received an acceptable offer  The business consists of products ranging from Advil to lip balms   The Established Medicines unit would include the majority of the company s off patent brands  including Viagra and neurological disease treatment Lyrica as well as some generic drugs  The changes would be effective at the start of fiscal 2019  
Pfizer shares were flat at  37 40 in premarket trading ",2018-07-11,Reuters,https://www.investing.com/news/stock-market-news/pfizer-inc-to-reorganize-company-into-three-units-1525103,1525103
220011,441527,PFE,Trump told Pfizer CEO price hikes hurt his drug plan  source,news,"By Michael Erman and Yasmeen Abutaleb NEW YORK WASHINGTON  Reuters    U S  President Donald Trump called  Pfizer   NYSE PFE  Chief Executive Ian Read on Tuesday to say the company s July 1 price hikes had complicated the administration s drug pricing plans  prompting the company to defer its planned increases  according to a source familiar with the matter  Pfizer said on Tuesday it was deferring its drug price increases on around 40 drugs for no more than six months after Read s conversation with Trump  U S  Health and Human Services secretary Alex Azar called Read previously  and the Pfizer CEO asked to speak directly with the president  the source said   The conversation took place around 4 30 p m  ET on Tuesday and lasted about 10 to 15 minutes  Trump  in Brussels for a NATO meeting  had arrived at the U S  ambassador s residence at about 3 30 p m  ET   Trump tweeted about the call at 6 37 p m  and Pfizer confirmed it soon after  The call and subsequent price rollback came a day after Trump took aim at Pfizer and other U S  drugmakers for raising prices on some of their medicines  saying in a tweet that they  should be ashamed  and that his administration would respond  Senator Ron Wyden  a Democrat from Oregon  said he was concerned that Trump had struck a  secret  sweetheart  deal with Pfizer and asked for Azar and Pfizer to release details about what was agreed on the calls   Instead of proposing meaningful changes that result in lower costs for families and taxpayers  Trump and his Administration are busy scoring cheap PR points that don t address the fundamental challenges that lead to higher prices every year   Wyden said in a press release  Trump rolled out a blueprint in May on how his administration planned to lower drug prices  Later that month  Trump said that some drug companies would announce  voluntary  massive  price decreases in two weeks  though none have materialized yet  Pfizer on Tuesday said it would defer price increases that went into effect on July 1 until the end of the year or until the president s drug pricing blueprint goes into effect   whichever is sooner  The company said it would return drug prices to their pre July 1 levels as soon as technically possible  Pfizer  one of the largest pharmaceutical companies  now likely will not raise drug prices until after the 2018 midterm elections in November   
That gives Trump  who made lowering prescription drug prices a top 2016 presidential campaign issue  a short term victory he can point to in the run up to the elections  which are being closely watched to see if Trump s fellow Republicans will be able to maintain control of both the Senate and the House of Representatives ",2018-07-11,Reuters,https://www.investing.com/news/stock-market-news/exclusive-trump-pfizer-ceo-ian-read-spoke-about-drug-pricing--source-1525664,1525664
220012,441528,PFE,Pfizer launches late stage study of hemophilia B gene therapy,news,Pfizer   PFE  0 4   initiates a Phase 3 open label lead in study evaluating current factor IX prophylaxis replacement therapy in the usual care setting for patients with hemophilia B The results will serve as the within subject control group for those patients that enroll in the next part of the trial assessing gene therapy fidanacogene elaparvovec for the treatment of hemophilia B  The interventional portion of the trial will involve patients who have completed at least six months in the lead in study The primary endpoint of the 110 subject study is change in annualized bleed rate from baseline over a six month treatment period  According to ClinicalTrials gov  the estimated completion date is November 2020 The company inked a collaboration agreement with Spark Therapeutics  ONCE  3 2   in December 2014 to develop the gene therapy and recently assumed full responsibility for the program Now read ,2018-07-16,Seeking Alpha,https://www.investing.com/news/stock-market-news/pfizer-launches-latestage-study-of-hemophilia-b-gene-therapy-1531366,1531366
220013,441529,PFE,Hikma raising injectable opioids output to help ease shortage at U S  hospitals,news,"LONDON  Reuters    London listed pharmaceutical group Hikma  L HIK  said on Wednesday it was increasing its supply of hydromorphone to U S  hospitals to help ease a shortage of injectable opioids used to treat patients  Injectable opioid painkillers  which hospitals use to manage pain after operations and in terminal illness  have been in short supply for more than a year largely due to production problems at  Pfizer   N PFE   the biggest supplier of the drugs  Pfizer has said it is making progress on its recovery plan  but it estimates that the supply of some of its injectables will not be fully restored until later this year or in 2019   Opioids are controlled substances and therefore manufacturers are allocated quota for their active ingredients by the Drug Enforcement Administration  limiting their ability to increase production  Hikma said it had released more than 5 million hydromorphone 2ml vials to U S  hospitals in June and expected to release 3 million vials in July  Daniel Motto  executive vice president of Hikma s U S  injectables division  said the company was prioritizing the manufacture of opioid products affected by this shortage including fentanyl  meperidine  morphine and hydromorphone  
 We have the capacity in our FDA inspected manufacturing facility in Cherry Hill  New Jersey  for all CII opioid injectable products  and believe we can now address the current shortage of these vital and urgently needed medications  pending increased quota allowances from the US Drug Enforcement Administration   he said ",2018-07-18,Reuters,https://www.investing.com/news/stock-market-news/hikma-raising-injectable-opioids-output-to-help-ease-shortage-at-us-hospitals-1534570,1534570
220014,441530,PFE,Novartis hints at 2018 outlook hike despite drug price freeze,news,"By John Miller ZURICH  Reuters     Novartis   S NOVN  may ratchet up its 2018 sales outlook  its finance chief said on Wednesday  despite halting planned U S  drug price hikes amid pressure on the industry from President Donald Trump s administration over the high cost of medicines  Shares in the Swiss drugmaker  whose decision to freeze prices this year in the world s largest drug market was mirrored by  Pfizer   N PFE   closed 2 5 percent higher in Zurich after the firm beat forecasts with second quarter results  Second quarter core operating profit rose 7 percent to  3 54 billion  it said  better than the average forecast of  3 46 billion in a Reuters poll  Sales climbed 5 percent to  13 16 billion  topping the  12 92 billion forecast  Full year 2018 sales are seen rising at low to mid single digit percentage rates  with operating profit rising in the mid to upper single digit percentages  But Chief Financial Officer Harry Kirsch told analysts on a conference call he expected  continued good momentum  for products including psoriasis and arthritis drug Cosentyx and heart failure medicine Entresto  That increased the likelihood that Novartis would upgrade its sales targets for 2018  he said   You may see us raise  the guidance  in quarter three   Kirsch said   It s a bit too early now  but I m quite confident we will be at the upper end of the guidance on sales   This would come without price hikes as Novartis keeps the lid on medicine costs under pressure from U S  lawmakers and Trump   A call from the president prompted Pfizer CEO Ian Read this month to reverse course on price hikes his company had enacted on July 1  Novartis said it made its own decision in June to forego what had been planned hikes  adding that a range of factors were considered  Novartis Chief Executive Narasimhan told Reuters that  unlike Pfizer s Read  he did not have a direct talk with Trump on drug prices but he said his company has been speaking to the federal Department of Health and Human Services about the U S  administration s  blueprint  to trim costs   We don t plan to take any further price increases in the United States for 2018   the Novartis CEO said   Right now  in a very dynamic environment in the United States     we view it as the prudent course   Novartis s net U S  drug prices this year are  flat to declining   he said  including the impact from its Sandoz generics unit where price pressure continues in the United States   Novartis now predicts Sandoz sales for 2018 will fall in the low single digit percentages  after previously holding out hopes for them to remain steady   Narasimhan is still reviewing options for the U S  generics business  but said Novartis remained committed to its Sandoz unit as a whole   Ahead of the planned spinoff of Novartis s Alcon eye care business to shareholders  set for early next year  Novartis raised the unit s sales guidance to mid single digit percentage growth for 2018 after revenue in the second quarter grew 5 percent to  1 8 billion  Second quarter growth was also helped by a 40 percent increase in Cosentyx sales to  701 billion  a development analysts said was a relief after sales of the medicine missed expectations at the start of 2018   It confirms Q1 s blip was a combination of not just rebates but also wholesaler destocking   Deutsche Bank s Tim Race wrote in a note   All in all  we sum up the quarter as solid   CASE CLOSED  Novartis has been in the firing line over a  1 2 million contract with Trump s former lawyer for consulting work  U S  lawmakers accused the firm last week of misleading the public about the depth of its contacts with Michael Cohen  Novartis disputes this  Narasimhan  who has said the contract was a mistake  said no outstanding U S  government or congressional inquiries remained into his company s ties to Cohen s firm that paid  130 000 to pornographic film actress Stormy Daniels    I view the Cohen issue as closed at this point   he said   We re really focused on our future   Narasimhan said Novartis was on track to file for regulatory approval by October of its gene therapy for spinal muscular atrophy  which came with its  8 7 billion purchase of AveXis  
He also said he expected the launch of multiple sclerosis drug BAF312 in early 2019 ",2018-07-18,Reuters,https://www.investing.com/news/stock-market-news/novartis-puts-brakes-on-price-hikes-bowing-to-us-pressure-1534248,1534248
220021,441537,PFE,Why Earnings Season Could Be Great For Pfizer  PFE ,opinion,Investors are always looking for stocks that are poised to beat at earnings season and Pfizer Inc    NYSE PFE   may be one such company  The firm has earnings coming up pretty soon  and events are shaping up quite nicely for their report That is because Pfizer is seeing favorable earnings estimate revision activity as of late  which is generally a precursor to an earnings beat  After all  analysts raising estimates right before earnings   with the most up to date information possible   is a pretty good indicator of some favorable trends underneath the surface for PFE in this report In fact  the Most Accurate Estimate for the current quarter is currently higher than the broader Zacks Consensus Estimate of 77 cents per share  This suggests that analysts have very recently bumped up their estimates for PFE  giving the stock a Zacks Earnings ESP of  0 65  heading into earnings season Pfizer Inc  Price and EPS Surprise   Why is this Important A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises  and outperforming the market  Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank  3  Hold  or better show a positive surprise nearly 70  of the time  and have returned over 28  on average in annual returns  see more   Given that PFE has a Zacks Rank  3 and an ESP in positive territory  investors might want to consider this stock ahead of earnings  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here Clearly  recent earnings estimate revisions suggest that good things are ahead for Pfizer  and that a beat might be in the cards for the upcoming report Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-04-28,Zacks Investment Research,https://www.investing.com/analysis/why-earnings-season-could-be-great-for-pfizer-pfe-200412282,200412282
220022,441538,PFE,Pfizer to pay  23 85 million to resolve U S  kickbacks case,news," Reuters     Pfizer  Inc  N PFE  has agreed to pay  23 85 million to resolve U S  government charges that the drugmaker illegally used a purportedly independent charity to pay kickbacks to Medicare patients covering their out of pocket drug costs  The settlement announced by the U S  Department of Justice resolves allegations that Pfizer violated the federal False Claims Act between 2012 and 2016  It resulted from an industrywide probe into drug companies  support of patient assistance charities  Pfizer did not immediately respond to a request for comment  The government accused Pfizer of improperly using the Patient Access Network Foundation  which claimed non profit status for tax purposes  as a conduit to cover the co pay obligations of Medicare patients taking three Pfizer drugs  These drugs included Sutent and Inlyta  which both treat renal cell carcinoma  and Tikosyn  which treats arrhythmia in patients with atrial fibrillation  the government said  
 Pfizer used a third party to saddle Medicare with extra costs   enabling the drugmaker to generate more revenue and mask price increases  Andrew Lelling  the U S  attorney in Boston  said in a statement ",2018-05-24,Reuters,https://www.investing.com/news/stock-market-news/pfizer-to-pay-2385-million-to-resolve-us-kickbacks-case-1461562,1461562
220023,441539,PFE,Kitov Pharma up 12  premarket ahead of FDA decision on KIT 302,news,Thinly traded nano cap Kitov Pharma Ltd   NASDAQ KTOV  is up 12  premarket on robust volume  Today is the FDA s action date for its review of the company s marketing application seeking approval for KIT 302 for osteoarthritis pain and high blood pressure KIT 302 is a combination drug that treats osteoporosis related pain  celecoxib  branded as Celebrex by  Pfizer   NYSE PFE   and hypertension  amlodipine besylate  branded as Norvasc  Now read ,2018-05-31,Seeking Alpha,https://www.investing.com/news/stock-market-news/kitov-pharma-up-12-premarket-ahead-of-fda-decision-on-kit302-1470000,1470000
220024,441540,PFE,Texas high court rules state must reveal supplier of execution drugs,news,By Jon Herskovitz AUSTIN  Texas  Reuters    Texas must reveal the source of the drugs it uses for executions  its Supreme Court affirmed on Friday  rejecting the state s arguments that doing so could lead to physical harm of the supplier and impede lethal injections  Ever since a sales ban of lethal injection drugs by major pharmaceutical companies a few years ago  most states have kept the suppliers of their drugs secret  This has prompted lawsuits on behalf of death row inmates  arguing that prisoners could be subjected to unconstitutional suffering from faulty drugs in lethal injection mixes from questionable suppliers  The Texas Supreme Court on Friday affirmed a May 2017 decision by an appellate court that said there was not enough compelling evidence provided by the state to show that there was a substantial threat of physical harm   Today s decision is a win for the fundamental principles of transparency and open government   Maurie Levin  one of the attorneys who helped bring the lawsuit on behalf of two Texas death row inmates  said in a statement  The Texas Department of Criminal Justice said in a statement that it intends to file a motion with the court for a rehearing  Texas has executed 551 people since capital punishment was reinstated in 1976  37 percent of all U S  executions and more than triple any other state  according to the Death Penalty Information Center   Texas has also been one of the few states in the country able to procure a steady supply of execution drugs  In 2016  pharmaceutical company  Pfizer  Inc  N PFE  joined a sales ban imposed years earlier by major European drug makers that did not want their products used in executions due to ethical concerns  This caused many states to scramble for suppliers and a few to suspend executions due to lack of drugs   Although 31 states have the death penalty  only eight have held executions since Pfizer s decision  which cut off the last major U S  source for drugs in the lethal mixtures  Many have turned to lightly regulated compounding pharmacies  which can mix chemicals  The states also have banned the release of the pharmacies  names  which they have said was a security precaution  For its lethal injection  Texas uses the barbiturate pentobarbital ,2018-06-01,Reuters,https://www.investing.com/news/world-news/texas-high-court-rules-state-must-reveal-supplier-of-execution-drugs-1477733,1477733
220025,441541,PFE,Pfizer to expand venture investing with  600M commitment to Pfizer ventures,news,Pfizer   NYSE PFE  plans to invest  600M       in biotechnology and other emerging growth companies through Pfizer       Ventures  Pfizer Ventures will seek to invest  25  of its available       capital   150M  in promising early stage neuroscience companies  Beyond neuroscience  Pfizer Ventures will continue to invest across a       broad range of therapeutic areas of interest such as oncology        inflammation and immunology  rare disease  internal medicine and       vaccines Shares are up a fraction premarket  Now read ,2018-06-06,Seeking Alpha,https://www.investing.com/news/stock-market-news/pfizer-to-expand-venture-investing-with-600m-commitment-to-pfizer-ventures-1482402,1482402
220026,441542,PFE,Drugmaker Lundbeck to settle U S  charity probe for  52 6 million,news,"By Nate Raymond BOSTON  Reuters    Danish drugmaker Lundbeck  CO LUN  said on Wednesday that it will pay  52 6 million to resolve a U S  probe into its financial support of patient assistance charitable foundations  The company  formally called H  Lundbeck A S  said it had reached an agreement with the U S  Justice Department  which has investigating drugmakers  support of charities that help Medicare patients cover out of pocket drug costs   Lundbeck  which develops and distributes drugs for neurological and psychological diseases such as depression and Alzheimer s  said the settlement would include no admission of wrongdoing and is subject to further negotiation  Drug companies are prohibited from subsidizing co payments for patients enrolled in the Medicare government healthcare program for the elderly  But companies may donate to non profits providing co pay assistance as long as they are independent   The U S  Attorney s Office in Massachusetts has been leading the industry wide investigation  A spokeswoman for the office declined to comment  The probe most recently resulted in  Pfizer  Inc  N PFE  on May 25 agreeing to pay  23 85 million to resolve claims that it used a purportedly independent charity as a conduit to pay illegal kickbacks to Medicare patients  In December   United Therapeutics Corp   O UTHR  reached a  210 million settlement to resolve similar allegations it improperly used a charity to cover co payments  
 Jazz Pharmaceuticals  Plc  O JAZZ  announced on May 8 that it had reached an agreement to pay  57 million to resolve a related investigation ",2018-06-06,Reuters,https://www.investing.com/news/stock-market-news/drugmaker-lundbeck-to-settle-us-charity-probe-for-526-million-1483223,1483223
220033,441549,PFE,Exact Sciences  EXAS  To Post Q1 Earnings  What s In Store  ,opinion,Exact Sciences Corporation   NASDAQ EXAS   is scheduled to report first quarter 2019 earnings results on Apr 30  2019  after the market closes The company s track record has been impressive so far  having delivered a positive surprise in each of the trailing four quarters  the average being 16 26   In the last reported quarter  Exact Sciences came up with an earnings surprise of 12  Shares of Exact Sciences have surged 46 1  in the year so far  outperforming the  increase of 2 9  Let s see how things are shaping up for the upcoming quarterly results Factors to ConsiderExact Sciences  top line mainly consists of laboratory service revenues generated from Cologuard  a non invasive screening test for colorectal cancer  Cologuard test volume increased both year over year and sequentially in the fourth quarter of 2018 as a large number of healthcare providers ordered their first Cologuard test  We expect this positive trend to continue in the first quarter as well In February 2019  Cologuard screening test volume crossed the 2 million mark since its launch in 2014  Exact Sciences is intensely focused on accelerating this momentum by adding a test lab facility and increasing its workforce  The company concentrates on raising awareness of the importance of colorectal cancer screening and early cancer detection of the dreadful disease  Going forward  we expect the number of people undergoing screening for colorectal cancer to burgeon  which will be a huge boon to Cologuard We would like to remind investors that Cologuard is the first and the only FDA approved non invasive DNA screening option for colorectal cancer  Last August  Exact Sciences entered into an agreement with the drug giant Pfizer   NYSE PFE   to co promote its Cologuard test for the detection of colorectal cancer in the United States  This nationwide co promotion deal will be valid through 2021 end We expect investors  focus to be on the sales volume generated by Cologuard during the upcoming earnings call Earnings WhispersOur proven model does not conclusively show that Exact Sciences is likely to beat on earnings this reporting cycle  This is because the stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  But that is not the case here as you will see below Earnings ESP  Exact Sciences has an Earnings ESP of 0 00   This is because the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at a loss of 64 cents each  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Exact Sciences carries a Zacks Rank  4  Sell   which lowers the predictive power of ESP  Moreover  a 0 00  ESP in the combination makes surprise prediction difficult for the stock this earnings season   We caution against stocks with a Zacks Rank of 4 or 5 going into an earnings announcement  especially when the company is seeing negative estimate revisions Exact Sciences Corporation Price and EPS Surprise   Stocks That Warrant a LookHere are a few health care stocks worth considering as our model shows that these have the right mix of elements to beat estimates this time around Aduro Biotech  Inc    NASDAQ ADRO   has a Zacks Rank  2 and an Earnings ESP of  82 00   You can see  Incyte Corporation   NASDAQ INCY   has an Earnings ESP of  14 47  and a Zacks Rank of 1  The company is scheduled to release first quarter results on Apr 30  before the market opens Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ,2019-04-21,Zacks Investment Research,https://www.investing.com/analysis/exact-sciences-exas-to-post-q1-earnings-whats-in-store-200409132,200409132
220034,441550,PFE,What s In Store For Bayer  BAYRY  This Earnings Season ,opinion,"Bayer  DE BAYGN  Aktiengesellschaft   OTC BAYRY   is scheduled to report first quarter 2019 results on Apr 25 
Bayer has surpassed expectations in the previous four quarters  the average positive earnings surprise being 6 98  
The stock has dipped 2 3  in the past year compared with the  s decline of 0 9  

 
Let s see how things are shaping up for this announcement 
Factors to Consider
In 2018  Bayer undertook a series of portfolio  efficiency and structural measures  including exiting the Animal Health business unit  and the Consumer Health brands  Coppertone and Dr  Scholl s  to strengthen its position  The company also plans to sell its 60  interest in German site services provider  Currenta  The company completed the acquisition of Monsanto  NYSE MON  in June 2018 
The combined enterprise will enable Bayer to bring innovations to the market faster  and provide customers with better solution  In December 2018  Visanne was approved by the Chinese regulatory authorities for the treatment of endometriosis  The drug is a once daily oral tablet containing dienogest 2 mg that has been developed specifically for the treatment of this chronic gynecological disease In August 2018  the FDA approved Jivi  BAY94 9027  for the routine prophylactic treatment of hemophilia A in previously treated adults and adolescents aged 12 years or older in the United States  The FDA also approved the same for on demand treatment and perioperative management of bleeding in the same population 
Jivi is a long acting PEGylated recombinant human Factor VIII  rFVIII  replacement therapy  In November 2018  the drug  BAY94 9027  was approved by the European Commission for the treatment and prophylaxis of bleeding in previously treated patients aged 12 years or older with hemophilia A 
Sales of these drugs should boost revenues for the company during the first quarter of 2019 
Bayer is developing Darolutamide for the treatment of non metastatic castration resistant prostate cancer  nmCRPC   In February 2019  the company completed the rolling submission of a new drug application  NDA  for darolutamide to the FDA 
However  Bayer is facing generic competition for many of its products  including the Yaz franchise  oral contraceptives  
What Our Model Indicates
Our proven model does not conclusively show that Bayer is likely to beat earnings in the to be reported quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to be able to beat estimates  But that is not the case here  as you will see below 
Earnings ESP  Bayer has an Earnings ESP of 0 00  as both the Zacks Consensus Estimate and the Most Accurate Estimate are pegged at 47 cents  You can uncover the best stocks to buy or sell before they re reported with our  
Zacks Rank  The company carries a Zacks Rank  2 
Note that Sell rated stocks  Zacks Rank  4 or 5  going into an earnings announcement are best avoided Bayer Aktiengesellschaft Price and EPS Surprise

   Stocks That Warrant a Look
Here are some stocks you may want to consider  as our model shows that these have the right combination of elements to post an earnings beat this quarter 
Pfizer Inc    NYSE PFE   has an Earnings ESP of  0 65  and a Zacks Rank  3  The company is scheduled to release its first quarter 2019 results on Apr 30  You can see  
Glaxo SmithKline plc    NYSE GSK   has an Earnings ESP of  2 63  and a Zacks Rank  3  The company is scheduled to release its first quarter 2019 results on May 1 
Novo Nordisk  CO NOVOb  A S   NYSE NVO   has an Earnings ESP of  0 8  and a Zacks Rank  3  The company is scheduled to release its first quarter 2019 results on May 3 
Is Your Investment Advisor Fumbling Your Financial Future  
See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ",2019-04-22,Zacks Investment Research,https://www.investing.com/analysis/whats-in-store-for-bayer-bayry-this-earnings-season-200409220,200409220
220035,441551,PFE,Pfizer  PFE  Expected To Beat Earnings Estimates  What To Know Ahead Of Q1 Release,opinion,"Wall Street expects flat earnings compared to the year ago quarter on lower revenues when Pfizer  PFE  reports results for the quarter ended March 2019  While this widely known consensus outlook is important in gauging the company s earnings picture  a powerful factor that could impact its near term stock price is how the actual results compare to these estimates 
The stock might move higher if these key numbers top expectations in the upcoming earnings report  which is expected to be released on April 30  On the other hand  if they miss  the stock may move lower 
While management s discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations  it s worth having a handicapping insight into the odds of a positive EPS surprise 
Zacks Consensus Estimate
This drugmaker is expected to post quarterly earnings of  0 77 per share in its upcoming report  which represents no change from the year ago quarter 
Revenues are expected to be  12 86 billion  down 0 3  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 0 65  higher over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  This insight is at the core of our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction  
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Pfizer 
For Pfizer  the Most Accurate Estimate is higher than the Zacks Consensus Estimate  suggesting that analysts have recently become bullish on the company s earnings prospects  This has resulted in an Earnings ESP of  0 65  
On the other hand  the stock currently carries a Zacks Rank of  3 
So  this combination indicates that Pfizer will most likely beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
While calculating estimates for a company s future earnings  analysts often consider to what extent it has been able to match past consensus estimates  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Pfizer would post earnings of  0 63 per share when it actually produced earnings of  0 64  delivering a surprise of  1 59  
Over the last four quarters  the company has beaten consensus EPS estimates four times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Pfizer appears a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-04-22,Zacks Investment Research,https://www.investing.com/analysis/pfizer-pfe-expected-to-beat-earnings-estimates-what-to-know-ahead-of-q1-release-200409444,200409444
220036,441552,PFE,Lannett  LCI  To Report Q3 Earnings  What s In The Cards ,opinion,"During Lannett Company  Inc  s   NYSE LCI   fiscal first quarter 2019 call  the focus is expected to be on product launches 
Lannett s shares have slumped 54 4  in the past year compared with the  s decline of 13  

 
Let s see how things are shaping up for this announcement 
Factors in Play
Lannett the generic pharmaceutical company launched 17 products in calendar year 2018  which are expected to contribute significantly to net sales in fiscal third quarter 2019  The company s product launches during the quarter are expected to contribute significantly to sales  Investors  focus will be on the launch of these products  as stated by the management earlier 
The company intends to realize  66 million in total savings with  33 million of reinvestment  In fact  a portion of these savings is expected to be realized in fiscal third quarter 2019 
In March 2019  Lannett received approval from the FDA for its abbreviated new drug application  ANDA  for Aspirin and Extended Release Dipyridamole Capsules  25 mg 200 mg  the therapeutic equivalent to the reference listed drug  Aggrenox Capsules  25 mg 200 mg  of Boehringer Ingelheim Pharmaceuticals  Inc  The drug should boost sales for the company in fiscal third quarter 2019 
What Our Model Indicates
Our proven model does not conclusively show that Lannett is likely to beat on earnings in the to be reported quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to be able to beat estimates  But that is not the case here  as you will see below 
Earnings ESP  Lannett has an Earnings ESP of 0 00  as both the Zacks Consensus Estimate and the Most Accurate Estimate are pegged at a profit of 62 cents  You can uncover the best stocks to buy or sell before they re reported with our  Lannett Co Inc Price and EPS Surprise

    
Zacks Rank  The company carries a Zacks Rank  2  which increases the predictive power of ESP  However  we need to have a positive Earnings ESP to be confident of an earnings beat 
Note that Sell rated stocks  Zacks Rank  4 or 5  going into an earnings announcement are best avoided 
Stocks That Warrant a Look
Here are some health care stocks you may want to consider  as our model shows that these have the right combination of elements to post an earnings beat this quarter 
Pfizer Inc    NYSE PFE   has an Earnings ESP of  0 65  and a Zacks Rank  3  The company is scheduled to release first quarter 2019 results on Apr 30  You can see  
Glaxo SmithKline plc    NYSE GSK   has an Earnings ESP of  1 27  and a Zacks Rank  2  The company is scheduled to release first quarter 2019 results on May 1 
Novo Nordisk  CO NOVOb  A S   NYSE NVO   has an Earnings ESP of  0 8  and a Zacks Rank  3  The company is scheduled to release its first quarter 2019 results on May 3 
Will you retire a millionaire  
One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ",2019-04-24,Zacks Investment Research,https://www.investing.com/analysis/lannett-lci-to-report-q3-earnings-whats-in-the-cards-200410575,200410575
220037,441553,PFE,Takeda CEO prescribes surgical R D cuts after  62 billion Shire deal,news,By Ben Hirschler LONDON  Reuters    For Christophe Weber  the boss of Japan s Takeda Pharmaceutical  T 4502   securing a  62 billion deal last week to buy drugmaker  Shire   L SHP  at the fifth time of asking was the easy bit  Now he has to steer what will be one of the world s most indebted drugmakers through the big spending cuts needed to make the financial sums work  without destroying the lifeblood of future innovation  At the same time he must win shareholders  support for the largest ever overseas purchase by a Japanese company   something he told Reuters could be helped by bringing in one or more long term  large strategic investor   Talks on this were now starting  he said  but declined to identify the parties involved   Weber said in a interview that his prescription for a smooth merger was planning  speed and a surgical focus on culling experimental drugs that fail to offer the high level of medical innovation demanded by cash strapped insurers and governments   It s really important that we don t waste resource on assets that are moderately innovative  When you combine two pipelines you can be more stringent   he said in London  where he is meeting investors and analysts  Takeda will either dispose of programs that don t make the cut or spin them off into separate biotech companies in which it could retain a stake  the latter being a strategy is has pursued around 10 times in the past  Weber said  It is a delicate task  For the past decade  ramming together two drugmakers in mega mergers has been unpopular  following the R D disruption caused by past deals like Pfizer s  N PFE  acquisition of Wyeth in 2009  Indeed  Frenchman Weber has direct experience of one such deal that fell short of expectations after working at GlaxoSmithKline  L GSK  when it was formed in 2000 by the combination of Glaxo Wellcome and SmithKline Beecham   It s very important that we keep the momentum and don t get disrupted   he said   We rely on R D to grow    LESS DISRUPTIVE  Takeda struck the agreement to take over London listed Shire on May 8  a deal that will propel the Japanese company from a mid size pharma player into the top 10 rankings of global drugmakers by sales  alongside the likes of  Novartis   S NOVN  and  Pfizer   N PFE   Days later  Weber appointed U S  based executive Helen Giza to oversee overall integration of the enlarged group  which will be tightly focused on gastroenterology  neuroscience  oncology  rare diseases and blood derived therapies  There is a big cultural divide to bridge  Takeda is a 237 year old Japanese institution that began life selling traditional Japanese and Chinese herbal medicines  while Shire was born above a shop in southern England in 1986  But Weber believes he has a key advantage because Shire has been focused on later drug development  rather than early research  so there is no large research center that needs to be closed   I think it will be much less disruptive than in typical M A because of the research set up   he said  A key testing ground for the merger will be in Boston  a global hub of life sciences research  where both Shire and Takeda have large teams that must work seamlessly once the deal closes in the first half of 2019  Takeda has forecast annual cost synergies of at least  1 4 billion three years after the deal closes  including  600 million in R D costs  achieved by cutting duplication and rationalizing research programs  Weber said savings would be helped by the fact that R D investment in certain established Takeda drugs was now winding down  Still   600 million remains a big bite out of two companies  current combined R D spend of  4 4 billion   They are cutting quite deep in R D and it is not clear if the amount of money they are saving is going to be beneficial or harmful   said John Rountree  a partner at pharmaceutical strategy consulting firm Novasecta   Merging R D is never easy  There are going to be lay offs and that creates uncertainty and disruption and sometimes the best talent just leaves   Takeda expects to reduce the overall workforce of 52 000 by 6 7 percent  with R D accounting for just under a third of the cuts  Weber said he recognized the risk of losing key staff and his team was currently working on a staff retention program   FINANCING FEARS Many investors have been lukewarm on the Shire deal because of the debt Takeda is taking on and uncertainty over how it will convert a  31 billion bridge loan into long term financing  Takeda has promised to bring the net debt of the enlarged group down to two times EBITDA within three to five years  from 4 5 times when the deal closes  and believes it can do this without significant disposals or shareholder dilution   In the refinancing mechanism we will use a lot of different instruments but none of them are dilutive   Weber said   Weber said he had never doubted he would persuade investors of the case for the transaction but he acknowledged there had been  uncertainty and misunderstanding  initially  More recently  investor comfort with the deal had improved  he said  The real test will come later this year when Weber will learn if he has secured the necessary two thirds support needed from Takeda shareholders and three quarters backing from Shire investors  One Japanese institutional investor who owns Takeda shares said there were some fears the deal would overstretch Takeda s finances but the benefit from business synergies should outweigh this   We hope Takeda will provide a good explanation to the market and ease the investors concerns   he said  Adding strategic investors could help alleviate some of those worries  potentially mirroring Bayer s  DE BAYGn  recent deal to raise  3 7 billion towards its planned takeover of  Monsanto   N MON  by selling a stake to Singapore s state investment company Temasek   There are multiple possibilities of long term investors  such as government funds or others   Weber said   A long term  strategic  stable investor would be great for us  ,2018-05-17,Reuters,https://www.investing.com/news/stock-market-news/takeda-ceo-prescribes-surgical-rd-cuts-after-62-billion-shire-deal-1451673,1451673
220059,441575,PFE,P G s vitamin boost could signal more to come,news,"By Martinne Geller and Richa Naidu LONDON CHICAGO  Reuters    Procter   Gamble s  4 2 billion deal for Merck s vitamin and supplements business is the latest example of a major consumer company stocking up on health related products  The U S  based maker of Tide detergent and Gillette razors announced the deal on Thursday  giving it brands such as Seven Seas vitamins and expanding its portfolio of healthcare products  Just last month  cleaning product maker Clorox Co agreed to buy multivitamin company Nutranext for  700 million  And in December  Nestle SA  SIX NESN  paid  2 billion for vitamin maker Atrium Innovations  The moves show how global consumer goods companies are looking to new  interesting areas to offset flagging growth in their core businesses  The vitamins and supplements sector is attractive due to the emergence of new brands marketing themselves digitally and selling directly online to young consumers  said investment banker William Hood of William Hood   Co   It s what the millennials are buying and how they re buying it   Hood said   Large companies are realizing they need to figure it out   A spokeswoman for P G declined to comment on the company s strategy to expand its vitamins  minerals and supplements business  P G already owns consumer health brands including Vick s  Metamucil and Pepto Bismol  Globally  the vitamin and supplements category has grown between 5 and 7 percent annually for the past five years  according to Euromonitor  The category is very fragmented  with market leader Amway Corp having only 3 6 percent share  Euromonitor data showed  That implies a consolidator could easily boost margins by building scale  Consumer goods firm Reckitt Benckiser has owned Schiff  maker of MegaRed tablets for heart health and Airborne for immunity  for five years  It was a very different business to other health or home goods  said CEO Rakesh Kapoor on a post earnings call in February  adding that sales and margins were improving after some stumbles   This is a category which is here to stay  It is one of the single largest categories in health   he said  A PRELUDE TO MORE  P G was in talks with  Pfizer   NYSE PFE  about buying the U S  drugmaker s consumer health business  CNBC reported earlier this month  Pfizer hoped to bring in  20 billion through an auction for the business  which includes Centrum vitamins and Advil painkillers   The auction hit a roadblock after GlaxoSmithKline and Reckitt Benckiser dropped out of the running  When asked about its interest in Pfizer on Thursday  P G chief executive David Taylor declined to comment  Referring to the P G Merck deal  Liberum analyst Robert Waldschmidt said   The question is   is it a prelude to more      Is P G still theoretically on the hunt for Pfizer   
Bernstein analysts noted that the Pfizer business  may still be an acquisition candidate  for P G  since it doesn t seem to raise anti trust concerns on the surface  ",2018-04-20,Reuters,https://www.investing.com/news/stock-market-news/pgs-vitamin-boost-could-signal-more-to-come-1404962,1404962
220060,441576,PFE,FDA advisory committees back cardiovascular safety data for Pfizer s Celebrex,news,The FDA s Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee have voted 15   5  1 abstain  in favor that the results from the large scale Phase 4 PRECISION study demonstrated comparable cardiovascular safety of  Pfizer  s  PFE  0 8   arthritis med CELEBREX  celecoxib  to naproxen  Aleve  and ibuprofen  Motrin  If formerly approved by the FDA  which seems likely  the data will be added to the labeling of CELEBREX Now read ,2018-04-25,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-advisory-committees-back-cardiovascular-safety-data-for-pfizers-celebrex-1413820,1413820
220074,441590,PFE,Why The Earnings Surprise Streak Could Continue For Pfizer  PFE ,opinion,"Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report  Pfizer  PFE   which belongs to the Zacks Large Cap Pharmaceuticals industry  could be a great candidate to consider 
This drugmaker has seen a nice streak of beating earnings estimates  especially when looking at the previous two reports  The average surprise for the last two quarters was 2 11  
For the last reported quarter  Pfizer came out with earnings of  0 64 per share versus the Zacks Consensus Estimate of  0 63 per share  representing a surprise of 1 59   For the previous quarter  the company was expected to post earnings of  0 76 per share and it actually produced earnings of  0 78 per share  delivering a surprise of 2 63  
Price and EPS Surprise

For Pfizer  estimates have been trending higher  thanks in part to this earnings surprise history  And when you look at the stock s positive Zacks Earnings ESP  Expected Surprise Prediction   it s a great indicator of a future earnings beat  especially when combined with its solid Zacks Rank 
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank  3  Hold  or better produce a positive surprise nearly 70  of the time  In other words  if you have 10 stocks with this combination  the number of stocks that beat the consensus estimate could be as high as seven 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Pfizer currently has an Earnings ESP of  5 13   which suggests that analysts have recently become bullish on the company s earnings prospects  This positive Earnings ESP when combined with the stock s Zacks Rank  3  Hold  indicates that another beat is possibly around the corner  We expect the company s next earnings report to be released on April 30  2019 
When the Earnings ESP comes up negative  investors should note that this will reduce the predictive power of the metric  But  a negative value is not indicative of a stock s earnings miss 
Many companies end up beating the consensus EPS estimate  but that may not be the sole basis for their stocks moving higher  On the other hand  some stocks may hold their ground even if they end up missing the consensus estimate 
Because of this  it s really important to check a company s Earnings ESP ahead of its quarterly release to increase the odds of success  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported ",2019-04-02,Zacks Investment Research,https://www.investing.com/analysis/why-the-earnings-surprise-streak-could-continue-for-pfizer-pfe-200403628,200403628
220075,441591,PFE,Sangamo Rises On Positive Phase I II Hemophilia Study Data,opinion,"Sangamo Therapeutics  Inc    NASDAQ SGMO   and its partner Pfizer   NYSE PFE   announced encouraging interim data from the phase I II Alta study evaluating their gene therapy candidate  SB 525  in patients with severe hemophilia A  Data showed that the gene therapy candidate holds potential Shares of Sangamo rallied almost 28  on Apr 2 following the data readout  However  shares of the company have increased 7  so far this year compared with the  s rise of 11 7  The phase I II study evaluated four doses of SB 525   9e11 vg kg  2e12 vg kg  1e13 vg kg and 3e13 vg kg   with two patients per cohort  Data from the study showed that patients treated with the highest dosage  3e13 vg kg  achieved normal factor VIII levels  Dose dependent increase in factor VIII levels were observed in the eight patients treated with SB 525 gene therapy across the four dosage cohorts  Factor VIII boosts blood clotting  which is a major symptom of haemophilia  Moreover  the candidate was well tolerated in every dosage cohort The company believes that SB 525 may achieve predictability and sustained treatment effect  which can lead to clinical benefit in haemophilia A patients Based on the data from the study  the Safety Monitoring Committee   SMC   recommended expansion of the 3e13 vg kg cohort  Total patients in the cohort will increase to five  Longer term follow up data will be presented at a future scientific meeting Although interim data from the study seems promising  the clinical development of SB 525 is in early stage with commercialization prospects years away We note that there are other treatments available for treating hemophilia A and several others are in development including gene therapies  In February 2019  Novo Nordisk s   NYSE NVO    was approved for the indication  Companies developing gene therapy candidates for treating hemophilia A include Spark Therapeutics   NASDAQ ONCE   and uniQure  The most advanced gene therapy for hemophilia A treatment in clinical studies is BioMarin s valoctocogene roxaparvovec  BMN 270   Late stage studies are evaluating 6e13 vg kg and 4e13 vg kg doses of the candidate Apart from SB 525  Sangamo is also developing gene therapies in collaboration with Pfizer for treating amyotrophic lateral sclerosis and frontotemporal lobar degeneration Sangamo Therapeutics  Inc  Price
    Zacks RankSangamo currently carries a Zacks Rank  3  Hold   You can see  Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ",2019-04-02,Zacks Investment Research,https://www.investing.com/analysis/sangamo-rises-on-positive-phase-iii-hemophilia-study-data-200403615,200403615
220076,441592,PFE,Pfizer s marketing applications for dacomitinib in first line NSCLC accepted in U S  and Europe,news,Pfizer   NYSE PFE  announces that its marketing applications seeking approval for dacomitinib for the first line treatment of patients with locally advanced or metastatic non small cell lung cancer  NSCLC  with EGFR activating mutations have been accepted for review in the U S  and Europe The FDA has designated the filing for Priority Review with an action date in September The data supporting the applications were generated in the Phase 3 ARCHER 1050 study that showed treatment with dacomitinib extended median progression free survival  PFS  to 14 7 months compared to 9 2 months with gefitinib  AstraZeneca s IRESSA  with 41  less risk of cancer progression or death  hazard ratio   0 59  Dacomitinib is an orally available pan human epidermal growth factor receptor  EGFR  tyrosine kinase inhibitor  TKI  Now read ,2018-04-04,Seeking Alpha,https://www.investing.com/news/stock-market-news/pfizers-marketing-applications-for-dacomitinib-in-firstline-nsclc-accepted-in-us-and-europe-1377408,1377408
220090,441606,PFE,Global Blood Focuses On Developing Lead Candidate Voxelotor,opinion,We initiated coverage on Global Blood Therapeutics   NASDAQ GBT   on Mar 28 Global Blood Therapeutics  lead product candidate is voxelotor  GBT440   an oral  once daily treatment for sickle cell disease  SCD  Shares of the company have increased 7 7  in the past year against the  s decline of 13 9  The company is evaluating voxelotor in a phase III HOPE study in adult and adolescent patients with SCD  It is also evaluating the safety and pharmacokinetics of single and multiple doses of voxelotor in a phase IIa study in adolescent and pediatric patients to treat SCD The company s clinical studies on voxelotor are progressing fast  Data from the phase III HOPE study in adult and adolescent patients  presented in December 2018  demonstrated rapid  robust and sustained improvements in hemoglobin levels and measures of hemolysis  with a favorable safety and tolerability profile for both 1500 mg and 900 mg doses  The company plans to present full data from the study in June 2019  However  with positive data in hand  Global Blood Therapeutics proposed an accelerated approval pathway to the FDA  using hemoglobin as the primary endpoint  The FDA has agreed to a rolling submission of its new drug application for the drug Global Blood Therapeutics plans to initiate a post approval confirmatory study later in 2019 to demonstrate stroke risk reduction benefit of voxelotor using transcranial doppler  TCD  flow velocity as the primary endpoint The potential approval of voxelotor will be a huge boost for the company as the current treatment options for SCD are limited  We note that SCD is marked by red blood cell or RBC destruction  occluded blood flow and hypoxia  leading to anemia  stroke  multi organ failure  severe pain crises and shortened patient life span  In clinical studies  it has been observed that voxelotor reduces markers of red blood cell destruction  leads to improvements in anemia and markers of tissue oxygenation  and reduces the number of sickled RBCs  As a result  the company is optimistic about voxelotor and its potential to treat this significantly unmet disease However  many companies are developing hematopoietic stem cell transplantation  gene therapies and gene editing therapies to treat SCD  bluebird bio   NASDAQ BLUE   is developing the LentiGlobin BB305 gene therapy and Novartis AG   NYSE NVS   is developing crizanlizumab  an anti P selectin monoclonal antibody for the treatment of vaso occlusive crises  VOC   in patients with SCD  Novartis expects to file a new drug application for crizanlizumab in the first half of 2019  Pfizer   NYSE PFE   is also developing rivipansel for the treatment of VOC in patients with SCD  So voxelotor  on approval  is expected to face significant competition  Global Blood Therapeutics  Inc  Price    Zacks Rank Global Blood currently carries a Zacks Rank  3  Hold  You can see  Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-03-28,Zacks Investment Research,https://www.investing.com/analysis/global-blood-focuses-on-developing-lead-candidate-voxelotor-200402275,200402275
220091,441607,PFE,Israel to launch Big Data health project,news,"By Maayan Lubell JERUSALEM  Reuters    Israel will invest nearly 1 billion shekels   287 million  in a project to make data about the state of health of its population available to researchers and private companies  Prime Minister Benjamin Netanyahu said on Sunday  Almost all of Israel s nine million citizens belong to four health maintenance organizations  HMOs  who keep members  records digitally  thus comprising a huge medical database   This is a major asset and we want to make it accessible to researchers and developers in order to achieve two things  one is preventive medicine  and the second is personal medicine tailored to each individual   Netanyahu told his cabinet  Nadav Davidovitch  head of the Public Health School at Ben Gurion University in southern Israel  said the country s push to harness big data for healthcare had huge potential  but also held risks in terms of privacy and medical confidentiality  In an interview with Reuters  he voiced concern that private companies would profit by using a publicly funded database while continuing to make some medication unaffordable to many patients  A statement from Netanyahu s office said that mechanisms would be put in place to keep information anonymous while protecting privacy  information security and restricting access as part of the government project   Patients will be able to refuse the use of their information for research  the statement said   Digital health records are valuable  Big data analytics   comparing information provided by large numbers of patients   give some of the world s biggest drugmakers indications of how medicines perform in the real world   Netanyahu said world leaders and international firms have already shown interest in the project and that the potential revenue for Israel could be in the billions of dollars  All the world s major drug companies now have departments focused on the use of real world data across multiple diseases  Several have completed scientific studies using the information to delve into key areas addressed by their drugs  They include diabetes studies by AstraZeneca and Sanofi  PA SASY   joint research by  Pfizer   NYSE PFE  and Bristol Myers Squibb into stroke prevention  and a Takeda Pharmaceutical project in bowel disease   
Real world evidence involves collecting data outside traditional randomised clinical trials  the current gold standard for judging medicines  and interest in the field is ballooning ",2018-03-25,Reuters,https://www.investing.com/news/world-news/israel-to-launch-big-data-health-project-1358485,1358485
220092,441608,PFE,Drugmaker Shire soars as Japan s Takeda considers bid,news,"By Kate Holton and Thomas Wilson LONDON TOKYO  Reuters    Japan s largest drugmaker Takeda Pharmaceutical  T 4502  is considering a bid for London listed  Shire   L SHP  that could top  40 billion and spark another takeover battle in the deal hungry pharma industry   Takeda said on Wednesday it was  at a preliminary and exploratory stage  of considering a bid  sending Shire s shares up as much as 26 percent  They were 17 percent higher at 1215 GMT  valuing the group at 32 7 billion pounds   46 3 billion   Shire sells treatments for rare diseases and attention deficit disorder  Takeda said buying it could create a global biopharmaceutical leader  boosting its position in the United States  oncology  gastrointestinal diseases and neuroscience  The drugs industry has seen a surge in dealmaking as large players look for promising assets to improve their pipelines   In recent months  Sanofi  PA SASY  beat  Novo Nordisk   CO NOVOb  in the race for Belgian biotech company  Ablynx   BR ABLX   while U S  based Celgene  O CELG  bagged cancer specialist Juno Therapeutics    The prospect of a bid for Shire  57 percent of whose employees are based in North America  immediately stoked expectations for a takeover battle    Takeda publicly saying it is considering an approach for Shire inevitably means that other big pharma players including AbbVie  Novartis   Pfizer   NYSE PFE  et al will equally be running the numbers with a very high likelihood of leading to a competitive M A multi bidder situation   said Michael Wegener  managing partner at hedge fund Case Equity Partners  which has a stake in Shire  Takeda said it had not approached Shire s board  Under UK takeover rules  it has until April 25 to decide whether to make a bid  Shire said it noted Takeda s statement  and confirmed it had not received an approach  Shire has been under pressure in the last year  with its shares down 24 percent  due to greater competition from generic drugs and a debt pile that stems from its biggest ever deal  the  32 billion acquisition of Baxalta in 2016  The company announced in January a plan to split into two separate businesses to boost performance  FRENCH CEO Takeda  Japan s largest drugmaker by sales  focuses its research on developing treatments for cancer and diseases of the digestive and nervous systems  It has made no secret of its ambition to become a more global company through acquisitions  although buying Shire would be the boldest move yet by its French CEO Christophe Weber   Clearly defined strategic and financial objectives are core to Takeda s disciplined approach to acquisitions  including in relation to its dividend policy and credit rating  which are well established   Takeda said in a statement   Any potential offer for Shire  if made  would have to align with this strict investment criteria   The statement came after Takeda s shares had closed 1 9 percent lower on the Tokyo stock exchange   An acquisition would likely have to include a considerable quantum of equity    Deutsche Bank   DE DBKGn  analysts said in a research note   As such  it remains to be seen as to if how a transaction could be structured or whether today s news will stimulate other potential acquirers in to action   Weber  a former GSK executive  was appointed CEO in April 2015 and has already done a number of deals   In January  Takeda agreed to buy Belgian biotech group TiGenix NV  BR G9U  for 520 million euros  funding the deal with cash on hand  and last year  it bought U S  cancer drug specialist Ariad for  5 2 billion  Takeda s overseas deals mirror those by other Japanese companies  which are facing bleak prospects at home as a rapidly shrinking population weighs on domestic demand   
  1   0 7061 pounds ",2018-03-28,Reuters,https://www.investing.com/news/stock-market-news/japans-takeda-considering-approach-for-british-drugmaker-shire-1366587,1366587
220093,441609,PFE,Cellectis to continue CAR T collaboration with Allogene  shares up 18 ,news,Cellectis   CLLS  17 8   is up on more than triple normal volume in response to its announcement that its CAR T development partnership with  Pfizer   NYSE PFE   consummated in 2014  will continue with Allogene Therapeutics  Earlier today  Pfizer announced an asset contribution deal with Allogene The company says Allogene will assume the Pfizer contract including exclusive rights to develop and commercialize previously defined allogeneic UCART programs directed at specific targets Cellectis remains eligible to receive up to  2 8B in milestones   185M per target for 15 targets  and tiered high single digit royalties on net sales Previously  Pfizer to contribute assets backing CAR T developer Allogene Therapeutics  April 3 Previously  Pfizer signs immunotherapy deal with Cellectis  June 18  2014 Now read ,2018-04-03,Seeking Alpha,https://www.investing.com/news/stock-market-news/cellectis-to-continue-car-t-collaboration-with-allogene-shares-up-18-1375951,1375951
220094,441610,PFE,Celgene underperforms after COO exit,news,It s more negative than positive  says Mizuho bull Salim Syed  who isn t thrilled the company isn t giving any additional color behind the move  He also notes Q1 is over and the company still hasn t said anything about full year guidance RBC s Brian Abrahams isn t too surprised to see someone from senior management axed given a series of recent missteps  The firing of Scott Smith shows a  seriousness about making hard decisions  Source  BloombergCELG  1   with the IBB down just marginally and the XLV up 0 6  Previously  Celgene operating chief departs abruptly  April 2 Now read ,2018-04-03,Seeking Alpha,https://www.investing.com/news/stock-market-news/celgene-underperforms-after-coo-exit-1376239,1376239
220100,441616,PFE,Aerie  AERI  Starts Phase II Study On Eye Candidate In Japan,opinion,Aerie Pharmaceuticals  Inc    NASDAQ AERI   announced that it has initiated the dosing in a phase II study on netarsudil ophthalmic solution in Japan for reducing elevated intraocular pressure  IOP  in patients with open angle glaucoma or ocular hypertension The study was designed to meet the requirements of Japan s Pharmaceuticals and Medical Devices Agency  PMDA  for supporting the eye care candidate s potential regulatory filing in the East Asian island country Netarsudil ophthalmic solution 0 02  is approved for the reduction of elevated IOP in patients with open angle glaucoma or ocular hypertension  The drug is currently marketed under the trade name Rhopressa in the United States Shares of Aerie were almost 7 4  up following this news on Thursday  In fact  so far this year  the stock has surged 36 4   outperforming the  rally of 17 3  The above mentioned multi center  placebo controlled phase II program will evaluate the IOP reducing effect and safety of three concentrations of netarsudil ophthalmic solution  0 01   0 02  and 0 04   in Japan  The study will enroll approximately 208 patients in four treatment arms  0 01   0 02   0 04  and placebo   all administered once daily in the evening for a period of 28 days Aerie expects to complete enrollment in the study on netarsudil ophthalmic solution in Japan before this year end and advance toward its phase III stage We would like to remind investors that in January 2019  Aerie announced positive top line results from its pilot phase II evaluation of netarsudil ophthalmic solution in a Japanese American population We would also like to put this forward that last week  Aerie received the FDA approval for Rocklatan to lower the elevated IOP in patients afflicted with open angle glaucoma or ocular hypertension Rocklatan is a once daily  quadruple action fixed dose combination of Rhopressa and Pfizer s   NYSE PFE   Xalatan  latanoprost  Zacks Rank   Other Stocks to ConsiderAerie currently carries a Zacks Rank  2  Buy   Two other top ranked stocks in the same sector are AIT Therapeutics  Inc    OTC AITB   and Assertio Therapeutics  Inc   NASDAQ ASRT    both sporting a Zacks Rank  1  Strong Buy   You can see  AIT Therapeutics  loss per share estimates have been narrowed 18 8  for 2019 and 11 8  for 2020 in the last 60 days  The stock has inched up 1 1  year to date Assertio Therapeutics  earnings estimates have moved 6 8  north for 2019 and 8 2  for 2020 over the past 60 days  The stock has surged 33 8  so far this year Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-03-21,Zacks Investment Research,https://www.investing.com/analysis/aerie-aeri-starts-phase-ii-study-on-eye-candidate-in-japan-200400218,200400218
220101,441617,PFE,Ascendis Pivotal Growth Hormone Deficiency Study Data Positive,opinion,"Ascendis Pharma A S   NASDAQ ASND   announced positive top line data from its pivotal phase III study evaluating TransCon Growth Hormone  hGH  for treating growth hormone deficiency   GHD   in children  Data from the study showed that hGH significantly increased annualized height velocity   AVH   compared to Pfizer s   NYSE PFE   Genotropin and has a better comparable safety and tolerability profile with the drug 
Ascendis  shares have gained 90 1  so far this year compared with the  s increase of 9 3  

The pivotal heiGHt study evaluated a once weekly subcutaneous administration of TransCon hGH for a period of 52 weeks compared to the daily subcutaneous administration of Genotropin  Patients treated with TransCon hGH achieved an AVH of 11 3 cm per year whereas Genotropin had a AVH of 10 3 cm per year  The data were presented at the Endocrine Society s annual meeting  ENDO 2019 
TransCon hGH is a sustained release formulation of unmodified hGH  which is used in currently approved daily therapies  It helps patients to manage deficiency in growth hormone with once weekly administration instead of daily intake  Hence  the candidate has significant potential to grab market share  if approved 
Another study   fliGHt   is evaluating TransCom hGH in patients who switch from daily growth hormone therapies to its weekly administration  Data from this study is expected in the second quarter of 2019  The company plans to submit a Biologics License Application for TransCom hGH for treating pediatric GHD in the first half of 2020 
The press release states that GHD in pediatric patients is a serious orphan disease characterized by short height and metabolic abnormalities  which can affect overall physical and mental health  Growth hormone deficiency in pediatric and adult patients represents a market opportunity of more than  3 billion 
Ascendis is a Denmark based clinical stage biopharmaceutical company developing several candidates for multiple indications  The company has three pipeline candidates  which are being developed for rare endocrinology diseases  One of them is being developed for treating achondroplasia and was granted orphan drug designation last month 
Ascendis is also focused on developing treatment for oncology indications  Moreover  the company has collaborations with Sanofi   NASDAQ SNY   in diabetes and Genentech  a subsidiary of Roche   OTC RHHBY   in the field of ophthalmology 
With no approved product  the company needs to successfully commercialize its pipeline candidate for growth  However  the company s resources are likely to support operations for more than a couple of years at the current rate of its operating expenses Ascendis Pharma A S Price
 

    
Zacks Rank
Ascendis currently carries a Zacks Rank  3  Hold   You can see  
Today s Best Stocks from Zacks
Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  
This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-03-25,Zacks Investment Research,https://www.investing.com/analysis/ascendis-pivotal-growth-hormone-deficiency-study-data-positive-200400827,200400827
220102,441618,PFE,Calithera  CALA  Initiates Phase I II Study Of Telaglenastat ,opinion,"Calithera Biosciences  Inc   NASDAQ CALA   initiated a phase I II open label study of the glutaminase inhibitor  telaglenastat  CB 839  in combination with Pfizer s   NYSE PFE   poly adenosine diphosphate ribose polymerase  PARP  inhibitor  talazoparib  also known as Talzenna  in patients with advanced or metastatic solid tumors  
Telaglenastat is an investigational  novel glutaminase inhibitor  specifically designed to block glutamine consumption in tumor cells 
The phase I II study  NCT03875313  will evaluate the safety and efficacy of the combination in patients with locally advanced metastatic renal cell carcinoma  RCC   triple negative breast cancer  TNBC  and colorectal cancer  CRC  that are refractory or intolerant to standard therapies 
Shares of the company have dipped 7 1  in the past year compared with the  s decline of 13 5  

 
In October 2018  Calithera entered into a collaboration agreement with Pfizer to evaluate telaglenastat in two studies  The first study is a combination of telaglenastat and Talzenna  and the second one is a combination of telaglenastat and palbociclib  also known as Ibrance  As part of this agreement  Pfizer will provide Ibrance and Talzenna along with financial support Calithera Biosciences  Inc  Price

    
Zacks Rank   Stocks to Consider
Calithera is a Zacks Rank  3  Hold  stock currently 
Some better ranked stocks worth considering are AstraZeneca Plc    NYSE AZN   and Roche Holding  SIX ROG  AG   OTC RHHBY    each carrying a Zacks Rank  2  Buy   You can see  
AstraZeneca s earnings per share estimates have increased from  1 74 to  1 79 for 2019 and from  2 14 to  2 20 for 2020 in the past 60 days  The company delivered a positive earnings surprise in all the trailing four quarters  with average of 106 40  
Roche s earnings per share estimates have increased from  2 31 to  2 35 for 2019 and from  2 34 to  2 37 for 2020 over the past 90 days 
Today s Best Stocks from Zacks 
Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  
This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-03-27,Zacks Investment Research,https://www.investing.com/analysis/calithera-cala-initiates-phase-iii-study-of-telaglenastat-200401626,200401626
220103,441619,PFE,Pfizer  PFE  Dips More Than Broader Markets  What You Should Know,opinion,"In the latest trading session  Pfizer  PFE  closed at  42 03  marking a  0 92  move from the previous day  This change lagged the S P 500 s 0 46  loss on the day  At the same time  the Dow lost 0 13   and the tech heavy Nasdaq lost 0 63  
Prior to today s trading  shares of the drugmaker had lost 1 39  over the past month  This has lagged the Medical sector s gain of 0 39  and the S P 500 s gain of 1 08  in that time 
Investors will be hoping for strength from PFE as it approaches its next earnings release  The company is expected to report EPS of  0 78  up 1 3  from the prior year quarter  Meanwhile  the Zacks Consensus Estimate for revenue is projecting net sales of  12 86 billion  down 0 32  from the year ago period 
Looking at the full year  our Zacks Consensus Estimates suggest analysts are expecting earnings of  2 86 per share and revenue of  52 90 billion  These totals would mark changes of  4 67  and  1 38   respectively  from last year 
Investors might also notice recent changes to analyst estimates for PFE  These recent revisions tend to reflect the evolving nature of short term business trends  As a result  we can interpret positive estimate revisions as a good sign for the company s business outlook 
Based on our research  we believe these estimate revisions are directly related to near team stock moves  To benefit from this  we have developed the Zacks Rank  a proprietary model which takes these estimate changes into account and provides an actionable rating system 
The Zacks Rank system  which ranges from  1  Strong Buy  to  5  Strong Sell   has an impressive outside audited track record of outperformance  with  1 stocks generating an average annual return of  25  since 1988  The Zacks Consensus EPS estimate remained stagnant within the past month  PFE is currently sporting a Zacks Rank of  3  Hold  
Valuation is also important  so investors should note that PFE has a Forward P E ratio of 14 81 right now  This represents a discount compared to its industry s average Forward P E of 15 28 
Meanwhile  PFE s PEG ratio is currently 2 43  This metric is used similarly to the famous P E ratio  but the PEG ratio also takes into account the stock s expected earnings growth rate  The Large Cap Pharmaceuticals was holding an average PEG ratio of 2 15 at yesterday s closing price 
The Large Cap Pharmaceuticals industry is part of the Medical sector  This group has a Zacks Industry Rank of 71  putting it in the top 28  of all 250  industries 
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
To follow PFE in the coming trading sessions  be sure to utilize Zacks com ",2019-03-27,Zacks Investment Research,https://www.investing.com/analysis/pfizer-pfe-dips-more-than-broader-markets-what-you-should-know-200401648,200401648
220104,441620,PFE,Sangamo Therapeutics Q4 revenues up 47   shares ahead 7  premarket,news,Sangamo Therapeutics  SGMO  Q4 results  Revenues   13 1M   47 2    Operating Loss    13 8M    40 8    Net Loss    13 1M    36 5    Loss Per Share    0 15    7 1    Quick Assets   244 6M   71 3   No guidance given Shares are up 7  premarket Now read ,2018-02-22,Seeking Alpha,https://www.investing.com/news/stock-market-news/sangamo-therapeutics-q4-revenues-up-47-shares-ahead-7-premarket-1293915,1293915
220105,441621,PFE,Voyager Therapeutics reports Q4 results,news,Voyager Therapeutics  VYGR  Q4 results  Revenues   6 3M  Operating Loss    12 3M    10 9    Net Loss    11 8M    19 7    Loss Per Share    0 40    29 8    Quick Assets   169 1M   3 0   2018 Guidance  Cash  cash equivalents and marketable debt securities    125M   135M Shares are up 2  premarket on light volume Now read ,2018-03-14,Seeking Alpha,https://www.investing.com/news/stock-market-news/voyager-therapeutics-reports-q4-results-1340966,1340966
220106,441622,PFE,FDA accepts Pfizer s marketing application for expanded use of Xtandi,news,Pfizer   NYSE PFE  and collaboration partner Astellas Pharma  OTCPK ALPMF  announce that the FDA has accepted under Priority Review the former s marketing application seeking approval for XTANDI  enzalutamide  for the treatment of men with non metastatic castration resistant prostate cancer  CRPC  The FDA approved XTANDI in August 2012 for metastatic CRPC The agency s action date is in July Now read ,2018-03-19,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-accepts-pfizers-marketing-application-for-expanded-use-of-xtandi-1349040,1349040
220107,441623,PFE,Reckitt Benckiser pulls out of Pfizer consumer health auction,news,"By Greg Roumeliotis and Carl O Donnell  Reuters    British consumer goods maker  Reckitt Benckiser  Group  L RB  said on Wednesday it had ended discussions with  Pfizer  Inc  N PFE  over buying its consumer healthcare business  a day before the U S  drug company was expecting binding offers for the unit  Reckitt s exit from the sale process strengthens the hand of British pharmaceutical company GlaxoSmithKline Plc  L GSK   which sources familiar with the matter said was working on an offer for the business  It is possible that Pfizer will receive more offers by Thursday s deadline for bids  the sources added   An acquisition for the whole Pfizer consumer health business did not fit our acquisition criteria and an acquisition of part of the business was not possible   Reckitt said  Reckitt s priority would remain organic growth and integration of Mead Johnson Nutrition  the British company said in a statement   Pfizer continues to evaluate potential strategic alternatives for the consumer healthcare business  which include a spin off  sale or other transaction  and Pfizer ultimately retaining the business  We have not yet made a decision  but continue to expect to make one in 2018   Pfizer said in a statement   A deal would be the boldest move to date for GlaxoSmithKline CEO Emma Walmsley  took over last April  It would further increase the company s already substantial position in consumer health  an increasingly lucrative sector as aging populations and health conscious consumers drive demand for self medication  Pfizer has been hoping to fetch as much as  20 billion for its consumer health business  which includes well known over the counter brands such as the Advil painkiller  Centrum multivitamins and Chapstick lip balm  according to the sources  Although consumer remedies sold over the counter have lower margins than prescription drugs  they are typically very well known and durable brands with loyal customers  GlaxoSmithKline has struggled with a scarcity of promising new drugs in its pipeline at a time of mounting competition in its core respiratory and HIV divisions  Adding Pfizer s consumer healthcare business would likely boost GlaxoSmithKline s earnings  given the economies of scale the enlarged business would enjoy  but would also stretch GlaxoSmithKline s finances  analysts have said   GlaxoSmithKline runs its consumer healthcare business via a joint venture with  Novartis  AG  S NOVN   Novartis has the right to sell down its minority stake starting from this month  although it has previously indicated it is in no rush to do so    You would expect us to take a serious look at any leading and very appealing assets in the sector because we are a world leader in consumer healthcare and have a very good track record of integrating businesses successfully   GlaxoSmithKline s Walmsley said last month   
 We will be extremely focused on discipline around returns and frankly  this is not a need to do  ",2018-03-21,Reuters,https://www.investing.com/news/stock-market-news/reckitt-benckiser-pulls-out-of-pfizer-consumer-health-auction-1353204,1353204
220119,441635,PFE,Sonoco  SON  Down 1 8  Since Last Earnings Report  Can It Rebound ,opinion,"A month has gone by since the last earnings report for Sonoco  SON   Shares have lost about 1 8  in that time frame  underperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is Sonoco due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers  Sonoco Earnings Beat   Sales Miss Estimates in Q4Sonoco fourth quarter 2018 adjusted earnings increased 16 7  year over year to 84 cents per share and were close to the high end of management s guided range of 79 85 cents  The reported figure beat the Zacks Consensus Estimate of 81 cents On a reported basis  including one time items  earnings per share came in at 77 cents compared with 6 cents in the year ago quarter Sonoco s net sales grew 4 6  year over year to  1 36 billion in the quarter  This improvement was driven by acquisitions and higher selling prices  partly offset by the negative impact of foreign exchange and lower volume in the Industrial Converted Products and Consumer Packaging and Paper segments  However  the sales figure missed the Zacks Consensus Estimate of  1 37 billion Operational UpdateCost of sales came in at  1 1 billion  up 4 7  year over year  Gross profit during the fourth quarter totaled  254 million  marking a 4  improvement year over year  Gross margin came in at 18 7  compared with 18 8  in the prior year quarter Selling  general and administrative expenses totaled  148 8 million  up 16  year over year  primarily resulting from acquisition related costs and wage inflation  Adjusted operating income was  116 million in the fourth quarter  down 1 4  year over year  Operating margin came in at 8 6  compared with 9  in the year ago quarter Segment PerformanceThe Consumer Packaging segment reported net sales of  574 million  up 3 6  from  554 million recorded in the prior year quarter  Operating profit came in at  43 7 million  down 34 7  from the year ago quarter Net sales at the Paper and Industrial Converted Products segment came in at  512 4 million  reflecting an increase of 8 8  year over year on the Conitex acquisition and higher selling prices  partly offset by foreign exchange and lower volume  Operating profit totaled  55 9 million  up 22 6  year over year The Display and Packaging segment s net sales came in at  141 2 million  relatively flat with the year ago quarter s  142 4 million owing to volume growth and higher selling prices  partly offset by reduced sales from exiting the Atlanta packaging center contract  The segment reported operating profit of  8 4 million in the fourth quarter against a loss of  4 1 million in the year earlier quarter The Protective Solution segment s net sales came in at  128 million  down 2 4  year over year primarily due to negative foreign exchange impact  Operating profit at the segment totaled  8 2 million  down 10 2  year over year Financial PerformanceSonoco reported cash and cash equivalents of  120 million at the end of fourth quarter 2018  down from  255 million recorded at end 2017  The company reported cash flow from operating activities of  589 9 million in 2018  compared with  348 3 million last year Long term debt was  1 19 billion as of Dec 31  2018  down from  1 29 billion as of Dec 31  2017  As of Dec 31 2018  the company s total debt to capital ratio was 43 9  compared with 45 6  as of Dec 31  2017 On Oct 1  2018  Sonoco acquired the remaining 70  interest in the Conitex Sonoco joint venture and a composite can operation in Spain from Texpack  Inc   for approximately  145 million  Also  Sonoco acquired an additional 19  interest in its Sonoco Asia  LLC  joint venture from PFE  NYSE PFE  Hong Kong Limited for  35 million  Conitex Sonoco s results will be included in Sonoco s Paper and Industrial Converted Products segment and the Spanish composite can operation in the Consumer Packaging segment 2018 ResultsSonoco reported adjusted earnings per share of  3 37 in 2018  up 21  from  2 79 in the prior year  Earnings beat the Zacks Consensus Estimate of  3 34  On a reported basis  including one time items  earnings per share came in at  3 10 compared with  1 74 in the year ago quarter Sales increased 7  year over year to  5 39 billion  The top line missed the Zacks Consensus Estimate of  5 41 billion GuidanceFor 2019  Sonoco maintained its adjusted earnings per share guidance to  3 47  3 57  The mid point of the guidance is at  3 52 a share  Operating cash flow is expected in the range of  600  620 million and free cash flow is anticipated between  225 million and  245 million For first quarter 2019  the company expects adjusted earnings per share of 77 83 cents compared with the year ago quarter s 74 cents 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed an upward trend in fresh estimates 
VGM Scores
Currently  Sonoco has a nice Growth Score of B  however its Momentum Score is doing a bit better with an A  However  the stock was allocated a grade of C on the value side  putting it in the middle 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of B  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been trending upward for the stock  and the magnitude of this revision looks promising  Notably  Sonoco has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-03-15,Zacks Investment Research,https://www.investing.com/analysis/sonoco-son-down-18-since-last-earnings-report-can-it-rebound-200398364,200398364
220120,441636,PFE,Aerie  AERI  Starts Phase II Study On Eye Candidate AR 1105,opinion,Aerie Pharmaceuticals  Inc    NASDAQ AERI   announced that it has initiated dosing in a phase II study to evaluate its investigational pipeline candidate  AR 1105  for treating patients with macular edema due to retinal vein occlusion  RVO  The phase II program will enroll up to 45 patients and be conducted at various sites in the United States  The primary endpoint of the study is to examine the safety  tolerability and efficacy of the dexamethasone intravitreal implant  AR 1105  Positive results from this study will help Aerie optimize the formulation of the candidate to achieve the clinical objective in phase III analyses AR 1105 is a bio erodible implant  designed to release the steroid dexamethasone over a six month period  It is commonly administered through intravitreal injection  The benefits of AR 1105 compared with other steroid products are its six month duration of efficacy  improved administration owing to a smaller needle size and a better safety profile on the back of lower peak drug levels In January 2019  the FDA reviewed the investigational new drug  IND  application for AR 1105 Apart from AR 1105  Aerie s retina pipeline includes AR 13503  rho kinase and protein kinase C inhibitor implant   The IND for AR 13503 is expected to be filed with the FDA in the first quarter of 2019 and if accepted  studies are expected to begin in the second quarter of 2019 for wet age related macular degeneration and DME  diabetic macular edema  Shares of Aerie have surged 30 4  so far this year  outperforming the 17  rise We would like to remind investors that last week  Aerie received the FDA approval for Rocklatan to reduce the elevated intraocular pressure  IOP  in patients with open angle glaucoma or ocular hypertension Rocklatan is a once daily  quadruple action fixed dose combination of Rhopressa  netarsudil  and Pfizer s   NYSE PFE   Xalatan  latanoprost  This is the second FDA approval that Aerie has received for treating glaucoma within a year of Rhopressa s launch in the United States  The company plans to launch Rocklatan in the second quarter of 2019 Zacks Rank   Other Stocks to ConsiderAerie currently carries a Zacks Rank  2  Buy   Two other top ranked stocks in the same sector are Lannett Co Inc   NYSE LCI   and AIT Therapeutics  Inc    OTC AITB    both sporting a Zacks Rank  1  Strong Buy   You can see  Lannett s earnings estimates have moved 1 9  north for 2019 and 2  for 2020 over the past 60 days  The stock has soared 58 8  so far this year AIT Therapeutics  loss per share estimates have been narrowed 18 8  for 2019 and 11 8  for 2020 in the last 60 days  The stock has inched up 1 6  year to date Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-03-19,Zacks Investment Research,https://www.investing.com/analysis/aerie-aeri-starts-phase-ii-study-on-eye-candidate-ar1105-200399153,200399153
220121,441637,PFE,Momenta Pharmaceuticals EPS in line  misses on revenue,news,Momenta Pharmaceuticals   NASDAQ MNTA   Q4 EPS of  0 18 in line Revenue of  64 61M   88 9  Y Y  misses by  1 97M Press ReleaseNow read ,2018-02-21,Seeking Alpha,https://www.investing.com/news/stock-market-news/momenta-pharmaceuticals-eps-inline-misses-on-revenue-1286511,1286511
220127,441643,PFE,Conatus   CNAT  Q4 Earnings Top Estimates  Emricasan In Focus,opinion,Conatus Pharmaceuticals Inc    NASDAQ CNAT   incurred a loss of 13 cents per share for the fourth quarter of 2018  narrower than the Zacks Consensus Estimate of 14 cents and the year ago quarter s loss of 15 cents Revenues came in at  7 4 million  down 15 9  year over year due to lower reimbursement from partner Novartis   NYSE NVS   for the costs incurred to support development of Conatus  lead pipeline candidate  emricasan  Moreover  the top line marginally beat the Zacks Consensus Estimate of  7 million Conatus has no approved product in its portfolio at the moment  The revenues generated by the company are all related to its collaboration with Novartis for the worldwide development and commercialization of emricasan Shares of Conatus have rallied 13 9  so far this year  outperforming the  increase of 9 9  Quarter in DetailIn the fourth quarter  research and development expenses were  8 9 million  down 18 3  from the year ago period s figure  mainly on account of lower spending associated with the ongoing ENCORE studies on emricasan  This was partially offset by higher spending related to new product candidate development General and administrative expenses were  2 5 million  marginally up from the year ago quarter s  2 3 million on higher personnel costs Full Year ResultsFor 2018  Conatus generated revenues of  33 6 million  indicating a decrease of 5 1  year over year  In 2018  the company incurred a total loss of 59 cents per share  narrower than the year ago loss of 61 cents Emricasan in FocusEmricasan  a caspase inhibitor  is being developed for the treatment of patients with fibrosis or cirrhosis caused by nonalcoholic steatohepatitis  NASH   Conatus acquired the worldwide rights to emricasan from Pfizer   NYSE PFE   in July 2010 The company is conducting three ongoing phase IIb ENCORE studies on emricasan for treating fibrosis or cirrhosis induced by nonalcoholic steatohepatitis  NASH   The programs are  namely ENCORE NF  for NASH fibrosis   ENCORE PH  for portal hypertension  and ENCORE LF  for liver function  Last December  Conatus announced top line results from a phase IIb ENCORE PH  In the program  emricasan demonstrated clinically meaningful treatment effects on compensated NASH cirrhosis patients  who stand at a risk of passing to the decompensation state  However  the study failed to meet its primary endpoint  Following a post hoc analysis  emricasan demonstrated a clinically meaningful treatment impact compared with placebo  Additional results are now expected in mid 2019 Meanwhile  in February 2019  Conatus completed enrolling patients in the phase IIb ENCORE LF  Top line data from the study is expected in mid 2019 Top line findings from the ENCORE NF are awaited in the first half of 2019 The company is focused on developing emricasan as positive outcomes from these investigations will pave the way for a phase III efficacy and safety assessment on the candidate for the given disease On fourth quarter conference call  Conatus announced that it has selected CTS 2090 currently in preclinical development  to move into clinical studies  CTS 2090 is an orally active  potent and highly selective inhibitor of caspase 1  The company plans to submit an investigational new drug  IND  application to begin clinical studies on the candidate by the first half of 2020 GuidanceConatus expects the 2019 end balance in the range of  10  15 million excluding any potential milestone payment under the Novartis collaboration As of December 31  2018  Conatus had cash  cash equivalents and marketable securities of  40 7 million compared with  49 6 million as of Sep 30  2018 Conatus Pharmaceuticals Inc  Price  Consensus and EPS Surprise   Zacks Rank   Key PickConatus carries a Zacks Rank  3  Hold   A better ranked stock in the same sector is Bovie Medical Corporation   NASDAQ APYX    sporting a Zacks Rank  1  Strong Buy   You can see  Bovie Medical s loss per share estimates have narrowed 6 8  for 2019 over the last 60 days Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-03-10,Zacks Investment Research,https://www.investing.com/analysis/conatus-cnat-q4-earnings-top-estimates-emricasan-in-focus-200396481,200396481
220128,441644,PFE,Aerie  AERI  Receives FDA Nod For Rocklatan To Treat Glaucoma ,opinion,Aerie Pharmaceuticals  Inc     NASDAQ AERI   announced that the FDA has approved Rocklatan 0 02  0 005  to reduce elevated intraocular pressure  IOP  in patients with open angle glaucoma or ocular hypertension   Rocklatan is a once daily  quadruple action fixed dose combination of Rhopressa  netarsudil  and Pfizer s   NYSE PFE   Xalatan  latanoprost  The FDA approval was supported by data from two phase III registration studies  MERCURY 1 and MERCURY 2  In these studies  Rocklatan achieved its primary 90 day efficacy endpoint  and positive 12 month safety and efficacy results  demonstrating statistically superior IOP reduction over latanoprost and netarsudil at every measured time point  Aerie s new drug application  NDA  for Rocklatan 0 02  0 005  was submitted to the FDA in May 2018 This is the second FDA approval that the company has received for the treatment of glaucoma within a year of the U S  launch of Rhopressa  The company plans to launch Rocklatan in the United States in the second quarter of 2019 Share price of the company decreased 21  in the past year compared with the  s decline of 16 6  Along with the approval  the company also announced full year 2019 net revenue and net cash burn guidance  The company expects revenue for 2019 to be  110  120 million  This guidance includes the combined net revenues of Rhopressa  netarsudil ophthalmic solution  0 02  and Rocklatan   As Rocklatan  has just received approval  a large portion of the company s net revenue guidance is expected to be achieved later this year  The company expects to gain meaningful Rocklatan market access for commercial and Medicare Part D plans as the year progresses Net cash burn for full year 2019 is expected to be  130  140 million  Including the  100 million undrawn credit facility available to the company  total liquidity at the end of 2019 is forecast to be  160  170 million based on the net cash burn guidance range  Aerie Pharmaceuticals  Inc  Price    Zacks Rank and Other Key PicksAerie currently carries a Zacks Rank  2  Buy  Some top ranked stocks from the same space are Celgene Corporation   NASDAQ CELG   and BioDelivery Sciences International  Inc    NASDAQ BDSI    While Celgene carries a Zacks Rank  1  Strong Buy   BioDelivery carries a Zacks Rank 2  Buy   You can see  Celgene s earnings per share estimates have increased from  10 34 to  10 73 for 2019 and from  12 28 to  12 76 for 2020 in the past 60 days  The company delivered a positive earnings surprise in all the trailing four quarters  with average of 2 65  BioDelivery Sciences  loss per share estimates have narrowed from 25 cents to 20 cents for 2019 over the past 60 days  The company delivered a positive earnings surprise in three of the trailing four quarters  with average of 8 57   Zacks  Top 10 Stocks for 2019 In addition to the stocks discussed above  wouldn t you like to know about our 10 finest buy and holds for the year From more than 4 000 companies covered by the Zacks Rank  these 10 were picked by a process that consistently beats the market  Even during 2018 while the market dropped  5 2   our Top 10s were up well into double digits  And during bullish 2012   2017  they soared far above the market s  126 3   reaching  181 9  This year  the portfolio features a player that thrives on volatility  an AI comer  and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs ,2019-03-13,Zacks Investment Research,https://www.investing.com/analysis/aerie-aeri-receives-fda-nod-for-rocklatan-to-treat-glaucoma-200397424,200397424
220129,441645,PFE,Resolution of regulatory issues at Pfizer s McPherson site boosts Achaogen  up 12 ,news,Achaogen  NASDAQ AKAO  is up 12  on increased volume in response to the news that the FDA GMP issues have been resolved at  Pfizer   NYSE PFE  s McPherson facility  the manufacturing site for plazomicin  The agency has classified the outcome of its Q4 2017 reinspection as  Voluntary Action Indicated  which means that some minor deficiencies were observed but the issues do not warrant further regulatory action The development should pave the way for FDA approval of the antibiotic by the June 25 action date Now read ,2018-01-30,Seeking Alpha,https://www.investing.com/news/stock-market-news/resolution-of-regulatory-issues-at-pfizers-mcpherson-site-boosts-achaogen-up-12-1171229,1171229
220130,441646,PFE,Pfizer sees upbeat 2018 on lower tax rate  shares dip after highs,news,"By Divya Grover  Reuters     Pfizer  Inc  N PFE  forecast 2018 profit and revenue well ahead of analysts  estimates on Tuesday as it expects to benefit from reduced tax rate following the recent changes to the U S  tax code  and recorded an  11 billion gain from the overhaul  The company s shares  which rose nearly 5 percent on Friday and hit their highest level since 2002 on Monday  fell 3 percent to  37 82 in morning trading  The drugmaker also beat fourth quarter profit and revenue estimates on strong demand for its pneumonia vaccine Prevnar and rheumatoid arthritis drug Xeljanz  Pfizer said it would invest about  5 billion in the United States over the next five years and pay about  15 billion in taxes over eight years to bring funds kept overseas back to the United States under the new tax laws  The above consensus fourth quarter results are  largely irrelevent  in the context of Pfizer s strong full year forecast  driven by the  dramatically improved  17 percent tax rate in 2018 and a strong currency tailwind  Leerink analysts said   Most investors were already assuming strong guidance in the wake of AbbVie Inc s  N ABBV  recent guidance   the analysts said   Pfizer said its 2018 forecast reflected a full year contribution from the consumer healthcare business  which the company plans to divest or spin off this year  The drugmaker has been under immense pressure from investors and Wall Street to pull off a large deal that could help reignite its growth  which has been reliant on drugs that are close to generic pressure following patent expirations    We believe that Pfizer has the financial flexibility to add to its product portfolio through potentially sizable acquisitions  particularly now that there is clarity on U S  tax reform   Edward Jones analyst Ashtyn Evans said   Pfizer booked a gain of  11 34 billion from the new tax law  leading to a surge in fourth quarter profit to  12 27 billion  or  2 02 per share   Excluding the tax gain and other items  the company earned 62 cents per share  Revenue rose marginally to  13 70 billion  Analysts on average were expecting a profit of 56 cents per share and revenue of  13 68 billion  according to Thomson Reuters I B E S  Prevnar raked in sales of  1 53 billion  up 8 3 percent from the year ago quarter  while Xeljanz jumped 47 5 percent to  410 million  Both the drugs significantly beat consensus estimates  compiled by  Barclays   LON BARC   However  sales of the company s breast cancer treatment  Ibrance  rose 11 4 percent to  716 million  but missed estimates of  978 million   Pfizer forecast full year adjusted earnings per share of between  2 90 and  3 and revenue of  53 5 billion to  55 5 billion  
Analysts on average were expecting a profit of  2 78 per share and revenue of  53 88 billion ",2018-01-30,Reuters,https://www.investing.com/news/stock-market-news/pfizer-reports-11-billion-gain-from-new-tax-law-1169408,1169408
220131,441647,PFE,Diffusion Pharma awarded two U S  patents covering lead candidate TSC  shares up 10 ,news,Diffusion Pharmaceuticals  DFFN  9 9   receives Notices of Allowance from the USPTO regarding two patent applications covering method of use and composition of matter for lead drug trans sodium crocetinate  TSC  TSC is in Phase 3 development for a type of brain cancer Previously  Late stage study of Diffusion Pharma s TSC in brain cancer underway  shares up 4  after hours  Jan  29 Now read ,2018-02-01,Seeking Alpha,https://www.investing.com/news/stock-market-news/diffusion-pharma-awarded-two-us-patents-covering-lead-candidate-tsc-shares-up-10-1182587,1182587
220137,441653,PFE,Aerie  AERI  Q4 Earnings Miss  Rhopressa Gains Traction,opinion,"Aerie Pharmaceuticals  Inc    NASDAQ AERI   reported a loss of  1 14 per share in fourth quarter 2018  wider than the Zacks Consensus Estimate of a loss of  1 02 but narrower than the year ago loss of  1 60 Aerie s shares have lost 4 5  in the past three months In December 2017  Rhopressa was approved by the FDA for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension  The drug was launched by the end of April Rhopressa s revenues came in at  14 5 million  beating the Zacks Consensus Estimate of  12 86 million Quarter in DetailIn the reported quarter  research and development expenses came down to  26 5 million from  38 1 million in the year ago quarter  Selling  general and administrative expenses surged to  31 9 million from  18 5 million in the year ago quarter As of Feb 25  2019  Rhopressa s market access increased to approximately 90  of commercial lives  including 55  in preferred brand Tier 2 and 35  in Tier 3  and Medicare Part D Tier 2 coverage currently represents approximately 40  of Medicare Part D lives  Aerie expects Medicare Part D Tier 2 equivalent coverage to increase to more than 70  within the next few weeks 2018 ResultsTotal Rhopressa revenues in 2018 came in at  24 2 million  which beat the Zacks Consenus Estimate of  22 4 million  Loss per share came in at  5 58  wider than the Zacks Consensus Estimate of  4 72 Pipeline UpdatesAerie s New Drug Application  NDA  for its second product candidate  Rocklatan  netarsudil latanoprost ophthalmic solution  0 02  0 005   which is a fixed dose combination of Rhopressa and Pfizer s   NYSE PFE   Xalatan  was submitted to the FDA in May 2018  The agency has completed its initial 60 day review of the NDA and determined that the application is sufficiently complete to permit a substantive review  The PDUFA  Prescription Drug User Fee Act  goal date for completion of the FDA s review of the Rocklatan NDA is set for Mar 14  2019 Early October 2018  the European Medicines Agency  EMA  accepted for review the Marketing Authorisation Application  MAA  for Rhokiinsa  marketed as Rhopressa in the United States   An opinion on approval is expected in the second half of 2019 The company had earlier  initiated a phase III trial  Mercury 3  to prepare for a regulatory submission in Europe Pre IND activities are well underway for further development of Aerie s retina program candidates   AR 13503  Rho kinase and Protein kinase C inhibitor implant  and AR 1105  dexamethasone steroid implant   Trials on AR 1105 are expected to begin in March 2019 for RVO  retinal vein occlusion  The IND  Investigational New Drug application  for AR 13503  Rho kinase and Protein kinase C inhibitor implant  is expected to be filed with the FDA in March 2019  and  if accepted  trials are expected to begin in the second quarter of 2019 for wet age related macular degeneration and DME  diabetic macular edema  Our TakeAerie reported mixed results for the fourth quarter  Though earnings missed estimates  Rhopressa sales comfortably beat estimates and doubled sequentially  The solid uptake in prescription volumes should propel sales further  as glaucoma is one of the largest segments in the global ophthalmic market  even though competition is stiff from the likes of Bausch Health s  BHC  Vyzulta  among others Finally  a tentative approval of Rocklatan  expected next monyth  will further boost prospects of the company Zacks Rank   Another Key PickAerie currently carries a Zacks Rank  2  Buy  
Another attractive stock in the healthcare sector is Celgene Corporation   NASDAQ CELG    which sports a Zacks Rank  1  Strong Buy   You can see  Celgene s earnings per share estimates increased from  10 37 to  10 75 for 2019 over the past 30 days  Estimates for 2020 also increased 35 cents Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-02-25,Zacks Investment Research,https://www.investing.com/analysis/aerie-aeri-q4-earnings-miss-rhopressa-gains-traction-200392603,200392603
220146,441662,PFE,Conatus  CNAT  Completes Enrollment In Phase II NASH Study,opinion,"Conatus Pharmaceuticals Inc    NASDAQ CNAT   announced that it has completed enrollment in ENCORE LF  a phase IIb study evaluating emricasan  a caspase inhibitor  which is being developed for the treatment of patients with decompensatednonalcoholic steatohepatitis  NASH   
The ENCORE LF study is being conducted in about 210 patients who were randomized 1 1 1 to receive 5 mg of emricasan  25 mg of emricasan  or placebo twice daily for at least 48 weeks  The primary endpoint is event free survival  Top line data from the study is expected to be presented in mid 2019 
Shares of Conatus have plummeted 59 7  in the past year compared with the  decline of 9 7  

 
Conatus is conducting three ongoing phase IIb ENCORE studies on emricasan for treating fibrosis or cirrhosis induced by NASH  The programs are called ENCORE NF  for NASH fibrosis   ENCORE PH  for portal hypertension  and ENCORE LF  for liver function  
In December  Conatus announced top line results from the ENCORE PH study  In the study  emricasan demonstrated clinically meaningful treatment effects on compensated NASH cirrhosis patients  who stand at a risk of passing to the decompensation state  The study evaluated the capacity of emricasan to reduce hepatic venous pressure gradient  HVPG  in NASH cirrhosis patients  However  the study failed to meet the primary endpoint 
Meanwhile  top line data from the ENCORE NF study is expected to be presented in the first half of 2019 
Positive results from these analyses will also pave the way for a phase III efficacy and safety study on the candidate
Please note that emricasan enjoys FDA s Fast Track status for the treatment of liver cirrhosis caused by NASH  This designation should expedite the review process of the candidate  The candidate also enjoys Orphan Drug status in both the U S  for the treatment of post orthotopic liver transplant  POLT  patients with re established fibrosis to delay the progression to cirrhosis and end stage liver disease  
Conatus acquired the worldwide rights to emricasan from Pfizer   NYSE PFE   in July 2010  It has an exclusive option  collaboration and license agreement with Novartis   NYSE NVS   for the worldwide development and commercialization of emricasan 
Another candidate in Conatus  portfolio is IDN 7314  which is currently being evaluated in a phase II study for the treatment of primary sclerosing cholangitis  PSC   a chronic liver disease  Notably  the candidate enjoys an Orphan Drug designation  ODD  for the indication in both the United States and the EU Conatus Pharmaceuticals Inc  Price

    
Zacks Rank   Other Key Pick
Conatus currently carries a Zacks Rank  2  Buy   Another top ranked stock in the same sector is Galectin Therapeutics Inc    NASDAQ GALT    carrying a Zacks Rank  1  Strong Buy   You can see  
Galectin s loss per share estimates has narrowed from 44 centsto 38 cents for 2019 and from  1 12 to 98 cents for 2020 in the last 60 days  The company delivered a positive earnings surprise in all of the trailing four quarters with average of 18 65  
3 Medical Stocks to Buy Now 
The greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline 
So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ",2019-02-13,Zacks Investment Research,https://www.investing.com/analysis/conatus-cnat-completes-enrollment-in-phase-ii-nash-study-200387687,200387687
220151,441667,PFE,At AstraZeneca  fewer drug projects bring big productivity jump,news,"By Ben Hirschler LONDON  Reuters    A focus on fewer diseases  together with cuts in laboratories and staff  has delivered a more than fourfold increase in research productivity at drugmaker AstraZeneca  L AZN   based on one key measure of success  The analysis published on Friday comes at a time of soul searching among large pharmaceutical companies as they compete with smaller biotech firms  which are getting new drugs to market more efficiently  The turnaround evident this decade at AstraZeneca follows a shrinking of its global research and development organization and a revision of R D strategy in 2011  a year before the arrival of current chief executive Pascal Soriot  Soriot has since continued the shift to a deeper and narrower focus on priority therapeutic areas  notably cancer   All these improvements have happened with less people  less sites and less money   Mene Pangalos  who leads AstraZeneca s Innovative Medicines and Early Development unit  told Reuters  Previously  AstraZeneca was a laggard in the pharmaceutical industry with a dismal track record in launching new medicines and a rapidly eroding base business  due to expiring patents on its older medicines  Its average success for getting a drug from the discovery phase through to successful completion of final stage Phase III clinical trials was at an all time low of 4 percent in 2005 10  below the industry average of 6 percent  But in the five years from 2012 to 2016  this jumped to 19 percent  while the industry average  according to consultancy CMR International  was little changed  AstraZeneca scientists published the latest findings in the journal Nature Reviews Drug Discovery  Significantly  there was a marked drop in the number of projects started at the discovery stage  with the total falling to just 76 in 2012 16 from 287 in 2005 10   We re working on far fewer programs and the probability of success on those programs is going up   Pangalos said   Going from 4 percent to nearly 20 percent is something we are all very happy with but I still want us to do better     we re still failing 80 percent of the time   INVESTOR SENTIMENT The productivity boost coincides with an improvement in shareholder sentiment as investors have started to bet on AstraZeneca s ability to replace older medicines with new products  particularly in oncology  A failed bid from  Pfizer   N PFE  in 2014 has also helped the investment story  Today  two thirds of analysts recommend buying the shares  up from one in five in 2012  
The decision by Pangalos and his colleagues to detail the company s successes and failures in two academic papers  the first of which appeared in 2014  is unusual  Rivals such as GlaxoSmithKline  L GSK  and Pfizer have published some details of R D productivity in the past but the AstraZeneca review is more comprehensive  Still  the data does not track the profitability of AstraZeneca s research activities  since even when a new drug succeeds in final clinical tests and wins regulatory approval  commercial success is not guaranteed  A report last month by consultancy Deloitte found projected returns at 12 of the world s top drugmakers had fallen in recent years  even though the overall of number of new drugs had increased  AstraZeneca itself has had some notable successes  such as its new cancer pills Tagrisso and Lynparza  but prospects for other approved products  including its high profile immunotherapy drug Imfinzi  have been more mixed  Imfinzi suffered a major lung cancer trial setback in July 2017  although it then went on to show impressive results in another lung cancer setting ",2018-01-18,Reuters,https://www.investing.com/news/stock-market-news/at-astrazeneca-fewer-drug-projects-bring-big-productivity-jump-1123370,1123370
220152,441668,PFE,Pfizer s biosimilar candidate to Roche s Rituxan MabThera shows equivalence in comparative lymphoma study,news,A comparative safety and efficacy study  REFLECTIONS B3281006  comparing  Pfizer  s  NYSE PFE  biosimilar candidate PF 05280586 to the reference product  Roche s  OTCQX RHHBY  Rituxan MabThera  rituximab   demonstrated equivalence in terms of overall response response rate in first line CD 20 positive  low tumor burden  follicular lymphoma Complete results will be submitted for presentation at a future medical conference or publication in a summary format Pfizer has seven biosimilars in late stage development  three in oncology  The results from REFLECTIONS B3281006 represent its fifth successful outcome Now read ,2018-01-24,Seeking Alpha,https://www.investing.com/news/stock-market-news/pfizers-biosimilar-candidate-to-roches-rituxanmabthera-shows-equivalence-in-comparative-lymphoma-study-1145088,1145088
220164,441680,PFE,Sangamo teams up with Pfizer to develop gene therapy to treat ALS  shares ahead 4  premarket,news,Sangamo Therapeutics  NASDAQ SGMO  is up 4  premarket on modest volume in response to its collaboration with  Pfizer   NYSE PFE  aimed at developing a gene therapy using zinc finger protein transcription factors  ZFP TFs  to treat amyotrophic lateral sclerosis  ALS  and frontotemporal lobar degeneration  FTLD  linked to mutations of the C90RF72 gene The companies will investigate allele specific ZFP TFs to potentially differentiate the mutant C90FR72 allele from the wild type allele and to specifically down regulate the mutant form Under the terms of the agreement  Sangamo will receive  12M upfront  up to  150M in milestones and tiered royalties on net sales  Sangamo will be responsible for developing ZFP TF candidates while Pfizer will be responsible for subsequent research  development  manufacturing and commercialization The companies are also collaborating on the development of gene therapies to treat hemophilia A under a May 2017 agreement Sangamo s ZFP TF technology is designed to down up regulate the expression of a specific gene or DNA sequence with a single administration Now read ,2018-01-03,Seeking Alpha,https://www.investing.com/news/stock-market-news/sangamo-teams-up-with-pfizer-to-develop-gene-therapy-to-treat-als-shares-ahead-4-premarket-1056940,1056940
220165,441681,PFE,Premarket Losers as of 9 05 am,news,MGI  8  after terminating merger deal with Ant Financial Services Group GROW  5  on Bitcoin boom  Now read ,2018-01-03,Seeking Alpha,https://www.investing.com/news/stock-market-news/premarket-losers-as-of-905-am-1056937,1056937
220166,441682,PFE,Pfizer teams up with Arvinas to develop small molecule drugs targeting disease causing cellular proteins,news,Privately held Arvinas LLC enters into a research collaboration and license agreement with  Pfizer   PFE  0 2   aimed at discovering and developing small molecule drugs that degrade disease causing cellular proteins The effort will leverage Arvinas  proprietary PROTAC  PROteolysis TArgeting Chimeras  platform  PROTAC degraders work by recruiting an enzyme called E3 ligase to tag the target protein for degradation through protein complexes called proteasomes  Arvinas says its approach is better than traditional small molecule inhibitors because it utilizes the cell s natural process to degrade and eliminate problematic proteins Under the terms of the multiyear agreement  Arvinas will be responsible for discovery while Pfizer will handle clinical development and commercialization  Arvinas will be eligible to receive up to  830M in upfront and milestone payments and tiered royalties on net sales Now read ,2018-01-04,Seeking Alpha,https://www.investing.com/news/stock-market-news/pfizer-teams-up-with-arvinas-to-develop-small-molecule-drugs-targeting-diseasecausing-cellular-proteins-1062818,1062818
220167,441683,PFE,GSK CEO says looking at Pfizer consumer business  but not a priority,news,"By Bill Berkrot  Reuters    GlaxoSmithKline s  L GSK  new chief executive said on Tuesday that the British drugmaker would have a look at  Pfizer  Inc s  N PFE  consumer products business  but would not overpay for the asset  Pfizer  the largest U S  drugmaker  said last year it was considering strategic alternatives  including a sale or spinoff  of the consumer business  which had sales of about  3 4 billion in 2016 and could cost more than  15 billion to acquire   At this stage it would be weird if we didn t look at it   GSK Chief Executive Emma Walmsley said  responding to questions at the JP Morgan Healthcare Conference in San Francisco  But she said it is only a look and very early  adding   we don t need it and we won t overpay for it    Despite her consumer products background  Walmsley repeatedly said that the company s pharmaceuticals business and pharma research and development is GSK s top priority  However  Walmsley said GSK has a good track record of integrating large acquisitions and that it s consumer business does have room to grow  Pfizer s consumer portfolio includes well known brands such as Advil  Chapstick lip balm and Centrum vitamins  Walmsley said there are a very small number of assets that would be completely complementary to GSK s existing consumer business   and this may be one of them   
 If we did it  it is cash generating   she said ",2018-01-09,Reuters,https://www.investing.com/news/stock-market-news/gsk-ceo-says-looking-at-pfizer-consumer-business-but-not-a-priority-1083565,1083565
220178,441694,PFE,Glaxo  GSK  Beats Earnings   Revenue Estimates In Q4,opinion,"GlaxoSmithKline plc   NYSE GSK    one of the largest health care companies  reshaped its business following the March 2015 completion of the three part  inter conditional transaction with Novartis related to its Consumer Healthcare  Vaccines and Oncology businesses  Under the deal  Glaxo sold its oncology assets to Novartis and acquired Novartis  Vaccines business  excluding influenza vaccines   Additionally  the companies created a joint venture   JV    thereby combining their consumer divisions to form a larger consumer health care business Following the completion of the deal  the UK based company now focuses on its three core businesses   Pharmaceuticals  respiratory  HIV   Vaccines  pediatric  adolescent  adult  and travel vaccines  and Consumer Healthcare  wellness  oral health  nutrition and skin health products   However  Glaxo is currently focusing on adding cancer drugs to boost its pharma pipeline Meanwhile  like many of its peers  Glaxo is facing challenges in the form of stiff competition  genericization  pricing pressure and slowing growth in emerging markets  In this scenario  investor focus remains on late stage pipeline candidates and their commercial potential  restructuring and cost cutting initiatives and performance of new products apart from the usual top and bottom line numbers Glaxo s performance has been mixed so far  with the company s earnings beating expectations twice in the trailing four quarters while missed in the other two  Overall  the company has delivered an average positive surprise of 1 61  Currently  Glaxo has a Zacks Rank  3  Hold   but that could definitely change following the company s earnings report which was just released  We have highlighted some of the key stats from this just revealed announcement below Earnings Beat  Glaxo reported core earnings of 80 cents per American depositary share in the fourth quarter of 2018  which beat our consensus estimate of 70 cents  The company s focus on cost control initiative has boosted margins Revenues Beat  Revenues were up 5  year over year at constant exchange rate  CER  to  10 54 billion   8 2 billion    Revenues beat the Zacks Consensus Estimate of  9 85 billion Key Stats  While sales in Consumer Healthcare and Pharmaceuticals were up 1  and 4   respectively  the Vaccines segment increased 18  at CER  Glaxo acquired TESARO and announced agreement with Merck KGaA to add oncology products to its pharma portfolio 2019 Guidance  Glaxo expects EPS to decline by 5 9  at CER in 2019 which includes impact of Advair generic  acquisition of TESARO  joint venture with Pfizer  NYSE PFE  for Consumer Healthcare business ad divestment of certain nutrition brands Share Price Impact  Shares rose almost 0 6  in pre market trading Check back later for our full write up on GSK earnings report later  1 286373GlaxoSmithKline plc Price and EPS Surprise
    Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2019-02-05,Zacks Investment Research,https://www.investing.com/analysis/glaxo-gsk-beats-earnings--revenue-estimates-in-q4-200384254,200384254
220179,441695,PFE,Will IPO ETFs Sizzle In 2019 ,opinion,"Expectations are high that IPOs will stage a great show in 2019  though January was freezing for the space   were priced globally  raising  2 7 billion  according to data compiled by Bloomberg  compared with 126 listings raising more than  13 billion last January  A month long government shutdown was held responsible for the worst January for IPOs in three years 
The situation was slightly better off beyond the border with 54 offerings raising  2 3 billion  It still marked a third of the  on non U S  exchanges in January 2018  per Bloomberg 
Inside the Market Pulse 
According to a December survey by BDO USA  71  of capital market executives at leading investment banks expect IPO activity to rise  or at least   which was the best year for deals since 2014  as quoted on MarketWatch 
The survey sees 37  of bankers expecting private equity portfolios to generate the most IPOs this year  while 35  expect venture capital to break new ground  The latest market rally despite the government shutdown should pave the path for IPOs 
Hurdles in Sight 
Government shutdown kept the space shut in January With the SEC deferring the completion of reviews  Q1 IPO activity may see a slowdown but the long term picture looks rosy  per the survey 
While the government has restarted operations at January end with a Feb 15 deadline for reaching a permanent deal on the Mexico border wall funding  the chance of a second round of shutdown is high  This is because Democrats are still against funding the border wall  However  once a deal is reached   can be offered to companies in the pipeline  read    
What s Hot Now 
Biotech IPOs are the trending right now  For example  two biotech IPOs with proposed billion dollar valuations   Alector plans to raise  176 million at a market cap of  1 4 billion  and will start trading on Feb 7  And Gossamer Bio looks to raise  230 million at a  1 0 billion market cap on Feb 8 
Meanwhile  BioNTech AG  a European biotechnology company  with Pfizer Inc   NYSE PFE  and Sanofi  PA SASY   is considering an initial public offering in the United States  TCR2 Therapeutics  known for improved immuno oncology treatments for various forms of cancer   of its common stock in an IPO 
There are names beyond the biotech  Cibus  which has created a platform for non transgenic seed modification   for its  100 million IPO  Then there are bigger names like Uber Technologies Inc  s planned listing  Lyft Inc  has also been awaiting the SEC s response on  
This year s other bigshot IPO candidates include Airbnb Inc   which is reportedly eyeing an IPO sometime between June and the end of 2020  And Slack Technologies  to go public 
IPO ETFs to Play
In the view of an upbeat environment  barring shutdown woes   one should keep a tab on IPO ETFs like First Trust US Equity Opportunities ETF   V FPX   and Renaissance IPO ETF   TO IPO    Both funds have been steady this year with a respective 13 8  and 20 9  return 
Want key ETF info delivered straight to your inbox 
Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2019-02-06,Zacks Investment Research,https://www.investing.com/analysis/will-ipo-etfs-sizzle-in-2019-200384594,200384594
220181,441697,PFE,Pfizer declares  0 34 dividend,news,Pfizer   NYSE PFE  declares  0 34 share quarterly dividend  6 3  increase from prior dividend of  0 32 Forward yield 3 66 Payable March 1  for shareholders of record Feb  2  ex div Feb  1 Now read ,2017-12-18,Seeking Alpha,https://www.investing.com/news/stock-market-news/pfizer-declares-034-dividend-1004854,1004854
220192,441708,PFE,Novartis  Ultibro Breezhaler beats Glaxo s Seretide in late stage COPD study,news,A Phase 3 clinical trial  FLASH  assessing chronic obstructive pulmonary disease  COPD  patients who directly switched from GlaxoSmithKline s  NYSE GSK  Seretide  salmeterol fluticasone  to Novartis   NYSE NVS  Ultibro Breezhaler  indacaterol glycopyrronium  demonstrated a significant improvement in lung function Seretide users switching to once daily Ultibro Breezhaler without a washout period  reflecting real world practice  experienced lower rates of exacerbations and improved lung function Safety and tolerability were similar between the two products Now read ,2017-11-27,Seeking Alpha,https://www.investing.com/news/stock-market-news/novartis-ultibro-breezhaler-beats-glaxos-seretide-in-latestage-copd-study-914918,914918
220193,441709,PFE,Updated late stage data continue to show effectiveness of Pfizer s Ibrance in ER  HER2  breast cancer,news,Updated results from the Phase 3 PALOMA 2 study evaluating  Pfizer  s  NYSE PFE  IBRANCE  palbociclib   combined with Novartis  FEMARA  letrozole   in patients with ER  HER2  metastatic breast cancer continue to show a durable treatment benefit  The data will be presented on December 8 at the San Antonio Breast Cancer Symposium The combination of IBRANCE and letrozole reduced the risk of cancer progression by 44  and improved median progression free survival  PFS  by more than one year compared to letrozole plus placebo  27 6 months versus 14 5 months  in a first line setting Previously  Late stage study of expanded use of Pfizer s Ibrance successful  global regulatory applications to follow  April 19  2016 Now read ,2017-12-06,Seeking Alpha,https://www.investing.com/news/stock-market-news/updated-latestage-data-continue-to-show-effectiveness-of-pfizers-ibrance-in-erher2-breast-cancer-959369,959369
220194,441710,PFE,Pfizer breast cancer drug superior to chemotherapy in late stage study,news,"By Bill Berkrot  Reuters    Patients with advanced breast cancer tied to an inherited gene mutation who were treated with an experimental  Pfizer  Inc  N PFE  drug went about three months longer before their disease worsened than those who received chemotherapy in a late stage study  according to data released on Friday  The drug  talazoparib  a once daily pill that Pfizer acquired with its  14 billion purchase of Medivation  belongs to a class of medicines called PARP inhibitors that may induce tumor cell death  They have shown promise in advanced ovarian and breast cancers  Patients in the Phase III study had mutations of the BRCA1 2 genes  the type of mutation that led actress Angelina Jolie to have preventive breast removal surgery  About 3 percent of breast cancers occur in people with inherited BRCA1 or BRCA2 mutations that lower a cell s ability to repair damaged DNA  Up to 65 percent of women who inherit the mutations will develop breast cancer  often much younger than is typical for the disease  In the 431 patient trial  those who received talazoparib went 8 6 months before half of them experienced disease progression  a measure known as median progression free survival  PFS   Among those who received standard chemotherapy  the median PFS was 5 6 months  In addition  62 6 percent of talazoparib patients experienced a complete or partial response to the treatment compared with a 27 2 percent response rate for chemotherapy  Twelve patients who received the Pfizer drug  or 5 5 percent  had a complete response  meaning no detectable sign of cancer  There were no complete responses in the chemotherapy group  The results  unveiled at the San Antonio Breast Cancer Symposium  were highly statistically significant  Researchers also reported a significant delay in time to meaningful deterioration of quality of life among talazoparib patients  Dr  Jennifer Litton  the study s lead investigator from MD Anderson Cancer Center  said there are currently no drugs specifically approved for this group of patients aside from standard chemotherapies  The results were consistent whether patient had received up to three courses of chemotherapy or none at all  or whether patients  cancers had spread to the brain  
The incidence of serious adverse side effects was similar in both groups    31 8 percent for the Pfizer drug and 29 4 percent for chemotherapy  Discontinuations due to adverse events occurred in 7 7 percent of talazoparib patients and 9 5 percent in the chemotherapy group ",2017-12-08,Reuters,https://www.investing.com/news/stock-market-news/pfizer-breast-cancer-drug-superior-to-chemotherapy-in-late-stage-study-970125,970125
220195,441711,PFE,FDA extends action date three months for review of Pfizer s marketing application for Xeljanz for UC,news,The FDA extends its action date  PDUFA  three months to June for its review of  Pfizer  s  NYSE PFE  marketing application seeking approval to use XELJANZ  tofacitinib  to treat adults with moderately to severely active ulcerative colitis  UC  The reason for the move was the submission of information by the company which constituted a major amendment to the filing which triggered a standard three month extension of the review clock XELJANZ is currently approved in the U S  for rheumatoid arthritis Now read ,2017-12-13,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-extends-action-date-three-months-for-review-of-pfizers-marketing-application-for-xeljanz-for-uc-986298,986298
220196,441712,PFE,Provectus Biopharmaceuticals receives third cancer combination therapy patent from USPTO,news,Provectus Biopharmaceuticals  NYSEMKT PVCT  announces the United States Patent and Trademark Office  USPTO  has granted U S  patent No  9 839 688 for the combination of intralesional PV 10 with systemic immunomodulatory therapy  including anti PD 1 and anti PD L1 agents  for the treatment of solid tumor cancers  This new patent is a continuation of Provectus  first and second cancer combination therapy patent granted in 2015 and in November  respectively   Pfizer   NYSE PFE  is a co assignee on all three patents  Now read ,2017-12-14,Seeking Alpha,https://www.investing.com/news/stock-market-news/provectus-biopharmaceuticals-receives-third-cancer-combination-therapy-patent-from-uspto-991291,991291
220209,441725,PFE,Clovis  Rubraca Gets Nod As Maintenance Therapy In Europe,opinion,"Clovis Oncology  Inc    NASDAQ CLVS   announced that the European Commission   EC   has granted approval to a label expansion of its PARP inhibitor  Rubraca  rucaparib   which will expand the drug s eligible patient population  The drug is now approved as a maintenance treatment in recurrent ovarian cancer patients  irrespective of BRCA mutation  who have received one prior platinum based chemotherapy  The company is planning to launch the drug this quarter in the new indication starting with Germany This is the second approved indication of Rubraca in Europe  The decision was expected as the CHMP had recommended the approval last month  The FDA approved a similar label expansion of the drug in April 2018 Investors cheered the European label expansion as shares of Clovis rose 3 9  on Jan 24  The company s shares have rallied 46 5  in the past three months compared with the  s rise of 3 5  In Europe  Rubraca was earlier approved for BRCA mutated  platinum sensitive and relapsing ovarian cancer in third  or later line setting The approval in second line maintenance setting and most importantly exclusion of BRCA mutation criteria for patient selection will broaden the patient population significantly  Moreover  this brings the drug on par with other approved PARP inhibitors   AstraZeneca s   NYSE AZN   Lynparza and GlaxoSmithKline s   NYSE GSK   Zejula   for ovarian cancer in both U S  and European markets  We remind investors that Glaxo added Zejula to its portfolio with the recently closed  of TESARO Inc  for  5 1 billion We believe Clovis is a potential acquisition target as the merger   acquisition space heats up in the United States  The recent approval should add to its appeal as a buyout target However  we note that Clovis has struggled to capture market in the maintenance setting market in the United States  Rubraca sales disappointed in the third quarter after surging in the second quarter following U S  label expansion  The effect of the company s promotional initiatives and label expansion in Europe remains to be seen Moreover  the other two PARP inhibitors belong to big pharma companies with strong cash resources to promote their drugs  which can push Clovis on the back foot The PARP inhibitor segment is also getting competitive as several pharma biotech companies are developing their candidates in multiple indications  In October  Pfizer s   NYSE PFE   Talzenna  talazoparib  received approval for treating breast cancer Please note that  the approval of Rubraca in maintenance setting by the EC was based on data from the confirmatory phase III study   ARIEL 3   which showed that Rubraca led to significant improvement in progression free survival in such patients  The company believes that Rubraca is the only PARP inhibitor to demonstrate tumor shrinkage as well as prolonged progression free survival in this setting  which may boost its adoption Meanwhile  a phase III confirmatory study  ARIEL4 is evaluating Rubraca compared with chemotherapy on patients who have failed two prior lines of therapy  Clovis is also looking to expand Rubraca s label into additional indications like prostrate  breast and pancreatic cancers among others either as monotherapy or in combination with other agents Clovis Oncology  Inc  Price
    Zacks RankClovis currently carries a Zacks Rank  4  Sell  You can see  Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ",2019-01-28,Zacks Investment Research,https://www.investing.com/analysis/clovis-rubraca-gets-nod-as-maintenance-therapy-in-europe-200379962,200379962
220210,441726,PFE,This Big Pharma Stock Sees Major Chart Support,opinion,"Pfizer Inc   NYSE PFE  is starting to look attractive  This pharma giant peaked out on December 4  2018 at  46 47 a share  On Monday  the stock traded lower by 0 76 to  39 89 a share  Currently  PFE stock is trading below its 200 day moving average  which signals near term weakness 
Support To Watch
The next key support area that I m watching for PFE stock is around  38  which is an important support level where the stock broke out in late July 2018  One of my favorite strategies is to look for stocks that are trading back into their prior break out levels  The institutional money is usually there to support and defend the equity ",2019-01-28,Nicholas Santiago,https://www.investing.com/analysis/this-big-pharma-stock-sees-major-chart-support-200380222,200380222
220211,441727,PFE,FDA OKs Roche s Alecensa for first line ALK  lung cancer,news,The FDA approves Roche  OTCQX RHHBY  unit Genentech s marketing application seeking approval to use Alecensa  alectinib  in a first line setting to treat patients with ALK positive non small lung cancer  NSCLC  The FDA first approved the drug in December 2015 for treating ALK  NSCLC patients previously treated with  Pfizer  s  PFE  0 7   Xalkori  crizotinib  Now read ,2017-11-06,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-oks-roches-alecensa-for-firstline-alk-lung-cancer-820336,820336
220212,441728,PFE,Argos up 70  premarket on positive late stage kidney cancer data on lead candidate Rocapuldencel T,news,Nano cap Argos Therapeutics  NASDAQ ARGS  jumps 70  premarket on robust volume in response to its announcement of positive data from a Phase 3 clinical trial  ADAPT  assessing lead candidate Rocapuldencel T  Roca   in combination with  Pfizer  s  NYSE PFE  SUTENT  sunitinib malate   for the treatment of metastatic renal cell carcinoma  RCC   The results were presented at the SITC conference in National Harbor  MD In 146 patients analyzed for immune response  the number of antigen specific memory T cells were found to increase only after Roca treatment  In patients who received at seven doses of Roca  n 100   there was a statistically significant 2x average increase In the group who received seven doses of Roca  there was also a statistically significant correlation between survival and the change in the number of antigen specific memory T cells from baseline Patients with higher than median levels of IL 12 experienced improved survival that those below the median  IL 12 plays a key role in the activities of immune cells called T lymphocytes and natural killer cells Rocapuldencel T is an individualized immunotherapy that captures both mutated and variant antigens that are unique to each patient s tumor  It is specifically designed to induce an immune response targeting the patient s particular tumor antigens Shares plummeted in February on the news that the Data Monitoring Committee recommended stopping the study because it was unlikely to demonstrate a treatment benefit  The company subsequently met with the FDA which agreed with its decision to continue the trial and also agreed to a protocol amendment to extend it beyond 290 events with a revised statistical analysis plan Management will host a conference call this morning at 8 30 am ET to discuss the results Previously  Late stage study unlikely to show treatment benefit of Argos Therapeutics  lead product candidate  shares plummet 65  premarket  Feb  22 Now read ,2017-11-13,Seeking Alpha,https://www.investing.com/news/stock-market-news/argos-up-70-premarket-on-positive-latestage-kidney-cancer-data-on-lead-candidate-rocapuldencelt-847957,847957
220213,441729,PFE,Pfizer names Bourla as chief operating officer,news,"NEW YORK  Reuters    Drugmaker  Pfizer  Inc  N PFE  on Monday named Albert Bourla to the position of Chief Operating Officer  a move it said would free up Chief Executive Ian Read to focus more on long term strategy and engaging with government and industry leaders 
Bourla  56  has been president of Pfizer s Innovative Health business since the beginning of last year  Pfizer does not currently have a COO and Bourla will start the position on January 1 ",2017-11-13,Reuters,https://www.investing.com/news/stock-market-news/pfizer-names-bourla-as-chief-operating-officer-849407,849407
220214,441730,PFE,Expanded use of AstraZeneca s Faslodex OK d in Europe,news,The European Commission approves the use of AstraZeneca s  NYSE AZN  Faslodex  fulvestrant   in combination with  Pfizer  s  NYSE PFE  IBRANCE  palbociclib   for the treatment of patients with hormone receptor positive  HR    human epidermal growth factor receptor 2 negative  HER2   locally advanced or metastatic breast cancer who have received prior endocrine therapy Faslodex was previously approved in the EU for estrogen receptor positive  ER   locally advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy or who have progressed relapsed after estrogen therapy Now read ,2017-11-14,Seeking Alpha,https://www.investing.com/news/stock-market-news/expanded-use-of-astrazenecas-faslodex-okd-in-europe-857210,857210
220221,441737,PFE,Is Global X SuperDividend U S  ETF  DIV  A Strong ETF Right Now ,opinion,"Designed to provide broad exposure to the Total Market  U S   ETFs category of the market  the Global X SuperDividend U S  ETF  DIV  is a smart beta exchange traded fund launched on 03 11 2013 
What Are Smart Beta ETFs 
The ETF industry has long been dominated by products based on market cap weighted indexes  a strategy created to reflect the market or a particular market segment 
Market cap weighted indexes offer a low cost  convenient  and transparent way of replicating market returns  and are a good option for investors who believe in market efficiency 
But  there are some investors who would rather invest in smart beta funds  these funds track non cap weighted strategies  and are a strong option for those who prefer choosing great stocks in order to beat the market 
By attempting to pick stocks that have a better chance of risk return performance  non cap weighted indexes are based on certain fundamental characteristics  or a combination of such 
Even though this space provides many choices to investors  think one of the simplest methodologies like equal weighting and more complicated ones like fundamental and volatility momentum based weighting  not all have been able to deliver first rate results 
Fund Sponsor   Index
The fund is managed by Global X Management  DIV has been able to amass assets over  404 69 M  making it one of the largest ETFs in the Total Market  U S   ETFs  DIV seeks to match the performance of the INDXX SuperDividend U S  Low Volatility Index before fees and expenses 
The INDXX SuperDividend US Low Volatility Index tracks the performance of 50 equally weighted common stocks  MLPs   REITs that rank among the highest dividend yielding equity securities in the US 
Cost   Other Expenses
Cost is an important factor in selecting the right ETF  and cheaper funds can significantly outperform their more expensive cousins if all other fundamentals are the same 
With one of the cheaper products in the space  this ETF has annual operating expenses of 0 45  
It s 12 month trailing dividend yield comes in at 6 76  
Sector Exposure and Top Holdings
While ETFs offer diversified exposure  which minimizes single stock risk  a deep look into a fund s holdings is a valuable exercise  And  most ETFs are very transparent products that disclose their holdings on a daily basis 
Taking into account individual holdings  Annaly Capital Management accounts for about 3 48  of the fund s total assets  followed by Brinker International Inc and Pfizer Inc   NYSE PFE 
The top 10 holdings account for about 26 82  of total assets under management 
Performance and Risk
The ETF return is roughly 4 69  so far this year and is down about  1 16  in the last one year  as of 01 16 2019   In the past 52 week period  it has traded between  21 69 and  25 59 
The fund has a beta of 0 55 and standard deviation of 9 95  for the trailing three year period  which makes DIV a medium risk choice in this particular space  With about 49 holdings  it has more concentrated exposure than peers 
Alternatives
Global X SuperDividend U S  ETF is a reasonable option for investors seeking to outperform the Total Market  U S   ETFs segment of the market  However  there are other ETFs in the space which investors could consider 
WBI Power Factor High Dividend ETF  WBIY  tracks Solactive Power Factor High Dividend Index and the Global X SuperDividend ETF  SDIV  tracks Solactive Global SuperDividend Index  WBI Power Factor High Dividend ETF has  90 10 M in assets  Global X SuperDividend ETF has  887 84 M  WBIY has an expense ratio of 0 70  and SDIV charges 0 58  
Investors looking for cheaper and lower risk options should consider traditional market cap weighted ETFs that aim to match the returns of the Total Market  U S   ETFs 
Bottom Line
To learn more about this product and other ETFs  screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe  please visit Zacks ETF Center ",2019-01-15,Zacks Investment Research,https://www.investing.com/analysis/is-global-x-superdividend-us-etf-div-a-strong-etf-right-now-200376142,200376142
220225,441741,PFE,Athenex Completes Enrollment Target For Breast Cancer Study,opinion,"Athenex  Inc     NASDAQ ATNX   announced that it has completed target enrollment of 360 patients in the Oraxol phase III study in metastatic breast cancer on schedule  Athenex also reaffirmed that top line data from the study is expected to be available in mid 2019 
Oraxol is an innovative oral formulation of paclitaxel  a very effective and commonly used anti cancer chemotherapy combined with HM30181A  a novel gastrointestinal tract specific P glycoprotein pump inhibitor   The Oraxol phase III study is an open label study  which will evaluate the safety  tolerability and tumor response of Oraxol compared with IV paclitaxel in patients with metastatic breast cancer  Secondary endpoints will measure progression free survival and overall survival  
In October 2018  the company reported encouraging efficacy and safety data of Oraxol in the treatment of metastatic breast cancer patients obtained from a phase II study  conducted in Taiwan  Results from twenty four patients with metastatic breast cancer were reported 
Eleven patients  45 8   achieved partial remission  PR   10 patients  41 7   had stable disease  SD  and 3 patients had progressive disease  PD   Drug related serious adverse events consisting of Grade 4 neutropenia were observed in 3 patients and all recovered completely  There was no dose limiting neuropathy observed   Oraxol is one of the lead candidates in the company s pipeline and a potential approval will boost the company s top line 
Shares of Athenex decreased 21 6  in the past year  compared with the  s decline of 19 5  

 
Athenex is a global biopharmaceutical company dedicated to the discovery  development and commercialization of novel therapies for the treatment of cancer through its Orascovery and Src Kinase Inhibition research platforms 
The breast cancer market is crowded and a lot of companies are developing drugs to combat this disease  In December 2018  Roche   OTC RHHBY   announced that its breast cancer drug  Kadcyla significantly reduced the risk of disease recurrence by 50  as an adjuvant  after surgery  therapy in phase III KATHERINE study compared to its other breast cancer drug  Herceptin 
The late stage KATHERINE study compared Kadcyla with Herceptin for risk of disease recurrence or death in HER2 positive early breast cancer patients with residual disease following a neoadjuvant  before surgery  therapy  Back in October  Roche announced that the study had met its primary endpoint of reduction in disease recurrence 
Kadcyla  an antibody drug conjugate  is approved as monotherapy in second line setting for treating metastatic breast cancer in patients who have received treatment with Herceptin or and taxane since 2013 
In December 2018  Puma Biotechnology  Inc    NASDAQ PBYI   announced positive top line results from the phase III NALA study  evaluating its only marketed drug  Nerlynx  neratinib  for the treatment of third line hormone receptor positive  HER2 positive  metastatic breast cancer 
Pfizer   NYSE PFE   also has Xtandi in its portfolio  which is in mid stage development for advanced breast cancer 
Zacks Rank
Athenex currently carries a Zacks Rank  3  Hold   You can see  
Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana 
Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-01-10,Zacks Investment Research,https://www.investing.com/analysis/athenex-completes-enrollment-target-for-breast-cancer-study-200374577,200374577
220226,441742,PFE,China biotech s  coming out party  masks long road ahead,news,By Ben Hirschler and Adam Jourdan LONDON SHANGHAI  Reuters    Investors are betting on China s potential to feed the global pharmaceutical pipeline  putting a multi billion dollar price tag on a handful of stocks  even as the country struggles to close a huge R D gap with the West  Shares in firms such as Chi Med  Beigene and Zai Lab have soared on international markets this year  fueled by hopes for their drugs and recent reforms to China s regulatory system that should speed up approvals   It s almost a coming out party for China biotech   said Christian Hogg  chief executive of Hutchison China MediTech or Chi Med  which presented promising data at a global medical congress this week on a lung cancer drug it discovered in China and is developing with AstraZeneca   China is in vogue because of the positive moves on the regulatory side  as well as advances at companies  It s a big  big change versus 10 years ago and it is accelerating   Importantly  national and provincial authorities are also moving faster to agree payments for innovative drugs  albeit after negotiating price discounts in many cases  Yet amid the euphoria it is easy to lose sight of the fact that China still has far to go  It contributes just 4 percent of global drug innovation   as measured by the number of products in development and recent launches   against 50 percent from the United States  according to an October 2016 report from four Chinese pharmaceutical associations   It is very apparent they are trying to transition to being more of a novel drug development environment and bring in more innovative research   Scott Gottlieb  head of the U S  Food and Drug Administration  FDA   told Reuters    I think it s going to be a long transition     we built up an ecosystem in this country over decades and decades   China s traditional strengths lie in generic drugs and the bulk production of active pharmaceutical ingredients that are found in pills in pharmacies worldwide  The shift in focus to original research is a change in mindset  although it builds on the success of contract research and manufacturing company WuXi Biologics  which does much of the legwork for China s budding biotechs   REFORMING DRUGS WATCHDOG Bi Jingquan  the reformist bureaucrat who has led China s drugs watchdog the CFDA since 2015  views innovative   and affordable   drugs as the key to meeting the country s growing clinical demands  China is now the world s second biggest drugs market after the United States  with more cases of cancer and diabetes than any other nation  fueled by fast food  smoking and pollution  But the CFDA head lamented in a recent speech that Chinese domestic drug industry R D investment was only 42 billion yuan   6 3 billion  last year  a small slice of the  157 billion spent worldwide by drug companies in 2016  according to market intelligence group EvaluatePharma  Redressing the balance is a priority   We want to make our pharma industry big and strong  make our drug companies more competitive  so that we can shift our country s long standing reliance on imported new drugs   said Bi Jingquan s deputy Wu Zhen  A big part of that involves overhauling regulation  with a new system now in place to accelerate full and conditional drug approvals as the CFDA strives to narrow a typical five to seven year lag between how long new drugs reach the market in China compared with Western countries  Plans announced last week mean the agency will now accept data from overseas clinical trials  That was applauded by  Pfizer   NYSE PFE   the top foreign drugmaker in China  highlighting the stiff competition still facing local biotechs  So far many of the new drugs discovered in China are follow on medicines in established therapeutic classes rather than ground breaking first in class treatments  Some global companies like Swiss based Novartis and Roche  with deeper institutional scientific knowledge  are also tapping into China s science base to discover their own promising new drugs in the country  Still  Chinese firms are notching up their first home grown successes  particularly in cancer  with Shenzhen Chipscreen Biosciences winning a CFDA green light for the first modern oncology drug  used to treat a rare lymph node cancer  in 2015   Now Chi Med  working with Eli Lilly  hopes for approval of what would be a broad use bowel cancer medicine  fruquintinib  around the end of this year  On the international stage  Beigene and Chi Med are also racing to be first to bring China discovered cancer drugs to U S  and European patients  often doing deals with global firms that can provide marketing expertise outside China  In July  Beigene signed a deal worth up to  1 4 billion with Celgene  NASDAQ CELG   licensing a promising cancer immunotherapy drug candidate to the U S  group in the largest ever transaction involving a Chinese medicine   LONG CYCLE BUSINESS Beigene CEO John Oyler is convinced Chinese drug discovery is on a roll  backed by powerful interests in Beijing who want to forge a leading position in the sector  just as China has done in energy  finance and telecoms   The day you see a China grown company that is one of the five major global pharmaceutical companies is approaching   he said  though he admitted recent big share price rises were  not commensurate with clinical data being reported   Others pointed to an under developed academic ecosystem in China and the fact most big local drugmakers were deeply rooted in generics  despite outward talk of innovation   It s easy to say I want to do new drug development  but then it s harder to see yourself spending  100 million and then fail   Samantha Du  chief executive of Zai Lab  told Reuters at the company s headquarters in Shanghai  Du was also a co founder and chief scientific officer of Chi Med until 2011  Zai Lab  which listed on the Nasdaq stock exchange in September  has a drug discovery program focused on immuno oncology  though for now its pipeline is dominated by molecules bought in from the likes of GlaxoSmithKline  Sanofi  PA SASY  and Tesaro  Du hopes to change that one day but says it won t happen overnight   It s such a long cycle  if you want to discover and develop drugs from ground zero  that s 12 15 years   she said   It s going to take time  ,2017-10-19,Reuters,https://www.investing.com/news/stock-market-news/china-biotechs-coming-out-party-masks-long-road-ahead-543952,543952
220227,441743,PFE,Glaxo would consider bid for Pfizer s consumer health business  CEO says,news,"GlaxoSmithKline  GSK  5   would consider bidding for  Pfizer   s  PFE  0 5   consumer health business if the PFE puts the unit up for sale  GSK CEO Emma Walmsley says 
PFE said earlier this month that it was exploring a sale or spinoff of the business  which analysts say could fetch more than  10B  GSK s consumer health business is one of the world s largest  with revenue of  7 19B   9 44B  last year 
Walmsley says regardless of any deal to strengthen its consumer health business  GSK s top priority is to sharpen the company s R D operations after trimming dozens of research programs earlier this year to focus on four key disease areas 
The CEO s comments come as GSK reported higher Q3 profits and revenues  driven by growing sales for its prescription drugs and consumer healthcare products 
Now read ",2017-10-25,Seeking Alpha,https://www.investing.com/news/stock-market-news/glaxo-would-consider-bid-for-pfizers-consumer-health-business-ceo-says-547540,547540
220230,441746,PFE,Aerie s Rhopressa Succeeds In Study On Japanese Patients,opinion,"Aerie Pharmaceuticals  Inc    NASDAQ AERI   announced positive top line results from its pilot phase II study of netarsudil ophthalmic solution in a Japanese American population  Netarsudil ophthalmic solution 0 02  is currently marketed by the name Rhopressa in the United States  The study was designed to meet the requirements of Japan s Pharmaceuticals and Medical Devices Agency  PMDA  to support the potential regulatory submission of netarsudil ophthalmic solution in Japan 
The primary objective of the study was to evaluate the ocular hypotensive activity of two different dose concentrations of netarsudil ophthalmic solution  0 02  and 0 04   relative to placebo over a 28 day period  for a total of three arms all dosed  The primary objective also included evaluating the ocular and systemic safety of netarsudil ophthalmic solution relative to placebo over the 28 day period   
In the study  both netarsudil arms  0 02  and 0 04   showed higher levels of intraocular pressure  IOP  reduction as compared to placebo to a statistically significant degree at Day 28  The safety findings were consistent with previous netarsudil studies 
This pilot study was initially designed as a larger phase II trial to be conducted in the United States  enrolling Japanese subjects and Japanese American subjects that are within second generation  However  due to lesser number of qualified subjects in the United States  the enrollment of this study was limited to approximately 40 subjects across three study arms 
Aerie expects to initiate a phase II study in Japan in the first quarter of 2019  as agreed with the PMDA  with the addition of a 0 01  concentration of netarsudil 
Shares of the company decreased 34 9  compared with the  s decline of 18 2  

Glaucoma is one of the largest segments in the global ophthalmic market  The Japanese glaucoma market  valued at approximately  1 billion annually  is one of the largest in the world 
Aerie is also evaluating Rocklatan  a once daily  quadruple action fixed dose combination of Rhopressa and Pfizer s   NYSE PFE   Xalatan  latanoprost   Rocklatan is a once daily eye drop designed to reduce intraocular pressure  IOP  in patients with glaucoma or ocular hypertension  Aerie s New Drug Application  NDA  for Rocklatan 0 02  0 005  was submitted to the FDA in May 2018  The action date for the completion of the FDA s review of the NDA is set for Mar 14  2019 
Along with the release  the company also announced the opening of its Japan branch office in Tokyo  and the addition of two well respected industry leaders to its Tokyo team Aerie Pharmaceuticals  Inc  Price

    
Zacks Rank   Stocks to Consider
Aerie currently carries a Zacks Rank  3  Hold  
Some better ranked stocks worth considering are Myriad Genetics  Inc    NASDAQ MYGN   and Editas Medicine  Inc    NASDAQ EDIT    While Myriad sports a Zacks Rank  1  Strong Buy   Editas carries a Zacks Rank  2  Buy   You can see  
Myriad s earnings per share estimates have increased from  1 77 to  1 78 for 2019 over the past 60 days  The company delivered a positive earnings surprise in all the trailing four quarters  with average of 25 62  
Editas  loss per share estimates have narrowed from  2 70 to  2 18 for 2018 and from  3 19 to  2 84 for 2019 in the past 60 days The company delivered a positive earnings surprise in two of the trailing four quarters  with average of 10 85  
3 Medical Stocks to Buy Now 
The greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline 
So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ",2019-01-07,Zacks Investment Research,https://www.investing.com/analysis/aeries-rhopressa-succeeds-in-study-on-japanese-patients-200373435,200373435
220231,441747,PFE,IBEX Drops on Fresh Political Concerns  Other European Markets Mixed,news,"Investing com   Spain s benchmark index moved lower on Monday  amid fresh concerns over the country s political turmoil  while the other European markets were mixed 
The EURO STOXX 50 eased 0 08   France s CAC 40 inched up 0 07   while Germany s DAX 30 added 0 17  and Spain s IBEX 35 was down 0 67  by 03 40 a m  ET  07 40 GMT  
Markets were jittery after Catalan President Carles Puigdemont failed to clarify whether he has declared the region s independence  in a letter to Madrid 
Spain had issued a Monday deadline for Puigdemont to clarify his intent  or face direct rule  Instead  the Catalan leader called for negotiation over the next two months 
Financial stocks were broadly lower  as French lenders Societe Generale  PA SOGN  and BNP Paribas  PA BNPP  declined 0 41  and 0 21   while Germany s Deutsche Bank  DE DBKGn  slid 0 33  
Among peripheral lenders  Italy s Intesa Sanpaolo  MI ISP  and Unicredit  MI CRDI  dropped 0 52  and 0 47  respectively  while Spanish banks Banco Santander  MC SAN  and BBVA  MC BBVA  tumbled 0 93  and 1 30  
Airbus Group  PA AIR  added to losses  with shares down 0 45  after the company s Chief Executive Officer Tom Enders said he saw no reason to resign over ongoing UK and French corruption investigations  but would be ready to do so if needed 
On the upside  Bayer  DE BAYGN  advanced 0 72  after the German drug and agrochemicals group on Friday announced the sale of selected crop science businesses to BASF for  7 billion as part of its strategy to complete acquisition of US biotech major Monsanto  NYSE MON  
In London  commodity heavy FTSE 100 inched up 0 07   supported by sharp gains in the mining sector 
Shares in BHP Billiton  LON BLT  and Anglo American  LON AAL  jumped 2 15  and 2 18  respectively  while Rio Tinto  LON RIO  rallied 2 28  and Antofagasta  LON ANTO  surged 3 05  
Meanwhile  financial stocks were mostly lower  Shares in Lloyds Banking  LON LLOY  fell 0 27  and Barclays  LON BARC  slid 0 71   while the Royal Bank of Scotland  LON RBS  retreated 0 78   HSBC Holdings  LON HSBA  overperformed however  with shares gaining 0 39  
GKN  LON GKN  was also on the downside  as shares tumbled 1 51  after the engineering group warned that its full year profits will only be  slightly above  last year s levels  due to difficulties in its U S  aerospace unit and costly legal claims 
Shares in Reckitt Benckiser Group PLC  LON RB  declined 1 25  following reports the drugmaker will be exploring a number of financing options  including a multibillion pound rights issue  when it enters the race for a division put up for sale by the U S  rival Pfizer  NYSE PFE  
In the U S   equity markets pointed to a steady to higher open  The Dow Jones Industrial Average futures pointed to a 0 05  gain  S P 500 futures signaled a 0 01  uptick  while the Nasdaq 100 futures indicated a 0 11  rise ",2017-10-16,Investing.com,https://www.investing.com/news/stock-market-news/ibex-drops-on-fresh-political-concerns-other-european-mixed-541834,541834
220240,441756,PFE,Conatus  CNAT  Focuses On Developing NASH Candidate Emricasan,opinion,"On Dec 27  we issued an updated research report on Conatus Pharmaceuticals Inc    NASDAQ CNAT    This San Diego based company has no approved product in its portfolio at the moment and focuses on developing its lead pipeline candidate  emricasan 
Emricasan  a caspase inhibitor  is being developed for the treatment of patients with fibrosis or cirrhosis caused by nonalcoholic steatohepatitis  NASH   Conatus acquired the worldwide rights to emricasan from Pfizer   NYSE PFE   in July 2010  It has an exclusive option  collaboration and license agreement with Novartis   NYSE NVS   for the worldwide development and commercialization of emricasan 
Conatus is conducting three ongoing phase IIb ENCORE studies on emricasan for treating fibrosis or cirrhosis induced by NASH  The programs are  namely ENCORE NF  for NASH fibrosis   ENCORE PH  for portal hypertension  and ENCORE LF  for liver function  
Earlier this month  Conatus announced top line results from phase IIb ENCORE PH study  which evaluated emricasan in patients with compensated or early decompensated NASH cirrhosis and severe portal hypertension  The study examined the capacity of emricasan to reduce hepatic venous pressure gradient  HVPG  in NASH cirrhosis patients  Although emricasan demonstrated clinically meaningful treatment effects in compensated NASH cirrhosis patients  who stand at a risk of passing to the decompensation state  it failed to meet the primary endpoint 
The ENCORE NF assessment is investigating emricasan for potential improvements in fibrosis and steatohepatitis pertaining to patients with fibrosis caused by NASH  Top line data from the study is expected in the first half of 2019 
The ENCORE LF study is inspecting emricasan in patients with decompensated NASH cirrhosis  Notably  top line results from the study will be presented in mid 2019  much earlier than the previously estimated timeline of the second half of 2019 
Notably  the NASH market holds untapped prospects  People afflicted with diabetes  high cholesterol or high triglycerides are often diagnosed with the disease  which is feared to become the fastest growing cause for liver transplant and liver cancer  With no treatments currently available for this indication  the market opportunity for emricasan seems significant  By 2025  the worldwide market for NASH treatments is estimated to reach a value of  35 billion 
Given such an upbeat scenario  we believe that emricasan has the power to capture a large market share on approval 
Apart from emricasan  another candidate in Conatus  portfolio is IDN 7314  which is currently being evaluated in a phase II study for the treatment of primary sclerosing cholangitis  PSC   a chronic liver disease  Notably  the candidate enjoys an Orphan Drug Designation  ODD  for the indication in both the United States and across the EU 
So far this year  shares of Conatus have plummeted 72 1   significantly wider than the  decrease of 7 4  

 
Zacks Rank   Other Key Pick
Conatus currently carries a Zacks Rank  2  Buy   Another top ranked stock in the same sector is Bovie Medical Corp    NYSE BVX    sporting a Zacks Rank  1  Strong Buy   You can see  
Bovie Medical s loss per share estimates has been narrowed 21 1  for 2018 and 13 5  for 2019 in the last 60 days  The stock has skyrocketed 134 3  year to date 
Will You Make a Fortune on the Shift to Electric Cars 
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2018-12-28,Zacks Investment Research,https://www.investing.com/analysis/conatus-cnat-focuses-on-developing-nash-candidate-emricasan-200371702,200371702
220243,441759,PFE,FDA OKs Glaxo s inhaled triplet therapy for COPD,news,"The FDA approves GlaxoSmithKline s  NYSE GSK  Trelegy Ellipta  fluticasone furoate umeclidinium vilanterol  FF UMEC VI    a once daily  single inhaler triplet therapy for the long term maintenance treatment of patients with chronic obstructive pulmonary disease  COPD   including chronic bronchitis and or emphysema  Market launch will commence shortly 
Glaxo developed the product with collaboration partner Innoviva  NASDAQ INVA   Approval in Europe should happen in Q4 
Now read ",2017-09-19,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-oks-glaxos-inhaled-triplet-therapy-for-copd-530412,530412
220251,441767,PFE,Should You Invest In The VanEck Vectors Pharmaceutical ETF  PPH  ,opinion,"The VanEck Vectors Pharmaceutical ETF  PPH  was launched on 12 20 2011  and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare   Pharma segment of the equity market 
Retail and institutional investors increasingly turn to passively managed ETFs because they offer low costs  transparency  flexibility  and tax efficiency  these kind of funds are also excellent vehicles for long term investors 
Investor friendly  sector ETFs provide many options to gain low risk and diversified exposure to a broad group of companies in particular sectors  Healthcare   Pharma is one of the 16 broad Zacks sectors within the Zacks Industry classification  It is currently ranked 2  placing it in top 13  
Index Details
The fund is sponsored by Van Eck  It has amassed assets over  263 22 M  making it one of the average sized ETFs attempting to match the performance of the Healthcare   Pharma segment of the equity market  PPH seeks to match the performance of the MVIS US Listed Pharmaceutical 25 Index before fees and expenses 
The MVIS US Listed Pharmaceutical 25 Index tracks the overall performance of companies involved in pharmaceuticals  including pharmaceutical research and development as well a production  marketing and sales of pharmaceuticals 
Costs
Since cheaper funds tend to produce better results than more expensive funds  assuming all other factors remain equal  it is important for investors to pay attention to an ETF s expense ratio 
Annual operating expenses for this ETF are 0 35   making it one of the cheaper products in the space 
It has a 12 month trailing dividend yield of 1 71  
Sector Exposure and Top Holdings
Even though ETFs offer diversified exposure which minimizes single stock risk  it is still important to look into a fund s holdings before investing  Luckily  most ETFs are very transparent products that disclose their holdings on a daily basis 
Looking at individual holdings  Merck   Co Inc  MRK  accounts for about 5 82  of total assets  followed by Pfizer Inc  PFE  and Novartis Ag  NVS  
The top 10 holdings account for about 52 65  of total assets under management 
Performance and Risk
The ETF return is roughly 2 58  and was up about 3 06  so far this year and in the past one year  as of 12 14 2018   respectively  PPH has traded between  54 84 and  64 61 during this last 52 week period 
The ETF has a beta of 0 90 and standard deviation of 14 85  for the trailing three year period  making it a medium risk choice in the space  With about 26 holdings  it has more concentrated exposure than peers 
Alternatives
VanEck Vectors Pharmaceutical ETF holds a Zacks ETF Rank of 2  Buy   which is based on expected asset class return  expense ratio  and momentum  among other factors  Because of this  PPH is an outstanding option for investors seeking exposure to the Health Care ETFs segment of the market  There are other additional ETFs in the space that investors could consider as well 
IShares U S  Pharmaceuticals ETF  IHE  tracks Dow Jones U S  Select Pharmaceuticals Index and the Invesco Dynamic Pharmaceuticals ETF  PJP  tracks Dynamic Pharmaceutical Intellidex Index  IShares U S  Pharmaceuticals ETF has  406 46 M in assets  Invesco Dynamic Pharmaceuticals ETF has  511 33 M  IHE has an expense ratio of 0 43  and PJP charges 0 57  
Bottom Line
To learn more about this product and other ETFs  screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe  please visit Zacks ETF Center ",2018-12-13,Zacks Investment Research,https://www.investing.com/analysis/should-you-invest-in-the-vaneck-vectors-pharmaceutical-etf-pph-200368219,200368219
220252,441768,PFE,Pfizer  PFE  Stock Moves  1 58   What You Should Know,opinion,"Pfizer  PFE  closed at  43 11 in the latest trading session  marking a  1 58  move from the prior day  This change was narrower than the S P 500 s daily loss of 2 08   Meanwhile  the Dow lost 2 11   and the Nasdaq  a tech heavy index  lost 2 27  
Heading into today  shares of the drugmaker had gained 1 37  over the past month  outpacing the Medical sector s loss of 1 48  and the S P 500 s loss of 3 6  in that time 
PFE will be looking to display strength as it nears its next earnings release  which is expected to be January 29  2019  On that day  PFE is projected to report earnings of  0 64 per share  which would represent year over year growth of 3 23   Meanwhile  the Zacks Consensus Estimate for revenue is projecting net sales of  13 73 billion  up 0 18  from the year ago period 
For the full year  our Zacks Consensus Estimates are projecting earnings of  3 per share and revenue of  53 40 billion  which would represent changes of  13 21  and  1 62   respectively  from the prior year 
It is also important to note the recent changes to analyst estimates for PFE  These recent revisions tend to reflect the evolving nature of short term business trends  As such  positive estimate revisions reflect analyst optimism about the company s business and profitability 
Our research shows that these estimate changes are directly correlated with near term stock prices  We developed the Zacks Rank to capitalize on this phenomenon  Our system takes these estimate changes into account and delivers a clear  actionable rating model 
The Zacks Rank system ranges from  1  Strong Buy  to  5  Strong Sell   It has a remarkable  outside audited track record of success  with  1 stocks delivering an average annual return of  25  since 1988  Within the past 30 days  our consensus EPS projection remained stagnant  PFE is holding a Zacks Rank of  3  Hold  right now 
Valuation is also important  so investors should note that PFE has a Forward P E ratio of 14 61 right now  This represents a premium compared to its industry s average Forward P E of 14 42 
Also  we should mention that PFE has a PEG ratio of 2 18  The PEG ratio is similar to the widely used P E ratio  but this metric also takes the company s expected earnings growth rate into account  The Large Cap Pharmaceuticals was holding an average PEG ratio of 2 04 at yesterday s closing price 
The Large Cap Pharmaceuticals industry is part of the Medical sector  This group has a Zacks Industry Rank of 62  putting it in the top 24  of all 250  industries 
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
To follow PFE in the coming trading sessions  be sure to utilize Zacks com ",2018-12-17,Zacks Investment Research,https://www.investing.com/analysis/pfizer-pfe-stock-moves-158-what-you-should-know-200368898,200368898
220253,441769,PFE,A biotech CEO who sold his last company for  14 billion explains why he wants to do things differently this time,news,"David Hung wants to do things differently at his new company 
Hung s the CEO of Axovant  a company that has a shot to launch the first new Alzheimer s drug in 15 years  Before joining the company in April  Hung founded Medivation  a cancer drugmaker based San Francisco that  Pfizer   NYSE PFE  bought for  14 billion in August 2016 
But selling Medivation wasn t initially part of the plan  And now he s trying to make sure it doesn t happen again 
 We never looked to get acquired   Hung said   We were on a great trajectory  we had created a drug that was the biggest selling prostate cancer drug in the world  we d crossed  2 billion in revenue  
The company was growing  and its pipeline looked solid as well   Our intention was to be a fully integrated large pharmaceutical company   Hung said 
In the end  that didn t happen 
Because Medivation was publicly traded  it was hard to turn down a  14 billion offer from Pfizer  a  over its stock price at the time  But now he thinks he can grow an even bigger company 
That s in part because Medivation shared the sales of its leading prostate cancer drug  Xtandi  with Astellas  That s not the case with Axovant  which entirely owns intepirdine  the drug Axovant s developing to treat Alzheimer s 
 Medivation was  14 3 billion  but we had less than half of Xtandi   Hung said   Had we owned all of Xtandi  Medivation should have been a  30 billion company  
Axovant  incorporated in Switzerland  also benefits from a lower tax rate than Medivation  which was incorporated in the US  The combination of owning all of intepirdine  the tax rate  and the number of patients who could potentially benefit from the drug has Hung convinced that if the trial is positive  Axovant could become even bigger than Medivation was  Axovant s current market cap is  2 5 billion 
 We think that we have the chance to make a really substantial company and with that we ll have the opportunity to impact many areas of neurology and perhaps even beyond neurology   Hung said ",2017-09-11,Business Insider,https://www.investing.com/news/stock-market-news/a-biotech-ceo-who-sold-his-last-company-for-14-billion-explains-why-he-wants-to-do-things-differently-this-time-527392,527392
220259,441775,PFE,Pfizer  PFE  Up 4 3  Since Last Earnings Report  Can It Continue ,opinion,"It has been about a month since the last earnings report for Pfizer  PFE   Shares have added about 4 3  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Pfizer due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers  Pfizer Beats on Q3 Earnings  Narrows ViewPfizer reported third quarter 2018 adjusted earnings per share of 78 cents  which beat the Zacks Consensus Estimate of 76 cents  Earnings rose 16  year over year driven by a lower tax rate and share count due to share buybacks in the quarter  Higher other income and currency tailwinds also contributed to bottom line growth The company recorded revenues of  13 3 billion  which slightly missed the Zacks Consensus Estimate  Revenues rose 1  from the year ago quarter on a reported basis  Currency fluctuation hurt sales by 1  in the quarter due to a strong dollar and weakening of certain emerging markets currencies and euro  On an operational basis  excluding the impact of currency  revenues rose 2  year over year Higher sales of key brands  Ibrance  Eliquis and Prevnar  were partially offset by loss of exclusivity for some products  lower sales of legacy Established Products in developed markets and continued supply shortages in legacy Hospira products International revenues rose 5   up 6  an operational basis  to  6 94 billion  U S  revenues declined 3  to  6 36 billion Revenues from the Consumer Healthcare segment  which Pfizer is considering selling  rose 2  to  839 million  Global Oncology revenues increased 11  to  1 78 billion  Global Vaccine revenues rose 13  to  1 85 billion  Internal Medicine rose 1  to  2 46 billion  The Inflammation   Immunology franchise rose 4  to  1 02 billion  However  the portfolio of Rare Disease declined 5  to  531 million Segment DiscussionPfizer s reporting segments are Pfizer Innovative Health  IH  and Pfizer Essential Health  EH  Pfizer IH sales grew 4  on a reported basis  up 5  an operational basis  from the year ago period to  8 47 billion as higher sales of Eliquis and Xeljanz globally  Ibrance in international markets and Prevnar 13 and Xtandi in the United States offset lower sales of Enbrel With Viagra losing exclusivity in December 2017  its U S  and Canada sales are now reported in the EH segment against IH previously  This hurt sales of the IH segment while adding to EH segment sales Ibrance revenues rose 18  year over year to  1 03 billion as higher international sales offset a decline in the United States  Ibrance sales outside the United States rose 98  driven by continued uptake in developed Europe and launch in Japan  In the United States  Ibrance sales declined 1  due to rising competition and increased rebates In the CDK inhibitors category  Ibrance holds 90  share in terms of new prescription volume despite rising competition  Xeljanz sales rose 26  to  432 million driven by continued growth in rheumatoid arthritis revenues and some early contributions from the drug s recent expansion into psoriatic arthritis and ulcerative colitis  Eliquis alliance revenues and direct sales rose 36  to  870 million  Chantix sales rose 9  to  261 million in the quarter  However  Lyrica sales declined 2  to  1 13 billion Xtandi recorded alliance revenues of  180 million in the quarter  up 20  year over year  In July  Xtandi s U S  label was expanded to include men with non metastatic castration resistant prostate cancer  Xtandi was approved for the same indication in the EU in October  This label expansion can drive growth in 2019 Global Prevnar 13 Prevenar 13 revenues rose 10  to  1 66 billion  Prevnar 13 revenues rose 12  in the United States due to higher government purchases than last year for the pediatric indication  Prevenar 13 revenues rose 6  in international markets driven by higher volumes for the pediatric indication due to increased orders from the Gavi Alliance and launch in China Enbrel revenues declined 11  to  531 million in key European markets due to continued biosimilar competition Pfizer EH segment sales declined 4   both on a reported and operational basis  to  4 83 billion EH revenues were hurt by the loss of exclusivity and associated generic competition for products  primarily Pristiq and Viagra in the United States and Lyrica in Europe and lower revenues from sterile injectables portfolio due to continued legacy Hospira product shortages in the United States  Pfizer is facing supply shortages for sterile injectable products  SIP  from the legacy Hospira portfolio mainly due to capacity constraints and technical issues  On the call  the company said it expects these issues to be resolved by end of 2019 Also  lower sales of legacy Established Products in developed markets driven by industry wide pricing challenges hurt EH segment sales Total Viagra sales declined 55  to  137 million due to generic competition that began in December 2017 However  in the EH business  biosimilars and emerging markets did well in the quarter  Biosimilars revenues rose 40  operationally while emerging markets revenues grew 11  operationally While Inflectra recorded sales of  71 million in the United States and  166 million globally  other biosimilars brought in sales of  31 million  up 6   Other DetailsAdjusted selling  informational and administrative  SI A  expenses were flat  operationally  in the quarter at  3 47 billion  Adjusted R D expenses rose 8  to  2 0 billion In the quarter 2018  Pfizer bought back shares worth  1 1 billion  As of Oct 30  2018  Pfizer s remaining share repurchase authorization was  7 4 billion 2018 GuidancePfizer narrowed its earnings as well as sales expectations for the full year Revenues are expected in the range of  53 0 billion to  53 7 billion compared with of  53 0 billion to  55 0 billion previously Pfizer attributed the lowered sales outlook to weaker than expected revenues in the EH segment  due to continued shortages in the sterile injections business  and currency headwinds The guidance assumes no generic competition for Lyrica in the United States until June 2019 Adjusted earnings per share are expected in the range of  2 98  3 02 compared with of  2 95  3 05 billion expected previously  At the mid point  adjusted EPS is still expected to increase 13  Research and development expenses guidance was maintained in the range of  7 7  8 1 billion while SI A spending is projected in the range of  14 0  14 5 billion versus  14 0  15 0 billion expected previously Adjusted tax rate is still expected to be approximately 16  in 2018 In 2018  Pfizer expects to buy back shares worth  12 billion with  9 0 billion of share repurchases already completed year to date  
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates 
VGM Scores
At this time  Pfizer has a subpar Growth Score of D  a grade with the same score on the momentum front  Charting a somewhat similar path  the stock was allocated a grade of C on the value side  putting it in the middle 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of D  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of these revisions indicates a downward shift  Notably  Pfizer has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-11-28,Zacks Investment Research,https://www.investing.com/analysis/pfizer-pfe-up-43-since-last-earnings-report-can-it-continue-200363574,200363574
220260,441776,PFE,QIAGEN s New Offerings To Broaden Hematology Testing Suite,opinion,QIAGEN N V    NYSE QGEN   recently announced the launch of two products for providing valuable insights on several types of blood cancer  The company will be showcasing the launches at the American Society of Hematology 2018 Annual Meeting and Exposition in San Diego The company s latest offering  QIAact Myeloid DNA UMI Panel for the GeneReader NGS System  aims at delivering an integrated Sample to Insight workflow targeting the genes and variants of most relevance to onco hematology research  Furthermore  the QIAact Myeloidpanel covers 25 highly relevant genes along with their variants Notably  the panel will be made available for research in December 2018 QIAGEN has also launched a web based clinical decision support platform for the QIAGEN Clinical Insight  QCI  Interpret bioinformatics solution for hematological malignancies  including leukemia  Non Hodgkin lymphoma  Hodgkin lymphoma and multiple myeloma Progress With Test Menu ExpansionQIAGEN is progressing well with its testing menu expansion strategy  It recently launched its next generation multiplex gastrointestinal panel   QIAstat Dx   in Europe  The QIAstat Dx system along with the gastrointestinal and respiratory panels was recently registered and launched in Australia  QIAGEN expects to receive FDA approval for QIAstat Dx and both the panels in 2019 The company also plans to launch a CE In Vitro Diagnostics  IVD  marked QIAstat Dx multiplex test for meningitis in 2019  Moreover  a wide range of assays for syndromic testing in oncology and other therapeutic areas are currently in the pipeline The company also announced the clearance of PMA Supplement for broadening the use of therascreen EGFR RGQ PCR Kit as a companion diagnostic with Pfizer Inc  NYSE PFE   s VIZIMPRO  dacomitinib  by the FDA QIAGEN also announced a new development under its long standing partnership with IVD player DiaSorin S p A  This time  the alliance is set to offer a fully automated CE Marked testing for latent tuberculosis  TB  infection with QuantiFERON TB Gold Plus Blood Collection Tubes  QFT Plus BCT  on DiaSorin LIAISON platforms Share Price PerformanceQIAGEN has been gaining investor confidence on consistently encouraging results  Over the past year  the company s share price has outperformed its   The stock has gained 10 7  against the industry s 14 7  fall  Zacks Rank   Key PicksQIAGEN currently carries a Zacks Rank  3  Hold  Some better ranked stocks in the broader medical space are Integer Holdings Corporation   NYSE ITGR    Surmodics  Inc    NASDAQ SRDX   and Veeva Systems   NYSE VEEV   Integer Holdings has an earnings growth rate of 31 2  for the next quarter and a Zacks Rank  2  Buy   You can see  Surmodics  long term earnings growth rate is projected at 10   The stock carries a Zacks Rank of 2 Veeva Systems  long term earnings growth rate is estimated at 19 3   The stock carries a Zacks Rank  2 3 Medical Stocks to Buy NowThe greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ,2018-11-29,Zacks Investment Research,https://www.investing.com/analysis/qiagens-new-offerings-to-broaden-hematology-testing-suite-200363953,200363953
220261,441777,PFE,Pfizer  PFE  Stock Moves  1 78   What You Should Know,opinion,"Pfizer  PFE  closed at  45 17 in the latest trading session  marking a  1 78  move from the prior day  This move was narrower than the S P 500 s daily loss of 3 24   Meanwhile  the Dow lost 3 1   and the Nasdaq  a tech heavy index  lost 3 8  
Coming into today  shares of the drugmaker had gained 7 13  in the past month  In that same time  the Medical sector gained 4 97   while the S P 500 gained 2 73  
Wall Street will be looking for positivity from PFE as it approaches its next earnings report date  This is expected to be January 29  2019  The company is expected to report EPS of  0 64  up 3 23  from the prior year quarter  Meanwhile  the Zacks Consensus Estimate for revenue is projecting net sales of  13 73 billion  up 0 18  from the year ago period 
For the full year  our Zacks Consensus Estimates are projecting earnings of  3 per share and revenue of  53 40 billion  which would represent changes of  13 21  and  1 62   respectively  from the prior year 
Investors might also notice recent changes to analyst estimates for PFE  These revisions typically reflect the latest short term business trends  which can change frequently  As a result  we can interpret positive estimate revisions as a good sign for the company s business outlook 
Research indicates that these estimate revisions are directly correlated with near term share price momentum  We developed the Zacks Rank to capitalize on this phenomenon  Our system takes these estimate changes into account and delivers a clear  actionable rating model 
Ranging from  1  Strong Buy  to  5  Strong Sell   the Zacks Rank system has a proven  outside audited track record of outperformance  with  1 stocks returning an average of  25  annually since 1988  Within the past 30 days  our consensus EPS projection remained stagnant  PFE is currently a Zacks Rank  3  Hold  
Digging into valuation  PFE currently has a Forward P E ratio of 15 34  Its industry sports an average Forward P E of 14 88  so we one might conclude that PFE is trading at a premium comparatively 
Meanwhile  PFE s PEG ratio is currently 2 29  This metric is used similarly to the famous P E ratio  but the PEG ratio also takes into account the stock s expected earnings growth rate  The Large Cap Pharmaceuticals was holding an average PEG ratio of 2 03 at yesterday s closing price 
The Large Cap Pharmaceuticals industry is part of the Medical sector  This industry currently has a Zacks Industry Rank of 104  which puts it in the top 40  of all 250  industries 
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Be sure to follow all of these stock moving metrics  and many more  on Zacks com ",2018-12-04,Zacks Investment Research,https://www.investing.com/analysis/pfizer-pfe-stock-moves-178-what-you-should-know-200365066,200365066
220262,441778,PFE,Pfizer nabs patent in India covering pneumonia vaccine Prevenar 13,news,Patient advocate and aid groups are unhappy with India s patent office after it issued a patent to  Pfizer   PFE  1   covering Prevenar 13  a pneumonia vaccine  The groups contend that the patent will put the vaccine   170 for a full course  out of reach for many people in poor countries  The action will enable the company to exclusively sell Prevenar 13 in county until 2026  It launched it there in 2010 Many emerging nations rely on Indian drug firms to supply inexpensive versions of medicines and vaccines  One Indian company  Panacea Biotec Ltd   is developing a cheaper version of Prevenar 13  It is mulling a formal opposition to the patent issuance Pfizer s patent on the vaccine was revoked in Europe last year and is being challenged in the U S  and South Korea The company has supplied Prevenar 13 at discounted prices under the Global Alliance for Vaccines and Immunisation  GAVI   an international public private partnership aimed at improving access to vaccines in the world s poorest countries Bowing to criticism over Prevenar 13 s cost  Pfizer reduced the price to non government institutions last November Now read ,2017-08-22,Seeking Alpha,https://www.investing.com/news/stock-market-news/pfizer-nabs-patent-in-india-covering-pneumonia-vaccine-prevenar-13-521133,521133
220263,441779,PFE,Pfizer s marketing applications for expanded use of blood cancer med Bosulif accepted for review in U S  and Europe,news,The FDA and European Medicines Agency have accepted for review  Pfizer  s  NYSE PFE  marketing applications seeking approval to use BOSULIF  bosutinib  to treat patients with newly diagnosed chronic phase Philadelphia chromosome positive  Ph   chronic myeloid leukemia  CML  The indication has Priority Review status in the U S  which shortens the review clock to six months  although Pfizer says the FDA s action date  PDUFA  is in December  It is currently approved in the U S  for adult patients with Ph  CML who have not responded to prior therapy  In Europe  it is approved for Ph  CML patients who have received prior treatment with one or more tyrosine kinase inhibitors and for whom imatinib  nilotinib and dasatinib are considered inappropriate treatment options Privately held Avillion LLP conducted the study supporting the filing under a 2014 agreement with the company  If approved  it will be eligible to receive milestone payments from Pfizer  the owner of global commercialization rights PFE is down 1  premarket on light volume Now read ,2017-08-29,Seeking Alpha,https://www.investing.com/news/stock-market-news/pfizers-marketing-applications-for-expanded-use-of-blood-cancer-med-bosulif-accepted-for-review-in-us-and-europe-523417,523417
220264,441780,PFE,FDA approves Pfizer s leukemia drug,news," Reuters    The U S  Food and Drug Administration  FDA  on Friday approved  Pfizer   NYSE PFE  Inc s drug  Mylotarg  for certain patients with acute myeloid leukemia  AML   The drug was cleared to treat adults with newly diagnosed AML whose tumors express the CD33 antigen  as well as patients aged 2 years and older with CD33 positive AML who have relapsed  or did respond to initial treatment  The FDA said the drug has a boxed warning as it may cause severe or fatal liver damage  including blockage of veins in the liver     Mylotarg got accelerated approval in 2000 as a standalone treatment for adult patients with CD33 positive AML who had experienced a relapse  but was voluntarily withdrawn as subsequent confirmatory studies failed to show clinical benefit and had safety concerns  including a high number of deaths  Friday s approval includes a lower recommended dose  a different dosing schedule and a new patient population  the FDA said  Mylotarg is thought to work by taking the anti tumor agent to the AML cells that express the CD33 antigen  blocking the growth of cancerous cells and causing cell death  AML is a cancer that originates in the bone marrow and progresses rapidly  resulting in an abnormal increase in white blood cells   
About 21 380 people will be diagnosed with AML this year and of that 10 590 patients will succumb to the disease  according to estimates from the National Cancer Institute ",2017-09-01,Reuters,https://www.investing.com/news/stock-market-news/fda-approves-pfizers-leukemia-drug-524822,524822
220274,441790,PFE,Spark Therapeutics  Luxturna Gets EU Approval For Vision Loss,opinion,"Spark Therapeutics  Inc    NASDAQ ONCE   announced that the European Commission   EC   has approved the marketing authorization application   MAA   for its gene therapy  Luxturna  voretigene neparvovec   The MAA sought approval for the therapy in adult as well as pediatric patients as a one time treatment for vision loss due to inherited retinal dystrophy caused by a genetic mutation in both copies of the RPE65 gene and who have enough viable retinal cells  The RPE65 mutations  a progressive disease  can lead to total blindness 
The EC decision was based on positive CHMP opinion  Data from a phase I clinical trial  its follow up trial  and the first randomized  controlled phase III gene therapy trial for an inherited disease supported the decision  Data from the phase III trial showed that vision improvement was recorded as early as 30 days following the treatment 
Please note that Spark Therapeutics has a licensing and commercialization agreement with Novartis Pharma   NYSE NVS    which granted the latter rights to develop and commercialize Luxturna outside the United States  Thus  Novartis will be responsible for launch and distribution of the gene therapy in Europe  Spark Therapeutics will manufacture and supply Luxturna to Novartis under a supply agreement 
Under the terms of the agreement  Spark Therapeutics received an upfront payment of  105 million and is eligible to receive additional  65 million in milestone payments from Novartis  However  the majority of the total  170 million in upfront and anticipated milestone payment will be considered as revenues as and when Luxtarna is supplied to Novartis  Novartis will also pay royalties on ex U S  net sales of Luxturna 
Adoption of Luxtarna in Europe remains to be seen along with its impact on Spark Therapeutics  revenues 
We remind investors that Luxturna was approved in December last year for a similar indication in the United States 
Spark Therapeutics  shares were up 1 5  on Nov 23  following the news  However  shares of the company have declined 47 7  in the past six months compared with the  s decrease of 11 1  

On its third quarter earnings call  the company stated that Luxturna has done well since its launch in the United States with sales growing every quarter  The gene therapy is covered under all the major national payers  making it more accessible  Spark Therapeutics also has its own contracting model  Spark PATH  under which a patient can purchase directly or pay in installments based on the therapy s outcome 
In the third quarter  the company recorded  8 9 million in sales of Luxturna  which was almost 32  higher than sales of  6 7 million achieved in the first six months of 2018  However  the company is concerned with timely identification of patients with RPE65 mutation  The company plans to shift its focus to support faster identification of patients in 2019 
The company also has a global collaboration agreement with Pfizer   NYSE PFE   under which it is developing a gene therapy for the treatment hemophilia B  Per the terms of the agreement  Spark Therapeutics transitioned a gene therapy candidate to Pfizer for late stage development  In July 2018  Pfizer initiated a phase III study to evaluate fidanacogene elaparvovec  Apart from this  Spark Therapeutics is also developing two gene therapies in early stage studies for treating choroideremia  a progressive vision loss disorder and hemophilia A Spark Therapeutics  Inc  Price
 

    
Zacks Rank   Stock to Consider
Spark Therapeutics currently carries a Zacks Rank  3  Hold  
Exelixis  Inc    NASDAQ EXEL   is a better ranked stock in the pharma sector carrying a Zacks Rank  2  Buy   You can see  
Exelixis  earnings estimates have moved up from  1 03 to  1 30 for 2018 and from  1 09 to  1 25 for 2019 over the past 30 days  The company delivered positive earnings surprise in all the trailing four quarters with the average beat being 83 43  
Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana 
Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-11-26,Zacks Investment Research,https://www.investing.com/analysis/spark-therapeutics-luxturna-gets-eu-approval-for-vision-loss-200362476,200362476
220275,441791,PFE,Pfizer  PFE  Gains But Lags Market  What You Should Know,opinion,"Pfizer  PFE  closed the most recent trading day at  44 90  moving  1 88  from the previous trading session  The stock lagged the S P 500 s daily gain of 2 3   Meanwhile  the Dow gained 2 5   and the Nasdaq  a tech heavy index  added 2 95  
Coming into today  shares of the drugmaker had gained 2 75  in the past month  In that same time  the Medical sector gained 3 55   while the S P 500 gained 1 21  
Investors will be hoping for strength from PFE as it approaches its next earnings release  which is expected to be January 29  2019  In that report  analysts expect PFE to post earnings of  0 64 per share  This would mark year over year growth of 3 23   Our most recent consensus estimate is calling for quarterly revenue of  13 73 billion  up 0 18  from the year ago period 
For the full year  our Zacks Consensus Estimates are projecting earnings of  3 per share and revenue of  53 40 billion  which would represent changes of  13 21  and  1 62   respectively  from the prior year 
It is also important to note the recent changes to analyst estimates for PFE  These recent revisions tend to reflect the evolving nature of short term business trends  As a result  we can interpret positive estimate revisions as a good sign for the company s business outlook 
Our research shows that these estimate changes are directly correlated with near term stock prices  Investors can capitalize on this by using the Zacks Rank  This model considers these estimate changes and provides a simple  actionable rating system 
The Zacks Rank system  which ranges from  1  Strong Buy  to  5  Strong Sell   has an impressive outside audited track record of outperformance  with  1 stocks generating an average annual return of  25  since 1988  Over the past month  the Zacks Consensus EPS estimate has moved 0 43  higher  PFE is currently a Zacks Rank  3  Hold  
Digging into valuation  PFE currently has a Forward P E ratio of 14 7  Its industry sports an average Forward P E of 14 58  so we one might conclude that PFE is trading at a premium comparatively 
Meanwhile  PFE s PEG ratio is currently 2 2  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  PFE s industry had an average PEG ratio of 2 01 as of yesterday s close 
The Large Cap Pharmaceuticals industry is part of the Medical sector  This industry currently has a Zacks Industry Rank of 78  which puts it in the top 30  of all 250  industries 
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Be sure to follow all of these stock moving metrics  and many more  on Zacks com ",2018-11-28,Zacks Investment Research,https://www.investing.com/analysis/pfizer-pfe-gains-but-lags-market-what-you-should-know-200363266,200363266
220276,441792,PFE,Ad Com approaches for Pfizer s application for expanded use of arthritis med Xeljanz,news,The FDA s Arthritis Advisory Committee will meet tomorrow  August 3  to review and discuss  Pfizer  s  PFE  0 9   supplemental New Drug Applications  sNDA  seeking approval for the use of XELJANZ  tofacitinib  to treat adults with active psoriatic arthritis  The company is seeking approval for both tablet and extended release tablet formulations The FDA approved XELJANZ in November 2012 for the treatment of rheumatoid arthritis and the extended release formulation in February 2016 FDA briefing doc Errata to FDA briefing doc Pfizer briefing doc Now read ,2017-08-02,Seeking Alpha,https://www.investing.com/news/stock-market-news/ad-com-approaches-for-pfizers-application-for-expanded-use-of-arthritis-med-xeljanz-513530,513530
220277,441793,PFE,FDA grants Priority Review for Roche s Alecensa for first line ALK  lung cancer,news,The FDA accepts Roche s  OTCQX RHHBY  supplemental New Drug Application  sNDA  seeking approval for Alecensa  alectinib  for the first line treatment of anaplastic lymphoma kinase  ALK  positive locally advanced metastatic non small cell lung cancer  NSCLC  under Priority Review  The agency s action date is November 30 The FDA originally approved Alecensa in December 2015 for ALK  NSCLC patients who have progressed on or are intolerant to crizotinib   Pfizer   NYSE PFE  s XALKORI  Now read ,2017-08-03,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-grants-priority-review-for-roches-alecensa-for-firstline-alk-lung-cancer-514201,514201
220278,441794,PFE,FDA Ad Com backs Pfizer s Xeljanz for psoriatic arthritis  shares ahead 2 ,news,The FDA s Arthritis Advisory Committee voted 10   1 in favor of approval for  Pfizer  s  PFE  1 9   XELJANZ  tofacitinib  for the treatment of psoriatic arthritis Previously  Ad Com approaches for Pfizer s application for expanded use of arthritis med Xeljanz  Aug  2 Now read ,2017-08-03,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-ad-com-backs-pfizers-xeljanz-for-psoriatic-arthritis-shares-ahead-2-514296,514296
220279,441795,PFE,FDA OK s Pfizer s leukemia med Besponsa,news,The FDA approves  Pfizer  s  PFE  0 6   Besponsa  inotuzumab ozogamicin  for the treatment of adults with relapsed refractory B cell precursor acute lymphoblastic leukemia  ALL   The agency approved the product under Priority Review and Breakthrough Therapy status Inotuzumab ozogamicin is an antibody drug conjugate comprised of a monoclonal antibody targeting CD22  a cell surface antigen expressed in  90  of B cell cancers  linked to a cytotoxic agent  When inotuzumab ozogamicin binds to the CD22 antigen on malignant B cells  it is internalized into the cell where the cytotoxin calicheamicin is released to kill the cell Now read ,2017-08-17,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-oks-pfizers-leukemia-med-besponsa-519824,519824
220282,441798,PFE,Pfizer  PFE  Gains As Market Dips  What You Should Know,opinion,"Pfizer  PFE  closed the most recent trading day at  44 20  moving  1 57  from the previous trading session  This change outpaced the S P 500 s 1 66  loss on the day  Meanwhile  the Dow lost 1 56   and the Nasdaq  a tech heavy index  lost 3 03  
Prior to today s trading  shares of the drugmaker had lost 1 11  over the past month  This has was narrower than the Medical sector s loss of 1 89  and the S P 500 s loss of 2 43  in that time 
Wall Street will be looking for positivity from PFE as it approaches its next earnings report date  This is expected to be January 29  2019  The company is expected to report EPS of  0 64  up 3 23  from the prior year quarter  Our most recent consensus estimate is calling for quarterly revenue of  13 73 billion  up 0 18  from the year ago period 
Looking at the full year  our Zacks Consensus Estimates suggest analysts are expecting earnings of  3 per share and revenue of  53 40 billion  These totals would mark changes of  13 21  and  1 62   respectively  from last year 
Investors should also note any recent changes to analyst estimates for PFE  These revisions help to show the ever changing nature of near term business trends  As a result  we can interpret positive estimate revisions as a good sign for the company s business outlook 
Based on our research  we believe these estimate revisions are directly related to near team stock moves  Investors can capitalize on this by using the Zacks Rank  This model considers these estimate changes and provides a simple  actionable rating system 
The Zacks Rank system ranges from  1  Strong Buy  to  5  Strong Sell   It has a remarkable  outside audited track record of success  with  1 stocks delivering an average annual return of  25  since 1988  The Zacks Consensus EPS estimate has moved 0 43  higher within the past month  PFE currently has a Zacks Rank of  3  Hold  
In terms of valuation  PFE is currently trading at a Forward P E ratio of 14 51  For comparison  its industry has an average Forward P E of 14 56  which means PFE is trading at a discount to the group 
We can also see that PFE currently has a PEG ratio of 2 19  The PEG ratio is similar to the widely used P E ratio  but this metric also takes the company s expected earnings growth rate into account  PFE s industry had an average PEG ratio of 2 01 as of yesterday s close 
The Large Cap Pharmaceuticals industry is part of the Medical sector  This group has a Zacks Industry Rank of 100  putting it in the top 39  of all 250  industries 
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Make sure to utilize Zacks  Com to follow all of these stock moving metrics  and more  in the coming trading sessions ",2018-11-19,Zacks Investment Research,https://www.investing.com/analysis/pfizer-pfe-gains-as-market-dips-what-you-should-know-200360769,200360769
220283,441799,PFE,Immunicum  Collaboration And Supply Agreement Signed ,opinion,"Immunicum AB  ST IMMUN  has announced that it has signed a collaboration and supply agreement with Pfizer  NYSE PFE  and Merck KGaA  Darmstadt  Germany for the checkpoint inhibitor  CPI  Bavencio to be used in combination with ilixadencel in the Phase Ib II ILIAD study  Bavencio  avelumab  is marketed by Pfizer and Merck KGaA  and approved in the US and EU  The availability of Bavencio at no cost to Immunicum in the ILIAD study potentially opens up European study sites  which will be aided by the recent share issues 

Icing on the cake
Building on a very busy summer  which included stock issues and agreement on the ILIAD study protocol with the FDA  Immunicum has now announced a collaboration and supply agreement with Pfizer and Merck KGaA for the CPI Bavencio  avelumab  to be used in combination with ilixadencel  We had already removed the cost of CPI supply from our model  but the endorsement by Pfizer and Merck KGaA makes expansion of the ILIAD study to European centres  where CPIs are not readily available  possible  and thus recruitment of the Phase II portion could be faster than we had estimated  Bavencio was approved by the FDA in March 2017 for metastatic Merkel cell carcinoma  MCC   and for urothelial carcinoma in May 2017  Bavencio was approved for metastatic MCC in the EU in September 2017  Before Immunicum s announcement  the PD L1 monoclonal antibody was in 18 combination studies in 2017  four of which were immunoncology  I O  combination studies 
To read the entire report Please click on the pdf File Below  ",2018-11-19,Edison,https://www.investing.com/analysis/immunicum-collaboration-and-supply-agreement-signed-200360469,200360469
220284,441800,PFE,Pfizer revenue misses as demand falls for older drugs  Prevnar,news,"By Natalie Grover  Reuters     Pfizer  Inc s  N PFE  quarterly revenue missed Wall Street estimates on Tuesday  hurt by falling demand for its blockbuster pneumonia vaccine Prevnar as well as older drugs   Sales of Prevnar declined 8 2 percent to  1 15 billion  largely due to the timing of government purchases for the pediatric indication   Sales of its copycat generics and biosimilars fell 13 5 percent in the quarter to  5 23 billion    Pfizer s ambition of stabilizing this book of business looks some way off   Berenburg analysts said in a note   Revenue from its patent protected drugs rose about 8 percent to  7 67 billion in the quarter   Sales of its key drugs  including rheumatoid arthritis treatment Xeljanz and breast cancer treatment Ibrance beat analyst estimates   However  overall revenue fell to  12 9 billion in the second quarter from  13 15 billion  below the analysts  estimate of  13 08 billion  according to Thomson Reuters I B E S    These results show that Pfizer s growth drivers are still insufficient to drive meaningful sales growth against the backdrop of generic erosion   Berenberg analysts said in a note   Net income attributable to the largest U S  drugmaker rose to  3 07 billion  or 51 cents per share  from  2 05 billion  or 33 cents per share  a year earlier  Excluding items  Pfizer earned 67 cents per share  beating the average analysts  estimate by a cent   Looming patent expirations on Pfizer s sexual dysfunction treatment Viagra  pain drug Lyrica and falling Prevnar sales has pushed analysts to prescribe deals to resuscitate the company s growth    Over the next five years  we project the potential for approximately 25 to 30 approvals  of which up to 15 have the potential to be blockbusters   Chief Executive Ian Read said in a statement on Tuesday  Last year  Pfizer acquired drugmaker Medivation for  14 billion and decided against splitting itself into two companies  one housing its patent protected drug business and the other its generics business  The drugmaker also narrowed its 2017 adjusted earnings forecast to a range of  2 54 per share to  2 60 per share  It had previously forecast a range of  2 50 per share to  2 60 per share   
The company s shares were marginally down at  33 10 before the bell on Tuesday ",2017-08-01,Reuters,https://www.investing.com/news/stock-market-news/pfizer-quarterly-revenue-slips-2-percent-512743,512743
220285,441801,PFE,Pfizer s stalled growth increases pressure for large deal,news,FiercePharma s John Carroll notes that  Pfizer   PFE  0 9    despite its impressive R D successes  remains under pressure to do a megadeal to rekindle stalled growth evidenced by Q2 results that showed a 2  drop in revenues and a modest 3  rise in non GAAP earnings Management says it has 25   30 potential product approvals over the next five years  including 15 that could achieve blockbuster status   1B in annual sales   Half could be approved by 2020  Front and center is the company s cancer pipeline  led by PARP inhibitor talazoparib  acquired in the Medivation transaction  It will need fresh offerings since Prevnar sales have softened and competition looms for Lyrica  Ibrance is a winner  up 67  in Q2 to  853M  but more are needed Mr  Carroll says the shortest path to growth is dealmaking  Although rebuffed in its first attempt at a takeover  AstraZeneca  AZN  0 3   arguably remains a target  considering its recent plunge after disappointing results on lung cancer candidate durvalumab Previously  AstraZeneca may again become a takeover target if growth fails to materialize  March 20  2015 Previously  Pfizer set to abandon bid for AstraZeneca  May 26  2014 Now read ,2017-08-01,Seeking Alpha,https://www.investing.com/news/stock-market-news/pfizers-stalled-growth-increases-pressure-for-large-deal-512962,512962
220294,441810,PFE,Pfizer  PFE  Stock Moves  0 38   What You Should Know,opinion,"Pfizer  PFE  closed the most recent trading day at  44 11  moving  0 38  from the previous trading session  This change was narrower than the S P 500 s daily loss of 1 97   Elsewhere  the Dow lost 2 32   while the tech heavy Nasdaq lost 2 78  
Heading into today  shares of the drugmaker had gained 3 43  over the past month  outpacing the Medical sector s loss of 1 15  and the S P 500 s loss of 3 33  in that time 
Investors will be hoping for strength from PFE as it approaches its next earnings release  which is expected to be January 29  2019  The company is expected to report EPS of  0 64  up 3 23  from the prior year quarter  Our most recent consensus estimate is calling for quarterly revenue of  13 73 billion  up 0 18  from the year ago period 
PFE s full year Zacks Consensus Estimates are calling for earnings of  3 per share and revenue of  53 40 billion  These results would represent year over year changes of  13 21  and  1 62   respectively 
Investors might also notice recent changes to analyst estimates for PFE  Recent revisions tend to reflect the latest near term business trends  With this in mind  we can consider positive estimate revisions a sign of optimism about the company s business outlook 
Research indicates that these estimate revisions are directly correlated with near term share price momentum  Investors can capitalize on this by using the Zacks Rank  This model considers these estimate changes and provides a simple  actionable rating system 
The Zacks Rank system ranges from  1  Strong Buy  to  5  Strong Sell   It has a remarkable  outside audited track record of success  with  1 stocks delivering an average annual return of  25  since 1988  Over the past month  the Zacks Consensus EPS estimate has moved 0 48  higher  PFE is holding a Zacks Rank of  3  Hold  right now 
Looking at its valuation  PFE is holding a Forward P E ratio of 14 77  This valuation marks a premium compared to its industry s average Forward P E of 14 76 
It is also worth noting that PFE currently has a PEG ratio of 2 23  The PEG ratio is similar to the widely used P E ratio  but this metric also takes the company s expected earnings growth rate into account  The Large Cap Pharmaceuticals was holding an average PEG ratio of 2 at yesterday s closing price 
The Large Cap Pharmaceuticals industry is part of the Medical sector  This group has a Zacks Industry Rank of 38  putting it in the top 15  of all 250  industries 
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
To follow PFE in the coming trading sessions  be sure to utilize Zacks com ",2018-11-12,Zacks Investment Research,https://www.investing.com/analysis/pfizer-pfe-stock-moves-038-what-you-should-know-200358445,200358445
220295,441811,PFE,Pfizer sells interest in Brazilian JV,news,Pfizer   NYSE PFE  was forced to take a large haircut on the sale of its 40  interest in Brazilian joint venture Laboratorio Teuto Brasileiro after failing to find interested buyers  reports Reuters  The exact terms of the eventual sale to Teuto founder Walterci Melo weren t disclosed  Generic drugmakers have had a tough time in Brazil due in part to the weak local currency and broad economic conditions  Now read ,2017-07-05,Seeking Alpha,https://www.investing.com/news/stock-market-news/pfizer-sells-interest-in-brazilian-jv-502220,502220
220296,441812,PFE,FDA meets next week to discuss Pfizer s resubmitted AML treatment,news,An FDA Advisory Committee will meet next week to discuss the BLA resubmission for Pfizer s  NYSE PFE  Mylotarg  a treatment for CD 33 positive acute myeloid leukemia that was pulled from the market in 2010 after patient deaths   Pfizer  now seeks approval for Mylotarg as a combo therapy with standard chemo and the original indication with differing dosage  according to a Pfizer email to Bloomberg                 An FDA advisory meeting will take place July 11 with a PDUFA date in September                 Mylotarg was developed by Pfizer and Celltech but Pfizer has sole manufacturing and development responsibilities                 Source  Bloomberg     Now read ,2017-07-07,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-meets-next-week-to-discuss-pfizer's-resubmitted-aml-treatment-503236,503236
220299,441815,PFE,Pfizer  PFE  Stock Sinks As Market Gains  What You Should Know,opinion,"Pfizer  PFE  closed the most recent trading day at  42 99  moving  1 22  from the previous trading session  This change lagged the S P 500 s daily gain of 0 63   At the same time  the Dow added 0 68   and the tech heavy Nasdaq gained 0 64  
Heading into today  shares of the drugmaker had lost 3 89  over the past month  outpacing the Medical sector s loss of 3 98  and the S P 500 s loss of 4 95  in that time 
PFE will be looking to display strength as it nears its next earnings release  which is expected to be January 29  2019  The company is expected to report EPS of  0 64  up 3 23  from the prior year quarter  Our most recent consensus estimate is calling for quarterly revenue of  13 91 billion  up 1 52  from the year ago period 
PFE s full year Zacks Consensus Estimates are calling for earnings of  3 per share and revenue of  53 40 billion  These results would represent year over year changes of  13 21  and  1 62   respectively 
It is also important to note the recent changes to analyst estimates for PFE  These revisions typically reflect the latest short term business trends  which can change frequently  As such  positive estimate revisions reflect analyst optimism about the company s business and profitability 
Research indicates that these estimate revisions are directly correlated with near term share price momentum  We developed the Zacks Rank to capitalize on this phenomenon  Our system takes these estimate changes into account and delivers a clear  actionable rating model 
The Zacks Rank system  which ranges from  1  Strong Buy  to  5  Strong Sell   has an impressive outside audited track record of outperformance  with  1 stocks generating an average annual return of  25  since 1988  Within the past 30 days  our consensus EPS projection has moved 0 48  higher  PFE is currently sporting a Zacks Rank of  3  Hold  
Valuation is also important  so investors should note that PFE has a Forward P E ratio of 14 51 right now  Its industry sports an average Forward P E of 14 5  so we one might conclude that PFE is trading at a premium comparatively 
Investors should also note that PFE has a PEG ratio of 2 19 right now  This metric is used similarly to the famous P E ratio  but the PEG ratio also takes into account the stock s expected earnings growth rate  The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 1 98 as of yesterday s close 
The Large Cap Pharmaceuticals industry is part of the Medical sector  This group has a Zacks Industry Rank of 69  putting it in the top 27  of all 250  industries 
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Make sure to utilize Zacks  Com to follow all of these stock moving metrics  and more  in the coming trading sessions ",2018-11-06,Zacks Investment Research,https://www.investing.com/analysis/pfizer-pfe-stock-sinks-as-market-gains-what-you-should-know-200355790,200355790
220302,441818,PFE,EC investigating price hikes for older drugs  Aspen Pharmacare targeted,news,Authorities in the EU are following the U S  s lead in probing prescription drug prices  particularly off patent meds that  in many cases  face limited competition Last month  the European Commission launched an investigation aimed at South Africa s Aspen Pharmacare to determine if it made  unjustified  hikes in the price of five old cancer drugs  If the company comes out on the short end of the inquiry  it could face a fine of up to 10  of sales or  290M Drug industry spokesperson Adrian van den Hoven says   The investigation may be needed to stop bad behavior  however  this should not lead to a set of fixed principles that are not adapted to different situations  which then creates additional risks and which could increase the pressure on companies to withdraw important older medicines that patients need  Italy s competition watchdog fined Aspen  5 5M last year over its cancer drugs  British regulators slapped  Pfizer   NYSE PFE  with  107M fine for its price hikes of an old epilepsy drug Pundits doubt that action will be taken against patented drugs since officials are sensitive about undermining innovation incentives ETFs  BIB BIS CNCR ARKG GNRX PJP IHE XPH PPH XBI BBHNow read ,2017-06-26,Seeking Alpha,https://www.investing.com/news/stock-market-news/ec-investigating-price-hikes-for-older-drugs;-aspen-pharmacare-targeted-499354,499354
220317,441833,PFE,These 1 Click  Dividend Machines  Yield 8 8  With 56  Upside,opinion,"Certain closed end fund  CEF  investors are getting a little desperate for dividends  It s tough to blame them for reaching for 5   6  and even 7   yields in a 2  to 3  world 
But by grossly overpaying for funds  they are risking too much capital to bank these payouts  If you own any of the five popular funds I m about to call out  you should consider selling them immediately 
 There are bargain replacements  after all  I m talking about funds trading as cheap as  0 88 on the dollar and yielding 7 2   We ll discuss specifics in a moment  
 First level  income seekers can be greedy one minute and fearful the next  We contrarians make our living  and retirement  by purchasing out of favor payouts and selling dividends that are too dear 
Today there are funds trading for as much as  1 39 per share for just  1 in assets  There are others selling at half that price for equivalent portfolios  Here s why this happens   and how we can capitalize on it 
This Discount Premium as Margin of Safety  or Lack Thereof 
CEFs  unlike their   open end   mutual fund cousins  have fixed share counts  This makes their prices subject to the animal spirit whims of the market   for better or for worse 
As usual  despair is our friend  When CEF investors throw in the towel  the funds they discard can see their shares trade at discounts to their net asset value  NAV   This is basically  free money  for us 
If a fund trades at a 12  discount to its NAV  it means we re able to buy its underlying assets for just 88 cents on the dollar  That s exactly the type of  discount to intrinsic value  that many successful stock market investors strive for 
Plus  savvy managers have ways they can force their own discount window to shut again  Such as buying back their own cheap shares 
On the other hand  when CEF investors get greedy  they actually pay premiums for funds  Bad idea  Let me show you why  and give you five  first level favorites  to avoid 
Don t Overpay  A 9   Payer Returns Just 2   Annually
Doubleline Opportunistic Credit  NYSE DBL  has traded at a rich 8  average premium for the last three years as investors flocked to its high  9    yield and celebrity  Bond God  manager Jeffrey Gundlach  An 8  premium means buyers paid  1 08 for just  1 in assets 
How d that bidding war work out  Not well  with the fund returning just 7  over the entire three year period   including the dividends 
A Lackluster Total Return  Just 7  in 3 Years
Income investors bought the generous dividend but lost most of it in price depreciation  They made the same mistake as those who pay a high price to earnings  P E  multiple for a stock  They simply got crushed when the multiple began to contract 
Why  The  Premium Multiple  Contracted
Unfortunately folks are still paying a 3  premium to get into this fund  And that doesn t make much sense with sister fund DoubleLine Income Solutions Fund  NYSE DSL  trading for a 1  discount to its NAV  Same brilliant bond guru  same wide mandate  way better price 
My Contrarian Income Report subscribers smartly chose DSL over DBL in April 2016  The discount disparity was even larger back then  making it extra lucrative to think contrarily 
Price Matters  DSL Returned 56  to DBL s 7 
If we re looking for yield to provide us with retirement income without having to worry about share prices  then we should generally fade premiums 
4 More First Level Favorites  for Mediocre Returns  or Worse 
You probably know the  Bond King  Bill Gross  How about his successor  Dan Ivascyn 
When Gross left PIMCO  a tide of cash followed him out the door  But the flow of money quickly subsided when Ivascyn stepped to the plate and outperformed Gross himself  PIMCO let the King walk because they had their next superstar in waiting 
A money manager of Ivascyn s caliber will usually cost 2  annually  plus 20  of profits   And it d take a million bucks or two to get his attention 
So it s understandable that investors would try to  reach  for Ivascyn and overpay for his fund  That s exactly what happened with PIMCO Global StocksPLUS   Income Fund  NYSE PGP  
In fact  two more PIMCO funds round out our  5 most overpriced  list  If Ivascyn   Co  are at fault  it s for being too good at what they do  Sadly  though  investors who buy today are paying too much   and likely to see their dividends eaten up by price declines  or worse  in the years ahead 
4 More Popular Premiums to Avoid
Don t despair though  While there is certainly some froth in CEF land  there are still some dividend superstars to be had  All we need is a bit of second level thinking 
Contrarian Income Tip  Buy Discounted CEFs as Rates Rise
Here s a little known secret that will help you identify funds that are unfairly discounted 
Higher rates don t really hurt CEFs 
The theory scares people because it sounds true  Closed ends have the benefit of borrowing money at Libor to leverage up their returns  Libor is tied closely to the Fed funds rate  So  the thinking goes  higher Fed rates will end the  cheap money  party that benefits CEFs 
Some funds today are selling at discounts to their NAVs on the fear that rate increases will hurt them  But this lazy conclusion is wrong 
In June 2004  Fed chair Alan Greenspan began boosting rates from then historic lows  Over a two year period  he increased the federal funds rate from 1  to 5 25   A dizzying pace by today s standards 
How d CEFs perform  Let s consider the tax advantaged Nuveen AMT Free Municipal Credit Income  NYSE NVG   which rose in harmony with Alan Greenspan s Fed Funds Rate 
Fed Rate and Muni CEFs Rose in Harmony Then 
And this rate hike cycle  we can simply update the months and years to see a similar picture 
  And Now
Other types of CEFs were also able to perform well in the face of rising rates  Here are three of the largest CEFs from the 2004 to 2006 time period 
CEFs Beat the Market as Rates Rose Then 
  And Now
With rates once ticking up  it s the perfect time to buy the few high quality funds that are still trading for discounts 
But which ones 
These 4 Cheap Funds are  Dividend Conversion Machines 
I ve found 4 lucrative  Dividend Conversion Machines  that let you buy blue chip stocks like Pfizer  NYSE PFE  for incredible 11 0  CASH payouts 
Plus these funds all trade at a discount to the value of the stocks and bonds they hold today  This is free money  For example  this fund  which yields 7 2   by the way  sells for just  11 71 and has a  free   1 56 discount to NAV baked in 

With these four amazing  Dividend Conversion Machines   you ll grab dividends of 6   8   10  and more for just 88  90 and 92 cents on the dollar 
And thanks to these discounts  these four yield kings are also set to explode with massive price upside  too  Remember the old DSL example we discussed earlier  These one click investments boast similar lucrative setups today 
I m talking 20   yearly price upside here  on top of dividends of 8   11  and even higher 
Just days ago  I released the whole incredible story on these 4 Dividend Conversion Machines to the public for the first time  including their names  ticker symbols  exactly how they work and how to buy  hint  you can grab these 4 incredible Dividend Conversion Machine straight from your brokerage account  
Simply click here and I ll share all the details with you  including full details on these 4 Dividend Conversion Machines and how to start their 6   8  and 10   payouts pumping into your account now 
Disclosure  Brett Owens and Michael Foster are contrarian income investors who look for undervalued stocks funds across the U S  markets  Click here to learn how to profit from their strategies in the latest report   7 Great Dividend Growth Stocks for a Secure Retirement  ",2018-10-10,Brett Owens,https://www.investing.com/analysis/these-1click-dividend-machines-yield-88-with-56-upside-200347791,200347791
220318,441834,PFE,Biotech Stocks  From Breakout To Breakdown In One Week,opinion,"Biotech stocks ran higher from May through to August  There were a couple of set backs along the way  but a strong move higher  Large cap healthcare was looking good  Companies like Eli Lilly and Pfizer  NYSE PFE  were climbing  The Medical Devices field was also showing strength  It seemed like a change of leadership in the stock market was upon us with healthcare taking the lead 
After a short pullback in September Biotech stock prices were rising again into the end of the month and finished September at 3 year highs  All looked well for the sector  And then October started  Of the first 7 trading days in October the Biotech Index has been down 6 of them including the last 4  A 6  drop in just over a week  Is it time to panic 

The pullback brought the Biotech Index ETF   IBB back to its 100 day SMA  It bounced the last time it touched there in June  But momentum is weaker this time  The RSI is making a 6 month low and pushing into the bearish range  And the MACD is negative  It has not dipped to negative since May  when it was rising out of the April low 
These alone do not state the case to sell Biotech yet  Looking at the price action  it has stalled in the move lower at the prior low from August  creating a channel  If it continues below the July dip there is likely trouble ahead as a double top would confirm  Time to protect you Biotech and watch closely 
The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my Disclaimer page for my full disclaimer 
Original post",2018-10-10,Gregory W. Harmon,https://www.investing.com/analysis/biotech--from-breakout-to-breakdown-in-1-week-200347819,200347819
220319,441835,PFE,European stocks mostly higher despite political tensions  DAX up 0 27 ,news,"Investing com   European stocks were mostly higher on Thursday  despite ongoing U S  political concerns and mounting uncertainty over the outcome of the upcoming U K  general elections 
During European morning trade  the EURO STOXX 50 dipped 0 01   France s CAC 40 advanced 0 45   while Germany s DAX 30 gained 0 27  
Investors remained cautious amid ongoing fears investigations into President Donald Trump s ties with Russia could hamper his administration s progress on promised stimulus measures 
The Trump administration is under investigation by the Federal Bureau of Investigation and several congressional panels over alleged Russian meddling in the 2016 presidential election and potential collusion with the Trump campaign 
Markets were also jittery after the latest YouGov poll released on Wednesday showed that Theresa May s Conservative Party is only 3 percentage points in front of the opposition Labour Party ahead of the June 8 election 
Financial stocks were mixed  as  BNP Paribas   PA BNPP  dropped 0 56  and  Societe Generale   PA SOGN  edged up 0 13  in France  while Germany s Commerzbank  DE CBKG  and  Deutsche Bank   DE DBKGn  declined 0 62  and 1 73  
Among peripheral lenders  Italy s  Intesa Sanpaolo   MI ISP  and Unicredit  MI CRDI  lost 0 17  and 1 50  respectively  while Spanish banks BBVA  MC BBVA  and  Banco Santander   MC SAN  edged up 0 11  and 0 17  
 Elsewhere  shares in Deutsche Telekom  DE DTEGn  dove 2 75  after the company said it is optimistic about the regulatory environment in the United States under the Trump administration 
On the upside   Linde  AG  DE LING  jumped 1 22  as the company s merger with U S  group Praxair  NYSE PX  seems more likely now that German labor opposition has started to waver 
 Vivendi   PA VIV  added to gains  with shares up 1 55  after the Brussels competition regulator on Tuesday approved the French company s controversial plans to take de facto control of  Telecom Italia   MI TLIT  on the condition that it sells its stake in broadcasting company Persidera 
In London  FTSE 100 gained 0 46   helped by DCC  LON DCC   whose shares rallied 1 46  after the energy and technology group said it completed the disposal of its environmental division to a private equity firm 
 Astrazeneca   LON AZN  was also on the upside  with shares climbing 1 72  after its brand Neksium was acquired by U S  drugmaker  Pfizer   NYSE PFE  
Financial stocks were mostly higher  as Lloyds Banking  LON LLOY  eased up 0 07  and  HSBC Holdings   LON HSBA  rose 0 35   while  Barclays   LON BARC  gained 0 69   The Royal Bank of Scotland  LON RBS  underperformed however  with shares down 1 04  
Meanwhile  mining stocks were broadly lower on the commodity heavy index  Shares in  Rio Tinto   LON RIO  slid 0 31  and  Glencore   LON GLEN  dropped 0 37   while rival BHP Billiton  LON BLT  declined 0 38  
 National Grid   LON NG  was one of the worst performers on the index  as shares plummeted 2 98  even as the company insisted this week that it can cope with increasing amounts of solar energy used in the UK energy   the technology set a new generation record last week 
In the U S   equity markets pointed to a steady to higher open  The Dow Jones Industrial Average futures pointed to a 0 05  uptick  S P 500 futures showed a 0 07  gain  while the Nasdaq 100 futures indicated a 0 23  rise ",2017-06-01,Investing.com,https://www.investing.com/news/stock-market-news/european-stocks-mostly-higher-despite-political-tensions;-dax-up-0.27-490552,490552
220320,441836,PFE,Pfizer and Astellas amend late stage study supporting expanded use of Xtandi  top line data expected this year,news,Pfizer   NYSE PFE  and collaboration partner Astellas Pharma  OTCPK ALPMF  have amended the protocol for the Phase 3 PROSPER clinical trial assessing XTANDI  enzalutamide  for the treatment of non metastatic castration resistant prostate cancer  CRPC   The change reduces the target sample size to 1 440 from 1 560 and will enable the reporting of top line results later this year rather than 2019 XTANDI is currently approved in the U S  to treat men with metastatic CRPC Pfizer is up a fraction premarket Now read ,2017-06-09,Seeking Alpha,"https://www.investing.com/news/stock-market-news/pfizer-and-astellas-amend-late-stage-study-supporting-expanded-use-of-xtandi,-top-line-data-expected-this-year-493796",493796
220325,441841,PFE,Pfizer to update investors on oncology business June 9,news,Pfizer   PFE  0 8   will host a conference call with analysts on June 9 at 11 00 am ET to discuss its oncology business and review ASCO presentations  Investors are invited to listen and view the webcast accessible on its website Now read ,2017-05-17,Seeking Alpha,https://www.investing.com/news/stock-market-news/pfizer-to-update-investors-on-oncology-business-june-9-485482,485482
220326,441842,PFE,FDA OKs expanded use of Novartis cancer med Zykadia,news,The FDA approves the use of Novartis   NYSE NVS  Zykadia  ceritinib  for the first line treatment of patients with metastatic ALK positive non small cell lung cancer  NSCLC   The agency first approved the ALK inhibitor in 2014 for the treatment of patients with ALK positive metastatic NSCLC who progressed on or were intolerant to crizotinib   Pfizer   NYSE PFE  s XALKORI  In the U S   Zykadia has Breakthrough Therapy status for first line ALK  NSCLC with metastases to the brain Now read ,2017-05-26,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-oks-expanded-use-of-novartis-cancer-med-zykadia-489165,489165
220327,441843,PFE,Novartis warns of U S  price pressure on Sandoz generics,news,"By John Miller
ZURICH  Reuters    Novartis warned on Wednesday that price pressure on its generics drugs in the United States has intensified in the second quarter  cutting into its Sandoz division s sales growth in the world s largest healthcare market 
The Swiss drugmaker  which is holding an investor event in Boston  also said in a statement that it continued to review  all options  for its struggling Alcon eyecare unit 
An update on the future of loss making Alcon  which is among  50 billion in assets Novartis is considering unloading  is expected by the end of the year 
Novartis s Sandoz business  whose  10 1 billion in revenue in 2016 made up a fifth of the company s total  joins generics makers including India s Sun Pharmaceutical Industries and Lupin that have said revenue growth will be muted this year amid intensifying U S  price pressure 
 The impact of U S  pricing pressure and prior year launch timing is expected to have a higher impact on second quarter 2017 sales growth than  in the  first quarter   Novartis said 
Even so  Novartis said it was leaving Sandoz s full year sales targets unchanged  as it still sees the division s revenue  broadly in line  with 2016 
Consolidation among drug distributors has hit generics makers  ability to negotiate on prices  while regulatory scrutiny has also made hikes tougher 
Beyond the price squeeze  Sandoz has also been hurt by the delay of a new generic version of Glatopa  a copy of Teva s multiple sclerosis drug Copaxone  due to a warning letter on a third party manufacturing site in Kansas run by  Pfizer   NYSE PFE  ",2017-05-31,Reuters,https://www.investing.com/news/stock-market-news/novartis-warns-of-u.s.-price-pressure-on-sandoz-generics-490033,490033
220333,441849,PFE,Pain  Durect Plunge As FDA Committee Votes Against Remoxy ER,opinion,"Shares of Pain Therapeutics  Inc    NASDAQ PTIE   and partner  Durect Corp    NASDAQ DRRX    plunged following the news that a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee  and Drug Safety and Risk Management Advisory Committee of the FDA voted 14 to 3 against the approval of pain drug  Remoxy ER   
Per the company  Remoxy is a new type of abuse deterrent  extended release  oral formulation of widely used opioid drug oxycodone  It is being evaluated for the management of pain  severe enough to require daily  around the clock  long term opioid treatment  and for which alternative treatment options are inadequate 
The news disappointed investors as Remoxy ER is Pain Therapeutics  lead candidate  The FDA has set a Prescription Drug User Fee Act  PDUFA  target action date of Aug 7  2018 for completion of its review of the New Drug Application  NDA  for Remoxy ER 
The NDA is requesting label claims for abuse deterrence against three routes of abuse  injection  inhalation and nasal  Per the company  Remoxy s thick  sticky  high viscosity formulation may deter unapproved routes of drug administration  such as injection  snorting or smoking 
However  given the committee s negative opinion on the formulation  a positive outcome from the FDA review is highly unlikely 
Pain Therapeutics  shares have lost 39 1  so far in 2018 compared to the  s gain of 0 4   Shares lost 70  of their value on the above mentioned news 

 
We note that Pain Therapeutics has a license agreement with Durect to use the latter s Oradur technology for Remoxy  While Pain Therapeutics is solely responsible for clinical development  Durect is responsible for furnishing suitable laboratory facilities  equipment and personnel  during pre clinical phases of development  Both the companies are jointly responsible for certain pre clinical activities  Pain Therapeutics is obligated to pay royalties to Durect on commercial sales of Remoxy  6 0  to 11 5   
The company had a collaboration agreement with Pfizer  Inc    NYSE PFE   for Remoxy  which was terminated by the latter in 2014 
The road to Remoxy s development has been bumpy  It has already been issued Complete Response Letter  CRL  a few times  Most recently  in September 2016  the FDA issues a CRL  stating that Remoxy could not be approved in its present form  and specified additional actions and data is needed for drug approval  Pain Therapeutics resubmitted the Remoxy NDA in the first quarter of 2018
The abuse of opioid drugs is a serious problem in the United States  with companies like Endo Pharmaceuticals   NASDAQ ENDP   having to withdraw its injectable formulation of Opana ER 
Zacks Rank
Pain Therapeutics currently carries a Zacks Rank  3  Hold   You can see   
5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ",2018-06-28,Zacks Investment Research,https://www.investing.com/analysis/pain-durect-plunge-as-fda-committee-votes-against-remoxy-er-200328411,200328411
220340,441856,PFE,Novartis wins U S  approval for breast cancer drug  to compete with Pfizer s Ibrance,news,"By John Miller
ZURICH  Reuters    Novartis has won U S  Food and Drug Administration approval for Kisqali to treat postmenopausal women who have a difficult to treat form of breast cancer  challenging U S  rival  Pfizer   NYSE PFE  s Ibrance 
The Swiss company has priced Kisqali to be cheaper than Ibrance  which analysts said could help it win business  though Kisqali s approval includes additional patient monitoring requirements that could work against the new drug 
Novartis considers Kisqali to be one of its stable of 13 new medicines with blockbuster potential for annual revenue in the billions of dollars  Analysts see global annual sales reaching  1 5 billion by 2022  Thomson Reuters data shows 
British biotech company Astex Pharmaceuticals  now part of Otsuka  will receive undisclosed payments from Novartis  having worked out the structure of the key protein targeted by Kisqali 
Approval for Kisqali  previously known as LEE011 and to be administered in combination with letrozole  is for first line treatment of hormone receptor positive  human epidermal growth factor receptor 2 negative  HR  HER2   advanced or metastatic breast cancer  Novartis said late on Monday 
The quick U S  approval provides Novartis with the jump off point to challenge Pfizer s Ibrance in the initial treatment of patients 
Ibrance hit about  2 1 billion in sales in 2016 
Novartis estimates that it has priced Kisqali at an 18 20 percent discount to Ibrance while providing for flexible dosing 
Leerink analyst Seamus Fernandez said in a note that the pricing could help to drive take up for prescriptions but that cost factors could be outweighed by patient monitoring requirements that are more rigorous than those for Ibrance 
Kisqali comes with warnings for so called QT prolongation  which can signal heart problems and liver issues 
 Physicians will likely find the monitoring requirements associated with Kisqali to be burdensome relative to Ibrance   Fernandez wrote 
Novartis said that no head to head studies of Kisqali and Ibrance had been done  making efficacy and safety comparisons impossible  But the company said that most health issues that arose during Kisqali s trials were mild to moderate and generally managed through interrupting or reducing the dose 
Kisqali plus letrozole reduced the risk of disease progression or death by 44 percent over letrozole alone  according to results of a study released last year 

The Novartis drug is also under review in Europe ",2017-03-14,Reuters,https://www.investing.com/news/stock-market-news/novartis-wins-u.s.-approval-for-breast-cancer-drug;-to-compete-with-pfizer's-ibrance-466003,466003
220352,441868,PFE,UK agency says Pfizer breast cancer drug too expensive,news,LONDON  Reuters    Pfizer s breast cancer drug Ibrance  or palbociclib  is too expensive to justify its use on Britain s state run health service  the country s healthcare cost effectiveness watchdog said on Friday  The National Institute for Health and Care Excellence  NICE  said in draft guidance that although the medicine was likely to offer some improvement in overall survival  this could not be quantified from clinical trials   Even when allowing for these potential benefits  it was still not enough to make palbociclib cost effective at its current price   Carole Longson  director of NICE s center for health technology assessment  said in a statement on Friday  Ibrance s list price is 2 950 pounds   3 700  per 28 days   Pfizer   NYSE PFE  UK s oncology head David Montgomery noted that the NICE decision was not final decision and said the U S  drugmaker was committed to working to try and find a solution to make the drug available ,2017-02-02,Reuters,https://www.investing.com/news/stock-market-news/uk-agency-says-pfizer-breast-cancer-drug-too-expensive-457619,457619
220360,441876,PFE,Pfizer Q4 EPS  0 47 vs  estimate  0 50  revenues in line ,news,Investing com    NYSE Pfizer  fourth quarter earnings missed estimates as sales were in line  Pfizer  reported an 11  YoY fall in adjusted  diluted Q4 EPS to  0 47 against an estimate of  0 50 Revenues were down 3  at  13 63  compared with a forecast of  13 61 bn The U S  drug maker attributed the YoY decline in revenues to fewer selling dates than a year earlier Full year EPS was up 9  at  2 40 as revenues rose 8  to  52 82 bn ,2017-01-31,Investing.com,"https://www.investing.com/news/stock-market-news/pfizer-q4-eps-$0.47-vs.-estimate-$0.50,-revenues-in-line-456856",456856
220372,441888,PFE,Are Dovish Central Banks Doing The USD Heavy Lifting ,opinion,"Currency Markets
The US dollar bulls continued to lead the charge as traders remain centered favorably on the entrenched US data flow  despite a slightly softer ISM  relative to those from other major economies that are cooling quickly  This suggests that central bank policy divergence and the widening interest rate differentials have G 10 traders taking the dollar bull by the horns  It s now over to the FOMC to hold up their side of the bargain as so far  the heavy lifting for the greenback has fallen on the global central bank community which has turned dovish on the first hint of economic slack 
Equity Markets 
After initially grumbling on Pfizer  NYSE PFE  results and dropping oil prices  US equity market rebounded convincingly in Tuesday s NY session  However  investors remain cautious that tariffs and higher oil prices could increase cost pressures and weigh on corporate profits  In addition  the negative equity market connotations from the prospects of higher US interest rates as the Federal Reserve Board concludes its two day policy meeting continues to weigh on markets 
Oil Markets
As the May 12 Iran nuclear deadline nears  headline risk continues to speak volumes  The market turned lower after peaking post Israeli Prime Minister Benjamin Netanyahu s televised expos  which accused Iran of lying about its past nuclear intentions when in fact the existence of a covert Iranian program was divulged in a 2011 report from the International Atomic Energy Agency 
Geopolitical developments will continue to drive sentiment  However  a stronger US dollar  soft ISM and a refocusing on rising US production have caused traders to turn to profit taking mode and capped upticks so far 
The API reported a larger than expected crude inventory build while the U S  Energy Information Administration said Monday that oil production rose to a record 10 264 million barrels a day in February 
Gold Markets
Gold market is melting as the surging US dollar takes hold  The revitalized greenback has all but crushed demand for bullion  and as we near the critical  1300 level  the specter of stop losses getting triggered on an upbeat FOMC statement has traders now positioning for the path of least resistance  which appears lower 
We re in a lull between geopolitical developments which is also offering little support for gold prices 
G 10
The USD is bid across the board after testing some significant levels as the market sits tight ahead of the FOMC  but more significantly  now pivots to this week s NFP which could make or break the resurgent dollar 
EUR  Some traders had not entirely positioned for downside exposure so on a break of the psychological key 1 2050 there was a mad dash for downs exposure which toppled the EUR below the 200 day moving average which set up a test of this year s low print  1 1915 
JPY  Interest rate differential and positive developments in the Korea Peninsula suggest a test of 110 is on the cards 
AUD  The RBA was a non event and was more or less a replay of past statements  With the RBA continuing to err dovish and barring a surprise uptick in global growth and commodities  the market continues to favor the Aussie short vs USD among G 10 peers 
Asia
MYR  Stronger dollar narrative coupled with political uncertainty should continue to pressure the ringgit 
Growing election uncertainty continues to keep investors at bay  While the chances of the opposition to pull off a surprise result remain low  a large scale knee jerk negative repricing of Malaysian assets suggests foreign bond buyers will stay on the sidelines  As such  the MYR will continue to trade defensively due to its heightened domestic political risk ",2018-05-02,Stephen Innes,https://www.investing.com/analysis/are-dovish-central-banks-doing-the-usd-heavy-lifting-200311553,200311553
220373,441889,PFE,Where Will The Dow Jones Industrial Average Go In May ,opinion,"Market technician Dave Chojnacki of Street One Financial recaps Tuesday s mixed market action and updates the important technicals to focus on as we progress through what promises to be a choppy month of May 
The major indices opened mixed on Tuesday  A combination of economic and earnings reports put a damper on the Dow Jones Industrial Average  DJIA   ISM and Construction spending came in lower than expected  and Pfizeer disappointed in their earnings report  These events sent the DJIA down over 354 points at one time  before reversing and finishing with a small loss 
Meanwhile the Nasdaq 100  NDX  was holding up much better powered by a good day in Techs and AAPL  The NDX ended the day with a significant gain  while the S P 500  SPX  eked out a small gain 
At the close  the DJIA was off 0 27   the SPX added 0 25   and the NDX moved up 1 1   Breadth was slightly positive  1 1 to 1  on slightly below average volume  ROC 10  s declined in the session  with all three major indices remaining in negative territory 
RSI s were mixed with the NDX moving higher and becoming the strongest at 51 2  The DJIA dropped to 44 8 and the SPX was little changed at 47 9  The DJIA continued with its MACD bel0ow signal  while the NDX and SPX remain above  The ARMS index ended the day at 1 37  a slightly bearish reading 
It was the third straight down day for the DJIA  with PFE  NYSE PFE  down 3 3  contributing to its poor performance  The DJIA closed at 24099  holding below its 20D SMA of 24340  It came within 80 points of its 200D SMAv 23727   Until it moves above its 50  retrace level of 25074  short term bias remains to the downside 
The SPX ended at 2654  near its high of the day  It remained just below its 20D SMA of 2659  The SPX must move through its 50  retrace at 2726 to reverse bias  Its 50D SMA is at 2684  The NDX closed at 6681  moving above its 20D SMA of 6628  It remains below its 50D SMA of 6742  The NDX 50  retrace stands at 6760  The VIX slipped 2 7  to end at 15 49 
Near term support for the NDX is at 6628 6600  Near term resistance is at 6700 and 6742  Near term support for the SPX is at 2625 and 2613  Near term critical resistance is at 2659 and 2684 
Europe is slightly higher in early trade Tuesday  while U S  Futures are slightly higher in the premarket  Major economic reports on tap today include the ADP Employment report at 8 15am  EIA Petro Report at 10 30am  and the FOMC Announcement at 2 00pm 
The SPDR Dow Jones Industrial Average  SI SPDR  ETF    rose  0 49   0 20   in premarket trading Wednesday  Year to date  DIA has declined  2 68   versus a  0 70  rise in the benchmark S P 500 index during the same period 
DIA currently has an  of A  Strong Buy   and is ranked  3 of 81 ETFs in the  category ",2018-05-02,ETF Daily News,https://www.investing.com/analysis/where-will-the-dow-jones-industrial-average-go-in-may-200311670,200311670
220375,441891,PFE,Macron momentum threatens French election frontrunners,news,"By Michel Rose PARIS  Reuters    In May last year  then French Economy Minister Emmanuel Macron sat down with Socialist lawmaker Christophe Sirugue in the steel town of Le Creusot and asked him to join his new political movement  He said No  Eight months on  others are saying Yes  A political outsider who has never run for office and hopes to transcend the classic Left Right divide  Macron suddenly seems to have a fighting chance of winning the keys to the Elysee Palace and becoming president before he turns 40  The latest polls show him breathing down the necks of conservative frontrunner Francois Fillon and the far right s Marine Le Pen and he is drawing larger crowds than both at rallies across France  Macron s rise is beginning to create cracks in the mainstream parties as more and more local officials disregard party orders and defect to the 39 year old s campaign  On the right  four former center right ministers have backed Macron  illustrating Fillon s struggle to rally moderates behind free market policies harking back to former British Prime Minister Margaret Thatcher  Macron s magnetic pull is also being felt at the center  When the management of the small UDI party endorsed Fillon  the party s youth wing sent a furious statement announcing that their 130 elected officials and supporters would back Macron  A  UDI Youth  sign now adorns the door of a small room at Macron s modest presidential campaign headquarters in the 15th district of the French capital   Long time centrist presidential hopeful Francois Bayrou  who may get about 5 percent of the vote  is facing growing calls from his base to throw in the towel and rally behind Macron   SOCIALIST PANIC The momentum behind Macron is starting to sow panic too in the ranks of the Socialists  who fear they have little chance of making the runoff in May after five years of uninspiring rule by President Francois Hollande  Fifty Socialist members of parliament have already joined Macron  according to his team  defying threats of expulsion from their own party  Even in remote regions of the country  he is attracting more people to rallies than his rivals  More than 2 000 supporters attended his event in the central city of Clermont Ferrand this month  for example   while former Prime Minister Manuel Valls  who is gunning for the Socialist ticket  only pulled in 300 people there  according to local media   There s a real possibility that at some point the dyke breaks and the Socialist party starts hemorrhaging officials towards Emmanuel Macron   Jerome Sainte Marie  head of pollster PollingVox  told Reuters  An Odoxa poll this month showed Macron would get 16 percent to 24 percent of votes in the first round in April  putting him within a whisker of Le Pen and Fillon  In the latest Harris Interactive poll  41 percent said they  trusted  Macron and he was more popular than Fillon for the first time in a December poll by Odoxa   FRESH FACE Macron followed a path well trodden by the French elite  attending the prestigious Sciences Po and Ecole national d administration  ENA  schools and then joining the finance ministry  He then moved to investment bank Rothschild   Cie in 2008 and made a small fortune brokering a  10 billion deal between Nestle and  Pfizer   NYSE PFE  before joining Hollande s presidential staff and becoming economy minister in 2014  Macron quit in November to focus on his  En Marche    or  Onwards    political movement which he established in April  Written off as a presidential hopeful then  Macron has become France s most popular politician in just a few months  his image a regular feature of Paris boulevard newsstands  Macron s popularity is an achievement in a country where many hold a disdain for the world of high finance and much of his broad popularity is down to his attempts to bridge the Left Right divide that dominates French politics  He made a name for himself criticizing sacred cows of the French  social model  such as the 35 hour working week  iron clad job protection and civil servants  jobs for life  But in a country where many often end up voting for the candidate they dislike least  part of Macron s appeal can also be put down to a deep yearning for a fresh face  He stands out in a race dominated by figures who have been sparring with each other for decades  He is a generation apart from 62 year old former prime minister Fillon and 10 years younger than Marine Le Pen  Many Socialist and conservative grandees have long dismissed the Macron phenomenon  deriding him as a shooting star destined to crash and burn in the run up to the two stage election  But with less than 100 days to the election there is no sign yet the media frenzy around him is starting to subside   TWO THIRDS One Socialist MP  who declined to be named  said as many as two thirds of the party s lawmakers could swing behind Macron if the Socialists choose one of the most left wing candidates at their primaries this month   Beyond the presidential election  those MPs are getting worried that if Macron remains high in the polls and fields his own candidates in the legislatives  they re dead   he told Reuters  Analysts warn  however  that as Macron s reform program becomes clearer  especially on how he intends to cut public spending  the harder it will be to appeal across the spectrum  He has yet to release a full manifesto but  aware of the need to attract left wing voters  now says he wants to reform the 35 hour working week and the country s wealth tax  rather than scrap these emblematic Socialist policies   There are some real question marks hanging over him   said Celine Bracq at the Odoxa polling institute   His popularity today will not necessarily foretell success in the presidential election   But others are prudently hedging their bets  Sirugue  the Socialist MP who turned down Macron in May  told Reuters that the presidential hopeful had since toned down his free market message and was now more presentable  
 We re not poles apart   said the lawmaker  who replaced Macron at the economy ministry   If you re asking me who I d choose between Macron and the Right s candidates  there isn t a shadow of a doubt  ",2017-01-17,Reuters,https://www.investing.com/news/world-news/macron-momentum-threatens-french-election-frontrunners-453563,453563
220380,441896,PFE,Chart Of The Day  Is Pfizer About To Retest Its January High ,opinion,"Analysts have recently increased Pfizer Inc  NYSE PFE  s EPS expectations from  0 74 to  0 75  Does this updated estimate indicate that the stock will retest its January  39 43 high 
The overall supply demand balance seems to indicate that it will not 

Pfizer is a Diamond in the Sky that is About to Fall
The price has been developing a diamond top formation  It is rare as it is a profitable pattern  upon the successful downside breakout  The right side of the top is dotted to indicate it is presumptive  assuming the pattern will continue to form and that the former February 28   37 28 peak will maintain resistance 
This pattern is made up of two smaller ones  On the left side  it started mid September to develop a Broadening Pattern  on the right side  it began forming what may be a triangle 
The pattern may be described as a Complex Head and Shoulders with a V shaped neckline 
Thomas Bulkowski is an investor and author  His research shows that 58 percent of the time the last rally before the Diamond Top is steep  Between August 21 and September 12  which is less than a three week period  the price surged by more than 10 percent  During the same period  the S P 500 Index climbed 3 1 percent  An advance three times that of the benchmark more than satisfies the requirement for a steep rise 
When this occurs his research shows that the odds increase that the breakout from the diamond will be downward and will be equally as steep  That means that should the price fall below  36  it should almost automatically fall quickly to the beginning of the last move on August 21 at  32 32 
Pullbacks occur about 54 percent of the time  When they occur  they do tend to detract from performance  in terms of optimum entry  An entry upon breakout with a stop loss above the pattern should eliminate performance weakness 
84 percent of downside breakouts provide a minimum of a 10 percent gain  The 10 percent failure percentage is 16 percent  below the average for most tops complete with a downside breakout  These numbers render the diamond pattern with an above average chance of being profitable with minimum risk 
The 200 DMA increases the weight of the evidence that this pattern as drawn is meaningful  as it  guards  the pattern bottom 
Trading Strategies   Short Position Setup
Conservative traders would wait for a 3 percent downside breakout and for the probable return move  which would demonstrate the pattern s resistance  with at least one red candle engulfing one green candle 
Moderate traders would be satisfied with a 2 percent breakout and might wait for a return move for a better entry 
Aggressive traders may enter a short position immediately  counting on the dual resistance of the former February 28   37 28 peak  The dotted downtrend line from the January 30 diamond top is presumptive  in case the previous peak would maintain resistance ",2018-04-30,Pinchas Cohen/Investing.com,https://www.investing.com/analysis/chart-of-the-day-200310739,200310739
220382,441898,PFE,U S  executions hit 25 year low as capital punishment wanes  study,news,"By Jon Herskovitz AUSTIN  Texas  Reuters    The number of U S  executions fell to a quarter century low in 2016 as new death sentences plummeted  indicating capital punishment is on the decline  a study released on Wednesday showed  The number of U S  executions in 2016 was 20  the lowest since 1991  according to the study from the Death Penalty Information Center  which monitors capital punishment   While 31 states have the death penalty  only five held executions in 2016  Georgia carried out the most at nine while Texas was next at seven  it said   The number of new death sentences in 2016 is expected to hit 30  a low not seen since the U S  Supreme Court declared existing death penalty statutes unconstitutional in 1972  it said  That figure is down by more than 90 percent from a recent high of 315 in 1996   Legal battles and a sales ban on execution drugs will likely hold down the number of executions next year while the high costs of death penalty cases is set to keep capital punishment prosecutions down as district attorneys instead seek sentences of life in prison without parole  legal experts said   America is in the midst of a major climate change concerning capital punishment   said Robert Dunham  the center s executive director and the report author  States have been scrambling to find drugs since European drug makers imposed a sales ban about five years ago due to ethical concerns  The problem was exacerbated when pharmaceutical giant  Pfizer   N PFE  imposed a sales ban this year  cutting off the last major U S  source of the drugs  Ohio  which has executed 53 inmates since the U S  Supreme Court reinstated the death penalty in 1976  had a U S  judge this week delay plans to end its nearly 3 year execution hiatus in 2017 to examine its drug procurement secrecy  Capital punishment advocates have said expenses or drug shortages should not be a factor  arguing the death penalty is an instrument of justice and must used for those who deserve it  Jordan Steiker  a University of Texas Law School professor and director of its Capital Punishment Center  said states looking to resume executions are going to face stiff legal challenges  
 We are on a path toward constitutional abolition  The length of that path will be dictated by uncertainties concerning the Supreme Court s composition and how much the withering of the death penalty continues   he said ",2016-12-21,Reuters,https://www.investing.com/news/stock-market-news/u.s.-executions-hit-25-year-low-as-capital-punishment-wanes:-study-449056,449056
220383,441899,PFE,Artificial leaf copies nature to manufacture medicine,news,"By Ben Hirschler  Reuters    Dutch scientists have developed an artificial leaf that can act as a mini factory for producing drugs  an advance that could allow medicines to be produced anywhere there is sunlight  The work taps into the ability of plants to use sunlight to feed themselves through photosynthesis  something industrial chemists have struggled to replicate because sunshine usually generates too little energy to fuel chemical reactions  The leaf inspired micro factory mimics nature s efficiency at harvesting solar radiation by using new materials called luminescent solar concentrators with very thin channels through which liquid is pumped  exposing molecules to sunlight   Theoretically  you could use this device to make drug compounds with solar energy anywhere you want   said lead researcher Timothy Noel at Eindhoven University of Technology  By doing away with the need for a power grid  it may be possible one day to make malaria drugs in the jungle or even medicines on Mars in some future space colony  he believes  The device  made from silicone rubber  can operate even when there is diffuse light  which means it will work under cloudy skies  However  there is still a way to go to scale up the process to make it commercially viable  Noel and his colleagues  who published their research in the science journal Angewandte Chemie on Wednesday  are now trying to improve energy efficiency further and increase output  Because the artificial leaf relies on micro channels to bring chemicals into direct contact with sunlight  each unit needs to be small   but they could be easily linked together to increase production   You can make a whole tree with many  many different leaves placed in parallel   Noel told Reuters   These are very cheap things to make  so there is a lot of potential   He thinks the process could start to become broadly available to chemical engineers within five to 10 years  
It is not the first time that scientists have drawn inspiration from plants when considering novel ways to manufacture pharmaceuticals  In 2012  the U S  Food and Drug Administration approved a drug called Elelyso from  Pfizer   NYSE PFE  and Protalix Biotherapeutics for Gaucher disease  a rare genetic condition  made with genetically modified carrot cells  Other researchers are also cultivating crops that have been specially bred to produce useful medicines and vaccines in their leaves ",2016-12-21,Reuters,https://www.investing.com/news/general-news/artificial-leaf-copies-nature-to-manufacture-medicine-449146,449146
220388,441904,PFE,Britain fines Pfizer record  107 million for huge drug price hike,news,By Ben Hirschler LONDON  Reuters    Britain s competition watchdog has fined  Pfizer   N PFE  a record 84 2 million pounds   107 million  for its role in ramping up the cost of an epilepsy drug by as much as 2 600 percent  The Competition and Markets Authority  CMA  also fined Flynn Pharma 5 2 million pounds for overcharging for phenytoin sodium capsules  following a dramatic price hike in 2012   The CMA s ruling comes amid a growing debate on both sides of the Atlantic about the ethics of price hikes for old off patent medicines that are only made by a few firms and where there is little competition  U S  drugmaker Turing Pharmaceuticals  led at the time by hedge fund manager Martin Shkreli  caused outrage last year by raising the U S  price of Daraprim  an old anti infective drug  by more than 5 000 percent to  750 a pill  In the case of phenytoin sodium capsules  the UK price charged for 100 mg packs of the drug jumped from 2 83 pounds to 67 50 in 2012  before reducing to 54 00 from May 2014  As a result  annual spending on the capsules by Britain s National Health Service rose from 2 million pounds in 2012 to about 50 million in 2013  The CMA said UK prices were many times higher than elsewhere in Europe  Pfizer used to market the medicine under the brand name Epanutin but sold the rights to Flynn  a privately owned British company  in September 2012  It was then debranded  meaning that it was no longer subject to price regulation  and the price soared   The companies deliberately exploited the opportunity offered by debranding to hike up the price for a drug which is relied upon by many thousands of patients   Philip Marsden  chairman of the CMA s case decision group  said on Wednesday   This is the highest fine the CMA has imposed and it sends out a clear message to the sector that we are determined to crack down on such behavior   The previous highest fine of 58 5 million pounds was handed to British Airways  L ICAG  in 2012 for colluding with rival Virgin Atlantic  VA UL  on fuel surcharges  That was imposed by the CMA s predecessor  the Office of Fair Trading  Pfizer said it planned to appeal all aspects of the verdict  The U S  drugmaker said the medicine had been loss making and it was therefore forced to consider whether it could continue supplying it  Pfizer added that the price set by Flynn was actually 25 to 40 percent less than the cost of an equivalent tablet form from another supplier  Flynn s chief executive David Fakes said punishing his company  which also plans to appeal  for selling phenytoin capsules for less than phenytoin tablets  beggars belief   The CMA also ordered both to reduce their prices  a move that lawyers said could trigger claims for redress from customers who had been over charged  In February it fined GlaxoSmithKline  L GSK  37 6 million pounds for striking deals to delay the launch of cheap generic copies of its former blockbuster antidepressant Seroxat  The watchdog has four other ongoing investigations into the pharmaceutical sector ,2016-12-07,Reuters,https://www.investing.com/news/stock-market-news/britain-fines-pfizer-record-$107-million-for-huge-drug-price-hike-446236,446236
220389,441905,PFE,Exclusive  Lonza says in talks to buy Capsugel  deal could top  5 billion   sources,news,"By Greg Roumeliotis  Reuters    Swiss pharmaceutical manufacturer Lonza Group AG  S LONN  on Monday confirmed it is in advanced talks with private equity firm KKR   Co LP  N KKR  to acquire Capsugel  a U S  maker of capsule products and other drug delivery systems  Sources familiar with the talks told Reuters that a potential transaction would be valued at more than  5 billion  Capsugel  would fit perfectly with Lonza s     strategy and strengthen its position as leading supplier to a number of important healthcare markets   Lonza said in a statement   A successful acquisition would be value adding and be within Lonza s stated acquisition criteria   The deal  which Lonza said still may not come to fruition  comes as the Swiss drug ingredient maker seeks to boost its life sciences capabilities and produce a wider range of molecules used in active pharmaceutical ingredients and drug delivery  It held unsuccessful talks to acquire U S  drug delivery technology company  Catalent Inc   N CTLT  earlier this year   Discussions between Lonza and KKR could lead to a deal as early this week  people familiar with the talks said on Sunday  The sources asked not to be identified because the negotiations are confidential  Capsugel and KKR did not immediately respond to requests for comment  Based in Morristown  New Jersey  Capsugel manufacturers empty two piece hard capsules as well as finished dosage forms for drug delivery  It serves more than 4 000 corporate customers in over 100 countries  Reuters reported in March that KKR was preparing to run a sale process for Capsugel this year  and also explore the possibility of an initial public offering of the company as an alternative to an outright sale  KKR acquired Capsugel from  Pfizer  Inc  N PFE  for  2 4 billion in 2011   
Lonza has been expanding its presence in the United States in recent years  buying up small biopharmaceutical companies and in 2011 acquiring chemical maker Arch Chemicals for  1 4 billion  Lonza has a market capitalization of 9 4 billion Swiss francs   9 25 billion  ",2016-12-12,Reuters,https://www.investing.com/news/stock-market-news/exclusive:-lonza-in-talks-to-buy-capsugel-for-more-than-$5-billion---sources-447087,447087
220393,441909,PFE,Cohen s SAC Capital in  135 million settlement with Elan investors,news,"By Jonathan Stempel and Nate Raymond NEW YORK  Reuters    Billionaire Steven A  Cohen s former hedge fund SAC Capital Advisors LP will pay  135 million to settle a lawsuit by investors in the drugmaker Elan Corp  who said they lost money because of insider trading by one of his portfolio managers  The preliminary class action settlement with SAC  now known as Point72 Asset Management LP  was filed on Wednesday with the federal court in Manhattan  and requires approval by U S  District Judge John Koeltl  It resolves claims over an estimated  275 million of illegal trading gains in Elan and the drugmaker Wyeth by Mathew Martoma  who worked at SAC s CR Intrinsic Investors unit  based on tips from a Michigan doctor about a 2008 Alzheimer s drug trial   We are pleased to have resolved this matter and close the books on this chapter of SAC era litigation   Point72 spokesman Mark Herr said in a statement  SAC pleaded guilty to fraud in 2013 and paid  1 8 billion in criminal and civil settlements with U S  authorities  It settled with Wyeth shareholders for  10 million last December  Martoma  meanwhile  is appealing his February 2014 insider trading conviction  while he serves a nine year prison term  Cohen  60  was not criminally charged  but in January accepted a two year ban on managing money for outside investors to end a U S  Securities and Exchange Commission civil probe into his supervision of Martoma  That ban ends on Jan  1  2018  and no fine was imposed  Point72 is based in Stamford  Connecticut  SAC and Cohen did not admit wrongdoing in settling with the former Elan investors  including purchasers of its American depositary receipts and stock options   Perrigo Co   N PRGO  bought Elan in 2013  while  Pfizer  Inc  N PFE  bought Wyeth in 2009  Lawyers for the Elan investors plan to seek up to  35 1 million for legal fees and  2 8 million for costs  which would be drawn from the  135 million settlement  court papers show  Cohen can donate leftover settlement funds to charities he chooses  with the consent of the Elan investors  He is worth  13 billion  Forbes magazine said  
The case is Kaplan et al v SAC Capital Advisors LP et al  U S  District Court  Southern District of New York  No  12 09350 ",2016-11-30,Reuters,https://www.investing.com/news/stock-market-news/cohen's-sac-capital-reaches-$135-million-settlement-with-elan-investors-444750,444750
220404,441920,PFE,Pfizer prices  6B debt offering,news,Pfizer   NYSE PFE  prices a  6B debt offering consisting of five tranches  1 00B aggregate principal amount of 1 700  notes due 2019  1 00B aggregate principal amount of 2 200  notes due 2021  1 75B aggregate principal amount of 3 000  notes due 2026  1 00B aggregate principal amount of 4 000  notes due 2036  1 25B aggregate principal amount of 4 125  notes due 2046 Net proceeds will fund the purchase of the company s 6 200  Senior Notes due March 15  2019  Remaining proceeds will be used for general corporate purposes  Closing date is November 21 ,2016-11-15,Seeking Alpha,https://www.investing.com/news/stock-market-news/pfizer-prices-$6b-debt-offering-440849,440849
220405,441921,PFE,Sanofi  GSK expect further price pressure  more M A under Trump,news,"By Ben Hirschler
LONDON  Reuters    Two of Europe s biggest drugmakers warned on Tuesday there would be no let up in pressure on U S  medicine prices after last week s presidential election win for Republican Donald Trump  which sent pharmaceutical and biotech shares soaring 
Mergers and acquisitions  M A  in the sector  meanwhile  could get a big boost if Trump pushes through plans for a U S   tax holiday  on repatriated overseas profits  executives said 
Both France s Sanofi  PA SASY  and Britain s GlaxoSmithKline  L GSK  have recent direct experience of U S  pricing pressure  with healthcare providers forcing big discounts for their top selling diabetes and respiratory medicines 
In the run up to the U S  election  investors had focused on the threat of price controls posed by Democrat Hillary Clinton  yet Trump also advocated a new role for government agencies in negotiating down drug costs 
 I don t think the pricing debate is over   Sanofi Chief Executive Olivier Brandicourt told an industry conference 
Drugmakers are already having to work much harder to justify U S  prices due to the rising power of U S  pharmacy benefit managers  PBMs   which administer drug benefits and negotiate rebates for employers and health plans 
The buying power of these middlemen has been brought to bear particularly in areas of medicine where there are several similar treatments to choose from  such as insulin injections and inhalers for asthma and chronic lung disease 
OVERSEAS CASH
The trend toward big buyers squeezing prices is only going to accelerate as the U S  healthcare system struggles to find the resources to pay for new medical interventions  GSK CEO Andrew Witty said 
 It doesn t really matter too much who won the U S  election because the direction of travel of the U S  marketplace  owned not by one stakeholder in the White House but by multiple stakeholders in public and private decision making environments  is already set   he told the Financial Times meeting 
Manufacturers contend that the discounts extracted by PBMs are not always passed on to patients 
 We are making significant concessions but patients are paying more   said Brandicourt  who believes legislation may eventually be needed to ensure patients gain from the discounts 
Another key question for investors is the potential for a further wave of deal making in the healthcare sector  given impetus by Trump s plan to work with Congress to allow U S  firms to pay a lower tax rate when bringing back overseas cash 
That would add tens of billions of dollars in firepower for pharma and biotech acquisitions  with deal hungry  Pfizer   N PFE  alone having more than  80 billion it wants to repatriate 
 I think there is likely to be quite a lot of M A next year   said GSK s head of strategy David Redfern   The only thing unclear is how big it gets  ",2016-11-15,Reuters,"https://www.investing.com/news/stock-market-news/sanofi,-gsk-expect-further-price-pressure,-more-m-a-under-trump-440958",440958
220406,441922,PFE,Roche  Bristol Myers cut cancer drug prices to win UK approval,news,"LONDON  Reuters    Roche and Bristol Myers Squibb on Thursday became the latest drugmakers to cut the price of cancer medicines in order to secure access to Britain s National Health Service  The National Institute for Health and Care Excellence  NICE  cost watchdog  which had rejected Roche s breast cancer treatment Perjeta in May  said a price discount now offered by the Swiss firm had helped win it a green light  Bristol s leukemia drug Sprycel was also recommended for routine use after the U S  company offered a bigger discount  Sprycel was previously covered by the Cancer Drugs Fund  CDF   which was overhauled earlier this year   Out of nine CDF treatments that NICE has looked at so far  seven have been cleared for general use  The remainder are in the process of being reappraised   Sensible pricing and in some cases better data is helping to secure access to important cancer medicines as they move out of the old Cancer Drugs Fund   said NICE Chief Executive Andrew Dillon  Other international drugmakers including Novartis and  Pfizer   NYSE PFE  have also offered increased discounts in recent months  The exact size of all these discounts is commercially confidential  
Roche s Perjeta is designed for use in combination with chemotherapy and Herceptin before breast cancer surgery  while Sprycel is used in certain types of chronic myeloid leukemia ",2016-11-16,Reuters,"https://www.investing.com/news/stock-market-news/roche,-bristol-myers-cut-cancer-drug-prices-to-win-uk-approval-441593",441593
220407,441923,PFE,Pfizer sues Texas AG over release of Medicaid discounts,news,Pfizer   PFE  0 6   takes exception to the release of Medicaid rebate data to state lawmakers by the Texas Health and Human Services Commission  The agency  which initially said no  acquiesced after the Texas Attorney General determined that the release would not violate state law  The state Senate wanted the information as part of their efforts to manage drug costs The company promptly filed a lawsuit requesting a temporary restraining order and preliminary injunction to prevent any further data disclosures  It also wants to be notified of any future requests  Pfizer claims that if other large customers were award of the pricing in Texas  it  would not be able to provide such pricing and rebates to every entity due to their unique differences in size  market and particular needs  ,2016-11-18,Seeking Alpha,https://www.investing.com/news/stock-market-news/pfizer-sues-texas-ag-over-release-of-medicaid-discounts-442406,442406
220408,441924,PFE,Currency drop hits Egypt s medicine supplies  angering public,news,"By Arwa Gaballa and Eric Knecht
CAIRO  Reuters    Pharmacies across Egypt are running short of medicines  some of them life savers  as a plunge in the value of the Egyptian pound coupled with strict government price caps has made scores of products unprofitable to produce or import 
The shortages include some cancer treatments as well as basic items like insulin  tetanus shots and contraceptive pills 
Unable to raise prices above levels set by the Health Ministry but now paying roughly twice as much to import drugs or active ingredients  pharmaceutical firms say they have been forced to phase out certain medicine to stay in business 
 We aren t a charity  We have expenses and production costs  and if a company isn t making profit it will have to halt production   said Said Ibrahim  factory manager at EIPICO  one of Egypt s largest pharmaceutical companies 
That brings no comfort to pharmacists and sick Egyptians 
Out of insulin for weeks  Ali Etman said he was recently forced to turn away eight diabetes patients from his Cairo pharmacy in a single day 
 Patients who come looking for insulin ask me   What am I supposed to do  Die   and I don t know what to tell them  I don t have the drugs they need   Etman said 
Egypt floated its currency on Nov  3  abandoning a peg of 8 8 pounds to the U S  dollar and allowing the currency to roughly halve in value to about 17 50 on Tuesday  
The float helped the cash strapped government clinch a  12 billion IMF loan it hopes will unlock investment and revive growth that has been hampered by political uncertainty since the 2011 uprising that toppled President Hosni Mubarak 
But the medicine shortages are piling pressure on the government of general turned president Abdel Fattah al Sisi  who has been at pains to reassure a populace already struggling with double digit inflation and intermittent shortages that they would be shielded from the worst effects of economic reforms 
Talk of a looming healthcare crisis has dominated popular evening chatshows  with doctors calling in nightly to report rapidly depleting stocks and patients being turned away from hospitals for lack of supplies 
The Health Ministry has blamed the problem on panicking Egyptians hoarding medicines and said it would not raise prices 
Drug shortages are not new to Egypt  More medicines had already begun disappearing from shelves early this year as a severe shortage of dollars in the banks meant pharmaceutical firms could not pay for the necessary imports 
Egypt has struggled to earn enough dollars since the 2011 uprising scared off foreign investors and tourists and the central bank drained its reserves defending the currency peg 
The Health Ministry set up a Drug Shortages Directorate in 2012 to minimize the impact by suggesting suitable substitutes for missing medicines  But the situation has only worsened 
EIPICO s vice president told Reuters about 1 600 drugs had gone short in recent months  including 35 that have no alternatives and would disappear from the market if price caps were not eased 
 Distributors are now telling pharmacies nothing imported is available  The problem has been going on for a while  but has only turned into a crisis in recent weeks   Etman said 
SITUATION WORSENING
Egypt s drugs market is 40 percent multinational   big suppliers include  Pfizer   NYSE PFE   Novartis  GlaxoSmithKline and Sanofi  PA SASY    and 60 percent domestic  Nearly all of it is in private hands  with annual sales worth a total of about 50 billion pounds before the float 
Ahmed al Ezaby  head of the medicine industry division at Federation of Egyptian Industries  said Egypt imports about  600 million in finished medicines per year and  1 8 billion in active ingredients 
Officials at multinationals said they were concerned at the worsening situation  One industry source said companies were now in talks with Egyptian ministries on the possibility of restoring some prices to pre Nov  3 levels  in dollar terms  to ensure supplies of the most critical medicines 
The multinationals have local factories set up but 15 20 percent of drugs are imported  while 80 85 percent are produced locally  About 70 percent of all drugs in Egypt are generic and domestic made 
A spokesman for Sanofi said the French group was  actively engaging local authorities to define a sustainable pricing mechanism  
Egypt s supply problems echo those in Venezuela  where a lack of dollars has also created drug shortages and left manufacturers nursing big losses    
Before the flotation  Egypt faced a dollar shortage that saw imported goods ranging from electronic equipment to sugar disappear briefly from shelves in the past year 
The central bank rationed supplies via weekly auctions  earmarking the little it had for essential items like medicine 
Dollar supply is less of an issue since the flotation  But the cost of buying the greenback is because companies import active ingredients they need to make generic medicines 
The government  which already raised prices on a slew of medicines this year  is under pressure to keep drugs affordable for tens of millions of poor Egyptians 
It has blamed the crisis on hoarding and greed   
 It s an orchestrated crisis  The decision to float the pound was taken   and two hours later people began saying we have a crisis and we don t have meds   Health Ministry spokesman Khaled Mogahed told the Egyptian TV channel Mehwar 
 It s a way to push for a rise in medicine prices  which will not happen  
Mogahed did not respond to requests from Reuters for comment 
The companies want the government to remove the price caps entirely or re adjust them to ease their losses 
The Health Ministry met last week with drug industry leaders to discuss an emergency plan  It has offered to subsidize pharmaceutical companies to the tune of  165 million to support imports of life saving drugs that have no viable substitutes  including some cancer treatments 
Companies said the amount was not nearly enough while rolling out a new subsidy program would take time 
 There s no way of knowing how long this amount will last because cancer drugs are expensive and it depends on the shortages  but the amount is not enough to solve the problem   said Adel Abdel Maksoud  head of the pharmacy division at the Cairo Chamber of Commerce 
TWITTER PHARMACY
In the meantime the companies say they have to stop offering the drugs which most cut into their profits  Some have already sent back shipments that were ordered before the float but arrived after  as selling them at the fixed prices would have created big losses  They all say they have to downsize and cut out certain drugs 
 We re working on a strategy to eliminate any product that s not profitable  But companies that depend on unprofitable products will be forced to shut down now given the new currency rate   said ITO Pharma s deputy general manager Mohamed Geoushy 
More life saving drugs will soon disappear  he said 
His company is one of only two suppliers of cyclosporine  a drug used to prevent organ rejection during transplants  It recently stopped importing the drug  he said  
Pharmacists say patients have no choice but to resort to a black market for once common items like saline and glucose at prices often 10 times higher than the official caps and far beyond the reach of most 
On Twitter  resourceful Egyptians have set up the hashtag  Twitter Pharmacy  to swap medicines they cannot find in shops  Hospitals are using social media to advertise their needs 
 Every minister should have sat down with the government after the float and discussed an emergency plan because it s a crisis if patients can t find life saving medicines   said Osama Tahoon  general manager of medicine producer Julphar Egypt 

 We can give up sugar or tea  but we can t give up medicine  ",2016-11-22,Reuters,"https://www.investing.com/news/economy-news/currency-drop-hits-egypt's-medicine-supplies,-angering-public-442990",442990
220411,441927,PFE,Agios Pharmaceuticals Shares Rise On Buyout Speculation,opinion,Shares of Agios Pharmaceuticals  Inc    NASDAQ AGIO   rallied almost 10  on Apr 9 after speculations were rife that the company might be acquired by other big players in the pharma and biotech industry  This bullish sentiment around the stock among investors was mainly triggered following Novartis    NYSE NVS   yesterday s announcement that it has inked a deal to acquire the U S  based clinical stage gene therapy company  AveXis  Inc   NASDAQ AVXS   Particularly  Celgene  NASDAQ CELG  which already notched up a collaboration agreement with Agios for developing novel therapies  utilizing Agios  innovative cellular metabolism research platform is being considered a front runner in buying Agios Let us have a look why Celgene or any other big drug biotech company may be interested in Agios Shares of Agios have surged 49 1  in a year s time  outperforming the  s increase of 11 4   FDA s last year approval of the Agios  only marketed drug  Idhifa  enasidenib   and the company s rapid progress on a robust pipeline in the past year accompanied with some study initiations and positive readouts have steadily pushed up its share price  In August 2017  the FDA approved Idhifa for treating patients with relapsed or refractory acute myeloid leukemia  AML  with an isocitrate dehydrogenase 2  IDH2  mutation  The drug provides a first ever alternative treatment to patients living with the aforementioned indication in the United States  Notably  Idhifa also enjoys an Orphan Drug status in the EU for treatment of AML Agios  progress with the pipeline has also been quite impressive  The company has some interesting candidates in its portfolio including an IDH1 mutant inhibitor  AG 120  ivosidenib  and a pan IDH mutant inhibitor  AG 881 Last June  Agios presented positive data from the dose escalation and expansion cohorts of the phase I study  evaluating single agent ivosidenib in mutant positive cholangiocarcinoma at the ASCO Ivosidenib is also being evaluated in a phase I expansion cohort for treatment of patients with IDH1m R R AML  Data from the study demonstrated durable responses  which allowed the company to submit a new drug application to the FDA for ivosidenib  late last December In the same month  the company also announced positive results from a phase I trial  assessing ivosidenib in combination with standard induction chemotherapy or Celgene s Vidaza  Azacitadine  for treatment of newly diagnosed AML patients  not eligible for intensive chemotherapy Presently  a phase III AGILE study examining ivosidenib in combination with Vidaza is also underway for the given indication Apart from ivosidenib  Agios is conducting phase I programs on AG 881 for treatment of patients with advanced IDH1 or IDH2 mutant positive solid tumors The company has another interesting candidate in its portfolio  Its lead rare genetic diseases candidate  AG 348  is under evaluation in a phase II study on adult  transfusion independent patients with Pyruvate kinase deficiency A consistent progress with these investigational candidates makes Agios one of the most lucrative takeover options for other large players in the drug biotech space at the moment M A activity is expected to be aggressive in the drug biotech sector this year following the new tax law  This was evident from Sanofi  PA SASY  and Celgene already announcing two deals each  Also  Pfizer   NYSE PFE   is aggressively on the lookout for a buyer to purchase its Consumer Healthcare unit after British firms Glaxo and Reckitt Benckiser Group pulled out of discussions  Moreover  this April  Japan based Takeda Pharmaceutical announced its intention to acquire Shire plc Agios Pharmaceuticals  Inc  Price    Zacks RankAgios carries a Zacks Rank  3  Hold   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-04-09,Zacks Investment Research,https://www.investing.com/analysis/agios-pharmaceuticals-shares-rise-on-buyout-speculation-200304400,200304400
220413,441929,PFE,Pfizer s Ibrance OK d in Europe for breast cancer,news,As expected  the European Commission approves  Pfizer  s  NYSE PFE  IBRANCE  palbociclib   in combination with an aromatase inhibitor  e g   AstraZeneca s  NYSE AZN  Arimidex  anastrozole   for the treatment of women with hormone receptor positive  human epidermal growth factor receptor 2 negative  HR  HER2   locally advanced or metastatic breast cancer  The approval also covers the use of IBRANCE in combination with fulvestrant  AZN s FASLODEX  who have received prior endocrine therapy Palbociclib is an inhibitor of cyclin dependent kinase  CDK  4 and 6  downstream signaling pathways which lead to cellular proliferation  When combined with an antiestrogen  it inhibits the growth of breast cancer by interfering with these pathways and promoting the deterioration of cancer cells  senescence  The advisory committee CHMP adopted a positive opinion in mid September backing approval ,2016-11-10,Seeking Alpha,https://www.investing.com/news/stock-market-news/pfizer's-ibrance-ok'd-in-europe-for-breast-cancer-439506,439506
220417,441933,PFE,Can Fite Bio awarded patent covering ED candidate,news,Can Fite BioPharma  NYSEMKT CANF  receives a Notice of Allowance from the U S  Patent and Trademark Office for its patent application covering A3 adenosine receptor  A3AR  ligands for use in the treatment of erectile dysfunction  ED   Specifically  the patent relates to methods for treating ED with different A3AR ligands including its candidate CF602 CF602 has a similar mechanism of action to  Pfizer  s  NYSE PFE  Viagra  sildenafil  ,2016-11-09,Seeking Alpha,https://www.investing.com/news/stock-market-news/can-fite-bio-awarded-patent-covering-ed-candidate-439128,439128
220421,441937,PFE,Ex Oppenheimer adviser pleads guilty to U S  insider trading charges,news,"By Nate Raymond
NEW YORK  Reuters    A former investment adviser at an Oppenheimer Holdings Inc unit pleaded guilty on Tuesday to charges that he engaged in an insider trading scheme based on information supplied by a childhood friend working at  Pfizer  Inc   NYSE PFE 
David Hobson  48  entered his plea in Manhattan federal court to conspiracy and securities fraud charges over conduct that began while he was at Royal Bank of Canada unit RBC Capital Markets and then continued at Oppenheimer   Co Inc 
Hobson  a Providence  Rhode Island  resident  admitted that he executed trades based on inside information supplied by Michael Maciocio  a friend at Pfizer who pleaded guilty in May as part of a deal to cooperate with prosecutors 
 I m sorry for these actions  and I apologize to the court and to my family   Hobson said in court 
Under a plea agreement  Hobson agreed to forfeit almost  386 000 and not appeal any prison sentence of 2 1 2 years or less  U S  District Judge Laura Taylor Swain scheduled his sentencing for March 2 
The case was announced in June amid a resurgence of insider trading cases this year in Manhattan  where prosecutors have wrestled with a 2014 appellate ruling that limited the scope of insider trading laws 
According to prosecutors  Hobson and Maciocio engaged in an insider trading scheme from 2008 to 2014 based on information obtained by Maciocio  a director of chemical research and development at Pfizer 
As part of that job  Maciocio at times evaluated Pfizer s capacity to manufacture drugs that other companies Pfizer considered potential acquisition targets or partners were developing  authorities said 
While Maciocio was not typically given the identity of a company in a potential deal  with Hobson s help he performed research to discern its identity  the indictment said 
After identifying the company  Maciocio then passed the information to Hobson  his stockbroker  who executed trades in accounts belonging to himself  Maciocio  and clients of Oppenheimer and RBC  prosecutors said 
Trades by Hobson in the stocks of Medivation Inc  Ardea Biosciences Inc and Furiex Pharmaceuticals Inc resulted in profits of  180 000 for himself   40 000 for Maciocio and  150 000 for certain of Hobson s clients  prosecutors said 
The case is U S  v  Hobson  U S  District Court  Southern District of New York  No  16 cr 351 ",2016-10-25,Reuters,https://www.investing.com/news/stock-market-news/ex-oppenheimer-adviser-pleads-guilty-to-u.s.-insider-trading-charges-434667,434667
220422,441938,PFE,Pfizer Q3 EPS estimate  0 49 on revenues up 7 2  at  13 03 bn ,news,Investing com    Pfizer   NYSE PFE  Q3 EPS estimated at  0 49  revenues seen up 7 2  yoy at  13 03 bn Global pharmaceutical firm reports Tuesday before the market opens Pfizer in September opted not to split business into two segments Prevenar 13 drug sales seen slowing  Lyrica to post single digit growth until patent expires Dividend may be hiked from  0 30 quarter  attractive yield of 3 75  Even with P E higher than sector average  Pfizer still seen safe investment ,2016-10-31,Investing.com,https://www.investing.com/news/stock-market-news/pfizer-q3-eps-estimate-$0.49-on-revenues-up-7.2-at-$13.03-bn-436214,436214
220423,441939,PFE,U S  stock index futures up as oil steadies ,news,Investing com   U S  stock index futures higher on Tuesday as oil steadied but still close to one month lows The Dow futures was up 0 18  at 05 45 ET  while the S P 500 futures added 0 24  The tech heavy Nasdaq futures advanced 0 21  U S  November rate hike odds very slim ahead of U S elections as FOMC meets Investing com s Fed Rate Monitor Tool shows 73  chance of 25 basis point hike in December  Pfizer   NYSE PFE  Q3 earnings report due out before market opens ,2016-11-01,Investing.com,https://www.investing.com/news/stock-market-news/u.s.-stock-index-futures-up-as-oil-steadies-436420,436420
220424,441940,PFE,Pfizer Q3 EPS  0 61 vs estimate  0 62  revenues mostly in line ,news,"Investing com    Pfizer   NYSE PFE  Q3 adjusted diluted EPS  0 61 vs estimate  0 62  year earlier  0 60 
Revenues rose 8  from a year earlier to  13 05 bn  just short of estimate of  13 06 bn 
Pfizer narrows full year EPS guidance range to  2 38  2 43 from  2 38  2 48 
Revenues guidance range adjusted to  52  53 bn from  51  53 bn 
Pfizer shares up 0 7  at  31 92 in pre market trade ",2016-11-01,Investing.com,https://www.investing.com/news/stock-market-news/pfizer-q3-eps-$0.61-vs-estimate-$0.62;-revenues-mostly-in-line-436449,436449
220425,441941,PFE,Wall St edges lower as FOMC kicks off  oil steadies ,news,Investing com   U S  stocks edged lower early Tuesday as FOMC meeting began and as oil steadied The DJI was down 0 08  at 10 30 ET as the S P 500 shed 0 11  The tech heavy Nasdaq composite was off 0 10  October manufacturing PMI higher than expected as the FOMC meeting began U S  Treasury yields higher as upbeat China data eases fears of global slowdown   Pfizer   NYSE PFE  was down 0 43  at  31 57 as Q3 earnings disappoint  cholesterol drug scrapped ,2016-11-01,Investing.com,"https://www.investing.com/news/stock-market-news/wall-st-edges-lower-as-fomc-kicks-off,-oil-steadies-436550",436550
220431,441947,PFE,Pfizer to seek more modern Manhattan headquarters,news, Reuters     Pfizer  Inc  NYSE PFE   the largest U S  drugmaker  said on Thursday it aims to sell its New York City world headquarters buildings in midtown Manhattan by the end of 2017 and begin moving into more modern Manhattan facilities no sooner than the first half of 2019   This move is being driven by the significant investment that would be required to bring the  existing  buildings to modern standards   Pfizer said in a statement  Company spokeswoman Joan Campion added that the company had notified employees of the plans on Wednesday   Pfizer s headquarters include two buildings in midtown Manhattan with about 1 million square feet of space  Pfizer began occupying the buildings at 235 and 219 East 42nd Street in 1961  A newer complex would have more work space and room for collaboration  Campion said  Pfizer  founded in 1849 in Brooklyn  New York  said it had not yet chosen the new location  A large majority of headquarters based employees will move to the more modern facility  Pfizer said  Some could be reassigned to other sites in the metropolitan area  Pfizer s plans follow its decision in April to abandon its proposed  160 billion purchase of Botox maker Allergan  NYSE AGN pa  Plc  The deal would have moved the company s tax address to Dublin  thereby sharply lowering its effective tax rate   But Pfizer terminated it after the U S  Treasury proposed new regulations that would have removed many of the tax advantages ,2016-10-06,Reuters,https://www.investing.com/news/stock-market-news/pfizer-to-seek-more-modern-manhattan-headquarters-430796,430796
220432,441948,PFE,Arizona execution procedures face review in U S  court,news,By Jon Herskovitz  Reuters    A federal judge in Phoenix will hear arguments this week about resuming executions in Arizona  where a 2014 lethal injection that took nearly two hours raised questions about the state s death chamber protocols and the chemicals it uses to kill inmates  The case is the latest to raise questions about the drugs used in many states to execute prisoners  and it may wind up putting the issue back for review by the U S  Supreme Court  Arizona last year changed its lethal injection procedures following the troubling 2014 execution of Joseph Wood  but lawyers for seven Arizona death row inmates contend new guidelines and drugs will violate U S  constitutional protections against cruel and unusual punishment  A major issue at the hearing set for Wednesday in U S  district court will be the sedative midazolam  a valium like drug critics contend does not achieve the level of unconsciousness required for surgery and is therefore unsuitable for executions  The drug was used in Wood s execution along with a narcotic  hydromorphone  He was seen gasping for air during a nearly two hour procedure where he received 15 rounds of drug injections  Lethal injections are supposed to result in death in a matter of minutes  Under the new protocols  Arizona plans to use midazolam along with a drug that causes paralysis and another that stops the heart  A similar combination was used in Oklahoma  which had a troubled execution where an inmate was seen twisting on a death chamber gurney  Lawyers for the inmates contend the source of the drugs and their purity have been cloaked in secrecy  since European makers and U S  pharmaceutical company  Pfizer  Inc  NYSE PFE  halted sales of drugs used in executions to prison systems in recent years  They also charge that if midazolam is truly effective there would be no need for a paralytic agent  which could be used to mask pain  The lawyers want executions to put future executions on hold while the court reviews the protocols   Officials in Arizona have fought tooth and nail to protect that secrecy  which  along with the use of an experimental drug combination  only serves to increase the risk of more problematic executions   said Dale Baich  an attorney for the inmates  The state contends its protocols correct previous problems  and point to a June 2015 U S  Supreme Court decision that allowed the use of midazolam in executions   I would ask the  district  court to remember that victims and state governments have rights and interests  too  including an important interest in the timely enforcement of a sentence and the state s interest to enforce its own laws   David Weinzweig argued on behalf of Arizona at a hearing this year ,2016-10-18,Reuters,https://www.investing.com/news/politics-news/arizona-execution-procedures-face-review-in-u.s.-court-433118,433118
220434,441950,PFE,Pfizer Gets FDA Panel Backing For New Indication For Xeljanz,opinion,Pfizer Inc    NYSE PFE   announced a positive outcome from FDA Gastrointestinal Drugs Advisory Committee  GIDAC  meeting that discussed the company s supplemental New Drug Application  sNDA  looking for label expansion of Xeljanz  tofacitinib  Pfizer is seeking to get Xeljanz approved for the treatment of adult patients with moderately to severely active ulcerative colitis  UC   Xeljanz  a Janus kinase  JAK  inhibitor  is already approved to treat rheumatoid arthritis and active psoriatic arthritis  The supplemental New Drug Application  sNDA  for Xeljanz is currently under review by the FDA Shares of Pfizer are up 7 2  in the past year  compared with a 9 2  increase for the  it belongs to The GIDAC gave its vote on two voting questions related to the use of the 10 mg twice daily  BID  dose beyond the eight week induction period  The sNDA included proposed dosing regimen of Xeljanz 10 mg  twice daily  BID  for eight weeks of induction followed by a dose of 5 mg BID for maintenance  It also proposed an extension of the use of tofacitinib 10 mg BID from eight to 16 weeks of induction in adult patients who have not achieved adequate therapeutic benefit by Week 8 and also 10 mg BID for maintenance therapy in patients with an inadequate response  loss of response  or intolerance to TNF blocker therapy  The 10 mg BID voted unanimously  15 0  for both the proposals  However  the Committee voted 8 7 against conducting a post marketing efficacy study comparing a tofacitinib 10 mg BID continuous dosing regimen with a regimen of tofacitinib 10 mg BID induction and 5 mg BID as maintenance in the UC population   The recommendations given by the GIDAC are not binding  The FDA s decision on whether or not to approve tofacitinib for UC is expected in June 2018 Pfizer Inc  Price    Zacks Rank   Other Stocks to ConsiderPfizer carries a Zacks Rank  2  Buy  Some other top ranked stocks from the same space are Regeneron   NASDAQ REGN    Ligand Pharmaceuticals   NASDAQ LGND   and Enanta Pharma   NASDAQ ENTA    While Regeneron and Ligand sport a Zacks Rank  1  Strong Buy   Enanta Pharma carries a Zacks Rank  2  You can see  Regeneron s earnings per share estimates have moved up from  17 13 to  18 65 and from  20 37 to  21 56 for 2018 and 2019  respectively in the last 30 days  The company pulled off a positive earnings surprise in three of the last four quarters  with an average beat of 9 15  Ligand s earnings per share estimates have moved up  3 78 to  4 15 from  4 75 to  5 75 for 2018 and 2019 respectively over the last 30 days  The company delivered positive earnings surprises in three of the trailing four quarters  with an average beat of 24 88   The company s shares have rallied 61  over a year Enanta Pharma delivered a positive earnings surprise in three of the last four quarters  with an average beat of 373 1   The company s shares surged 184 4  over a year Don t Even Think About Buying Bitcoin Until You Read This The most popular cryptocurrency skyrocketed last year  giving some investors the chance to bank 20X returns or even more  Those gains  however  came with serious volatility and risk  Bitcoin sank 25  or more 3 times in 2017 Zacks has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly ,2018-03-08,Zacks Investment Research,https://www.investing.com/analysis/pfizer-gets-fda-panel-backing-for-new-indication-for-xeljanz-200296886,200296886
220435,441951,PFE,Basilea Pharmaceutica  Strength In Numbers ,opinion,"Basilea Pharmaceutica AG  SIX BSLN  reported a definable FY17  as a multitude of licensing distribution agreements announced in 2016 17 for launched anti infective drug assets Cresemba  isavuconazole  and Zevtera  ceftobiprole  aided reported product sales  royalty and milestone income  Total revenues grew 54  to CHF101 5m  of which CHF16 3m related to product sales and CHF15 0m to royalty income  Operating losses declined by 68  to CHF14 1m  For 2018  we expect operating losses to reduce further as higher R D costs are offset by growth in total revenues  We value Basilea at CHF1 231m 

Numerous partnerships aid anti infectives growth
Cresemba is currently available in the US  Nordic regions and Europe through partners  Astellas  Unimedic and Pfizer  NYSE PFE   respectively   We anticipate market share growth in launched territories to be supported by new roll outs over 2018 19 20  depending on whether MAA has been granted or if a regulatory submission is the next step   Zevtera will benefit from partner Cardiome launching the product in additional European countries  however  the significant value driver for Zevtera is the US market  the largest market by value for branded hospital antibiotics  
To read the entire report Please click on the pdf File Below ",2018-03-09,Edison,https://www.investing.com/analysis/basilea-pharmaceutica-strength-in-numbers-200296789,200296789
220437,441953,PFE,FDA panel recommends dropping serious warning on Pfizer s Chantix,news,"By Natalie Grover  Reuters    A serious warning on  Pfizer  Inc s  N PFE  quit smoking drug should be removed  10 of 19 independent panelists to the U S  Food and Drug Administration recommended on Wednesday  after reviewing additional trial data on the controversial treatment  Pfizer s Chantix was approved about a decade ago  but thousands of reports of mental health problems in users led to the FDA imposing the  black box  warning   the most severe available   in 2009   On Wednesday  four of the 19 panelists voted to update the language in the box warning   of neuropsychiatric risks including suicidal thoughts  hostility and agitation   while five recommended retaining it  The 10 who voted in favor of removal stressed that the benefits of quitting smoking far outweighed the potential severe side effects of the drug  and that the evidence of causality between Chantix and the side effects was not clear enough to warrant a black box   Cigarette smoking is the leading cause of preventable disease and death in the United States  accounting for about 1 of every 5 deaths  according to the U S Centers for Disease Control and Prevention   Pfizer failed a previous attempt to get rid of the boxed warning  after the FDA went along with a panel recommendation in 2014 to retain it pending the outcome of the additional study   Since then Pfizer has released results from the study that compared either Chantix or GlaxoSmithKline Plc s  L GSK  Zyban  with a placebo or a nicotine patch in patients with and without a history of psychiatric disorders  FDA staff on Monday issued a scathing review of how the study was conducted by Pfizer  flagging multiple inconsistencies across the 140 sites and multiple countries in which data was collected   But when the FDA conducted its own analysis  excluding data they deemed unreliable  the results appeared to be consistent with Pfizer s conclusion that Chantix does not significantly increase the incidence of such side effects   The discussion among panelists on Wednesday ranged from whether certain adverse events were the result of tobacco withdrawal or the drug  as well as the trend of a higher number of psychiatric side effects seen in patients with a history of mental illness  Patients with psychiatric disorders are far more vulnerable to tobacco addiction  and less likely to be prescribed treatments for smoking cessation  they noted  saying that the exclusion of the boxed warning would go a long way in improving statistics  Some panelists who voted to modify the warning or retain it in its present form  said they were fearful of setting a dangerous precedent for other drugmakers looking to remove such warnings off of their products  or that Pfizer s implementation of trial design left a lot to be desired  
The FDA is not obligated to follow the recommendations of its panel  but typically does so ",2016-09-14,Reuters,https://www.investing.com/news/stock-market-news/fda-panel-recommends-dropping-serious-warning-on-pfizer's-chantix-426256,426256
220438,441954,PFE,Pfizer down 1  as global drugs firm opts not to pursue split ,news,Investing com    Pfizer   NYSE PFE  said Monday it will not split Innovative Health and Essential Health into separate companies  Our two distinct businesses will remain separately managed units within Pfizer   the firm said in a statement It said by operating two separate units  Pfizer already enjoys many of the potential benefits of a split A split was first debated by the giant U S  drugs firm as early as 2012 Pfizer shares were down 1 08  at  33 9 in pre market trade at 08 00 ET ,2016-09-26,Investing.com,https://www.investing.com/news/stock-market-news/pfizer-down-1-as-global-drugs-firm-opts-not-to-pursue-split-428453,428453
220439,441955,PFE,Wall St lower in early trade ahead of presidential debate ,news,Investing com   U S  stocks were lower early Monday ahead of the first presidential debate The DJI was off 0 61  at 08 30 ET  while the S P 500 lost 0 50  The tech heavy Nasdaq composite shed 0 56    Pfizer   NYSE PFE  was down 1 58  at  33 72 after opting not to split the company in two Financials were lower as  Deutsche Bank   DE DBKGn  hit record lows  benchmark bond yields ease Oil stocks edged higher as crude futures advanced 3  on output freeze hopes ,2016-09-26,Investing.com,https://www.investing.com/news/stock-market-news/wall-st-lower-in-early-trade-ahead-of-presidential-debate-428497,428497
220441,441957,PFE,BioXcel IPO And Its Many Challenges,opinion,"Machine learning has been used from everything to learning how to play Go to building better chat bots to improving search engines  Now a small  new biotech company aims to use machine learning to save lives  BioXcel Therapeutics  a subsidiary of BioXcel Corp   has filed for a  69 million IPO  In its   BioXcel says that it is  focused on drug development that utilizes novel artificial intelligence  or AI  to identify the next wave of medicines across neuroscience and immuno oncology  
But while BioXcel wants to portray itself as a bold innovator using AI and machine learning  its actual advertised products are a peculiar combination of conservative yet risky  BioXcel has a great idea  but execution matters more than ideas and there is little reason to think it can pull off such an ambitious dream 
BioXcel and BioXcel
The first problem with BioXcel is what it actually is  As noted above  the company which is going public is called BioXcel Therapeutics  BioXcel Therapeutics was split off from BioXcel Corp  last year  and the parent company owns 93 percent of the subsidiary  BioXcel Corp  will continue to own the majority of the company after this IPO  though the exact percentage is unknown as of this time 
BioXcel Therapeutics talks about leveraging a research and development engine called EvolverAI  but this engine is owned by BioXcel Corp  Rather than doing AI development itself  BioXcel Therapeutics exists to develop the drugs found by EvolverAI and BioXcel Corp 
It is not like BioXcel Corp  is the only biotech company interested in leveraging AI and machine learning   points out that medical titans like Pfizer  NYSE PFE   Roche  and GlaxoSmithKline  NYSE GSK  are using artificial intelligence in novel ways to discover new combinations of drugs  find new compounds  and link diseases with treatments  EvolverAI by contrast works by using millions of data points to discover new potential therapeutic uses for drugs which already exist  at which point BioXcel Therapeutics reformulates them 
So what are the drugs which EvolverAI discovered and BioXcel Therapeutics is working on  The two main ones are called BXCL501 and BXCL701  also known as dexmedetomidine and talabostat respectively  Dexmedetomidine is used today under the brand name Precedex as a sedative  Talabostat was tested as a potential treatment for lung cancer by the now defunct Point Therapeutics   over a decade ago  By reformulating them  BioXcel believes that dexmedetomidine can fight Alzheimer s and schizophrenia  and talabostat can fight pancreatic cancer 
Unfortunately  these drugs are only in the latter stages of Phase 1 testing  with plans to start Phase 2 testing later this year  BioXcel hopes that the fact that the drugs have already passed prior levels of testing in the past will help them get past the drug approval process quicker  but the reality is that investors will be waiting even by biotech companies longer than normal for these drugs to hit the market 
Long Term Viability
Like most biotech IPOs  BioXcel s revenue is nonexistent  and it in fact reports no revenue whatsoever in 2016 and 2017  Over those two years  it decided to  its debts and earned a net loss of  2 1 and  4 5 million respectively  BioXcel also reported  1 3 million in assets and  2 3 million in liabilities as of December 31  2017 
Given these losses  raising  69 million may seem to be adequate to keep BioXcel running until its drugs are developed  but net losses will exponentially increase as it moves further in the development process  Unfortunately  BioXcel does not state how long it will be able to keep itself running with the raised IPO proceed  though they do concede that  we expect that we will need to obtain substantial additional funding in order to complete our clinical trials  
But if BioXcel will need substantial additional funding  why did they choose now to go public  Plenty of other companies  biotech or otherwise  are staying private because they can continue to secure rounds of funding from private investors  BioXcel s decision to eschew said funding and go public very quickly is strange and may have happened because said investors lack confidence in their product 
Some Good  Plenty Concerning
BioXcel Therapeutics has some things going for it compared to other biotech IPOs  Its close relationship with BioXcel Corp  means that it is not nearly as dependent on one or two drugs getting past FDA testing  especially as BioXcel Corp  will likely continue to have it test whatever drugs it discover with EvolverAI  A connection to machine learning  even it is indirect  is also a useful tool to attract investors  But it will take longer than normal for its drugs to get through the development pipeline and its disinterest or inability to secure private funding is seriously concerning  There are much better pipelines to take advantage of the growing interest in machine learning in the biotech industry  Investors may want to pay attention to what BioXcel Therapeutics has to say on the roadshow  but should not show any interest in this IPO as it currently stands ",2018-02-15,Alex Newman,https://www.investing.com/analysis/bioxcel-ipo-and-its-many-challenges-200291161,200291161
220443,441959,PFE,Wall St lower in early trade as U S  hike debate refuelled  oil retreats ,news,Investing com   U S  stocks were lower in early trade as U S  rate hike talk re emerged A sharp retreat in oil prices also weighed on the market The DJI was down 0 37  at 09 45 ET  while the S P 500 shed 0 30  The tech heavy Nasdaq composite declined 0 12  Medivation was up 19 9  at  80 51 as  Pfizer   NYSE PFE  bid  81 5 per share for the firm ,2016-08-22,Investing.com,"https://www.investing.com/news/stock-market-news/wall-st-lower-in-early-trade-as-u.s.-hike-debate-refuelled,-oil-retreats-421641",421641
220444,441960,PFE,U S  stocks lower while digesting Fed comments  oil slumps 3 ,news,"Investing com   Market participants opted to sell U S  equities on Monday despite the lack of news flow as traders continued to digest comments from Federal Reserve  Fed  officials and started the countdown to the U S  central bank head Janet Yellen s speech on Friday  while oil slumped 3   ending a seven day rally 
At 15 34GMT  or 11 34AM ET  the Dow 30 lost 52 points  or 0 28   the S P 500 fell 6 points  or 0 27   while the tech heavy Nasdaq Composite traded down 10 points  or 0 20  
Fed vice chair Stanley Fischer said on Sunday that the U S  economy was close to hitting the central bank s targets for full employment and 2  inflation 
Fischer s speech was just the latest piece of hawkish rhetoric from top Fed officials  Last week  San Francisco Fed president John Williams  New York Fed chief William Dudley and Atlanta Fed president Dennis Lockhart all said a September rate hike may be on the table 
Yellen will give a speech at the end of the week at the Economic Symposium at Jackson Hole and investors will look for clues on the future path of monetary policy 
However  according to Investing com s Fed Rate Monitor Tool  investors are pricing in just a 15  chance of a rate hike by September  up from just 6  at the start of last week 
Still  the probability of an increase at the December meeting once again surpassed the 50  threshold on Monday 
With no major macro data set for release on Monday  Fischer s remarks were helping support the dollar against major rivals  while causing gold to slump to a two week low 
The U S  dollar index  which measures the greenback s strength against a trade weighted basket of six major currencies  edged forward 0 05  at 94 53  at 15 36GMT or 11 36ET  while gold for December delivery on the Comex division of the New York Mercantile Exchange dropped 0 27   or  3 65  to  1 342 55 
Meanwhile  oil snapped a seven session win streak on Monday as reports surfaced that Iraq would increase crude exports by 5   further undermining recent speculation that OPEC could take measures to control output when it meets on the sidelines of the International Energy Forum in September 
Additionally  indications of an ongoing recovery in U S  drilling activity also kept prices under pressure  According to oilfield services provider Baker Hughes  the number of rigs drilling for oil in the U S  last week increased by 10 to 406  the eighth consecutive weekly rise and the 11th increase in 12 weeks 
U S  crude futures slumped 2 99  to  47 64 by 15 38GMT  or 11 38AM ET  while Brent oil traded down 2 91  to  49 40 
In company news   Medivation  Inc  NASDAQ MDVN  jumped almost 20  after  Pfizer  Inc  NYSE PFE  confirmed a deal to acquire the U S  cancer drug company for close to  14 billion 
Intersil Corporation  NASDAQ ISIL  was also up almost 19  on a report that Japan s Renesas Electronics was close to deal to buy the U S  chipmaker for  3 billion ",2016-08-22,Investing.com,"https://www.investing.com/news/stock-market-news/u.s.-stocks-lower-while-digesting-fed-comments,-oil-slumps-3-421658",421658
220445,441961,PFE,Pfizer to buy  AstraZeneca anti infective unit for  725 mn ,news,Investing com    Pfizer   NYSE PFE  to buy AstraZeneca ant infective unit for  725 mn Pfizer said Wednesday the deal involves an upfront payment of  550 mn AstraZeneca will receive a deferred payment of  175 mn in January 2019 Also to get up to  250 mn in milestone payments and  600 mn in sales related payments Pfizer on Monday agreed to buy cancer treatment firm Medivation for  14 bn ,2016-08-24,Investing.com,https://www.investing.com/news/stock-market-news/pfizer-to-buy--astrazeneca-anti-infective-unit-for-$725-mn-422028,422028
220446,441962,PFE,Animal spirits  consumers  devotion lifts pet care stocks,news,"By Marcus E  Howard NEW YORK  Reuters    Americans  attachment to their pets has fostered a  60 billion industry that is producing best in breed stock performance   Shares of a clutch of companies that sell pet food  develop diagnostic tests for animals and offer veterinary care have far outrun the wider market this year  delivering an average total return of nearly 35 percent versus around 8 3 percent for the Standard   Poor s 500  SPX    Shares of animal health testing company Idexx Laboratories Inc  O IDXX   for example  have skyrocketed more than 50 percent this year  while vet clinic operator VCA Inc  O WOOF  is up 31 percent and pet food maker  Blue Buffalo Pet Products Inc   O BUFF  is up 40 percent   What you see driving that growth is the humanization of pets and consumers  willingness to spend on their pets very heavily   said Joe Edelstein  an analyst at Stephens Inc   Part of that is because pets are part of the family   Edelstein follows Blue Buffalo and rival  Freshpet Inc   O FRPT   which is up 25 percent in 2016   Last year  U S  pet related spending totaled a record  60 3 billion  a 3 9 percent increase over the previous year  according to the American Pet Products Association  According to the U S  Bureau of Economic Analysis  U S  consumers  spending on their pets rose 5 percent in inflation adjusted terms last year while overall consumer spending rose 3 2 percent  It was the fourth straight year that growth in spending on pet services and products exceeded growth of consumer spending overall  Blue Buffalo and Freshpet are representative of the success of pet food  the industry s leading source of revenue  and are making the most of the trend toward natural  locally sourced ingredients    We see continued growth of  better for them  pet food products in both cat and dog   said Phil Terpolilli  a Wedbush Securities analyst   Adoptions in U S  dogs continue to grow meaningfully   PRICED TO PURR FECTION   The surge in the stock prices has lifted price to earnings ratios for the group  leaving investors to wonder just how much further the puppies have to run  Idexx shares now trade at about 43 times analysts  estimates of its earnings for the next 12 months  their highest level in about 20 years   It is not alone  The comparable price to earnings multiple of  Heska Corp   O HSKA   a maker of animal lab testing products  is 41 compared with a five year median of 35  VCA s is 22 6 versus a five year median of 16 8  Blue Buffalo and Freshpet  which both have fewer than two years on the public market  trade at multiples of 31 and 115  respectively  Big investors appear to be staying put  though  A review of the top 20 shareholders in eight companies in the pet market at the end of the second quarter showed that a majority added to or retained their positions in those stocks  Only Heska saw more of its top investors pare back positions than add to them  although none of the changes were large  Its shares are up 30 percent this year   We continually look at our names  the results and our expectations  and as long as we think they warrant the multiple that we ve paid for the stock  we re going to be owners   said Jarl Ginsberg  portfolio manager of the Columbia Small Mid Cap Value Fund that owns shares of VCA  the vet clinic chain  One company that may catch the eye of investors is  Zoetis Inc   N ZTS   one of the world s largest animal health companies and the weakest performer of the group this year  Shares of the company  which spun off from  Pfizer  Inc  N PFE  in 2013  have gained around 7 percent so far this year  But they do not feature the same valuation risks  trading at about 24 times estimated earnings for the next 12 months  just above the long term median of 22 8  Zoetis is increasing its earnings and revenues well above broader pet healthcare spending trends  said investor James Tierney Jr   chief investment officer at money manager AB s Concentrated US Growth fund  
 This is a company that should post 14 percent earnings growth over the 2013 to 2017 time frame   he said   This is a time period where the broader market  meaning the S P  has had modest growth  if any  ",2016-08-24,Reuters,https://www.investing.com/news/stock-market-news/animal-spirits:-consumers'-devotion-lifts-pet-care-stocks-422168,422168
220447,441963,PFE,Clinton spokeswoman defends drug plan after Pfizer comments,news,NEW YORK  Reuters    U S  Presidential candidate Hillary Clinton s spokeswoman said on Friday Clinton s plan to curb drug spending was not the blow to medical innovation that  Pfizer  Inc  NYSE PFE  Chief Executive Ian Read described it as being on Thursday   Throughout this campaign  Hillary Clinton has called for expanding investments in innovation for healthcare  from a cure for Alzheimer s to building on Vice President Biden s Cancer Moonshot initiative   campaign spokeswoman Julie Wood said in an emailed statement   She s said clearly that our pharmaceutical and biotech industries are great sources of innovation and she wants to support their development of new treatments   she said  Last week  Clinton unveiled a plan to create an oversight panel that would protect consumers from  unjustified  price hikes on life saving drugs  On Thursday  while speaking at an investor conference  Read said Clinton s plan would be  very negative for innovation   A Pfizer spokeswoman had no further comment on Friday  Drugmakers have been criticized for raising drug prices in the United States  where citizens pay the most worldwide for medicines ,2016-09-09,Reuters,https://www.investing.com/news/politics-news/clinton-spokeswoman-defends-drug-plan-after-pfizer-comments-425310,425310
220452,441968,PFE,Hedge funds made big changes at drug companies in second quarter  filings,news,"By Svea Herbst Bayliss BOSTON  Reuters    For many prominent hedge fund managers who bet  Pfizer  Inc  NYSE PFE  and Allergan  NYSE AGN pa  Plc would merge to become the world s biggest pharmaceuticals company  the second quarter started with a thud that sent many in search of new opportunities  John Griffin s Blue Ridge Capital  Andreas Halvorsen s Viking Global Investors each slashed their firm s stakes in Allergan by more than half after news broke that Pfizer was walking away from the deal  according to so called 13F regulatory filings released on Monday  Senator Investment Group and Jana Partners yanked their money from Pfizer  The filings  which show U S  stocks owned by investment managers at the end of the past quarter  are backward looking but they do identify by name the managers who moved after fresh regulation scuttled the  160 billion Pfizer Allergan deal  As investors mulled alternatives  even embattled drug maker Valeant Pharmaceutical International Inc s name emerged as a possible winner amid the wreckage  Mutual fund giant Fidelity Investments  for example  bought 10 million Valeant shares to own 15 5 million at the end of the quarter  North Tide Capital put on a new position of 2 5 million shares  while Hexavest Inc raised its stake by more than ten fold to 1 8 million shares  Allergan s stock price dropped 14 percent  suggesting fund managers such as Eric Mindich s Eton Park  which sold all of its 1 8 million shares  made the right call  Viking Global cut its holdings by 60 percent to 1 93 million shares and Blue Ridge cut its stake by 53 percent to 700 000 shares  Sachem Head Capital Management reduced its position by 57 percent  Not all big investors ran  Daniel Loeb s Third Point kept its Allergan investment largely intact at 4 9 million shares  while Seth Klarman s Baupost Group raised it by 16 percent to 2 million  Carl Icahn took a new position in Allergan  buying 3 4 million shares  At Pfizer  which has been seeking a way to compete better with rivals that pay lower tax rates  Jana Partners sold 13 million shares and Senator sold 15 million shares  Jason Karp s Tourbillon exited its position and sold 7 million shares  But the exits may have been premature since the stock rose 16 percent  benefiting managers such as Diamond Hill  which increased its stake modestly to 11 6 million  Tourbillon also exited all of its 3 4 million shares of Valeant  joining long time holders Brave Warrior and Hound Partners  which had finally had enough  Even though Valeant brought in a new chief executive and a big investor continued to support the stock  it dropped 23 percent during the second quarter  Hound sold 4 9 million shares  while Brave Warrior exited 2 million shares  
There were some bright spots on the broader pharmaceutical sector  with a number of managers placing new bets on St  Jude Medical Inc  a manufacturer and distributor of medical devices whose stock surged 42 percent during the quarter  Farallon Capital made a new bet with 4 6 million shares  while Carlson Capital put on a wager with 2 05 million shares  Adage Capital boosted its holding by 227 percent to just under 1 million shares ",2016-08-15,Reuters,https://www.investing.com/news/stock-market-news/hedge-funds-made-big-changes-at-drug-companies-in-second-quarter:-filings-420456,420456
220453,441969,PFE,Icahn makes new bet on Allergan in second quarter  filing,news,"BOSTON  Reuters    Carl Icahn  the octogenarian investor whose stock investments still create a buzz on Wall Street nearly 50 years after he first got into the business  made a new bet on Allergan  NYSE AGN pa   a new filing shows  Icahn who invests his personal fortune estimated by Forbes to be roughly  17 billion largely kept his portfolio unchanged  reporting no change on his investments in Cheniere Energy  Freeport McMoRan and  Herbalife   NYSE HLF  during the second quarter  But he did make one significant addition when he bought 3 4 million shares of drugmaker Allergan  valued at  785 7 million  Icahn kept his holding in Hertz Global Holdings Inc mostly unchanged  but the share count was lower after the company issued a 5 for 1 reverse stock split on the last trading day of the second quarter   Icahn like other investors on Monday filed a so called 13 F filing that shows what U S  stocks he owned at the end of the second quarter   He made smaller adjustments to his biggest holdings including a 2 percent hike in AIG  bringing his ownership to 45 6 million shares  PayPal Holdings  was cut by 10 percent to 33 9 million shares  the filing shows  Icahn  like some other billionaire investors  has made big bets on energy companies  betting on a recovery that has been spotty so far  Allergan s stock price dropped 14 percent during the second quarter after  Pfizer   NYSE PFE  walked away from a planned merger  but some investors expect that Allergan will tie up with another company  suggesting that the stock price will rebound  
 Corrects headline  first and third paragraphs to show no change in Hertz Global Holdings  adds that cut in shares was related to reverse stock split ",2016-08-16,Reuters,"https://www.investing.com/news/stock-market-news/icahn-makes-new-bet-on-allergan,-cuts-hertz-in-second-quarter:-filing-420457",420457
220454,441970,PFE,Pfizer is reportedly close to spending  14 billion on cancer drugmaker Medivation,news,Pfizer   NYSE PFE  is reportedly close to scooping up cancer drugmaker Medivation for  14 billion  The  and  are reporting that the deal could close as soon as Monday  citing people close to the deal  A  14 billion deal would value Medivation at more than  80 a share  a notable premium to the  52 50 a share offer the pharma giant Sanofi  PA SASY  had made earlier this year  Medivation shares ended trading at  67 16 on Friday  Sanofi went public with its  9 3 billion bid for the company in April  Medivation had rejected that bid but it wasn t long before it was fielding other offers and analysts were speculating about possible buyers  including reports that Pfizer   which in  after the    was in the mix  Pfizer declined to comment  Medivation did not immediately respond to request for comment  The San Francisco based biotech already has one drug on the market to treat prostate cancer  And its big appeal comes from an experimental breast cancer treatment called talazoparib  It still hasn t been approved for use  but the drug also has potential as a treatment of cervical  lung  and ovarian cancers  In a July conference call    saying that it has the potential to be  best in class  among so called PARP inhibitors   a new type of medicine that blocks a particular enzyme that s used by our cells to  so that tumors can t survive  Here s what s in Medivation s pipeline that could make it worth a  14 billion sale  Medivation s one drug on market already is called Xtandi  or enzalutamide  which the company developed with Japan s Astellas  It s an oral drug that used to treat is used to treat late stage prostate cancer  It was originally approved   based on a study that evaluated its ability to increase how long patients survived  median overall survival was 18 4 months for those who took Xtandi in the trial  compared to 13 6 months median overall survival for those who took a placebo   It does cost a list price of  129 000 in the US  which has gotten it   Medivation is also researching how enzalutamide works in people with other types of prostate  breast and liver cancers  Medivation also has two other cancer drugs in late stage trials  including talazoparib  which it acquired   The drug is being studied in certain types of breast cancer  as well as other kinds of cancers including cervical  lung  and ovarian  Another drug to treat a certain kind of blood  pidilizumab  is also in a late stage trial  The big thing with these drugs is that they re being explore in combination with   or treatments that use the immune system to fight off cancer cells  Response rates   instances in which the cancer stops spreading or shrinks in response to immunotherapy drugs   on their own are   but researchers hope that cancer immunotherapies combined with other treatments  say  Medivation s oral drugs   could push that response rate way up  And immunotherapies are a huge business  with   setting up funds for companies developing immunotherapies  NEXT   RELATED ,2016-08-22,Business Insider,https://www.investing.com/news/stock-market-news/pfizer-is-reportedly-close-to-spending-$14-billion-on-cancer-drugmaker-medivation-421574,421574
220455,441971,PFE,Medivation up 21  on reports Pfizer to make  14 bn takeover bid ,news,Investing com    Medivation   NASDAQ MDVN  shares were sharply higher Monday on reports of  Pfizer   NYSE PFE  bid Shares of the U S  cancer therapy firm were up 20 9  at  81 20 in pre market trade Pfizer reportedly is set to make an offer of close to  14 bn as early as Monday A bid of that size would represent as 26  premium to Medivation s closing price Friday of  67 16 ,2016-08-22,Investing.com,https://www.investing.com/news/stock-market-news/medivation-up-21-on-reports-pfizer-to-make-$14-bn-takeover-bid-421585,421585
220456,441972,PFE,U S  futures lower as markets digest Fed remarks ahead of Yellen ,news,"Investing com  Wall Street futures pointed to a lower open on Monday as investors weighed weekend comments from the Federal Reserve  Fed  and looked ahead to a speech by the U S  central bank chief Janet Yellen on Friday 
The blue chip Dow futures lost 43 points  or 0 23   by 10 56AM GMT  or 6 56AM ET  the S P 500 futures fell 4 points  or 0 19   while the tech heavy Nasdaq 100 futures traded down 9 points  or 0 20  
Fed vice chair Stanley Fischer said on Sunday that the U S  economy was close to hitting the central bank s targets for full employment and 2  inflation 
Fischer s speech was just the latest piece of hawkish rhetoric from top Fed officials  Last week  San Francisco Fed President John Williams  New York Fed Chief William Dudley and Atlanta Fed President Dennis Lockhart all said a September rate hike may be on the table 
Yellen will give a speech at the end of the week at the Economic Symposium at Jackson Hole and was widely expected to show an optimistic outlook on the U S  economy that could reinforce these recent comments that the next meeting was  in play  
However  according to Investing com s Fed Rate Monitor Tool  investors are pricing in just a 15  chance of a rate hike by September  up from just 6  at the start of last week with the probability of an increase not passing the 50  threshold until the February 2017 meeting 
With no major macro data set for release on Monday  Fischer s remarks were helping push the dollar higher against major rivals on  while causing gold to slump to a two week low 
The U S  dollar index  which measures the greenback s strength against a trade weighted basket of six major currencies  gained 0 25  to 94 72 by 10 58 AM GMT  or 6 58AM ET  while gold for December delivery on the Comex division of the New York Mercantile Exchange dropped 0 43   or  5 85  to  1 340 35 
Meanwhile  oil snapped a seven session win streak on Monday as reports surfaced that Iraq would increase crude exports by 5   further undermining recent speculation that OPEC could take measures to control output when it meets on the sidelines of the International Energy Forum in September 
Additionally  indications of an ongoing recovery in U S  drilling activity also kept prices under pressure  According to oilfield services provider Baker Hughes  the number of rigs drilling for oil in the U S  last week increased by 10 to 406  the eighth consecutive weekly rise and the 11th increase in 12 weeks 
U S  crude futures tumbled 2 79  to  47 74 by 11 00AM GMT  or 9 00AM ET  while Brent oil slumped 3 20  to  49 25 
In company news   Medivation  Inc  NASDAQ MDVN  jumped 19  in pre market trade after reports that  Pfizer  Inc  NYSE PFE  set to announce a deal to acquire the U S  cancer drug company for close to  14 billion ",2016-08-22,Investing.com,https://www.investing.com/news/stock-market-news/u.s.-futures-lower-as-markets-digest-fed-remarks-ahead-of-yellen-421601,421601
220457,441973,PFE,U S  stock index futures edge lower as U S  rate hike talk re emerges ,news,Investing com   U S  stock index futures edged lower Monday Comments by Fed vice chair Fischer re sparks U S  rate hike talk The Dow futures was down 0 15  at 06 15 ET  while the S P 500 futures shed 0 14 The tech heavy Nasdaq 100 futures gave up 0 13  U S two year bond yield up 2 16  at 0 762  after high of 0 783   Medivation   NASDAQ MDVN  up 19 5  on reports  Pfizer   NYSE PFE  may make  14 bn bid for cancer therapy firm ,2016-08-22,Investing.com,https://www.investing.com/news/stock-market-news/u.s.-stock-index-futures-edge-lower-as-u.s.-rate-hike-talk-re-emerges-421602,421602
220458,441974,PFE,Pfizer confirms to buy Medivation  for about  14 bn ,news,Investing com    Pfizer   NYSE PFE  Monday confirmed it is to buy Medivation for about  14 bn Pfizer said it will pay  81 50 a share in cash for the U S  pharmaceutical firm Medivation shares were up 19 9  at  80 50 in pre market after closing at  67 16 Friday Pfizer said the acquisition would add  0 05 to its annual diluted EPS  The deal will  accelerate revenue growth and drive overall earnings   Pfizer CEO Ian Read said Medivation s XTANDI cancer treatment generated  2 2 bn in global sales over past four quarters ,2016-08-22,Investing.com,https://www.investing.com/news/stock-market-news/pfizer-confirms-to-buy-medivation--for-about-$14-bn-421623,421623
220464,441980,PFE,Pfizer To Post Upbeat Earnings,opinion,"Before the market opens on Tuesday  American pharmaceutical company Pfizer Inc  NYSE PFE  is set to deliver its earnings report for the quarter that ended in December  Despite the recent decline in pharmaceutical stocks over the past couple of quarters  most analysts are optimistic on the earnings of the company with the stock expected to rise following the earnings report  Aside from solid earnings  the company is also expected to make an updated on their plans this year 
During the third quarter  the market saw a steady growth from the company following a jump in the sales of a number of its products including the Prevnar pneumonia vaccine and Ibrance breast cancer treatment  Pfizer posted earnings of 67 cents per share on a revenue of  13 17 billion which is 1  higher  Net income of the company came in at 47 cents per share to  2 84 billion 
Sales of the company from its Ibrance treatment jumped by nearly 60  during the previous quarter to sales of  878 million  However  this missed most market expectations of the company posting  914 million in sales  The company then faced competition from due to the approval of the Kisqali drug from competitor company Novartis 
During the third quarter  Pfizer was also able to sell more than  1 5 billion worth of the Prevnar drug pushing the shares of the company to trade above  35 per share  The boost in the earnings of the company was largely led by the sales of the Prevnar drug 
Pfizer stock has gained 11 5  last year and is expected to grow this year despite the slightly weaker operational sales growth 
For the fourth quarter  the company is expected to post growth in the sales in the number of its drugs and products especially  Pfizer is also expected to make an update regarding its psoriatic arthritis treatment Xeljanz which was approved by the FDA last December  Sales of the company from Chantix and the Lyrica nerve pain drug is also expected to pick up for the quarter 
The company currently has a full year earnings expectations of  2 57 per share on a revenue of  53 billion for the year 2017  Pfizer is included in the number of companies expected to benefit from the U S  tax overhaul  Pfizer is also expected to make an update on a number of pending programs and drugs ",2018-01-30,Trade12,https://www.investing.com/analysis/pfizer-to-post-upbeat-earnings-200284831,200284831
220467,441983,PFE,Spiders and scorpions join fight against superbugs,news,By Matthew Stock  Reuters    A British lab is searching for new medicines in the poisonous secretions of some of the world s deadliest creatures  addressing the increasingly desperate challenge of finding viable new drugs  Over prescription and over use in farming of antibiotics has given rise to so called  superbugs   multi drug resistant infections that can evade even the medicines designed to kill them  Experts have warned since the 1990s that lethal superbugs were on the horizon  but few drugmakers have attempted to develop drugs against them  Venomtech  based in south east England  believe help could be found in the unlikeliest of sources  the venom of spiders  scorpions and snakes that is often fatal to humans  Millions of years of evolution has given these creature s venom the ability to target and attack their prey while avoiding the body s defenses  Venomtech scientists hope that an injected drug could perform the same function  When broken down at the molecular level a tiny droplet of venom contains hundreds of individual components that could eventually be made into new drugs  explained Venomtech founder Steven Trim   The principle of Venomtech is separating venoms out into their component parts and targeting them to the right disease area   Trim told Reuters   He added that his drug discovery team was  putting the right venom for the right drug target so we maximize the hits   and a hit is an interesting peptide that might make it to a drug   Around 400 animals are kept at his lab in Kent  including about 70 species of tarantula and 30 species of scorpion  Many of these kill their prey with venoms that contain hundreds of protein molecules  some of which block nerve activity  Venomtech keep a number of invertebrates which can be deadly to humans  namely the black widow spider and deathstalker scorpion  Trim  who worked for pharmaceutical company  Pfizer   NYSE PFE  before founding Venomtech  stressed that the venom extraction process causes no discernible harm to the creatures   We anesthetize the invertebrates  just to temporarily put them to sleep  it makes it safer for us because if they re immobile they can t bite us  But also it s better for the animals as well  And using a very tiny electrical stimulation  just to contract the muscle and squeeze the gland we get a small amount of venom produced   he said  The venom extracted from each creature can be measured in micro liters  a thousandth of a milliliter  Nevertheless  this tiny volume holds hundreds of useful molecules   The average scorpion will only produce 2 or 3 micro liters  So it s a really small amount  But in that small amount there s a lot of interesting peptides  several hundred different components and several micro grams of protein in there  so there s plenty for us to work with   Trim said   We separate that out in a two phase process called high pressure liquid chromatography  And that gives us typically about a hundred fractions per venom  and each one of those fractions may contain 1 to 5 individual peptides  And it s those individual peptides and proteins that are the real interesting things  these are the molecules that convey the biological activity of the venom   Working with scientists from nearby Canterbury Christ Church University  they ve been screening their venom derived  chemical library  against different diseases   Trim said they ve had some extremely encouraging results   Some of them we found can kill bacteria  bacteria like E Coli and Staphylococcus  so very relevant at the moment where modern medicines are failing  And we re also finding venoms that are modifying and killing cancer cells   he said  adding that Venomtech is now working with pharmaceutical companies to turn their venom discoveries into the next generation of drugs  OLUSSCIENCE Reuters US Online Report Science News 20160809T152712 0000,2016-08-09,Reuters,https://www.investing.com/news/general-news/spiders-and-scorpions-join-fight-against-superbugs-419338,419338
220471,441987,PFE,Pfizer  PFE  Q4 Earnings   Sales Top  2018 View Upbeat,opinion,"Pfizer Inc  s   NYSE PFE   is one of the most well known names in the pharmaceutical sector not just for its medicines and vaccines but also for its consumer healthcare products  This New York based company is well known for products like Prevnar  Lyrica  Lipitor and Celebrex among others However  like many of its peers  PFE is facing generic competition and pricing pressure for several products  Other than that lost alliance revenues  supply shortages in legacy Hospira products  pricing pressure and rising competition are hurting the top line In this scenario  investor focus remains on late stage pipeline candidates and their commercial potential and performance of new products apart from the usual top and bottom line numbers The pharma giant has a fairly decent record of earnings surprises  The company s earnings surpassed expectations in three of the last four quarters while missing in one  resulting in an average positive surprise of 0 79  Pfizer  Inc  Price and Consensus
    Currently  PFE has a Zacks Rank  3  Hold   but that could definitely change following the company s earnings report which was just released  We have highlighted some of the key stats from this just revealed announcement below Earning Beat  PFE beat fourth quarter earnings which came in at 62 cents while our consensus called for EPS of 56 cents  Earnings rose 32  year over year Revenues Beat  Revenues also expectations  Pfizer posted revenues of  13 70 billion  which beat the Zacks Consensus Estimate of  13 61 billion  Revenues rose 1  from the year ago quarter on a reported basis  On an operational basis  revenues were flat year over year 2018 Guidance  Revenues are expected in the range of  53 5 billion to  55 5 billion in 2018  The Zacks Consensus Estimate is pegged at  53 72 billion Adjusted earnings per share are expected in the range of  2 90    3 00 which was above the Zacks Consensus Estimate of  2 77 per share Pre Market Trading  Shares rose more than 2  in pre market trading Check back later for our full write up on this PFE earnings report later Don t Even Think About Buying Bitcoin Until You Read ThisThe most popular cryptocurrency skyrocketed last year  giving some investors the chance to bank 20X returns or even more  Those gains  however  came with serious volatility and risk  Bitcoin sank 25  or more 3 times in 2017 Zacks  has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly ",2018-01-29,Zacks Investment Research,https://www.investing.com/analysis/pfizer-pfe-q4-earnings--sales-top-2018-view-upbeat-200284922,200284922
220472,441988,PFE,Stocks slip on Japan fiscal stimulus approval  yen rallies,news,"By Saqib Iqbal Ahmed NEW YORK  Reuters    Wall Street stocks opened lower on Tuesday after weak U S  economic data disappointed investors  further dragging on global equity prices after the approval of a fiscal stimulus package by Japan s cabinet failed to cheer markets  Oil rebounded strongly after having fallen as much as 10 percent in one week  but concerns about oversupply lingered  Japanese Prime Minister Shinzo Abe s cabinet approved 13 5 trillion yen   132 billion  in fiscal measures on Tuesday  The easing moves were perceived as less aggressive than anticipated and the yen rallied to a three week high against the U S  dollar   There s quite a lot of skepticism in the market as to whether this fiscal package can change anything   said Alvin Tan  a strategist at  Societe Generale   PA SOGN   Last week  the Bank of Japan announced easing steps that disappointed investors who had hoped for more   These governments are flailing about looking for something that will get it back on track  and certainly public confidence that they have really done enough has been something that has been difficult to achieve   said Bruce McCain  chief investment strategist at Key Private Bank in Cleveland  MSCI s world stocks index  which tracks shares in 45 nations  was down 0 75 percent  Wall Street added to Monday s modest losses after data showed inflation still muted and below the U S  Federal Reserve s 2 percent target  despite a better than expected rise in consumer spending in June  The Dow Jones industrial average fell 111 97 points  or 0 61 percent  to 18 292 54  the S P 500 lost 16 99 points  or 0 78 percent  to 2 153 85 and the Nasdaq Composite dropped 53 84 points  or 1 04 percent  to 5 130 36  Dow component  Pfizer   NYSE PFE  was one of the biggest drags on the S P 500 after revenue from its array of branded patent protected medicines disappointed investors  European stocks dropped to a three week low  dragged down by banks  after Commerzbank s shares slid to a record low after the bank warned that its earnings would fall this year  Oil rose more than 2 percent in early trading after falling by around  4 a barrel in one week  But investors remained concerned about oversupply weighing on prices  which subsequently turned lower  Brent crude was off 1 percent at  41 72 a barrel  while U S  crude fell 1 5 percent to  39 48  The U S  dollar dropped to a six week low against a basket of currencies  pressured by expectations that the Federal Reserve would delay raising interest rates after the recent soft U S  economic data  The dollar index was down 0 64 percent at 95 096  In bond trading  U S  Treasury yields surged on the Japanese fiscal stimulus measures  dampening demand for U S  government debt and sending long dated U S  yields to their highest levels in more than a week   U S  30 year yields rose the most among U S  Treasuries and hit 2 332 percent  their highest since July 21  as prices fell more than two full points  Benchmark 10 year yields hit a six day high of 1 573 percent  
Spot gold prices were up 1 percent to  1 366 35an ounce ",2016-08-02,Reuters,"https://www.investing.com/news/stock-market-news/asian-shares-retreat,-australia-central-bank-cuts-rate-to-all-time-low-417887",417887
220479,441995,PFE,Exclusive  Medivation discusses potential sale to Sanofi   sources,news,"By Michael Flaherty and Greg Roumeliotis  Reuters    U S  cancer drug company  Medivation  Inc  O MDVN  is discussing opening its books to Sanofi SA  PA SASY  after the French pharmaceutical company sweetened its  9 3 billion acquisition offer  people familiar with the matter said on Tuesday  The talks come after Medivation rejected Sanofi s  52 50 per share cash offer in April  prompting Sanofi to embark on a campaign to convince Medivation shareholders to oust Medivation s board of directors and replace them with its nominees in a so called written consent process   Medivation is negotiating the terms of a confidentiality agreement with Sanofi that would allow the two companies to engage in deal negotiations  the people said   Medivation has already signed confidentiality agreements to discuss a potential sale with other companies  including  Pfizer  Inc  N PFE  and  Celgene Corp   O CELG   the people added  There is no certainty that Medivation will agree to a sale with any party  the people cautioned  The sources asked not to be identified because the deliberations are confidential  Medivation and Sanofi declined to comment  while Pfizer and Celgene did not immediately respond to requests for comment  Medivation shares jumped as much as 4 2 percent on the news and were trading up 2 5 percent at  61 62 in afternoon trading in New York  Sanofi s new offer  whose terms could not be immediately learned  came following conversations with Medivation shareholders  Last month  shareholder advisory firm Glass Lewis   Co recommended that Medivation s shareholders should not support Sanofi s efforts to replace the company s board members   Sanofi wants Medivation   which sells a successful prostate cancer drug called Xtandi   so Sanofi can expand in the lucrative oncology sector  as it seeks new businesses to compensate for flagging diabetes revenues  Reuters had reported in May that Medivation had signed confidentiality agreements with some companies  including Pfizer  
Medivation had previously argued that Sanofi s offer had failed to value fairly the prospects for Xtandi  as well as two other products currently in clinical trials   Talazoparib  for the treatment of breast cancer  and Pidilizumab  for the treatment of blood cancers ",2016-07-05,Reuters,https://www.investing.com/news/stock-market-news/exclusive:-medivation-discusses-potential-sale-to-sanofi---sources-412573,412573
220480,441996,PFE,Pfizer shares tick up after FDA approves pneumonia vaccine for adult use,news,"Investing com     Pfizer  Inc  NYSE PFE  shares ticked up on Tuesday after the U S  Food and Drug Administration  FDA  approved the major pharmaceutical company s pneumonia vaccine for an expanded age indication for adults ages 18 to 49  
With the approval from the FDA  the vaccine  Prevenar 13  became the lone treatment on the market available to patients of all ages  Previously  the vaccine had already gained regulatory clearance for treatment of pneumococcal disease affecting adults ages 50 or over  
The expanded age indication  according to Pfizer  now more closely aligns the immunization practices for adults 19 or older with the 2012 U S  Centers for Disease Control  CDC  and Prevention s Advisory Committee s guidelines for patients with a number of serious diseases  The list ranges from HIV and cancer to other conditions such as cerebral spinal fluid leaks and cochlear implants   
 This expanded age indication in adults 18 to 49 offers an important public health benefit as appropriate vaccination against S  pneumoniae is critical to reducing the risk of pneumococcal disease  including in those with immunocompromising conditions   said Dr  Luis Jodar  Chief Medical and Scientific Affairs Officer  Pfizer Vaccines 
Prevenar 13 was first approved in the European Union in 2009 for use in infants and young adults  Currently  Prevenar 13 is the most widely used pneumococcal conjugate vaccine in the world  according to Pfizer and is used in pediatric immunization programs in more than 100 nations worldwide  
Shares in Pfizer inched up 0 02 or 0 06  to 36 26 in after hours trading  Pfizer closed Tuesday s regular session at 36 24  up 0 09 or 0 25  ",2016-07-12,Investing.com,https://www.investing.com/news/stock-market-news/pfizer-shares-tick-up-after-fda-approves-pneumonia-vaccine-for-adult-use-413977,413977
220485,442001,PFE,Ex Oppenheimer adviser arrested for trading on Pfizer employee s tips,news,"By Nate Raymond NEW YORK  Reuters    A former Oppenheimer   Co Inc investment adviser was arrested on Friday on charges he traded on inside information supplied by a childhood friend working at  Pfizer  Inc  N PFE  about deals that drugmaker was considering   David Hobson  who during the alleged scheme also worked for  RBC  Capital Markets  was charged in an indictment filed in Manhattan federal court for making illegal trades that earned him over  187 000 and about  145 000 for his customers  His friend  Michael Maciocio  secretly pleaded guilty on May 20 to charges related to the scheme  which ran from 2008 to 2014 and which the U S  Securities and Exchange Commission in a lawsuit said earned him  116 000 from his own insider trading  Hobson  47  was arrested at his home in Providence  Rhode Island on charges of conspiracy and securities fraud  He was released later in the day following a court hearing  His lawyer declined comment  Maciocio  46  has agreed to cooperate with prosecutors pursuing the case  according to his plea agreement  His lawyer did not respond to requests for comment  The charges were brought by Manhattan U S  Attorney Preet Bharara  who since 2009 has overseen an insider trading crackdown that has resulted in charges against 104 and the conviction of 79  According to authorities  Maciocio in his role at Pfizer as director of chemical research and development  received information about potential deals relevant to his tasks evaluating manufacturing demands and capacity  While Maciocio was not typically given the identity of the company in a potential deal  he used the information to perform research to discern its identity  sometimes with Hobson s help  authorities said  After identifying the company  Maciocio then passed the information to Hobson  who executed trades in accounts belonging to himself  Maciocio  and clients of Oppenheimer and RBC  charging documents said  The tips enabled Hobson to illegally trade in the stocks of  Medivation  Inc  O MDVN   Ardea Biosciences Inc and Furiex Pharmaceuticals Inc  the indictment said  The former employers of Hobson and Maciocio were not named in the court papers  but Pfizer  Oppenheimer  a unit of  Oppenheimer Holdings Inc   N OPY   and RBC  a unit of Royal Bank of Canada  TO RY   confirmed their employment  Oppenheimer said it has  cooperated extensively  with authorities  Pfizer said it  takes these allegations seriously and is cooperating fully with the authorities   
The cases in the U S  District Court  Southern District of New York  are U S  v  Hobson  No  16 cr 351  and Securities and Exchange Commission v  Maciocio  No  16 cv 4139 ",2016-06-03,Reuters,https://www.investing.com/news/stock-market-news/ex-oppenheimer-adviser-arrested-for-trading-on-pfizer-employee's-tips-406425,406425
220486,442002,PFE,Pfizer s opioid painkiller can be manipulated for abuse  FDA,news," Reuters    A long acting opioid painkiller being developed by  Pfizer  Inc  N PFE  has the potential to deter abuse but can be manipulated  a preliminary review by the U S  Food and Drug Administration showed 
The drug is designed for the management of pain severe enough to require around the clock treatment in patients who have not derived enough benefit from other treatments 
The treatment  whose proposed trade name is Troxyca ER  contains commonly used opioid  oxycodone  The abuse deterrence mechanism relies on the incorporation of naltrexone in the drug pellets    
Troxyca ER is designed such that if the pellets are crushed in an attempt to abuse the painkiller  naltrexone is released to counteract the effects of oxycodone 
The panel is being asked to decide whether the drugmaker should be allowed to claim on the drug s label that it deters abuse  The panel will vote separately on whether it likely deters abuse when swallowed  snorted or injected 
FDA reviewers said in a report published on Monday that oxycodone could be selectively extracted from intact pellets by a number of straightforward techniques and certain common solvents appear to be capable of removing naltrexone from crushed pellets 
However  studies did demonstrate that negligible oxycodone is released from heated Troxyca ER vapor  reducing the likelihood of abuse by those seeking to inhale it  the reviewers added 
The review comes ahead of a June 8 meeting of outside experts  who will recommend whether the drug should be approved  The FDA is not obliged to follow the advice of its advisory panels but typically does 
The abuse of opioids   a class of drugs that includes heroin and prescription painkillers   has reached epidemic proportions in the United States  The Centers for Disease Control and Prevention  CDC  estimates that 78 Americans die every day from opioid overdose 
There is increasing political pressure on the FDA to address the problem of opioid abuse 
Earlier this year  FDA Commissioner Robert Califf said the agency would reform its process for approving opioids after a number of senators threatened to block his nomination as the agency s head 
The CDC recommended in March that doctors prescribe non opioids  including acetaminophen and ibuprofen  for patients with pain unless they have active cancer or are receiving end of life care 
The FDA also announced that short acting opioids would carry new warnings about the potential for abuse  bringing the labels in line with the warnings on long acting pills ",2016-06-06,Reuters,https://www.investing.com/news/stock-market-news/pfizer's-opioid-painkiller-can-be-manipulated-for-abuse:-fda-406763,406763
220487,442003,PFE,Pfizer to invest  350 million in China biotech hub  first in Asia,news,SHANGHAI  Reuters     Pfizer  Inc  N PFE  will invest  350 million to build a biotech center in China  the latest in a series of moves by pharma industry giants to set up shop in the world s no  2 drugs market with the aim of securing faster approvals for their products  The facility in eastern Hangzhou region   Pfizer s first biotech center in Asia   is expected to be completed by 2018  the firm said in a statement on Tuesday  Global  Big Pharma  is increasingly looking for smart ways to tap China s healthcare market  estimated by consultancy IMS Health to be worth around  185 billion by 2018  From investing in China facilities to acquisitions  licensing deals and joint ventures  the aim is to seek an edge in dealings with domestic regulators and government  John Young  group president for Pfizer s essential health division  said in the statement that the Hangzhou facility should  help support China s aim to increase the complexity and value of its manufacturing sector by 2025   Pfizer said it would  work closely  with local regulators to bring the drugs  to market as soon as possible   The center will mostly on biologic drugs   made from living micro organisms rather than chemically synthesized   and lower cost  biosimilars   of generic versions of biologics   Pharmaceutical executives have long complained about the slow process of getting drugs to market in China  while others have run up against regulatory roadblocks  Pfizer had to close its vaccine business in the country last year after a license for its top selling vaccine Prevenar was not renewed  China s overall healthcare spending is set to hit  1 3 trillion by 2020  but drug market growth has slowed to a low single digit percentage pace from over 20 percent just four years ago as branded generics have lost their shine and Beijing has looked to drive down prices to keep a lid on costs ,2016-06-28,Reuters,"https://www.investing.com/news/stock-market-news/pfizer-to-invest-$350-million-in-china-biotech-hub,-first-in-asia-410990",410990
220495,442011,PFE,Pfizer s Anacor deal showcases new wave of eczema therapies ,news,"By Ransdell Pierson NEW YORK  Reuters     Pfizer  Inc s  N PFE  purchase of Anacor Pharmaceuticals Inc  O ANAC  heralds an approaching wave of potentially safer and more effective treatments for millions who suffer from eczema  a common skin condition which causes infection prone rashes that can feel like having poison ivy 24 hours a day   More than two dozen drugmakers are working on novel medicines to treat the condition affecting about 20 million Americans  also known as atopic dermatitis  and Pfizer s  5 2 billion deal positions it to become a market leader   Anacor s steroid free topical ointment crisaborole is the first of the new treatments to be reviewed by U S  regulators  An injectable therapy called dupilumab from Regeneron Pharmaceuticals Inc  O REGN  is expected to be submitted for U S  approval later this year    Until a few years ago  I don t think we had any message of hope for eczema patients who have tried everything   said Gil Yosipovitch  chairman of dermatology at Temple University School of Medicine who is a paid consultant for both companies   Now we do    The two medicines greatly reduced eczema symptoms in late stage trials without side effects accompanying current treatments  They could eventually see combined annual global sales of over  9 billion and face no significant competition for years   Yosipovitch said Anacor s crisaborole could be a valuable option for the 60 percent to 80 percent of patients with mild and moderate eczema on localized areas of the body  Dupilumab would be used for patients with more severe disease  he said  The global eczema drug market is currently worth about  4 billion in sales  mostly of topical steroids than can cause skin atrophy and increase risk of glaucoma and cataracts  Doctors may also prescribe oral drugs that suppress the immune system  such as cyclosporine  but they are not approved for eczema and can cause infections  shingles and cancer  There are no approved systemic drugs for the condition   However  the cost of the new treatments may limit patient access  Regeneron s injectable dupilumab could cost  25 000 a year  similar to psoriasis drugs  at a time when U S  health insurers are resisting rising drug prices  Analysts say it could eventually capture annual sales of  6 billion  with Anacor s drug costing more than  1 200 a year and having peak annual sales of up to  3 billion    Payers know this will be a big market and will put up a lot of barriers and restrictions   said Yatin Suneja  an analyst with Suntrust Robinson Humphrey    Express Scripts Inc   O ESRX  last month said it would scrutinize new eczema treatments and their expected prices   LONG TERM EFFECTS  Crisaborole blocks an inflammation causing protein called PDE 4  In large clinical trials that included children and adults  it cleared or almost cleared treated areas of skin in half of patients with mild to moderate disease  with mild side effects    We badly need a nonsteroidal topical that can get around serious steroid concerns and this drug showed no skin atrophy or other significant side effects   said Dr  Lawrence Eichenfield of the University of California San Diego and lead author of American Academy of Dermatology eczema treatment guidelines  Regeneron and Sanofi  PA SASY  aim to seek approval for dupilumab this year for adults with moderate to severe eczema  It blocks two proteins  IL 4 and IL 13  believed to cause eczema and allergic conditions like asthma   In big trials  dupilumab led to an average 70 percent improvement in rash area and severity  Fewer serious side effects  including infections  were reported for dupilumab than for placebos  In separate studies it reduced incidence of asthma   One concern over drugs like dupilumab  which regulate the immune system  is potential for serious side effects over time  including lymphoma  Such problems typically do not show up until a patient has used a medicine many years  said Dr  Cameron Rokhsar  a New York dermatologist with no financial ties to the drugmakers  Roche Holding AG  S ROG  and AstraZeneca Plc  L AZN  are developing injectable eczema treatments several years behind dupilumab   Data from mid stage trials of the Roche drug  lebrikizumab  are expected in the second quarter  AstraZeneca plans this year to disclose data from a mid stage trial of its tralokinumab in adults with moderate to severe eczema   Nemolizumab from Japan s Chugai  T 4519  is also being tested in a mid stage trial  The injectable drug targets IL 31  a protein associated with itch  a hallmark of eczema   The main concept of our drug is to break the vicious itch scratch cycle because scratching damages the skin and causes more intense inflammation   Dr  Michiaki Tanaka  a senior Chugai research executive  said in an interview   Celgene Inc  O CELG  recently tested its psoriasis drug apremilast in about 200 patients with moderate to severe eczema   
It has not publicized the results  but researchers and analysts say it could become the first approved oral treatment for eczema  The pill has caused nausea and other gastrointestinal problems in psoriasis patients   I m very excited about apremilast because we have no approved oral drug for eczema   said Dr  Emma Guttman Yassky of Mt  Sinai Medical Center in New York  She helped conduct trials of apremilast and dupilumab ",2016-05-17,Reuters,https://www.investing.com/news/stock-market-news/pfizer's-anacor-deal-showcases-new-wave-of-eczema-therapies-402420,402420
220496,442012,PFE,Pascal Soriot s big experiment  reinventing AstraZeneca,news,"By Ben Hirschler LONDON  Reuters    AstraZeneca Chief Executive Pascal Soriot is a big believer in science  and the biggest experiment of his career is the reinvention of the drugmaker   The  500 million corporate headquarters and research hub emerging amid cranes on the southern edge of the university town of Cambridge symbolizes his aim to create a science led company with uniquely close ties to academia  For employees  these are uncomfortable times  Thousands of job have been cut globally at the company in the past three years  with more to come  Some staff are also reluctant to move to Cambridge  with its high house prices  from north west England where the company has a strong presence dating from its time as part of the old ICI chemicals empire   Soriot  however  relishes the chance to shake things up by setting up home near world renowned university labs   where he says the firm is better placed to hire the  best of the best    while shrinking its operations to focus on core areas like cancer  respiratory and cardiovascular disease    In the past  we ve had too much stability   the CEO said in an interview with Reuters that gives some of the clearest indications yet of the scale of the cultural change he intends to push through at the company    We had people who never moved and turnover of 1 or 2 percent  That might sound good but it s actually not  because you don t have new ideas flowing through the place    The stakes are high  Two years after spurning a  100 billion bid from  Pfizer   NYSE PFE   AstraZeneca is going through the biggest  cliff  of patent expiries the drug industry has ever seen  wiping off more than half of its sales   or  17 billion   in 2011 2017  That has forced Soriot to seek new routes to profit and his overhaul of the company is now entering a pivotal phase  with make or break trial results and drug approvals due over the next 12 months  coinciding with the move to Cambridge   As with any experiment  the outcome of Soriot s reinvention is uncertain   and investors are divided   Neil Woodford of Woodford Investment Management  the seventh largest AstraZeneca shareholder  is convinced the company will re emerge as a successful player focused on specialty drugs like cancer treatments rather than mass market medicines  He has added to his stake recently   But Andy Smith  chief investment officer at fund manager Mann Bioinvest  says Soriot has yet to prove his plan will pay off   The big question hanging over his tenure is how close he can get to showing actual value from the pipeline  rather than promised value   he said    IMPLODING  No other pharmaceutical company has moved itself wholesale to an academic center  Soriot argues the move is already paying off for some 1 600 staff  nearly a quarter of its UK workforce  now in rented space around Cambridge who are liaising far more closely with academic researchers   It is fundamentally changing the way we operate   said the 56 year old  who trained as a veterinarian in France  Most of the staff will move into the new building from late 2017  Soriot said he had no choice but to overhaul AstraZeneca when he took over in October 2012  due to the patent  cliff    The company was imploding   he said bluntly  His answer has been to invest in internal research and bolt on acquisitions  including more than  7 billion of deals at the end of 2015  to rebuild the company s drug pipeline   This includes cancer drugs that boost the immune system  which are the hottest area of drug research right now  although AstraZeneca also has high hopes for other approaches to fighting tumors  That makes oncology the area with the greatest potential to drive future sales at AstraZeneca  as the company grapples with a wave of patent expiries on older products  such as its cholesterol fighter Crestor and stomach acid pill Nexium  Investors are anxious for proof Soriot s prescription will work  since AstraZeneca shares are languishing 28 percent below the 55 pounds offered by Pfizer and earnings are expected to fall in 2016 and 2017  AstraZeneca has also had to cope recently with some senior executive departures  including the loss on Tuesday of its North America head to Novartis   At the height of the takeover battle  the company went public with a forecast that sales would rise by three quarters to  45 billion by 2023   a hostage to fortune  perhaps  but a target Soriot remains confident will be met    I might not be here to see if we achieve that in 2023 but people won t have to wait until then  If we succeed  the share price will reflect the value of the company much earlier than that   he said   I think it is going to take another 12 months and then hopefully we can show people what they want to see    STEPS FORWARD  BACK  So far  there have been some steps forward  like success with lung cancer drug Tagrisso and with good results for a new asthma drug   But there have also been setbacks  including the loss of a fast to market opportunity for AstraZeneca s big immuno oncology hope durvalumab   The latter has increased the pressure to prove that a combination treatment mixing durvalumab and tremelimumab can help in lung cancer  giving AstraZeneca a foothold in a market currently dominated by Bristol Myers Squibb   Pascal has played his hand well but now he s at the point where it gets harder   said one top executive at a rival company   He s going down to the valley floor on earnings and we don t know how the clinical data will play out to get the business up the other side    AstraZeneca has also used so called externalization income from licensing out non core products to underpin profits  leading to criticism over earnings quality from some analysts   With R D spending equivalent to 24 percent of sales  AstraZeneca s science budget exceeds the industry average  But Soriot aims to push selling  general and administrative expenses down to 30 32 percent from 35 percent   The CEO says investors need patience to see through a turnaround story that  with luck  will mirror the recovery Bristol Myers  now the star of the pharma sector  
 There will be a tipping point where people see a sufficient number of projects progressing positively and then they can see the future is bright  ",2016-05-18,Reuters,https://www.investing.com/news/stock-market-news/pascal-soriot's-big-experiment:-reinventing-astrazeneca-402730,402730
220497,442013,PFE,French drugmaker Sanofi to step up push into China,news,By Matthias Blamont and No lle Mennella PARIS  Reuters    Sanofi  PA SASY  will step up its push into China  its second biggest market after the United States  in the next five years as part of a wider expansion into emerging countries  where it sees a large part of its future growth  The French drugmaker is under pressure to diversify geographically and expand in areas such as oncology as it faces declining sales of its diabetes blockbuster Lantus  The company went public with an unsolicited  9 3 billion offer to buy U S  cancer firm  Medivation   O MDVN  in April  setting up what could be a lengthy takeover battle   In the past years we have always managed to come up with a 5 10 percent growth in emerging economies and I think we will remain in this range this year  even if we should be closer to 5 percent than 10 percent   Peter Guenter  Sanofi s executive vice president for general medicines and emerging markets  said in an interview with Reuters  Emerging markets  with expanding middle class populations  are a big opportunity for global drug companies  although growth rates have slowed in recent years  China has been particularly tough  following imposed price cuts and more cautious drug promotion in the wake of a record bribery fine for GlaxoSmithKline  L GSK  in 2014  Sanofi  however  has recently done better there than some of its rivals  Guenter will move to a new position on June 1 as head of diabetes and cardiovascular  replacing Pascale Witz who is leaving the company  The group s 2015 revenues in emerging markets reached 10 6 billion euros   11 83 billion   up 8 percent at constant currency exchange rates   There are still a lot of unmet medical needs in China   Guenter said  with rapid urbanization leading to the spread of  western diseases  such as diabetes   Patients still travel long distances to meet an established specialist in the big cities of the east coast because they fear they won t get the right treatment at home   Guenter said  Sanofi  which vies with China market leaders  Pfizer   N PFE  and AstraZeneca  L AZN   as well as local manufacturers  has set up a research and development center in Shanghai both to reinforce its presence and boost its credibility with authorities  The company has been marketing Eloxatine    usually prescribed for colorectal cancer    for Chinese patients suffering with liver cancer for the past three years   The prevalence of liver cancer is very high China and very low elsewhere   we don t know quite why   Guenter said  The company does not break out its sales figures by country but Guenter said the growth potential in China was particularly promising  especially with improved access to health insurance in rural areas of the country   Of course  the reforms aimed at implementing better healthcare in China will put some pressure on pricing in the coming years but our hypothesis is that volumes will compensate  ,2016-05-25,Reuters,https://www.investing.com/news/stock-market-news/french-drugmaker-sanofi-to-step-up-push-into-china-404326,404326
220504,442020,PFE,Sanofi sees  strong strategic  fit with U S  Medivation,news,"PARIS  Reuters    Sanofi  PA SASY  sees a strong strategic fit with  Medivation   O MDVN  even though its tie up proposal was rejected by the U S  cancer drug maker last week  the company s chief executive said on Wednesday  The French drugmaker went public with a  9 3 billion proposal to buy Medivation on April 28 but the target said offer undervalued the company and its pipeline of drugs  U S firm  Pfizer   N PFE  has also approached Medivation to express interest in an acquisition  raising the possibility of a bid rivaling Sanofi s  people familiar with the matter said on Tuesday   We have a strong strategic complementarity with this company   Sanofi Chief Executive Olivier Brandicourt said of Medivation at the group s annual shareholder meeting in Paris  He didn t say if Sanofi would raise its offer   We will only move forward to a point where we create value   Sanofi chairman Serge Weinberg said   Of course  it is out of question to say here where that point is   Sanofi is keen to boost its presence in cancer treatments and already has teamed up last year with U S firm Regeneron  O REGN  in immuno oncology   Immuno oncology differs from traditional treatments such as chemotherapy or radiotherapy as its uses or enhances the patient s own immune system to be able to stop the growth of cancer cells  Brandicourt said much had still to be done to catch up with rivals such as Switzerland s Roche  S ROG  or  Novartis   S NOVN    We are making progress with Regeneron but coming back to Medivation  the complementarity comes from the fact they are very involved in prostate cancer   Brandicourt said  
Based in San Francisco  Medivation is known for its prostate cancer treatment Xtandi while Sanofi markets its own drug for the disease  Jevtana ",2016-05-04,Reuters,https://www.investing.com/news/stock-market-news/sanofi-says-sees-'strong-strategic'-fit-with-medivation-399855,399855
220505,442021,PFE,Sanofi ready to up offer for drugmaker Medivation  could oust board,news,"PARIS NEW YORK  Reuters    France s Sanofi  PA SASY  said it could raise its proposed  9 3 billion deal to buy Medivation if the U S  cancer drugmaker engaged in talks  threatening to go directly to shareholders to oust the board if not  Sanofi Chief Executive Olivier Brandicourt wrote in a letter to the board of Medivation published on Thursday that the transaction was a priority for the French drugmaker and it was committed to seeing it through  San Francisco based Medivation said on Thursday it had received a letter from Sanofi that  simply restates an inadequate proposal that    substantially undervalues the Company  its leading oncology franchise  and innovative late stage pipeline   Brandicourt said Sanofi had spoken to top Medivation shareholders and the proposal had  overwhelming  support   If you engage in good faith discussions with us and demonstrate additional value  we could be in a position to revise our offer   the CEO wrote   If you are not prepared to engage with us  we have no choice but to go directly to your shareholders   Sanofi said rules in the state of Delaware  where Medivation is registered  gave shareholders owning a majority of the company the power to oust the board   If the Medivation board of directors continues to refuse to engage with us  then we intend to commence a process to remove and replace members of the board   Brandicourt said  In its quarterly earnings call on Wednesday  Medivation s Chief Executive Officer David Hung said that Medivation s major shareholders had been  very supportive  of the board s choice to reject Sanofi s bid   He declined to comment on whether Medivation would run a sale process to explore offers from other potential bidders   Sanofi went public with the takeover proposal on April 28  but Medivation rejected the  52 50 a share deal outright  saying it undervalued the company  substantially   The stock has since risen to over  59   We believe we have offered a fair price  and a very attractive premium   Brandicourt wrote in the letter   We remain enthusiastic about a potential combination with Medivation   Medivation s first quarter earnings missed most analysts  forecasts  The San Francisco based company reported non GAAP net income of 11 cents per diluted share  up from 8 cents a year earlier  but much less than the average 23 cents expected by analysts in a Thomson Reuters poll   Sanofi is keen to boost its presence in cancer treatments and teamed up last year with U S firm Regeneron in immuno oncology  This differs from traditional treatments such as chemotherapy or radiotherapy as it uses or enhances the patient s own immune system to stop the growth of cancer cells  
Medivation  known for its Xtandi prostate cancer treatment  said on Thursday its board of directors  believes the execution of Medivation s business plan will deliver value to its stockholders that is far superior to Sanofi s proposal   The U S  company will announce first quarter results after the market closes on Thursday  U S drug maker  Pfizer   NYSE PFE  has also approached Medivation to express interest in an acquisition  raising the possibility of a bid rivaling Sanofi s  people familiar with the matter said on Tuesday ",2016-05-05,Reuters,"https://www.investing.com/news/stock-market-news/sanofi-says-ready-to-raise-medivation-offer,-threatens-hostile-bid-400117",400117
220506,442022,PFE,Ackman s Pershing Square cuts stake in Zoetis,news," Reuters    Billionaire investor William Ackman s Pershing Square  NYSE SQ  now holds a 5 percent stake in  Zoetis Inc   NYSE ZTS  after the hedge fund sold about  800 million worth of shares in the animal health company  according to a regulatory filing  Ackman sold 16 85 million Zoetis shares at an average price of  46 55 each  the filing showed on Tuesday  The fund had reported an 8 6 percent stake in the company in a filing on April 22  Zoetis  which was spun off from  Pfizer  Inc  NYSE PFE  in 2013  reported better than expected quarterly revenue and profit last week  
Pershing Square was a top industry performer in 2014  when it delivered a 40 percent return  But more recently it has been close to the bottom  losing 20 percent last year ",2016-05-11,Reuters,https://www.investing.com/news/stock-market-news/ackman's-pershing-square-cuts-stake-in-zoetis-401186,401186
220509,442025,PFE,Pfizer s Leukemia Drug Gets FDA Nod In First Line Setting,opinion,"Pfizer  Inc    NYSE PFE   announced that the FDA has approved its leukemia drug  Bosulif in first line setting 
We remind investors that Bosulif is currently approved for the treatment of chronic  accelerated or blast phase Philadelphia chromosome positive  Ph   chronic myelogenous leukemia  CML  in adults who are resistant or intolerant to prior therapy 
The drug is now approved for the first line treatment of patients suffering from chronic phase Ph  CML  Please note that Pfizer has a partnership with Avillion for Bosulif
Shares of Pfizer have risen 13 8  this year so far  comparing unfavorably with a 17 3  increase for the  

 
The supplemental New Drug Application  sNDA  filed by Pfizer for the label expansion was granted priority review by the FDA in August  The sNDA filing was based on data from a phase III study  BFORE   In December last year  Pfizer and Avillion announced that the study had met the primary endpoint  demonstrating superiority of Bosulif  bosutinib  over Novartis    NYSE NVS   Gleevec 
Additionally  the European Medicines Agency  EMA  accepted a similar regulatory application for review 
Bosulif recorded revenues of  163 million  up 35  year over year  With the approval to treat newly diagnosed patients  which will expand the eligible patient population  the drug s sales should improve further 
Bosulif s label expansion makes it the third approval for a hematology indication in five months  Two leukemia treatments   Besponsa for relapsed refractory acute lymphoblastic leukemia  ALL  and Mylotarg for newly diagnosed CD33 positive acute myeloid leukemia  AML    were approved in third quarter of 2017 
Zacks Rank   Stocks to Consider
Pfizer carries a Zacks Rank  3  Hold  
Some better ranked stocks in the pharma biotech sector include H  Lundbeck A S   OTC HLUYY    and XOMA Corp    NASDAQ XOMA    While XOMA carries a Zacks Rank  1  Strong Buy   H  Lundbeck has a Zacks Rank  2  Buy   You can see  
Shares of Lundbeck have risen 21 8  so far this year while 2018 earnings estimates have gone up 3 2  in the past 60 days 
While XOMA shares have skyrocketed 651  year to date  its 2018 loss estimates have narrowed almost 20  over the past 60 days 
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia and other conditions 
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ",2017-12-20,Zacks Investment Research,https://www.investing.com/analysis/pfizers-leukemia-drug-gets-fda-nod-in-firstline-setting-200274884,200274884
220512,442028,PFE,In China s tougher drug market  minnows open back door for  Big Pharma ,news,By Adam Jourdan SHANGHAI  Reuters    Armed with Beijing funds and friends in the right places  Chinese drug minnows are thriving  luring money from  Big Pharma  majors struggling to restore the strong growth they once enjoyed in the world s second largest medicine market  Chinese healthcare mergers and acquisitions nearly tripled last year to more than  50 billion  helped by giants like GlaxoSmithKline PLC and Eli Lilly and Co tapping small biotech and research innovators  The targets offer vital regulatory know how as Beijing builds a domestic drug industry   For Big Pharma  acquisitions  licensing deals and joint ventures offer a back door into a market where Beijing expects healthcare spending to rise to  1 3 trillion by 2020  The majors need the opening  their China growth has stalled to low single digit pace from over 20 percent just four years ago as branded generics have lost their shine   As a China biotech  company  we have the advantage of knowing policy  understanding the environment and being able to mobilize resources to get things done   said Li Chen  54  chief executive of Hua Medicine  Hua has a deal in place to develop drugs including a diabetes treatment licensed from Swiss giant Roche Holding  SIX ROG  AG  While firms like Hua can help global drugmakers navigate complex regulatory risks  speeding up approvals in treatment areas like diabetes and cancer  they get something in return   access to what Hua s Li calls  good assets  and in some cases potential partners to sell their wares overseas   For Li  a former Roche scientist  Hua s partnership deal brings the advantages of a tie up with a global industry leader to a company with a staff of around just 25 people  which he founded himself in Shanghai five years ago   We were looking for assets around the world so that s a really great match   and I know this asset really well   Li said  Among his firms peers  interest in such tie ups is growing  M A BOOM The buzz around China s healthcare industry has helped it outstrip hotspots like India to become the most active region in Asia for pharmaceutical tie ups  said Wei Zheng  healthcare analyst at BMI Research  Chinese healthcare M A last year surged to  54 billion from  18 8 billion the year before  according to Thomson Reuters data  not including the value of numerous joint ventures and licensing deals   There have already been deals worth more than  9 billion this year  the data shows  showing demand for the assets remains robust  As well as acquisitions  partnership deals are increasingly being sought after  industry executives say   A lot of firms are coming here to tap into a cost effective way of doing drug development   said Mireille Gillings  chief executive of U S  firm HUYA Bioscience International  which has scouts around China hunting for drug development breakthroughs  At the same time  other small firms are keen to find overseas partners to push their drugs overseas  HUYA has in licensed a Chinese immunotherapy cancer treatment that is undergoing trials in Japan and the United States  LOCAL NETWORKS Shanghai based research firm WuXi AppTec is one company that may fit that bill  It now employees around 11 000 people worldwide and said this month it was setting up a joint venture with U S  listed Juno Therapeutics Inc to develop innovative cancer drugs   in China   Honestly  if you manufacture locally  test local and file local  that will give you a time advantage   the firm s chief executive  Ge Li  told Reuters   It s as simple as that   The tilt in strategy for the majors comes as Beijing accelerates efforts to promote a  Made in China  drug industry  GlaxoSmithKline s China head  Herve Gisserot  told Reuters late last year that Beijing was putting pressure on off patent generics  reining in prices and trying to cut out low quality drugs   positive moves longer term  but which created short term challenges   The only thing for pharma is that some of the things will happen sooner than others  Price erosion will likely be faster than the accelerated approval of new medicines   he said   SEA TURTLES  Chinese partners bring an extra dimension  The domestic start ups aren t shy about their government backing and political connections  an important element to help attract funding and navigate complex regulations  Samantha Du  chief executive of Shanghai based Zai Lab  which has in licensed cancer treatment drugs from  Pfizer  Inc  NYSE PFE  and struck a partnership in March with German pharmaceutical giant Boehringer Ingelheim  said her firm had  lots of government funding   Du  52  like Hua Medicine s Li Chen  is a so called  sea turtle    one of China s best and brightest  who has returned home after studying and working overseas  She has served on various government linked committees  she said  noting this had done nothing to harm the firm s prospects   Over 18 months  we ve raised around  140 million and haven t even spent the first round   she said  Her firm  founded in 2013  employs 30 staff in house   There s plenty of money to spend  ,2016-04-28,Reuters,"https://www.investing.com/news/stock-market-news/in-china's-tougher-drug-market,-minnows-open-back-door-for-'big-pharma'-398734",398734
220513,442029,PFE,New drugs fuel strong Pfizer results  company raises 2016 forecasts,news,"By Ransdell Pierson  Reuters     Pfizer  Inc  NYSE PFE   which last month abandoned its  160 billion quest for  Allergan Inc   NYSE AGN pa   reported quarterly results that blew past analyst estimates on sales of its new cancer and arthritis treatments and the acquisition last year of hospital products company  Hospira   NYSE HSP   The largest U S  drugmaker also raised its revenue and earnings forecast for the year  helped in part by the weakening dollar  Shares of the company rose 2 4 percent in morning trading on Tuesday  Global company sales jumped 20 percent to  13 billion in the first quarter  which was  1 billion more than Wall Street had expected  But the quarter included five more days of sales in the United States than the year ago quarter  adding revenue of  900 million in the most recent period  Pfizer said sales would be hurt in the fourth quarter of 2016  however  when those added days will be offset by fewer days   Credit Suisse   SIX CSGN  analyst Vamil Divan said the results were impressive  with most drug categories beating sales expectations  But he said investors are eager to hear how Pfizer s overall strategy might change  given its dashed hopes for Allergan   Pfizer walked away from the deal after the U S  Treasury issued new rules curbing tax inversion deals  under which American companies move overseas to cut taxes  Many analysts believe Pfizer needs to buy new medicines or entire biotech companies to ensure competitive earnings growth  Meanwhile  its recently launched breast cancer treatment  Ibrance  is on its way to becoming a mega blockbuster product  Its sales jumped to  429 million  from  38 million in the year ago quarter   Morningstar analyst Damien Conover said sales of rheumatoid arthritis pill Xeljanz more than doubled to  197 million after new treatment guidelines from the American College of Rheumatology put it on par with standard injectable treatments for patients that have failed prior therapy   With the Allergan deal scratched  Pfizer has said it will decide this year whether to sell or split off its hundreds of generic medicines  called established products  into a separate business  When it announced its planned Allergan deal last November  Pfizer put off making the decision until 2019  Conover said Pfizer is likely for the remainder of 2016 to seek far smaller  bolt on  deals  possibly in the  5 billion to  20 billion range   They really need to figure out whether to break into two pieces before doing a lot of big mergers   Conover said  Sales of Pfizer s generic medicines rose 17 percent in the quarter to  5 97 billion  while sales of its array of patent protected drugs jumped 23 percent to  7 03 billion   Pfizer in September 2015 completed its  16 billion purchase of Hospira  which makes a wide array of drugs and devices used in hospitals  especially sterile injectable products  Hospira products posted sales of  1 2 billion in the quarter  Net income rose to  3 02 billion  or 49 cents per share  from  2 38 billion  or 38 cents per share  a year earlier  according to Thomson Reuters I B E S  Excluding special items  Pfizer earned 67 cents per share  well above the average analyst estimate of 55 cents per share  
Pfizer now expects 2016 revenue of  51 billion to  53 billion  from its earlier view of  49 billion to  51 billion  and earnings of  2 38 to  2 48 per share  from  2 20 to  2 30 per share ",2016-05-03,Reuters,https://www.investing.com/news/stock-market-news/pfizer-quarterly-revenue-soars-19.7-percent-399499,399499
220516,442032,PFE,Pfizer Hikes Dividend  Announces  10B Share Buyback Plan,opinion,"The board of directors of Pfizer  Inc    NYSE PFE   announced a 6  hike in the pharma giant s quarterly dividend for 2018 while also authorizing a new  10 billion share repurchase program The quarterly dividend was raised from 32 cents to 34 cents  which adds up to an annual dividend of  1 36 per share  This amounts to an annual dividend yield of 3 7   The increased dividend for the first quarter of 2018 will be payable on Mar 1  2018  to shareholders of record at the close of business on Feb 2  2018 Shares of Pfizer have risen 14 3  this year so far  comparing unfavorably with a 17 1  increase for the  Pfizer regularly rewards shareholders through share buybacks and dividends  The company returned about  13 1 billion to shareholders in the form of dividends and share buybacks in 2015 and  12 3 billion in 2016  including the completion of a  5 billion accelerated share repurchase agreement  In 2017 so far  the company has bought back shares worth  5 billion  It has  6 4 billion remaining under the company s current buyback plan Pfizer is exploring strategic alternatives for its Consumer Healthcare segment  the proceeds of which it plans to use to return value to shareholders in the form of share buybacks and dividends  For the Consumer Healthcare segment  Pfizer is considering either a partial or a full separation through a spin off  sale or other transaction  A decision regarding the same is expected to be made next year  It may even choose to retain the business  The divestment of the Consumer Healthcare business will help Pfizer focus on its Innovative Health segmentZacks Rank   Stocks to ConsiderPfizer carries a Zacks Rank  3  Hold  Some better ranked stocks in the pharma biotech sector include H  Lundbeck A S   OTC HLUYY    ANI Pharmaceuticals  Inc    NASDAQ ANIP   and XOMA Corporation   NASDAQ XOMA    While XOMA carries a Zacks Rank  1  Strong Buy   H  Lundbeck and ANI Pharmaceuticals have a Zacks Rank  2  Buy  You can see ANI Pharmaceuticals  earnings estimates have moved up 2 4  for 2018 over the last 60 days  Share price of the company has risen 9 3  year to date While XOMA shares have skyrocketed 665 2  year to date  its 2018 loss estimates have narrowed almost 20  over the past 60 days Shares of Lundbeck have risen 21  so far this year while 2018 earnings estimates have gone up 3 2  in the past 60 days 
Zacks Editor in Chief Goes   All In   on This Stock 
Full disclosure  Kevin Matras now has more of his own money in one particular stock than in any other  He believes in its short term profit potential and also in its prospects to more than double by 2019  Today he reveals and explains his surprising move in a new Special Report ",2017-12-18,Zacks Investment Research,https://www.investing.com/analysis/pfizer-hikes-dividend-announces-10b-share-buyback-plan-200274424,200274424
220518,442034,PFE,U S  plans to curb tax  inversions  could hit foreign companies,news,"By Tom Bergin
LONDON  Reuters    Planned changes that President Barack Obama says are aimed at ensuring American companies do not avoid tax by shifting their headquarters overseas could also force foreign companies to adopt more conservative U S  tax planning strategies 
One of the measures restricts the ability of U S  subsidiaries of foreign companies to deduct the interest they pay on loans from their parent firms from their taxable income 
It aims to stop a redomiciled American firm from reducing its U S  tax bill by piling inter group debt on its U S  operations  and effectively shifting profits overseas 
But it could also affect European companies that use similar strategies to reduce their tax bills in the United States after buying U S  firms 
The new rules announced by the Treasury department this week aim to curb so called  inversions    where a U S  group acquires a smaller overseas company and shifts its domicile to a lower tax jurisdiction 
Drugmaker  Pfizer   NYSE PFE  s plan to buy rival Allergan  NYSE AGN pa  and move to Ireland was one of the planned inversions that prompted the Obama administration to act  The  160 billion deal fell apart last week as a result of other aspects of the Treasury reforms 
Under the new rule regarding debt  if a U S  subsidiary transfers money to its overseas parent within three years before or after borrowing money from it  by paying a dividend or buying shares in the parent  then U S  tax authorities could potentially treat the loan as if it was equity 
This means the interest on the debt would not be deductible for U S  income tax purposes 
Experts said that European companies would still be able to shift profits via inter group debt  but may have to do so gradually over a longer period of time 
 It  without doubt  significantly changes the rules of the game   said Stephen Shay  professor of law at Harvard University 
 In the old days you bought and then you levered up as much as you can and that is not going to happen in the same way  but how much of a constraint that becomes is unclear   he added 
Nancy McLernon  president of the Organization for International Investment  a trade group for the U S  subsidiaries of foreign companies  denied non U S  groups were routinely shifting profit overseas through debt 
 Where s the problem they  U S  authorities  are trying to fix  It feels more like a tax grab   she said 
She said the complexity of the issue and uncertainty over how the Internal Revenue Service  IRS   the U S  tax authority  would seek to use their new powers would make investing in new U S  projects less attractive 
 It will have a chilling effect on foreign direct investment in the United States   McLernon added 
BILLIONS AT STAKE
The Treasury says it is targeting situations where large debts are incurred to fund dividends shortly after an inversion or foreign acquisition  rather than the most common way U S  subsidiaries accumulate inter group debt  That is by having the subsidiary gradually pay all its profit to its parent as dividends and then borrow money from its parent for new investment 
 The proposed regulations generally do not apply to related party debt that is incurred to fund actual business investment  such as building or equipping a factory   a Treasury factsheet released last week said 
Providing the money a foreign company takes out of its U S  subsidiary is in line with the U S  company s profits  the transactions should escape IRS scrutiny  Shay said 
Companies don t usually publish details of their inter group financing so it s impossible to put a figure on how much profit foreign companies shelter from U S  tax through inter group loans  Richard Murphy  professor of practice in international political economy at City University London  estimates the IRS could lose tens of billions of dollars in taxes each year in this way 
Companies that have reduced their U S  tax bills via inter group lending include drugmaker GlaxoSmithKline  education group  Pearson   LON PSON   utility Scottish Power and telecoms group  Vodafone   LON VOD  
All said their lending to U S  subsidiaries had been unwound and that they complied with all tax rules  Details of their lending arrangements came to public attention following data leaks or legal action with tax authorities 
A 2013 Reuters examination of tax planning by Europe s largest software group  SAP AG  DE SAPG   showed how the German company shifted profits from the United States  which has a corporate tax rate of at least 35 percent  to Ireland whose headline rate is 12 5 percent 

HIGH INTEREST LOANS
According to Reuters calculations based on 2015 corporate filings  SAP America Inc reduces its U S  tax bill by around  200 million a year by borrowing  7 4 billion from SAP Ireland US Financial Services Ltd at an interest rate of at least 7 percent 
The debt  which helped fund the acquisition of U S  software groups  cuts its taxable income by around  600 million a year 
A spokesman for SAP group declined to comment on the Reuters calculations but said the company followed all tax rules and that its funding structure was driven by business rather than tax reasons 
Some measures previously proposed by Obama and the Organization for Economic Co operation and Development  OECD   which advises developed nations on tax policy  would have limited interest deductions to the extent that they reflected an operating unit s share of total group interest costs 
Since SAP group s total net interest expense was just 5 million euros last year  most of its U S  subsidiary s deduction may have been disallowed under such proposals 
But the Treasury plan is far more limited than these proposals  SAP filings suggest that it has not taken large amounts of cash from its acquired U S  subsidiaries and recapitalized them with debt 
Debts accumulated as SAP has done   by acquiring and expanding U S  companies   should not be captured by the new measures  even if that debt is out of proportion to the parent s overall debt burden 
But it s hard to be certain 
Inter group debts usually run for a period of a few years  and each time they extend them  there is an opportunity for the IRS to re examine the arrangement 

 There is certainly is a risk when they roll over that instrument  that it is going to be recharacterised as equity   said Victor Fleischer  professor of law at the University of San Diego  said of the SAP loans ",2016-04-11,Reuters,https://www.investing.com/news/stock-market-news/u.s.-plans-to-curb-tax-'inversions'-could-hit-foreign-companies-394651,394651
220519,442035,PFE,Obama tax inversion rules may overstep authority  U S  lawmaker,news,"By David Morgan WASHINGTON  Reuters    President Barack Obama s proposed rules to stop U S  companies from reincorporating abroad  if only on paper  to avoid U S  income taxes appear to overstep legal authority  a top Republican lawmaker said on Friday  Representative Kevin Brady said his staff is scrutinizing the rules  which were unveiled last week by the U S  Treasury Department  Legal experts have offered mixed views on the viability of any court challenge   The new rules  intended to discourage tax  inversions   led to the collapse of U S  drugmaker  Pfizer   NYSE PFE  Inc s  160 billion acquisition of Ireland s Allergan  NYSE AGN pa  Plc   We recognize there is broad discretion in some areas of that tax code   Brady  a Texas Republican and chairman of the tax writing House of Representatives Ways and Means Committee  said in a speech to the U S  Chamber of Commerce   But it certainly appears that Treasury overstepped its authority  especially in effect  taking legislative proposals that haven t passed this Congress or any other Congress and essentially making it law through regulation   Brady gave no indication of what his committee might do  It was unclear what action  if any  the Republican controlled Congress would take against the inversion rules in an election year marked by voter anger over taxes and international trade   I share the concern about inversions  Everyone does  But there s a right way and a wrong way to tackle them   Brady said   An inversion is a tax driven deal in which a U S  company acquires a smaller  foreign business and adopts its tax domicile to reduce the combined company s overall tax burden  The deals most often involve reincorporating in Ireland or Britain  Though inversions have been going since the 1980s  a new wave has been under way for about five years  The Pfizer Allergan deal would have been the biggest inversion of all time  There is bipartisan agreement on the need for comprehensive tax reform to address inversions  but the deeply divided Congress is unlikely to tackle this until 2017  especially with elections coming in November  analysts said  In the interim  the Obama administration has tightened inversion rules in limited areas  drawing Republican criticism   
 The administration s strategy won t solve the fundamental problem and likely will make it worse   Brady said ",2016-04-15,Reuters,https://www.investing.com/news/politics-news/obama-tax-inversion-rules-may-overstep-authority:-u.s.-lawmaker-395827,395827
220520,442036,PFE,U S  Treasury readies new tax rules as G20 vows to fight evasion,news,"By David Lawder WASHINGTON  Reuters    The U S  Treasury Department is finalizing new tax rules aimed at combating the use of shell companies to evade taxes  U S  Treasury Secretary Jack Lew said on Saturday amid increased pledges by global finance leaders to cooperate on tax issues  In a statement to the International Monetary Fund s steering committee  Lew said the Treasury was finalizing a rule that would require banks to identify the beneficial owners of new customers that are companies    In addition  we are about to propose a regulation that would require the beneficial owners of single member limited liability companies to identify themselves to the Internal Revenue Service  thus closing a loophole that some have been able to exploit   Lew said  In the wake of controversy stirred by the so called Panama Papers  which revealed widespread use of tax havens and shell companies by wealthy global elites  officials from the Group of 20 major economies on Friday threatened to penalize tax haven countries that do not comply with new information sharing efforts and moves to reduce tax mismatches between countries  They called for criteria by July to identify non cooperative jurisdictions   Defensive measures will be considered by G20 members against non cooperative jurisdictions  if progress toward tax goals is not made  the group said in its statement  Lew said the United States fully supports calls for all countries to automatically exchange financial account information  The new U S  shell company rules will follow steps taken by the Treasury earlier this month to curb corporate  inversion  deals in which U S  firms buy foreign rivals to move their tax jurisdictions offshore  Those changes were cited as scuttling a  160 billion merger between U S  drug maker  Pfizer  Inc  NYSE PFE  and Dublin based Allergan  NYSE AGN pa  Plc that would have shifted the combined company headquarters to Ireland  where corporate tax rates are 12 5 percent  compared to the top U S  corporate tax rate of 35 percent before deductions and credits   Tax evasion and tax avoidance hurt government budgets  reduce the equity of our tax systems and hinder global growth   Lew said  In his statement  Lew also repeated calls for euro area countries and Japan to use available fiscal policy space to stimulate domestic demand while enacting structural reforms to their economies   Japan should deploy a flexible fiscal policy in the near term that provides a supportive fiscal impulse  while accelerating the implementation of structural reforms  including labor market reforms and opening the service sector to increased competition   
He offered up a long to do list for China  saying the world s second largest economy  should prioritize reforms that strengthen its social safety net  reduce industrial over capacity  open up the services sector to competition  tackle rising corporate leverage  confront the associated challenges to the banking system  and allow for a market determined allocation of credit  ",2016-04-16,Reuters,https://www.investing.com/news/economy-news/u.s.-treasury-readies-new-tax-rules-as-g20-vows-to-fight-evasion-395921,395921
220521,442037,PFE,Pfizer to pay  784 6 million to resolve Wyeth false claims lawsuit,news,WASHINGTON  Reuters     Pfizer  Inc  N PFE  has agreed to pay  784 6 million to resolve allegations that Wyeth  which it acquired in 2009  underpaid drug rebates to Medicaid  the federal health insurance program  the Justice Department said Wednesday  The settlement resolves claims by the U S  and states that Wyeth knowingly reported false and fraudulent prices on two of its anti acid drugs  Protonix Oral and Protonix IV  the Justice Department said   Pfizer acquired Wyeth in 2009  about three years after Wyeth had ended the conduct that led to settlement  the Justice Department said   We are pleased to have finalized the agreement to resolve these cases  which involve historic conduct that occurred at least 10 years ago  before we acquired Wyeth   said Doug Lankler  executive vice president and general counsel  in a statement    The resolution of these claims reflects our desire to put these historic cases behind us and to focus on the needs of patients   Lankler said  About  93 7 million of the settlement will resolve claims relating to New York state s Medicaid program  said New York Attorney General Eric Schneiderman in a statement on Wednesday  New York will receive  55 6 million of that sum ,2016-04-27,Reuters,https://www.investing.com/news/stock-market-news/pfizer-to-pay-$784.6-million-to-resolve-wyeth-false-claims-lawsuit-398319,398319
220523,442039,PFE,Pfizer Cresemba Deal Extended To Asia And China  ,opinion,"Basilea has announced an extension to its licence agreement with Pfizer  NYSE PFE  for Cresemba  for invasive fungal infections   The original deal granted PFE exclusive commercialisation rights to the product in Europe  ex Nordics   Russia  Turkey and Israel and the new amendment includes China and 16 countries within Asia Pacific  The extension of Cresemba s global footprint at this stage highlights PFE s commitment to the product in areas outside of Europe  Concomitantly Basilea has updated its guidance for FY17 to a reduced operating loss of CHF1m per month vs CHF2m per month  Our valuation rises slightly to CHF1 222m 

PFE to commercialise Cresemba in China   Asia Pac
Pfizer is to use its extensive footprint in China and Asia Pac to commercialise Cresemba  isavuconazole  contingent on approval in each territory  The revised agreement includes a  3m upfront payment  deferred  and up to   223m in additional payments dependent upon the achievement of pre specified regulatory and sales milestones  Basilea will also receive royalties in the mid teen range on Pfizer s sales in these territories  Importantly  as of November 2017 PFE has launched Cresemba into Spain so it is now available in the top five EU markets  In addition  Swissmedic has granted marketing authorisation for Switzerland 
To read the entire report Please click on the pdf File Below ",2017-12-07,Edison,https://www.investing.com/analysis/pfizer-cresemba-deal-extended-to-asia-and-china-200271280,200271280
220527,442043,PFE,Democratic White House hopefuls cheer end of Pfizer  Allergan deal,news," Reuters    Democratic presidential candidates Hillary Clinton and Bernie Sanders on Wednesday cheered the end of U S  drugmaker  Pfizer   NYSE PFE  Inc s  160 billion merger with Ireland based Allergan  NYSE AGN pa  Plc   Glad to hear Pfizer is calling off the merger  We need to close the loopholes that let corporations escape paying their taxes   Clinton said on Twitter   
Sanders said on the social media site that he applauded President Barack Obama for new rules aimed at curbing so called inversion deals  which Pfizer said led it to scrap the deal ",2016-04-06,Reuters,"https://www.investing.com/news/politics-news/democratic-white-house-hopefuls-cheer-end-of-pfizer,-allergan-deal-393828",393828
220531,442047,PFE,Obama to deliver statement on economy Tuesday  after inversions move,news,"WASHINGTON  Reuters    President Barack Obama will deliver a statement at 12 15 ET on Tuesday on the economy following Monday s Treasury Department announcement on corporate tax inversions  the White House said 
The U S  Treasury Department took new steps to curb tax avoiding corporate  inversions  late on Monday that threw a series of proposed mergers into question  including  Pfizer   NYSE PFE  Inc s  160 billion agreement to buy Allergan  NYSE AGN pa  Plc ",2016-04-05,Reuters,"https://www.investing.com/news/politics-news/obama-to-deliver-statement-on-economy-tuesday,-after-inversions-move-393620",393620
220532,442048,PFE,Obama urges Congress to take action on corporate tax reform,news,WASHINGTON  Reuters    U S  President Barack Obama on Tuesday urged Congress to take action to stop U S  companies from taking advantage of tax loopholes that allow them to avoid paying taxes   When companies exploit loopholes like this    it sticks the rest of us with the tab and it makes hard working Americans feel like the deck is stacked against them   Obama told reporters at the White House  adding that wealthy corporations and individuals should not be  gaming the system   Obama  a Democrat  has called repeatedly for action by the Republican controlled U S  Congress on tax avoiding corporate inversions  which lowers companies  tax bills by allowing them to redomicile overseas even though their core operations and management usually remain in the United States  So far  lawmakers have done little  The U S  Treasury Department took more decisive actions to crack down on inversions late on Monday  that imperils a number of proposed mergers  including  Pfizer   NYSE PFE  Inc s  160 billion agreement to buy Dublin based Allergan  NYSE AGN pa  Plc   I want to be clear  While the Treasury Department s actions will make it more difficult    to exploit this particular corporate inversions loophole  only Congress can close it for good   Obama said ,2016-04-05,Reuters,https://www.investing.com/news/politics-news/obama-urges-congress-to-take-action-on-corporate-tax-reform-393644,393644
220539,442055,PFE,Pfizer s  160 billion mega merger is in trouble,news,"Because the move can be seen as fleeing the US  tax inversions are not particularly politically popular  In November  when the deal was announced  everyone from US Sen  Bernie Sanders  I Vermont  to  took a stance against the deal 
This isn t the first time the Treasury has tried to squash a tax inverting merger  In 2014  AbbVie called off its inversion deal with Shire after Treasury announced  
The government can discourage inversions by eliminating some of their economic benefits  One practice Treasury said it would target on Monday  is a practice called    which is a way of jacking up interest payments in order to lower tax bills 
 Pfizer   NYSE PFE  said it will review the newest actions  and declined  to speculate on any potential impact  until it is done with that 
Shares of Allergan  NYSE AGN pa  fell more than 16  on Tuesday morning to  232 19  while Pfizer rose less than one percent 
The companies have anticipated the potential for the government to make rule changes that could kill the deal 
When the announced the deal in November  Pfizer and Allergan said  that if a deal between Pfizer and Allergan doesn t go through because shareholders of one company object  or a  superior proposal  appears  the companies would pay a breakup fee of up to  3 5 billion 
But  if the deal breaks because of a change in the law  under which this Treasury move would fall   that termination fee falls to just  400 million 
The Treasury Department didn t specifically reference Pfizer s deal in its statement  US  
Treasury has taken action twice to make it harder for companies to invert  These actions took away some of the economic benefits of inverting and helped slow the pace of these transactions  but we know companies will continue to seek new and creative ways to relocate their tax residence to avoid paying taxes here at home ",2016-04-05,Business Insider,https://www.investing.com/news/stock-market-news/pfizer's-$160-billion-mega-merger-is-in-trouble-393613,393613
220543,442059,PFE,Indian court grants temporary relief to Abbott  Glenmark in drug ban case,news,"NEW DELHI  Reuters    An Indian court on Tuesday granted interim injunction to U S  drugmaker Abbott s India unit  NS ABOT   and domestic companies  Glenmark Pharmaceuticals   NS GLEN  and Macleods Pharmaceuticals  on the prohibition on sale of several combination drugs  India banned 344 drug combinations over the weekend  including Abbott s codeine based cough syrup  after a government panel of experts found they had  no therapeutic justification   The judge in the Delhi High court granted an interim stay to the pharmaceutical companies and said regulators should take  no coercive steps  against them  The case will now be heard on March 21   
The Indian unit of U S  drugmaker  Pfizer   N PFE   NS PFIZ  had on Monday won a similar reprieve on a ban on its popular cough syrup Corex ",2016-03-15,Reuters,"https://www.investing.com/news/stock-market-news/indian-court-grants-temporary-relief-to-abbott,-glenmark-in-drug-ban-case-389971",389971
220544,442060,PFE,Pfizer CEO Ian Read s total compensation falls more than 20  in 2015,news,"Investing com     Pfizer  Inc  NYSE PFE  CEO Ian Read s total compensation package fell more than 20  in 2015 primarily due to a sharp reduction in stock awards over the calendar year 
In total  Read s compensation decreased by 23  to  18 037 million last year  down from approximately  24 million a year earlier  It came as Read s compensation through stock options and Total Shareholders Return Unit  TSRUs  exercises fell considerably to  2 879 million for the year 
Read  who became Pfizer s CEO in December  2010  saw his base salary increase moderately to  1 859 million in 2016  up from  1 8 million a year earlier  Read s incentive award also rose to  4 3 million last year from  3 million in 2014 
Over the course of the year  Read said Pfizer advanced the company s drug pipeline by developing nearly 40 compounds and made significant advancements with its development of Xelianz  its Rheumatoid Arthritis treatment  Ibrance  its drug to treat metastic breast cancer and Prevanac  a pneumococcal conjugate vaccine 
 Every part of the business turned in a strong performance and achieved significant milestones across our four strategic imperatives   Read said in the company s annual 2015 report   We grew several of our brands that are early in their life cycle and achieved our first year of operational revenue growth in five years  
Pfizer has been widely criticized by U S  Republican presidential candidate Donald Trump and others for its proposed  160 billion merger with Allergan  NYSE AGN pa  last November  Under the proposed deal  Pfizer will reduce its effective corporate tax rate from 25  in the U S  to between 17 18  for the new company by moving its corporate headquarters to Dublin  The deal takes advantage of a so called corporate inversion strategy when a company acquires a legal address abroad to lower its effective corporate tax rate 
Shares in Pfizer ticked up 0 07 or 0 24  to 29 58 in after hours trading ",2016-03-15,Investing.com,https://www.investing.com/news/stock-market-news/pfizer-ceo-ian-read-39;s-total-compensation-falls-more-than-20-in-2015-390128,390128
220545,442061,PFE,U S  stocks broadly higher after Fed lowers rate forecast for 2016,news,"Investing com    U S  stocks rose broadly on Wednesday after the Federal Reserve voted to maintain short term interest rates at their current level  while cutting its forecast for future rate hikes in 2016 
On Wednesday afternoon  the Federal Open Market Committee  FOMC  held the Federal Funds Rate at a target range between 0 25  and 0 50   leaving its benchmark interest unchanged for the second consecutive month  Citing increased global and economic and financial risks and a modest uptick in inflation  Fed chair Janet Yellen emphasized that conditions in the economy will likely warrant gradual interest rate hikes for the remainder of the year  Notably  the FOMC lowered its projections for future rate increases by 50 basis points for each of the next two years  The Fed now expects to raise interest rates twice in 2016  down considerably from December forecasts of four potential interest rate hikes this year 
Any rate hikes from the Fed this year are viewed as bearish for equities  as investors pile into bonds and U S  Treasuries in an effort to capitalize on higher yields 
Yellen s comments provided a boost to the major indices late in the session  as the Dow Jones Industrial Average added 73 07 or 0 42  to 17 324 60  The Dow reversed territory following the release of the relatively dovish statement  gaining more than 125 points at session highs  With the gains  the Dow ended Wednesday s session at its highest closing level of 2016 
The NASDAQ Composite index gained 35 30 or 0 75  to 4 763 97  while the S P 500 Composite index rose 11 35 or 0 56  to 2 027 32  On the S P 500  nine of 10 sectors closed in the green  as stocks in the Energy  Basic Materials and Technology industries led  Stocks in Health Care sector lagged  ending the session as the lone industry in the red  While analysts largely expected little action from the Fed after the European Central Bank and the Bank of Japan held rates in negative territory over the last week  the Fed s decision to slash its rate outlook came as a mild surprise 
The top performer on the Dow was  Caterpillar  Inc  NYSE CAT   which jumped 1 90 or 2 62  to 74 34  Shares in the world s largest manufacturer of mining and construction equipment moved higher  as commodities surged following the Fed s statement  The worst performer was  Pfizer  Inc  NYSE PFE   which lost 0 50 or 1 69  to 29 04  Pfizer  NYSE PFE  shares dipped on Wednesday  one day after the pharmaceutical giant reported that CEO Ian Read s total compensation fell by more than 20  last year 
The biggest gainer on the NASDAQ was  Charter Communications  Inc  NASDAQ CHTR   which added 10 99 or 5 88  to 197 92  The worst performer was VRTX  which lost 3 85 or 4 65  to 78 98  Slumping pharmaceutical stocks continued to drag down the health care sector  as Alexion Pharmaceuticals Inc  NASDAQ ALXN   Biomarin Pharmaceutical Inc  NASDAQ BMRN  and Celgene Corporation  NASDAQ CELG  were among the worst performers of the session 
The top performer on the S P 500 was Freeport McMoran Copper   Gold Inc  NYSE FCX   which soared 0 97 or 10 46  to 10 24 as gold futures surged by more than  30 an ounce on Wednesday afternoon  Gold  which is not attached to interest rates or dividends  struggles to compete with high yield bearing assets in rising rate environments  The worst performer was  Mallinckrodt   NYSE MNK   which lost 3 05 or 5 13  to 56 46 
On the New York Stock Exchange  advancing issues outnumbered declining ones by a 2 513 604 margin ",2016-03-16,Investing.com,https://www.investing.com/news/stock-market-news/u.s.-stocks-broadly-higher-after-fed-lowers-rate-forecast-for-2016-390347,390347
220546,442062,PFE,Company News For Nov 1  2017,opinion,Shares of Pfizer Inc    NYSE PFE   fell 0 3  after posting third quarter 2017 revenues of  13 168 million  below the Zacks Consensus Estimate of  13 169 millionShares of Under Armour  Inc    NYSE UA   plummeted almost 22  after posting third quarter 2017 earnings of  0 22 a share  lower than  0 29 a share in the year ago quarterShares of Aetna Inc    NYSE AET   dipped 0 7  after posting third quarter 2017 revenues of  14 948 million  below the Zacks Consensus Estimate of  15 108 millionShares of Acorda Therapeutics  Inc    NASDAQ ACOR   declined 2 7  after posting third quarter 2017 revenues of  141 million  below the Zacks Consensus Estimate of  151 million,2017-10-31,Zacks Investment Research,https://www.investing.com/analysis/company-news-for-nov-1-2017-200257611,200257611
220548,442064,PFE,Trump calls global currency devaluations  dangerous  for U S,news,"By Megan Cassella WASHINGTON  Reuters    Republican presidential candidate Donald Trump on Thursday blasted currency devaluations around the world for hurting the U S  economy and costing American jobs  and defended his calls for a tougher U S  stance on trade  Asked about the European Central Bank s decision on Thursday to cut interest rates  Trump told CNBC that such devaluations were driving manufacturing and other jobs outside of the United States   We just sit back and do nothing   Trump said   That s getting to be very dangerous as far as I m concerned   A more effective economic move than devaluations would be charging a tax on products made abroad and sold in the United States  particularly those from China  Trump said   China is the grand master of all   Trump said   I have great relationships and business relationships with China  and even those people say they can t believe what they re getting away with   Additionally  the front runner for the Republican nomination in the Nov  8 U S  presidential election said that while he supports free trade if it is  fair   the United States has been taken advantage of in negotiations  Trump also said if elected president he would move quickly to stop corporate inversions   when a U S  company acquires an overseas firm and reduces its tax bill by moving its headquarters to the purchased firm s location  Trump said he thinks corporate inversions cost the United States twice as much as estimated  He said drugmaker  Pfizer  Inc  NYSE PFE  and other companies that have recently left the country show  there are things that are very structurally wrong with what we re doing    I think it s  5 trillion  but I don t think our country has any idea what it is  but I think it s much more than  2 5 trillion   he said  referring to U S  tax revenue lost when companies pull off corporate inversions  Trump said Republicans and Democrats agree they want to halt such inversions  but  they can t make a deal because they don t have leadership   
 I could make a deal in 15 minutes by getting people in a room   Trump said   Everybody wants that money to come into the United States      It would be so easy  ",2016-03-10,Reuters,https://www.investing.com/news/politics-news/trump-calls-global-currency-devaluations-'dangerous'-for-u.s-389156,389156
220550,442066,PFE, Pfizer earnings beats estimates  as pneumonia vaccine sales grow ,news,"Investing com   U S  drugmaker  Pfizer   N PFE  reported better than expected quarterly revenue on Tuesday  helped by demand for its pneumonia vaccine and its  Hospira   N HSP  acquisition 
Revenue rose 7  to  14 05 billion in the fourth quarter  ahead of the average analyst estimate of  13 56 billion 
Net income fell to  613 million  or 10 cents per share  from  1 23 billion  or 19 cents per share  a year earlier 
But the company provided full year revenue and earnings forecasts below analysts  estimates  citing generic competition and a strong dollar 
Pfizer said it expects reported revenue of  49 billion  51 billion for 2016 and adjusted earnings of  2 20  2 30 per share ",2016-02-02,Investing.com,"https://www.investing.com/news/stock-market-news/pfizer-earnings-beats-estimates,-as-pneumonia-vaccine-sales-grow-382867",382867
220554,442070,PFE,Emerald Health Therapeutics Nears Phase 2 Of Major Growth Strategy,opinion,"On October 2  2012  Emerald Health Therapeutics  SG TBD  announced that it had appointed Chris Wagner as company CEO  On the appointment  previous CEO Bin Huang shifted to focus on the management of the company s operations and expansion as President of Emerald Health Botanicals  Emerald Health Therapeutics  wholly owned subsidiary 
With this reshuffle  the company has shown its cards as far as future operational focus is concerned and  in doing so  has made itself very much one to watch in the biotechnology space going forward 
Here is why 
Those familiar with Emerald Health Therapeutics will know the company as a Canadian medical cannabis grower and producer  based out of Victoria  BC  The company is a well established player in its sector and the legality of both medical and recreational cannabis in Canada has led to it being able to achieve substantial growth over the last 12 months  raising revenues over this period from  36 000 during the third quarter of 2016 to just shy of  200 000 during the second quarter of 2017   an increase of more than 450  
Over the coming 12 months  however  recent activity suggests that management is seeking to implement what we might refer to as the second phase of Emerald Health Therapeutics  growth efforts and this second phase could very quickly outweigh even the triple digit percentage point topline increase detailed above 
There are two separate elements of near term operational activity that are going to support this last statement  with one being the operational focus implied by the appointment of the above mentioned Chris Wagner 
Before outlining that one  however  let s address the other one   production capacity expansion 
Emerald Health Therapeutics announced during the early part of September that it has put together a joint venture with a company called Village Farms  The latter is another cannabis grower and distributor in Canada and the joint venture will see the two companies combine to create 1 100 000 ft   of fresh greenhouse space  with Village Farms providing the space and Emerald Health Therapeutics putting up  20 million in initial capital to get the facility into production 
Why is this important 
Because right now  Emerald Health Therapeutics  total grow space is just 100 000 ft    An additional 1 100 000 ft   is going to allow the company to compete with some of its much larger  billion dollar peers in the Canadian grow arena and is going to do so with the above mentioned investment of only  20 million  Emerald Health Therapeutics and Village Farms are going to split profits 50 50 but even just taking 50  of the earnings from the project  Emerald Health Therapeutics is going to be in a different league as compares to its current situation 
Moving on  let s now look at why the Chris Wagner appointment is important 
As noted above  it represents something of a pivot for Emerald Health Therapeutics and  specifically  a pivot into the biotechnology sector 
Chris Wagner has a history of leading successful biotechnology companies  with perhaps the most notable being Contextual Genomics Inc  Contextual Genomics  under Wagner s leadership  teamed up with some of the biggest names in the healthcare space  including Astrazeneca  NYSE AZN   Pfizer  NYSE PFE  and Sanofi  NYSE SNY   to develop and eventually commercialize a range of groundbreaking oncology therapies 
What this means  then  is that Emerald Health Therapeutics is trying to capitalize on the dramatically improved grow space that it has picked up as part of the Village Farms deal through the development of its own range of cannabis based pharmaceutical products  Additionally  it looks as though the company is not only becoming a biotechnology play but is also looking to create its own supply chain  minimizing production and manufacturing risk and  the assumption being  reducing operational cost as and when any of its development stage products hit the shelves 
Right now  the company is producing medical cannabis for sale as dried flower and oils at what it calls its Saanich facility  In conjunction with this production  the Saanich facility also serves as Emerald Health Therapeutics  research and product development facility in Canada  Management has submitted some licensing applications to Health Canada  the Canadian equivalent of the FDA in the US  and these licenses are a key first step in getting the facility accepted as a medical product development location in Canada  This makes the response to these applications a potential near term catalyst for the company during late 2017  early 2018 
To sum up  Emerald Health Therapeutics has been growing reasonably well in a rapidly expanding industry in Canada but  with a new CEO and a JV that s going to allow it to dramatically increase production capacity near term  the company is going to look completely different in 12 months than it does today  If the operational execution goes to plan  this transformation could serve up a considerable upside revaluation across the period  meaning Emerald Health Therapeutics is a stock to watch between now and the end of 2018 
Disclosure  The author holds no positions in any of the stocks mentioned in this piece ",2017-10-18,Samuel Rae,https://www.investing.com/analysis/emerald-health-therapeutics-is-about-to-enter-phase-2-of-a-major-growth-strategy-200219527,200219527
220556,442072,PFE,Clinton  exit tax  to take aim at companies  inversion deals ,news,"By Amanda Becker WASHINGTON  Reuters    U S  Democratic presidential candidate Hillary Clinton will announce a planned crackdown on corporations that shift profits overseas  including a new  exit tax  against so called inversion deals  her campaign said on Monday   Clinton will call for spending the revenue raised by her proposed tax to boost manufacturing jobs in the United States  the Associated Press reported   In an inversion deal  a company merges with a corporation in another country to lower its tax bill   Pfizer  Inc  N PFE  last month announced it would buy Allergan  N AGN pa  Plc in a deal worth  160 billion in part to slash its U S  tax bill  The purchase    an example of a huge inversion deal    would create the world s largest drugmaker and shift Pfizer s headquarters to Ireland  Clinton said in a statement at the time it would  leave U S  taxpayers holding the bag   Clinton  the Democratic front runner  will discuss her plan to deal with corporations shifting profits overseas at a campaign event in Iowa on Wednesday  On Tuesday  she is slated to discuss boosting manufacturing at another event in New Hampshire   
The two states hold the first party nominating contests early next year for the November 2016 presidential election ",2015-12-07,Reuters,https://www.investing.com/news/stock-market-news/clinton-'exit-tax'-to-take-aim-at-companies'-inversion-deals-374827,374827
220557,442073,PFE,Clinton aims to stop  earnings stripping  to curb inversion deals,news,"By Amanda Becker WATERLOO  Iowa  Reuters    U S  Democratic presidential candidate Hillary Clinton will continue her push to crack down on companies that shift profits overseas  at a campaign stop on Wednesday in Iowa  where she will unveil her plan to rein in the practice  known as earnings stripping  Clinton is spending this week detailing how she will address tax avoiding  inversion  deals in which a company buys or merges with a foreign rival and relocates on paper to lower its U S  tax bill   Clinton and her campaign have made clear they are viewing the real life implications of inversion deals through the lens of the  160 billion plan by U S  pharmaceutical maker  Pfizer  Inc  N PFE  to purchase smaller rival Allergan  N AGN pa  Plc and move its headquarters to Ireland  The deal would  leave U S  taxpayers holding the bag   Clinton said in a statement at the time  Clinton has called on the U S  Congress to stop such deals by requiring the acquiring foreign entities to control at least a 50 percent stake in the combined company instead of the 20 percent under current law   On Monday  her campaign confirmed she will suggest an  exit tax  on the untaxed earnings of corporations that use inversion deals to relocate overseas  Clinton s campaign said one of the  primary benefits  of the Pfizer Allergan deal is earnings stripping  She will on Wednesday discuss how she believes that she would have the executive authority as president to address earnings stripping  and encourage the U S  Treasury Department to use its regulatory authority to  crack down on this loophole   Earnings stripping is widely used and covers a range of deals that shrink the taxable U S  profits of multinational corporations  while still allowing them to take advantage of some U S  tax deductions  The Treasury Department  after a wave of inversion deals  announced new regulations in September 2014 targeting certain tax avoidance deals  The regulations did not take on earnings stripping directly  but the department reserved the right to make any future regulation retroactive to that date   That was a signal to me that they thought they could do something by regulation   Harvard Law School lecturer Stephen Shay said in an interview   Shay said the  sentiment in the tax community today is yes there is regulatory authority to do something  about earnings stripping  Shay has written on the topic and has spoken to Clinton s campaign in recent weeks  
Clinton s campaign estimates that closing the  earnings stripping loophole  would raise  60 billion over 10 years that could be used to provide incentives for manufacturing  research and small business ",2015-12-09,Reuters,https://www.investing.com/news/politics-news/clinton-aims-to-stop-'earnings-stripping'-to-curb-inversion-deals-375273,375273
220558,442074,PFE,Alibaba names new head of anti counterfeiting  IP unit,news," Reuters     Alibaba   N BABA  Group Holding Ltd appointed Matthew Bassiur as head global intellectual property enforcement to oversee the company s anti counterfeiting and intellectual property rights protection efforts  The appointment comes days after the Chinese e commerce giant avoided being named on a U S  blacklist for sites hosting the sale of fake goods  Alibaba s Taobao Marketplace and Alibaba com were both previously on the piracy blacklist  which highlights markets linked to significant intellectual property infringement  Alibaba com was removed in 2011 and Taobao in 2012 after efforts to work with sellers of legitimate goods to clean up the sites  Since then  the Chinese e commerce giant has worked toward enforcing anti counterfeit procedures  but the U S  trade office said it was unclear what effect these measures have had  Bassiur  whose appointment is effective January 2016  will report to Michael Evans  president of Alibaba  
Prior to joining Alibaba  Bassiur was vice president and deputy chief security officer at  Pfizer  Inc  N PFE  ",2015-12-21,Reuters,"https://www.investing.com/news/stock-market-news/alibaba-names-new-head-of-anti-counterfeiting,-ip-unit-377068",377068
220559,442075,PFE,SAC Capital to pay  10 million in investors  insider trading lawsuit,news,"By Nate Raymond NEW YORK  Reuters    Billionaire Steven A  Cohen s former hedge fund SAC Capital Advisors LP has agreed to pay  10 million to resolve a lawsuit by shareholders of drugmaker Wyeth  who claimed they lost money because the fund engaged in insider trading in Wyeth s stock  The proposed settlement was disclosed in court papers filed on Wednesday in federal court in Manhattan and would resolve a class action launched following the arrest of a former SAC Capital portfolio manager  Mathew Martoma  for insider trading  Martoma was sentenced in 2014 to nine years in prison after being convicted of engaging in insider trading based on confidential results of a clinical trial of an Alzheimer s drug being developed by Elan Corp and Wyeth  Prosecutors said the trades enabled SAC Capital to make  275 million  making it the most lucrative insider trading case ever charged in the United States  The  10 million class action accord  which requires court approval  follows earlier deals with U S  authorities in which SAC Capital agreed to pay  1 8 billion and plead guilty following investigations into insider trading by its employees  Those accords included a  602 million settlement with the U S  Securities and Exchange Commission by an SAC Capital unit resolving claims related to insider trading in Elan and Wyeth  Elan and Wyeth are now part of  Perrigo Co   N PRGO  Plc and  Pfizer  Inc  N PFE   respectively  City of Birmingham Retirement and Relief System and KBC Asset Management NV served as lead plaintiff in the Wyeth class action  which was filed in 2013 and sought to recover investor losses from the defendants  who included Cohen himself   A separate case by Elan investors remains pending  SAC Capital has been in runoff mode  and Cohen s fortune is now traded through his family office  Point72 Asset Management   We are pleased to have resolved the Wyeth matter and are prepared to vigorously contest the remaining class action   Point72 spokesman Mark Herr said  In total  six ex SAC Capital employees have been convicted of insider trading  Prosecutors in October dropped charges against two others  including Michael Steinberg  who was convicted in 2013 and sentenced to 3 1 2 years in prison  Cohen was never criminally charged  But the SEC filed an administrative action against him in 2013 for failing to supervise Martoma and Steinberg  The SEC on Monday said that given the dismissal of charges against Steinberg  it would pursue a narrower case against Cohen over his supervision of Martoma  Trial is scheduled for April 11  
The case is Birmingham Retirement and Relief System v  SAC Capital Advisors LP  U S  District Court  Southern District of New York  No  13 02459 ",2015-12-24,Reuters,https://www.investing.com/news/stock-market-news/sac-capital-to-pay-$10-million-in-investors'-insider-trading-lawsuit-377489,377489
220566,442082,PFE,Basilea Pharmaceutica  Future Looks Bright ,opinion,"Basilea Pharmaceutica s  SIX BSLN  prognosis looks good  Multiple licensing distribution agreements announced for launched assets Cresemba and Zevtera should drive top line growth faster than we had expected  Major deals include  Cresemba in Europe  ex Nordics   Russia  Turkey and Israel with Pfizer  NYSE PFE   CHF70m upfront plus up to  427m in regulatory and sales milestones and mid teen royalties   Zevtera in China with CR Gosun  and in Europe with Cardiome  These licensing and distribution deals validate the commercial potential for both assets and enable the financial fire power to bolster Basilea s existing  innovative R D pipeline  with a focus on cancer and anti infective drug resistance   Our upgraded valuation is CHF1 188m or CHF110 share  excluding treasury shares  vs CHF1 048 previously 

2017 a successful year for partnerships
Basilea has announced multiple licensing distribution agreements for key assets Cresemba  isavuconazole  for invasive mould infections and Zevtera Mabelio  ceftobiprole  for bacterial infections  The significant licensing deal with Pfizer for Cresemba  in Europe ex Nordics  Russia  Turkey and Israel  makes strategic and commercial sense given its expertise in this niche therapeutic indication  As a result we have upgraded our global Cresemba peak sales forecasts to  0 8bn from  0 6bn  the bulk of the upgrade relates to the European opportunity 
To read the entire report Please click on the pdf File Below ",2017-10-11,Edison,https://www.investing.com/analysis/basilea-pharmaceutica-the-future-looks-bright-200218177,200218177
220568,442084,PFE,Shares in Asia mixed with Tokyo gaining on strong PMI,news,"Investing com   Asian shares were mixed on Tuesday with Tokyo edging higher on manufacturing data  but other markets down 
The Nikkei 225 gained 0 09   while the S P ASX 200 fell 0 52  and the Shanghai Composite dropped 0 73  
Overnight  U S  stocks closed slightly lower on Monday on a volatile day of trading  as a rally in the health care and energy sectors faded late in the session 
Investors reacted to a major merger in the pharmaceutical industry after  Pfizer  Inc  N N PFE  acquired Allergan  N AGN pa  Plc  N AGN  in a  160 billion  the biggest deal ever in the healthcare sector 
The Dow Jones Industrial Average lost 31 13 or 0 17  to 17 792 68  while the NASDAQ Composite index fell 2 44 or 0 05  to 5 102 48  erasing some of their gains from late last week  The S P 500 Composite index also lost 2 58 or 0 12  to 2 086 59  as six of 10 sectors closed in the red  Stocks in the Utilities  Telecommunications
Federal Reserve Chair Janet Yellen said Monday she and her colleagues hope and expect the economy will continue to expand and if that is the case  it will be appropriate to raise interest rates 
 Most of us expect the pace of that normalization to be gradual   Yellen said in a letter to Ralph Nader released by the Federal Reserve 
Nader penned an open letter to Yellen Oct  30  calling on the policymaking Federal Open Market Committee to raise the fed funds rate off the zero lower bound where it has been since December 2008 
Japan reported its PMI for November rose to 52 8  compared to 52 1 seen and up from 52 4 in October 
Overnight  the release of disappointing U S  housing sector data was eyed as expectations for a December rate hike by the Federal Reserve continued 
The U S  National Association of Realtors said that existing home sales decreased by 3 4  to 5 36 million units last month from 5 55 million in September  Analysts had expected existing home sales to fall 2 3  to 5 40 million units in October 
New York Fed President William Dudley said Friday that there is a  strong case  for hiking rates at the central bank s next meeting in December as long as economic data continues to remain solid 
Also on Monday  the Federal Reserve Board of Governors scheduled a closed door meeting  held under expedited procedures  to review the discount rates charged by its regional banks 
The discount rate is the interest rate charged to commercial banks on loans they receive from their regional Federal Reserve Bank lending facilities  also known as the discount window  When the Fed increases the discount rate  it makes the borrowing costs for banks more expensive  decreasing the money supply in the system 
The discount rate differs from the Federal Funds Rate  which is the rate banks lend to one another on overnight loans for funds maintained at the Federal Reserve  In February  2010  the Fed increased the spread between the discount rate and the top of the target range of the Federal Funds Rate to 50 basis points  It came nearly two years after the Fed reduced the spread to 25 points in March  2008  in an effort to bolster liquidity 
The Federal Funds Rate has remained at a level between zero and 0 25  for nearly seven years  since December  2008  The announcement of the previously unscheduled meeting helps raise speculation that the U S  central bank will lift the Fed Funds Rate when it meets next on Dec  15 16  The Fed last held an unscheduled meeting in December  2012  An initial rate hike is viewed as bearish for gold  which is not attached to dividends or interest rates and struggles to compete with high yield bearing assets ",2015-11-23,Investing.com,https://www.investing.com/news/stock-market-news/shares-in-asia-mixed-with-tokyo-gaining-on-strong-pmi-372652,372652
220569,442085,PFE,Exclusive  Lazard works with Sanofi on  12 7 billion animal health unit deal   sources,news,"By Pamela Barbaglia  Olivia Oran and Arno Schuetze LONDON NEW YORK FRANKFURT  Reuters    Investment bank Lazard is working with Sanofi s management to prepare a sale or listing of its Merial animal health unit  aiming to land the leading advisory job for the deal  which could value the business at up 12 billion euros   12 7 billion   sources familiar with the matter said  Lazard is expected to win the role for the so called dual track process having helped Sanofi s management in the ongoing review  the sources said  speaking on condition of anonymity   If successful  the deal will play a pivotal role in getting France s most valuable company back on track and delivering on its five year strategic plan  after the business was hit by lagging diabetes sales and boardroom rows  Sanofi  PA SASY  and Lazard declined to comment   Lazard has a close relationship with Sanofi Chairman Serge Weinberg who has often recommended the investment bank on deals carried out by his private equity firm Weinberg Capital Partners  another source said   Sanofi s new boss Olivier Brandicourt  59  took the helm of the drugmaker in April and on Nov  6 unveiled plans to cut costs by 1 5 billion euros by 2018 while seeking bolt on acquisitions to continue growing its product offering   But he also hinted at possible disposals  namely Merial and the company s European generic drugs business   The company said on Nov  6 these two units provide  limited synergies  and all options would be considered including retention  Led by Carsten Hellmann  Merial provides veterinary products such as antiparasitics and vaccines and is present in more than 150 countries   The unit  which employs around 6 500 people  expects to exceed 2 4 billion euros in sales this year  Sanofi could favor an initial public offering  IPO  for Merial as any takeover attempts by industry rivals would face antitrust challenges  a banker familiar with the matter said  Merial competes head to head with Pfizer s former animal health business Zoetis  N ZTS   which Brandicourt helped to list on the New York Stock Exchange in a previous job at  Pfizer   N PFE  in 2013  Zoetis  with a market capitalization of  23 4 billion  trades at a multiple of enterprise value to forecast earnings before interest  taxes  depreciation and amortization  EBITDA  of 16 2  according to Thomson Reuters data  Sanofi could also pursue an outright sale of its European generics business  worth up to 3 billion euros  But any process would only start in the second half of 2016 due to the lengthy legal work needed to disentangle the European business from its global operations  the sources said  Sanofi s global generics unit had overall sales of 1 8 billion euros in 2014  In Western Europe generics sales grew 5 6 percent to 135 million euros in the third quarter  
  1   0 9434 euros ",2015-11-27,Reuters,https://www.investing.com/news/stock-market-news/exclusive:-lazard-works-with-sanofi-on-$12.7-billion-animal-health-unit-deal---sources-373327,373327
220577,442093,PFE,Race Oncology  Expecting To Start Pivotal US Trial In 2018 ,opinion,"Race Oncology  AX RAC  is developing bisantrene  which had been the subject of over 40 clinical trials in the 1980s and 1990s as part of Lederle s search for a safer anthracycline chemotherapy 
Despite positive responses in a variety of cancers  especially AML  it was even approved for the treatment of AML in France  but never commercialised   development stopped after Lederle was sold to Wyeth and then Wyeth to Pfizer  NYSE PFE   Race will be developing bisantrene initially for relapsed refractory AML and expects to start a pivotal trial for approval in the US around the end of 2018 ",2017-10-09,Edison,https://www.investing.com/analysis/executive-interview--race-oncology-200217686,200217686
220582,442098,PFE,Race Oncology  Rediscovering A Lost Chemotherapeutic  ,opinion,"Race Oncology Ltd  AX RAC  is currently focused on the development of bisantrene  which had been the subject of over 40 clinical trials in the 1980s and 1990s as part of Lederle s search for a safer anthracycline  a widely used class of chemotherapeutics that is associated with cardiotoxicity   Despite positive efficacy data across a variety of cancers  especially AML  it was even approved for the treatment of AML in France in 1990 but never commercialised   development stopped after Lederle was sold to Wyeth and then Wyeth was sold to Pfizer  NYSE PFE   Race will be developing bisantrene for relapsed refractory AML and expects to initiate a pivotal trial for approval in the US around the end of 2018 
Efficacy indicated in relapsed refractory AML
Bisantrene had been investigated in trials covering a plethora of different cancers and some efficacy had been indicated in leukaemias and lymphomas  as well as breast and ovarian cancer  AML in particular was especially compelling  In five studies totalling 85 heavily pretreated patients  bisantrene demonstrated a 48  complete response rate  Earlier studies also indicated that the cardiotoxicity typically seen with anthracyclines was greatly reduced with bisantrene 
To read the entire report Please click on the pdf File Below ",2017-09-27,Edison,https://www.investing.com/analysis/race-oncology-rediscovering-a-lost-chemotherapeutic-200215555,200215555
220583,442099,PFE,Nightstar To Raise  86 3M In IPO,opinion,"United Kingdom based biotech company Nightstar Therapeutics  NASDAQ NITE  announced last week that it plans to raise around  86 million to help fund its gene therapy trials in an initial public offering  Nightstar has hinted back in April its plans to launch its IPO 
The biotech company which started back in 2013 plans to study rare retinal diseases by developing gene therapies and running trials intends to fund the project as it offers around 5 4 million shares at a price of around  13 to  15 per share 
Earlier this month  the company filed an amended F 1 form at the U S  Securities and Exchange Commission SEC  with the aforementioned provisions along with an option to allow another 804 000 shares  The initial public offering has the potential to reach a value of as much as  92 46 million should it be offered at the maximum price 
Nightstar Therapeutics which is also known as a retinal gene therapy company has been developing therapies that targeted blind causing diseases  These includes projects such as treatment for choroideremia 
According to the company s F 1 filing  they have been able to see an improved visual acuity in around 90  of those patients that participated in their study which is one year since undergoing the company s gene therapy treatment 
The company which would be moving into the third phase of the study by next year was not able to generate revenue last year and even reported a loss of 69 cents per share or a total of  12 2 million 
Nightstar is currently headed by a team of biopharma vets with experience in the study  Its F 1 filing also revealed that it has spent around  40 million since the beginning of the year until June as it kicks of the third phase of its study 
The company reportedly has created a team which will focus on the expansion of their clinical trial program in public markets  Former Pfizer  NYSE PFE  clinical lead Tuyen Ong is set to become the company s chief development officer 
The gene therapy company intends to use the ticker symbol  NITE  and list its American depositary shares on the Nasdaq composite index  Among the underwriters for the initial public offering of Nightstar shares includes BMO Capital Markets and Jefferies  Leerink Partners ",2017-09-27,Trade12,https://www.investing.com/analysis/nightstar-to-raise-863m-in-ipo-200215752,200215752
220585,442101,PFE,AstraZeneca s potential  3 billion cancer pill wins early approval  ,news,"By Ben Hirschler LONDON  Reuters    A new lung cancer pill from AstraZeneca  L AZN   designed for patients whose disease has worsened after treatment with other therapies  won early U S  approval on Friday  in a boost for the British drugmaker  Tagrisso  also known as AZD9291  is one of several cancer medicines AstraZeneca hopes will rebuild its sales following patent losses on older drugs  During its defense against a takeover attempt by  Pfizer   N PFE  last year  the firm forecast the drug could eventually sell as much as  3 billion a year   Industry analysts are more cautious about sales in the next few years  with consensus expectations pointing to revenue of  1 1 billion in 2020  according to Thomson Reuters Cortellis  The U S  Food and Drug Administration  FDA  approved the once daily tablet to treat a sub set of patients with advanced non small cell lung cancer earlier than analysts had expected  the official date for a decision was February 2016  A spokeswoman said AstraZeneca would make Tagrisso available to eligible U S  patients as soon as possible and its price would be  comparable to other oral cancer therapies   Like a rival product in development at  Clovis Oncology   O CLVS   Tagrisso targets a genetic mutation  known as T790M  that helps tumors evade current lung cancer pills  The FDA also approved a new companion diagnostic test for use with Tagrisso  made by Roche  VX ROG   to detect this mutation  Tagrisso s path to market has been unusually fast  taking just over 2 1 2 years from the start of clinical trials to approval in the world s top drugs market  That pace reflects an accelerated approval process at the FDA and AstraZeneca s determination to push development as fast as possible  In fighting off Pfizer s approach last year  Chief Executive Pascal Soriot had warned that the new cancer pill s progress could be disrupted by the distraction of a mega merger  Mizuho Securities analyst Eric Criscuolo said the speedy FDA decision suggested a similarly early approval of Clovis  rival drug rociletinib  whose official FDA decision date is at the end of March   Rociletinib could be right behind   he said in a note  AstraZeneca shares rose 0 5 percent in a weaker European stock market  while Clovis was up 1 percent on Nasdaq   In two clinical trials  57 and 61 percent of patients experienced a complete or partial reduction in their tumor size  with the most common side effects being diarrhea and skin and fingernail problems  
The green light for Tagrisso follows AstraZeneca s recent launch of Lynparza for ovarian cancer  taking the company closer to its goal of bringing six new cancer treatments to market by 2020 ",2015-11-13,Reuters,https://www.investing.com/news/stock-market-news/astrazeneca's-potential-$3-billion-cancer-pill-wins-early-approval-371228,371228
220589,442105,PFE,Can Pfizer  PFE  Prove To Be An Apt Value Investment ,opinion,Value investing is easily one of the most popular ways to find great stocks in any market environment  After all  who wouldn t want to find stocks that are either flying under the radar and are compelling buys  or offer up tantalizing discounts when compared to fair value One way to find these companies is by looking at several key metrics and financial ratios  many of which are crucial in the value stock selection process  Let s put Pfizer  Inc    NYSE PFE   stock into this equation and find out if it is a good choice for value oriented investors right now  or if investors subscribing to this methodology should look elsewhere for top picks PE RatioA key metric that value investors always look at is the Price to Earnings Ratio  or PE for short  This shows us how much investors are willing to pay for each dollar of earnings in a given stock  and is easily one of the most popular financial ratios in the world  The best use of the PE ratio is to compare the stock s current PE ratio with  a  where this ratio has been in the past  b  how it compares to the average for the industry sector  and c  how it compares to the market as a whole On this front  Pfizer has a trailing twelve months PE ratio of 14 8  This level compares pretty favorably with the market at large  as the PE ratio for the S P 500 comes in at about 20 4 If we focus on the long term trend of the stock the current level puts Pfizer s current PE above its median over the observed period  which stands at 13 8x   Hence  we could infer that the stock is slightly overvalued in this respect  especially in light of its historical trend Nevertheless  the stock s PE compares favorably with its industry s trailing twelve months PE ratio  which stands at 16 5  At the very least  this indicates that the stock is relatively overvalued right now  compared to its peers PS RatioAnother key metric to note is the Price Sales ratio  This approach compares a given stock s price to its total sales  where a lower reading is generally considered better  Some people like this metric more than other value focused ones because it looks at sales  something that is far harder to manipulate with accounting tricks than earnings Right now  Pfizer has a P S ratio of about 4 2  This is lower than the industry average  which comes in at 4 6x right now PFE is actually in the higher zone of its trading range in the time period per the P S metric  which suggests that the company s stock price has already appreciated to some degree  relative to its sales Broad Value OutlookIn aggregate  Pfizer currently has a Value Score of B  putting it into the top 40  of all stocks we cover from this look  This makes Pfizer an apt choice for value investors  and some of its other key metrics make this pretty clear too For example  the company s P B ratio  used to compare a stock s market value to its book value  stands at 3 6  lower than the industry average of 5 9  Additionally  its P CF ratio  another great indicator of value  comes in at 10 5  which is far better than the industry average of 15 9  Clearly  PFE is a solid choice on the value front from multiple angles What About the Stock Overall Though Pfizer might be a good choice for value investors  there are plenty of other factors to consider before investing in this name  In particular  it is worth noting that the company has a Growth grade of C and a Momentum score of B  This gives PFE a Zacks VGM score or its overarching fundamental grade of B   You can read more about the Zacks Style Scores   Meanwhile  the company s earnings estimates have been mixed at best  The current quarter has seen one estimate go higher in the past sixty days compared to four lower  while the full year estimate has seen four upward revisions and one downward revision in the same time period This has had small impact on the consensus estimate though as the current quarter consensus estimate has remained constant over the past two months  while the full year estimate has inched up 0 4   You can see the consensus estimate trend and recent price action for the stock in the chart below Pfizer  Inc  Price and Consensus   Pfizer has just a Zacks Rank  3  Hold   which indicates that while analysts have some apprehensions about the stock in the immediate future  the stock s growth story might be good over the long term  Thus  we are looking for in line performance from the company in the near term Bottom LinePfizer is an inspired choice for value investors  as it is hard to beat its incredible lineup of statistics on this front  Moreover  a strong industry rank  Top 17  out of more than 250 industries  further supports the growth potential of the stock  In fact  year to date  the industry has clearly outperformed the broader market  as you can see below Notably  Pfizer has been working on strengthening its product portfolio through acquisitions and licensing deals  However  Pfizer continues to face headwinds in the form of genericization of key drugs  lost alliance revenues  pricing pressure and rising competition which is hurting the top line Though Pfizer s growing immuno oncology portfolio offers strong potential  many of these assets are in early stage of development  Nonetheless  we believe that new products like Ibrance  contribution from acquisitions  cost cutting efforts and share buybacks should help the company achieve its guidance Pfizer also boasts a strong pipeline and expects approximately 25 to 30 drug approvals over the next five years  including around 15 products that have blockbuster potential So  despite a Zacks Rank  3  we believe that bullish analyst sentiment for the long term and favorable industry factors make this value stock a compelling pick Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2017-09-20,Zacks Investment Research,https://www.investing.com/analysis/can-pfizer-pfe-prove-to-be-an-apt-value-investment-200214626,200214626
220592,442108,PFE,Why Did Pfizer  PFE  Stock Pop Today ,opinion,"Shares of Pfizer   NYSE PFE   and Astellas Pharma   OTC ALPMY   moved higher in morning trading Thursday after the companies said their new prostate cancer drug  Xtandi  met the main goal of an important clinical trial 
Xtandi is actually already approved to treat metastatic castration resistant prostate cancer  CRPC   but today s results showed statistically significant improvement in the survival rate of men with non metastatic CRPC 
 Many prostate cancer patients who initiate androgen deprivation therapy will experience disease progression illustrated by a rising PSA level  and currently  there are no FDA approved treatment options for patients with non metastatic CRPC until they develop confirmed radiographic metastatic disease   said Carolina Urologic Research Center director Neal Shore  M D 
If Xtandi is approved to treat non metastatic CRPC  it will create a brand new revenue channel for Pfizer  The drug was added to the pharma giant s portfolio through the company s  14 billion acquisition of Medivation last year 
With its current approvals  Xtandi witnessed U S  sales of about  141 million in Pfizer s most recent quarter  Astellas Pharma  which is based in Japan  owns the rights to distribute the drug outside of the United States 
Pfizer shares surged more than 1 8  in early morning trading  hitting an intraday high of  35 74 per share in the process  Shares of Astellas gained as much as 2  to touch an intraday high of  12 90 
PFE has now gained more than 6  in the past four weeks  which has helped the stock earn an  A  grade for Momentum in our Style Scores system 
Want more stock market analysis from this author  Make sure to follow   on Twitter 
New Report  An Investor s Guide to Cybersecurity 
Cyberattacks have become more frequent and destructive than ever  In fact  they re expected to cause  6 trillion per year in damage by 2020  The cybersecurity industry is expanding quickly in response to these threats  and a projected  170 billion per year will be spent to protect consumer and corporate assets 
Zacks has just released Cybersecurity  An Investor s Guide to Locking Down Profits which reveals 4 promising investment candidates ",2017-09-13,Zacks Investment Research,https://www.investing.com/analysis/why-did-pfizer-pfe-stock-pop-today-200213307,200213307
220593,442109,PFE,Allergan says in talks on merger with Pfizer,news,"By Bill Berkrot and Ransdell Pierson  Reuters    Botox maker Allergan  N AGN pa  Plc on Thursday said it was in preliminary  friendly talks with  Pfizer  Inc  N PFE  on a potential merger  a deal that would create the world s largest drugmaker  Ireland based Allergan said there was no certainty the talks would lead to a deal  and did not discuss the terms that might lead to a tie up with Pfizer   Pfizer Chief Executive Officer Ian Read earlier Thursday said he was open to any moves that produce the best long term value for the company  but declined to directly comment on reports of talks with Allergan  Speaking at a Wall Street Journal event  Read said he was looking at various growth strategies  including a deal   if that would add value to shareholders   
 Or we could sit tight or we could do a split  Or we could do a business development deal and then do a split  whatever produces the best long term value   Read said ",2015-10-29,Reuters,"https://www.investing.com/news/stock-market-news/drugmakers-pfizer,-allergan-considering-a-combination:-wsj-368576",368576
220599,442115,PFE,3 Alternative Mutual Funds To Ride Out A Spooky September,opinion,Though President Trump s support toward the extension of the debt limit deadline might have helped stocks book modest gains on Sep 6  a slew of headwinds will continue to spook investors in the month of September  Investors are expected to grapple with issues pertaining to North Korea  The rogue nations  testing of its deadliest ballistic missile had sent shockwaves through Wall Street  while drawing widespread rebuke from across the globe A potential catastrophic hurricane Irma and persistent worries about elevated stock valuations also raise concerns for investors  A record number of fund managers see the U S  market as the most overvalued in the world  Among the 20 valuation metrics tracked by Ned Davis Research  16 of them indicate that the U S  stocks are extremely overvalued As if all this wasn t enough  September is historically the worst month for the stock market  Weighing all the cons  alternative mutual funds seem to be the best way out for investors  Such funds are known for their potential to hedge risks  provide unwavering returns particularly in difficult times and a diversified portfolio What Are Alternative Mutual Funds These funds mostly include long short equity funds  market neutral funds and trading leveraged equity funds  These types of funds are available to investors of all income groups  Let us now discuss the three types of funds in some  Mutual FundsEquity long short funds seek to gain from both winning and losing stocks  irrespective of the market scenario  These funds use conventional methods to identify stocks that are either undervalued or overvalued  It profits from shorting the overvalued stocks and buying the undervalued ones  Weights are subject to change and are dependent on management s view on the market For example  Say an investor buys a long short mutual fund for  100  then the fund manager will invest it in assets that are expected to fare well  The manager shorts  30 in stocks that are believed to be overvalued  In the process  he receives  30 in cash  He will now use the  30 to buy more assets with an upside potential  Thus  now he has a total of  130 invested in long positions and  30 in short positions  This type of long short fund is called a 130 30 mutual fund Market Neutral Mutual FundsMarket neutral funds aim to adopt a precision approach by shorting 50  of their assets and holding 50  long  This approach seeks to identify pairs of assets that have related price movements  The fund goes long on the outperforming asset and shorts the underperformer  For instance  you take a  1 million long position in Pfizer  NYSE PFE  and a  1 million short position in Wyeth  both of which are large pharmaceutical companies  Now  if pharmaceutical stocks fall  you will lose because of your long position in Pfizer but will gain because of the short position in Wyeth A market neutral fund is designed to provide stable returns at relatively lower levels of risk regardless of market direction  This is particularly relevant in today s highly volatile scenario when the objective is to protect the capital invested Trading Leveraged Equity FundsLeveraged funds use borrowed money to increase returns in a short spell of time  These funds generally strive to return a certain multiple of the short term returns of an equity index  For example  a 2X S P 500 fund aims to generate twice the returns that the S P 500 manages to achieve  Leveraged funds are primarily marked  ultra    bull  or  2X  Leveraged funds also offer benefits such as diversification  These funds invest in a diversified portfolio of assets which minimize risk  while escalating returns  In addition to this  investors enjoy the benefits of  dollar cost averaging   where a young investor depositing  10 000 in these funds reaps the same benefits that a high net worth individual receives  say by depositing  50 000 000  These funds also enjoy tax deductions 3 Alternative Mutual Funds to Buy NowThe investment community is a dynamic one where new products will come into play and make the most of the stock market  In times of market uncertainty  alternative mutual funds are such new product classes that are equipped to protect investors  portfolio and provide steady returns Here we have selected three such alternative mutual funds that boast a Zacks Mutual Fund Rank  1  Strong Buy  or 2  Buy   have positive 3 year and 5 year annualized returns and carry a low expense ratio Aberdeen Equity Long Short A  invests a large portion of its assets in long and short positions in equity securities of publicly traded companies in the United States  MLSAX s 1 year and 5 year annualized returns are 7  and 3 9   respectively  Annual expense ratio of 1 59  is below the category average of 1 91   The fund has a Zacks Mutual Fund Rank  2 Calamos Market Neutral Income A  invests mainly in convertible securities and employs short selling to enhance income and hedge against market risk  CVSIX s 1 year and 5 year annualized returns are 4 5  and 3 4   respectively  Annual expense ratio of 1 08  is lower than the category average of 1 71   The fund has a Zacks Mutual Fund Rank  1 ProFunds Internet UltraSector Investor  seeks daily investment results  before fees and expenses that correspond to one and one half times the daily performance of the Dow Jones Internet CompositeSM Index  INPIX s 1 year and 5 year annualized returns are almost 40  and 31 2   respectively   Annual expense ratio of 1 5  is lower than the category average of 1 98   The fund has a Zacks Mutual Fund Rank  1 Want key mutual fund info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing mutual funds  each week ,2017-09-06,Zacks Investment Research,https://www.investing.com/analysis/3-alternative-mutual-funds-to-ride-out-a-spooky-september-200211997,200211997
220604,442120,PFE,Historic Pacific trade deal faces skeptics in U S  Congress,news,"By Krista Hughes and Kevin Krolicki ATLANTA  Reuters    Twelve Pacific Rim countries on Monday reached the most ambitious trade pact in a generation  aiming to liberalize commerce in 40 percent of the world s economy in a deal that faces skepticism from U S  lawmakers  The Trans Pacific Partnership  TPP  pact struck in Atlanta after marathon talks could reshape industries  change the cost of products from cheese to cancer treatments and have repercussions for drug companies and automakers   Tired negotiators worked round the clock over the weekend to settle tough issues such as monopoly rights for new biotech drugs  New Zealand s demand for greater access for its dairy exports was only settled at 5 a m  EDT  0900 GMT  on Monday  If approved  the pact would cut trade barriers and set common standards from Vietnam to Canada  It would also furnish a legacy shaping victory for U S  President Barack Obama  who will promote the agreement on Tuesday in remarks to business leaders in Washington  The Obama administration hopes the pact will help the United States increase its influence in East Asia and help counter the rise of China  which is not one of the TPP nations   Lawmakers in the United States and other TPP countries must approve the deal  Five years in the making  it would reduce or eliminate tariffs on almost 18 000 categories of goods  Initial reaction from U S  Congress members  including Democrats and Republicans  ranged from cautious to skeptical   Vermont Senator Bernie Sanders  a Democratic presidential candidate  warned the pact would cost jobs and hurt consumers   In the Senate  I will do all that I can to defeat the TPP agreement   he tweeted  Many of Obama s Democrats  as well as labor groups  fear the TPP will cost manufacturing jobs and weaken environmental laws  while some Republicans oppose provisions to block tobacco companies from suing governments over anti smoking measures  Republican Senator Orrin Hatch  who heads the Senate Finance Committee  was wary   I am afraid this deal appears to fall woefully short   said Hatch  who had urged the administration to hold the line on intellectual property protections  including for drugs  U S  lawmakers can approve the deal or vote it down  but not amend it  CURRENCY  DRUGS  DAIRY  AUTO POLICIES Ministers said the agreement would include a forum for finance ministers from participating countries to discuss currency policy principles  This takes into account  in part  concerns among U S  manufacturers and critics who suggest Japan has driven the yen lower to benefit its car exporters and other companies  But Democratic Representative Debbie Dingell from Michigan  home of the U S  auto industry  said currency has not been fully dealt with   Nothing that we have heard indicates negotiators sufficiently addressed these issues   she said  The United States and Australia negotiated a compromise on the minimum period of protection to the rights for data used to make biologic drugs  Companies such as  Pfizer  Inc  NYSE PFE   Roche Group s Genentech and Japan s Takeda Pharmaceutical could be affected  The agreed terms fell short of what the United States had sought  Under the deal  countries would give drugmakers at least five years  exclusive access to clinical data used to win approval for new drugs  An additional period of regulatory review would likely mean drug companies would have an effective monopoly for about eight years before facing lower cost  generic competition  Politically charged dairy farming issues were addressed in the final hours of talks  New Zealand  home to the world s biggest dairy exporter  Fonterra  wanted increased access to U S   Canadian and Japanese markets  New Zealand Prime Minister John Key said the deal would cut tariffs on 93 percent of New Zealand s exports to the United States  Japan  Canada  Mexico and Peru   We re disappointed there wasn t agreement to eliminate all dairy tariffs but overall it s a very good deal for New Zealand   Key said   The United States  Mexico  Canada and Japan agreed to auto trade rules on how much of a vehicle must be made within the TPP region to qualify for duty free status  The TPP would give Japan s automakers  led by Toyota MotorCorp  a freer hand to buy parts from Asia for vehicles sold in the United States  but sets 25 30 year phase out periods for U S  tariffs on Japanese cars and light trucks  The deal between Australia  Brunei  Canada  Chile  Japan  Malaysia  Mexico  New Zealand  Peru  Singapore  the United States and Vietnam also sets minimum standards on issues ranging from workers  rights to environmental protection  Trade ministers said the TPP would in future be open to other countries  including potentially China   There is a real opportunity for China to be a part of this   Malaysian Trade Minister Mustapa Mohamed said  
Though Obama painted the deal in part as a way of stopping China from writing the rules of the global economy  China s Ministry of Commerce broadly welcomed the agreement in the hope it would  promote and make common contributions to Asia Pacific trade  investment and economic development  ",2015-10-06,Reuters,https://www.investing.com/news/stock-market-news/historic-pacific-trade-deal-faces-skeptics-in-u.s.-congress-364627,364627
220605,442121,PFE,Lilly pill trumps Humira in arthritis study,news," Reuters    Eli Lilly and Co s experimental pill for rheumatoid arthritis proved superior to Abbvie Inc s leading injectable Humira treatment in a large study  which analysts said could prod them to raise sales forecasts for the medicine 
Lilly said on Wednesday it was the first study to show that a once daily oral treatment was superior to  13 billion a year Humira  the world s best selling drug  in improving signs and symptoms of rheumatoid arthritis 
It was the fourth successful late stage trial for Lilly s medicine  called baricitinib  which it is developing in partnership with Incyte Corp 
 What is disclosed is quite impressive   about as good an outcome as Lilly could hope for   Sanford Bernstein analyst Tim Anderson said in a research note 
Baricitinib works through a similar mechanism as  Pfizer  Inc  N PFE  s approved twice daily Xeljanz pill for rheumatoid arthritis  by blocking proteins called Janus kinases that cause inflammation  Xeljanz  with annual sales of  500 million  has not yet become the blockbuster product Wall Street had hoped  when it was approved in 2012 
If approved  baricitinib could achieve annual sales of  831 million by 2020  Anderson said  adding he may raise his forecast as more data is made public  Incyte would collect a royalty of about 20 percent on sales  he added 
Baricitinib met its primary goal in the latest study by proving superior to placebo after 12 weeks  as judged by its ability to produce at least a 20 percent improvement in disease severity 
In another arm of the trial  baricitinib at 12 weeks was superior to Humira on key secondary objectives related to the number of patients achieving at least 20 percent improvement  as well as in improvement based upon another standard arthritis measure called a DAS28 hsCRP score 
Moreover  after 24 weeks of treatment  baricitinib was shown to be better than placebo at preventing further structural joint damage  Lilly said 
Treatment benefits on all measures continued through a full year of therapy  Lilly said  Lilly plans to release full data at a November scientific meeting 
Analysts said more data is needed  including how many patients achieved 50 percent or 70 percent reductions in disease severity 
The number of serious side effects seen with baricitinib were similar to placebo  while those taking Humira had fewer side effects than placebo  Serious infection rates were similar in all patient groups  Lilly said 
Shares of Lilly were down 0 3 percent in morning trading  while those of Incyte rose 5 percent ",2015-10-14,Reuters,https://www.investing.com/news/general-news/lilly-pill-trumps-humira-in-arthritis-study-366125,366125
220608,442124,PFE,Strength Seen In Catalent  CTLT   Stock Soars 13 9 ,opinion,Catalent  Inc    NYSE CTLT   was a big mover last session  as the company saw its shares rise almost 14  on the day  The move came on solid volume too with far more shares changing hands than in a normal session  The stock picked up sharply from the near flat trend of  33 75 to  35 68 in the past one month time frame The move came after the company reported solid fourth quarter fiscal 2017 results  Also  management revealed that it has inked a long term supply agreement to make the next generation of Pfizer  NYSE PFE  s over the counter pain relief  along with the launch of Advil Liqui Gels Minis The company has not seen any estimate revisions over the past one month  while the Zacks Consensus Estimate for the current quarter also remained unchanged  The recent price action is encouraging though  so make sure to keep a close watch on this firm in the near future Catalent currently carries a Zacks Rank  2  Buy  while its  is 0 00   Catalent  Inc  Price   Another player in the Medical   Drugs industry  which looks attractive at current levels is Akebia Therapeutics  Inc    NASDAQ AKBA    which has the same Zacks Rank as Catalent  You can see Is CTLT going up  Or down  Predict to see what others think   or 4 Surprising Tech Stocks to Keep an Eye On Tech stocks have been a major force behind the market s record highs  but picking the best ones to buy can be tough  There s a simple way to invest in the success of the entire sector  Zacks has just released a Special Report revealing one thing tech companies literally cannot function without  More importantly  it reveals 4 top stocks set to skyrocket on increasing demand for these devices  I encourage you to get the report now   before the next wave of innovations really takes off ,2017-08-30,Zacks Investment Research,https://www.investing.com/analysis/strength-seen-in-catalent-ctlt-stock-soars-139-200210461,200210461
220609,442125,PFE,3 Biotechs Among Top 4 Charts To Watch,opinion,"Abeona Therapeutics Inc 
Abeona  NASDAQ ABEO  rocketed  1 75  or 18   to close at  11 25 on very heavy volume of 2 7 million shares traded Tuesday  The move came on news that the FDA granted breakthrough therapy status to the company s skin healing therapy  The stock had been pulling back in a flag pattern after its July high at  10 26  and recently broke out of the flag  with Tuesday s move thrusting the stock through that July high  In the short term  price may reach  14  15  and may well climb to  17 50 in the longer term  Short interest of 10 8 times its average volume could fuel the move as shorts cover on a rally 
Health Insurance Innovations Inc 
Health Insurance Innovations  NASDAQ HIIQ   reached an all time high of  36 70 on Tuesday before settling to close at  35 95  up by  1 10  on heavy volume of 874 532 shares traded and no news  The online insurance stock has risen more than 150  since March 27 and 33  since its positive earnings announcement on August 3  Price broke out of a bull flag consolidation pattern August 24  Next target range   39  40 
ImmunoGen Inc 
ImmunoGen  NASDAQ IMGN  popped 17  to close at  7 58 on a whopping 12 million shares traded    that is more than four times its average volume and the largest volume the stock has seen since January  The move came on news that the cancer drug company will collaborate with Jazz Pharmaceuticals on the development of blood cancer therapies  If price can move through the prior high of  8 04 from July 6  the next targets will be  9 50 and  12 50 
Sangamo Therapeutics Inc 
Sangamo Therapeutics  NASDAQ SGMO  rose 11   or  1 30  and closed at  12 80 on heavy volume of 3 3 million shares traded  Price broke above the prior high of  12 05 from August 14  The gene therapy company recently began a clinical trial with Pfizer  NYSE PFE  for a hemophilia treatment  Price is up 250  year to date  The near term target is  13 and the possibility for acceleration up to  17 in the coming weeks ",2017-08-30,Harry Boxer,https://www.investing.com/analysis/3-biotechs-among-top4-charts-to-watch-200210490,200210490
220620,442136,PFE,Pfizer s revenue  profit beat as vaccine sales rise,news," Reuters     Pfizer  Inc  NYSE PFE  on Tuesday reported better than expected second quarter profit and revenue  helped by strong demand for its pneumonia vaccine and new breast cancer drug  sending its shares up 1 percent  The largest U S  drugmaker  which raised its full year earnings forecast  said revenue from its global vaccines unit rose 44 percent to  1 58 billion  The unit  which includes the Prevnar 13 pneumonia vaccine  accounted for about 13 percent of Pfizer s total revenue  The breast cancer drug Ibrance  which gained U S  approval in February  generated  140 million in sales in its first full quarter on the market  nearly double analysts  expectations   The Ibrance launch is progressing well   JP Morgan analyst Chris Schott said in a note  The company is planning to file for European approval of Ibrance in the current quarter  Overall  sales of cancer drugs rose 25 percent to  713 million for the quarter  Despite years of competition from cheaper generic copies  Pfizer s cholesterol fighter Lipitor contributed sales of  509 million in the second quarter  At its height  Lipitor generated annual sales of  13 billion  Sales of consumer healthcare products were weak  falling 8 percent to  840 million  The drugmaker raised its adjusted profit forecast for 2015 to  2 01  2 07 per share from  1 95  2 05 per share   It increased the lower end of its full year revenue forecast to  45 billion from  44 billion  maintaining the upper end at  46 billion  Pfizer  which got nearly two thirds of its 2014 revenue from markets outside the United States  had cut its full year revenue and profit forecasts in April  citing a strong dollar  The company s second quarter net income fell to  2 63 billion  or 42 cents per share  from  2 91 billion  or 45 cents per share  a year earlier  Excluding items  Pfizer earned 56 cents per share  topping analysts  average expectations by 4 cents a share  according to Thomson Reuters I B E S  The earnings beat  was particularly impressive given that top line foreign exchange headwind of 8 percent   1 billion  was 1 percent higher than our forecast   BMO Capital Markets analyst Alex Arfaei said in a research note  Revenue fell 7 percent to  11 85 billion  Wall Street was looking for  11 42 billion   
Pfizer s shares were up 36 cents at  34 70 on the New York Stock Exchange ",2015-07-28,Reuters,https://www.investing.com/news/stock-market-news/pfizer-revenue-falls-7-percent-353232,353232
220621,442137,PFE,Pfizer wins EU approval for  15 billion Hospira buy,news,"BRUSSELS  Reuters    U S  drugmaker  Pfizer   N PFE  gained European Union antitrust approval on Tuesday for its proposed  15 billion acquisition of U S  rival  Hospira   N HSP  after pledging to sell some drugs to allay competition concerns 
 The approval is conditional on Pfizer divesting certain sterile injectable drugs  as well as its infliximab biosimilar drug  which is currently under development   the European Commission said 

The deal  the biggest ever for Pfizer  will boost its portfolio of generic injectable drugs and copies of biotech medicines ",2015-08-04,Reuters,https://www.investing.com/news/stock-market-news/pfizer-wins-eu-approval-for-$15-billion-hospira-buy-354400,354400
220622,442138,PFE,India rejects patent on Pfizer s arthritis drug,news,MUMBAI  Reuters    India has again denied  Pfizer  Inc  NYSE PFE  a patent on its rheumatoid arthritis drug tofacitinib  the latest setback for a multinational drugmaker seeking to enforce its intellectual property rights in the country  Pfizer sought a patent that covers an important chemical formulation of the active compound in the medicine  but the Indian Patent Office said the company would have to establish that the compound for which it is seeking a patent is therapeutically more effective than the active compound   The invention disclosed and claimed in the instant application     is not considered as an invention under the provisions of the Act   Bharat N S  an assistant controller at the patent office  wrote in an order dated Sept  3  Pfizer is reviewing its options for further action  a Mumbai based company spokesman said in an emailed statement   Drug patents have become a thorny issue for global drugmakers seeking to expand in India s fast growing healthcare market   Companies including Pfizer  Bayer and Roche have in recent years struggled to retain exclusivity on drugs in India  and have blamed patent laws they say are designed to favor the local industry  India  however  has said its drug patents policy is designed to ensure medicines remain affordable for the country where less than 15 percent of the population has health insurance   India s patent office had rejected Pfizer s application to patent tofacitinib in 2011  but was ordered to reconsider the decision by the Intellectual Property Appellate Board  after Pfizer appealed ,2015-09-07,Reuters,https://www.investing.com/news/stock-market-news/india-rejects-patent-on-pfizer's-arthritis-drug-360330,360330
220626,442142,PFE,Pfizer offers concessions in bid to win EU okay for Hospira deal,news,"BRUSSELS  Reuters    U S  drugmaker  Pfizer   N PFE  has offered concessions in a bid to win European Union regulatory approval for its  15 billion takeover of U S  rival  Hospira   N HSP   the European Commission said on Tuesday  The EU competition authority did not provide details of Pfizer s proposal in line with its policy  It extended the deadline for its decision to Aug  4 from July 20 to examine the concessions  It can either clear the deal if it considers Pfizer has allayed competition concerns regarding the deal or open a full scale investigation  Pfizer  maker of impotence treatment Viagra and cholesterol drug Lipitor  is making its biggest ever acquisition aimed at expanding its portfolio of generic injectable drugs and copies of biotech medicines  
Hospira makes generic versions of injectable drugs used in hospitals  pumps to deliver such medicine and also sells biosimilars or copies of biotech drugs ",2015-07-14,Reuters,https://www.investing.com/news/stock-market-news/pfizer-offers-concessions-in-bid-to-win-eu-okay-for-hospira-deal-351127,351127
220627,442143,PFE,Pfizer rises 1 8  in pre market after upbeat Q2 earnings  ,news,"Investing com   U S  pharmaceutical giant  Pfizer   NYSE PFE  reported better than expected second quarter earnings ahead of Tuesday s opening bell  sending its shares higher in pre market trade 
Pfizer said adjusted earnings per share came in at 56 cents in the three months ended June 30  above expectations for adjusted earnings of 52 cents per share 
The company s second quarter revenue totaled  11 9 billion  beating forecasts for revenue of  11 42 billion 
Ian Read  Chairman and Chief Executive Officer  stated   Our second quarter and year to date financial performance is the result of continued business momentum  driven by solid execution of recent product launches in our Innovative Products business  
Pfizer raised midpoint of 2016 revenue by 3 cents due to strong performance to date and an improved business outlook 
Following the release of the report  shares in Pfizer rose 1 77  in pre market trade to  34 99 compared to Monday s closing price of  34 38 
Meanwhile  U S  stock futures pointed to a mildly higher open  The Dow futures indicated a gain of 0 45  at the open  the S P 500 futures pointed to a rise of 0 55   while Nasdaq 100 futures advanced 0 6  ",2015-07-28,Investing.com,https://www.investing.com/news/stock-market-news/pfizer-rises-1.8-in-pre-market-after-upbeat-q2-earnings-353230,353230
220636,442152,PFE,In Cuba  New York Governor Cuomo seeks to open doors to trade,news,"By Marc Frank HAVANA  Reuters    New York Governor Andrew Cuomo met senior Cuban officials in Havana on Monday as the head of a high powered business delegation looking to take advantage of President Barack Obama s easing of restrictions with the Communist led island   Cuomo  a Democrat  is the first governor to visit Cuba since a December announcement by Obama and Cuban President Raul Castro that they would restore diplomatic relations and work to normalize trade and travel ties after more than a half century of hostility and confrontation  Cuomo termed the agreement  courageous  in opening remarks to a business conference and said   We want to do everything we can to help   Cuomo was joined by top executives from JetBlue Airways Corp    Pfizer  Inc  NYSE PFE   and MasterCard Inc   who were among 18 business leaders and academics on the trip   Cuomo said the purpose of his visit was to see what can be done now and look to the future should full trade be restored  He also mixed in some fun  drinking a mojito at the Hotel Nacional  while Cuban officials gave him what he said was his first ever Cuban cigar  Cuomo joked that if he rushed through his speech  he would have time to smoke it  As part of a deal hammered out over 18 months of secret talks  the Obama administration has loosened travel regulations  opened the door to some financial services  trade in information technology  aviation and other sectors and announced it will eliminate Cuba from the State Department s list of state sponsors of terrorism  But the trade embargo remains largely in place and can be lifted only by the Republican controlled Congress  Marilu B Hamel  director of North American affairs at the foreign trade and investment ministry  said the visit was welcomed and would  serve to explore the potential between our two countries and support the progress of normalization   MasterCard says it is ready to provide service in Cuba and JetBlue has said it wants to begin direct commercial flights to Cuba  Neither has reached a deal with Cuban officials  but by Monday afternoon the delegation was in initial talks with Cubans from biotechnology  aviation  banking and tourism after lunching with the Foreign Trade and Investment Minister Rodrigo Malmierca   Our meeting with Minister Malmierca was very exciting and informative   Cuomo said   There is much hope for the future   The delegation was due to meet with Cuban First Vice President Miguel Diaz Canal on Monday and Cuomo is scheduled to hold a news conference on Tuesday before departing  
Ten previous U S  governors have visited Cuba since 1999 but none since 2010  according to the U S  Cuba Trade and Economic Council ",2015-04-20,Reuters,"https://www.investing.com/news/politics-news/in-cuba,-new-york-governor-cuomo-seeks-to-open-doors-to-trade-338041",338041
220637,442153,PFE,Pfizer shares fall on weak guidance,news,Investing com   U S  pharmaceutical giant  Pfizer   NYSE PFE  provided weak guidance for the rest of year ahead of Tuesday s opening bell  despite reporting better than expected first quarter earnings Pfizer said adjusted earnings per share was  0 51 cents in the first quarter  above expectations for adjusted earnings of  0 49 cents per share The company s first quarter revenue totaled  10 86 billion  beating forecasts for revenue of  10 73 billion Pfizer said it expected full year adjusted revenue to come in a range between  44 7 billion and  46 0 billion  compared to a previous range forecast of  44 5 billion to  46 5 billion Pfizer s 2015 financial guidance was updated solely to reflect changes in foreign exchange rates in relation to the U S  dollar from mid January 2015 to mid April 2015  primarily the weakening of the euro For the full year  the company expects adjusted earnings per share in a range between  1 32 to  1 47  compared to a previous outlook of  1 37 to  1 52 per share Ian Read  Chairman and Chief Executive Officer  stated   We began the year with good performance on both the top and bottom line and I believe the company is well positioned in terms of in line products  recent product launches  geographic reach and product pipeline  Following the release of the report  shares in Pfizer dipped 0 23  in pre market trade to  34 51 from a closing price of  34 59 on Monday Meanwhile  U S  stock futures pointed to a mildly lower open  The Dow futures indicated a loss of 0 4  at the open  the S P 500 futures pointed to a drop of 0 35   while Nasdaq 100 futures declined 0 15  ,2015-04-28,Investing.com,https://www.investing.com/news/stock-market-news/pfizer-shares-fall-on-weak-guidance-339238,339238
220642,442158,PFE,PBYI Shares Climb Up As Company Announced FDA Approval For NERLYNX,opinion,"Puma Biotechnology Inc  NASDAQ PBYI 


Puma Biotechnology  Inc   PBYI   a biopharmaceutical company yesterday announced that the U S Food and Drug Administration approved NERLYNX  neratinib   Neratinib is the company s inhibitor used to treat adult patients in early stages of breast cancer 

The treatment showed a statistically significant reduction in invasive disease recurrence versus the placebo  Neratinib will be the first anti HER2 treatment to be approved by the FDA 

Puma expects neratinib to hit the market by September 2017 


Puma Biotechnology  Inc  CEO s Comments


 Despite advances in the treatment of early stage HER2 positive breast cancer  there remains a need for further therapeutic improvements in order to attempt to further reduce the risk of disease recurrence   said Puma Biotechnology CEO and President Alan H  Auerbach   We are pleased to be able to bring this new medicine to patients with breast cancer  We would like to express our appreciation to the patients  caregivers and physicians who contributed to the neratinib clinical development program and  more specifically  the ExteNET trial   



PBYI Technical Analysis



PBYI opened trading yesterday at  89 50 which was down from the previous day s trading close of  89 55  PBYI closed trading yesterday at  86 10 and spiked up after market to  94 00  equivalent to a 9  increase from the closing price  Taking a look at the daily chart we can see the last time PBYI traded above these levels we have to go back to July 13th when it traded at  94 70 

Taking a closer look at the daily chart we can see that before the spike up PBYI had already been in an overall upward trend dating back to May 8th when it traded at  29 00  PBYI has a float of 23 08 million shares and traded below the normal daily trading volume on Monday 

For  purposes  I would like to see PBYI open trading on Tuesday above  91 50 or the  and if it does I would be looking to take a long position at the bell  My  would be  0 50 from my entry position fearing anything more than that and the stock would start to fill in the gap up 

Company Profile

Puma Biotechnology  Inc   a biopharmaceutical company  focuses on the development and commercialization of products to improve cancer care 

Its drug candidates include PB272  neratinib  oral   for the treatment of early stage breast cancer  metastatic breast cancer  non small cell lung cancer  HER2 mutation positive solid tumors  and HER2 mutated non amplified breast cancer  and PB272  neratinib  intravenous   

The company also develops PB357  an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors  HER1  HER2  and HER4 
It has a license agreement with Pfizer  NYSE PFE   Inc  for the development  manufacture  and commercialization of PB272 neratinib  oral   PB272 neratinib  intravenous   PB357  and certain related compounds  Puma Biotechnology  Inc  was founded in 2010 and is headquartered in Los Angeles  California ",2017-07-18,Warrior Trading,https://www.investing.com/analysis/puma-biotechnology-$pbyi-stock-shares-climb-up-as-company-announced-200201757,200201757
220644,442160,PFE,Pfizer in  5 billion accelerated buyback deal with Goldman  Sachs   Co,news," Reuters    Drugmaker Pfizer Inc  N PFE  said it entered into an agreement with Goldman  Sachs   Co to buy back  5 billion of its stock  Pfizer said the accelerated share repurchase was assumed in the forecast for the full year it provided last month  Under the agreement  which forms a part of Pfizer s existing buyback authorization  about 150 million shares will be bought  The settlement is expected during or prior to the third quarter  
Shares of the New York based company closed at  33 06 on the New York Stock Exchange on Monday ",2015-02-09,Reuters,"https://www.investing.com/news/stock-market-news/pfizer-in-$5-billion-accelerated-buyback-deal-with-goldman,-sachs--amp;-co-327313",327313
220645,442161,PFE,As CEOs seek tax cuts  senator slams corporate tax haven use,news,"By David Lawder WASHINGTON  Reuters    Senator Bernie Sanders lashed out on Wednesday at widespread use of offshore tax havens by U S  companies  and the liberal independent targeted a group that represents CEOs of big corporations and wants corporate taxes lowered  Sanders  top opposition member on the U S  Senate Budget Committee  released a report decrying what he called  legalized tax fraud   It showed that 111 of the 201 member companies of the Business Roundtable are sheltering more than  1 trillion in profits overseas  where they are not subject to U S  taxes  Using the Cayman Islands  Bermuda and other tax havens  these companies have saved more than  280 billion in tax liabilities  Sanders concluded in the report  The senator from Vermont delivered his broadside a day ahead of a media event the Business Roundtable scheduled at its Washington office  The group was expected to call again for a rewrite of the U S  tax code including a lower corporate income tax rate  Sanders said Business Roundtable companies account for roughly half of an estimated  2 trillion in profits held overseas by U S  companies under a loophole that lets them defer taxation on profits from overseas subsidiaries  The  last thing  Congress should do is provide more tax breaks to such profitable businesses  Sanders said    Instead of sheltering profits in the Cayman Islands and other offshore tax havens  the largest corporations in this country must pay their fair share of taxes so that our country has the revenue we need to rebuild America and reduce the deficit   Sanders said in a statement  Many business groups have sought a  repatriation holiday  that would allow them to bring home overseas profits at a reduced tax rate  The senator s report relies heavily on data compiled in June 2014 by Citizens for Tax Justice  a left leaning activist group  and U S  Public Interest Research Group  a consumer advocacy group that says it  stands up to powerful special interests   The report said the data comes from Securities and Exchange Commission filings compared with offshore subsidiaries listed in a 2008 Government Accountability Office report on tax havens  Among Business Roundtable members listed in the report with large amounts of profits held abroad were General Electric Co with  110 billion  Pfizer Inc  NYSE PFE  with  69 billion and IBM Corp with  52 3 billion  
A spokeswoman for the Business Roundtable said the group was studying the report and could not immediately comment on it ",2015-02-18,Reuters,"https://www.investing.com/news/politics-news/as-ceos-seek-tax-cuts,-senator-slams-corporate-tax-haven-use-328644",328644
220648,442164,PFE,Basilea Pharmaceutica  Hat Trick ,opinion,"Basilea Pharmaceutica AG  SIX BSLN  announced a hat trick of positive news flow in June  This includes two separate licensing deals covering Cresemba  for invasive mould infections  and Zevtera  as well as triggering the allocation of  54 8m reimbursement funding from the Biomedical Advanced Research and Development Authority  BARDA  relating to the advancement of Zevtera s US phase III clinical programme for bacterial infections  trials to initiate H217   Most notable is the major licensing deal with Pfizer  NYSE PFE  for Cresemba in Europe  Russia  Turkey and Israel  Pfizer is the partner of choice given its long standing expertise in this market  Additionally  Avir Pharma has licensed both Cresemba and Zevtera for the Canadian market  Our forecasts and valuation are under review  we will update both post further disclosure on the PFE deal at the interim results on 10 August 

Double dealings
Basilea has entered into a licence agreement with Pfizer for Cresemba  isavuconazole  commercialisation in Europe  ex Nordics   Russia  Turkey and Israel  The deal with Pfizer could be a game changer for Cresemba  Pfizer has the expertise to manufacture and commercialise Cresemba rapidly throughout its in licensed territories using its established existing marketing infrastructure during a period where its own anti fungal Vfend has lost patent protection in key markets  Under the terms of the deal Basilea will receive an upfront payment of CHF70m and will be eligible to receive up to  427m in additional payments upon achievement of pre specified regulatory and sales milestones  Basilea will also receive royalties in the mid teen range on Pfizer s sales in the territories mentioned 
To read the entire report Please click on the pdf File Below ",2017-07-11,Edison,https://www.investing.com/analysis/basilea-pharmaceutica---hat-trick-200200265,200200265
220649,442165,PFE,4 Momentum Stocks To Watch,opinion,"Strong technical momentum and positive news are powering some of the stocks we follow 
Four To watch

Amicus Therapeutics  NASDAQ FOLD  performed phenomenally on Tuesday  popping  2 66  or 26   to  12 92  on 24 million shares traded  The move followed positive FDA submission news for the company  which may have wider implications for quicker drug approvals in the wider biopharma market  The expected next targets at  11 and  13 were both hit  The large breakaway gap created Tuesday from an established 6 month base could be a sign that this stock is going higher  The next targets are  15 and then  18  Short interest of 12 7 times its average volume could fuel the move as shorts cover on a rally 
Kronos Worldwide  NYSE KRO  ran all the way up to  20 64 Tuesday before closing at  20 47  up 88 cents  or about 4 5   to  20 47 on 1 million shares traded  That s the biggest volume for the chemicals stock since its move up in early May  It was also the stock s highest closing price since 2012  Price had broken out of its 50 day moving average on July 3  From here  watch for an extension up to  23  24 
Sangamo Therapeutics  NASDAQ SGMO  may have broken out of a 2 week bull flag consolidation  closing up 55 cents  or 6 3   to  9 25 on 1 2 million shares traded Tuesday  The biopharma stock had begun its ascent when a clinical partnership with Pfizer  NYSE PFE  was announced in May and then continued up following a public stock offering announced in June  Price has risen 112  since earnings two months ago  If it extends  watch for a move through  9 65 to get up to  10 25  and then into the  11 50  11 75 range 
Square  NYSE SQ  broke out of its bull flag consolidation  moving as high as  25 56 and closing at  25 44 on 17 6 million shares traded Tuesday  The move came after an analyst at Loop Capital Markets suggested that PayPal Holdings  NASDAQ PYPL  should buy the company  The mobile payments stock has gained  4 49  or 21   since May 22  and could continue higher into the  27  28 zone 

No Holdings ",2017-07-12,Harry Boxer,https://www.investing.com/analysis/4-momentum-stocks-to-watch-200200718,200200718
220651,442167,PFE,Pfizer s 2015 forecast disappoints  crimped by generics  dollar,news, Reuters    Pfizer Inc  N PFE  reported stronger than expected quarterly results as sales of vaccines and cancer drugs increased  but the company forecast 2015 earnings below Wall Street expectations  citing patent expirations and the stronger dollar   The largest U S  drugmaker said on Tuesday that it earned  1 23 billion  or 19 cents per share  in the fourth quarter  That compared with  2 57 billion  or 39 cents per share  a year earlier   Excluding special items  Pfizer earned 54 cents per share  Analysts on average expected 53 cents  according to Thomson Reuters I B E S ,2015-01-27,Reuters,"https://www.investing.com/news/stock-market-news/pfizer's-2015-forecast-disappoints,-crimped-by-generics,-dollar-325270",325270
220652,442168,PFE,Puma  PBYI  Ends Patient Enrollment In Phase III Cancer Trial,opinion,Puma Biotechnology  Inc    NASDAQ PBYI   announced that it has completed enrollment of patients in a phase III study to evaluate its lead pipeline candidate PB272  neratinib  in combination with Roche Holding  SIX ROG  AG s   OTC RHHBY   Xeloda  capecitabine  for treatment of third line HER2 positive metastatic breast cancer Presently  neratinib is under review in the U S  as a single agent for extended adjuvant treatment of patients with early stage HER2 over expressed amplified breast cancer while in the EU  it is under review for an extended adjuvant treatment of HER2 positive early stage breast cancer Puma s shares have significantly outperformed the Zacks classified  industry so far this year  The stock has soared 181 6  compared with the broader industry s advance of 6 4  The phase III study is designed to evaluate the use of neratinib in combination with Xeloda as against the combination of GlaxoSmithKline s   NYSE GSK   Tykerb with Xeloda in patients with third line HER2 positive metastatic breast cancer The trial will be conducted on approximately 600 patients at sites in North America  Europe and Asia Pacific  The co primary endpoints of the trial are progression free survival  PFS  and overall survival  OS   The company expects an initial data from the study in the first half of 2018 Notably  the NALA trial was designed with a special protocol assessment by the FDA  Subsequently  the European Medicines Agency  EMA  has also provided a follow on scientific advice  SA   consistent with the FDA assessment of the design and endpoints of the study The company is also planning to develop this combination for treating patients with HER2 positive breast cancer that has metastasized to the brain and in patients with HER2 non amplified tumors that have a HER2 mutation We remind investors that the breast cancer market is heavily crowded with drugs like AstraZeneca s Faslodex  Pfizer Inc  s   NYSE PFE   Ibrance and Novartis s Femara among others With no approved product in the company s portfolio and neratinib being its lead pipeline candidate  we expect investors  focus to remain on the updates  pertaining to its development  A potential approval will enable the company to generate product revenues for the first time Puma Biotechnology Inc Price    Zacks RankPuma currently carries a Zacks Rank  3  Hold   You can see  Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2017-07-06,Zacks Investment Research,https://www.investing.com/analysis/puma-(pbyi)-ends-patient-enrollment-in-phase-iii-cancer-trial-200199721,200199721
220656,442172,PFE,Merck Tries To Acquire Cubist Pharmaceuticals For More Than  7B,news,"By   

Merck   Co  is near closing a deal to buy Cubist Pharmaceuticals Inc  NASDAQ CBST   an antibiotics maker  in a deal worth more than  7 billion  reports said Friday citing company officials  The deal  which is expected to be announced next week  comes as a part of Merck s strategy to buy mid size drug makers to expand its business 
New Jersey based Merck would pay nearly  100 per share for Cubist  valuing the company at nearly  7 5 billion  about 34 percent more than Cubist s closing price on Friday  The Wall Street Journal reported  Massachusetts based Cubist makes drugs that fight infectious diseases and manufactures its flagship drug Cubicin  which recorded sales of  967 million in 2013  Although antibiotics are not considered to be a lucrative option for the drug industry  analysts expect that new versions could earn high profits for the companies 
The deal would also allow Merck to access Cubist s medicines  which are mostly used in hospitals  according to CNBC 
Cusbist s focus area for its products is on manufacturing drugs that could address  significant unmet medical needs   including diseases that lead to global pandemics  according to the New York Times  The company reported sales of  309 million in the third quarter of this year  showing an increase of 16 percent over the last year for the same quarter  Last year  Cubist had also acquired smaller businesses like Trius and Optimer  further expanding its foothold on antibiotics segment  CNBC reported 
Merck  which is the second largest American drugmaker after Pfizer  NYSE PFE   has a market value of over  174 billion and reported sales worth  10 56 billion in the third quarter of 2014  the Times reported  While the company s vaccine for cervical cancer faces increased competition  its diabetes drug  the largest line for the company  continues to clock high sales 
In October  Merck also closed a deal to sell its consumer business to Bayer for  14 2 billion  In June  Merck bought Idenix Pharmaceuticals  which makes drugs for treating human viral diseases  for  3 85 billion ",2014-12-06,International Business Times,https://www.investing.com/news/stock-market-news/merck-tries-to-acquire-cubist-pharmaceuticals-for-more-than-$7b-319272,319272
220661,442177,PFE,Epizyme Progressing Well On Two Lead Pipeline Candidates,opinion,We issued an updated research report on Epizyme  Inc    NASDAQ EPZM   on Jun 23  2017 Currently  Epizyme is a development stage biopharmaceutical company  focused on bringing novel epigenetic therapies for the treatment of cancer and other diseases to market Key candidates in Epizyme s pipeline include tazemetostat  selective inhibitor of the EZH2 HMT  and pinometostat  an inhibitor of the DOT1L HMT  We note that  Epizyme has made significant progress with its lead candidate  tazemetostat for the treatment of multiple types of hematological malignancies and genetically defined solid tumors  Tazemetostat is being evaluated as monotherapy in multiple phase II studies for indications such as relapsed or refractory non Hodgkin lymphoma and in patients with certain molecularly defined solid tumors The company also announced positive interim efficacy data in June 2017 from the its ongoing phase II clinical trial of tazemetostat  as a single agent treatment for relapsed or refractory patients with follicular lymphoma  FL  or diffuse large B cell lymphoma  DLBCL  grouped by EZH2 mutational status  In fact  these interim data findings represent an important step forward for the tazemetostat program In May 2017  Epizyme  announced positive interim data on tazemetostat  from the epithelioid sarcoma cohort of its ongoing phase II study in adult patients with molecularly defined solid tumors  Further  the company announced that it conducted a positive meeting with the FDA and has identified a path to submission for accelerated approval of tazemetostat based on the 60 patient cohort from its phase II study  The company will target a new drug application  NDA  submission in 2018 Again  in June  the FDA granted Orphan Drug designation to tazemetostat for the treatment of patients with soft tissue sarcoma  STS   This is an important milestone for Epizyme as it advances tazemetostat through clinical development   Earlier  the FDA granted Fast Track designation to tazemetostat for the treatment of patients with relapsed or refractory follicular lymphoma  FL   either with type EZH2 or EZH2 activating mutations in April  We note that tazemetostat enjoys orphan drug designation in the U S  for the treatment of malignant rhabdoid tumors  MRT   The orphan drug designation applies to INI1 negative MRT as well as SMARCA4 negative malignant rhabdoid tumor of ovary  MRTO  Meanwhile  Epizyme s second pipeline candidate  pinometostat  is being evaluated in a phase I dose escalation study on pediatric patients suffering from an acute leukemia with genetic alterations of the MLL gene  MLL r   It has an agreement with Celgene Corporation   NASDAQ CELG   for the discovery  development and commercialization of small molecule HMT inhibitors including pinometostat in the ex U S  markets Epizyme also has an agreement with Celgene for the discovery  development and commercialization of small molecule HMT inhibitors including pinometostat in the ex U S  markets However  Epizyme s products are still several years from commercialization while several big names like Glaxo  Novartis   NYSE NVS   and Pfizer   NYSE PFE   are already developing new epigenetic treatments for cancer The Best   Worst of ZacksToday you are invited to download the full  up to the minute list of 220 Zacks Rank  1  Strong Buys  free of charge  From 1988 through 2015 this list has averaged a stellar gain of  25  per year  Plus  you may download 220 Zacks Rank  5  Strong Sells   Even though this list holds many stocks that seem to be solid  it has historically performed 6X worse than the market ,2017-06-26,Zacks Investment Research,https://www.investing.com/analysis/epizyme-progressing-well-on-two-lead-pipeline-candidates-200197531,200197531
220662,442178,PFE,Sanofi Regeneron s Kevzara Gets Marketing Approval In EU ,opinion,Sanofi  PA SASY    NYSE SNY   and partner Regeneron Pharmaceuticals  Inc    NASDAQ REGN   announced that the European Commission has granted marketing approval to its rheumatoid arthritis  RA  drug Kevzara The IL 6R antibody has been approved for the treatment of adult patients in combination with methotrexate  MTX  with moderate to severely active RA  who have had an inadequate response or intolerance to one or more biologic or non biologic disease modifying anti rheumatic drugs  DMARDs  such as MTX So far this year  Sanofi s shares are up 22 8   better than a 15  increase for the Zacks classified industry Kevzara was approved in the U S  in May and in Canada in February this year for the same indication We remind investors that the European Medicine Agency s  EMA  Committee for Medicinal Products for Human Use  CHMP  had granted a positive opinion recommending marketing approval of Kevzara in the EU in April this year The marketing approval in the EU was based on results from seven phase III trials in the global SARIL RA clinical development program conducted in more than 3 300 adults with moderate to severely active RA who had an inadequate response to previous treatment regimens  Kevzara demonstrated statistically significant  clinically meaningful improvements in combination with conventional DMARDs  including MTX in two pivotal phase III studies While Kevzara has blockbuster potential  the RA market is highly crowded given the presence of treatments like AbbVie  Inc  s   NYSE ABBV   Humira and Pfizer  Inc  s   NYSE PFE   Xeljanz among others  Moreover  the patient population is huge with many patients spending years on different treatments without achieving their treatment goals  With RA affecting about 2 9 million people in Europe  Kevzara represents a new treatment option for patients Sanofi currently has a Zacks Rank  2  Buy   You can see  Sell These Stocks  Now Just released  today s 220 Zacks Rank  5 Strong Sells demand urgent attention  If any are lurking in your portfolio or Watch List  they should be removed immediately  These are sinister companies because many appear to be sound investments  However  from 1988 through 2016  stocks from our Strong Sell list have actually performed 6X worse than the S P 500 ,2017-06-26,Zacks Investment Research,https://www.investing.com/analysis/sanofi-regeneron's-kevzara-gets-marketing-approval-in-eu-200197699,200197699
220663,442179,PFE,AstraZeneca s Faslodex Recommended By CHMP For 1st Line Use,opinion,"AstraZeneca PLC   NYSE AZN   announced that the Committee for Medicinal Products for Human Use  CHMP  of the European Medicines Agency  EMA  has adopted a positive opinion recommending the marketing authorisation of Faslodex  fulvestrant  for 1st line treatment for postmenopausal women with HR  advanced breast cancer Presently  Faslodex is approved for advanced breast cancer in later lines of treatment  Faslodex is used to treat postmenopausal women with hormone receptor   positive metastatic breast cancer whose disease has spread after treatment with antiestrogen medicine  It is also is also approved  in combination with Pfizer Inc  s   NYSE PFE   Ibrance  palbociclib   for the treatment of women with HR   HER2 negative advanced or metastatic breast cancer  whose cancer has progressed after endocrine medicine AstraZeneca is looking to get the drug approved  for the treatment of HR  locally advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy  or with disease relapse on or after adjuvant anti oestrogen therapy  or disease progression on anti estrogen therapy AstraZeneca s shares have outperformed the Zacks classified  industry so far this year  The company s shares have gained 27 5  compared with the industry s gain of 14 9  Coming back to the release  we note that the CHMP recommendation is based on positive data from the phase III FALCON study  Data from the study showed that Faslodex 500mg was more effective over Arimidex  anastrozole  1mg in the treatment of locally advanced or metastatic breast cancer in post menopausal women  who had not received prior hormonal based medicine for HR  breast cancer  In addition  the study revealed that patients treated with Faslodex experienced 2 8 months longer delay in disease worsening or death than those treated with anastrozole Notably  the CHMP s positive opinion will now be reviewed by the European Commission and the final decision will be applicable to all 28 the European Union  EU  member countries plus Iceland  Norway and Liechtenstein Also  in Mar 2017  Novartis AG   NYSE NVS   announced that the FDA has approved Kisqali  formerly known as ribociclib  LEE011   for use in combination with an aromatase inhibitor for the first line treatment of postmenopausal women with hormone receptor positive  human epidermal growth factor receptor 2 negative  HR  HER2   advanced or metastatic breast cancer In May 2017  another company  Puma Biotechnology  Inc   NASDAQ PBYI   announced that an FDA advisory committee recommended the approval of its lead pipeline candidate  neratinib for the treatment of some breast cancers  The FDA s Oncologic Drugs Advisory Committee  ODAC  committee voted 12   4 to recommend approval of neratinib for the extended adjuvant treatment of HER2 positive early stage breast cancer as a single agent Zacks RankAstraZeneca currently sports a Zacks Rank  2  Buy   You can see   Astrazeneca  LON AZN  PLC Price and Consensus
    Sell These Stocks  Now Just released  today s 220 Zacks Rank  5 Strong Sells demand urgent attention  If any are lurking in your portfolio or Watch List  they should be removed immediately  These are sinister companies because many appear to be sound investments  However  from 1988 through 2016  stocks from our Strong Sell list have actually performed 6X worse than the S P 500 ",2017-06-26,Zacks Investment Research,https://www.investing.com/analysis/astrazeneca's-faslodex-recommended-by-chmp-for-1st-line-use-200197772,200197772
220665,442181,PFE,Pfizer s  11 billion buyback plan deflates AstraZeneca bid hopes,news,"LONDON NEW YORK  Reuters    U S  drugmaker Pfizer is to continue buying back stock  with the board authorizing a new  11 billion share repurchase plan  deflating expectations that it will make a new bid for AstraZeneca 
Shares in AstraZeneca fell 1 2 percent by 0800 GMT on Friday following the news 
The largest American pharmaceuticals company  whose shares gained more than 1 percent after the announcement late on Thursday  said the move was in addition to the  1 3 billion remaining on its current share buyback program 
Pfizer  which has a market valuation of about  180 billion  earlier this year failed in its  118 billion bid to buy British rival AstraZeneca  It has an opportunity to make a fresh run at its target from late November under British takeover rules 
Pfizer Chief Executive Ian Read has said the company is continuing to look at deals but investor hopes for a new bid have dwindled recently because of the introduction of new U S  tax rules 
The U S  government s tax proposals are designed to make it harder for American firms to shift their tax bases out of the country and into lower cost jurisdictions in Europe  as Pfizer would do by buying AstraZeneca 
The likelihood of Pfizer resuming its pursuit has also been diminished following the collapse of U S  drugmaker AbbVie s  55 billion plan to buy Dublin based Shire  as a result of the new U S  tax regulations 

But while investors may well view the big new share buyback as another blow to the idea of a Pfizer bid  ISI Group analyst Mark Schoenebaum cautioned against reading too much into it   We cannot and should not necessarily make that read across   he said in a note 
 Reporting by Ben Hirschler and Bill Berkrot  editing by Andrew Hay and Susan Thomas ",2014-10-24,Reuters,https://www.investing.com/news/stock-market-news/pfizer's-$11-billion-buyback-plan-deflates-astrazeneca-bid-hopes-314128,314128
220666,442182,PFE,Pfizer rises 1 8  in pre market after upbeat Q3 earnings,news,"Investing com   U S  pharmaceutical giant Pfizer reported better than expected third quarter earnings ahead of Tuesday s opening bell  sending its shares higher in pre market trade 
Pfizer said adjusted earnings per share was  0 57 cents in the third quarter  above expectations for adjusted earnings of  0 55 cents per share 
The company s third quarter revenue totaled  12 36 billion  beating forecasts for revenue of  12 26 billion 
Ian Read  Chairman and Chief Executive Officer  stated   Our key in line products continued to perform well with our most recent product launches exhibiting further momentum during the quarter  
Pfizer said it expected full year adjusted revenue to come in a range between  48 7 billion and  49 7 billion  compared to a previous range forecast of  48 7 billion to  50 7 billion 
Following the release of the report  shares in Pfizer Inc  NYSE PFE  rose 1 8  in pre market trade 
Meanwhile  U S  stock futures pointed to a mildly higher open  The Dow futures indicated a gain of 0 45  at the open  the S P 500 futures pointed to a rise of 0 55   while Nasdaq 100 futures advanced 0 6  ",2014-10-28,Investing.com,https://www.investing.com/news/stock-market-news/pfizer-rises-1.8-in-pre-market-after-upbeat-q3-earnings-314488,314488
220670,442186,PFE,Clovis Oncology Shares Shoot Up On Impressive Results,opinion,"Clovis Oncology Inc  NASDAQ CLVS 
Clovis Oncology  Inc   CLVS   a global biopharmaceutical company yesterday announced positive results from its Phase 3 Ariel 3 trial of rucaparib  Rucaparib is a maintenance therapy used for the treatment of ovarian cancer 
The trial reached its primary endpoints  and rucaparib showed statistical significance over the placebo 
Clovis Oncology  Inc  CEO s Comments

 We are very pleased with these positive ARIEL3 topline results that strongly demonstrate the potential of rucaparib to help women with platinum sensitive  advanced ovarian cancer  These results reinforce the potentially foundational role of rucaparib in the management of advanced ovarian cancer  as demonstrated by both investigator review and the blinded independent central review  Most importantly  we are grateful to the patients  caregivers and investigators who participated in this study  We look forward to sharing these data in greater detail at a medical meeting later this year and submitting our sNDA as rapidly as possible  with the ultimate goal of making rucaparib available to more women battling ovarian cancer   

CLVS Technical Analysis

CLVS opened trading yesterday at  87 73 which was up from the previous day s trading close of  59 97 equivalent to a 47  increase  CLVS closed trading yesterday at  87 88 and moved down after market to  86 70  Taking a look at the daily chart we can see the last time CLVS traded above these levels we have to go back to November 13th  2015 when it traded at  99 43 
Taking a closer look at the daily chart we can see that before the spike up CLVS had already been in an overall upward trend dating back to May 11th when it traded at  45 93  CLVS has a float of 31 22 million shares and traded 8 38 times the normal daily trading volume on Monday 
For trading purposes  I would like to see CLVS open trading on Tuesday above  83 00 and if it does I would be looking to take a long position at the bell  My stop loss would be  0 50 from my entry position fearing anything more than that and the stock would start to fill in the gap up 
Company Profile
Clovis Oncology  Inc   a biopharmaceutical company  focuses on acquiring  developing  and commercializing anti cancer agents in the United States  Europe  and internationally  Its commercial product includes Rubraca  rucaparib  tablet  an oral and small molecule poly ADP ribose polymerase inhibitor as monotherapy for the treatment of patients with deleterious breast cancer mutation associated advanced ovarian cancer  who have been treated with two or more chemotherapies  and selected for therapy by an FDA approved companion diagnostic for Rubraca 
The company is also involved in the ARIEL3 and ARIEL4 confirmatory trials of rucaparib as a potential maintenance therapy and treatment for ovarian cancer  trial of rucaparib in prostate indications  TRITON  2  a Phase 2 single arm study in men with metastatic castrate resistant prostate cancer  and TRITON3  a Phase 3 comparative study in men with mCRPC enrolling BRCA mutant and ATM  as well as engages in the various clinical studies for other indications 
It distributes its product primarily through specialty distributors and pharmacy providers to patients and health care providers  The company has license agreements with Pfizer Inc   NYSE PFE   AstraZeneca UK Limited  Advenchen Laboratories LLC  and Celgene Corporation  NASDAQ CELG   and collaboration and license agreement with Les Laboratoires Servier  Clovis Oncology  Inc  was founded in 2009 and is headquartered in Boulder  Colorado ",2017-06-20,Warrior Trading,"https://www.investing.com/analysis/clovis-oncology,-inc.-|-$clvs-stock-|-shares-shoot-up-on-impressive-resu-200196234",200196234
220678,442194,PFE,Acceleron  XLRN  Kidney Cancer Candidate Fails In Phase II,opinion,"Acceleron Pharma Inc  s   NASDAQ XLRN   stock had gone down earlier and then regained ground by almost 5  after the company announced disappointing top line results from a phase II DART study evaluating its pipeline candidate dalantercept in combination with Pfizer s   NYSE PFE   Inlyta  axitinib  for treatment of advanced renal cell carcinoma  RCC   Following the disappointing phase II results  the company decided to discontinue further development of the said kidney cancer candidate The increase in share price despite failing the phase II study reveals that dalantercept had become a secondary priority for Acceleron  while the company s primary focus is on the late stage anemia candidate luspatercept  Shares of Acceleron have outperformed the Zacks classified  industry so far this year  The stock has soared 16  compared with the broader industry s increase of 2 6  We remind investors that Acceleron has a collaboration  license and option agreement with Celgene Corp    NASDAQ CELG   for luspatercept Presently  Celgene is conducting two phase III study  MEDALIST and BELIEVE  for luspatercept  one for treating patients with lower risk Myelodysplastic syndromes  MDS  and another for the treatment of patients with beta thalassemia  Results from the studies are expected in mid 2018 The phase II study was designed to evaluate the safety and tolerability of the combination therapy of dalantercept  The study did not meet the primary end points and was unable to demonstrate a statistically significant increase in progression free survival  PFS   when treated with dalantercept compared with placebo plus axitinib in advanced RCC patients 
The median PFS for the combination therapy was 6 8 months  versus 5 6 months for placebo  Moreover  dalantercept plus axitinib did not decrease the rate of disease progression or death Apart from luspatercept  the company has two other internally discovered therapeutic candidates  currently in clinical trials  sotatercept and ACE 083 Acceleron expects to initiate a phase II study with ACE 083 in Charcot Marie Tooth disease  Previously  the company reported positive data from a phase I study for ACE 083  demonstrating marked increases in muscle volume  treated with ACE 083 We expect the investors  focus to remain on the company s updates relating to the development of pipeline candidates Acceleron Pharma Inc  Price

   Zacks Rank   Key Picks
Acceleron currently carries a Zacks Rank  3  Hold   A better ranked stock in the healthcare sector includes VIVUS  Inc    NASDAQ VVUS    which sports a Zacks Rank  1  Strong Buy   You can see  
VIVUS s loss per share estimates narrowed down from 50 cents to 39 cents for 2017 in the last 60 days  The company posted positive earnings surprises in all four trailing quarters with an average beat of 233 69  
Zacks  2017 IPO Watch List
Before looking into the stocks mentioned above  you may want to get a head start on potential tech IPOs that are popping up on Zacks  radar  Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential  This Special Report gives you the current scoop on 5 that may go public at any time 
One has driven from 0 to a  68 billion valuation in 8 years  Four others are a little less obvious but already show jaw dropping growth ",2017-06-14,Zacks Investment Research,https://www.investing.com/analysis/acceleron-(xlrn)-kidney-cancer-candidate-fails-in-phase-ii-200195243,200195243
220679,442195,PFE,Pfizer  PFE  Buys Exclusive EU Rights To Anti Fungal Drug,opinion,Pfizer  Inc    NYSE PFE   announced a deal to buy exclusive EU commercialization rights to an anti fungal treatment  Cresemba from Swiss pharma company  Basilea Pharmaceutica Ltd Cresemba  an intravenous  IV  and oral azole antifungal for the treatment of two serious infections  invasive aspergillosis and invasive mucormycosis  is presently marketed both in the U S  and EU Per the deal  Pfizer will be exclusively entitled to distribute and commercialize Cresemba  isavuconazole  in Europe  including Austria  France  Germany  Italy and the United Kingdom where Cresemba is already available  However  Pfizer does not have any marketing rights in Nordic countries  Denmark  Finland  Norway  Sweden  Iceland  or in the U S  Cresemba is marketed by Basilea s license partner  Astellas Pharma in the U S Meanwhile  Pfizer will also be responsible for launching the medicine in additional countries  mainly in Europe  over this year and next  However  Basilea will continue to hold the marketing authorization for EU  Basilea mentioned that it received an upfront payment of 70 million swiss francs from Pfizer while being entitled to additional milestones of up to  427 million and double digit royalties on salesPfizer s shares have risen 0 7  so far this year  compared with an increase of 10 7  for the Zacks classified  industry Pfizer enjoys a strong position in the anti infective space and markets many antifungals like Vfend  Zithromax and Zavicefta   Zavicefta was added to Pfizer s portfolio with the Dec 2016 acquisition of AstraZenecaplc s   NYSE AZN   anti infectives business  The latest collaboration strengthens its position in this therapeutic market Pfizer carries a Zacks Rank  3  Hold   You can see  Some better ranked stocks in the large cap pharma sector are Bayer Aktiengesellschaft   OTC BAYRY   and Sanofi   NYSE SNY    both carrying a Zacks Rank  2  Buy  Shares of Bayer have risen 31  this year so far while estimates for both 2017 and 2018 have risen 1 3  in the past 30 days Shares of Sanofi have risen 17 9  this year so far  While estimates for 2017 have risen 3 2  that for 2018 are up 1 2  in the past 30 days3 Stocks to Ride a 588  Revenue Explosion                    At Zacks  we re mostly focused on short term profit cycles  but the hottest of all technology mega trends is starting to take hold   By last year  it was already generating  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for those who make the right trades early ,2017-06-14,Zacks Investment Research,https://www.investing.com/analysis/pfizer-(pfe)-buys-exclusive-eu-rights-to-anti-fungal-drug-200195427,200195427
220680,442196,PFE,Here s What To Look For From Axovant Sciences  Alzheimer s Study,opinion,"Axovant Sciences  NYSE AXON  just   and alongside the numbers  gave markets and update as to the progress of its development pipeline  The star of said pipeline is a drug called Intepirdine  which the company is attempting to bring to market as a potential treatment for Alzheimer s disease  As part of the latest release  management reiterated a previously stated target timeframe for the release of data from a phase 3 study of Intepirdine  when used in combination with an already approved  and well established  drug called donepezil 
This is a bit of a controversial asset  with the asset class to which it belongs having had a rocky development history to date  However  there is some suggestion that Axovant can buck this trend and successfully prove efficacy where others have failed to do so  If this proves to be the case  there is a high probability of an immediate upside revaluation for the company 
Right now  the company trades for just shy of  22 a share at a market capitalization of  2 4 billion  If the data in question comes out as indicative of clinical benefit  and just as importantly  as we will get to shortly  does so with a clean safety profile  we are probably looking at  1 billion added to its market capitalization overnight 
Of course  the same can be said for failure  but in the other direction 
With this in mind  here is a look at the drug  and what we are looking out for from the data as underlying a bullish thesis 
So  as mentioned  it s called Intepirdine  and it s a selective 5 HT6 receptor antagonist  The 5 HT6 receptor is a subtype of the 5 HT receptor that plays a key role in the transmission of things like serotonin and other neurotransmitters in the brain  On its own  it s generally regarded as what s called an excitatory receptor  that is  it stimulates and promotes activity  However  a large portion of these receptors are co localized  or in other words  located near to  what are called GABA neurotransmitters  These basically block neuroactivity  so the co localization leads to the 5 HT6 receptor stimulating the blocking of neuroactivity 
The idea behind a 5 HT6 receptor antagonist like this  then  is that it stops the 5 HT6 receptor from stimulating this blocking of activity and   in turn   should promote brain function 
It is a pretty roundabout way of going about things  but studies to date have shown that   in concept  at least   it works  In a phase II trial conducted by GlaxoSmithKline plc  ADR   NYSE GSK   the addition of Intepirdine to donepezil  in a statistically significant improvement in two of the gold standard test scales in Alzheimer s   the ADAS cog scale and ADCS ADL scale   when compared to patients that just took donepezil alone 
The phase III that Axovant is conducting is attempting to build on this study in a larger population  the FDA generally requires at least 1000 patients in an Alzheimer s study to underpin a New Drug Application  or NDA  and replicate the results 
There are some doubts  however 
Other companies have tried to prove efficacy and safety in these sorts of drugs  and have had a tough time doing it  Most notably  Lundbeck  OTC HLUYY  tried to combine a 5 HT6 receptor antagonist with Pfizer s  NYSE PFE  PF 05212377  and midway through a phase II trial  found that patients were reporting elevated liver enzymes  In a trial environment  this isn t too much of a problem  as it can be treated relatively easily  If the drug was approved  however  and was taken as a general population therapeutic  there is good chance that this elevated liver enzyme level would not be spotted early enough and could lead to permanent liver damage or  worse  failure altogether  Lundbeck played about with the dosing to try and address the issue  but the trial eventually ended up failing 
What this one comes down to  then  is whether investors feel that it was the altered protocol  as necessitated by the tolerability problems  that caused the failure of the Lundbeck and Pfizer trial  as opposed to any inherent problems with the drug from a clinical benefit perspective  i e  the drug works  but not in this trial due to various protocol errors  
If that s the case  an Axovant position ahead of the company s releasing of its phase III data could well be justified 
So what are we looking for from the data when it hits 
The primary endpoint is set up to mimic that which determines the outcome of the above described phase 2 trial  the one that GSK carried out    improvement from baseline  statistically significant when compared to placebo  in the ADAS cog scale and ADCS ADL scale  There are also a few key secondary endpoints that  if hit  would shore up the success of the primary 
Of course  and just as importantly  we need to see a clean safety profile  Specifically  we don t want the drug to go down the same pathway as did Lundbeck s asset and induce elevated liver enzyme levels in patients 
September 2017 is the month to watch ",2017-06-15,Samuel Rae,https://www.investing.com/analysis/here's-what-to-look-out-for-from-axovant-sciences'-alzheimer's-study-200195465,200195465
220681,442197,PFE,3 Biotech Stocks That More Than Doubled Year To Date,opinion,"We are almost half way through 2017 and the biotech sector  which had a rough and challenging 2016  has been showing signs of recovery despite some ups and downs  Year to date  YTD   the NASDAQ Biotechnology Index is up 10 4  providing a glimmer of hope to biotech investors who saw the Index sliding 19 1  in 2016      While the drug pricing issue remains a headline risk this year as well  confidence in the sector has been boosted by strong results  R D success and innovation  FDA approvals  ramp up in new product sales and continued strong performance from legacy products  There is also a lot of hope that M As will pick up this year Moreover  so far into 2017  the FDA has approved more drugs than it did during the same period last year  Till the end of Jun 2016  the agency had approved 14 new drugs while so far this year  21 new drugs have gained FDA approval  In fact  the total tally for the whole of 2016 was 22 With President Trump saying that the FDA will be streamlined and the drug approval process will be much faster  expectations are that there will be more innovation in the sector and  maybe  a surge in new drug approvals However  the sector does face some challenges    additional competition  high profile pipeline setbacks  slowdown in growth of mature products and loss of exclusivity for certain key drugs Keeping all this in mind  here is a look at three biotech stocks that more than doubled YTD FDA Advisory Panel Vote Boosts PumaLos Angeles  CA based Puma Biotechnology  Inc    NASDAQ PBYI   got a huge boost last month with the company getting support from the FDA s Oncologic Drugs Advisory Committee for its experimental breast cancer treatment  neratinib  The panel voted 12   4 in favor of approving neratinib for the extended adjuvant treatment of HER2 positive early stage breast cancer based on a favorable risk benefit profile  Given the positive vote  chances of gaining FDA approval look pretty high  While the FDA is not required to follow the advice of its advisory panels  it usually does so  With Puma being a development stage company  neratinib s approval would be a major milestone for the stock   Puma s shares are up 153 5  YTD  outperforming the Zacks categorized  industry which is up 2  so far in 2017 
Sangamo Skyrockets on Deal with PfizerSangamo Therapeutics  Inc    NASDAQ SGMO    another California based company  saw its shares shoot up this year on the signing of a deal with pharma major Pfizer   NYSE PFE    The companies are collaborating for the development and commercialization of gene therapy programs for hemophilia A  The exclusive  worldwide collaboration and license agreement covers SB 525  one of Sangamo s four lead pipeline candidates  The agreement will see Pfizer pooling its expertise in rare disease  gene therapy  and hemophilia with Sangamo s deep knowledge in genomic therapies  Sangamo will not only get an upfront payment of  70 million  it could get milestone payments of up to  475 million  including up to  300 million related to SB 525 and up to  175 million for additional hemophilia A gene therapy candidates that may be developed under the collaboration  Tiered double digit royalties on net sales also form a part of the deal Sangamo has fast track status in the U S  for SB 525  As per data from the Centers for Disease Control and Prevention  hemophilia occurs in about one of every 5 000 male births  with about 20 000 males in the U S  living with the disorder The Pfizer collaboration could prove to be a transformational deal for the clinical stage biotech company which is focused on translating ground breaking science into genomic therapies  Sangamo s shares are up 144 9  YTD 
Celyad Gets a Boost with Novartis Licensing DealBelgian biotech company  Celyad   NASDAQ CYAD    which is focused on the discovery and development of cell therapies  saw its shares moving up following the announcement of a non exclusive license agreement with Novartis   NYSE NVS   for the company s U S  patents for the production of allogeneic CAR T cells  The agreement covers two targets being developed by Novartis Under the deal  Celyad could earn up to  96 million    this includes an upfront payment as well as success based clinical  regulatory and commercial milestone payments  Celyad will also get single digit royalties based on net sales of the licensed target associated products Celyad s shares are up 163 2  so far in 2017 
While Puma  Sangamo and Celyad are all Zacks Rank  3  Hold  stocks  you can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-06-19,Zacks Investment Research,https://www.investing.com/analysis/3-biotech-stocks-that-more-than-doubled-year-to-date-200196008,200196008
220683,442199,PFE,European stocks edge higher  E Z  PMIs in focus  Dax up 0 16 ,news,"Investing com   European stocks edged higher on Thursday  after the release of positive German manufacturing and service sector data  while investors still awaited reports for the entire euro zone 
During European morning trade  the DJ Euro Stoxx 50 rose 0 35   France s CAC 40 added 0 28   while Germany s DAX edged 0 16  higher 
Markit research group said that Germany s preliminary manufacturing purchasing managers  index slipped to 52 0 this month  from a reading of 52 4 in July  compared to expectations for a fall to 51 8 
Markit said that Germany s preliminary services PMI ticked down to 56 4 in August  from a reading of 56 7 last month  confounding expectations for a fall to 55 7 
Financial stocks were mixed  as French lenders BNP Paribas  PARIS BNPP  and Societe Generale  PARIS SOGN  dropped 0 50  and 0 25   while Germany s Deutsche Bank  XETRA DBKGn  rose 0 22  
Among peripheral lenders however  Italy s Intesa Sanpaolo  MILAN ISP  and Unicredit  MILAN CRDI  added 0 14  and 0 20  respectively  while Spanish banks Banco Santander  MADRID SAN  and BBVA  MADRID BBVA  edged up 0 11  and 0 17  
Elsewhere  Nobel Biocare  SIX NOBN  surged 2 10  after the dental implant manufacturer raised its 2014 profit margin forecast 
On the downside  Air Berlin  XETRA AB1  dove 7 55  after posting a quarterly profit and saying it will reduce its capacity 
In London  FTSE 100 edged up 0 18   led by Astrazeneca  LONDON AZN   up 1 46   amid reports that under new U K  takeover rules Pfizer  NYSE PFE  can make the first steps toward a renewed bid on August 26 August for the British drugmaker 
Pfizer had abandoned a  69 5 billion effort to buy London based AstraZeneca on May 26  The U S  company was also said to be looking at other possible targets  including Ireland s Actavis 
Meanwhile  mining stocks were broadly lower  Shares in Glencore Xstrata  LONDON GLEN  slipped 0 19  and Rio Tinto  LONDON RIO  declined 0 61   while rivals Randgold Resources  LONDON RRS  and Fresnillo  LONDON FRES  tumbled 1 11  and 2 16  respectively 
In the financial sector  stocks were also mostly lower  The Royal Bank of Scotland  LONDON RBS  inched down 0 06  and Lloyds Banking  LONDON LLOY  fell 0 10   while Barclays  LONDON BARC  slumped 0 29   HSBC Holdings  LONDON HSBA  overperformed however  adding 0 15  
In the U S   equity markets pointed to a steady open  The Dow 30 futures pointed to a 0 09  gain  S P 500 futures signaled a 0 05  uptick  while the Nasdaq 100 futures indicated a 0 01  dip 
Later in the day  the euro zone was to publish preliminary data on private sector activity  while the U S  was to produce data on unemployment claims  manufacturing activity and existing home sales ",2014-08-21,Investing.com,"https://www.investing.com/news/stock-market-news/european-stocks-edge-higher,-e.z.-pmis-in-focus;-dax-up-0.16-304685",304685
220684,442200,PFE,U S  judge won t toss insider trading conviction of SAC s Martoma,news,"By Joseph Ax NEW YORK  Reuters    A federal judge on Thursday refused to throw out the insider trading conviction of former SAC Capital portfolio manager Mathew Martoma  saying the trial evidence  overwhelmingly demonstrated Martoma s guilt  
The decision from U S  District Judge Paul Gardephe  who oversaw the trial earlier this year  was in response to a request from Martoma and came ahead of his sentencing on Monday on conspiracy and securities fraud convictions 
A jury found Martoma  40  guilty in February of engaging in what prosecutors claimed was the most lucrative insider trading scheme in history  enabling SAC to make profits and avoid losses of  275 million in trades in Elan Corp and Wyeth 
Elan was acquired last year by Perrigo Company Plc  N PRGO   while Wyeth is now a unit of Pfizer Inc  N PFE  
SAC itself pleaded guilty last year to insider trading and agreed to pay  1 8 billion to settle criminal and civil charges 
Martoma was convicted of trading on confidential tips from two doctors about a clinical trial for an Alzheimer s drug that was eventually deemed ineffective 
In addition to refusing to toss Martoma s conviction  Gardephe denied his request for a new trial  The judge rejected his contention that the key government witness   Sidney Gilman  a doctor who testified as part of a cooperation deal that he had given Martoma the clinical results   was unreliable 
 To the contrary  Dr  Gilman s account was   as to the key issues   supported by strong circumstantial evidence   Gardephe wrote 
Martoma also claimed the jury was tainted by widespread media reports regarding his expulsion from Harvard for doctoring a transcript 
But Gardephe said there was no evidence any juror had been exposed to that information 
Martoma s defense lawyer  Richard Strassberg  did not immediately respond to a request for comment 
Manhattan U S  Attorney Preet Bharara has recommended a  substantial  prison term beyond the eight years recommended by probation officers  according to court filings 
An eight year term would be among the stiffest insider trading penalties handed down in recent years  Lawyer Matthew Kluger received the longest U S  insider trading sentence at 12 years after pleading guilty in 2011 to participating in a  37 million scheme 
Martoma is one of eight SAC employees to be convicted of insider trading  SAC s founder  Steven A  Cohen  has not been criminally charged 
The firm has changed its name to Point72 Asset Management and no longer manages outside money  instead focusing on Cohen s family fortune 

The case is U S  v  Martoma  U S  District Court for the Southern District  No  12 973 
 Reporting by Joseph Ax  editing by Andrew Hay ",2014-09-04,Reuters,https://www.investing.com/news/stock-market-news/u.s.-judge-won't-toss-insider-trading-conviction-of-sac's-martoma-307862,307862
220685,442201,PFE,SAC s Martoma gets nine years prison for insider trading,news,"By Nate Raymond NEW YORK  Reuters    Mathew Martoma  a former portfolio manager at billionaire Steven A  Cohen s SAC Capital Advisors LP hedge fund  was sentenced on Monday to nine years in prison for engaging in what authorities called the most lucrative insider trading scheme in U S  history 
U S  District Judge Paul Gardephe in New York said he had to account for the  enormous   275 million gain SAC obtained as a result of illegal trades in pharmaceutical stocks  Prosecutors said the trades were based on tips Martoma received about a clinical trial for an Alzheimer s drug 
 I cannot and will not ignore that the gain is hundreds of millions of dollars more than ever seen in an insider trading prosecution   Gardephe said 
The sentence came despite appeals for leniency by Richard Strassberg  Martoma s lawyer  who cited  fragile family circumstances   Gardephe also ordered Martoma to forfeit  9 3 million  including his Boca Raton  Florida  home 
While Martoma  40  faced up to 19 1 2 years in prison under federal sentencing guidelines  Gardephe said such punishment should be reserved for repeat offenders or criminal enterprise leaders 
But the judge said a severe sentence was nonetheless necessary  saying  there was nothing accidental about Mr  Martoma s conduct or the gain realized  
Martoma  whom a jury convicted in February of securities fraud and conspiracy  made no comment as he left the court holding his wife s hand 
The ex trader and his family were  devastated by the outcome   said Lou Colasuonno  a spokesman for Martoma  saying an appeal is planned 
The nine year sentence is among the longer prison terms in U S  insider trading cases  reflecting a trend of increasingly lengthy sentences in recent years 
In 2012  corporate lawyer Matthew Kluger was sentenced in New Jersey to 12 years for trading on information from law firms about mergers  A year earlier  Galleon Group hedge fund founder Raj Rajaratnam was sentenced in New York to 11 years 
Manhattan U S  Attorney Preet Bharara  whose office is engaged in a broad crackdown on insider trading  called the nine year sentence  well suited to the audacity of the illegal trading in this case  
The case against Martoma  who worked in SAC s CR Intrinsic Investors unit  stemmed from a long running insider trading investigation of the hedge fund 
Eight employees have been convicted  and SAC last year agreed to pay  1 8 billion in criminal and civil settlements and plead guilty to fraud charges 
SAC recently changed its name to Point72 Asset Management  and the Stamford  Connecticut firm was transformed into a family office managing Cohen s fortune 
Prosecutors said Martoma sought confidential information from doctors involved in a clinical trial of an Alzheimer s drug being developed by Elan Corp  since acquired by Perrigo Co  N PRGO   and Wyeth  now a unit of Pfizer Inc  N PFE  
Based on a tip Martoma received from Sidney Gilman  a former University of Michigan professor who chaired the drug s safety monitoring committee  SAC Capital in July 2008 began selling its  700 million position in Elan and Wyeth  prosecutors said 
They said most of the trading occurred in accounts controlled by Cohen  who had a 20 minute phone call with Martoma after receiving information about the negative results of the study 
Cohen has not been criminally charged 
He faces a U S  Securities and Exchange Commission civil action seeking to bar him from the financial services industry for failing to supervise Martoma and Michael Steinberg  an SAC portfolio manager convicted of insider trading in a separate trial in December 
Cohen denies wrongdoing  A spokesman declined to comment 
The case is U S  v  Martoma  U S  District Court  Southern District of New York  12 cr 00973 
 Additional reporting by Jonathan Stempel ",2014-09-08,Reuters,https://www.investing.com/news/stock-market-news/sac's-martoma-gets-nine-years-prison-for-record-insider-trading-scheme-308577,308577
220695,442211,PFE,Roche Announces Data On Perjeta  Alecensa And Tecentriq ,opinion,"Roche Holdings AG   OTC RHHBY   announced data from the phase III study  APHINITY  on breast cancer drug Perjeta  The data from the study showed that the combination of Perjeta  Herceptin and chemotherapy  the Perjeta based regimen  significantly reduced the risk of breast cancer recurrence or death  invasive disease free survival  iDFS  by 19  in patients suffering from HER2 positive early breast cancer  eBC  compared with Herceptin and chemotherapy alone  
94 1  of people treated with the Perjeta based regimen did not experience the recurrence of cancer compared with 93 2  treated with Herceptin and chemotherapy at the end of three years  The results will be presented in an oral session today at the 53rd Annual Meeting of the American Society of Clinical Oncology  ASCO  
We remind investors that Roche has a strong presence in the oncology market  The company dominates the breast cancer space with strong demand for HER2 franchise drugs like Herceptin  Perjeta and Kadcyla 
However  competition is becoming stiff in the breast cancer market with companies like Novartis   NYSE NVS   getting a boost with approval of new drugs like Kisqali 
Pfizer Inc    NYSE PFE   also announced data from its phase II study  ABRAZO  which is evaluating talazoparib in advanced breast cancer patients with germline BRCA 1 2 positive  gBRCA   mutations  showing anti tumor activity at the ASCO 

Roche s share price shows that the company has outperformed the Zacks classified industry year to date  The stock is up 14 6  compared with the  industry s gain of 10 8  
Coming back to the ASCO meet  Roche also announced positive data from the phase III study  ALEX  on lung cancer drug Alecensa  The data from the study showed that Alecensa significantly reduced the risk of disease worsening or death  progression free survival  PFS  by more than half  53   compared with crizotinib when given as initial  first line  treatment for people with anaplastic lymphoma kinase  ALK  positive advanced non small cell lung cancer  NSCLC   The primary endpoint of the study was not reached 
Alecensa lowered the risk of tumour spread or growth in the brain or central nervous system  We note that Alecensa is approved as a monotherapy for patients suffering from ALK positive NSCLC who have progressed on or are intolerant to crizotinib in Europe and the U S 
Alecensa was granted conditional marketing authorisation in Feb 2017 in the EU as a monotherapy for patients suffering from ALK positive advanced NSCLC previously treated with crizotinib  Hence  Roche is submitting the data from the ALEX study as the specific obligation to obtain full approval of Alecensa as an initial treatment for ALK positive advanced NSCLC 
New drug launches  such as Tecentriq  Cotellic and Alecensa boosted sales and are expected to continue to do so in the upcoming quarters 
Earlier  Roche also presented new encouraging data on immunotherapy drug Tecentriq along with updates from its cancer immunotherapy development program at ASCO 2017 
Data from a study on Tecentriq plus Avastin in metastatic Renal Cell Carcinoma  mRCC  highlight the combination s potential to increase infiltration  trafficking  of T cells into tumors and other immune modulatory properties 
Alongside  two phase Ib studies in melanoma combining Tecentriq plus Cotelic and Tecentriq plus Cotellic plus Zelboraf showed that the addition of Zelboraf and or Cotellic may alter the tumor micro environment  enhancing the anti tumor activity of Tecentriq 
Immuno oncology is a key focus area for Roche  with the company currently having multiple candidates under development  The FDA granted accelerated approval to immuno oncology drug  Tecentriq in May 2016 for the treatment of patients suffering from locally advanced or metastatic urothelial carcinoma  Initial uptake of the drug has been encouraging 
Zacks Rank   Key Pick
Roche currently carries a Zacks Rank  3  Hold  
A better ranked stock in the health care sector is VIVUS  Inc    NASDAQ VVUS    The stock currently sports a Zacks Rank  1  Strong Buy   You can see  
VIVUS  loss per share estimates narrowed from 50 cents to 39 cents for 2017 over the last 60 days  The company posted positive earnings surprises in each of the trailing four quarters  with an average beat of 233 69  
Looking for Stocks with Skyrocketing Upside  
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana 
Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-06-06,Zacks Investment Research,"https://www.investing.com/analysis/roche-announces-data-on-perjeta,-alecensa-and-tecentriq-200193590",200193590
220696,442212,PFE,Pfizer s  PFE  Tafamidis Gets Fast Track Status In The U S ,opinion,Pfizer Inc    NYSE PFE   has been granted with fast track status by FDA for treating patients with transthyretin cardiomyopathy  TTR CM   This rare disease is associated with progressive heart failure and is universally fatal  Currently tafamidis is in phase III study for TTR CM Incidentally in 2011  tafamidis was first approved in the EU for treatment of transthyretin familial amyloid polyneuropathy  TTR FAP  in adult patients under the brand name Vyndaqel  Presently  the drug is approved for TTR FAP in 40 countries  including Europe  Japan  Brazil  Mexico  Argentina  Israel  Russia and South Korea Shares of Pfizer have underperformed the Zacks classified  industry so far this year  The stock has lost 1 3  compared to the broader industry s 10 4  gain Investors should be reminded that in Jun 2012  FDA had issued a complete response letter to Pfizer with respect to its application to approve tafamidis for TTR FAP  The FDA has asked for additional information on the data within the current tafamidis new drug application  NDA    Subsequently in Dec 2013  the company had initiated a global phase III study to evaluate safety and tolerability profiles of tafamidis in patients with TTR CM  This category also comprised those with TTR FAC and wild type cardiomyopathy  WT CM   Data from the study is expected in 2018 Notably  tafamidis became a part of Pfizer s portfolio with its October 2010 acquisition of FoldRx Per the company s press release  approximately 1 000 patients are diagnosed with TTR CM globally  However  the disease is still believed to be largely under diagnosed  Hence approval of the concerned drug for TTR CM will cater to the development of critically needed treatment options for people living with this rare disease In an attempt to boost its rare disease and gene therapy pipelines  Pfizer has entered into an exclusive  worldwide collaboration and license agreement with Sangamo Therapeutics  Inc    NASDAQ SGMO   for developing and commercializing gene therapy programs for hemophilia A in May 2017  This deal covers SB 525  one of Sangamo s four lead pipeline candidates  slated to enter the clinic this quarter Pfizer  Inc  Price   Zacks Rank   Key PicksPfizer currently carries a Zacks Rank  3  Hold   Better ranked stocks in healthcare sector include VIVUS  Inc    NASDAQ VVUS    and Regeneron Pharmaceuticals  Inc    NASDAQ REGN    While VIVUS sports a Zacks Rank  1  Strong Buy   Regeneron carry a Zacks Rank  2  Buy   You can see  VIVUS s loss per share estimates narrowed down from 50 cents to 39 cents for 2017 in last 60 days  The company posted positive earnings surprises in all four trailing quarters with average beat of 233 69  Regeneron s earnings per share estimates increased from  10 16 to  10 52 for 2017 and from  10 90 to  12 10  over the last 60 days  The company posted positive earnings surprises in two of the four trailing quarters with average beat of 0 45  3 Stocks to Ride a 588  Revenue ExplosionAt Zacks  we re mostly focused on short term profit cycles  but the hottest of all technology mega trends is starting to take hold   By last year  it was already generating  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for those who make the right trades early ,2017-06-06,Zacks Investment Research,https://www.investing.com/analysis/pfizer's-(pfe)-tafamidis-gets-fast-track-status-in-the-u.s.-200193814,200193814
220698,442214,PFE,Lawsuits Against Pfizer s Lipitor Spike In Past 5 Months,news,"By    New York based pharmaceutical giant Pfizer Inc  NYSE PFE saw a steep hike in the number of lawsuits filed against it by American women claiming that the company knew about the side effects of its blockbuster cholesterol drug Lipitor but did not issue an official warning 
The number of federal court filings against the company has reportedly increased from 56 to 1 000 in the last five months  where plaintiffs claim that the use of Lipitor for lowering cholesterol levels  gave them type 2 diabetes  The recent spike in lawsuits against the company follows an order from a federal judicial panel to bring all the cases filed across the U S  against Pfizer into a single courtroom  Pfizer  which plans to contest the claims  has reportedly declined to follow the order claiming it will trigger copycat lawsuits 
 We will ask a jury to decide what it s worth to take five years of someone s life   H  Blair Hahn  of Mount Pleasant  South Carolina  and the plaintiffs  lead lawyer said  according to Reuters  Hahn also said that the 1 000 cases filed so far represent nearly 4 000 women  and estimated that the number of cases could rise ten fold to 10 000 
Lipitor belongs to a class of drugs called statins  which work in the liver to reduce the production of cholesterol  while diabetes takes away the body s ability to produce insulin  which helps convert food to energy 
In 2012  the U S  Food and Drug Administration  or FDA  reportedly issued a warning that the use of statin drugs like Lipitor could increase the risk of diabetes and memory loss  In January  the FDA warning was updated to provide a detailed list of side effects  including muscle damage and liver injury in extreme cases 

 Clearly we think that the heart benefit of statins outweighs this small increased risk   Amy G  Egan  deputy director for safety in FDA s Division of Metabolism and Endocrinology Products  said in the FDA statement  adding that the patients might have to be tested for their blood sugar levels regularly  after they begin treatment with statins 
A recent report by the World Health Organization stated that heart disease was the leading cause of deaths in 2011 and 2012 while one out of three children have high cholesterol ",2014-08-08,International Business Times,https://www.investing.com/news/stock-market-news/lawsuits-against-pfizer's-lipitor-spike-in-past-5-months-302185,302185
220704,442220,PFE,Sanofi Regeneron s Kevzara Gets FDA Approval For Arthritis,opinion,Sanofi  PA SASY    NYSE SNY   and partner Regeneron Pharmaceuticals  Inc    NASDAQ REGN   announced that the FDA has approved their pipeline candidate sarilumab to be marketed under the trade name of Kevzara Kevzara has been approved for the treatment of moderately to severely active rheumatoid arthritis  RA  in adult patients who have had an inadequate response or intolerance to one or more disease modifying anti rheumatic drugs  DMARDs   such as methotrexate  MTX   We remind investors that Kevzara was approved in Canada in February this year for the same indication while it is under review in the EU So far this year  Sanofi s share price has risen 21 5   better than an 8 6  increase for the Zacks classified industry We remind investors that in Oct 2016  the companies got a Complete Response Letter  CRL  from the FDA for sarilumab  While the CRL did not raise any issues regarding sarilumab s efficacy or safety  the agency cited certain deficiencies observed during a routine good manufacturing practice inspection of the Sanofi Le Trait facility in France where sarilumab is filled and finished  Last month  the FDA accepted the resubmission of the Biologics License Application for Kevzara  following the successful inspection of the Le Trait manufacturing site The U S  approval was supported by data from the global SARIL RA clinical study  conducted in approximately 2 900 adults with moderate to severely active RA who had an inadequate response to previous treatment regimens  Kevzara demonstrated statistically significant  clinically meaningful improvements in combination with conventional DMARDs  including methotrexate in two pivotal phase III studies Sanofi projects that Kevzara and five other new drugs   Toujeo  diabetes   Praluent  Dengvaxia vaccine Soliqua and Dupixent dupilumab   to generate aggregate peak sales of  12 billion    14 billion by 2025  while up to 18 new products are on track to be launched by 2020 Dupixent was also recently approved by the FDA for treating atopic dermatitis in March and is now available to adult patients in the U S  The drug is under review in the EU for the same indication  We are optimistic on the sales prospects of Dupixent  which could prove to be an important growth driver for the company  Soliqua  a once daily titratable fixed ratio combination of Lantus and Lyxumia  was launched in the U S  this year in January and is expected to be launched in Europe later this year The list price of Kevzara is  39 000 year for the 200 mg and 150 mg doses  which is at a discount of approximately 30  to that of the two most widely used competitive drugs in a highly crowded space  Pfizer  Inc  s   NYSE PFE   Xeljanz is already approved for the treatment of moderate to severely active RA in patients who respond inadequately or are intolerant to methotrexate  Other drugs approved for RA include Roche Holding  SIX ROG  AG s   OTC RHHBY   Actemra AbbVie s Humira and Bristol Myers  Orencia Sanofi currently has a Zacks Rank  2  Buy   You can see  Zacks  2017 IPO Watch List Before looking into the stocks mentioned above  you may want to get a head start on potential tech IPOs that are popping up on Zacks  radar  Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential  This Special Report gives you the current scoop on 5 that may go public at any time One has driven from 0 to a  68 billion valuation in 8 years  Four others are a little less obvious but already show jaw dropping growth ,2017-05-22,Zacks Investment Research,https://www.investing.com/analysis/sanofi-regeneron's-kevzara-gets-fda-approval-for-arthritis-200190897,200190897
220705,442221,PFE,3 Hot Biotech Stocks To Buy In June,opinion,"The biotech sector  which started the year on a strong note  has been witnessing a decline especially from March    year to date  YTD   the Zacks categorized  industry is down 1 1  while the overall market is up 8 2   A key concern for the sector remains the drug pricing issue which remains an overhang  Given the intense political and media focus on this issue  investors remain jittery about putting their money in this corner of the market 
With the industry currently ranked among the bottom 40  of the 256 Zacks ranked industries  should one avoid stocks in this segment of the market  Not really    while we admit that the sector is facing challenges like declining sales of legacy products  biosimilar competition  mixed earnings results  high profile pipeline setbacks and slower than expected new product launches  there are some factors that provide upside potential The industry will continue to witness demand for its products given an aging population and the increasing prevalence of a wide variety of diseases  Strong late stage pipelines  innovative treatments  impressive results  and increased health care spending should support growth  According to a report issued by the QuintilesIMS Institute  medicine spending through 2021 is expected to grow in mid single digits  Trump s pro business stand is also expected to benefit the sector  A faster drug approval process and the proposed removal of outdated regulations that drive up costs and slow down innovation should also work in favor of the sector While drug pricing will remain a headline risk until some plan is announced by the administration  here are a few biotech stocks that have performed well YTD and look well positioned First on our list is Tarrytown  NY based Regeneron Pharmaceuticals  Inc    NASDAQ REGN    While eye drug  Eylea  the company s key growth driver continues to perform well  Regeneron has been working on diversifying its portfolio and gained FDA approval for two drugs this year    Dupixent  moderate to severe atopic dermatitis  and Kevzara  moderately to severely active rheumatoid arthritis   Both drugs have blockbuster potential with Dupixent already off to a strong start  The company also has a strong pipeline comprising 16 candidates including for cancer  Regeneron  a Zacks Rank  2  Buy  stock  has outperformed the Zacks categorized Medical Biomedical Genetics industry with shares gaining 25  YTD  Estimated earnings growth for the current year is 27 4  
Next on the list is Richmond  CA based Sangamo Therapeutics  Inc    NASDAQ SGMO    Sangamo got a shot in the arm last month with Pfizer  NYSE PFE  collaborating with the company for the development and commercialization of gene therapy programs for hemophilia A  The agreement covers SB 525  one of Sangamo s four lead pipeline candidates  and will see Sangamo getting an upfront payment of  70 million  Sangamo could also get milestone payments of up to  475 million  including up to  300 million related to SB 525 and up to  175 million for additional hemophilia A gene therapy candidates that may be developed under the collaboration  Tiered double digit royalties on net sales also form a part of the deal  This deal bodes well for the long term prospects of the company  Shares of this Zacks Rank  2 stock are up a whopping 123 9  YTD 
Another Zacks Rank  2 biotech stock that has had a strong run so far this year is Puma Biotechnology  Inc    NASDAQ PBYI    Puma s shares are up 149 4  YTD with the company receiving a huge boost with an FDA advisory panel voting in favor of its experimental breast cancer treatment  neratinib  The FDA s Oncologic Drugs Advisory Committee voted 12   4 in favor of approving neratinib for the extended adjuvant treatment of HER2 positive early stage breast cancer based on a favorable risk benefit profile  Given the favorable vote  chances of gaining approval look pretty high  FDA approval would be a major boost for Puma which currently has no marketed products in its portfolio While all three stocks mentioned above are Zacks Rank  2 stocks  you can see  Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2017-05-31,Zacks Investment Research,https://www.investing.com/analysis/3-hot-biotech-stocks-to-buy-in-june-200192613,200192613
220706,442222,PFE,Universal Display  Hewlett Packard  Regeneron Pharmaceuticals  Sangamo Therapeutics And Puma Biotechnology Highlighted As Zacks Bull And Bear Of The Day,opinion,"For Immediate Release

	Chicago  IL   June 02  2017   highlights Universal Display Corporation  NASDAQ          as the Bull of the Day Hewlett Packard Enterprise  NYSE         as the Bear of the Day  In addition  Zacks Equity Research provides analysis on Regeneron Pharmaceuticals  Inc   NASDAQ           Sangamo Therapeutics  Inc   NASDAQ          and Puma Biotechnology  Inc   NASDAQ          

	Here is a synopsis of all five stocks 

   

	One of the best purchases for my somewhat new place was an OLED TV  If you aren t familiar with the technology  OLED  or Organic Light Emitting Diode     and does not require backlighting 

	This allows displays made with this technology to be thin and flexible  and it gives a huge contrast ratio including blacker blacks and whiter whites  relative to many other types of displays  The TV looks great 

	But from an investment perspective  this technology is sweeping not only across TVs  but various other devices in the tech world such as phones and computer screens  And the company behind much of this technology  Universal Display Corporation  NASDAQ           is looking like an especially intriguing investment these days 

OLED Stock in Focus

	In the company s most recent earnings report  the company easily beat expectations  and actually posted a pretty incredible beat  The stock was expected to see earnings of one cent per share and actually posted 22 cents per share instead  The firm also said there was building    for products using OLED displays  so guidance is looking pretty promising as well 

	Thanks to this strength  analysts have been raising their estimates for OLED stock  pretty much across the board  In fact  we haven t seen any estimate cuts in the past sixty days to the current quarter  current year  or next year consensus  We have actually seen a surging consensus for the full year as analysts clearly believe in the momentum too  The company s consensus has moved higher by about 27  in the past month  while we are seeing a seven percent increase for the following year 

	There is a lot to like about the story in the OLED market these days  and that is further backed up by the impressive industry and sector rank for the stock  Shares have a top 40  rank for both the industry and the sector  while Universal Display Corporation has a Zacks Rank  1  Strong Buy  rating itself 

	Bear 

	One of the big stories so far this year has been the incredible performance of the tech sector at large  Many of the big caps in this space have dominated the market  and have put up double digit percentage gains in the process too 

	But  it hasn t been that way for every name in the space  Take Hewlett Packard Enterprise  NYSE         for example  Sure  the company had a spin off so the chart for this year might look incredibly bad  but the recent earnings report and price performance signal that HPE investors might want to get used to seeing red in their positions 

Recent Earnings Report

	Hewlett Packard Enterprise just released earnings  and the numbers left much to be desired from the company  Revenues plunged 12 5  for the continuing operations part of the business  and was led by a double digit percentage slump in revenues for servers  storage  and a 30  slump for networking  Earnings were also pretty weak  as they easily missed estimates on the bottom line too 

	And worst of all  things don t appear as though they are going to be turning around anytime soon  Guidance was also sluggish  and it isn t like the competitive pressures are going to diminish in the coming quarters either 

	Analysts have already taken note of these trends and we saw several cuts to HPE s consensus estimate heading into the report  And now  with the weak outlook and tough position against peers  it isn t unreasonable to think that this trend will continue in the weeks ahead too  No wonder HPE currently has an  F  growth score  and why we have a Zacks Rank  5  Strong Sell  on the company too 

Other Choices

	Though things aren t looking great for HPE in the near term  there are plenty of other choices out there for investors  Sure  the computer integrated systems industry has a rank in the bottom 25   but the tech sector has a rank in the top 40   So  investors just have to look outside of HPE s industry for some better options in the tech space 

	Additional content 

3 Hot Biotech Stocks to Buy in June

	The biotech sector  which started the year on a strong note  has been witnessing a decline especially from March    year to date  YTD   the Zacks categorized  industry is down 1 1  while the overall market is up 8 2   A key concern for the sector remains the drug pricing issue which remains an overhang  Given the intense political and media focus on this issue  investors remain jittery about putting their money in this corner of the market 
	With the industry currently ranked among the bottom 40  of the 256 Zacks ranked industries  should one avoid stocks in this segment of the market  Not really    while we admit that the sector is facing challenges like declining sales of legacy products  biosimilar competition  mixed earnings results  high profile pipeline setbacks and slower than expected new product launches  there are some factors that provide upside potential 
	The industry will continue to witness demand for its products given an aging population and the increasing prevalence of a wide variety of diseases  Strong late stage pipelines  innovative treatments  impressive results  and increased health care spending should support growth  According to a report issued by the QuintilesIMS Institute  medicine spending through 2021 is expected to grow in mid single digits  Trump s pro business stand is also expected to benefit the sector  A faster drug approval process and the proposed removal of outdated regulations that drive up costs and slow down innovation should also work in favor of the sector 
	While drug pricing will remain a headline risk until some plan is announced by the administration  here are a few biotech stocks that have performed well YTD and look well positioned 
	First on our list is Tarrytown  NY basedRegeneron Pharmaceuticals  Inc   NASDAQ           While eye drug  Eylea  the company s key growth driver continues to perform well  Regeneron has been working on diversifying its portfolio and gained FDA approval for two drugs this year    Dupixent  moderate to severe atopic dermatitis  and Kevzara  moderately to severely active rheumatoid arthritis   Both drugs have blockbuster potential with Dupixent already off to a strong start  The company also has a strong pipeline comprising 16 candidates including for cancer  Regeneron  a Zacks Rank  2  Buy  stock  has outperformed the Zacks categorized Medical Biomedical Genetics industry with shares gaining 25  YTD  Estimated earnings growth for the current year is 27 4  
	Next on the list is Richmond  CA basedSangamo Therapeutics  Inc   NASDAQ          Sangamo got a shot in the arm last month with Pfizer  NYSE PFE  collaborating with the company for the development and commercialization of gene therapy programs for hemophilia A  The agreement covers SB 525  one of Sangamo s four lead pipeline candidates  and will see Sangamo getting an upfront payment of  70 million  Sangamo could also get milestone payments of up to  475 million  including up to  300 million related to SB 525 and up to  175 million for additional hemophilia A gene therapy candidates that may be developed under the collaboration  Tiered double digit royalties on net sales also form a part of the deal  This deal bodes well for the long term prospects of the company  Shares of this Zacks Rank  2 stock are up a whopping 123 9  YTD 
	Another Zacks Rank  2 biotech stock that has had a strong run so far this year is Puma Biotechnology  Inc   NASDAQ          Puma s shares are up 149 4  YTD with the company receiving a huge boost with an FDA advisory panel voting in favor of its experimental breast cancer treatment  neratinib  The FDA s Oncologic Drugs Advisory Committee voted 12   4 in favor of approving neratinib for the extended adjuvant treatment of HER2 positive early stage breast cancer based on a favorable risk benefit profile  Given the favorable vote  chances of gaining approval look pretty high  FDA approval would be a major boost for Puma which currently has no marketed products in its portfolio 
	While all three stocks mentioned above are Zacks Rank  2 stocks  you can see  Will You Make a Fortune on the Shift to Electric Cars 
	Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge 
	With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research 
	It s not the one you think 

About the Bull and Bear of the Day

	Every day  the analysts at Zacks Equity Research select two stocks that are likely to outperform  Bull  or underperform  Bear  the markets over the next 3 6 months 

About Zacks Equity Research

	Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term 

	Continuous analyst coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons 

Strong Stocks that Should Be in the News

	Many are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year  











	Follow us on Twitter  

	Join us on Facebook  NASDAQ FB   

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Media Contact

	Zacks Investment Research

	800 767 3771 ext  9339





	Zacks com provides investment resources and informs you of these resources  which you may choose to use in making your own investment decisions  Zacks is providing information on this resource to you subject to the Zacks  Terms and Conditions of Service  disclaimer   

Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2017-06-01,Zacks Investment Research,"https://www.investing.com/analysis/universal-display,-hewlett-packard,-regeneron-pharmaceuticals,-sangamo-therapeutics-and-puma-biotechnology-highlighted-as-zacks-bull-and-bear-of-the-day-200192888",200192888
220710,442226,PFE,Shire  AbbVie to announce  53 billion merger by Friday  sources,news,"By Olivia Oran and Soyoung Kim  Reuters    Shire Plc and U S  drugmaker Abbvie Inc plan to announce a  53 billion merger as soon as Friday morning  two people said on Thursday 
Dublin based Shire  which sells drugs for rare diseases  said earlier this week it was ready to recommend a deal to shareholders after AbbVie increased its offer 
AbbVie  which is based in Chicago and makes top selling arthritis drug Humira  boosted its bid for Shire to 53 20 pounds per share on Sunday  Shire has rejected four previous bids 
The people cautioned the deal could still take longer to complete and the deadline for an offer could be extended 
Under British takeover rules AbbVie has until July 18 to announce a firm offer for Shire  extend the deadline for an offer  or walk away 
AbbVie is eager to buy Shire both to reduce its U S  tax bill by moving its tax base to Britain   a tactic known as inversion   and to diversify its drug portfolio  AbbVie currently generates nearly 60 percent of its revenue from Humira  the world s top selling medicine  which loses U S  patent protection in late 2016 

AbbVie s move is the second attempt by a U S  drugmaker to buy a London listed rival after Pfizer Inc s  118 billion pursuit of AstraZeneca Plc failed in May over price 
Reuters reported on Saturday that Shire had asked AbbVie to sweeten its offer to near 53 pounds per share so it could recommend the deal  Shire confirmed the news on Monday 
Representatives for Shire and AbbVie declined to comment 
 This version of the story corrects paragraph 7 to show failed bid for AstraZeneca happened in May not June 
 Reporting by Olivia Oran  Editing by Andre Grenon ",2014-07-17,Reuters,"https://www.investing.com/news/stock-market-news/shire,-abbvie-to-announce-$53-billion-merger-by-friday:-sources-295900",295900
220711,442227,PFE,Pfizer s need for deal looms larger with earnings report,news,"By Ransdell Pierson NEW YORK  Reuters    Pfizer Inc s vulnerability to cheaper generics and its weak roster of experimental medicines will be on display Tuesday when the company reports quarterly earnings  reviving interest in its pursuit of AstraZeneca Plc or other deals to fortify its pipeline 
The largest U S  drugmaker  whose laboratories have not come up with any big selling new medicines for a decade  is expected to report significantly lower second quarter revenue 
While many industry watchers expect Pfizer to re engage with Britain s AstraZeneca in coming months  some say the U S  drugmaker should consider targets more focused on biotechnology  a strategy that has paid off for Merck   Co and Bristol Myers Squibb Co 
Although Pfizer is conducting trials of promising products   including breast cancer drug palbociclib and vaccines against meningitis and staph aureus   it needs far more drugs to generate meaningful sales growth  said Ori Hershkovitz  analyst with the Tel Aviv based Sphera Fund  which holds Pfizer shares 
     Pfizer is in a very desperate spot  having seen most of its pipeline disappoint and facing multiple patent expirations   he said   It needs growth  it needs to buy a pipeline  
Pfizer on May 26 officially abandoned its six month quest for AstraZeneca after its final  118 billion offer was spurned  Investors still see a rationale for the deal  which would allow Pfizer to enjoy lower corporate tax rates as a UK based company and a promising pipeline of new cancer treatments 
Under British takeover law  AstraZeneca could reach out to Pfizer in August and Pfizer could make renewed overtures to its smaller rival in November 
 I definitely think Pfizer will come back for Astra at a somewhat higher bid   Hershkovitz said  But he recommended Pfizer consider smaller targets whose treatments might broaden its existing research priorities  such as Belgium s UCB SA and Switzerland s Actelion Ltd 
UCB  which makes treatments for epilepsy  rheumatoid arthritis and Parkinson s disease  has annual sales of  5 billion  and a market value of  17 billion  Actelion sells lucrative drugs for orphan diseases  rare and often life threatening conditions that command high prices  It has annual sales of  2 billion and a market capitalization of  15 billion 
Leerink Swann analyst Jason Gerberry has said it might make sense for Pfizer to buy Dublin based generic drugmaker Actavis  which itself just bought U S  specialty drugmaker Forest Laboratories for  25 billion 
Disappointment with Pfizer is reflected in its stock price  which has fallen 1 4 percent this year  against a 11 percent gain for the ARCA Pharmaceutical Index of large U S  and European drugmakers  Over the past two years  its shares have risen 27 percent  versus a 44 percent jump for the drug sector 
A fresh wave of patent expirations on Pfizer s top drugs is approaching  Its Celebrex painkiller faces generics in the United States late this year  while impotence treatment Viagra goes generic in 2017  The company s biggest product  Lyrica for nerve pain  loses U S  patent protection by 2018  The three drugs have combined annual sales of almost  9 billion  and account for almost 20 percent of Pfizer s total revenue 
    Biotechs with drugs already on the market and which also have exciting technologies should be on Pfizer s wish list  said Navid Malik  analyst with London based Cenkos Securities  He cited companies such as Celgene Inc and Vertex Pharmaceuticals Inc 
Roger Pomerantz  who headed business development at Merck from 2010 until last summer  said the potential of Merck s immuno oncology drugs   medicines which train the immune system to recognize cancer cells   was not recognized even within the company for several years after it acquired them 

 It s who you have on the inside helping you understand the science  that counts  he said 
 Reporting by Ransdell Pierson  Editing by Michele Gershberg and Lisa Shumaker ",2014-07-28,Reuters,https://www.investing.com/news/stock-market-news/pfizer's-need-for-deal-looms-larger-with-earnings-report-298234,298234
220712,442228,PFE,Pfizer rallies 1 4  in pre market after upbeat Q2 earnings,news,"Investing com   U S  pharmaceutical giant Pfizer  NYSE PFE  reported better than expected second quarter earnings ahead of Tuesday s opening bell  sending its shares higher in pre market trade 
Pfizer said adjusted earnings per share came in at 58 cents in the second quarter  above expectations for adjusted earnings of 57 cents per share 
The company s second quarter revenue totaled  12 8 billion  beating forecasts for revenue of  12 5 billion 
Ian Read  Chairman and Chief Executive Officer  stated   I am pleased with our operating performance to date  
 I continue to see Pfizer as well positioned to effectively execute on our strategy to further strengthen each of our businesses on a global basis and deliver value to all of our stakeholders   Mr  Read concluded 
Pfizer said it expected full year adjusted revenue to come in a range between  48 7 billion and  50 7 billion  compared to expectations for full year revenue of  49 4 billion 
Following the release of the report  shares in Pfizer  NYSE PFE  rose 1 4  in pre market trade 
Meanwhile  the outlook for U S  equity markets was higher  The Dow indicated a gain of 0 2  at the open  the S P 500 pointed to an increase of 0 15   while Nasdaq 100 added 0 2  ",2014-07-29,Investing.com,https://www.investing.com/news/stock-market-news/pfizer-rallies-1-in-pre-market-after-upbeat-q2-earnings-298625,298625
220718,442234,PFE,Sangamo s  SGMO  Hemophilia A Drug Gets Fast Track Status ,opinion,"Sangamo Therapeutics  Inc    NASDAQ SGMO   announced that the FDA has granted fast track designation to pipeline candidate  SB 525 

Sangamo s shares declined 145 9  year to date compared with the Zacks classified  industry s gain of 2 1  
SB 525 is Sangamo s clinical stage cDNA gene therapy candidate for hemophilia A 
The fast track designation from the FDA will facilitate the development and expedite the review of drugs and biologics to treat serious conditions and fill an unmet medical need 
We remind investors that SB 525 already enjoys orphan drug status in the U S  The FDA has cleared an Investigational New Drug application for this program  and a phase I II clinical trial evaluating SB 525 in adults with hemophilia A is expected to open and begin screening subjects for enrolment by the end of second quarter 2017  Data from this study are expected in late 2017 or early 2018 
SB 525 is one of Sangamo s four lead product candidates  The candidate is being developed as part of an exclusive  global collaboration and license agreement with Pfizer Inc    NYSE PFE    Earlier in this month  Sangamo announced an exclusive  global collaboration and license agreement with Pfizer for the development and commercialization of gene therapy programs for Hemophilia A 
Hemophilia A is a monogenic  rare bleeding disorder in which the blood does not clot normally  As per the Centers for Disease Control and Prevention  hemophilia occurs in about one of every 5 000 male births  with an estimated 20 000 males in the U S  living with the disorder 
Meanwhile  Sangamo also has a collaboration agreement with Shire International GmbH   NASDAQ SHPG   to develop therapeutics for Huntington s disease 
Zacks Rank   Key Picks 
Sangamo currently carries a Zacks Rank  3  Hold   
A better ranked stock in the health care sector is VIVUS  Inc    NASDAQ VVUS   which sports a Zacks Rank  1  Strong Buy   You can see  
VIVUS s loss per share estimates narrowed from 50 cents to 39 cents for 2017  over the last 30 days  The company posted positive earnings surprises in all of the four trailing quarters with an average beat of 233 69  
Will You Make a Fortune on the Shift to Electric Cars 
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge 
With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research 
It s not the one you think ",2017-05-17,Zacks Investment Research,https://www.investing.com/analysis/sangamo's-(sgmo)-hemophilia-a-drug-gets-fast-track-status-200189783,200189783
220719,442235,PFE,Glycomimetcs Shares Shoot Up On Announcement Of FDA Breakthrough,opinion,"Glycomimetc  NASDAQ GLYC 
GlycoMimetics  Inc   GLYC   a national clinical stage biotechnology company yesterday announced that they received FDA Breakthrough Therapy Designations for treatment of adult relapsed refractory acute myeloid leukemia  AML  of the company s drug candidate GMI 1271 
During a Phase 2 study the drug GMI 1271 achieved better than expected mortality rates in patients with relapsed refractory AML as well as newly diagnosed patients 
GlycoMimetics  Inc  CMO s Comments

 The FDA s granting to GMI 1271 of Breakthrough Therapy designation will further help GlycoMimetics to accelerate the development of GMI 1271 as a treatment for this very difficult to treat patient population   said   MD  Chief Medical Officer of GlycoMimetics   We believe GMI 1271 when combined with chemotherapy has the potential to address an unmet therapeutic need for individuals living with AML  We are encouraged by our clinical results to date  and look forward to working closely with the FDA to bring this novel therapy to patients as quickly as possible   

GLYC Technical Analysis

GlycoMimetics Chart
GLYC opened trading yesterday at  5 38 which was up from the previous day s trading close of  5 37  GLYC closed trading yesterday at  5 37 and spiked up after market to  7 52  equivalent to a 40  increase from the closing price  Taking a look at the daily chart we can see the last time GLYC traded above these levels we have to go back to September 20th  2016 when it traded at highs of  7 58 
Taking a closer look at the daily chart we can see that before the spike up GLYC had already been in an overall downward trend dating back to August 1st  2016 when it traded at  8 84  GLYC has a float of 12 22 million shares and traded 1 77 times the normal daily trading volume on Wednesday 
For trading purposes  I would like to see GLYC open trading on Thursday above  6 80 and if it does I would be looking to take a long position at the bell  My stop loss would be  0 20 from my entry position fearing anything more than that and the stock would start to fill in the gap up 
Company Profile
GlycoMimetics  Inc   a clinical stage biotechnology company  focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the United States 
The company is developing its lead product candidates include rivipansel  a pan selectin antagonist  which is in Phase III clinical trials for the treatment of vaso occlusive crisis  a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease  and GMI 1271  an E selectin antagonist to treat acute myeloid leukemia and other hematologic cancers  It is also developing GMI 1359  a drug candidate targeting E selectin and CXCR4  and galectin 3 and galectin 9 inhibitors 
The company has a collaborative research and development agreement with Pfizer Inc   NYSE PFE  GlycoMimetics  Inc  was founded in 2003 and is headquartered in Rockville  Maryland ",2017-05-18,Warrior Trading,"https://www.investing.com/analysis/glycomimetics,-inc.-|-$glyc-stock-|-shares-shoot-up-nn-announcement-of-f-200189945",200189945
220720,442236,PFE,Shire  SHPG  Up On Positive Phase III Study Data On HAE Drug ,opinion,"Shire plc   NASDAQ SHPG   announced positive top line results from the phase III study  HELP  on pipeline candidate  lanadelumab 

Shire s shares have rallied 10 6  so far this year  outperforming the Zacks classified  industry s 7 0  rise 
The global  multi center  randomized  double blind  placebo controlled parallel group trial evaluated the efficacy and safety of subcutaneously administered lanadelumab versus placebo over 26 weeks in patients 12 years of age or older with Hereditary Angioedema  HAE  
The study met its primary endpoint and all secondary endpoints with highly statistically significant and clinically meaningful results for all three lanadelumab treatment arms compared to placebo 
The study results showed that 300 mg dose administered once every two weeks resulted in a statistically significant reduction in mean HAE attack frequency of 87  compared to placebo  p  0 001  
Consequently  Shire plans to submit a biologics license application  BLA  to the FDA by late 2017 or early 2018  We note that lanadelumab enjoys both Orphan Drug Designation and Breakthrough Therapy Designation in the U S  and Orphan Drug Designation in the EU  Following the news  shares moved up 7 8  in session 
The successful development and commercialization of lanadelumab will boost Shire s HAE portfolio which currently boasts Cinrzye and Firazyr   Shire had earlier acquired the biotech company  Dyax Corp   to strengthen its position in the HAE market further  The acquisition added an approved HAE treatment  Kalbitor  to Shire s portfolio 
Concurrently  Shire announced that results from a phase II study  NCT01620255  investigating an anti mucosal addressin cell adhesion molecule 1  MAdCAM 1  antibody SHP647  formerly PF 00547659  for the treatment of moderate to severe ulcerative colitis in adults were published in The Lancet 
The results from the phase II study showed that candidate met its primary endpoint demonstrating significantly greater remission rates in patients receiving anti MAdCAM antibody compared to placebo in three of four tested dose groups 
Shire plans to initiate a phase III trial on SHP647 in the second half of 2017  We note thet Shire had licensed the global rights to all indications for SHP647 from Pfizer Inc    NYSE PFE   in Jun 2016 to strengthen its GI portfolio  Shire s efforts to develop its GI franchise are encouraging  The Feb 2015 NPS Pharma acquisition  worth  5 2 billion  added Gattex Revestive  short bowel syndrome  and Natpara Natpar  an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism  to Shire s portfolio 
Zacks Rank   Key Picks
Shire currently carries a Zacks Rank  3  Hold  
Some better ranked stocks in the health care sector include VIVUS  Inc    NASDAQ VVUS    and Aeglea BioTherapeutics   NASDAQ AGLE    While VIVUS sports a Zacks Rank  1  Strong Buy   Aeglea carries a Zacks Rank  2  Buy   You can see  
VIVUS s loss per share estimates narrowed from 50 cents to 39 cents for 2017  over the last 30 days  The company posted positive earnings surprises in all of the four trailing quarters with an average beat of 233 69  
Aeglea s loss per share estimates narrowed from  3 64 to  2 48 for 2017  over the last 60 days  The company posted positive earnings surprises in three of the four trailing quarters with an average beat of 20 75  
Zacks  Hidden Trades
While we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them 
Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ",2017-05-19,Zacks Investment Research,https://www.investing.com/analysis/shire-(shpg)-up-on-positive-phase-iii-study-data-on-hae-drug-200190329,200190329
220721,442237,PFE,This Big Pharma Stock Is Nearing A Buy Level,opinion,"Traders and investors should note that Pfizer  NYSE PFE  has been steadily declining since late February 2017  Back then  PFE was trading above  34 a share   today it s around  32  The pharmaceutical giant is now trading below the important 200  and 50 day moving averages  which puts it in a weak technical position on the daily chart 
Buy Levels
Pfizer will have major chart support around  30  which is where the stock was defended in April and November 2016  Quite often  past breakout levels serve as major chart support when retested  The  30 level should be an area where PFE can be bought  Traders should look for a move back up to the  34 area  If you buy the stock  place a stop loss below  27 50  using a weekly chart close ",2017-05-22,Nicholas Santiago,https://www.investing.com/analysis/this-big-pharma-stock-is-nearing-a-buy-level-200190650,200190650
220723,442239,PFE,Asian shares edge higher on Wall Street lead  Hang Seng up 0 83 ,news,"Investing com   Asian shares followed Wall Street s lead from overnight  gaining on Wednesday after the S P 500 closed at its second straight record 
The gains in Asia however were modest with the Hang Seng index up 0 83   the Shanghai Composite gaining 0 16  and the Nikkei 225 edging 0 04  in morning trade 
Ahead  China s official manufacturing purchasing managers  index due at the weekend will be crucial for regional bourses 
Australia s S P ASX 200 was up 0 2  as Sydney hit a four week high and South Korea s KOSPI added 0 4  
In corporate news  Mitsui Fudosan Co   Ltd   TOKYO 8801  sank 6 4  in Japan after the real estate firm announced that it would raise up to  325 billion via a share offering  the company s first in three decades 
Overnight  U S  stocks rose on upbeat economic indicators and on mergers and acquisitions news 
The Dow 30 rose 0 42   the S P 500 index rose 0 60   while the NASDAQ Composite Composite index rose 1 22  
The Conference Board reported earlier that its consumer confidence index rose to 83 0 this month from 81 7 in April  in line with market expectations 
Elsewhere  the Standard   Poor s  Case Shiller house price index rose 12 4  in March from a year earlier  beating forecasts for a gain of 11 8  and following a rise of 12 9  in February 
Healthy wholesale pricing data firmed the greenback as well 
The Commerce Department reported earlier U S  durable goods orders rose 0 8  in April  confounding expectations for a 0 5  fall  after a 3 6  increase in March  whose figure was revised up from a previously estimated 2 9  rise 
Mergers and acquisitions news moved stock prices as well 
Pfizer Inc  NYSE PFE  shares rose after the pharmaceutical giant abandoned its  116 billion bid to acquire Astrazeneca Plc 
Separately  poultry producer Pilgrims Pride Corp  NASDAQ PPC  offered to buy Hillshire Brands Company  NYSE HSH  in a  5 6 million deal ",2014-05-28,Investing.com,"https://www.investing.com/news/stock-market-news/asian-shares-edge-higher-on-wall-street-lead,-hang-seng-up-0.83-286511",286511
220724,442240,PFE,FDA Approval Of MannKind s Inhaled Insulin A Breath Of Fresh Air,news,"By    Almost seven years since inhaled insulin appeared to have been an idea whose time had come    and gone    the MannKind Corporation s  NASDAQ MNKD  success in securing U S  Food and Drug Administration marketing approval for its Afrezza Inhalation Powder has breathed new life into this class of treatments for adults with diabetes mellitus 
The first inhaled insulin offering to win FDA marketing approval did not have a happy history  Pfizer Inc s  NYSE PFE  Exubera was available in the U S  between September 2006 and October 2007  but the major drug manufacturer pulled the plug when it failed in the marketplace  where competing products historically have been administered by injection 
Alfred E  Mann  MannKind s founder  chairman and CEO  seems unlikely to follow in Pfizer s footsteps should Afrezza s sales falter in its first year or so on the market  Announcing its FDA approval on Friday  Mann said in a statement   We are excited for patients  as we believe that Afrezza s distinct profile and noninjectable administration will address many of their unmet needs for mealtime insulin therapy  and has the potential to change the way that diabetes is treated  
Afrezza is a rapid acting inhaled insulin that is administered either at the beginning of each meal or within 20 minutes of starting it 
About 29 1 million Americans  or 9 3 percent of the U S  population  are believed to have diabetes  according to the  National Diabetes Statistics Report  2014  prepared by the Centers for Disease Control and Prevention  Accordingly  Afrezza s addressable market is massive 
Equity investors and trader appeared to be focusing on the size of this addressable market after the close of trading on Friday  when MNKD s share price advanced in the postmarket session to  11 00 from  10 00  a gain of  1 00  or 10 percent  following the FDA announcement of Afrezza s approval 

Animal spirits in the stock market may have been restrained    a little or a lot    by the FDA s noting that Afrezza has a Boxed Warning advising that acute bronchospasm has been observed in patients with asthma and chronic obstructive pulmonary disease  COPD   As a result  the agency pointed out Afrezza should not be used in patients with chronic lung disease  such as asthma or COPD 
Based in Valencia  Calif   MannKind is also being required to conduct four postmarketing studies for Afrezza  According to the FDA  the drug s efficacy and safety were evaluated in a total of 3 017 clinical trial participants    1 026 with type 1 diabetes and 1 991 with type 2 diabetes ",2014-06-29,International Business Times,https://www.investing.com/news/stock-market-news/fda-approval-of-mannkind's-inhaled-insulin-a-breath-of-fresh-air-291983,291983
220726,442242,PFE,European stocks mixed to lower  eyes on Draghi  Dax down 0 05 ,news,"Investing com   European stocks were mixed to lower on Tuesday  as the U K  FTSE re opened after a public holiday  while investors eyed further comments by European Central Bank President Mario Draghi later in the day 
During European morning trade  the DJ Euro Stoxx 50 slipped 0 21   France s CAC 40 fell 0 31   while Germany s DAX dipped 0 06  
On Monday  ECB President Draghi said the bank saw a risk of a deflationary cycle taking hold in the euro zone 
Draghi said the ECB is ready to act should it see signs of a negative inflation spiral taking hold  and indicated that the bank is weighing a wide range of policy options  including interest rate cuts  and liquidity injections or broad based asset purchases to help shore up the fragile recovery in the euro area 
The comments were made at the new ECB annual conference in Sintra  Portugal 
Financial stocks were mixed  as French lenders BNP Paribas  PARIS BNPP  slid 0 34  and Societe Generale  PARIS SOGN  gained 0 80   while Germany s Deutsche Bank  XETRA DBKGn  edged up 0 08  
Among peripheral lenders  Italy s Unicredit  MILAN CRDI  and Intesa Sanpaolo  MILAN ISP  added 0 04  and 0 12  respectively  while Spain s Banco Santander  MADRID SAN  and BBVA  MADRID BBVA  slipped 0 09  and 0 35  
Elsewhere  Accor  PARIS ACCP  rallied 2 16  after agreeing to buy hotels in Germany and the Netherlands for about  900 million  The hotel operator added that is in exclusive talks to buy another 11 hotels in Switzerland 
In London  FTSE 100 rose 0 26   supported by gains in the financial sector 
Shares in the Royal Bank of Scotland  LONDON RBS  added 0 30  and Barclays  LONDON BARC  climbed 0 55   while Lloyds Banking  LONDON LLOY  and HSBC Holdings  LONDON HSBA  advanced 0 95  and 1 08  respectively 
Lloyds Banking earlier said that it will sell a 25  stake in its TSB consumer bank in an initial public offering next month  The decision came as the European Commission ruled in 2009 that the lender should have to sell part of its business in response to its U K  government bailout 
Meanwhile  mining stocks were mixed  as Vedanta Resources  LONDON VED  and Glencore Xstrata  LONDON GLEN  gained 0 56  and 0 60  while Bhp Billiton  LONDON BLT  and Rio Tinto  LONDON RIO  slid 0 38  and 0 48  
On the downside  Astrazeneca  LONDON AZN  plummeted 2 35  after Pfizer  NYSE PFE  ended its six month effort to buy the U K  drugmaker after offering  69 4 billion  saying the rejected public bid represented  full value  
In the U S   equity markets pointed to a higher open  The Dow 30 futures pointed to a 0 26  rise  S P 500 futures signaled a 0 31  gain  while the Nasdaq 100 futures indicated a 0 35  increase 
Later in the day  the U S  was to produce data on durable goods orders  house price inflation and consumer confidence ",2014-05-27,Investing.com,"https://www.investing.com/news/stock-market-news/european-stocks-mixed-to-lower,-eyes-on-draghi;-dax-down-0.05-286248",286248
220727,442243,PFE,European stocks turn broadly higher  Dax gains 0 35 ,news,"Investing com   European stocks turned broadly higher on Tuesday  as the U K  FTSE re opened after a public holiday  while investors eyed further comments by European Central Bank President Mario Draghi later in the day 
During European afternoon trade  the DJ Euro Stoxx 50 added 0 18   France s CAC 40 inched up 0 05   while Germany s DAX gained 0 35  
On Monday  ECB President Draghi said the bank saw a risk of a deflationary cycle taking hold in the euro zone 
Draghi said the ECB is ready to act should it see signs of a negative inflation spiral taking hold  and indicated that the bank is weighing a wide range of policy options  including interest rate cuts  and liquidity injections or broad based asset purchases to help shore up the fragile recovery in the euro area 
The comments were made at the new ECB annual conference in Sintra  Portugal 
Financial stocks turned broadly higher  as French lenders BNP Paribas  PARIS BNPP  and Societe Generale  PARIS SOGN  gained 0 23  and 0 95   while Germany s Deutsche Bank  XETRA DBKGn  jumped 1 05  
Among peripheral lenders  Italy s Unicredit  MILAN CRDI  and Intesa Sanpaolo  MILAN ISP  advanced 0 99  and 1 08  respectively  while Spain s BBVA  MADRID BBVA  and Banco Santander  MADRID SAN  rose 0 20  and 0 42  
Elsewhere  Accor  PARIS ACCP  rallied 2  after agreeing to buy hotels in Germany and the Netherlands for about  900 million  The hotel operator added that is in exclusive talks to buy another 11 hotels in Switzerland 
In London  FTSE 100 rose 0 46   still supported by gains in the financial sector 
Shares in Barclays  LONDON BARC  climbed 0 50  and the Royal Bank of Scotland  LONDON RBS  advanced 0 70   while HSBC Holdings  LONDON HSBA  and Lloyds Banking  LONDON LLOY  rallied 1 25  and 1 36  respectively 
Lloyds Banking earlier said that it will sell a 25  stake in its TSB consumer bank in an initial public offering next month  The decision came as the European Commission ruled in 2009 that the lender should have to sell part of its business in response to its U K  government bailout 
Meanwhile mining stocks remained mixed  as Vedanta Resources  LONDON VED  and Glencore Xstrata  LONDON GLEN  added 0 09  and 0 27  while Rio Tinto  LONDON RIO  and Fresnillo  LONDON FRES  declined 0 60  and 0 70  
Astrazeneca  LONDON AZN  continued to lead losses on the index  plummeting 2 09   after Pfizer  NYSE PFE  ended its six month effort to buy the U K  drugmaker after offering  69 4 billion  saying the rejected public bid represented  full value  
In the U S   equity markets pointed to a higher open  The Dow 30 futures pointed to a 0 39  rise  S P 500 futures signaled a 0 40  gain  while the Nasdaq 100 futures indicated a 0 49  increase 
Later in the day  the U S  was to produce data on durable goods orders  house price inflation and consumer confidence ",2014-05-27,Investing.com,https://www.investing.com/news/stock-market-news/european-stocks-turn-broadly-higher;-dax-gains-0.35-286276,286276
220738,442254,PFE,AstraZeneca Leaves Door Ajar To Pfizer  Despite Hurdles,news,"By    Astrazeneca s  LONDON AZN  boss said on Wednesday he would engage with Pfizer Inc  NYSE PFE  if the price was right and the risks posed from forcing the British drugmaker s operations into the U S  company s new three unit model were addressed 
Chief Executive Pascal Soriot stressed his company had a bright future as a stand alone firm but acknowledged that shareholders would expect AstraZeneca s board to negotiate if terms were sufficiently attractive in a sweetened offer 
 Every shareholder says at the right level with the right offer you should consider it    that is very clear  But there is nobody who has told us a specific price at which we should engage   he told Reuters in an interview 
 If the offer was reflecting the value of the company but also addressing some of the integration aspects  the operating model and execution risks we are concerned about  then we certainly should engage   there s no doubt  
Soriot and his team have held talks with the group s leading investors during a round of meetings in London  Sweden and the United States over the past week 
Pfizer made a cash and stock takeover approach on May 2 worth 50 pounds a share to create the world s largest drugs company  valuing AstraZeneca at  106 billion  The bid was promptly dismissed by the British group s board   a decision that Soriot said had the firm backing of investors 
 There is no single shareholder who has told me or our CFO  chief financial officer  or our chairman that we should have accepted the offer   he said 
Buoyed by progress with its new drug pipeline   including a lung cancer medicine called AZD9291 for which data was released late on Wednesday   Soriot believes AstraZeneca can enjoy a strong independent future  but he has left the door ajar to a compelling offer 
In addition to price and the share of cash in any increased offer  Soriot said AstraZeneca would also need assurances about the risks faced by Pfizer in implementing a complex merger and integrating operations across two sprawling organizations 
In particular  he highlighted the problems posed by the fact
that Pfizer is now separating its operations into three business units   a structure that would clash with AstraZeneca  where the MedImmune biotech unit  for example  serves all parts the group 
Pfizer provided detailed financial results for its three business units for the first time last week  when it reported first quarter results  as a prelude to possibly divesting one or more of them in 2017 
Soriot is also worried about diluting the focus on science in the new group and the risk to reputation in Pfizer s controversial plan to re domicile in Britain in order to minimize its tax payments 
 All those issues will need to be discussed  but step one is to get to an offer that reflects the value of the company   Soriot said 
He was speaking after being questioned for two days by British politicians who are concerned about the impact of a Pfizer takeover on British science jobs 
CANCER DRUG HOPES
Soriot stressed there was  no inevitability  to a deal with Pfizer  since AstraZeneca s improving pipeline of new drugs was transforming its prospects  following a lean period in its research labs and a wave of patent expiries 
AstraZeneca predicted last week that its sales would increase by 75 percent to more than  45 billion a year by 2023 
Much of the hope for the pipeline hinges on the company s suite of experimental cancer drugs  further details of which are due at the annual American Society of Clinical Oncology  ASCO  conference on May 30 June 3 
One of those drugs  lung cancer treatment AZD9291  has produced promising results in an early stage clinical trial  details of which were released ahead of the ASCO meeting  The drug  which shrank tumors in more than half of patients  is a potential replacement for established lung cancer pills Tarceva and Iressa 
Soriot also highlighted the potential of MEDI4736  a medicine designed to boost the immune system  and a promising combination of two other cancer drugs  olaparib and cediranib 
 We think we can succeed because we have innovative products  not because we have a large commercial offering   Soriot said 
 At ASCO  we will show Phase I  clinical trial  results but also share some information about our development plans  which will show people where we think we can be first and where we think we can potentially come up with treatment algorithms that will totally change the way some types of cancer are treated  ",2014-05-14,International Business Times,"https://www.investing.com/news/stock-market-news/astrazeneca-leaves-door-ajar-to-pfizer,-despite-hurdles-284359",284359
220739,442255,PFE,Pfizer Raises Bid For AstraZeneca To  117B,news,"By    LONDON   U S  drugmaker Pfizer  NYSE PFE  said on Sunday it had raised its offer for British rival Astrazeneca  LONDON AZN  to 69 3 billion pounds   116 6 billion   or 55 pounds a share  and would walk away if AstraZeneca did not accept it               
Pfizer wants to create the world s largest drugs company  with a headquarters in New York but a tax base in Britain  where corporate tax rates are lower than in the United States  It has met entrenched opposition from AstraZeneca  as well as many politicians and scientists who fear cuts to jobs and research               
The U S  group said its new offer was final and could not be increased  It said it would not make a hostile offer directly to AstraZeneca shareholders and would only proceed with an offer with the recommendation of the AstraZeneca board               
Pfizer also increased the cash element in its offer to 45 percent  with AstraZeneca shareholders set to receive 1 747 shares in the enlarged company for each of their AstraZeneca shares and 24 76 pounds in cash 
The new offer represents a 15 percent premium over the current value of a cash and share approach made on May 2   worth 50 pounds a share at the time   which was swiftly rejected by AstraZeneca 
Nonetheless  two analysts   Raghuram Selvaraju of Aegis Capital and ISI Group s Mark Schoenebaum   said they believed the sweetened offer would boost Pfizer s earnings quickly  with Schoenebaum predicting an uplift from 2015               
Pfizer also revealed it had written to AstraZeneca s chairman on May 16 offering 53 50 pounds a share   40 percent in cash   but had been told that this still substantially undervalued the company  prompting it to make the latest last ditch offer               
 We believe our proposal is compelling for AstraZeneca s shareholders and that a Pfizer AstraZeneca combination is in the best interests of all stakeholders   Pfizer Chief Executive Ian Read said in a statement 
He expressed frustration at AstraZeneca s refusal to engage in talks and urged the British company s shareholders to pressure its board to start discussions               
 Following a conversation with AstraZeneca earlier today  we do not believe that the AstraZeneca board is currently prepared to recommend a deal at a reasonable price   Read said   We remain ready to engage in a meaningful dialogue but time for constructive engagement is running out                
Two banking sources earlier described 55 pounds a share as the  magic number  at which a deal could get done and Selvaraju of Aegis said Pfizer s declaration that its offer was  final  would concentrate minds at AstraZeneca 
 The main thing that will be likely to get AstraZeneca to engage is that Ian Read  who is a tough guy  has basically said this is our final offer   he said 
In the absence of further discussions or an extension of the deadline for making a firm offer under British takeover rules  Pfizer s proposal will expire at 5 p m  London time on May 26               
An AstraZeneca spokeswoman said she had no immediate comment on Pfizer s latest proposal  which would see Pfizer shareholders owning 74 percent of the combined company  with AstraZeneca shareholders holding 26 percent 
The increased offer had been widely expected  Pfizer said last week it would consider a higher offer as it urged AstraZeneca s board to enter talks               
DRUG PIPELINE HOPES              
The British firm has laid out details of its pipeline of new drugs and argues there is no inevitability about a Pfizer deal  although its management also acknowledges the board would have to consider a compelling bid  Investors have backed AstraZeneca in rejecting 50 pounds a share  but many have said they would want it to engage in discussions if Pfizer came back with an improved offer  They fear AstraZeneca shares will tumble if Pfizer walks away               
There has been a mounting political backlash against the proposed deal in Britain  the United States and Sweden  where AstraZeneca has half its roots 
The Swedish government launched a concerted effort on Friday against a merger it fears will lead to cuts in science jobs and research  echoing concerns aired by British lawmakers at two parliamentary hearings last week and fears for U S  jobs in states where AstraZeneca has a large presence               
Pfizer s bid would be the largest foreign takeover of a British firm and is opposed by many scientists and politicians who fear it will undermine Britain s science base               
British Prime Minister David Cameron has said he wants more assurances from Pfizer  and science minister David Willetts said last week he would like to see longer guarantees on investment than the five years currently promised by Pfizer               
The UK government has held exploratory discussions with Brussels about strengthening its ability to force Pfizer to honor commitments on jobs and research under European Union rules               
But Cameron  head of the free market Conservative Party  has also said Britain does not want to be seen to be pulling up the drawbridge to foreign companies 
Although Pfizer has given a five year commitment to complete AstraZeneca s new research centre in Cambridge  retain a factory in northern England and put a fifth of its research staff in Britain  it has said this could be adjusted if circumstances change  significantly                
Pfizer s Read said on Sunday   We stand by our unprecedented commitments to the UK government                
The tax aspects of the deal  meanwhile  have sparked anger in the United States  where lawmakers are now considering legislation to prevent so called corporate inversions  under which U S  companies re incorporate overseas to avoid U S  taxes               
Inversions have helped fuel a wave of deals in the pharmaceuticals sector in recent months  but buying AstraZeneca would allow Pfizer to carry out the largest such deal yet ",2014-05-18,International Business Times,https://www.investing.com/news/stock-market-news/pfizer-raises-bid-for-astrazeneca-to-$117b-284920,284920
220740,442256,PFE,AstraZeneca rejects Pfizer s final offer,news,"Investing com   U K  drugs company Astrazeneca  LONDON AZN  said Monday that it had rejected a final offer from U S  drugmaker Pfizer  NYSE PFE   saying the increased offer failed to recognize its full value 
On Sunday Pfizer had made a new offer of  55 per share  valuing AstraZeneca at approximately  70 billion  and said the new offer was final 
AstraZeneca chairman Leif Johansson said the final proposal was inadequate and  undervalues the company and its attractive prospects  
 We have rejected Pfizer s Final Proposal because it is inadequate and would present significant risks for shareholders  while also having serious consequences for the Company  our employees and the life sciences sector in the U K   Sweden and the U S    he said 
Mr  Johansson said Pfizer s motivation for a merger had been  fundamentally driven  by corporate financial benefits 
Pfizer planned to create the world s largest pharmaceuticals company  with its headquarters in New York  but based in the U K  for tax purposes 
That plan met with opposition from unions  politicians and scientists  amid fears over cuts to employment and research ",2014-05-19,Investing.com,https://www.investing.com/news/stock-market-news/astrazeneca-rejects-pfizers-final-offer-284935,284935
220741,442257,PFE,European stocks edge lower in cautious trade  Dax down 0 20 ,news,"Investing com   European stocks edged lower on Monday  as investors remained cautious amid sustained expectations for further easing measures by the European Central Bank 
During European morning trade  the DJ Euro Stoxx 50 slipped 0 22   France s CAC 40 eased 0 08  higher  while Germany s DAX fell 0 20  
European equities strengthened last week amid mounting expectations that the ECB will ease monetary policy at its upcoming June meeting to safeguard the recovery in the euro zone and stop inflation from falling too low 
Recent comments by ECB officials have indicated that the bank is open to easing and is prepared to act swiftly if necessary 
Financial stocks were broadly lower  as French lenders BNP Paribas  PARIS BNPP  and Societe Generale  PARIS SOGN  declined 0 29  and 0 80   while Germany s Deutsche Bank  XETRA DBKGn  slid 0 46  
Germany s biggest lender came under pressure after selling about 60 million shares to the Qatari royal family as it announced plans to raise  8 billion in its second biggest capital increase 
Among peripheral lenders  Italy s Unicredit  MILAN CRDI  and Intesa Sanpaolo  MILAN ISP  plummeted 2 14  and 2 25  respectively  while Spain s Banco Santander  MADRID SAN  and BBVA  MADRID BBVA  retreated 0 32  and 0 49  
Sporting goods giant Adidas  XETRA ADSGN  was also on the downside  with shares dropping 0 54   after Chief Executive Officer Herbert Hainer said in an interview that the company will probably need more time to meet its 2015 sales and margin targets because of the strong euro 
In London  FTSE 100 declined 0 48   led by Astrazeneca  LONDON AZN   down 13 63  after rejecting a sweetened  69 4 billion takeover offer from Pfizer  NYSE PFE   considered as too low 
Financial stocks were also mostly lower  as Lloyds Banking  LONDON LLOY  slipped 0 25  and HSBC Holdings  LONDON HSBA  retreated 0 55   while Barclays  LONDON BARC  tumbled 1 40   The Royal Bank of Scotland  LONDON RBS  hold steady  with shares easing up 0 06  
On the upside  Ryanair  LONDON RYA  surged 5 28  after the discount airline company said that sales rose 3  to  85 04 billion in the year ending March 31 
Adding to gains  services and maintenance company Mitie Group  LONDON MTO  climbed 0 64  after saying full year sales rose to  2 22 billion pounds  beating expectations for  2 12 billion 
In the U S   equity markets pointed to a lower open  The Dow 30 futures pointed to a 0 18  fall  S P 500 futures signaled a 0 18  decline  while the Nasdaq 100 futures indicated a 0 17  loss ",2014-05-19,Investing.com,https://www.investing.com/news/stock-market-news/european-stocks-edge-lower-in-cautious-trade;-dax-down-0.20-284940,284940
220742,442258,PFE,Forex   Pound little changed vs  dollar in sluggish trade,news,"Investing com   The pound was almost unchanged against the dollar in sluggish trade on Monday as investors awaited Federal Reserve minutes later in the week  while signs that a major U K  merger deal will fail looked likely to weigh on sterling 
GBP USD was trading at 1 6820  up fractionally from 1 6812 late Friday 
Cable was likely to find support at 1 6750 and resistance at 1 6873  the high of May 14 
Sterling s strong performance this year has been boosted by talk of a merger between U K  drug company Astrazeneca  LONDON AZN  and one of the world s largest pharmaceutical companies  Pfizer Inc  NYSE PFE  
The merger looked likely to fail after AstraZeneca said Monday that it had rejected a final offer from Pfizer  saying the increased bid failed to recognize its full value 
Demand for the pound continued to be underpinned by expectations that the Bank of England will raise interest rates ahead of other central banks as the recovery in the U K  continues to deepen 
Investors remained cautious as they looked to the minutes from the Fed s latest monetary policy meeting  due for release on Wednesday  for insight on the central bank s view of the economy 
Data on Friday showed that U S  housing starts recorded the largest increase in five months in April  indicating that the economy is shaking off the effect of a weather related slowdown over the winter 
However  the upbeat housing data was overshadowed by a report showing that consumer confidence in the U S  deteriorated this month 
Elsewhere Monday  the euro edged higher against the pound  EUR GBP eased 0 11  to 0 8155  but was still close to last week s 16 month trough of 0 8125 
The euro s gains looked likely to remain limited amid growing expectations for fresh monetary easing by the European Central Bank at its next meeting in June  to safeguard the recovery in the euro zone and stop inflation from falling too low 
Recent comments by ECB officials have indicated that the bank is open to easing and is prepared to act swiftly if necessary 
Data late last week showing that the euro zone economy grew at a slower than expected rate in the first three months of the year added to pressure on the bank to act ",2014-05-19,Investing.com,https://www.investing.com/news/forex-news/forex---pound-little-changed-vs.-dollar-in-sluggish-trade-284958,284958
220743,442259,PFE,European stocks push lower in cautious trade  Dax down 0 35 ,news,"Investing com   European stocks pushed lower on Monday  as investors remained cautious amid sustained expectations for further easing measures by the European Central Bank and amid growinc concerns over the outlook for growth in China 
During European afternoon trade  the DJ Euro Stoxx 50 declined 0 44   France s CAC 40 edged 0 12  lower  while Germany s DAX slid 0 35  
Market sentiment was hit after China s financial regulators tightened rules on bank lending on Friday  sparking fears that limited credit could act as a drag on growth 
Meanwhile  data on Sunday showing that property prices in Beijing fell at the fastest rate in two years in April added to signs of a slowdown in the world s second largest economy 
European equities had strengthened last week amid mounting expectations that the ECB will ease monetary policy at its upcoming June meeting to safeguard the recovery in the euro zone and stop inflation from falling too low 
Financial stocks extended losses  as French lenders BNP Paribas  PARIS BNPP  and Societe Generale  PARIS SOGN  plummeted 1 51  and 2 95   while Germany s Deutsche Bank  XETRA DBKGn  tumbled 1 30  
Germany s biggest lender came under pressure after selling about 60 million shares to the Qatari royal family as it announced plans to raise  8 billion in its second biggest capital increase 
Among peripheral lenders  Italy s Intesa Sanpaolo  MILAN ISP  and Unicredit  MILAN CRDI  plunged 3 92  and 4 33  respectively  while Spain s Banco Santander  MADRID SAN  and BBVA  MADRID BBVA  lost 1 88  and 2 06  
Sporting goods giant Adidas  XETRA ADSGN  was also on the downside  with shares dropping 0 63   after Chief Executive Officer Herbert Hainer said in an interview that the company will probably need more time to meet its 2015 sales and margin targets because of the strong euro 
In London  FTSE 100 declined 0 32   led by Astrazeneca  LONDON AZN   down 12 14  after rejecting a sweetened  69 4 billion takeover offer from Pfizer  NYSE PFE   considered as too low 
Financial stocks also remained broadly lower  as HSBC Holdings  LONDON HSBA  retreated 0 40  and Lloyds Banking  LONDON LLOY  tumbled 1 44   while Barclays  LONDON BARC  and the Royal Bank of Scotland  LONDON RBS  plummeted 1 93  and 1 52  respectively 
On the upside  Ryanair  LONDON RYA  surged 6 30  after the discount airline company said that sales rose 3  to  85 04 billion in the year ending March 31 
Adding to gains  services and maintenance company Mitie Group  LONDON MTO  edged up 0 16  after saying full year sales rose to  2 22 billion pounds  beating expectations for  2 12 billion 
In the U S   equity markets pointed to a lower open  The Dow 30 futures pointed to a 0 40  decline  S P 500 futures signaled a 0 38  drop  while the Nasdaq 100 futures indicated a 0 37  loss ",2014-05-19,Investing.com,https://www.investing.com/news/stock-market-news/european-stocks-push-lower-in-cautious-trade;-dax-down-0.35-284973,284973
220748,442264,PFE,Why Is Pfizer  PFE  Up 8 7  Since The Last Earnings Report ,opinion,"It has been about a month since the last earnings report for Pfizer  Inc    NYSE PFE    Shares have added about 8 7  in that time frame  outperforming the market 
Will the recent positive trend continue leading up to the stock s next earnings release  or is it due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers Pfizer Fourth Quarter Earnings Lag  Sales Top  2017 Sales View SoftPfizer s fourth quarter adjusted earnings per share of  0 47 missed the Zacks Consensus Estimate of  0 50 by 6  Earnings also declined 11  year over year due to lower revenues and higher costs and taxes than year ago quarter Foreign exchange negatively impacted fourth quarter adjusted earnings by approximately  0 04 per share Pfizer posted revenues of  13 63 billion  slightly higher than the Zacks Consensus Estimate of  13 55 billion  However  revenues declined 3  from the year ago period  Fewer selling days compared to the year ago quarter hurt sales in the fourth quarter Sales in DetailWhile currency movement impacted Pfizer s fourth quarter revenues by 2    228 million   operational declined 1    191 million  Pfizer s standalone business  excluding the impact of foreign exchange  and the legacy Hospira and Medivation operations  recorded revenues of  12 32 billion  down 2  year over year on an operational basis  Hospira contributed  1 17 billion to sales Lower sales of the Prevnar Prevenar 13 vaccines franchise and loss of exclusivity for some products  offset strong performance of key products like Ibrance  breast cancer   Lyrica  neuropathic pain  and Xeljanz  rheumatoid arthritis  International revenues declined 7   4  on an operational basis  to  6 82 billion  Meanwhile  the U S  revenues rose 1  to  6 81 billion Segment DiscussionFrom the second quarter of 2016  Pfizer has reorganized its reporting segments to Pfizer Innovative Health  IH  and Pfizer Essential Health  EH  Pfizer IH sales grew 1   up 2  operationally  from the year ago period to  7 73 billion Pfizer IH revenues were driven by persistently strong momentum of Ibrance in the U S   robust operational growth of Eliquis globally  and growth of Lyrica and Xeljanz primarily in the U S  Also  revenues from the blockbuster prostate cancer drug Xtandi  added to Pfizer s portfolio following the Sep 2016 Medivation acquisition  also propelled U S  revenues  This was partially offset by continued decline in revenues from Prevnar 13 for adults in the U S  and lower revenues of Enbrel  down 22   in key European markets due to biosimilar competition  The 2015 expiration of the collaboration agreement to co promote Rebif in the U S  also hurt revenues Prevnar revenues tanked 33  in the U S  due to  high initial capture rate  of the eligible adult patient population following Prevnar 13 s successful 2014 launch  which resulted in a smaller remaining  catch up  opportunity in the fourth quarter compared to the year ago quarter  Meanwhile  the unfavorable timing of government purchases for the pediatric indication also hurt Prevnar sales  In 2017  the company expects global Prevnar 13 revenues to remain flat to slightly down with sales declining in the U S While Consumer Healthcare revenues rose 2  to  950 million  Global Oncology revenues surged 46  to  1 36 billion driven by Xalkori and Ibrance  Ibrance received EU approval in Nov 2016 and will begin to launch across Europe in 2017  This should boost revenues further  primarily in the second half of the year Global Vaccine revenues declined 22  to  1 5 billion  While Internal Medicine rose 9  to  2 30 billion  the Inflammation   Immunology franchise declined 7  to  1 02 billion  Additionally  the portfolio of Rare Disease declined 7  to  602 million Pfizer EH segment sales recorded a decline of 8   down 6  operationally  to  5 90 billion EH revenues were hurt by the loss of exclusivity and associated generic competition from products like Zyvox  Celebrex  Lyrica as well as lower revenues from legacy Hospira products Pfizer launched Inflectra  a biosimilar version of Remicade  in November last year  While Inflectra recorded sales of  4 million in the U S  and  61 million globally  all other biosimilars brought in sales of  30 million  down 8   from outside the U S  markets Adjusted selling  informational and administrative  SI A  expenses declined 4  during the quarter to  4 40 billion  while adjusted R D expenses rose 8  to  2 51 billion  on the other 2016 ResultsFull year sales rose 8  to  52 82 billion  falling short of the Zacks Consensus Estimate of  52 83 billion  However  sales were within the guidance range of  52 billion to  53 billion Adjusted earnings for 2016 were  2 40 per share  missing the Zacks Consensus Estimate of  2 41  Nevertheless  earnings were up 9  year over year  Earnings were within the guided range of  2 38  2 43 per share The Hospira acquisition contributed  4 6 billion to revenues in 2016 2017 GuidancePfizer s 2017 sales outlook fell short of expectations  Revenues are expected in the range of  52 billion to  54 billion  This was lower than the then Zacks Consensus Estimate of  54 26 billion Adjusted earnings per share are expected in the range of  2 50  2 60 The sales guidance includes the negative impact of  0 9 billion from foreign exchange headwinds   1 2 billion from the pending sale of the Hospira infusion systems business to medical device maker ICU Medical and  2 4 billion from loss of exclusivity on products  The adjusted EPS guidance includes the negative impact of product losses of exclusivity as well as currency headwinds At the mid point of the ranges  revenues are expected to be slightly above 2016 level  while adjusted EPS is expected to increase 6   Excluding negative impacts of the pending disposition of HIS and foreign exchange  revenues and earnings are expected to record operational growth of 4  and 10   respectively R D expenses are expected in the range of  7 5  8 0 billion  while SI A spending is projected in the range of  13 7  14 7 billion  In 2017  the company expects to buy back shares worth  5 billion In 2017  Pfizer is expecting pivotal top line study results in oncology and biosimilars 
How Have Estimates Been Moving Since Then 
Analysts were quiet during the last one month period as none of them issued any earnings estimate revisions Pfizer  Inc  Price and Consensus
    VGM Scores
At this time  Pfizer s stock has an average Growth Score of  C   though it is lagging a bit on the momentum front with a  D   However  the stock was allocated a grade of  B  on the value side  putting it in the second quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of  C   If you aren t focused on one strategy  this score is the one you should be interested in 
Our style scores indicate that the stock is more suitable for value investors than growth investors 
Outlook
The stock has a Zacks Rank  3  Hold   We are looking for an inline return from the stock in the next few months ",2017-04-19,Zacks Investment Research,https://www.investing.com/analysis/why-is-pfizer-(pfe)-up-8.7-since-the-last-earnings-report-200183647,200183647
220749,442265,PFE,Pfizer Falls On Department Of Justice Subpoena,opinion,"Pfizer  NYSE PFE  didn t have the best of times in the market last week  and for good reason  The company was served subpoenas on Wednesday  leading to investor fears  Today  we ll talk about the subpoena s  why investors pushed the stock down as a result  and what traders should be watching for ahead  So  let s get right to it 
Pfizer Served Subpoenas In US Antitrust CaseAs mentioned above  Pfizer had a rough week in the market last week  and a good portion of the declines can be attributed to subpoenas the company was served by the United States Department of Justice  The subpoenas are part of a widespread antitrust investigation surrounding saline fluids during the flu season about 3 years ago 
You see  during this season  saline fluids are in high demand as more and more consumers find themselves ill and dehydrated  As the law of supply and demand tells us  when supplies are low and demand is high  the price of the product must rise  Well  rise it did  However  there s a strong argument that the price of saline fluids went far above natural supply and demand growth  In fact  those prices went up by around 200  and 300  at Hospira  a company that Pfizer acquired and is now dealing with the backlash surrounding 
While normal supply and demand based growth in price is completely legal  the Department of Justice is investigating to see if the gains in the price were legal or an illegal activity known as price gouging  Of course  if price gouging did take place with regard to a product as important as saline fluid  chances are that there will be quite a bit of legal recourse as a result 
Why This Is Leading To Fear Among InvestorsAt the end of the day  the reason that Pfizer is down is a big deal  You see  Pfizer is one of the many companies that has centered its business around saving lives and improving the quality of life among the ill  While price gouging alone is a bad thing  price gouging with regard to products that are needed in the medical community is a major concern 
As a result  investors are expecting that Pfizer will have quite a bit of money coming out of its pockets in relation to this issue  After all  even if the company didn t do anything wrong  these investigations usually lead to legal expenses that can reach into the millions  On the other hand  if Hospira  previously acquired by Pfizer  did price gouge on such an important product  well  the cost to Pfizer could prove to be a major one 
What Traders Should Be Watching For AheadMoving forward  traders should be keeping a close eye on Pfizer as the stock is likely to present several opportunities ahead  However  if you d like to take advantage of these opportunities  it s important that you pay very close attention to the news  In particular  keep a close eye on the antitrust case that Pfizer is facing at the moment  As mentioned above  if this thing goes the wrong way  it could prove to be an incredibly large cost to the company  and ultimately lead to declines  However  that s not the only story to watch  Continue to watch the company s work with regard to its pipeline  sales  and other key business metrics as any news with regard to these will likely cause movement as well ",2017-04-24,anyoption,https://www.investing.com/analysis/pfizer-falls-on-department-of-justice-subpoena-200184533,200184533
220751,442267,PFE,Pfizer Presses AstraZeneca Case As CEO Faces UK Grilling,news,"By    U S  drugmaker Pfizer Inc  NYSE PFE  pressed the scientific case for its controversial plan to acquire Astrazeneca  LONDON AZN  on Monday as its chief executive prepared for a grilling from British lawmakers 
In the latest phase of Pfizer s campaign to counter critics of its proposed  106 billion deal  research head Mikael Dolsten said he had been through five different mergers and acquisitions and denied such big transactions disrupted drug research 
 If you keep your sense of curiosity and an open mind  you can learn tremendously   he said in a video posted on the company s website 
 We must stay laser focused on our important projects  And that s  of course  true for Pfizer scientists and AZ scientists and will be true also if we can make a potential combination come together  
British lawmakers are due to quiz Dolsten s boss  Scottish born Chief Executive Ian Read  on May 13 about his plans to acquire Britain s second biggest pharmaceuticals business   a deal driven in large part by Pfizer s wish to cut its tax bill  
They will also interrogate AstraZeneca CEO Pascal Soriot and business minister Vince Cable 
A second parliamentary committee on May 14 will question both CEOs again about the science aspects of the deal  along with Pfizer s Dolsten and science minister David Willetts 

Buying AstraZeneca would be the largest foreign takeover of a British firm  Pfizer s approach has been rejected by AstraZeneca and the idea of a merger is opposed by many scientists and some politicians who fear it would damage the country s science base 
Dolsten said there was  a really great fit  with the products that AstraZeneca had in its portfolio  with potential for combining drugs in areas such as lung cancer to offer much more effective treatments 
Pfizer has given a five year commitment to complete AstraZeneca s new research center in Cambridge  retain a factory in the northwestern English town of Macclesfield and put a fifth of its research staff in Britain if the deal goes ahead 
But the U S  firm has also said it could adjust those promises if circumstances change  significantly   prompting demands for more watertight pledges 
Prime Minister David Cameron said on Sunday he had made  very good progress  in securing guarantees from Pfizer  However  Dolsten s remarks contained no new pledges on preserving British science jobs 
SWEETENED OFFER 
Pfizer is widely expected to come back with a sweetened offer for AstraZeneca this week  though people familiar with the matter said it was likely to wait until after the parliamentary select committee hearings 
The British group rejected a May 2 cash and stock offer worth 50 pounds a share from its larger American rival  and CEO Soriot has been on a roadshow to meet leading investors and lay out his strategy for a prosperous independent future 
Soriot has secured the backing of several high profile shareholders  but others have told Reuters they would like him to engage with Pfizer if the U S  group makes an improved offer 
In addition to wanting a higher price   many analysts think Pfizer will have to offer around 55 pounds a share   investors are also keen to increase the proportion of cash in any deal from 32 percent at present 
Pfizer is limited in the amount of cash it can offer since in order to keep the tax advantages of re domiciling to Britain it must ensure at least 20 percent of the enlarged group is British owned 
Under British takeover rules  Pfizer has until May 26 to make a firm bid for AstraZeneca or walk away 
A slide in Pfizer s share price following its first quarter results last week has reduced the current value of its May 2 offer to just under 48 pounds  AstraZeneca shares traded barely changed at 46 pounds early on Monday 
Political concerns about the proposed takeover have been fuelled by Pfizer s record of making big job cuts after past acquisitions  It also has a tarnished reputation in Britain after shutting down most of its drug research in Sandwich  southern England  where Viagra was invented  with the loss of some 1 700 jobs 
Pfizer s Read also laid out the case for a merger in videos posted by the U S  group on Saturday  when he said strong British research was a key reason for the deal ",2014-05-12,International Business Times,https://www.investing.com/news/stock-market-news/pfizer-presses-astrazeneca-case-as-ceo-faces-uk-grilling-283466,283466
220757,442273,PFE,Roche Launches Antibody Test To Diagnose Prostate Cancer,opinion,"Roche Holding  SIX ROG  AG   OTC RHHBY   announced that it has launched the anti p504s  SP116  Rabbit Monoclonal Primary Antibody for prostate cancer diagnosis on a world wise basis 
Roche s share price shows that the company has outperformed the Zacks classified industry year to date  The stock rallied 12 9  compared with the  industry s gain of 5 9  

 
The antibody is designed in a way that it can be used in a dual stain with the VENTANA Basal Cell Cocktail  34 E12 p63   This enables it to differentiate morphologically difficult cases as benign  a typical or cancerous on a single slide  In fact  elevated expression of p504s has become a useful biomarker in the diagnosis of prostate adenocarcinoma  It helps in reducing the need for multiple slides to make a diagnosis  Also  it aids the clinicians in making a more accurate diagnosis with a smaller tissue sample 
Roche is expanding its presence in the diagnostics market  The division added nine key instruments and tests to its portfolio in 2016  In 2016  revenues at the Diagnostics division climbed 7  on the back of solid performance of the Centralised and Point of Care Solutions  9   unit 
In addition  the company also launched four new medicines  Cotellic  advanced melanoma   Alecensa  lung cancer   Venclexta  chronic lymphocytic leukemia  jointly commercialised with AbbVie  and Tecentriq  bladder and lung cancer   In addition  five FDA breakthrough therapy designations were granted for Roche medicines in 2016 
We note that the company has a strong presence in the oncology market  It dominates in the breast cancer space with strong demand for HER2 franchise drugs like Herceptin  Perjeta and Kadcyla  We are also impressed by the company s efforts to develop its portfolio immunology  Evidently  new drug launches such as Tecentriq  Cotellic and Alecensa boosted sales and are expected to continue to do so in the upcoming quarters as well 
Recently  Roche presented encouraging results from the phase III study  ALUR  evaluating its lung cancer drug Alecensa  The study met its primary endpoint as Alecensa significantly improved progression free survival  PFS  in patients In fact  patients suffering from anaplastic lymphoma kinase  ALK  positive advanced  metastatic  non small cell lung cancer  NSCLC  and had progressed following treatment with one prior line of both platinum based chemotherapy and Pfizer s   NYSE PFE   Xalkori  compared with chemotherapy are likely to benefit from the same 
Notably  Alecensa received conditional marketing authorization from the European Commission for patients suffering from ALK positive NSCLC  who were treated with Xalkori in Feb 2017  Also  it is approved as a monotherapy for patients suffering from ALK positive NSCLC  who have shown progress or are intolerant to Xalkori Roche Holding AG Price
    Zacks Rank   Other Stocks to Consider
Roche currently carries a Zacks Rank  1  Strong Buy   Other top raked stocks in the health care sector include Heska Corporation   NASDAQ HSKA   and Galena Biopharma  Inc    NASDAQ GALE    You can see  
Heska s earnings estimates moved up from  1 53 to  1 65 for 2017 and from  1 90 to  2 01 for 2018  over the last 60 days  The company posted a positive earnings surprise in all of the last four quarters  with an average beat of 291 54   Its share price increased 40 7  year to date 
Galena Biopharma s loss estimates narrowed from  2 27 to 58 cents for 2017 and from 92 cents to 73 cents for 2018  over the last 60 days  The company posted a positive earnings surprise in two of the four trailing quarters with an average beat of 53 83    
The Best   Worst of Zacks
Today you are invited to download the full  up to the minute list of 220 Zacks Rank  1  Strong Buys  free of charge  From 1988 through 2015 this list has averaged a stellar gain of  25  per year  Plus  you may download 220 Zacks Rank  5  Strong Sells   Even though this list holds many stocks that seem to be solid  it has historically performed 6X worse than the market ",2017-04-13,Zacks Investment Research,https://www.investing.com/analysis/roche-launches-antibody-test-to-diagnose-prostate-cancer-200182841,200182841
220758,442274,PFE,Roche s Hemophilia A Drug Positive In Second Phase III Study,opinion,"Roche Holding  SIX ROG  AG s   OTC RHHBY   unit Genentech announced positive interim results from the Phase III HAVEN 2 study evaluating its pipeline candidate emicizumab prophylaxis  Emicizumab was being assessed in children less than 12 years of age with hemophilia A and inhibitors to factor VIII  
The study revealed that emicizumab reduced the number of bleeds in children with hemophilia A and inhibitors to factor VIII after 12 weeks of treatment over time 
Roche s share price shows that the company has outperformed the Zacks classified industry year to date  The stock rallied 11 8  compared with the  industry s gain of 5 4  during the period 

Notably  the results were in line with data from the phase III HAVEN 1 study in adults and adolescents  12 years of age or older  for the same indication   The data from the study announced in Dec 2016 showed a statistically significant reduction in the number of bleeds over time in patients treated with emicizumab prophylaxis as compared to those patients who do not receive prophylactic treatment 
Going forward  data from both HAVEN 1 and the interim results from HAVEN 2 studies will be presented at an upcoming medical meeting and submitted toregulatory authorities in order to get an approval 
Roche has been in the news this month for data readouts and regulatory updates 
Last week  Roche announced that the global randomized phase III study  ALEX  on lung cancer drug Alecensa met its primary endpoint as an initial  first line  treatment  According to the evaluation  Alecensa significantly reduced the risk of disease worsening or death  progression free survival  PFS  compared with Pfizer s   NYSE PFE   Xalkori in patients suffering from anaplastic lymphoma kinase  ALK  positive advanced non small cell lung cancer  NSCLC  
Also  earlier this month  Roche announced encouraging results from another phase III study  ALUR Alecensa  This study also met its primary endpoint as data from the study demonstrated that Alecensa significantly improved progression free survival  PFS  in patients  Importantly  last month  Roche received FDA approval for its highly awaited multiple sclerosis  MS  drug  Ocrevus  which is expected to have blockbuster potential Roche Holding AG Price
    Zacks Rank   Key Picks
Roche currently sports a Zacks Rank  1  Strong Buy   Other top ranked stocks in the health care sector include Heska Corp    NASDAQ HSKA   and Galena Biopharma  Inc    NASDAQ GALE    Both the companies carry Zacks Rank  1  Strong Buy   You can see  
Heska s earnings estimates moved up from  1 53 to  1 65 for 2017 and from  1 90 to  2 01 for 2018  over the last 60 days  The company posted a positive earnings surprise in all of the last four quarters  with an average beat of 291 54   Its share price increased 41 9  year to date 
Galena Biopharma s loss estimates narrowed from  2 27 to 58 cents for 2017 and from 92 cents to 73 cents for 2018  over the last 60 days  The company posted a positive earnings surprise in two of the four trailing quarters with an average beat of 53 83    
Sell These Stocks  Now 
Just released  today s 220 Zacks Rank  5 Strong Sells demand urgent attention  If any are lurking in your portfolio or Watch List  they should be removed immediately  These are sinister companies because many appear to be sound investments  However  from 1988 through 2016  stocks from our Strong Sell list have actually performed 6X worse than the S P 500 ",2017-04-17,Zacks Investment Research,https://www.investing.com/analysis/roche's-hemophilia-a-drug-positive-in-second-phase-iii-study-200183224,200183224
220762,442278,PFE,European stocks mixed to lower after Spanish PMI  Dax down 0 14 ,news,"Investing com   European stocks were mixed to lower on Friday  weighed by the release of disappointing Spanish manufacturing data  while investors eyed an upcoming U S  nonfarm payrolls report to be published later in the trading session 
During European morning trade  the DJ Euro Stoxx 50 slid 0 35   France s CAC 40 declined 0 44   while Germany s DAX fell 0 14  
Markit research group said Spain s manufacturing purchasing managers  index ticked down to 52 7 in April  from a reading of 52 8 the previous month  compared to expectations for a rise to 53 4 
Meanwhile  global equitiy markets remained under pressure after the Federal Reserve on Wednesday said it would reduce its bond purchases by  10 billion to a total of  45 billion a month  in a widely expected decision 
Investors were looking ahead to the upcoming April nonfarm payrolls report  which was expected to show that the recovery in the labor market was continuing 
Financial stocks were mixed  as BNP Paribas  BNPP PARIS  plummeted 2 24  and Societe Generale  SOGN PARIS  gained 0 54  in France  while Germany s Deutsche Bank  DBKGn XETRA  slid 0 41  
Among peripheral lenders  Intesa Sanpaolo  ISP MILAN  dipped 0 01  and Unicredit  CRDI MILAN  advanced 0 58  in Italy  while Spanish banks Banco Santander  SAN MADRID  and BBVA  BBVA MADRID  shed 0 16  and 0 53  respectively 
Elsewhere  Pernod Ricard  PERP PARIS  was down 0 06  after saying it doesn t plan to acquire additional wineries in the U S  following last week s agreement to buy Kenwood Vineyards in California 
In London  FTSE 100 inched up 0 08   led by the Royal Bank of Scotland  RBS LONDON   whose shares surged 10 18   after the bank said its first quarter profit tripled as impairments fell and its Irish unit posted its first profit since the financial crisis 
Meanwhile  other U K  lenders were mixed as Lloyds Banking  LLOY LONDON  climbed 0 70   while Barclays  BARC LONDON  and HSBC Holdings  HSBA LONDON  lost 0 03  and 0 34  
Mining stocks were also mixed  with Glencore Xstrata  GLEN LONDON  and Bhp Billiton  BLT LONDON  down 0 19  and 0 15  respectively  while Rio Tinto  RIO LONDON  added 0 16  and Vedanta Resources  VED LONDON  gained 0 43  
On the downside  Astrazeneca  AZN LONDON  slipped 0 13  after U S  drugmaker Pfizer  NYSE PFE  raised ts bid for the company to about  63 1 billion 
In the U S   equity markets pointed to a steady open  The Dow 30 futures pointed to a 0 06  gain  S P 500 futures signaled a 0 10  rise  while the Nasdaq 100 futures indicated a 0 07  uptick 
Later in the day  the euro zone was to produce data on the unemployment rate ",2014-05-02,Investing.com,https://www.investing.com/news/stock-market-news/european-stocks-mixed-to-lower-after-spanish-pmi;-dax-down-0.14-281505,281505
220763,442279,PFE,Pfizer Q1 2014 Sales Disappoint  Profit Down 15 ,news,"By    Pfizer Inc  NYSE PFE   the biggest U S  drugmaker  on Monday reported revenues well below Wall Street expectations  hurt by falling sales of generic medicines it calls established pharmaceuticals 
Pfizer  which is trying to take over Britain s Astrazeneca Plc  LONDON AZN   earned  2 33 billion  or 36 cents per share  in the first quarter ended March 31  That compared with  2 75 billion  or 38 cents  in the year earlier period  when the company reported gains from the transfer of product rights 

Excluding special items  Pfizer earned 57 cents per share  Analysts  on average  expected 55 cents per share  according to Thomson Reuters I B E S  Total revenues fell 9 percent to  11 35 billion  which was  730 million below Wall Street expectations 
Pfizer pulled its prior 2014 forecast  saying it will update its outlook its outlook  as soon as practicable  ",2014-05-05,International Business Times,"https://www.investing.com/news/stock-market-news/pfizer-q1-2014-sales-disappoint,-profit-down-15-281815",281815
220767,442283,PFE,BeiGene To Build Biologics Plant In China,opinion,"Fast growing biotechnology company BeiGene Ltd   NASDAQ BGNE  recently announced that they will be constructing a new biologics manufacturing plant in Guangdong Province in China  This would make the project one of the biggest manufacturing ventures for the year 
The company  which would be working with the Guangzhou Development District  is set to build the state of the art biologics manufacturing plant worth  330 million  The joint venture to construct the commercial scale biologics facility will also be allocating funding for the research and development of biologic drug candidates in China 
Beigene  which is known for their focus on developing a portfolio of immuno oncology  is set to compete with Western companies in the same field and will be prioritizing the production of high quality and large scale products that will be distributed not just in China but in the global markets as well 
 It is our strategic priority to secure high quality large scale manufacturing capacity based on the increasing biologics opportunity  We believe the joint venture will provide a valuable asset for our long term growth   said Beigene CEO John Oyler 
Beigene currently is developing PARP inhibitors  which can compete with Astrazeneca s  NYSE AZN  Lynparza and Pfizer s  NYSE PFE  latest Medivation 
 Biologics represent an important part of BeiGene s overall R D and manufacturing capabilities  This joint venture will enable BeiGene to keep pace with a growing demand for the development and use of biologics in China and global markets   said BeigeneCo founder and director Dr  Wang Xiaodong  Wang also serves as the Chairman of the Scientific Advisory Board of Beigene 
The company  which would be receiving  30 million from Beigene Hong Kong and another  150 million from the Guangzhou GET Technology Development Co  Ltd   would include an equity investment in cash from JV Company  An additional funding of  150 million will also be given to the manufacturing factory from a subsidiary of the JV company 
The announcement of the project has been received positively by both investors and the Chinese government who stated that the venture will help biotechnology in the area and therefore promote growth 
 We attach great importance to this project and believe that the successful introduction of BeiGene Biologics will transform Guangzhou Development District into a center for the innovative biopharmaceutical industry  promote the development of the biotechnology industry in the region  and provide a powerful driving force for economic transformation and upgrade  The government will provide strong support in funding  management service  and creating a good business environment   said the Administrative Committee of Guangzhou Municipal Government and Guangzhou Development District ",2017-03-28,trade 12,https://www.investing.com/analysis/beigene-to-build-biologics-plant-in-china-200180453,200180453
220768,442284,PFE,Roche s Lung Cancer Drug Alecensa Meets Primary Endpoint,opinion,"Roche Holdings   OTC RHHBY   announced that the global  randomized phase III study  ALEX  on lung cancer drug Alecensa met its primary endpoint as an initial  first line  treatment  Alecensa significantly reduced the risk of disease worsening or death  progression free survival  PFS  compared with Pfizer s   NYSE PFE   Xalkori in patients suffering from anaplastic lymphoma kinase  ALK  positive advanced non small cell lung cancer  NSCLC  
We remind investors that Alecensa was granted accelerated approval by the FDA in Dec 2015 for the treatment of patients with ALK positive NSCLC who have progressed on or are intolerant to Xalkori  Roche is conducting the ALEX study to convert the current accelerated approval of Alecensa in patients with ALK positive  metastatic NSCLC who have progressed on or are intolerant to Xalkori to a full approval as an initial treatment 
Meanwhile  this is the second phase III trial to show that Alecensa was better as an initial treatment compared to Xalkori  The FDA also has granted Alecensa Breakthrough Therapy Designation  BTD  for advanced ALK positive NSCLC without prior treatment with an ALK inhibitor 
Roche expects to present full data from the study later at an upcoming medical meeting 
Roche s share price shows that the company has outperformed the Zacks classified industry year to date  The stock rallied 11 1  compared to the  industry s gain of 5 7  

We remind investors that Novartis   NYSE NVS   is also evaluating Zykadia  ceritinib  as a first line treatment for patients with metastatic non small cell lung cancer  NSCLC  whose tumors are ALK positive as detected by an FDA approved test 
Roche has a strong presence in the oncology market  The company dominates the breast cancer space with strong demand for HER2 franchise drugs like Herceptin  Perjeta and Kadcyla  We are also impressed by the company s efforts to develop its portfolio beyond oncology into immunology  New drug launches  such as Tecentriq  Cotellic and Alecensa boosted sales and are expected to continue to do so in the upcoming quarters as well 
Zacks Rank   Stock to Consider
Roche currently sports a Zacks Rank  1  Strong Buy  
Another top stock in the healthcare sector is Heska Corp    NASDAQ HSKA    You can see 
Heska s earnings estimates increased from  1 53 to  1 65 for 2017 and from  1 90 to  2 01 for 2018 over the last 60 days  The company posted a positive earnings surprise in all the four trailing quarters with an average beat of 291 54  
Zacks  Hidden Trades
While we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them 
Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ",2017-04-10,Zacks Investment Research,https://www.investing.com/analysis/roche's-lung-cancer-drug-alecensa-meets-primary-endpoint-200182111,200182111
220770,442286,PFE,Pfizer Chasing AstraZeneca In Potential  100B Deal,news,"By     Reuters    U S  drugmaker Pfizer Inc  NYSE PFE  is working on its next move in a potential  100 billion bid battle for Britain s Astrazeneca Plc  AZN LONDON  after having two bids rejected  as deal making grips the healthcare industry 
Pfizer said on Monday it made a 58 8 billion pounds   98 9 billion  bid approach to AstraZeneca in January and had contacted its British rival again on April 26 seeking further discussions about a takeover 
AstraZeneca shares jumped 15 percent in early trade 
The cash and shares takeover  if it happens  would be the biggest ever foreign takeover of a British company and one of the largest ever pharmaceuticals deals 
The renewed approach comes amid a wave of mergers and acquisitions in the sector  as the industry restructures in the face of healthcare spending cuts and cheap generic competition 
In a statement to the London stock market  Pfizer said AstraZeneca had declined to engage in discussions on both occasions and the U S  group said it was now considering its options 
Pfizer s original proposal  made to the board of AstraZeneca on January 5  included a combination of cash and shares and would have valued AstraZeneca shares at 46 61 pounds each   a premium of around 30 percent at the time 
Pfizer said it was now considering a possible transaction in which AstraZeneca shareholders would again receive a significant premium above the value of their shares on April 17  before takeover rumors started 

Citi analyst Andrew Baum said he believed there was now a 90 percent chance that Pfizer would acquire AstraZeneca for at least around 49 pounds a share 
Shares in the British group shot up to 46 54 pounds by 0805 GMT  4 05 a m  EDT  on Monday  after touching an all time high of 47 14 
Given that Pfizer is likely to have to offer more this time  due to a run up in AstraZeneca shares since January  the final value of any deal could be above  100 billion 
An AstraZeneca spokeswoman said the company had no immediate comment on the Pfizer statement  adding the company would be considering its response 
Under British takeover rules  Pfizer has until May 26 to announce a firm intention to make an offer for AstraZeneca or back away 
CANCER DRUG DRAW
Buying AstraZeneca would give Pfizer a number of promising   though still risky   experimental cancer medicines known as immunotherapies that boost the body s immune system to fight tumors  It could also generate significant cost savings for the U S  group 
Acquiring a foreign company also makes sense for Pfizer because it has tens of billions of dollars accumulated through foreign subsidiaries  which if repatriated to the United States would be heavily taxed 
Pfizer has a long track record of making major acquisitions  with the  68 billion purchase of Wyeth in 2009 its last major deal  after earlier acquisitions of Pharmacia and Warner Lambert 
The drugmaker has more recently been divesting certain operations  while mega mergers had fallen out of fashion in the pharmaceuticals industry following skepticism about how well some of them have worked 
But Chief Executive Ian Read said he was ready to consider large deals that made sense  adding that buying AstraZeneca would  maintain the flexibility for the potential future separation of our businesses  
The transaction would complement both Pfizer s innovative drug businesses and also its established products business   comprising older and off patent medicines   which many analysts expect to be eventually spun off 
 We believe that a transaction would further strengthen our ability to generate strong and consistent cash flow  targeted for both investment in our business and return to shareholders  while at the same time offering an efficient operating structure and the anticipated realization of attractive synergies   Read said 
The suggested deal  which first surfaced a week ago in the Sunday Times  has triggered worries about jobs in Britain s pharmaceuticals sector  which is viewed as a key industry by the government 
AstraZeneca has already laid off thousands of scientists and other staff as it shrinks its cost base to cope with a fall in sales due to patent losses on blockbuster medicines  while Pfizer has shuttered a large research site in Sandwich  southern England 
However  Britain s finance minister George Osborne has indicated a hands off approach to any deal  which he described on Friday as  a commercial matter between the companies  
Pfizer said the transaction  if completed  was expected to result in the combination of the two companies under a new UK incorporated holding company  although the head office would remain in New York 
Bank of America Merrill Lynch  JP Morgan and Guggenheim Securities are advising Pfizer ",2014-04-28,International Business Times,https://www.investing.com/news/stock-market-news/pfizer-chasing-astrazeneca-in-potential-$100b-deal-279877,279877
220771,442287,PFE,Dollar broadly lower as euro and sterling strengthen,news,"Investing com   The dollar moved lower against a basket of other major currencies on Monday as the euro gained ground ahead of euro zone inflation data later in the week   and the pound surged to multi year highs 
EUR USD touched highs of 1 3876  the most since April 11 and was last up 0 22  to 1 3864 
The euro was supported by hopes that Wednesday s report on euro zone inflation would show that consumer prices ticked higher this month  easing pressure on the European Central Bank to implement additional monetary policy measures 
The single currency received an additional boost after ECB Governing Council member Christian Noyer said Monday that while the strong euro was weighing on consumer prices the euro area was not at risk of falling into deflation 
Meanwhile  sterling rose to fresh four and a half year peaks of 1 6853 against the dollar  and GBP USD was last up 0 22  to 1 6836 
Demand for the pound continued to be underpinned by expectations that the Bank of England could raise interest rates in the early part of next year 
Market participants were looking ahead to preliminary data on U K  first quarter growth due for release on Tuesday  amid expectations that growth accelerated in the first three months of this year 
Sterling was also boosted by expectations for merger and acquisition inflows after U S  drugs giant Pfizer Inc  NYSE PFE  confirmed Monday that wanted to take over Britain s Astrazeneca Plc  AZN LONDON  in a deal worth almost  60 billion 
Elsewhere  USD JPY was up 0 16  to 102 34  ahead of monetary policy statements by the Bank of Japan and the Federal Reserve later in the week  The BoJ was expected to keep the size of its stimulus program unchanged  while the Fed was expected to stick to its current timetable for tapering its asset purchase program 
Meanwhile  Friday s U S  nonfarm payrolls report for April was expected to indicate that the recovery in the labor market is continuing 
USD CHF was down 0 42  to trade at 0 0 8778 
The Australian dollar was higher  with AUD USD rising 0 22  to 0 9289  while NZD USD slipped 0 23  to 0 8559  The Canadian dollar was slightly higher  with USD CAD losing 0 17  to trade at 1 1019 
The US Dollar Index  which tracks the performance of the greenback versus a basket of six other major currencies  was at 79 65  down 0 23  ",2014-04-28,Investing.com,https://www.investing.com/news/forex-news/dollar-broadly-lower-as-euro-and-sterling-strengthen-279885,279885
220772,442288,PFE,European stocks push higher on aquisition news  Dax up 0 77 ,news,"Investing com   European stocks pushed higher on Monday  boosted by news Britain s Astrazeneca could be aquired by U S  drugmaker Pfizer  while markets continued to eye developments in the Ukraine 
During European afternoon trade  the DJ Euro Stoxx 50 gained 0 74   France s CAC 40 climbed 0 51   while Germany s DAX advanced 0 77  
Investors remained cautious as hostilities between Russia and Ukraine continued  On Friday  U S  Secretary of State John Kerry warned that Washington was ready to step up sanctions on Russia 
The West is accusing Russia of leading a separatist revolt in eastern Ukraine after it annexed Crimea last month 
In a joint statement on Monday  G 7 nations said they would  move swiftly to impose additional sanctions on Russia  because the latter has not moved to comply with the Geneva accord 
Financial stocks turned broadly higher  as French lenders BNP Paribas  BNPP PARIS  and Societe Generale  SOGN PARIS  gained 1 23  and 0 23   while Germany s Deutsche Bank  DBKGn XETRA  climbed 0 40  
Among peripheral lenders  Italy s Unicredit  CRDI MILAN  and Intesa Sanpaolo  ISP MILAN  gained 0 51  and 1 12  respectively  while Spanish banks Banco Santander  SAN MADRID  and BBVA  BBVA MADRID  advanced 0 68  and 0 86  
Elswhere  Bayer  BAYGN XETRA  surged 4 33  after the German pharmaceutical and chemicals conglomorate said it is exploring a sale of its  10 billion plastics unit to focus on boosting its health business 
The news came after the company reported a 12  rise in first quarter profit  helped by new medicines and a rebound at its plastics unit 
In London  FTSE 100 rose 0 33   still led by Astrazeneca  AZN LONDON   up 14 63   after Pfizer  NYSE PFE  confirmed that it is interested in acquiring the U K  drugmaker for about  58 8 billion  The acquisition would be one of the largest takeovers in the industry s history 
Meanwhile  financial stocks turned mixed  as Barclays  BARC LONDON  inched up 0 01  and HSBC Holdings  HSBA LONDON  gained 0 46   while Lloyds Banking  LLOY LONDON  retreated 0 43  and the Royal Bank of Scotland  RBS LONDON  plummeted 1 86  
In the mining sector  stocks remained mostly lower  Bhp Billiton  BLT LONDON  declined 0 89  and Glencore Xstrata  GLEN LONDON  lost 1   while rival company Rio Tinto  RIO LONDON  saw shares plunge 2 01  
In the U S   equity markets pointed to a higher open  The Dow 30 futures pointed to a 0 35  increase  S P 500 futures signaled a 0 33  rise  while the Nasdaq 100 futures indicated a 0 32  gain 
Later in the day  the U S  was to release private sector data on pending home sales ",2014-04-28,Investing.com,https://www.investing.com/news/stock-market-news/european-stocks-push-higher-on-aquisition-news;-dax-up-0.77-279907,279907
220773,442289,PFE,Dollar mixed market looks past housing data  eyes Friday jobs report,news,"Investing com   The dollar gave back gains and traded mixed to lower against most major currencies on Monday after investors applauded robust housing data and later jumped to the sidelines to prep for Friday s April jobs report 
In U S  trading on Monday  EUR USD was up 0 14  at 1 3853 
The dollar firmed earlier after the National Association of Realtors reported that pending home sales jumped 3 4  in March  far surpassing expectations for a 1  gain 
Pending home sales for February were revised to a 0 5  drop from a previously reported decline of 0 8  
On a year over year basis  pending home sales were still down 7 9  in March  though the data firmed the dollar by reminding investors that the Federal Reserve will continue tapering monthly asset purchases as the year unfolds 
Profit taking nudged the greenback down later in the session  as investors jumped to the sidelines to prepare for Friday s April jobs report 
The euro  meanwhile  saw support from expectations that euro zone inflation data due out on Wednesday will reveal an uptick in consumer prices 
An increase in the euro zone s consumer price index would ease pressure on the European Central Bank to implement additional monetary policy measures 
In March  the euro zone s annual inflation rate slowed to 0 5   the lowest since November 2009  The ECB targets an inflation rate of close to but just under 2  The consensus forecast is for the inflation rate to rise to 0 8  
The dollar was up against the yen  with USD JPY up 0 34  at 102 54 and down against the Swiss franc  with USD CHF down 0 17  at 0 8801 
The greenback was down against the pound  with GBP USD up 0 07  at 1 6811 
Sterling rose on expectations for merger and acquisition inflows after U S  drugs giant Pfizer Inc  NYSE PFE  confirmed Monday that it wanted to take over Britain s Astrazeneca Plc  AZN LONDON  in a deal worth almost  60 billion 
The dollar was mixed against its cousins in Canada  Australia and New Zealand  with USD CAD down 0 13  at 1 1024  AUD USD down 0 12  at 0 9258 and NZD USD down 0 48  at 0 8539 
The US dollar index  which tracks the performance of the greenback versus a basket of six other major currencies  was down 0 08  at 79 77 
On Tuesday  the U S  is to a report compiled by the Conference Board on consumer confidence ",2014-04-28,Investing.com,"https://www.investing.com/news/forex-news/dollar-mixed-market-looks-past-housing-data,-eyes-friday-jobs-report-280063",280063
220774,442290,PFE,Pfizer Chases AstraZeneca For Potential  100 Billion Deal,news,"By     Reuters    U S  drugmaker Pfizer Inc approached Britain s AstraZeneca Plc two days ago to reignite a potential  100 billion takeover and was rebuffed  raising investor expectations it will have to increase its offer to close the deal 
Pfizer said on Monday it proposed a takeover to AstraZeneca in January worth 58 8 billion pounds   98 9 billion   or nearly 47 pounds per share  It had contacted its British rival again on Saturday  seeking to discuss further a takeover 
The chase was welcomed by investors in both companies  as deal making grips the healthcare industry  Astrazeneca Plc  AZN  shares were up 11 7 percent at  76 69 in New York on news of the latest offer  which would be the biggest foreign acquisition of a British company and one of the largest pharmaceutical deals  Pfizer Inc  NYSE PFE  shares were up 3 8 percent at  31 92 on the New York Stock Exchange on Monday afternoon 
AstraZeneca said Pfizer s suggested offer undervalued the company  very significantly   adding that Pfizer wanted to pay 70 percent in shares and only 30 percent in cash  AstraZeneca urged its shareholders to take no action and said it remained confident of its independent strategy 
 I feel pretty confident of a higher bid coming   said Neil Veitch  global and UK investment director at SVM Asset Management  which owns AstraZeneca shares   I think it s more likely than not that we ll see an agreed deal somewhere in that 52 to 53 pound range  
Buying AstraZeneca would boost Pfizer s pipeline of cancer drugs and create significant cost and tax savings  Under British takeover rules  Pfizer has until May 26 to announce a firm intention to make an offer or back away 
The renewed approach comes amid a wave of mergers and acquisitions in the sector  pushing the value of deals to  153 billion so far this year  as the industry restructures amid healthcare spending cuts and competition from cheap generics 
 Society wants products faster  they want more products and they want value   Pfizer Chief Executive Ian Read told reporters   Industry is responding to society s request for increased efficiencies and productivity  
Read said AstraZeneca had declined to engage in talks and the U S  group was now considering how to proceed  but he remained convinced that combining the two companies made strategic sense and would benefit AstraZeneca investors 
NEW DRUG PIPELINES
Pfizer s original proposal  made to the board of AstraZeneca on January 5  would have valued AstraZeneca shares at 46 61 pounds each   a premium of around 30 percent at the time 
AstraZeneca said the proposal comprised 13 98 pounds in cash and 1 758 Pfizer shares for each AstraZeneca share 
 My guess is it will go for somewhere between 50 and 55  pounds a share    said Dan Mahony  a fund manager at Polar Capital  who raised his stake in AstraZeneca in February last year   I doubt Pfizer will want to go completely hostile  
Most of Pfizer s past deals have been conducted on a friendly basis  including its 2009 purchase of Wyeth for  68 billion  But it has been willing to play hardball if needed  as it did in 2000 with its  90 billion purchase of U S  rival Warner Lambert  with which it won full ownership of cholesterol fighter Lipitor  the best selling drug of all time 

Read told U S  analysts that since the initial approach to AstraZeneca  both companies had seen experimental drugs fare well in trials  At the same time  Pfizer concluded it was too difficult to pursue big deals domestically while being on the hook for higher U S  tax rates 
 We re coming from a position of strength  on our near term pipeline  of experimental drugs  Read said 
Recent favorable data includes results for Pfizer s experimental breast cancer medicine palbociclib 
INDEPENDENT FUTURE
Pfizer s declaration turns up the heat under AstraZeneca Chief Executive Pascal Soriot  who has been in the job since October 2012 and who made clear last week he saw an independent future for the group  flagging spin offs of two noncore units as one option to create more value 
Soriot has been credited with reviving AstraZeneca s previously thin pipeline of new drugs  badly needed to offset a wave of patent expiries on older drugs  and shares in the group have now risen more than 60 percent under his tenure 
However  his overhaul   including an ambitious plan to move the company s research and corporate headquarters to Cambridge  England   is still a work in progress and he has also come under fire from some shareholders over executive pay 
Read said it was premature to say who would lead a combined company 
Buying AstraZeneca would give Pfizer a number of promising   though still risky   experimental cancer medicines known as immunotherapies that boost the body s immune system to fight tumors  It could also generate significant cost savings for the U S  group 
Acquiring a foreign company also makes sense for Pfizer as it has tens of billions of dollars accumulated through foreign subsidiaries  which  if repatriated  would be heavily taxed 
The drugmaker has more recently been divesting certain operations  while mega mergers had fallen out of fashion in the pharmaceuticals industry following skepticism about how well some of them have worked 
HEFTY RETURN
But CEO Read said large deals could also make good sense and buying AstraZeneca would  maintain the flexibility for the potential future separation of our businesses  
The transaction would complement both Pfizer s innovative drug businesses and also its established products business   comprising older and off patent medicines   which many analysts expect to be eventually spun off 
In addition to using offshore cash  buying AstraZeneca would be tax efficient since Pfizer could redomicile to Britain and enjoy lower tax rates  thanks to attractive incentives to companies that manufacture and hold patents in the country 
Pfizer envisages combining the two drugmakers under a new UK incorporated holding company  although the head office and stock market listing would remain in New York  But the suggested deal has triggered worries about jobs in Britain s drug sector  viewed as a key industry by the government 
AstraZeneca has already laid off thousands of staff as it shrinks its cost base to cope with a fall in sales due to patent losses on blockbuster medicines  while Pfizer has shuttered a research site in Sandwich  southern England 
Read said Pfizer had contacted the British government about its plans on Monday  after Finance Minister George Osborne said on Friday that any deal was  a commercial matter between the companies  
A spokesman for Prime Minister David Cameron told reporters on Monday that any Pfizer takeover bid would be assessed by  independent procedures and frameworks  
Bank of America Merrill Lynch  JP Morgan and Guggenheim Securities are advising Pfizer  while Goldman Sachs  Morgan Stanley and Evercore Partners are working for AstraZeneca ",2014-04-28,International Business Times,https://www.investing.com/news/stock-market-news/pfizer-chases-astrazeneca-for-potential-$100-billion-deal-280158,280158
220775,442291,PFE,Asian shares end weaker  markes in Japan shut for holiday,news,"Investing com   Asian shares edged out gains on Tuesday with markets in Japan closed and otherwise thin trade ahead of the May 1 holiday 
China s Shanghai Composite rose 0 16  and the Hang Seng index gained 0 39  in morning sessions 
In China  among actives  Shanghai Port rose 0 7   Chongqing Gangjiu was up 2 3  and Wuhu Port  600575 SS  gained 0 6  as Premier Li Keqiang urged the invigoration of businesses along the Yangtze River 
Overnight  upbeat U S  home sales data and a possible mega merger of pharmaceutical giants Pfizer Inc  NYSE PFE  and Astrazeneca Plc  AZN LONDON  sent U S  stock prices with the Dow 30 up 0 53   the S P 500 index gaining 0 32   while the NASDAQ Composite Composite index fell 0 03  
Stocks rose after the National Association of Realtors reported that pending home sales jumped 3 4  in March  far surpassing expectations for a 1  gain 
Pending home sales for February were revised to a 0 5  drop from a previously reported decline of 0 8  
On a year over year basis  pending home sales were still down 7 9  in March  though stocks applauded the improvement 
Elsewhere  U S  drugs giant Pfizer confirmed Monday that it wanted to take over Britain s AstraZeneca in a deal worth almost  60 billion  which sent large cap U S  stocks rising 
In other news  the U S  slapped fresh sanctions on Russia earlier  with this the third round targeting seven individuals and 17 companies
Still  reports that Russian troops were returning to their bases after conducting military exercises on the Ukrainian border sparked relief buying on Wall Street 
After the close of European trade  the DJ Euro Stoxx 50 rose 0 46   France s CAC 40 rose 0 38   while Germany s DAX rose 0 48   Meanwhile  in the U K  the FTSE 100 rose 0 22  
On Tuesday  the U S  is to a report compiled by the Conference Board on consumer confidence ",2014-04-29,Investing.com,"https://www.investing.com/news/stock-market-news/asian-shares-end-weaker,-markes-in-japan-shut-for-holiday-280165",280165
220776,442292,PFE,European stocks rise  focus on inflation data  Dax up 0 91 ,news,"Investing com   European stocks were higher on Tuesday  despite disappointing Spanish employment data  as investors eyed a highly anticipated inflation report due on Wednesday  as well as the Federal Reserve s upcoming policy statement 
During European morning trade  the DJ Euro Stoxx 50 advanced 0 63   France s CAC 40 rose 0 26   while Germany s DAX jumped 0 91  
Official data earlier showed that Spains unemployment rate ticked up to 25 9  in the first quarter  from 25 7  in the fourth quarter of 2013  whose figure was revised from a previously estimated rate of 26 0  
Anlaysts had expected the unemployment rate to fall to 25 6  in the last quarter 
Separately  an uptick in the euro zone s inflation rate would ease pressure on the European Central Bank to implement additional monetary policy measures 
Last month the annual rate of inflation in the euro zone slowed to 0 5   the lowest since November 2009  The ECB targets an inflation rate of close to but just under 2  The consensus forecast is for the euro zone inflation rate to rise to 0 8  
Financial stocks were broadly higher  as French lenders BNP Paribas  BNPP PARIS  and Societe Generale  SOGN PARIS  gained 0 22  and 2 50   while Germany s Deutsche Bank  DBKGn XETRA  surged 3 10  
Among peripheral lenders  Italy s Intesa Sanpaolo  ISP MILAN  and Unicredit  CRDI MILAN  climbed 0 58  and 0 74  respectively  while Spanish banks BBVA  BBVA MADRID  and Banco Santander  SAN MADRID  rose 0 30  and 0 47  
Elswhere  Italian oil company Eni Spa  EIPAF PK  rallied 1 53  even after saying that first quarter profit fell 14  due to weakening demand in its European businesses and declining refining margins 
Peugeot  PEUP PARIS  added to gains  with shares soaring 5 57   after the French carmaker said it is offering stock to investors at  6 77 a share after selling stakes to Chinese partner Dongfeng Motor  DNFGF PK  and the French state 
In London  FTSE 100 climbed 0 53   led by Shire  SHP LONDON   up 3 64   amid reports Allergan  NYSE AGN  is preparing to approach the Dublin based biopharmaceutical company again about a potential takeover after being rebuffed in recent months 
BP  BP LONDON  was also on the upside  jumping 1 03   even as the oil and gas giant said profit fell due to lower output and a drop in earnings at refineries  Earnings were in line with analysts  estimates however 
In the financial sector  stocks were mostly higher  The Royal Bank of Scotland  RBS LONDON  saw shares gain 0 46  and Lloyds Banking  LLOY LONDON  advanced 0 64   while HSBC Holdings  HSBA LONDON  rallied 1 08   Barclays  BARC LONDON  underperformed on the other hand  dropping 0 92  
Meanwhile  Astrazeneca  AZN LONDON  shares plummeted 1 37   after skyrocketing over 11  on Monday when Pfizer  NYSE PFE  confirmed that it is interested in acquiring the U K  drugmaker for about  58 8 billion  The acquisition would be one of the largest takeovers in the industry s history 
Mining stocks were also broadly lower  as Bhp Billiton  BLT LONDON  slid 0 37  and Rio Tinto  RIO LONDON  declined 0 69   while rivals Randgold Resources  RRS LONDON  and Fresnillo  FRES LONDON  lost 1 02  and 1 74  respectively 
In the U S   equity markets pointed to a higher open  The Dow 30 futures pointed to a 0 25  rise  S P 500 futures signaled a 0 27  gain  while the Nasdaq 100 futures indicated a 0 35  increase 
Later in the day  Germany was to release preliminary data on consumer price inflation  while the U S  was to publish a report compiled by the Conference Board on consumer confidence ",2014-04-29,Investing.com,"https://www.investing.com/news/stock-market-news/european-stocks-rise,-focus-on-inflation-data;-dax-up-0.91-280188",280188
220782,442298,PFE,Why Actinium Pharmaceutics Stock May Be Even Better Than Celator,opinion,"Actinium Pharmaceuticals Inc  NYSE ATNM  
If you think that I wrote a presumptuous Actinium Pharmaceuticals headline to simply grab your attention  you are mistaken  After extensive analysis of the company  I hold a firm belief that ATNM has the potential to mimic the dramatic rise of Celator  which saw its market cap increase from roughly  50 million dollars in 2016 to  1 5 BILLION dollars  the price at which Jazz Pharmaceuticals paid to acquire the company  For Celator shareholders  this windfall came after the company provided clinical trial results that proved an increase in the survival rates of patients with AML by approximately three months  Celator stock went from around  1 60 in March of 2016 to over  30 00 by the end of May 
Celator did a great job extending patient survival  and additional survival time offers the potential to find a cure and ultimately create higher overall survival rates  Thus  the spike for Celator was merited  At the time  Celator focused on building upon the technology for combination therapy  utilizing older chemotherapy drugs in new directions  via liposomal nanoparticles that were intended to more efficiently target the delivery of the chemotherapeutic agents to the tumors 
While ATNM is not tracking the same scientific pathway as Celator  the results being demonstrated by the ATNM medical team may be equally impressive in many respects  To that end  Actinium Pharmaceuticals deserves a closer look by investors  as the potential for a Celator type spike is not out of the question  At the very least  the Celator deal defined the enormous value being given to leaders in the AML space  a market of which the company sits at the very core 
ATNM may very well be a victim of the decoupling that can occur between share price and a realistic and encompassing valuation  Most vulnerable are the companies like Actinium Pharmaceuticals  who have built an extraordinary clinical data set  but are unfortunately annihilated by investors that are nagged by the constant fear of a continued plan of stock dilution and convertible debt funding 
If current and potential ATNM investors are being spooked by either of those two specters  its time to exorcise those demons and come to the realization that the company is both financially and clinically sound  The  10 million cash raise in October and the lack of convertible debt provisions on the balance sheet should extinguish those investor concerns 
Actinium s Clinical AdvantageBefore getting to the Actinium Pharmaceuticals company fundamentals  the main interest of many short term investors  there needs to be a greater focus in vetting the company s clinical and strategic progress  as well as evaluating the overall strategy and current clinical programs at the company  From that vantage point  ATNM investors should clearly be able to sight the overall leadership position in at least two advanced clinical stage programs that hold enormous potential in treating AML  in addition to a host of other targeted indications 
As a quick overview  ATNM currently has two clinical stage trials  Iomab B  CD45  and Actimab A  CD33   and in addition to this  the company is also strategically positioned to capitalize on its Proprietary Alpha Particle Immunotherapy  APIT  platform  The APIT platform is generating reliable data that is demonstrating its potential to deliver multiple cancer drugs and treatments  several that may have blockbuster potential  In addition to APIT  the company has also staked out a leadership position in linking alpha particles to antibody drug conjugates that are intended to generate new therapies for both liquid and solid tumors 
To accentuate the potential of the two clinical trials  Iomab B is demonstrating the strength to position the company as a leading franchise in the field of bone marrow transplants  BMT   having the advantage of an expert team of professionals that possess both the vision and knowledge to advance the studies with the intent of creating innovative new therapies and enhancing shareholder value 
For its part  Actimab A has the potential to become a best in class solution in CD33 applications  CD33 is a transmembrane receptor expressed on cells of myeloid lineage  a key component within ATNM trial design  with an emerging data set that may bring forward both partnership and strategic opportunities for the company 
While the previous and quick introduction includes a host of scientific acronyms and jargon that even savvy biotech investors may find difficult to follow  the following spelled out explanation of what these ATNM compounds and trials are doing should be much easier to comprehend 
Iomab BCD45 is a molecule that is expressed on leukemia cells  bone marrow cells  and stem cells  and is active in targeting CD45  Iomab B works to deliver a powerful radiation shock to the DNA of these CD45 cells  eradicating the leukemic cell and enabling a patient to proceed with a bone marrow transplant  In simplest terms  Iomab B is the starting point intended to increase survival rates  but there is much scientific research that has built up the therapy 
The significant and driving force behind Iomab B is that is used as an induction and conditioning agent to enable patients with relapsed or refractory acute myeloid leukemia to receive a bone marrow transplant  Iomab B has become a possible life saving therapy  bringing potential for a BMT where one did not exist before 
Iomab B is not a new therapy option  The drug was first developed at the Fred Hutchinson Cancer Research Center  a recognized and Nobel prize winning leader in the field of bone marrow transplants  Iomab B has been studied in roughly 300 patients in several phase I and phase II clinical trials in cancer centers throughout the United States  targeting various forms of leukemia and lymphoma in physician sponsored trials  These trials are on going and have demonstrated meaningful and impressive data in the fight against different forms of leukemia 
When targeted to CD45 expressing cells  Iomab B has resulted in effective induction and conditioning of the cell in preparation for a BMT  while being well tolerated and showing minimal patient reported side effects  In comparison to chemotherapy and or radiation  the option may become a clear choice for patients  with potential to become a first line standard of care based on Iomab B s safety and tolerability profile compared to existing methods of BMT preparation 
Iomab B Is A Pathway Toward HealthThe best way to look at Iomab B  from layman s terms  is that it is the most efficient and well tolerated therapy to prepare a patient for a potential life saving BMT procedure  By targeting the  bad  CD45 cells in the bone marrow  its radioisotope payload works to deliver a knockout blow to the cells in the marrow  essentially eradicating all of the cells in the bone marrow and clearing a space for the newly transplanted cells 
Current methods of treatment that include repetitive rounds of chemotherapy come with a host of complications  as well as costs  The conditioning regimen in the chemotherapy process can take as long as 42 days to prepare a patient for transplant  at a cost approaching one million dollars  Unfortunately  due to the severe toxicity  complications  and side effects  not all patients will survive the regimen  and despite the arduous regimen  many of the patients will not have responded well enough to the treatment to prepare them to accept a BMT transplant 
In contrast  Iomab B is showing tremendous efficacy results  with 100  of patients responding to the therapy  Additionally  100  of the patients responded to cell engraftment by the 28th day of treatment  This important and differentiating factor is further demonstrated by the overall survival rate of patients  with only a 10  overall rate of survival for chemo patients compared to upwards of 30  survival in data taken from the Fred Hutchinson Cancer Research Center for Iomab B phase I II trials 
The supporting data from both FHCRC and the internally generated company trial data have allowed ATNM to progress to its Pivotal Phase III SIERRA Trial 
ATNM SIERRA TrialThe SIERRA trial is a study of Iomab B in elderly relapsed refractory AML  As mutually agreed with the FDA  the trial design is a single pivotal study  with dependence on trial results to indicate direction  and is enrolling patients 55 years of age or older with relapsed or refractory AML  The study will have a control arm of the physicians choice  using conventional standards of care with curative intent  The primary endpoint is a durable and complete response after six months  180 days  
The trial is designed to efficiently provide distinguishable data sets  with 150 patients being randomly assigned into either the Iomab B arm or the control arm of the trial  Between day 28 42 of the trial  there may be a crossover  whereby patients that have not enjoyed a complete response in the control arm may be subsequently treated with Iomab B  All patients  irrespective of group  will be followed through to the 180 day evaluation period for final efficacy data and response measurement 
Because the control arm is being addressed with curative intent  the comparative analysis will be useful in determining the distinguishing affects of Iomab B over current forms of treatment  The evaluation period will also extend 180 days from the start date  and evaluate safety  tolerability  efficacy  and other modalities and observations 
Taking Iomab B Commercial
Assuming the data is convincing  ATNM then has to define its market  By all indications  the commercial market for Iomab B is compelling  With a highly concentrated BMT market  whereby the top 30 centers perform over 50  of the AML BMT procedures in the United States  Actinium can position themselves to benefit from the current Prospective Payment System  whose exempt cancer centers perform over 20  of all AML BMT procedures  These PPS centers could be reimbursed immediately if Iomab B is approved  increasing the likelihood of its use 
Furthermore  with the reimbursement issue affably addressed  ATNM will also be in a position to benefit commercially from marketing Iomab B independently and will retain full economic rights  enabling ATNM to entertain other strategic opportunities 
The potential financial benefit to Actinium Pharmaceuticals for an approved Iomab B could be extremely lucrative  Transplant activity in the U S  alone is estimated to exceed  4 billion by the year 2020  and with Iomab B being studied in several phase II III trials  inclusive of the SIERRA trial  the opportunities are broad  especially when additional therapeutic focus can be made toward MDS  ALL  NHL HL and MM  different forms of leukemia that Iomab B may be able to effectively treat 
Iomab B has shown every indication of being a winner in treating and conditioning patients for a BMT  The market is craving an alternative to current standards of care  and the early data certainly supports the likelihood for a continued profile that exhibits strong safety and efficacy data  Investors can also anticipate an update from several near term data and value drivers expected from clinical programs and strategic initiatives  These drivers include Phase III trial investigator meeting updates  EU Orphan Designation updates  the completion of patient enrollment by the end of 2017  periodic data publication  and  importantly to investors  interim trial updates throughout 2017 and full top line data expected in the first half of 2018 Identifying the potential in Iomab B  inherent with its clinical successes and near term catalysts  offers less than half the story to be told by ATNM  And  therein lay the safety net for lofty investor prognostications 
Actimab A  ATNM s second clinical trial  holds just as much promise  and similar to Iomab B  does not appear to be even remotely reflected in the share price 
Actimab A And CD33
Actimab A is a treatment for elderly patients that have been newly diagnosed with AML  and is a second and equally compelling reason behind the probable near and long term success for ATNM  Developed at the Memorial Sloan Kettering Cancer Center  Actimab A is a second generation therapy from Actinium Pharmaceuticals  HuM195 alpha program that has been studied in almost 90 patients in four clinical trials 
Actimab A targets CD33  a molecule that is expressed on 90  of AML cells  Actinium 225  the radioisotope used in Actimab A has strong cytotoxicity  which has been pointed out by somepundits as a point of vulnerability in its use  However  ATNM has been keen to demonstrate in explicit terms that even though there is cytotoxins present  they travel only a very small distance  and has demonstrated the toxicity profile to be benign 
This second generation therapy was born through Bismab A  a therapy that showed a clear anti leukemic effect  and was able to clearly demonstrate increased survival rates among patients  However  the isotope bismuth 213 was not a commercially viable product due to various reasons  But  the reason that the term  practicing medicine  is used to describe the profession is that the facilitators of both procedure and science are always in practice  receptive to learning the answers to questions that constantly present themselves 
Therefore  when Bismab A proved itself to not be a commercially viable option  the evolution of the therapy developed into Actimab A by utilizing the commercially viable isotope 225  which has not only shown a clear anti leukemic effect  but also supports an excellent safety and tolerability profile  As for CD33  it has become a validated target in treating AML  and has earned strong interest from major pharmaceutical companies  This interest places ATNM in an enviable position to capitalize on their own clinical studies  as Actimab A is one of the most advanced programs addressing CD33  and has the potential to be best in class in terms of therapeutic value 
While being best in class is a milestone  in and of itself  ATNM made a strategic addition to the management team by hiring Dr  Mark Berger as Chief Medical Officer  and plans to leverage upon his expertise to enhance the clinical development capabilities at the company  Dr  Berger brings to Actinium Pharmaceuticals over 20 years of drug development experience  highlighted by the FDA approvals of Mylotarg for AML  the only drug approved in AML in almost forty years  and Tykerb for breast cancer 
Dr  Berger s skill and experience are a tremendous asset for the company  as they now have a key team member in place that can build a robust clinical development program to execute on the clinical progress of Iomab B  Actimab A  and future clinical programs 
CD33 Interest Invigorated
There is typically little argument when presented with the fact that ATNM is among the leaders in targeting CD33  While Pfizer  NYSE PFE  at one time had a drug on the market  Mylotarg  it was so plagued with debilitating issues that it was withdrawn from the market in 2010  Although Pfizer pulled the drug due to issues unrelated to CD33 targeting  the issues that arose that demonstrated a link to cytotoxic agents  response rates of less than 30  in patients over the age of 60 years old  and serious side effects and tolerability issues reported by patients 
Actimab A  on the other hand  is also a CD33 targeting radiomuunotherapy  addressing ADC  alpha emitters  The product is labeled with alpha emitting Actinium 225  offers a higher dose of energy and a focused range of therapeutic value  Unlike Pfizer s failed product  Actinium s next generation Actimab A has shown significantly less toxicity and a far less degree of adverse side effect in patients  ATNM commenced its phase II trial in September of 2016 
Actimab A  in its own right  is far more deserving of investor respect and value than it is currently realizing  especially when compared to other pharmaceutical companies in the CD33 target space  ATNM has a valuation that is dwarfed by its competitors  irregardless of the fact that ATNM is equal to the task of advancing through its phase II and III trials in relative short order 
Immunogen  for instance  has a market cap of roughly  206 million dollars  significantly higher than the current valuation of  75 million dollars for ATNM  While not necessarily an apples to apples comparison  the stark difference in valuation is questionable  as Actinium Pharmaceuticals is further ahead in clinical trials than IMGN  is targeting New AML  and is utilizing the same ADC alpha emitters  But  markets are rarely efficient when it comes to valuing small and emerging companies  While this is a detriment to ATNM now  it may play in favor of early adopting investors who can clearly see the value drivers behind the company s platforms 
Actimab A Phase II
The current phase II trial for Actimab A has treated 18 patients to date  with patient age being 60 years or older  Where the phase I trial treated patients with relapsed refractory conditions  the phase II trial is targeting newly diagnosed patients  The phase II trial is a dose escalating trial  using a fractionated dosing regimen  compared to the single dose treatment used in the phase I trial 
Safety and tolerability showed compelling and positive results  with no severe or unexpected reports of unfavorable effects  In addition to having a favorable safety and tolerability profile  much was learned from the phase I trial  which has led to a refined and more responsive approach in the phase II data 
The phase II data is showing that the fractionalized dosing of patients led to the hypothesis that peripheral blast burden can have a material impact on patient response  The data showed that fractionalized dosing led to corrections in peripheral blasts  which have led to higher patient response rates  Additionally  these response rates appear to be independent of patient population or severity of disease 
While the preliminary data from the phase II trial is encouraging  there is still work to be done  The phase II trial  which was initiated in September of 2016  will enroll a total of 53 patients  The FDA has agreed to allow the removal of LDAC  low dose cytrabine   which is expected to generate a more straight forward trial protocol  Additionally  ATNM will incorporate PB burden thresholds as part of the inclusion criteria  with a stipulation that hydroxyurea control of PB is allowed  To facilitate the trail in an expeditious and efficient manner  ATNM has planned on doubling the number of trial centers  and to expand the clinical development team  If the trials prove efficacious  there is potential to move into a pivotal trial based on reporting positive data to the FDA  Of further and welcome interest for investors  the open label trail design will allow for one or more interim data analyses and updates 
Drivers For 2017
While the science is often difficult to understand  the main questions that investors typically sift down to are related to the near term value drivers for a company  For ATNM investors  quite a few can be expected 
On the Iomab B front  investors can expect updates and analyses from the phase III SIERRA trial  as well as information generated from the phase III SIERRA trial investigator meeting  Orphan Designation from the EMA was announced in 2016   to compliment the already announced Orphan Designation from the FDA  and the company should be providing regular updates related to continuing enrollment and reports from the Data Monitoring Committee  Investors can expect top line data to be released in the second half of 2018  which will highlight data from the expected 150 patients enrolled in the trial 
Information from the Actimab A trial is also expected to provide some key insight as to progress of that study  Investors can expect interim data in mid 2017 from the recently announced phase II trial  as well as to be informed of the developmental pathway for Actimab A after the meeting with the FDA 
ATNM has a host of opportunities to leverage from  which is expected to lead to additional therapeutic indications and may also target additional clinical programs in 2017 and 2018  with ambitious plans to host four simultaneous clinical programs  Based on the position of the current trials  ATNM may be in a strong position to attract both partnership and licensing opportunities  as well as collaborative and strategic opportunities 
As of October 2016  ATNM had roughly 55 7 million shares outstanding  and approximately  25 million in cash  Liabilities totaled to roughly  3 million dollars  with some of that liability related to derivative liabilities Actinium In 2017
Investors that have been watching ATNM stock during the prior year may have not liked what they have seen from a valuation standpoint  But  from a clinical perspective  they should be excited for the future  In an investment world driven by short term motive and quick gains  investors too often get caught up in a current headline and forget the value in maintaining a disciplined and thought out investment strategy 
A company like ATNM deserves time to develop  as does any company that is working on developing best in class therapeutic treatments  Companies like ATNM are setting the bar for others to follow  and while it may take slightly longer than expected  once that bar is set it will be tough for competitors to clear  ATNM is well funded for the near and intermediate term and is well into the later stages of its clinical trials  With the stock trading at a paltry  75 million market cap  it is unjustly undervalued in relation to its peers 
Just several months ago  ATNM traded almost three times higher in price with data that was less compelling than what is being demonstrated today  While markets remain inefficient  they do ultimately correct  and it is likely that the share price may soon catch up with the fundamentals at ATNM 
With a full plate of data expected to be released in 2017 and 2018  exclusive of the anticipated additional trials planned by ATNM  the current share price may offer a compelling case for investors to take an early position and hold confidence that management will execute on its strategic mission  While no stock goes straight up  there does come a point when valuations for companies that are demonstrating proof of concept  coupled with a strong balance sheet  border on becoming ridiculously mispriced  Based on all of the action at ATNM  supported by strong data and concurrent phase II and phase III trials  calling the current pps  ridiculously low  is an understatement 
Finally  while it may be premature to call ATNM a potential  30 bagger   as was the case for Celator  it is not unreasonable to project the potential for ATNM to enjoy a transformational rise in share price as they begin to release more robust data in the next several months  In the meantime  it may be fair to also infer that just about no value has been given to either Iomab B or Actimab A  two clinical trials that clearly deserve far more respect and consideration than they are getting 
Disclosure  This article reflects my own opinions and unique articulation  This article is not intended to offer investing advice  guarantee 100  accurate predictions or to be interpreted as providing a personal recommendation  What I can guarantee  though  is accurate research  thoughtful analysis and an enthusiasm about any stock that I cover Additional Disclosure  I have no position in any stock mentioned  but may initiate a long position in ATNM within the next 72 hours 
 This article was originally featured on  ",2017-02-07,CNA Finance,https://www.investing.com/analysis/why-actinium-pharmaceutics-(atnm)-stock-may-be-even-better-than-celator-200174977,200174977
220783,442299,PFE,The Week Ahead  Trump Versus Yellen  Round One,opinion,"A week featuring the Fed Chair s semi annual Congressional testimony  and daily speeches by most of her Fed colleagues  would normally represent a commanding first choice for the upcoming theme  This time is different   Yes  I know that you are never supposed to say that   The first weeks of the Trump Administration have generated daily news on a wide range of topics  each of which draws attention 
The combination of the two will provide an irresistible topic for the punditry  It will be 
Trump v  Yellen  round one 
Last Week
Last week the light economic calendar provided mixed news  but there was still a rally in stocks 
Theme Recap
In my last WTWA I predicted a discussion about whether the current market optimism was justified  Despite some breaking news during the week  especially about earnings  that theme got plenty of attention 
The Story in One Chart
I always start my personal review of the week by looking at this great chart of the S P 500  via Jill Mislinski  She notes the new high and the overall gain of 0 81  for the week 

Doug has a special knack for pulling together all the relevant information  His charts save more than a thousand words  Read his entire post for several more charts providing long term perspective 
The News
Each week I break down events into good and bad  Often there is an  ugly  and on rare occasions something very positive  My working definition of  good  has two components  The news must be market friendly and better than expectations  I avoid using my personal preferences in evaluating news   and you should  too 
This week s news was again mixed  with a tilt to the positive side 
The Good
Framing lumber prices strengthen  
Jobless claims are so low they are in   Scott Grannis discusses the implications  with a chart packed review of policy proposals and the labor force 

JOLTS signaled a healthy labor market  Many try to use JOLTS as a measure of job growth  This is unhelpful  since there are better measures for that  It is an example of writing about what you think people want to hear  The data are best interpreted as a measure of the health and structure of the labor market 
The quit rate is seen as a measure of health  since it reflects those who voluntarily leave jobs  expressing confidence in other opportunities  There is a nice discussion of JOLTS and several charts from  



The Beveridge Curve is the most important interpretation  emphasized by Yellen  What we really want to know is the tightness of the labor market  Here is a   noting what is needed for labor market improvement and the general counter clockwise movement after a recession   Readers looking for a Silver Bullet Award might want to check out the very lame interpretation at ZH  where one of the Tylers only discusses the gap  not the trend or slope  The most recent update is a month old  from the BLS 

Corporate earnings  I am scoring this as a slight positive  I want to discuss it  so I put it somewhere  The results are mixed  Earnings are below expectations  revenues are higher  and outlook  always negative  is not as bad as the long term average  There is a year over year gain for a second consecutive quarter  not seen for two years      Brian Gilmartin  the leading sectors  He also has something you will not find anywhere else   an analysis of the   Great work 

The Bad
Michigan sentiment dipped to 95 7 on the preliminary estimate  down a bit from last month s 98 5 and missing expectations  This month s report has a special feature that we need to know   divided perceptions based upon politics  From the  

When asked to describe any recent news that they had heard about the economy  30  spontaneously mentioned some favorable aspect of Trump s policies  and 29  unfavorably referred to Trump s economic policies  Thus a total of nearly six in ten consumers made a positive or negative mention of government policies  In the long history of the surveys  this total had never reached even half that amount  except for five surveys in 2013 and 2014 that were solely dominated by negative references to the debt and fiscal cliff crises  Moreover  never before have these spontaneous references to economic policies had such a large impact on the Sentiment Index  a difference of 37 Index points between those that referred to favorable and unfavorable policies  These differences are troublesome  the Democrat s Expectations Index is close to its historic low  indicating recession  and the Republican s Expectations Index is near its historic high  indicating expansion   While currently distorted by partisanship  the best bet is that the gap will narrow to match a more moderate pace of growth  Nonetheless  it has been long known that negative rather than positive expectations are more influential in determining spending  so forecasts of consumer expenditures must take into account a higher likelihood of asymmetric downside risks 


High frequency indicators are a touch more negative  New Deal Democrat does an   I always read it and any serious investor should join me 
The Ugly
Scamming 9 11 heroes and NFL concussion victims  Pretty low  if true  Some will go to any lengths to make a buck     
The Silver Bullet
I occasionally give the Silver Bullet award to someone who takes up an unpopular or thankless cause  doing the real work to demonstrate the facts  No award this week  Nominations are welcome  For inspiration  you might test yourself on the misleading visualization techniques described by   I see these daily  and so do you  The most common in financial posts is this one 

The Week Ahead
We would all like to know the direction of the market in advance  Good luck with that  Second best is planning what to look for and how to react  That is the purpose of considering possible themes for the week ahead  You can make your own predictions in the comments 
The Calendar
We have a normal week for economic data 
The  A  List
Housing starts and building permits  Th   Little change expected in these important leading indicators 
Leading indicators  F   Popular economic gauge expected to remain strong 
Retail sales  W   Little is expected from the January data 
Initial jobless claims  Th   How long can the amazing strength continue 
The  B  List
Industrial production  W   A small gain is expected in the volatile series 
Philly Fed  Th   Popular report is the first look at February data 
PPI  T   Starting to run a bit hotter  That will attract more attention if it continues 
CPI  W   See PPI above 
Business inventories  W   December data affecting Q4 GDP  Favorite spin target  Voluntary or involuntary build up 
Crude inventories  Th   Recently showing even more impact on oil prices  Rightly or wrongly  that spills over to stocks 
Chair Yellen gives her semi annual Congressional testimony on Tuesday  Senate  and Wednesday  House   The presentations are the same and the order alternates  If you don t know why  then you missed that class in Congressional Government  There are also appearances by a host of other Fed Governors and Presidents  Questions will probe the state of the economy  the new political environment  and the likely pace of rate hikes 
Earnings reports will remain important  Early actions from the Trump Administration have captured the spotlight and will continue to do so 
Next Week s Theme
During the campaign  Candidate Trump had plenty of criticism for the Fed and for Chair Yellen  Since the election  he has had much less to say  With Fed Gov  Daniel Tarullo s resignation  the President will now have three openings to fill  out of seven   Next year he can replace Yellen as Chair  Although technically her term continues  most resign when replaced as Chair  He has the power to change the style  background of members  and policies 
Yellen is testifying before Congress this week on Tuesday and Wednesday  While the topic is the state of the economy  we should expect some aggressive questioning  Will her testimony or answers draw a Presidential tweet  which we are calling a T Wop   The punditry will find this combination irresistible  I expect plenty of media coverage for a clash that will probably be repeated  We can think of it as 
Trump v  Yellen  Round One
The basic possibilities are interesting  but mostly speculative so far  Here is what Trump might do 
Trump will support some of the various moves to  audit  the Fed and reduce its power 
Trump will T Wop Yellen this week  and remove her at the first opportunity 
Trump will resume the Fed criticism  and start his process for filling the vacancies 
Trump will moderate criticism while Yellen is still at the reins 
Trump will seek candidates that have some traditional credentials 
Trump will decide to keep Yellen as Chair 
Here is what Yellen might do 
Make an aggressive statement criticizing some Trump policies 
Avoid  Trump  issues in the statement  but provide some frankly critical answers to questions 
Announce that she plans to stay on the Fed if replaced as Chair 
Suggest that the Fed policy is changing in a way that Trump sought 
Make conciliatory remarks about the direction of Trump policy  especially economic stimulus 
What fun  Expect the pundits and their guests to go wild 
What does this mean for investors  As usual  I ll have a few ideas of my own in today s  Final Thought  
Quant Corner
We follow some regular great sources and the best insights from each week 
Risk Analysis
Whether you are a trader or an investor  you need to understand risk  Think first about your risk  Only then should you consider possible rewards  I monitor many quantitative reports and highlight the best methods in this weekly update 
The Indicator Snapshot

The Featured Sources 
Bob Dieli  The  C Score  which is a weekly estimate of his Enhanced Aggregate Spread  the most accurate real time recession forecasting method over the last few decades   His subscribers get  including both an economic overview of the economy and employment   see below  
Holmes  Our cautious and clever watchdog  who sniffs out opportunity like a great detective  but emphasizes guarding assets 
Brian Gilmartin  Analysis of  for the overall market as well as coverage of many individual companies 
Doug Short  The World Markets Weekend Update  and much more  
RecessionAlert  Many  for both economic and market analysis  While we feature his recession analysis  Dwaine also has several interesting approaches to asset allocation  Try out his new public  
Georg Vrba  The  and much more  for an array of interesting methods  Georg  Bob Dieli s enhanced aggregate spread  considering when it might first give a recession signal  The most recent update is for the Business Cycle Indicator 

 that the early commentary is in  S P 2018 earnings estimates at  148  Nearly everyone will regard that as too high  but others will start citing it  This happens even more after the third quarter of each year 
 that their GDP Now model has been running too hot due to net exports  A change might be in the works 
How to Use WTWA  especially important for new readers 
In this series  I share my preparation for the coming week  I write each post as if I were speaking directly to one of my clients  Most readers can just  listen in   If you are unhappy with your current investment approach  we will be happy to talk with you  I start with a specific assessment of your personal situation  There is no rush  Each client is different  so I have eight different programs ranging from very conservative bond ladders to very aggressive trading programs  A key question 
Are you preserving wealth  or like most of us  do you need to create more wealth 
Most of my readers are not clients  While I write as if I were speaking personally to one of them  my objective is to help everyone  I provide several free resources  Just write to info at newarc dot com for our current report package  We never share your email address with others  and send only what you seek   Like you  we hate spam  
Best Advice for the Week Ahead
The right move often depends on your time horizon  Are you a trader or an investor 
Insight for Traders
We consider both our models and the top sources we follow 
Felix and Holmes
We continue with a strongly bullish market forecast  All our models are now fully invested  The group meets weekly for a discussion they call the    In each post I include a trading theme  ideas from each of our four technical experts  and some rebuttal from a fundamental analyst  usually me   We try to have fun  but there are always fresh ideas  Last week there was a great discussion about whether your trading results are skill or luck  Do you know  And BTW  Athena likes Advanced Micro Devices Inc  NASDAQ AMD  
Top Trading Advice
 how to measure your trading performance   and you must do this 
  Yes  it is a little late  but you can join in just as others quit going to the gym  Dave Landry has a nice list of ideas  Some of these seemed wise  but others sounded like the Delphic Oracle  What do you think 

Trading methods not working  Here is an idea  When you hear about a hot IPO look for a stock with a similar name  Buy it on the confusion greater fool theory  It worked for   OTC STVI   This is not the first such occasion   I hope readers can recognize tongue in cheek  

Insight for Investors
Investors have a longer time horizon  The best moves frequently involve taking advantage of trading volatility 
Best of the Week
If I had to pick a single most important source for investors to read this week it would be this post from Seeking Alpha Editor Gil Weinreich   He cites  of the current retirement risks  responding to a Kiplinger article that retirement was now 10 times riskier 
Wow  This is a great discussion of a topic with widespread significance  With all of the scary stories about retirement  it is helpful to read something that is calm and analytical 
Gil s daily column is a must read for financial advisors and usually valuable for individual investors as well 
Stock Ideas
Eddy Elfenbein s best ideas are in his new ETF     which is off to a nice start  That does not stop him from making valuable commentary on news  markets  and other stocks  Last week he   NYSE INGR   an intriguing idea 
Our trading model  Holmes  has joined our other models in a weekly market discussion  Each one has a different  personality  and I get to be the human doing fundamental analysis   the dip buying Holmes  who has been very hot  liked Casey s  CASY   In a big surprise  Holmes sold the next morning  so I did a rapid update for readers  This is very unusual behavior  but it is only one of sixteen Holmes positions  Holmes is worth watching 
Seeking yield 
 five dividend stocks that should do reasonably well in a market correction  These are the kind of stocks where we  enhance yield  with sales of rapidly decaying near term calls  We make four times as much from the call sales as we do from the dividends 
 does a deep dive on Pfizer  NYSE PFE   I agree  but I see it as another call selling candidate 
Portfolio Management
David Merkel provides  about rebalancing your portfolio  I love it  and not just because the featured band is from one of my old schools  The band is great and the  Tuba March  is awesome 
Personal Finance
Professional investors and traders have been making Abnormal Returns a daily stop for over ten years  If you are a serious investor managing your own account  this is a must read  Even the more casual long term investor should make time for a weekly trip on Wednesday  Tadas always has first rate links for investors in his  This week may be the finest entry in a long series  I strongly recommend a look at the great links cited  Look at all the posts on the fiduciary rule  The average investor needs to understand who is selling and who is acting in his interest  For retirees or near retirees  the  is very valuable  Most people do not think about the priority of various retirement needs  but they should 
Thinking about Social Security 
 has a nice explanation of the tradeoffs in choosing when to start benefits 

Watch out for 
Trading the VXX  a  nearly perfectly engineered tool to separate worried investors from their money  It is the unfenced swimming pool of ETF ETNs   See Paul Kedrosky s  
Warnings about value traps     Once again  one person s value trap is my candidate for selling near term calls  There is always a way to profit if you are right about the major stock characteristics 
And more on value investing
  You need mental toughness  Strategies that work very well in the long term will have dry spells 
Final Thoughts
Before turning to the Fed  I want to comment on a major news theme from last week  in line with what we expected  Is the Trump Rally running out of steam  Some might find this ironic when results remain strong  Here is the three part problem 
Pundits and investors  seeking a simple post election explanation for the stock rally  attributed it to Trump policies 
Now that some of these policies seem delayed  they expect markets to get softer 
But what if the rally was a return to earnings fundamentals and the elimination of pre election uncertainty  as I suggested last week  with some support from Dr  Ed  
What about the Fed 
Once in office  Presidents always like low interest rates  Trump will probably replace Yellen  but with whom  If the cabinet provides any precedent  we can expect some non Ivy League  non economists  I have frequently argued that most intelligent people with a reasonable background would be part of a Fed consensus after their appointment 
The importance of the issues  the venue  and the evidence presented by staff all nudge in this direction  I once had the chance to suggest this idea to former Dallas Fed President Bob McTeer  and he agreed   It is easy to draw out a confirming answer in such conversations  but we talked at some length and I really wanted to know  
Parsing through the possibilities described above  I expect to see little change in Fed policy  The new President will wind up appointing people with traditional credentials  but perhaps with different policy viewpoints  He will not reappoint Yellen  although people forget that the Fed Chair is often appointed by Presidents of both parties   Greenspan and Bernanke are the most recent examples   He will not aggressively push for a change in policy  In fact  some are already claiming that the modest Fed rate increases are anti Trump  Yellen will probably not remain after her term as chair  unless the new appointees are jarringly different in methods or policy preferences 
The Fed news has dramatically different significance for traders and investors 
For traders  this week will be especially difficult to game  Since that community has over emphasized the Fed for the entire rally  unable to explain the gains any other way  there might be some big fluctuations  Since there is little precedent for this  we cannot even guess what the content based algorithms will do 
For investors  it is another opportunity  Since the events have little real impact on expected earnings and the economic cycle  we can have shopping lists ready  My portfolio rebalancing has raised my cash levels  It is not fear of a correction  but a natural process ",2017-02-12,Jeff Miller,https://www.investing.com/analysis/weighing-the-week-ahead:-trump-v.-yellen-round-one-200175379,200175379
220784,442300,PFE,Investors Are Closely Watching Pfizer Inc ,opinion,"Pfizer Inc  NYSE PFE  has been included in the investors  watch list in the Healthcare space  which focused on drug manufacturers 
The stock remained positive and changed hands at  33 51  up from the previous close of 2 32  in recent sessions  As the stock continues to show good signs  analysts have taken a closer look at the company s recent data 
The pharmaceutical company has been competing well with others in the Healthcare space and continues to offer an integrated factor 
The company is currently changing hands with a market capitalization of  203 54 billion  suggesting a positive adjustment for revenues that are constantly growing by 7 93  on a quarterly year basis ahead of its recent quarterly report announcement 
Meanwhile  Pfizer Inc  gained 4 62  last month  which came in at a relatively strong transaction volume  The stock has underperformed the S P 500 by 23 32  which stood there in a less volatile market  compared with most of the other stocks on the exchange  
Will Pfizer Move Higher 
Research firms covering shares of the pharmaceutical company are expecting the stock to change hands between  30 and  52 within the next year  The mean consensus price target settled at  37 846 
Analysts are expecting the company to post an earnings per share  EPS  of  0 66 for the current quarter  topping the actual earnings of  0 47  which was recently announced for the period ending on December 31  2016 
Given the anticipated next release of the company  it is expected that investors will closely watch on the company s next earnings report estimated on May 2  2017 
The chart below illustrates the price movement of the Pfizer Inc  ahead of the anticipated next earnings release 
The stock is showing a bullish tone  after shares posted four straight gains  both in a light and heavy trading volume  Additionally  the RSI currently stood at 72 3494  which suggest that the overbought level was already reached 
ConclusionGiven that market participants are expected to closely watch the company s next earnings release  along with the bullish tone  the RSI could give a signal for the stock to reach its peak as the overbought level has already been reached 
Moreover  investors are recommended to close any buy position  as shares could decline until the next earnings report ",2017-02-17,FSM News,https://www.investing.com/analysis/pfizer-inc:-active-stock-200176085,200176085
220786,442302,PFE,European stocks edge higher in light trade  Dax up 0 26 ,news,"Investing com   European stocks edged higher on Monday  as trading volumes were expected to remain light in the absence of any major economic reports to be released from the euro zone  while markets continued to eye developments in the Ukraine 
During European morning trade  the DJ Euro Stoxx 50 gained 0 39   France s CAC 40 edged up 0 12   while Germany s DAX rose 0 26  
Investors remained cautious as hostilities between Russia and Ukraine continued  On Friday  U S  Secretary of State John Kerry warned that Washington was ready to step up sanctions on Russia 
The West is accusing Russia of leading a separatist revolt in eastern Ukraine after it annexed Crimea last month 
Financial stocks were mixed  as French lenders BNP Paribas  BNPP PARIS  and Societe Generale  SOGN PARIS  gained 0 71  and 0 10   while Germany s Deutsche Bank  DBKGn XETRA  declined 0 56  
Among peripheral lenders  Intesa Sanpaolo  ISP MILAN  rose 0 21  and Unicredit  CRDI MILAN  shed 0 31  in Italy  while Spanish banks Banco Santander  SAN MADRID  and BBVA  BBVA MADRID  climbed 0 41  and 0 42  
Elswhere  Bayer  BAYGN XETRA  surged 4 12  after the German pharmaceutical and chemicals conglomorate said it is exploring a sale of its  10 billion plastics unit to focus on boosting its health business 
The news came after the company reported a 12  rise in first quarter profit  helped by new medicines and a rebound at its plastics unit 
In London  FTSE 100 added 0 20   led by Astrazeneca  AZN LONDON   up 11 99   after Pfizer  NYSE PFE  confirmed that it is interested in acquiring the U K  drugmaker for about  58 8 billion  The acquisition would be one of the largest takeovers in the industry s history 
Meanwhile  financial stocks were mostly lower  as HSBC Holdings  HSBA LONDON  dipped 0 03  and Lloyds Banking  LLOY LONDON  slipped 0 13   while the Royal Bank of Scotland  RBS LONDON  tumbled 1 06   Barclays  BARC LONDON  overperformed on the other hand  adding 0 21  
In the mining sector  stocks were mostly lower  Glencore Xstrata  GLEN LONDON  dropped 0 70  and Bhp Billiton  BLT LONDON  retreated 0 86   while rival company Rio Tinto  RIO LONDON  saw shares plummet 1 90  
In the U S   equity markets pointed to a higher open  The Dow 30 futures pointed to a 0 14  rise  S P 500 futures signaled a 0 16  increase  while the Nasdaq 100 futures indicated a 0 12  gain 
Later in the day  the U S  was to release private sector data on pending home sales ",2014-04-28,Investing.com,https://www.investing.com/news/stock-market-news/european-stocks-edge-higher-in-light-trade;-dax-up-0.26-279867,279867
220792,442308,PFE,Market Update  The May Affect,opinion,"A break up is never easy and that s what the markets are struggling with this morning  Theresa May s speech yesterday has shaken the market  Although  indices have rebounded slightly  Cable is moving downwards after enjoying a rally on the back of May s speech 

The Asian Market

Asian Markets were lower yesterday after British Prime Minister Theresa May announced that Britain would be leaving the single market 

Fears circulating around what Brexit really means for trade caused investors to shy away from Asian markets  The Nikkei 225 index lost about 0 6  following May s speech  It has now regained some of those losses  up 0 2   trading at  18805  The S P 200 was down 0 8   it has rebounded slightly  trading upwards 0 9   trading at  2264 50 

China s President Xi Jinping opened the World Economic Forum in Davos yesterday to promote globalisation  Nationalist and populist movements will hurt trade with China  The nation is worried about barriers to trade arising from the western world 

 Pursuing protectionism is like locking oneself in a dark room  No one will emerge as a winner in a trade war     President Xi Jinping

The UK Market

Cable is down 0 6  this morning  trading at  1 23  The pound has lost momentum following May s speech  The current trend of GBPUSD is directly related to May s Brexit priorities  Repeatedly reminding the market that there will be a  global Britain  and that the nation is still a part of the European mindset  that they remain  friends   The final Brexit deal  made with the European Union  will be put to parliament to vote on  which eased investor s concerns 

FTSE was down 1  as investors fear that a stronger pound could hurt exports  The index is recovering slightly  trading 0 09  higher at  7153 50

The US Market

Trump s comments that the dollar is overvalued sent USD currency pairs lower yesterday  US stocks also suffered from the statement  trading lower on Tuesday 

During the beginning of the year  the dollar was caught in a horizontal trend  In the week of Trump s inauguration  the dollar could be correcting itself from the gains seen in the fourth quarter of 2016  A decline in bond yields is also a concern for investors  The 10 year Treasury prices dropped 2 3   the lowest level in seven weeks 

Political news dominated the market  overshadowing earning releases so far 

Market Watchlist

Big Pharmaceutical companies could be under serious constraint once Donald Trump takes the oval office  Eighteen million people in the US could become uninsured in the coming year and premiums could shoot up 

Last week  congress approved a budget that accelerates the time it takes to repeal the heath care law  However  with no concrete replacement bill  the repeal could be a disaster for millions of healthcare recipients 

Watch out for Pfizer  NYSE PFE  and Perrigo in the next coming weeks 
Pfizer  
Perrigo",2017-01-18,AvaTrade,https://www.investing.com/analysis/market-update:-the-may-affect-200172824,200172824
220809,442325,PFE,Pfizer Q1 earnings weaker than expected  shares drop 3 ,news,Investing com   U S  pharmaceutical giant Pfizer reported weaker than expected first quarter earnings  sending its shares lower in pre market trade  it said on Tuesday Earlier in the day  in its first quarter earnings report  Pfizer said adjusted earnings per share came in at USD0 54  below expectations for USD0 55 per share The company s first quarter revenue totaled USD13 5 billion  missing expectations for revenue of USD14 billion Pfizer said it expected full year earnings to come in a range between USD2 14 to USD2 24 per shares  compared to a previous forecast of USD2 20 to USD2 30 per share  Following the release of the report  shares in PFE fell 3  in pre market trade The outlook for U S  equity markets remained modestly lower  The Dow Jones Industrial Average futures indicated a loss of 0 1  at the open  S P 500 futures pointed to a decline of 0 15  and Nasdaq 100 futures indicated a fall of 0 1  ,2013-04-30,Investing.com,https://www.investing.com/news/stock-market-news/pfizer-q1-earnings-weaker-than-expected;-shares-drop-3-247187,247187
220814,442330,PFE,Pfizer  PFE  Ibrance Positive In Phase III Breast Cancer Study,opinion,"Pfizer Inc    NYSE PFE   announced that detailed results of phase III PALOMA 2 study evaluating the combination of its breast cancer drug Ibrance  palbociclib  and Novartis AG s   NYSE NVS   Femara  letrozole  for the treatment of first line ER   HER2  metastatic breast cancer were published in The New England Journal of Medicine In the study  it was seen that a combination of Ibrance and Femara led to an improvement in progression free survival  PFS   or the time before tumor growth  by more than 10 months compared with Femara plus placebo  In other words  the study demonstrated median PFS for women treated with Ibrance plus Femara of 24 8 months  compared with 14 5 months on the Femara  placebo combination arm  indicating a 42  reduction in the risk of disease progression  PALOMA 2 had enrolled a total of 666 women from 186 global sites in 17 countries  We remind investors that this data was presented at the 52nd American Society of Clinical Oncology  ASCO  Annual Meeting in June On the basis of the phase II PALOMA 1 study  Ibrance was approved under accelerated approval in Feb 2015 for use in combination with Femara for the treatment of post menopausal women with estrogen receptor positive  human epidermal growth factor receptor 2 negative  ER   HER2   advanced or metastatic breast cancer who did not received previous systemic treatment for their disease  Pfizer believes that the PALOMA 2 confirmatory trial has proven the clinical benefit of the combination therapy and should help the company obtain continued approval in the U S in this indication A supplemental New Drug Application to support the conversion of the accelerated approval into a regular approval based on the PALOMA 2 results has been submitted to the FDA Earlier this year  the FDA approved a label expansion for Ibrance to include the treatment of hormone receptor positive  HR    HER2 advanced or metastatic breast cancer in combination with AstraZeneca plc s   NYSE AZN   Faslodex in patients whose disease has progressed following endocrine therapy Meanwhile  the European Medicines Agency s  EMA  Committee for Medicinal Products for Human Use  CHMP  has rendered a positive opinion on the approval of Pfizer s marketing authorization for Ibrance for the treatment of women with HR  HER2  locally advanced or metastatic breast cancer  Presently  Ibrance is approved in over 50 countries Ibrance has been off to a strong start  having registered sales of  1 5 billion in the second half of 2016 compared with  0 4 million in the year ago period  The drug s label and geographical expansion would boost its commercial potential significantly  Going forward  we expect investor focus to remain on the commercialization and sales ramp up of Ibrance PFIZER INC Price
 

   Zacks Rank   Key Picks
Pfizer currently carries a Zacks Rank  3  Hold   A better ranked stock in the health care sector is Cambrex Corp    NYSE CBM    which sports a Zacks Rank  1  Strong Buy   You can see  
Cambrex s earnings estimates increased from  2 46 to  2 55 for 2016 and from  2 91 to  3 06 for 2017 over the last 60 days  The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 19 78   Its share price has increased 9 7  year to date 
Zacks  Top Investment Ideas for Long Term Profit
How would you like to see our best recommendations to help you find today s most promising long term stocks  Starting now  you can look inside our portfolios featuring stocks under  10  income stocks  value investments and more  These picks  which have double and triple digit profit potential  are rarely available to the public  But you can see them now ",2016-11-17,Zacks Investment Research,https://www.investing.com/analysis/pfizer-(pfe)-ibrance-positive-in-phase-iii-breast-cancer-study-200165342,200165342
220815,442331,PFE,Novartis Buys Selexys On Favorable Phase II Data On SelG1,opinion,"Swiss drug maker Novartis AG   NYSE NVS   announced that it has acquired Selexys Pharmaceuticals Corporation  a privately held company specializing in the development of therapeutics for certain hematologic and inflammatory disorders  following the receipt of results from the phase II SUSTAIN study on SelG1 for the treatment of patients with sickle cell disease  SCD  The study evaluated the use of SelG1  an anti P selectin antibody  in the reduction of vaso occlusive pain crises in SCD patients  Results were presented at the plenary scientific session of the American Society of Hematology As per the terms of the agreement  the value of the transaction could reach  665 million  including upfront  acquisition and milestone payments We remind investors that Novartis had obtained the exclusive right to acquire Selexys and SelG1 in 2012 The acquisition of Selexys represents an important step toward the continued development of SelG1  which will complement and expand Novartis  hematology pipeline Considering the lack of FDA approved drugs for SCD  there exists significant unmet for new treatment options Meanwhile  among other companies  GlycoMimetics  Inc    NASDAQ GLYC   is evaluating its pan selectin antagonist  rivipansel  in a phase III study for the treatment of vaso occlusive crisis in SCD  in collaboration with Pfizer Inc    NYSE PFE    Rivipansel enjoys a Fast Track in the U S   and orphan drug status in both the U S  and the EU NOVARTIS AG ADR Price
    Zacks Rank   Key PicksNovartis currently carries a Zacks Rank  3  Hold   Vanda Pharmaceuticals  Inc    NASDAQ VNDA   is a better ranked stock in the health care sector  with a Zacks Rank  1  Strong Buy   You can see  Vanda s loss estimates narrowed from 68 cents to 56 cents for 2016 over the last 60 days  while its earnings estimates increased from 16 cents to 17 cents for 2017  The company posted a positive earnings surprise in three of the last four quarters with an average beat of 56 65  The Best Place to Start Your Stock SearchToday  you are invited to download the full list of 220 Zacks Rank  1  Strong Buy  stocks   absolutely free of charge  Since 1988  Zacks Rank  1 stocks have nearly tripled the market  with average gains of  26  per year  Plus  you can access the list of portfolio killing Zacks Rank  5  Strong Sells  and other private research ",2016-11-21,Zacks Investment Research,https://www.investing.com/analysis/novartis-buys-selexys-on-favorable-phase-ii-data-on-selg1-200166055,200166055
220839,442355,PFE,European stocks add to gains in choppy trade  DAX up 0 48 ,news,Investing com   European stocks added to gains in choppy trade on Tuesday  as markets continued to hope that Spain would request a full scale bailout  allowing the European Central Bank to start buying Spanish government bonds During European afternoon trade  the EURO STOXX 50 gained 1 11   France s CAC 40 rose 0 80   while Germany s DAX 30 was up 0 48  The financial sector remained in focus after shares of British bank Standard Chartered bank plunged 29 29  in London  following steep losses in Asia after the New York State Department of Financial Services threatened to strip its state banking license  claiming it was a  rogue institution  Officials from the DFS said Standard Chartered concealed GBP160 billion in transactions tied to Iran  in violation of U S  sanctions In Germany  shares in the financial sector were lower  with shares of German lender Deutsche Bank down 0 16  and Commerzbank shares also losing 0 16      However  automakers were leading gains  with shares of Volkswagen up 1 09   while BMW and Daimler rallied 1 11  and 1 02  respectively Meanwhile  shares of German energy provider RWE surged 1 48  after the company said that it has increased its Polish wind energy portfolio on Monday In France  shares of insurer Axa were up 1 38   while lenders BNP Paribas and Societe Generale were up 0 35  and 1 37  respectively In London  the FTSE 100 dipped 0 03   led lower by declines the financial sector Shares of lenders Barclays and Royal Bank of Scotland lost 0 80  and 1 44  respectively Gains in the commodity sector supported the FTSE  with shares of Anglo American surging 2 76   Xstrata jumping 2 32  and BP Plc gaining 2 14  Also Tuesday  shares in pharmaceutical company Elan tumbled 12 79  on the Irish Stock Exchange after a partnership with Johnson   Johnson and Pfizer to develop an Alzheimer s drug ended following a second failure in a clinical trial In the U S   equity markets pointed to a modestly higher open  The Dow Jones Industrial Average futures pointed to a 0 16  rise  S P 500 futures signaled a 0 33  gain  while the Nasdaq 100 futures indicated a 0 55  increase ,2012-08-07,Investing.com,https://www.investing.com/news/stock-market-news/european-stocks-add-to-gains-in-choppy-trade;-dax-up-0.48-236803,236803
220840,442356,PFE,Euro stocks soar on Spanish bailout hopes  DAX up 0 71 ,news,Investing com   European stocks closed higher Tuesday  as markets  speculate that Spain would request a full scale bailout  allowing the European Central Bank to start buying Spanish government bonds   At the close of European trade  the EURO STOXX 50 gained 1 71   France s CAC 40 soared 1 52   while Germany s DAX 30 added 0 71    The financial sector remained in focus after shares of British bank Standard Chartered bank plunged 29 29  in London  following steep losses in Asia after the New York State Department of Financial Services threatened to strip its state banking license  claiming it was a  rogue institution    Officials from the DFS said Standard Chartered concealed GBP160 billion in transactions tied to Iran  in violation of U S  sanctions   In Germany  shares in the financial sector were lower  with shares of German lender Deutsche Bank down 0 16  and Commerzbank shares also losing 0 16        However  automakers were leading gains  with shares of Volkswagen up 1 09   while BMW and Daimler rallied 1 11  and 1 02  respectively   Meanwhile  shares of German energy provider RWE surged 1 48  after the company said that it has increased its Polish wind energy portfolio on Monday   In France  shares of insurer Axa were up 1 38   while lenders BNP Paribas and Societe Generale were up 0 35  and 1 37  respectively   In London  the FTSE 100 jumped 0 56   despite declines the financial sector   Shares of lenders Barclays and Royal Bank of Scotland lost 0 80  and 1 44  respectively   Gains in the commodity sector supported the FTSE  with shares of Anglo American surging 2 76   Xstrata jumping 2 32  and BP Plc gaining 2 14    Also Tuesday  shares in pharmaceutical company Elan tumbled 12 79  on the Irish Stock Exchange after a partnership with Johnson   Johnson and Pfizer to develop an Alzheimer s drug ended following a second failure in a clinical trial   Stocks followed higher in the U S  with the Dow up 0 64   the S P 500 higher by 0 80  and the tech heavy Nasdaq moving ahead by 0 95   Wednesday  traders are awaiting US non farm productivity  New Zealand and Australia Unemployment numbers as well as China s CPI and PPI ,2012-08-07,Investing.com,https://www.investing.com/news/stock-market-news/euro-stocks-soar-on-spanish-bailout-hopes;-dax-up-0.71-236819,236819
220843,442359,PFE,Fed s Policy Meeting Starts Today,opinion,"Members of the Federal Open Market Committee  FOMC  or The Fed  are meeting today and tomorrow to discuss U S  policy regarding interest rates  With the presidential election one week from today  it is highly unlikely the Fed will make a move  lest they get caught up in the media circus that has become the 2016 race for the White House 

	Chances for an interest rate hike of 25 basis points are roughly 70  for next month  when the Fed meets again in mid December  With strong domestic employment and the global economy gaining traction of late  it would seem an optimum time for the first raise since a year ago December 

	Biggest movers in the early market this morning  Gannett  has announced it is no longer pursuing the acquisition of TRONC   the media business formerly part of The Tribune Company  It is unclear whether some agreement will be made to combine services of the two firms  but a straight takeover is now off the table  GCI shares  which had tumbled 50  over the past 6 months  are up 8  on this news  TRNC  on the other hand  is down 30  in the pre market 

	Q3 earnings season continues  Pfizer  NYSE PFE   missed slightly on both top and bottom lines    13 05 billion insoles and 61 cents per share were a touch lower than the  13 1 billion and 62 cents expected  Archer Daniels Midland  beat bottom line estimates easily   59 cents per share topped the 47 cents expected   on  15 83 billion in the quarter  which was down from the Zacks consensus estimate of  16 05 billion  Kellogg  also posted a big beat on earnings   96 cents zoomed past the 87 cents estimated   but revenues of  3 25 billion was short the  3 29 billion expected 

	However  with the omnipresent General Election looming  little else matters to investors at this point  A surprise move by the Fed is the only thing that could shock the market near term  Although chances of a Hillary Clinton victory are roughly 3 to 1 right now  market participants remain wary of the spectre of a Donald Trump upset  which would infuse a big dose of uncertainty into the stock market 

	Don t take my word for it  check out Zacks Executive VP Steve Reitmeister s take on the effects of the election in his latest Profit From the Pros article ",2016-10-31,Zacks Investment Research,https://www.investing.com/analysis/fed's-policy-meeting-starts-today-200161974,200161974
220845,442361,PFE,Euro stocks  plunge on Fed words  Spanish auction  DAX slammed 2 84 ,news,Investing com   European shares plunged Wednesday as the Federal Reserve lowered expectations for additional monetary easing and Spain missed its maximum target in a bond sale   At the close European trade  the EURO STOXX 50 fell 2 46   France s CAC 40 dropped 2 74   while Germany s DAX traded lower by 2 84    Meanwhile  in the U K  the FTSE 100 gave back 2 30     Igniting the risk off flight   yesterday the Federal Reserve revealed in its meeting minutes that it is holding off from increasing monetary easing  unless prices climb at a rate slower than its 2  target    Meanwhile  Spain sold EUR2 6 billion of bonds  near the minimum target and borrowing costs increased in its first auction    Spain had set a range of EUR2 5 billion to EUR3 5 billion for the sale    In additional euro zone news  the ECB kept its interest rate unchanged at the record low of 1     Contraction continues in the euro zone with retail sales declining 0 1  and a purchasing managers composite index fell from 49 3 to 49 1 in March weighing on equities    However  on the bullish front  Germany factory orders increased 0 3  but still missed the 1 5  increase forecasted by analysts    Volvo gave back 4 8  after a report indicated truck orders were below expectations for North America    In addition  automakers Peugot and Porsche fell 5 6  and 2 3  respectively on decreased U S  auto sales    Hikma Pharmaceuticals dropped 3 4  after it was sued by GlaxoSmithKline and Pfizer for a patent infringement    U S  stocks are trading lower with the Dow off  1 11   the S P 500 down 1 12  and the Nasdaq slipping 1 72     Traders are awaiting German industrial production  The Bank of England s interest rate and statement  as well as U S  unemployment claims on Thursday ,2012-04-04,Investing.com,"https://www.investing.com/news/stock-market-news/euro-stocks--plunge-on-fed-words,-spanish-auction;-dax-slammed-2.84-232241",232241
220846,442362,PFE,European stocks extend losses on debt fears  DAX down 2 73 ,news,Investing com   European stock markets extended losses on Monday  as weak euro zone economic data and signs of a contraction in Chinese manufacturing activity continued to weigh on sentiment  During European afternoon trade  the EURO STOXX 50 tumbled 2 37   France s CAC 40 plummeted 2 30   while Germany s DAX 30 plunged 2 73  Data showed earlier that manufacturing activity in Germany slowed to the lowest level in almost three years in April  adding to concerns over the economic outlook of the euro zone s largest economy A separate report showed that manufacturing activity in the euro zone deteriorated in April  growing at the slowest pace since June 2009  while service sector activity declined to the lowest level in five months in April Meanwhile  markets were also jittery after a preliminary report showed that manufacturing activity in China remained in contraction territory in April for the sixth consecutive month  The data overshadowed news on Friday that the Group of 20 leading economies agreed to boost the International Monetary Fund s lending capacity by USD430 billion  to help shield the global economy from the debt crisis roiling the euro zone Financial stocks were broadly lower  led by Dutch lender ING Group  down 7 04  after Holland s Prime Minister Mark Rutte failed to reach an agreement with one of the parties in his coalition over austerity measures France s BNP Paribas and Societe Generale also saw shares drop 4 07  and 4 16   while German lenders Deutsche Bank and Commerzbank retreated 4  and 5 26  respectively Deutsche Bank  Germany s largest lender  was also slated to book an additional charge of as much as EUR400 million euros tied to the sale of Actavis Group hf On the upside  Danone gained 2 25  after Nestle SA agreed to buy Pfizer Inc  s baby food unit for USD11 9 billion  edging out the French company in a contest for a business that gets most of its sales in emerging markets  In London  commodity heavy FTSE 100 lost 1 75   weighed by strong losses in mining stocks Shares in Rio Tinto plunged 3 53  and Bhp Billiton tumbled 2 97   while copper producers Xstrata and Kazakhmys dropped 2 12  and 3 91  respectively Financial stocks also remained on the downside  as U K  lenders tracked their European counterparts sharply lower  Barclays saw shares decline 3 38  and the Royal Bank of Scotland slid 3 25   while shares in Lloyds Banking and HSBC Holdings dropped 2 46  and 2 24   Elsewhere  Cable   Wireless Worldwide skyrocketed 15 47  after Vodafone  the world s largest wireless operator  agreed to buy the U K  company  offering 38 pence a share Vodafone  whose shares added 0 76  after the news  became the sole bidder after India s Tata Communications Ltd  last week failed to agree on a price and decided against making an offer In the U S   equity markets pointed to a lower open  The Dow Jones Industrial Average futures pointed to fall of 0 98   S P 500 futures signaled a 1 04  decline  while the Nasdaq 100 futures indicated a 0 96  loss Sentiment also came under pressure amid uncertainty over the result of France s presidential election  after President Sarkozy performed poorly against challenger Francois Hollande in the first round of the vote Hollande has said he wants to renegotiate the euro zone fiscal pact in order to stimulate growth in the euro zone  rather than enforcing strict austerity measures ,2012-04-23,Investing.com,https://www.investing.com/news/stock-market-news/european-stocks-extend-losses-on-debt-fears;-dax-down-2.73-232875,232875
220851,442367,PFE,Pfizer  PFE  To Post Q3 Earnings  How Will The Stock React ,opinion,"Pfizer Inc    NYSE PFE   will be reporting third quarter 2016 earnings on Nov 1  before market open  Last quarter  the company delivered a positive earnings surprise of 3 23  The pharma giant has been consistently beating earnings expectations  The company s earnings surpassed expectations in each of the last four quarters  with an average positive surprise of 11 16  PFIZER INC Price and EPS Surprise
    Let s see how things are shaping up for this announcement Factors to ConsiderWhile new products like Eliquis  Xalkori  Xeljanz and Ibrance as well as older products like Lyrica should contribute to the top line meaningfully  the bottom line should be driven by cost savings and share buybacks Ibrance has already earned broad patient and physician acceptance with an encouraging feedback while Eliquis continues to perform well due to market penetration and market share gains in the U S  and Japan Meanwhile  the Hospira acquisition should continue to be an important growth driver as well with sterile injectables  biosimilars and infusion system segments performing well  The Anacor acquisition which closed in June should contribute to revenues in the third quarter  We note that Pfizer closed the acquisition of Medivation for approximately  14 billion in Sep 2016 However  Pfizer will continue to face headwinds in the form of genericization and the expiration of a few co promotion agreements  which will continue to hamper top line growth  Moreover  new product launch expenses and R D investments are expected to hurt profits On the third quarter call  investor focus is expected to remain on the company s performance along with the performance of new products and pipeline progress including biosimilars and immuno oncology Earnings WhispersOur proven model does not conclusively show that Pfizer is likely to beat on earnings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here  as you will see below Zacks ESP  The Earnings ESP is  1 59  as the Most Accurate estimate stands at 62 cents while the Zacks Consensus Estimate is pegged higher at 63 cents  Please check our  that enables you find stocks that are expected to come out with earnings surprises Zacks Rank  Pfizer s Zacks Rank  3 increases the predictive power of ESP  However  we need to have a positive ESP to be confident about an earnings beat We caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderSome stocks in the healthcare sector that have both a positive Earnings ESP and a favorable Zacks Rank are 
ARIAD Pharmaceuticals Inc    NASDAQ ARIA   is expected to release results on Nov 1  The company has an Earnings ESP of 5 26  and a Zacks Rank  1  You can see  Shire plc   NASDAQ SHPG   with an Earnings ESP of  1 26  and a Zacks Rank  2  The company is scheduled to release results on Nov 1 Aerie Pharmaceuticals  Inc    NASDAQ AERI    which is slated to report results on Nov 2  The company has an Earnings ESP of  8 57  and a Zacks Rank  3 Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-26,Zacks Investment Research,https://www.investing.com/analysis/pfizer-(pfe)-to-post-q3-earnings:-how-will-the-stock-react-200161183,200161183
220852,442368,PFE,ARIAD  ARIA   Is A Beat In The Cards This Earnings Season ,opinion,"ARIAD Pharmaceuticals  Inc    NASDAQ ARIA   is expected to report third quarter 2016 results on Nov 1 In the last reported quarter  the company recorded a positive earnings surprise of 670   Overall  ARIAD has posted an average positive earnings surprise of 153 54  in the four trailing quarters  Let s see how things are shaping up for third quarter Why a Likely Positive Surprise Our proven model shows that ARIAD is likely to beat earnings because it has the right combination of two key ingredients Zacks ESP  The Earnings Surprise Prediction or   which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  stands at  5 26   This is very meaningful and a leading indicator of a likely positive earnings surprise for shares Zacks Rank  ARIAD carries a Zacks Rank  2  Buy   Note that stocks with a Zacks Rank  1  Strong Buy    2 and  3  Hold  have a significantly higher chance of beating earnings  The Sell rated stocks  Zacks Rank  4 or 5   on the other hand  should never be considered going into an earnings announcement  especially when the company is witnessing negative estimate revisions The combination of ARIAD s favorable Zacks Rank and positive ESP makes us reasonably confident of a positive earnings beat this season  Please check our  that enables you find stocks that are expected to come out with earnings surprises Focus on Iclusig s PerformanceARIAD s revenues are primarily generated by sales of its sole marketed product  Iclusig  The company expects Iclusig product and royalty revenues of  170  180 million in 2016  Sales should be driven by continued demand  new patient additions and launch in additional territories  Moreover  sequential growth in Iclusig sales should be driven by field team expansion  label expansion  increasing clinical experience and patient retention programs ARIAD s divestment of its EU operations to Incyte Corporation   NASDAQ INCY   and out licensing of the drug s rights in the region will allow the company to earn royalties on Iclusig sales in these regions In addition  the Japanese approval of Iclusig triggered a milestone payment of  10 million from Otsuka in the third quarter Apart from Iclusig s performance  investor s focus should also be on its late stage candidate  brigatinib  The company has completed the rolling submission of the New Drug Application  NDA  for brigatinib in the U S  for the treatment of patients with metastatic ALK positive  ALK   non small cell lung cancer  NSCLC  who are resistant or intolerant to Pfizer Inc  s   NYSE PFE   Xalkori  crizotinib   An approval would allow the company to launch the experimental cancer treatment in the U S  in 2017 ARIAD PHARMA Price and EPS Surprise
    Stocks to ConsiderHere is another health care stock that you may want to consider  as our model shows that it also have the right combination of elements to post an earnings beat this quarter Infinity Pharmaceuticals  Inc    NASDAQ INFI   is expected to report quarterly numbers on Nov 3  The company has an Earnings ESP of  5 81  and a Zacks Rank  1  You can see  Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-27,Zacks Investment Research,https://www.investing.com/analysis/ariad-(aria):-is-a-beat-in-the-cards-this-earnings-season-200161431,200161431
220856,442372,PFE,European stocks tumble after Fed comments  DAX down 1 31 ,news,Investing com   European stock markets were sharply lower on Wednesday  after the Federal Reserve dampened expectations for further monetary stimulus for the world s largest economy and amid sustained concerns over the economic outlook in the euro zone During European morning trade  the EURO STOXX 50 tumbled 1 04   France s CAC 40 plummeted 1 02   while Germany s DAX 30 plunged 1 31  The minutes of the Fed s March meeting showed that policymakers will refrain from launching a third round of quantitative easing unless the rate of growth falters or inflation drops below the central bank s 2  targeted rate Meanwhile  market sentiment remained under pressure amid concerns that Spain will be the next country to require a bailout mounted ahead of an auction of government debt later in the day Market participants were also looking ahead to the European Central Bank s policy meeting later in the day  although the bank was expected to leave interest rates unchanged at 1   The financial sector led losses as shares in French lenders BNP Paribas and Societe Generale plunged 2 56  and 2 68   while Germany s Deutsche Bank and Commerzbank retreated 1 10  and 2 60  respectively Peripheral lenders were also sharply lower  Spain s Banco Santander and BBVA saw shares plummet 2 36  and 2 35   while Italian lenders Unicredit and Intesa Sanpoalo dropped 2 50  and 2 29  Car makers contributed to losses as Daimler shares lost 1 61   while BMW and Volkswagen sunk 1 40  and 1 13  In London  FTSE 100 dropped 0 54   as U K  lenders tracked their European counterparts sharply lower while industry data showed that U K  house prices rose unexpectedly in March The Royal Bank of Scotland was among the session s top losers with shares declining 2 68  following reports that the lender pulled a USD207 million sale of bonds backed by its own derivative trades in February  Shares in Barclays and Lloyds banking tumbled 2 26  and 1 79  respectively Mining giants Rio Tinto and Bhp Billiton were also on the downside  with shares slumping 1 90  and 1 23   while copper producers Xstrata and Kazakhmys retreated 1 86  and 1 77  Elsewhere  shares in Hikma lost 0 88  after Glaxo and Pfizer sued the pharmaceutical company for planning to sell an injectable blood clot treatment  saying it infringes a patent licensed by Glaxo for argatroban Glaxo also fell 0 42  although the U K  s largest drug maker said the latest test results on its experimental drug albiglutide show it helps diabetics and may serve as the backbone for a regulatory filing In the U S   equity markets pointed to a lower open  The Dow Jones Industrial Average futures pointed to a fall of 0 51   S P 500 futures signaled a 0 57  decline  while the Nasdaq 100 futures indicated a 0 54  loss Later in the day  Germany was to release official data on retail sales  In the U S   a report on non farm employment change was to be published  as well as data from the Institute of Supply Management on service sector activity ,2012-04-04,Investing.com,https://www.investing.com/news/stock-market-news/european-stocks-tumble-after-fed-comments;-dax-down-1.31-232206,232206
220857,442373,PFE,European stocks extend losses on weak data  DAX tumbles 1 94 ,news,Investing com   European stock markets extended losses on Wednesday  as disappointing euro zone economic data and a weak Spanish debt auction added to concerns over a further slowdown in the single currency bloc  while investors eyed the European Central Bank s interest rate decision During European afternoon trade  the EURO STOXX 50 plummeted 1 36   France s CAC 40 tumbled 1 47   while Germany s DAX 30 plunged 1 94  Market sentiment was hit as the cost of insuring Spain s debt against default climbed earlier after the country auctioned EUR2 59 billon of government bonds  short of the maximum targeted amount of EUR3 5 billion On Tuesday  Spain s government announced that the country s public debt will rise to a record 79 8  of gross domestic product this year Earlier Wednesday  data confirmed that the euro zone service sector contracted for the sixth time in seven months in March  increasing the likelihood that the economy has entered a technical recession Financial stocks remained sharply lower  led by Dutch lender ING Group  down 2 48   France s BNP Paribas and Societe Generale also tumbled 1 79  and 0 78  respectively  while German lenders Deutsche Bank and Commerzbank declined 1 87  and 1 30  Meanwhile  French group Veolia sank 3 40  on reports it may decide today to take sole control of Coriscan ferry services operator Societe Nationale Maritime Corse Mediterranee  On the upside  Telecom Italia added 0 57  after Chairman Franco Bernabe said in an interview with Il Sole 24 Ore that the company may consider a spinoff of its network if it allows  a more favorable regulatory framework  In London  FTSE 100 retreated 1 26   after data showed that U K  house prices rose unexpectedly in March while the country s service sector expanded more than forecast U K  lenders remained broadly lower with shares in Barclays plummeting 3 37  and the Royal Bank of Scotland tumbling 2 79   while Lloyds Banking and HSBC Holdings declined 1 42  and 0 38  Earlier in the day  the Royal Bank of Scotland reportedly pulled a USD207 million sale of bonds backed by its own derivative trades in February  Mining giants Rio Tinto and Bhp Billiton were also on the downside  extending earlier losses as shares slumped 3 12  and 2 16   while copper producers Xstrata and Kazakhmys retreated 2 25  and 2 94  respectively Elsewhere  shares in Hikma Pharmaceuticals plunged 2 05  after Glaxo and Pfizer sued the company for planning to sell an injectable blood clot treatment  saying it infringes a patent licensed by Glaxo for argatroban In the U S   equity markets pointed to a sharply lower open  The Dow Jones Industrial Average futures pointed to a fall of 0 75   S P 500 futures signaled a 0 83  decline  while the Nasdaq 100 futures indicated a 0 76  loss Also Wednesday  a report showed that euro zone retail sales fell by 0 1  in February  against expectations for a 0 1  increase and were 2 1  lower year on year Meanwhile  official data showed that German factory orders rose 0 3  in February  below expectations for a 1 2  increase  renewing concerns over the economic outlook for the bloc s largest economy Later in the day  the ECB was to release its interest rate decision  In the U S   a report on non farm employment change was to be published  as well as data from the Institute of Supply Management on service sector activity ,2012-04-04,Investing.com,https://www.investing.com/news/stock-market-news/european-stocks-extend-losses-on-weak-data;-dax-tumbles-1.94-232221,232221
220860,442376,PFE,3 Sector ETFs With Revenue Growth Potential,opinion,"In the ongoing third quarter reporting cycle  earnings have the same old moderate flavor of the last few quarters  but are on the verge of a turnaround  Revenues are displaying better trends after having entered into the growth territory in Q2  As per the report issued on October 12  2016  earnings for the S P 500 are expected to be down 2 9  in Q3 while revenues are likely to rise 1 2  
Investors should note that while earnings normally draw maximum attention  we would like to emphasize that sales are equally important  This is because sales are harder to be influenced in an income statement than earnings  A company can land up on decent earnings numbers by adopting cost cutting or some other measures that do not speak for its core strength  But it is harder for a company to mold its revenue figure 
Both factors make it necessary to look at sectors that are expected to exhibit strong revenue growth this reporting cycle  no matters what their earnings growth picture look likes  read    
Consumer Discretionary
The consumer discretionary sector is projected to register the highest revenue growth of 11 8  in Q3  With the job market strengthening  wages rising and energy prices still at lower levels  consumers are likely to splurge on leisure and entertainment activities and products 
The reading for U S  consumer confidence was 104 1 in September  higher than the market expectation of 99 0 and August s reading of 101 8  The latest level was the highest   Plus  according to   the seasonal strength for this sector stretches from October 17 to April 12  This trend opens up the opportunity for Consumer Discretionary Select Sector SPDR ETF   read    
Medical
The medical or health care sector appears the best positioned with a 7 4  revenue growth estimate  the third best in the universe of 16 S P sectors categorized by Zacks  The rise in mergers and acquisitions  higher chances of Clinton winning the presidential election and supporting the Affordable Care Act  an aging global population and the sector s non cyclical nature amid uncertainty can go in favor of the sector  read    
However  investors should note that the going has become tough for the sector recently on the price gouging issue  Investors can take a look at SPDR S P Health Care Services ETF   see  here  
Retail Wholesale
U S  retail sales turned around in Septemberafter a soft August  The sentiment was strong in several pockets of the economy in September  helping many to feel better about the economic situation  Retail Wholesale is projected to register 5 3  revenue growth in Q3 
However  the upcoming presidential election and rising rate worries may weigh on the apparently optimistic retail outlook for the coming month  Thus it will be wiser to pick a quality and trendy product like Amplify Online Retail ETF   which may score ahead irrespective of where the sector is heading  The reason for this is that there has been a gradual but steady shift toward online retailing lately which gives it a clear edge over brick and mortar retailing 
Want key ETF info delivered straight to your inbox  
Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2016-10-17,Zacks Investment Research,https://www.investing.com/analysis/3-sector-etfs-with-revenue-growth-potential-200159364,200159364
220868,442384,PFE,ARIAD  ARIA  Leukemia Drug Iclusig Gets Approval In Japan,opinion,"ARIAD Pharmaceuticals Inc    NASDAQ ARIA   announced that its partner Otsuka Pharmaceutical Co   Ltd  has gained approval from the Japanese Pharmaceuticals and Medical Devices Agency for leukemia drug  Iclusig  Iclusig is approved for the treatment of patients with chronic myeloid leukemia  CML  resistant or intolerant to prior drug treatment  and relapsed or treatment resistant Philadelphia chromosome positive acute lymphoblastic leukemia  Ph  ALL   The approval has triggered a milestone payment of  10 million to ARIAD from Otsuka under the two companies  collaboration agreement  In Dec 2014  ARIAD had entered into a collaboration with Otsuka for the commercialization and development of Iclusig in Japan and nine other Asian countries  Given that Japan represents huge market opportunity for Iclusig and this marks the drug s first approval in Asia  we are positive about the latest development on the regulatory front  Otsuka has also filed marketing applications for Iclusig in Korea and Taiwan  We note that ARIAD has struck quite a few deals for the development and commercialization of Iclusig in various countries  These deals provide the company with a steady stream of funds in the form of upfront  milestone and other payments  ARIAD has a non dilutive synthetic royalty financing agreement with PDL BioPharma   NASDAQ PDLI    under which the company could receive up to  200 million as revenue interest in exchange for royalties on net sales of Iclusig  Further  in Jun 2016  ARIAD divested its European operations and licensed the rights to Iclusig in Europe and other select countries to Incyte Corporation   NASDAQ INCY    ARIAD is eligible to receive 32 50  of the European net sales  going forward  Meanwhile  ARIAD completed the rolling submission of the new drug application for its most advanced pipeline candidate  brigatinib  to the FDA last month  The company is looking to get brigatinib approved for the treatment of metastatic ALK positive non small cell lung cancer in patients who are resistant or intolerant to Pfizer Inc  s   NYSE PFE   Xalkori  If all goes well on the regulatory front  ARIAD could potentially launch brigatinib in 2017 ARIAD PHARMA Price
    Confidential from Zacks Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-09-29,Zacks Investment Research,https://www.investing.com/analysis/ariad-(aria)-leukemia-drug-iclusig-gets-approval-in-japan-200156491,200156491
220869,442385,PFE,Roche Alecensa Wins Second Breakthrough Status In The U S ,opinion,"Roche Holding  SIX ROG  AG   OTC RHHBY   announced that its lung cancer drug  Alecensa  was granted a second breakthrough therapy designation in the U S  for the treatment of advanced anaplastic lymphoma kinase  ALK  positive non small cell lung cancer  NSCLC  in adult patients who have not received prior treatment with an ALK inhibitor This designation is granted by the FDA to expedite the development and review of drugs that are intended to treat serious diseases and provide access to patients as early as possible ROCHE HLDG LTD Price
    The designation was based on data from the phase III J ALEX study  which demonstrated that Alecensa could reduce the risk of disease worsening or death by 66   in comparison to Pfizer Inc  s   NYSE PFE   Xalkori  crizotinib   in patients with ALK positive  advanced or recurrent NSCLC  who had either not been treated with chemotherapy or had received one prior line of chemotherapy We remind investors that in Jun 2013  the company had received the first breakthrough therapy designation for Alecensa for the treatment of patients with ALK positive NSCLC whose disease progressed on treatment with Xalkori Currently  Alecensa is approved in the U S  for the treatment of ALK positive metastatic NSCLC patients who have progressed on or are intolerant to Xalkori Meanwhile  Alecensa is being evaluated in the phase III ALEX study  in comparison to Xalkori  as an initial  first line  treatment for people with advanced ALK positive NSCLC We note that the lung cancer treatment market is highly crowded with drugs like Opdivo  Keytruda and Zykadia among others As per information provided by the company  lung cancer causes 1 59 million deaths each year globally Roche has a strong presence in the oncology market  In particular  the company dominates the breast cancer space with strong demand for its HER2 franchise drugs Herceptin  Perjeta and Kadcyla  The company s efforts to grow its portfolio beyond oncology and foray into new avenues such as multiple sclerosis and asthma are encouraging The company currently carries a Zacks Rank  3  Hold  Stocks to ConsiderA couple of better ranked stocks in the health care sector include Achillion Pharmaceuticals  Inc    NASDAQ ACHN    and VIVUS Inc    NASDAQ VVUS    All these stocks sport a Zacks Rank  1  Strong Buy   You can see  Achillion has posted a positive earnings surprise in each of the last four quarters  with an average beat of 364 79   The company s share price has tanked 22 3  year to date VIVUS has posted a positive earnings surprise thrice in the last four quarters  with an average beat of 39 88   The company s share price gained 7 5  year to date Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-03,Zacks Investment Research,https://www.investing.com/analysis/roche-alecensa-wins-second-breakthrough-status-in-the-u.s.-200156949,200156949
220871,442387,PFE,US STOCKS Futures off after Chinese trade data  scrapped IPO,news,"  Chinese export growth slows
   Ally Financial IPO delayed
   Futures off  Dow 33 pts  S P 500 2 8 pts  Nasdaq 4 25
   For up to the minute market news see  STXNEWS US 
  Adds Pfizer price in last paragraph 
 By Edward Krudy
 NEW YORK  June 10  Reuters    Disappointing trade data from
China and the scrapping of a large IPO fed into fears about
market volatility and the economy on Friday  sending futures
lower a day after stocks bounced from a six day losing streak 
 China s export growth slowed in May  raising questions over
the outlook for global growth at a time when investors have
been rattled by a barrage of reports showing the U S  economy
is slowing down  For details  see  ID nL3E7HA0B2 
  It indicates there is some slowing in world demand for
Chinese products and that feeds right into the fears that our
economy is slowing   said Jack de Gan  chief investment officer
at Harbor Advisory Corp in Portsmouth  New Hampshire 
 Ally Financial   an auto and mortgage lender
majority owned by the U S  government  delayed a  6 billion
initial public offering  troubling investors worried about the
poor performance of financial stocks during the market s recent
decline   ID nN09285068 
 In another negative for U S  stocks  the euro fell as
worries about the Greek debt crisis eclipsed any support from a
likely euro zone interest rate rise next month  Traders have
been trading the correlation between stocks and the dollar
recently 
 S P 500 futures  dipped 2 8 points and were below
fair value  a formula that evaluates pricing by taking into
account interest rates  dividends and time to expiration on the
contract  Dow Jones industrial average futures  fell 33
points  and Nasdaq 100 futures  were off 4 25 points 
 U S  shares ended higher on Thursday for the first time in
over a week  though equities closed off session highs as the
mood among investors remained fragile following a 6 percent
drop in the S P 500 from its highs in May 
 Overseas markets were lackluster  European shares on the
FTSEurofirst 300  dipped 0 3 percent in early trade and
were on track for a sixth straight week of losses  Japan s
Nikkei  ended up 0 5 percent 
 Crude oil futures fell  paring earlier gains after Brent
rose to a five week high of  120 a barrel as Saudi Arabia began
offering more oil to Asian refiners  easing worries about
supplies following an inconclusive OPEC meeting 
 U S  drugmaker Pfizer Inc  won European regulatory
clearance to acquire Danish medical services company Ferrosan s
consumer healthcare business from Altor 2003 Fund Ltd  Pfizer
edged lower by 0 2 percent to  20 70 in premarket trade 
 ID nBRQ010171 
   Editing by Jeffrey Benkoe ",2011-06-10,Reuters,"https://www.investing.com/news/stock-market-news/us-stocks-futures-off-after-chinese-trade-data,-scrapped-ipo-216990",216990
220872,442388,PFE,US STOCKS Wall St flat as Greece loan delay rekindles fears,news,"  Decision delayed on Greece loans
   S P 200 day moving average 1 259 closely eyed strategist
   Indexes  Dow up 0 2 pct  S P  Nasdaq flat
   For up to the minute market news see  STXNEWS US 
   Updates to mid morning trading 
 By  Angela Moon
 NEW YORK  June 20  Reuters    U S  stocks were little
changed on Monday as investors were hesitant to buy riskier
assets after a decision was delayed on emergency loans to
Greece and Moody s said it may downgrade Italy s credit
rating 
 The market seesawed between modest gains and losses  Wall
Street started lower  but erased losses as the S P dipped
toward 1 259  its 200 day moving average  encouraging buyers  A
drop below that level would be the first since September 2010 
  From a technical point of view  the 200 day moving average
is where the market gains support   said Jason Ware  senior
equity analyst at Albion Financial Group in Salt Lake City 
Utah 
 The Dow Jones industrial average  was up 20 02
points  or 0 17 percent  at 12 024 38  The Standard   Poor s
500 Index  was down 0 27 points  or 0 02 percent  at
1 271 23  The Nasdaq Composite Index  was down 0 85
points  or 0 03 percent  at 2 615 63 
 Euro zone finance ministers delayed a decision on extending
12 billion euros   17 billion  in emergency loans to Greece 
saying Athens would first have to introduce austerity
measures 
 The ministers expect the money  the next tranche in a 110
billion euro bailout by the European Union and the
International Monetary Fund  to be paid by mid July  Greece
needs the loans by then to avoid a debt default  For details 
see  ID nLDE75I0FM 
  It blows the confidence out of the market  especially when
the expectation was that there will be some kind of support or
help to solve the situation 
 Adding to concerns  Moody s threatened to cut Italy s
credit ratings in the next 90 days on worries that the Greece
crisis may drive interest rates higher and derail Italy s
fragile economic recovery   ID nN17266057 
 In company news  the U S  Food and Drug Administration
approved a tamper resistant pain drug from Pfizer Inc 
and Acura Pharmaceuticals Inc   Acura shares jumped 34
percent to  5 18  while Pfizer shares fell 0 7 percent to
 20 12   ID nL3E7HK1T0 
   Reporting by Angela Moon  editing by Jeffrey Benkoe ",2011-06-20,Reuters,https://www.investing.com/news/stock-market-news/us-stocks-wall-st-flat-as-greece-loan-delay-rekindles-fears-217661,217661
220873,442389,PFE,European stocks slide on Fed outlook  DAX down 0 9 ,news,Investing com   European stock markets were broadly lower on Thursday  after the Federal Reserve cut its outlook for U S  economic growth and gave no indications of further monetary stimulus  dampening demand for riskier assets During European morning trade  the EURO STOXX 50 tumbled 1 2   France s CAC 40 slumped 0 95   while Germany s DAX 30 fell 0 9   The Federal Reserve on Wednesday downgraded its 2011 U S  economic growth forecast to a range of 2 7  to 2 9   down from a previous estimate of 3 1  to 3 3   Fed Chairman Ben Bernanke confirmed that the bank was winding up its USD600 billion bond buying program at the end of June and said further easing was unlikely  Meanwhile  shares in the financial sector were pressured after European Central Bank President Jean Claude Trichet said late Wednesday that risk signals for financial stability in the euro zone are flashing  red  and that the debt crisis was threatening to infect European lenders Shares in Deutsche Bank and Commerzbank each slumped 1 5   while French lenders Societe Generale and BNP Paribas saw shares fall 1 35  and 1 2  respectively Peripheral euro zone banks also performed poorly  with Spain s Banco Santander dropping 2   rival BBVA slumping 2 8   while shares in Italian banking giant Unicredit sank 1 85   European leaders are to hold the first day of a two day economic summit in Brussels later Thursday Meanwhile  shares in German pharmaceutical firm Bayer tumbled 5 3  after U S  rivals Pfizer and Bristol Myers Squibb reported a successful trial of their blood thinner drug  Bayer is developing its own blood thinner in partnership with Johnson   Johnson   In London  the FTSE 100 fell 0 75  as major U K  banks extended sharp losses from the previous session  when HSBC downgraded the sector  Barclays shares sank 1 9   shares in Lloyds Banking Group tumbled 2 7   while Royal Bank of Scotland saw shares fall 2 4  Commodity linked shares were also lower  as metal and oil prices were pressured by a stronger U S  dollar  Mining giant BHP Billiton declined 1 5   copper producer Xstrata saw shares fall 1 4   while shares in Royal Dutch Shell slipped 1  The outlook for U S  equity markets was downbeat  The Dow Jones Industrial Average futures pointed to a loss of 0 2   S P 500 futures shed 0 32   while the Nasdaq 100 futures fell 0 3      Later in the day  the U S  was to publish government data on initial jobless claims  as well as official data on new home sales ,2011-06-23,Investing.com,https://www.investing.com/news/stock-market-news/european-stocks-slide-on-fed-outlook;-dax-down-0.9-217901,217901
220874,442390,PFE,US STOCKS Market up slightly  factory orders on tap,news,"  Upcoming data to reveal state of economy
   Futures  Dow up 24 pts  S P up 0 2  Nasdaq up 8 5
   For up to the minute market news see  STXNEWS US 
  Adds quote  updates prices 
 By Chuck Mikolajczak
 NEW YORK  July 5  Reuters    U S  stock index futures rose
slightly on Tuesday before factory orders data and after stocks
had their best week in two years last week 
 The Commerce Department releases May factory orders data at
10 a m   1400 GMT   Economists in a Reuters survey expect a
rise of 1 0 percent compared with a 1 2 percent drop in the
prior month 
 Equities have rallied for five straight days  rebounding
from a spate of weakness over the last two months  Moves to
avert a debt crisis in Europe and surprisingly strong regional
business data helped lift some of the gloom on Wall Street 
  We do have factory orders  The market certainly could be
headed for some sort of a pullback  We ve had a strong
performance over the past week and any slight disappointment
would invite some profit taking   said Peter Cardillo  chief
market economist at Avalon Partners in New York 
  We are going to begin to see some of the data actually
turn up and pointing to better times ahead in terms of the
economy and certainly negating any new downward trend    the
soft patch obviously temporary  
 S P 500 futures  added 0 2 point and were slightly
above fair value  a formula that evaluates pricing by taking
into account interest rates  dividends and time to expiration
on the contract  Dow Jones industrial average futures 
gained 24 points  and Nasdaq 100 futures  rose 8 5
points 
 Volume is expected to remain low in the holiday shortened
week  which could increase volatility  Markets were closed on
Monday for the U S  Independence Day holiday 
 Specialty chemicals maker OM Group Inc  is making a
push into Europe with the acquisition of German magnetic
materials maker Vacuumschmelze GmbH   Co KG for  993 2 million 
 ID nL3E7I50NI 
 Healthy  middle aged smokers who take Pfizer s 
Chantix or Champix  one of the most popular quit smoking drugs 
have a higher risk of suffering heart attacks or other serious
heart problems  a study found on Monday   ID nL6E7I425W 
 China s Baidu  is to partner with Microsoft
 for English language search  giving the U S  software
giant a chance to expand its tiny Web presence in a market
Google  has stepped back from  The venture will help
the Chinese company s international ambitions 
 Microsoft shares gained 0 5 percent to  26 15 in premarket
trading and Baidu added 1 percent to  144 72 
 European shares edged up  extending the rises for a seventh
session  though strategists were advising caution as weak euro
zone economic data cast fresh doubts on the strength of the
recovery    EU 
 Asian stocks pulled back slightly from a one month high as
some investors took profits from their recent rally 
 ID nL3E7I502Z 
 U S  stocks started July with a bang on Friday as Wall
Street scored its best week in two years on strong
manufacturing data that eased concerns about slowing growth 
 ID nN1E7601LI 
  Reporting by Chuck Mikolajczak  Editing by Kenneth Barry ",2011-07-05,Reuters,"https://www.investing.com/news/stock-market-news/us-stocks-market-up-slightly,-factory-orders-on-tap-218703",218703
220878,442394,PFE,Regeneron  Sanofi Skin Disease Drug Under Priority Review,opinion,"Regeneron Pharmaceuticals  Inc    NASDAQ REGN   and partner Sanofi   NYSE SNY   received encouraging news after their biologics license application  for experimental skin disease treatment dupilumab  was accepted for priority review by the FDA  The companies are looking to get dupilumab approved for the treatment of adults with inadequately controlled moderate to severe atopic dermatitis  AD  
With the FDA granting priority review  a response should be out by Mar 29  2017 
Per company sources  AD affects about 7 8 million adults in the U S  and 1 3  of adults across the world  Further  there are roughly 1 6 million patients in the U S  diagnosed with moderate to severe AD  that are still living with inadequately controlled disease  in spite of being treated 
REGENERON PHARM Price   Considering the lack of approved systemic treatments in the U S  for moderate to severe AD  there exists significant unmet need for drugs addressing this serious  chronic inflammatory skin disease  Approval would be a huge boost  and dupilumab could bring in blockbuster sales  given the immense commercial potential in the target market 
SANOFI AVENTIS Price   Apart from AD  dupilumab is being evaluated for additional inflammatory indications including asthma  phase III   nasal polyposis  phase II  and eosinophilic oesophagitis  phase II   A phase III study on dupilumab for nasal polyposis is anticipated to start in the first quarter of 2017 
We note that Pfizer Inc    NYSE PFE   is also looking to get its AD treatment  crisaborole topical ointment 2   approved for the treatment of patients with mild to moderate AD  It is currently under FDA review with a response expected by Jan 7  2017 
Meanwhile  Regeneron and Sanofi have an importantly regulatory event coming up late next month  Oct 30  with the FDA expected to decide on the approval of sarilumab  Sarilumab is currently under review in the U S  for the treatment of patients with active  moderate to severe rheumatoid arthritis  It is also under review in the EU 
While Regeneron is a Zacks Rank  2  Buy  stock  Sanofi carries a Zacks Rank  4  Sell  
A Stock to Consider
A better ranked stock in the health care sector is Ligand Pharmaceuticals Inc    NASDAQ LGND    sporting a Zacks Rank  1  Strong Buy   You can see  
For 2016  Ligand witnessed a 12 13  increase in its earnings estimates over the past 60 days  The company has also posted an average positive earnings surprise of 36 66  over the last four trailing quarters  Its share price has surged nearly 13  year to date 
Confidential from Zacks 
Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-09-26,Zacks Investment Research,"https://www.investing.com/analysis/regeneron,-sanofi-skin-disease-drug-under-priority-review-200155631",200155631
220879,442395,PFE,Markets Tumble Ahead Of Tonight s Showdown,opinion,"U S  equities finished the first session of the week lower following a broad based decline overseas  as investors await the Presidential debate and after capital concerns swirled around Deutsche Bank  Treasuries were higher  as new home sales decline and some regional manufacturing data improved  and the U S  dollar was lower  Meanwhile  gold was little changed and crude oil prices gained solid ground despite uncertainty ahead of this week s OPEC meeting  M A news dominated the equity front 
The Dow Jones Industrial Average  DJIA  declined 167 points  0 9   to 18 095  the S P 500 Index lost 19 points  0 9   to 2 146  and the Nasdaq Composite fell 48 points  0 9   to 5 258  In moderate volume  781 million shares were traded on the NYSE and 1 7 billion shares changed hands on the Nasdaq  WTI crude oil rose  1 45 to  45 93 per barrel  wholesale gasoline was  0 03 higher at  1 39 per gallon and the Bloomberg gold spot price inched  0 98 lower to  1 337 64 per ounce  Elsewhere  the Dollar Index a comparison of the U S  dollar to six major world currencies decreased 0 2  to 95 31 
CBOE Holdings Inc  NASDAQ CBOE    CBOE  67  announced an agreement to acquire BATS Global Markets Inc  NYSE BATS    BATS  30  for  32 50 per share in cash and stock  in a transaction valued at about  3 2 billion  Under the terms of the deal  BATS shareholders will receive  10 00 per share in cash and 0 3201 shares of CBOE Holdings common stock for each share they own  CBOE said the deal is expected to strengthen its global position in innovative tradable products and services and achieve meaningful cost and operational efficiencies  Shares of both companies were lower 
Chemtura Corp  NYSE CHMT    CHMT  33  announced an agreement to be acquired by German specialty chemicals company Lanxess AG  DE LXSG   LNXSF  59  for  33 50 per share in cash  valued at about  2 1 billion  CHMT rallied over 15   while LNXSF also gain solid ground 
Dow member Pfizer Inc   NYSE PFE  34  saw some pressure after the company announced that after an extensive evaluation  its board has determined to not pursue splitting into two companies at this time 
New home sales decline to kick off economic week 
New home sales    decreased 7 6  month over month  m m  in August to an annual rate of 609 000  but above the Bloomberg forecast of 600 000 units  The median home price declined 5 4  year over year to  284 000  The supply of new home inventory rose to 4 6 months at the current sales pace as sales tumbled in the Northeast m m  fell in the South and declined in the Midwest  while sales in the West grew  Compared to last year  sales in all regions were sharply higher  except in the Northeast  New home sales are based on contract signings instead of closings 
The Dallas Fed Manufacturing Index rose to  3 7 for September  from August s unrevised  6 2 level  with economists forecasting an increase to  3 0  A reading below zero denotes contraction in manufacturing activity 
Treasuries finished higher  as the yield on the 2 Year note declined 2 basis points  bps  to 0 73   while the yields on the 10 Year note and the 30 Year bond dropped 4 bps to 1 58  and 2 31   respectively  
Tomorrow s  will include more manufacturing and housing data  in the form of the S P CoreLogic Case Shiller Home Price Index  expected to show housing prices in the 20 city composite were 5 1  higher year over year  y y   but flat on a seasonally adjusted basis month over month  m m   and the Richmond Fed Manufacturing Index  forecasted to improve to  2 during September from the  11 the month prior  with a reading below zero denoting contraction in manufacturing activity  As well  Markit s preliminary Services PMI Index will be released  with economists forecasting a September reading of 51 2  up slightly from August s 51 0  while Consumer Confidence will round out the busy day  expected to decline to 99 0 in September from the prior month s 101 1 
Europe and Asia mostly lower as oil and U S  politics stymie conviction
European equities traded lower  with financials falling to lead a broad based decline amid a drop in shares of Deutsche Bank AG  DE DBKGn   DB  12  as media reports saying the government will not offer any state aid for the German lender fueled capital concerns  The German lender is facing speculation that it may need to raise capital in the wake of a record  14 0 billion fine being sought by the U S  Department of Justice in relation to DB s alleged practices leading up to the 2008 mortgage crisis  DB said that at no point did it ask the government for assistance and a German government spokesperson said there are no grounds for speculation over state funding for the bank  Also  oil and gas issues saw pressure amid uncertainty regarding if this week s informal OEPC meeting will yield a new production agreement  The negative movement for stocks came even as German business confidence rose solidly in September to the highest level since May 2014  The euro gained ground and the British pound was little changed versus the U S  dollar  while bond yields in the region dipped  Also  the global markets awaited tonight s first Presidential debate in the U S   while European Central Bank President Mario Draghi spoke today  reiterating the need for fiscal and structural policies to aid economic growth  per Bloomberg  
Stocks in Asia finished mostly lower with the global markets pulling back amid focus on tonight s first Presidential debate in the U S   along with festering uncertainty regarding the Bank of Japan s monetary policy  Moreover  volatility in the energy sector also hamstrung conviction as uncertainty ramped up ahead of this week s OPEC meeting  Japanese equities declined  with the yen showing some strength  while mainland Chinese stocks and those traded in Hong Kong dropped  Meanwhile  India s markets traded lower  as did those in South Korea  while Australian stocks finished flat ",2016-09-26,Marvin Clark,https://www.investing.com/analysis/markets-tumble-ahead-of-tonights-showdown-200155673,200155673
220882,442398,PFE,Pfizer investors on alert for more shrinkage clues,news,"  Q1 profit seen falling slightly  hurt by generics	
   Investors eager for news of asset sales	
   Recent share gain tied to hopes of weathering Lipitor hit	
 
 By Ransdell Pierson	
 NEW YORK  May 3  Reuters    Pfizer Inc is expected
to report slightly lower quarterly earnings on Tuesday  but
investors will be more focused on any signs the world s biggest
drugmaker will further shrink itself to weather looming
competition from generic drugs for its Lipitor cholesterol
fighter 	
  We will be listening for commentary around potential
divestitures as well as any color around potential larger
moves   such as breaking up its pharmaceuticals business  JP
Morgan analyst Chris Schott said on Monday 	
 Many investors fear Pfizer  which has bought three of the
largest U S  drugmakers over the past decade  will be far too
big to deliver strong profit growth once its  10 7
billion a year Lipitor faces cheaper generics in November and
more than a half dozen other Pfizer drugs lose U S  patent
protection in the next few years 	
 Wall Street expects Pfizer s new chief executive  Ian Read 
to eventually sell parts of the company or cut Pfizer to a size
commensurate with its expected narrowing revenue base 	
 In addition to its core pharmaceuticals business  Pfizer has
an animal health business  nutritional products business and
consumer products that could wind up on the auction block 	
 Three months ago Read delighted investors by vowing to slash
the company s research budget by up to  2 billion  to between
 6 5 billion and  7 billion  eliminating thousands of research
positions 	
 The move allowed Pfizer  which turned over the reins to Read
in December after the abrupt departure of Jeffrey Kindler  to
stick to its earlier 2012 profit forecast of  2 25 to  2 35 per
share  That would reflect some actual growth over earnings of
 2 23 per share last year and  2 24 per share expected this year
by Wall Street 	
 Pfizer further endeared itself to investors in early April
by announcing plans to sell its Capsugel unit  the world s
largest maker of hard capsules  to private equity firm KKR   Co
 for  2 38 billion  The deal will enable Pfizer to make
additional share repurchases this year beyond its previous plans
for  5 billion in buybacks for 2011 	
 Its shares have risen 12 percent since Feb  1  when Read
pointed his axe at the company s R D budget 	
 Schott said Pfizer  even more than other drugmakers that
have already reported first quarter results  should get an
earnings boost from the weaker dollar 	
 Even so  Schott and other Wall Street analysts expect Pfizer
earnings to be slightly below the year ago period  hurt by
tumbling sales of drugs already facing competition from
generics  They include the antidepressant Effexor acquired
through Pfizer s purchase in 2009 of rival U S  drugmaker Wyeth 	
  Editing by Bernard Orr and Matt Driskill ",2011-05-03,Reuters,https://www.investing.com/news/stock-market-news/pfizer-investors-on-alert-for-more-shrinkage-clues-212885,212885
220883,442399,PFE,RPT UPDATE 2 Pfizer drugs wilt  lower margin units shine,news," Refiling to remove extra word from paragraph 1 
   Q1 EPS  excluding items  60 cents  vs  59 cents forecast
   Q1 sales narrowly miss Wall Street expectations
   Drug sales fall 2 pct  hurt by overseas Lipitor generics
   Lower margin animal health  consumer units shine
   Shares fall 1 3 pct premarket
  Adds details on product sales  investor hopes 
 NEW YORK  May 3  Reuters    U S  drugmaker Pfizer Inc
 reported quarterly results roughly in line with
expectations  as falling sales of prescription drugs undermined
strong demand for consumer and animal health products that some
investors want the company to sell off 
 Sales of Pfizer s core business of prescription drugs fell
2 percent to  14 2 billion  Cholesterol fighter Lipitor  the
company s biggest product  led the downturn  as its revenue
tumbled 13 percent to  2 39 billion due to generic competition
in overseas markets 
 The world s largest drugmaker  whose shares fell 1 3
percent in premarket trading  said it earned  2 22 billion  or
28 cents per share  in the first quarter  That compared with
 2 03 billion  or 25 cents per share  in the year earlier
period  when Pfizer took charges related to its late 2009
purchase of rival U S  drugmaker Wyeth 
 Excluding special items  including its Capsugel business
that is being sold and is now considered to be a discontinued
operation  Pfizer earned 60 cents per share  Analysts on
average expected 59 cents per share  according to Thomson
Reuters I B E S 
 Global company revenue of  16 5 billion was a bit lower
than the year earlier quarter and slightly trailed Wall Street
expectations of  16 63 billion 
 Revenue would have fallen 2 percentage points if not for
the weaker dollar  which boosts the value of overseas sales 
and for new products obtained in Pfizer s recent purchase of
specialty drugmaker King Pharmaceuticals 
 Many investors fear Pfizer  which has bought three of the
largest U S  drugmakers over the past decade  will be far too
big to deliver strong profit growth once Lipitor faces cheaper
U S  generics in November  and more than a half dozen other
Pfizer drugs lose U S  patent protection in the next few
years 
 Wall Street expects Pfizer s new chief executive  Ian Read 
will eventually sell off one or more of its non pharmaceutical
businesses  or perhaps even its generic drugs operation 
 By divesting such products  which have far lower profit
margins than branded prescriptions drugs  the hope is that
newly approved medicines will have a better chance to bolster
overall earnings of the smaller company 
 Pfizer on Tuesday said it aims in the second half of the
year to complete its ongoing assessment of what businesses it
may sell 
 Animal health sales jumped 16 percent to  982 million in
the quarter  while sales of consumer healthcare products rose
12 percent to  745 million  Nutritional product sales rose 3
percent to  470 million 
  Reporting by Ransdell Pierson and Lewis Krauskopf  Editing by
Maureen Bavdek ",2011-05-03,Reuters,"https://www.investing.com/news/stock-market-news/rpt-update-2-pfizer-drugs-wilt,-lower-margin-units-shine-213006",213006
220884,442400,PFE,CORRECTED   US STOCKS Wall St edges lower on dollar bounce,news," Corrects to show in 5th paragraph that dollar rise makes
commodities more expensive 
   Pfizer falls  MasterCard rises after earnings reports
   Dollar advances  drags commodities
   Indexes off  Dow 0 1 pct  S P 0 2 pct  Nasdaq 0 2 pct
   For up to the minute market news see STXNEWS US
 By Chuck Mikolajczak
 NEW YORK  May 3  Reuters    U S  stocks dipped on Tuesday
as a move higher in the dollar pressured commodity prices and
investors weighed the potential for some consolidation in
equities after a recent run up 
 The dollar edged off three year lows as a buildup of bets
to sell the currency  based on loose U S monetary policy  ran
out of steam  The dollar index   measured against a
basket of major currencies  was last up 0 3 percent  For
details  see  ID nLDE7421B7 
 Brent crude  fell 1 3 percent to  123 53 a barrel 
and U S  crude futures  shed 1 1 percent to  112 31  The
S P energy index  lost 1 2 percent 
 Gold slipped Tuesday from record highs above  1 570 an
ounce  The NYSEArca gold bugs index  dipped 1 7 percent 
 A rise in the greenback saps interest in U S  dollar priced
commodities as they become more expensive 
  Some of the markets were getting a little overdone   said
Frank Lesh  a futures analyst and broker at FuturePath Trading
LLC in Chicago 
  Markets gets overbought  dollar is oversold    yes  You ve
got a corrective bounce of the dollar coming  it s not a change
in trend by any means  
 The Dow Jones industrial average  dropped 10 25
points  or 0 08 percent  to 12 797 11  The Standard   Poor s
500 Index  slipped 2 79 points  or 0 20 percent  to
1 358 43  The Nasdaq Composite Index  shed 4 93 points 
or 0 17 percent  to 2 859 15 
 Pfizer Inc  fell 2 4 percent to  20 52 after the
drugmaker reported lower than expected quarterly revenue 
 ID nN03286398 
 MasterCard Inc  rose 3 4 percent to  284 62 after the
world s second largest credit card processing network posted a
24 percent jump in quarterly profit   ID nN02251522 
 At 10 a m  EST  1400 GMT   the Commerce Department releases
March factory orders  Economists forecast a 1 9 percent rise 
compared with a 0 1 percent drop in February 
   Reporting by Chuck Mikolajczak  editing by Jeffrey Benkoe ",2011-05-03,Reuters,https://www.investing.com/news/stock-market-news/us-stocks-wall-st-edges-lower-on-dollar-bounce-213036,213036
220888,442404,PFE,FDA AdCom Votes On Pfizer And Spectrum Drugs   What Next ,opinion,"Yesterday  a couple of drugs came up before FDA advisory panels for review   large cap pharma Pfizer  Inc  s   NYSE PFE   Chantix and biotech company Spectrum Pharmaceuticals  Inc  s   NASDAQ SPPI   Qapzola Chantix   Qapzola under ReviewData on Pfizer s smoking cessation product  Chantix  from the EAGLES  Evaluating Adverse Events in a Global Smoking Cessation Study  study was reviewed by a joint meeting of the FDA s Psychopharmacologic Drugs Advisory Committee and Drug Safety Risk Management Advisory Committee  The randomized  blinded  placebo controlled study was conducted by Pfizer in collaboration with GlaxoSmithKline plc   NYSE GSK   and was designed in consultation with the FDA and the European Medicines Agency  EMA   The safety and efficacy of all three currently approved smoking cessation therapies  including Chantix  was compared in this study in more than 8 000 smokers with and without a history of psychiatric disorders Pfizer is looking to get the Chantix label updated based on the safety and efficacy outcomes of EAGLES  The company has applied for the removal of the boxed warning in Chantix s label while at the same time it has proposed that the Warnings and Precautions section in the label regarding serious neuropsychiatric events occurring in patients attempting to quit smoking should be retained and updated with EAGLES data  According to the company  such a warning would be enough to inform prescribers of the possibility of the occurrence of such events Meanwhile  Spectrum is looking to get Qapzola approved for immediate intravesical instillation post transurethral resection of bladder tumors  post TURBT  in patients with non muscle invasive bladder cancer  NMIBC  How Did the Vote Go Pfizer got a favorable response with the advisory committees giving a majority vote in favor of removing the boxed warning regarding serious neuropsychiatric adverse events from the Chantix label 
Price
   However  Spectrum s Qapzola did not fare so well with the FDA s Oncologic Drugs Advisory Committee  ODAC  voting that Qapzola did not show substantial evidence of a treatment effect over placebo  Shares were down 8 2  on the news 
Price
   What Next While the FDA is not required to do so  it usually follows the advice of its advisory panels  So  in Chantix s case  the agency is likely to decide to remove the boxed warning from the label which should have a positive impact on scrips and product sales  Chantix brought in total sales of  671 million last year and  434 million in the first six months of 2016  Chantix s  EU trade name  Champix  EU label has already been updated to include the EAGLES data  The black triangle symbol  which indicated that additional safety monitoring was required for Champix in the EU  was removed as well Meanwhile  as far as Spectrum is concerned  the vote did not really come as a surprise considering Qapzola failed to meet the primary endpoint in two phase III studies  A final decision from the FDA is expected on Dec 11  2016  but right now it looks like chances for gaining approval are low  With Spectrum currently conducting a phase III study on Qapzola under the FDA s Special Protocol Assessment  SPA  program  we think the agency will ask the company for additional data before granting final approval Both Pfizer and Spectrum are Zacks Rank  3  Hold  stocks  You can see  Confidential  Zacks  Best Investment Ideas  Would you like to see a hand picked  all star  selection of investment ideas from the man who heads up Zacks  trading and investing services  Steve Reitmeister knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-09-15,Zacks Investment Research,https://www.investing.com/analysis/fda-adcom-votes-on-pfizer-and-spectrum-drugs---what-next-200153754,200153754
220890,442406,PFE,US STOCKS Wall St flat in face of strong resistance,news,"  S P 500 seen testing its 2011 high
   Pfizer to sell unit to KKR for about  2 4 billion
   Dow  S P flat  Nasdaq down 0 1 pct
  Updates to market open  updates graphic 
 By Rodrigo Campos
 NEW YORK  April 4  Reuters    U S  stocks were little
changed after a higher open on Monday  with the S P 500 facing
levels where selling has clustered in recent sessions 
 The benchmark hovered near 1 333  a level it has been
unable to close above since mid February  That level is double
the 12 year low hit in March 2009 and is not far from 1 344 
the S P s 2011 high and its highest since June 2008 
  I think the market has enough inertia and the retest of
1 344 is in store   said Richard Ross  global technical
strategist at Auerbach Grayson in New York   We re looking for
a marginal new high on the S P 500 setting you up for the next
leg of the advance  
  If you did have a breakout which failed  those false
breakouts often lead to a fast move in the opposite
direction  
 On Friday  the S P recorded its best two week period since
December  and the Dow industrials hit its highest intraday
level since June 2008 
  It wouldn t be unhealthy to see a period of consolidation
in the short term  but with this kind of momentum you sometimes
don t get that pause   Ross said 
  The Dow Jones industrial average added just 2 54 points 
or 0 02 percent  to 12 379 26  The Standard   Poor s 500 edged
up 0 05 point to 1 332 46  The Nasdaq Composite Index slipped
3 95 points  or 0 14 percent  to 2 785 65 
 The lack of significant economic data on Monday  nuclear
and other quake related problems in Japan and unrest in Libya 
Syria and other states in the oil rich region could translate
into low volumes in Wall Street  Last week was the lowest in
volume so far in 2011 
 In acquisition news  Pfizer Inc rose 0 8 percent to  20 54
after the drugmaker agreed to sell its Capsugel unit  the
world s largest maker of hard capsules  to private equity firm
KKR   Co for nearly  2 4 billion 
  Reporting by Rodrigo Campos  Editing by Kenneth Barry ",2011-04-04,Reuters,https://www.investing.com/news/stock-market-news/us-stocks-wall-st-flat-in-face-of-strong-resistance-205650,205650
220891,442407,PFE,GLOBAL MARKETS World stocks rally on M A oil up on Middle East,news,"  M A activity supports global shares
   Wall Street opens higher
   Euro slips back after hitting multi month highs
   Oill hits 2 1 2 year highs on Middle East unrest
  Updates with Wall Street open  prices  changes byline 
dateline previously LONDON 
 By Leah Schnurr and Jeremy Gaunt
 NEW YORK LONDON  April 4  Reuters    Merger and acquisition
activity helped lift global equities on Monday  though Wall
Street struggled to maintain gains in early trade
 Crude oil prices hit 2 1 2 year highs as the unrest in
Libya continued to unnerve investors 
 Expectations that the European Central Bank will raise euro
zone interest rates at its meeting on Thursday drove the euro
briefly to an 11 month high against the Japanese yen  but later
slipped because expectations of higher rates have already been
priced in 
 World stocks as measured by MSCI  were up
0 6 percent  rising to the highest level in more than a month
and up more than 5 percent for the year to date 
 In the latest acquisition news  Pfizer Inc  rose 0 8
percent to  20 54 after the drugmaker agreed to sell its
Capsugel unit  the world s largest maker of hard capsules  to
private equity firm KKR   Co  for nearly  2 4 billion 
 And in Europe Belgian chemicals group Solvay 
launched a bid for French rival Rhodia    driving up
Rhodia s shares 48 percent  For details  see  ID nLDE66P0SY 
 Vodafone  rose after selling its 44 percent stake in
France s second biggest telecom operator SFR to Vivendi
   ID nLDE73319N 
 On Wall Street the broad S P 500  faced levels where
selling has clustered in recent sessions  hovering just above
1 333  a level that it has been unable to close above since
mid February 
 The Dow Jones industrial average  was up 11 88
points  or 0 10 percent  at 12 388 60  The Standard   Poor s
500 Index  was up 0 91 points  or 0 07 percent  at
1 333 32  The Nasdaq Composite Index  was down 1 51
points  or 0 05 percent  at 2 788 09 
 On Friday  the S P recorded its best two week period since
December  and the Dow industrials  hit the highest
intraday level since June 2008 
  European stocks added to three week highs hit Friday with
a 0 2 percent rise for the FTSEurofirst 300   Japan s
Nikkei  closed up 0 1 percent 
 The improving macroeconomic backdrop has been primarily
responsible for the bounce back in equities after tumbling in
March on Japan s disaster and unrest in North Africa and the
Middle East 
 The economic growth improvement has cemented expectations
that the ECB will raise interest rates Thursday and led to
speculation the U S  Federal Reserve may be getting closer to
withdrawing exceptional liquidity   ID nLDE7330AC 
  As the economy turns the corner and gets back on its feet 
central bankers are beginning to see inflation as a greater
threat than lack of growth   said Jonathan Sudaria  dealer at
Capital Spreads 
 RATES DRIVE EURO
 Reflecting expectations of differing rate paths  the euro
hit 11 month highs against the yen and touched a five month
peak against the dollar  The single currency later slipped back
with expectations of an increase in rates already priced in by
investors 
 In contrast to the ECB  the Bank of Japan is likely to
downgrade its economic assessment at its meeting Wednesday and
may consider finding more ways to help the economy recover from
last month s massive earthquake and devastating tsunami 
 Key euro priced bank to bank lending rates hit new 21 month
highs Monday  boosted by rate hike expectations 
 ID nLDE7330V9 
 The euro briefly popped above 120 yen  for the
first time since May 2010 and was later at 119 55 yen  It hit a
five month high against the dollar of  1 4269 and was later at
 1 42138  
  I think the euro is close to putting in a top now as the
monetary policy divergence story is almost fully priced   said
Lee Hardman  currency strategist at BTM UFJ 
 There was little respite for the euro zone periphery s bond
sector with Fitch cutting Portugal s credit ratings by three
notches to BBB minus late Friday  one notch above junk  and
signaling further downgrades are likely 
 Traders also said Spanish Prime Minister Jose Luis
Rodriguez Zapatero s decision not to seek a third term in 2012
elections would raise questions over Madrid s future commitment
to economic reforms 
 In commodities markets  North Sea Brent crude oil hit a
2 1 2 year high of almost  120 a barrel on Monday as the unrest
in the Middle East and North Africa kept the focus on oil
supplies as economic growth bolstered demand for fuel 
  The focus remains on headlines out of the Middle East  
said Edward Meir  senior commodity analyst at brokers MF
Global  despite what he called a  less than compelling
fundamental backdrop  
 ICE Brent  rose  1 25 to a high of  119 95 a barrel 
its highest since August 2008  before slipping back to trade
around  119 70 by 1345 GMT  U S  crude  was up 20 cents
at  108 14 a barrel by 1345 GMT  after touching  108 78 earlier
in the session  its highest since September 2008 
 Analysts say the loss of oil from Libya has been more or
less offset by Saudi Arabia  while the Japanese crisis should
also reduce oil import demand  suggesting  there likely is a
statistical surplus in the system right now   Meir said 
  Reporting by Leah Schnurr  Additional reporting by Kirsten
Donovan  Neal Armstrong  Ian Chua and Masayuki Kitano  Editing
by Leslie Adler ",2011-04-04,Reuters,https://www.investing.com/news/forex-news/global-markets-world-stocks-rally-on-m-a;-oil-up-on-middle-east-205656,205656
220892,442408,PFE,GLOBAL MARKETS World stocks rise on M A oil up on Middle East,news,"  M A activity supports global shares
   Wall Street edges up but faces resistance
   Euro slips back after hitting multi month highs
   Brent crude hits  120 a barrel on Middle East unrest
  Updates prices  adds details 
 By Leah Schnurr
 NEW YORK  April 4  Reuters    Merger and acquisition
activity helped buoy global equities on Monday  but gains were
kept in check after recent highs  while expectations of higher
euro zone interest rates took the euro briefly to an 11 month
high against Japan s yen 
 Brent crude oil prices rose above  120 a barrel to the
highest level since before the collapse of Lehman Brothers and
the global financial crisis in September 2009  driven up on
worries over the unrest in Libya and the Middle East and
potential supply threats 
 On Wall Street the broad S P 500  edged higher as it
faced levels where selling has clustered in recent sessions  It
was hovering just above 1 333  a level that it has been unable
to close above since mid February 
 The S P recorded its best two week period since December on
Friday and the Dow industrials  hit its highest intraday
level since June 2008 
  It wouldn t be unhealthy to see a period of consolidation
in the short term  but with this kind of momentum you sometimes
don t get that pause   said Richard Ross  global technical
strategist at Auerbach Grayson in New York 
 The Dow Jones industrial average  added 15 18 points 
or 0 12 percent  to 12 391 90  The Standard   Poor s 500 Index
 edged up 0 81 points  or 0 06 percent  at 1 333 22  The
Nasdaq Composite Index  gained 1 51 points  or 0 05
percent  to 2 791 11 
 World stocks as measured by MSCI  were up
0 3 percent  hovering around a one month high and up nearly 5
percent for the year to date  European shares rose to a
three week closing high 
  Positive sentiment is coming from mergers  We will see
more mergers and acquisitions and it is one of the reasons why
the stock market is still trading at these higher levels   a
London based equity trader said 
 In the latest acquisition news  Pfizer Inc  rose
nearly 1 percent to  20 57 after the drugmaker agreed to sell
its Capsugel unit  the world s largest maker of hard capsules 
to private equity firm KKR   Co  for nearly  2 4
billion  Pfizer shares rose 0 8 percent to  20 55  For details 
see  ID nN04165993 
 In Europe Belgian chemicals group Solvay  launched
a bid for French rival Rhodia    driving up Rhodia s
shares 48 percent   ID nLDE66P0SY 
 Vodafone  gave back earlier gains to close lower
after selling its 44 percent stake in France s second biggest
telecom operator SFR to Vivendi    ID nLDE73319N 
 The FTSEurofirst 300  closed up up 0 1 percent at
1 142 84 points  the highest close since March 9  Japan s
Nikkei  also closed up 0 1 percent 
 The improving macroeconomic backdrop has been primarily
responsible for the bounce back in equities after tumbling in
March on Japan s disaster and unrest in North Africa and the
Middle East 
 RATES DRIVE EURO
 The economic growth improvement has cemented expectations
that the ECB will raise interest rates Thursday and led to
speculation the U S  Federal Reserve may be getting closer to
withdrawing exceptional liquidity   ID nLDE7330AC 
  As the economy turns the corner and gets back on its feet 
central bankers are beginning to see inflation as a greater
threat than lack of growth   said Jonathan Sudaria  dealer at
Capital Spreads 
 A top Federal Reserve official said on Monday that U S 
inflation is likely to remain low for now  but policymakers
will keep a close eye on potentially self fulfilling consumer
expectations for higher prices   ID nN04244409 
 Reflecting expectations of differing rate paths  the euro
hit an 11 month high against the yen and touched a five month
peak against the dollar  The single currency later slipped back
with expectations of an increase in rates already priced in by
investors 
 In contrast to the ECB  the Bank of Japan is likely to
downgrade its economic assessment at its meeting Wednesday and
may consider finding more ways to help the economy recover from
last month s massive earthquake and devastating tsunami 
 The euro briefly popped above 120 yen  for the
first time since May 2010 and was later at 119 55 yen  It hit a
five month high against the dollar of  1 4269 and was later at
 1 42138  
 In commodities markets  North Sea Brent crude oil rose to
 120 a barrel 
  The focus remains on headlines out of the Middle East  
said Edward Meir  senior commodity analyst at brokers MF
Global  despite what he called a  less than compelling
fundamental backdrop  
 ICE Brent  was most recently trading up  1 61 at
 120 31  U S  crude  rose 45 cents to  108 39 a barrel 
after touching  108 78 earlier in the session  its highest
since September 2008 
 Analysts say the loss of oil from Libya has been more or
less offset by Saudi Arabia  while the Japanese crisis should
also reduce oil import demand  suggesting  there likely is a
statistical surplus in the system right now   Meir said 
  Reporting by Leah Schnurr  Additional reporting by Rodrigo
Campos in New York  Christopher Johnson in London  Editing by
Leslie Adler ",2011-04-04,Reuters,https://www.investing.com/news/forex-news/global-markets-world-stocks-rise-on-m-a;-oil-up-on-middle-east-205673,205673
220893,442409,PFE,US STOCKS Market flat  earnings could pierce resistance,news,"  Profit news next week could prove catalyst
   S P 500 seen testing its 2011 high
   Pfizer to sell unit to KKR for about  2 4 billion
   Dow up 0 2 pct  S P up 0 1 pct  Nasdaq up 0 1 pct
  Updates to midday 
 By Edward Krudy
 NEW YORK  April 4  Reuters    The S P 500 met tough
resistance on Monday  with the next major catalyst that could
push stocks higher not expected until quarterly earnings
reports start to arrive next week 
 Investors were cautious against a backdrop of geopolitical
risks that have weighed on equities for months 
 The benchmark S P 500 hovered near 1 333  which it has not
closed above since mid February  The level is double the
12 year low hit in March 2009 and not far from 1 344  the S P s
highest since June 2008 
 Bruce Zaro  chief technical strategist at Delta Global
Asset Management in Boston  said earnings season would likely
push the S P 500 to 1 400 by mid May as stocks come off the
seasonally strong November April period 
  If we make a successful break from here  I think you ve
got the 1 400 range and I think that s probably likely during
the final seasonally favorable push   he said 
 On Friday  the S P recorded its best two week period since
December  and the Dow industrials hit their highest intraday
level since June 2008  Encouraging jobs data during the week
helped cement hopes of a labor market recovery points  or 0 17
percent  to 12 397 65  The Standard   Poor s 500 Index rose
1 04 points  or 0 08 percent  to 1 333 45  The Nasdaq Composite
Index added 2 77 points  or 0 10 percent  to 2 792 37 
 The lack of significant economic data on Monday  nuclear
and other quake related problems in Japan and unrest in Libya 
Syria and other countries in the oil rich region of North
Africa and the Middle East could translate into low volume on
Wall Street  By midday the volume was the lowest so far this
year and followed the lowest weekly volume of 2011 last week 
 Brent crude extended gains to a 2 1 2 year peak above  120
a barrel on concerns over Libya s conflict  Middle East unrest
and potential supply threats  Investors are concerned that a
spike in oil could choke off a consumer recovery 
 Richard Ross  global technical strategist at Auerbach
Grayson in New York  said the S P 500 could retake its yearly
high this week 
  I think the market has enough inertia and the retest of
1 344 is in store   he said   We re looking for a marginal new
high on the S P 500 setting you up for the next leg of the
advance  
 Japanese investment bank Nomura maintained a neutral view
on semiconductor stocks  citing weakened demand  peak gross
margins and higher capital spending in the sector 
 The Philadelphia semiconductor index fell 1 percent and has
lost 2 9 percent over the past four days 
 Pfizer Inc rose 0 8 percent to  20 55 after the drugmaker
agreed to sell its Capsugel unit  the world s largest maker of
hard capsules  to private equity firm KKR   Co for nearly  2 4
billion 
 Shares of defense contractor General Dynamics dropped 5 7
percent to  73 after on of its Gulfstream Aerospace jets
crashed on a test flight  killing four 
 Southwest Airlines Co shares dropped 2 percent to  12 41
after about 70 flights were canceled for safety inspections  A
Southwest jet made an emergency landing with a hole in the
cabin on Friday  
 Reporting by Edward Krudy  Editing by Kenneth Barry ",2011-04-04,Reuters,"https://www.investing.com/news/stock-market-news/us-stocks-market-flat,-earnings-could-pierce-resistance-205692",205692
220894,442410,PFE,GLOBAL MARKETS Oil up on Middle East  equities helped by MA,news,"  M A activity supports global shares
   Wall Street edges down as S P hits resistance
   Euro slips back after hitting multi month highs
   Brent crude hits  120 a barrel on Middle East unrest
  Rewrites  updates prices  adds details  quotes 
 By Leah Schnurr
 NEW YORK  April 4  Reuters    Merger and acquisition
activity helped global equities eke out mild gains on Monday 
while oil rose to 2 1 2 year highs on worries geopolitical
risks will hit supply 
 The M A cheer did little for Wall Street with the broad S P
500  little changed as it encountered levels where
selling has clustered in recent sessions 
 Expectations of higher euro zone interest rates took the
euro briefly to an 11 month high against Japan s yen  but the
currency eased back with expectations of an increase already
priced in 
 Brent crude oil prices rose above  120 a barrel to the
highest level since before the collapse of Lehman Brothers and
the global financial crisis in September 2008  U S  crude was
choppy after rising to  108 78  the highest intraday price
since September 2008 
 Libya s continuing conflict and unrest in Yemen could pose
threats to supply in the Middle East  while investors expect
demand for oil could grow on signs of improvement in the U S 
economy 
  Brent is up on Libya  Yemen unrest and the Nigerian
election   said Phil Flynn  analyst at PFGBest Research in
Chicago 
  U S  crude is hesitant because there is still worry that
the Federal Reserve might be nearing a rate hike or tighter
policy  which would lower liquidity and demand and strengthen
the dollar   he added 
 World stocks as measured by MSCI  were up
0 2 percent  hovering around a one month high and up nearly 5
percent for the year to date  European shares rose to a
three week closing high 
  Positive sentiment is coming from mergers  We will see
more mergers and acquisitions and it is one of the reasons why
the stock market is still trading at these higher levels   a
London based equity trader said 
 In Europe Belgian chemicals group Solvay  launched
a bid for French rival Rhodia    driving up Rhodia s
shares 48 percent   ID nLDE66P0SY 
 Vodafone  gave back earlier gains to close lower
after selling its 44 percent stake in France s second biggest
telecom operator SFR to Vivendi    ID nLDE73319N 
 The FTSEurofirst 300  closed up 0 04 percent at
1 142 84 points  the highest close since March 9  Japan s
Nikkei  also closed up 0 1 percent 
 On Wall Street  Pfizer Inc  rose 0 5 percent to
 20 48 after the drugmaker agreed to sell its Capsugel unit 
the world s largest maker of hard capsules  to private equity
firm KKR   Co  for nearly  2 4 billion  For details  see
 ID nN04165993 
  But the S P was slightly lower in the early afternoon 
hovering just under 1 333  a level that it has been unable to
close above since mid February 
 The S P recorded its best two week period since December on
Friday and the Dow industrials  hit its highest intraday
level since June 2008 
  If we make a successful break from here  I think you ve
got the 1 400 range and I think that s probably likely during
the final seasonally favorable push   said Bruce Zaro  chief
technical strategist at Delta Global Asset Management in
Boston 
 The Dow Jones industrial average  dipped 2 04 points 
or 0 02 percent  to 12 374 68  The Standard   Poor s 500 Index
 slipped 3 04 points  or 0 23 percent  to 1 329 37  The
Nasdaq Composite Index  was off 10 40 points  or 0 37
percent  to 2 779 20 
 RATES DRIVE EURO
 Economic improvement has cemented expectations that the ECB
will raise interest rates Thursday and led to speculation the
U S  Federal Reserve may be getting closer to withdrawing
exceptional liquidity   ID nLDE7330AC 
 A top Federal Reserve official said on Monday that U S 
inflation is likely to remain low for now  but policymakers
will keep a close eye on potentially self fulfilling consumer
expectations for higher prices   ID nN04244409 
 Reflecting expectations of differing rate paths  the euro
hit an 11 month high against the yen and touched a five month
peak against the dollar  The euro later slipped back 
 The euro briefly popped above 120 yen  for the
first time since May 2010 and was later at 119 50 yen  It hit a
five month high against the dollar of  1 4269 and was later at
 1 4223  
 In commodities  ICE Brent  was up  1 50 at  120 20 a
barrel  U S  crude  rose 16 cents to  108 08 a barrel 
  Reporting by Leah Schnurr  Additional reporting by Edward
Krudy and Robert Gibbons in New York  Atul Prakash in London 
Editing by Kenneth Barry ",2011-04-04,Reuters,"https://www.investing.com/news/forex-news/global-markets-oil-up-on-middle-east,-equities-helped-by-m-a-205716",205716
220895,442411,PFE,REFILE US STOCKS Wall St struggles to break through resistance,news," Refiles to fix typo in paragraph 9 to read  strategist  
    Profit news next week could prove catalyst
    S P 500 seen testing its 2011 high
    Pfizer to sell unit to KKR for about  2 4 billion
    Dow up 0 1 pct  S P off 0 1 pct  Nasdaq down 0 2 pct
   For up to the minute market news see  STXNEWS US 
  Updates to afternoon trade  changes byline 
 By Angela Moon
 NEW YORK  April 4  Reuters    The S P 500 struggled to
break above its high for the year on Monday as investors
awaited the coming earnings season that begins next week to
assess the strength of the stock market 
 Investors were also on the lookout for the expected
increase in euro zone interest rates this week 
 The benchmark S P 500 hovered slightly below 1 333  which
it has not closed above since mid February  The level is
double the 12 year low hit in March 2009 and not far from
1 344  the S P s highest since June 2008 
 Bruce Zaro  chief technical strategist at Delta Global
Asset Management in Boston  said earnings season would likely
push the S P 500 to 1 400 by mid May as stocks come off the
seasonally strong November April period 
  If we make a successful break from here  I think you ve
got the 1 400 range and I think that s probably likely during
the final seasonally favorable push   he said 
 The Dow Jones industrial average  was up 12 22
points  or 0 10 percent  at 12 388 94  The Standard   Poor s
500 Index  was down 1 35 points  or 0 10 percent  at
1 331 06  The Nasdaq Composite Index  was down 6 22
points  or 0 22 percent  at 2 783 38 
 On Friday  the S P recorded its best two week period since
December  and the Dow industrials  hit their highest
intraday level since June 2008  Encouraging jobs data during
the week helped cement hopes of a labor market recovery 
  
  S P 500 faces resistance 
                                                         
 The European Central Bank  at its policy meeting on
Thursday  is expected to raise rates by 25 basis points from a
record low in reaction to rising inflationary pressures in the
euro zone  Two more 25 basis point rate hikes are factored in
by year end  
  With the ECB on Thursday expected to raise interest rates
and the minutes from the March FOMC meeting out tomorrow where
maybe we ll get some color on the exit strategy debate  the
question this all brings is what will the impact be of higher
interest rates on still overleveraged economies   said Peter
Boockvar  equity strategist at Miller Tabak   Co in New York 
 The lack of significant economic data on Monday  nuclear
and other quake related problems in Japan and unrest in Libya 
Syria and other countries in the oil rich region of North
Africa and the Middle East could translate into low volume on
Wall Street  By the afternoon  the volume was the lowest so
far this year and followed the lowest weekly volume of 2011
last week 
 Brent crude extended gains to a 2 1 2 year peak above  120
a barrel on concerns about Libya s conflict  Middle East
unrest and potential supply threats  U S  crude oil futures
settled at  108 47 a barrel  up 53 cents  for the highest
close since September 2008  Investors are concerned that a
spike in oil could choke off a consumer recovery 
 Japanese investment bank Nomura maintained a neutral view
on semiconductor stocks  citing weakened demand  peak gross
margins and higher capital spending in the sector 
 The Philadelphia semiconductor index  fell 1 2
percent and has lost 2 9 percent over the past four days 
 Pfizer Inc  rose 0 5 percent to  20 48 after the
drugmaker agreed to sell its Capsugel unit  the world s
largest maker of hard capsules  to private equity firm KKR  
Co  for nearly  2 4 billion 
 Shares of defense contractor General Dynamics 
dropped 5 4  percent to  73 23 after one of its Gulfstream
Aerospace jets crashed on a test flight  killing four 
 Southwest Airlines Co  shares dropped 2 2 percent
to  12 39 after about 70 flights were canceled for safety
inspections  A Southwest jet made an emergency landing with a
hole in the cabin on Friday   ID nN04246437  
  Reporting by Angela Moon  Editing by Jan Paschal ",2011-04-04,Reuters,https://www.investing.com/news/stock-market-news/us-stocks-wall-street-struggles-to-break-through-resistance-205719,205719
220896,442412,PFE,US STOCKS S P ends flat  fails to break through resistance,news,"  Trading volume ends at lowest of the year
    Earnings news next week could prove catalyst
    S P 500 seen testing its 2011 high
    Dow up 0 2 pct  S P and Nasdaq end flat
  Updates to close 
 By Angela Moon
 NEW YORK  April 4  Reuters    The S P 500 met tough
resistance on Monday  failing to break a level that has held
since mid February even as a spate of deals and underlying
strength in the economy spurred optimism 
 But caution ahead of earnings season held volume to its
lowest level this year and suggested the recent rally may be
fading 
 The benchmark S P 500 hovered slightly below 1 333  which
it has not closed above since mid February  The level is
double the 12 year low hit in March 2009 and not far from
1 344  the S P s highest since June 2008 
  Volume has dried up here as investors and traders are
sitting on their positions to see what happens  in the
upcoming earnings season  said Tim Ghriskey  chief investment
officer of Solaris Asset Management in Bedford  New York 
 Larry McMillan  president of McMillan Analysis Corp  said
the market is due for a short term correction as technical
indicators suggest the market is overbought 
  Overall  the picture is still bullish  but the market is
acting tired because it s overbought  With the month end
bullish influences winding down  there could be a short lived
pullback at hand   he said in a note 
 The Dow Jones industrial average rose 23 31 points  or
0 19 percent  to end at 12 400 03  The Standard   Poor s 500
Index was up just 0 46 of a point  or 0 03 percent  at
1 332 87  The Nasdaq Composite Index was down 0 41 points  or
0 01 percent  at 2 789 19 
 On Friday  the S P recorded its best two week period since
December  and the Dow industrials hit their highest intraday
level since June 2008  Encouraging jobs data during the week
helped cement hopes of a labor market recovery 
 About 5 84 billion shares traded on the New York Stock
Exchange  NYSE Amex and Nasdaq  the lowest of the year and
below last year s estimated daily average of 8 47 billion 
 Investors were also on the lookout for the expected
increase in euro zone interest rates this week 
 The European Central Bank  at its policy meeting on
Thursday  is expected to raise rates by 25 basis points from a
record low in reaction to rising inflationary pressures in the
euro zone  Two more 25 basis point rate hikes are factored in
by year end 
 Japanese investment bank Nomura maintained a neutral view
on semiconductor stocks  citing weakened demand  peak gross
margins and higher capital spending in the sector 
 The Philadelphia semiconductor index fell 0 9 percent  It
has lost 2 9 percent over the past four days 
 Pfizer Inc rose 0 8 percent to  20 54 after the drugmaker
agreed to sell its Capsugel unit  the world s largest maker of
hard capsules  to private equity firm KKR   Co for nearly  2 4
billion 
 Shares of defense contractor General Dynamics dropped 5 2
percent to  73 37 after one of its Gulfstream Aerospace jets
crashed on a test flight  killing four 
 Southwest Airlines Co shares dropped 1 7 percent to  12 46
after about 70 flights were canceled for safety inspections  A
Southwest jet made an emergency landing with a hole in the
cabin on Friday 
 Advancing stocks outnumbered declining ones on the NYSE by
1 602 to 1 344  while on the Nasdaq  advancers beat decliners
by 1 387 to 1 230 
  Reporting by Angela Moon  Additional reporting by Doris
Frankel  Editing by Jan Paschal ",2011-04-04,Reuters,"https://www.investing.com/news/stock-market-news/us-stocks-s-p-ends-flat,-fails-to-break-through-resistance-205751",205751
220897,442413,PFE,US STOCKS S P closes flat  fails to break through resistance,news,"  Texas Instruments to buy National Semi for  6 5 bln
    Trading volume ends at lowest of the year
    Earnings news next week could prove catalyst
    S P 500 seen testing its 2011 high
    Dow up 0 2 pct  S P and Nasdaq end flat
   For up to the minute market news see  STXNEWS US 
  Updates with Texas Instruments National Semi deal  latest
volume 
 By Angela Moon
 NEW YORK  April 4  Reuters    The S P 500 met tough
resistance on Monday  failing to break a level that has held
since mid February and ending flat even as a spate of deals
and underlying strength in the economy spurred optimism 
 But caution ahead of earnings season held volume to its
lowest level this year and suggested the recent rally may be
fading 
 The benchmark S P 500 hovered slightly below 1 333  which
it has not closed above since mid February  The level is
double the 12 year low hit in March 2009 and not far from
1 344  the S P s highest since June 2008 
  Volume has dried up here as investors and traders are
sitting on their positions to see what happens  in the
upcoming earnings season  said Tim Ghriskey  chief investment
officer of Solaris Asset Management in Bedford  New York 
 Larry McMillan  president of McMillan Analysis Corp  said
the market is due for a short term correction as technical
indicators suggest the market is overbought 
  Overall  the picture is still bullish  but the market is
acting tired because it s overbought  With the month end
bullish influences winding down  there could be a short lived
pullback at hand   he said in a note 
 The Dow Jones industrial average  rose 23 31 points 
or 0 19 percent  to end at 12 400 03  The Standard   Poor s
500 Index  was up just 0 46 of a point  or 0 03 percent 
at 1 332 87  The Nasdaq Composite Index  was down 0 41
of a point  or 0 01 percent  at 2 789 19 
 On Friday  the S P recorded its best two week period since
December  and the Dow industrials hit their highest intraday
level since June 2008  Encouraging jobs data during the week
helped cement hopes of a labor market recovery 
  
  S P 500 faces resistance 
                                                         
 About 5 94 billion shares traded on the New York Stock
Exchange  NYSE Amex and Nasdaq  the lowest of the year and
below last year s estimated daily average of 8 47 billion 
 DANCE OF THE CHIPMAKERS
 After the bell  Texas Instruments Inc  said it
plans to buy smaller rival National Semiconductor  for
about  6 5 billion in one of the microchip industry s largest
deals in years   ID nN04281619 
 Following the announcement  Texas Instruments  stock fell
1 8 percent to  33 50 in extended trade  while National
Semiconductor s shares surged 73 4 percent to  24 39 
 During the regular session  the Philadelphia semiconductor
index  fell 0 9 percent  It has lost 2 9 percent over
the past four days 
 Japanese investment bank Nomura maintained a neutral view
on semiconductor stocks  citing weakened demand  peak gross
margins and higher capital spending in the sector 
 Investors were also on the lookout for an expected
increase in euro zone interest rates this week 
 The European Central Bank  at its policy meeting on
Thursday  is expected to raise rates by 25 basis points from a
record low in reaction to rising inflationary pressures in the
euro zone  Two more 25 basis point rate hikes are factored in
by year end  
 Pfizer Inc  rose 0 8 percent to  20 54 after the
drugmaker agreed to sell its Capsugel unit  the world s
largest maker of hard capsules  to private equity firm KKR  
Co  for nearly  2 4 billion 
 Shares of defense contractor General Dynamics 
dropped 5 2 percent to  73 37 after one of its Gulfstream
Aerospace jets crashed on a test flight  killing four 
 Southwest Airlines Co  shares dropped 1 7 percent
to  12 46 after about 70 flights were canceled for safety
inspections  A Southwest jet made an emergency landing with a
hole in the cabin on Friday   ID nN04246437  
 Advancing stocks outnumbered declining ones on the NYSE by
1 602 to 1 344  while on the Nasdaq  advancers beat decliners
by 1 387 to 1 230 
  Reporting by Angela Moon  Additional reporting by Doris
Frankel  Editing by Jan Paschal ",2011-04-04,Reuters,"https://www.investing.com/news/stock-market-news/us-stocks-s-p-closes-flat,-fails-to-break-through-resistance-205758",205758
220903,442419,PFE,ARIAD Finishes Rolling NDA For Lung Cancer Drug Brigatinib,opinion,"ARIAD Pharmaceuticals  Inc    NASDAQ ARIA   announced the completion of the rolling submission of the new drug application  NDA  for its experimental ALK inhibitor  brigatinib  to the FDA  ARIAD is looking to get brigatinib approved for the treatment of patients with metastatic ALK positive  ALK   non small cell lung cancer  NSCLC  in patients who are resistant or intolerant to Pfizer Inc  s   NYSE PFE   Xalkori 
ARIAD is seeking accelerated approval for brigatinib from the FDA and has requested a priority review of the application  which could shorten the review period from the standard 12 months to just 8 months 
We note that brigatinib enjoys Breakthrough Therapy status in the U S  for the treatment of patients with ALK  NSCLC whose tumors are resistant to Xalkori  Brigatinib also has Orphan Drug status in the U S  for the treatment of ALK  NSCLC 
The regulatory application included data from its phase I II and pivotal phase II ALTA studies on brigatinib  With a median follow up of 8 3 months  data demonstrated that 54  of patients  when treated with a 180 mg regimen with a seven day lead in at 90 mg  witnessed an investigator assessed confirmed objective response   the primary endpoint of the study  In addition  median progression free survival exceeded one year  12 9 months  in this arm 
ARIAD plans to submit a marketing authorization application for brigatinib to the European Medicines Agency in early 2017 ARIAD PHARMA Price
    Meanwhile  the company has initiated a first line phase III study  ALTA1L  comparing the efficacy and safety of brigatinib to Xalkori in patients with locally advanced or metastatic ALK  NSCLC who have not previously been treated with an ALK inhibitor 
We are encouraged by the company s progress with brigatinib  Currently  ARIAD has only one marketed product in its kitty   leukemia drug Iclusig  If brigatinib is finally approved  it could become a two product commercial company by early 2017 
ARIAD is a Zacks Rank  3  Hold  stock  A couple of better ranked stocks in the health care sector are ANI Pharmaceuticals  Inc    NASDAQ ANIP   and Geron Corporation   NASDAQ GERN    Both the stocks sport a Zacks Rank  1  Strong Buy  
Confidential from Zacks 
Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-08-30,Zacks Investment Research,https://www.investing.com/analysis/ariad-finishes-rolling-nda-for-lung-cancer-drug-brigatinib-200151088,200151088
220904,442420,PFE,Pfizer s Lung Cancer Drug Xalkori Label Expanded In The EU,opinion,"Pfizer  Inc    NYSE PFE   announced that its lung cancer drug Xalkori has been approved for an additional indication by the European Commission  EC  The EC has approved Xalkori for the treatment of adult patients with advanced NSCLC whose tumors are ROS1 positiveWe note that Xalkori is already approved in the EU for the first line treatment of adults with anaplastic lymphoma kinase  ALK  positive advanced NSCLC and for the treatment of adults with previously treated ALK positive advanced NSCLC  It is also approved in the U S  for the treatment of metastatic NSCLC in patients whose tumors are ALK positive  In March this year  the drug received approval in the U S  for expanded use in metastatic NSCLC in patients whose tumors are ROS1 positive PFIZER INC Price
    With the latest approval in the EU  Xalkori can now be used to treat patients with either ALK positive or ROS1 positive advanced NSCLC in both the EU and U S The EC approval was based on a positive opinion issued by European Medicine s Agency s Committee for Medicinal Products for Human Use  CHMP   backed by positive efficacy and safety data from a multicenter phase I study Pfizer posted worldwide Xalkori sales of  275 million in the first half of 2016  up 20  from the year ago figure  The expanded indication of the drug should drive sales further NSCLC is a difficult to treat disease  accounting for about 85  of lung cancer cases  At present  the lung cancer treatment market is highly crowded with drugs like Opdivo  Keytruda  Alecensa  Zykadia and Taxotere among others Currently  Pfizer carries a Zacks Rank  3  Hold   Some better ranked stocks in the healthcare sector include Actelion Ltd    OTC ALIOF    Geron Corporation   NASDAQ GERN   and ANI Pharmaceuticals  Inc    NASDAQ ANIP    All these stocks sport a Zacks Rank  1  Strong Buy  Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-09-01,Zacks Investment Research,https://www.investing.com/analysis/pfizer's-lung-cancer-drug-xalkori-label-expanded-in-the-eu-200151357,200151357
220907,442423,PFE,U S  stocks rise on health care reform  Dow Jones up 0 37 ,news,Investing com   U S  stock markets turned positive on Monday  as drugmakers gained after the House of Representatives approved a far reaching overhaul of the U S  healthcare system  During early U S  trade  the Dow Jones Industrial Average was up 0 37   the S P 500 index rose 0 28  and the Nasdaq Composite Index was up 0 46  Pharmaceutical companies  which are expected to gain from the healthcare legislation  were among the top performers  with Merck gaining 2 58  and Pfizer rising 1 1  Earlier in the day  House Democrats approved the health care reform  voting over Republican opposition to provide tens of millions of uninsured Americans with medical coverage Meanwhile  stock markets in Europe pared losses but were still in negative territory  France s CAC 40 was down 0 46   Germany s DAX slipped 0 36   Britain s FTSE 100 was down 0 52   and the EURO STOXX 50 shed 0 74  Later Monday  U S  Treasury Secretary Timothy Geithner was set to speak about financial reforms to a Washington based think tank  the American Enterprise Institute ,2010-03-22,Investing.com,https://www.investing.com/news/forex-news/u.s.-stocks-rise-on-health-care-reform;-dow-jones-up-0.37-126714,126714
220908,442424,PFE,European stocks advance ahead of Fed meeting  DAX up 0 27 ,news,Investing com   European stocks posted modest gains on Tuesday  as gains in the commodity sector offset losses in the financial sector  while U S  futures indexes pointed to a higher open on Wall Street  During European morning trade  the EURO STOXX 50 was up 0 10   France s CAC 40 rose 0 11   while Germany s DAX gained 0 27  Shares in Spain s second largest lender BBVA tumbled 2 20  after the company announced it would pay approximately EUR 4 2 billion for a 24 7  stake in Turkey s second largest bank Turkiye Garanti Bankasi Elsewhere within the sector  lenders were mixed  with shares in Italy s largest financial service provider Unicredit jumping 1 27   shares in Deutsche Bank gained 0 63   while Spanish lender Banco Santander saw shares fall 1 25        In London  the commodity heavy FTSE 100 gained 0 79  after shares in the world s third largest oil and gas company British Petroleum gained 2 03  after adjusted net profit rose 18  to USD 5 5 billion  beating analyst expectations  The company said third quarter net profit fell 67  to USD 1 79 billion  due largely to costs related to the oil spill in the Gulf of Mexico Elsewhere in the commodity sector  shares in the world s fourth largest copper producer Xstrata soared 1 55   mining giants BHP Billiton jumped 1 26   while silver producer Fresnillo saw shares rise 1 83  as a weaker U S  dollar lifted crude oil and metal prices In earnings news  shares in German retailer Metro jumped 1 40  after the company reported higher than expected third quarter net profit  The retail giant also raised its full year profit outlook  citing higher sales and cost cuts   The outlook for U S  equity markets  meanwhile  was upbeat ahead of earnings reports from MasterCard and pharmaceutical giant Pfizer The Dow Jones Industrial Average futures indicated a gain of 0 20   S P 500 futures pointed to an increase of 0 30  and Nasdaq 100 futures indicated a rise of 0 33  Later in the day  Federal Reserve policy makers were set to start their 2 day November policy meeting  which was widely expected to result in the unveiling of fresh monetary easing ,2010-11-02,Investing.com,https://www.investing.com/news/stock-market-news/european-stocks-advance-ahead-of-fed-meeting;-dax-up-0.27-171142,171142
220909,442425,PFE,U S  stocks jump on earnings optimism  Dow Jones up 0 53 ,news,Investing com   U S  stocks were broadly higher after the open on Tuesday  as a string of upbeat corporate earnings results boosted sentiment and as markets shrugged off concerns over political turmoil in the Middle East During early U S  trade  the Dow Jones Industrial Average gained 0 53   the S P 500 index jumped 0 82   while the Nasdaq Composite index surged 1 03   Shares in pharmaceutical giant Pfizer added 3 02  after it reported fourth quarter profit jumped by 73  to USD2 89 billion  compared to USD767 million a year earlier  The company said that revenue in the quarter rose to USD17 6 billion  beating market expectations for revenue of USD16 99 billion The world s largest corn processor Archer Daniels Midland saw shares rally 7 11  after it said that fiscal second quarter earnings jumped by 30  to USD729 million  Sales in the quarter rose by 24  to USD20 93 billion  as rising grain prices and robust global demand bolstered results Meanwhile  printer manufacturer Lexmark saw shares jump 9 15  after it posted a 31  increase in fourth quarter profit  rising to USD87 6 million  helped by strong sales of laser printers    Elsewhere  shares in the world s largest Chinese search engine Baidu leaped 6 78  after it reported fourth quarter revenue soared by 94  to USD370 9 million  The internet search giant said that it increased its market share in China after rival Google curtailed its operations following a fallout with Beijing over censorship  Also Tuesday  shares in the world s largest maker of multiple sclerosis drugs Biogen Idec climbed 3 04  after it said that revenue in the fourth quarter rose by 8  to USD1 22 billion  The biotechnology firm lifted its full year earnings outlook  However  shares in Orexigen Therapeutics plunged 71 35  after the U S  Food and Drug Administration said it would not consider approving the company s new diet drug unless an additional study was conducted Across the Atlantic  European stock markets posted sharp gains  The EURO STOXX 50 surged 1 37   France s CAC 40 jumped 1 21   Germany s DAX gained 1 15   while Britain s FTSE 100 rallied 1 36  Later in the day  the Institute of Supply Management was to publish data on U S  manufacturing growth ,2011-02-01,Investing.com,https://www.investing.com/news/stock-market-news/u.s.-stocks-jump-on-earnings-optimism;-dow-jones-up-0.53-191406,191406
220917,442433,PFE,Market Fence Sitting Persists,opinion,"Last week s uncertainty has carried over to this week  as U S  equities finished mixed and near the unchanged mark  amid evident caution ahead of the start to the Federal Reserve s annual symposium in Jackson Hole  Wyoming this week  which culminates with Friday s speech by Fed Chairwoman Janet Yellen  
A pullback in crude oil prices from last week s rally also fostered some negative sentiment  while some M A news gave the healthcare sector a boost  Treasuries finished higher and the U S  dollar was flat  while gold was lower 
The Dow Jones Industrial Average  DJIA  decreased 23 points  0 1   to 18 529  the S P 500 Index shed 1 point  0 1   to close at 2 183  while the Nasdaq Composite gained 6 points  0 1   to 5 245  In lighter volume  693 million shares were traded on the NYSE and 1 5 billion shares changed hands on the Nasdaq 
WTI crude oil fell  1 70 to  47 41 per barrel  wholesale gasoline lost  0 03 to  1 48 per gallon and the Bloomberg gold spot price declined  3 03 to  1 338 44 per ounce  Elsewhere  the Dollar Index a comparison of the U S  dollar to six major world currencies was nearly unchanged at 94 55 
Dow member    NYSE PFE  35  announced an agreement to acquire oncology bio pharmaceutical company    NASDAQ MDVN  80  for  81 50 per share in cash for a total enterprise value of about  14 0 billion 
PFE said the deal is expected to be immnew ediately accretive to its earnings upon closing and it does not expect it to impact its current 2016 guidance  PFE was modestly lower  while shares of MDVN rallied nearly 20  
Domestic economic docket dormant but Fed gathering set to command attention
Treasuries were higher amid a dormant economic calendar  as the yield on the 2 year note dipped 1 basis point  bp  to 0 74   the yield on the 10 year note declined 4 basis points  bps  to 1 54   and the 30 year bond rate fell 5 bps to 2 24  
Fed policy focus and accompanying volatility is likely to begin to ramp back up this week  with the U S  economic calendar yielding key data on the housing sector in the form of tomorrow s new home sales  with economists expecting a 2 0  month over month decline during July to an annual rate of 580 000 units  as well as Wednesday s release of existing home sales 
As well  some manufacturing data may also likely garner some attention  with Thursday s durable goods orders report in focus  as well as two reports tomorrow Markit s Manufacturing PMI Index  forecasted to tick lower to 52 7 during July from the 52 9 posted in June  with a reading above 50 denoting expansion in activity  as well as the Richmond Fed Manufacturing Index 
However  the highlight of the week will likely be the Fed s highly anticipated annual monetary policy symposium in Jackson Hole  Wyoming  which will culminate with Friday s speech by Federal Reserve Chairwoman Janet Yellen 
A period of peace has reigned in the market over the past month  but the lull in volatility likely won t last  However  we do believe the secular bull market has further to run  The third quarter is shaping up to improve on lackluster first half U S  economic results  but weak corporate confidence remains an impediment to stronger growth  Fed uncertainty is likely to heat up heading toward the September Federal Open Market Committee  FOMC  meeting 
Europe and Asia mixed on commodity weakness and Fed focus
European equities finished mixed  with basic materials and oil   gas issues seeing pressure as commodity prices fell  led by crude oil prices amid lingering supply speculation  The U S  dollar gained modest ground as Fed rate hike expectations continued to resurface following comments over the weekend from Fed Vice Chair Stanley Fischer that the Central Bank was close to reaching its targets for full employment and 2 0  inflation 
The euro dipped compared to the greenback  while bond yields in the region moved to the downside  However  the British pound was higher versus the dollar  continuing its recent rebound from a sell off that followed the Bank of England s  BoE  decision earlier this month to cut its benchmark interest rate further and boost its asset purchases 
The BoE s decision was aimed at bolstering the economy on the heels the late June vote by the U K  to leave the European Union  known as Brexit  The pound has also found support from last week s July economic data that showed retail sales easily topped forecasts  jobless claims unexpectedly declined and consumer price inflation surprisingly rose 
Stocks in Asia finished mixed  with the global markets continuing to focus on the divergent monetary policy landscape following comments over the weekend by U S  Fed Vice Chair Fischer and ahead of this week s annual Fed policy gathering 
Also  Bank of Japan  BoJ  Governor Kuroda hinted at further stimulus measures  while uncertainty regarding more policy action in China persisted  The yen weakened versus the U S  dollar  though crude oil prices gave back some of a recent run 
Japanese equities  as well as those traded in Hong Kong  advanced  while mainland Chinese fell  Meanwhile  securities traded in Australia  South Korea and India all saw declines for the session 
Tomorrow s international economic calendar will be dominated by the Markit Manufacturing PMI from around the globe  as well as trade data from the U K ",2016-08-23,Marvin Clark,https://www.investing.com/analysis/fence-sitting-persists-200149450,200149450
220918,442434,PFE,Pfizer To Buy Medivation For  14B  Boost Cancer Franchise  revised ,opinion,"Putting rumors to rest  Pfizer Inc    NYSE PFE   and Medivation  Inc    NASDAQ MDVN   announced that they have entered into a definitive merger agreement under which Pfizer will acquire Medivation for  81 50 per share in cash or a total enterprise value of about  14 billion The acquisition  slated to close in the third or fourth quarter  is expected to be immediately accretive to Pfizer s earnings   earnings is expected to be boosted by about 5 cents in the first full year after close with additional accretion and growth expected thereafter  Pfizer does not expect the deal to affect its guidance for 2016 Xtandi a BlockbusterWith this acquisition  Pfizer will add Medivation s prostate cancer treatment  Xtandi  to its portfolio  Xtandi generated global sales of about  2 2 billion in the last four quarters  as recorded by Medivation s partner  Astellas Pharma Inc Xtandi is currently being evaluated in several studies including a couple of late stage studies in non metastatic prostate cancer and another phase III study in hormone sensitive prostate cancer  It is also in mid stage development for the treatment of advanced breast cancer and hepatocellular carcinoma Moreover  Medivation s pipeline candidate talazoparib  an orally available PARP inhibitor  represents significant upside potential  PARP inhibitors are currently being considered to be the next major class of therapeutics in oncology  Interest in this area has increased considerably following the announcement of impressive late stage data on another company s PARP inhibitor  niraparib  in Jun 2016  Top line results from Medivation s first talazoparib registrational study  EMBRACA  in germline BRCA mutated breast cancer are expected in the first half of 2017 According to Medivation  the addressable patient population for talazoparib in the U S  and Europe is about 760k including 10k for the EMBRACA population  while the addressable market opportunity is more than  30 billion Pfizer will also add pidilizumab to its pipeline with this acquisition  Pidilizumab is an immuno oncology  IO  asset which is being developed for diffuse large B cell lymphoma and other hematologic malignancies and which could be combined with IO therapies in Pfizer s portfolio Our TakeThe Medivation acquisition will strengthen Pfizer s cancer franchise which currently consists of products like Ibrance and Sutent  Pfizer is also working on strengthening its immune oncology pipeline and the Medivation acquisition will be a good strategic fit for the company The acquisition goes to show the increasing interest in cancer which remains the second leading cause of death in the U S  and a  Top 10  killer worldwide We note that Medivation was a part of acquisition talks for quite a while with the company first receiving an offer from French drugmaker Sanofi   NYSE SNY    Sanofi had initially approached Medivation with an offer of  52 50 in cash which was rejected by the company and came back with a sweetened bid of  58 00 per share in cash plus a Contingent Value Right  CVR  for talazoparib sales representing a potential payment in 2022 of up to  3 00 per share Pfizer s offer price of  81 50 represents a huge premium to Sanofi s last offer MEDIVATION INC Price   Pfizer is a Zacks Rank  3  Hold  stock  Actelion Ltd    OTC ALIOF   is a better ranked stock in the health care sector with a Zacks Rank  1  Strong Buy  Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days  
 We are reissuing this article to correct a mistake  The original article  issued on August 22  2016  should no longer be relied upon  ",2016-08-23,Zacks Investment Research,"https://www.investing.com/analysis/pfizer-to-buy-medivation-for-$14b,-boost-cancer-franchise-(revised)-200149515",200149515
220919,442435,PFE,Middle Of A Market Slow Down Period,opinion,"You know you re in the middle of a market slow down period when before the bell  news  focuses on the 2016 Economic Symposium in Jackson Hole  WY when Fed Chair Janet Yellen doesn t speak publicly until Friday  and nobody expects the Fed to hike interest rates in September anyway  In fact  most analysts don t expect a rate hike until after the General Election in November 

	Actually  many analysts now think an incremental interest rate hike of 0 25 0 50  won t happen until December or sometime in early 2017  If there is any drama to wring out of this  it may be in noting how tricky the balancing act toward raising rates essentially is  if they raise rates too quickly  they run the risk of quashing the slow but steady economic policy  Wait too long to raise and the FOMC fails to keep enough dry powder to counteract any macroeconomic downturn that may occur 

	In Q2 earnings news  La Z Boy  posted worse than expected numbers ahead of today s market on a fiscal Q4 revenue miss  Lower foot traffic in stores and worsening product demand led to the miss  Shares of LZB are down 15  before regular Wednesday trading 

	Pfizer s  M A pursuits continue  as European pharma company AstraZeneca  has agreed to sell part of its antibiotics business in a deal that may be worth  1 5 billion  depending on the success of the drugs  This follows the Monday announcement of Pfizer s  14 billion buyout of cancer focused biopharma company Medivation  

	Tesla  confirms it will bring to market a battery upgrade for its Model S that will enhance acceleration from 0 60 mph in an astounding 2 5 seconds  It will also run 315 miles on a single charge  allowing for a straight drive from Los Angeles to San Francisco  the first such claim by an electric car maker 

	This is part of founder and CEO Elon Musk s push to bring the world s fastest car to market  The battery upgrade  aptly named Ludicrous P100D  will  not be coming soon   according to Musk   but  will  happen long term   See what I mean about a slow news day 

	Markets are in modestly positive territory again this morning  following a barely positive regular trading session Tuesday  S P 500 futures are  1  Dow  4 and Nasdaq  3  I hope everyone not on the trading floor is enjoying their vacation ",2016-08-23,Zacks Investment Research,https://www.investing.com/analysis/middle-of-a-market-slow-down-period-200149761,200149761
220920,442436,PFE,Pfizer To Acquire Rights To AstraZeneca s Antibiotics Business,opinion,"Pfizer Inc    NYSE PFE   announced that it has entered into an agreement to acquire the rights to AstraZeneca plc s   NYSE AZN   late stage small molecule anti infectives business  primarily in the ex U S  markets The transaction will give Pfizer the rights to Zavicefta  which gained approval in the EU in Jun 2016  for complicated urinary tract infections  cUTI   complicated intra abdominal infections  cIAI   hospital acquired pneumonia ventilator associated pneumonia  HAP VAP   and for the treatment of aerobic gram negative infections in adult patients with limited treatment options The portfolio also includes marketed agents  Merrem Meronem and Zinforo  and pipeline candidates  ATM AVI and CXL Under the terms of the agreement  AstraZeneca will receive an upfront payment of  550 million from Pfizer upon the closing of the transaction  Pfizer will also make a deferred payment of  175 million in Jan 2019  Moreover  AstraZeneca is eligible to receive up to  250 million in milestone payments  and up to  600 million in sales related payments from Pfizer  In addition  AstraZeneca will earn tiered royalties on sales of Zavicefta and ATM AVI in certain markets The transaction is slated to close in the fourth quarter of 2016 PFIZER INC Price
    We note that acquiring the rights to AstraZeneca s antibiotics business will help Pfizer focus on infectious diseases and gain expertise in this space  It will also help the company expand patient access and enhance the global capability of its anti infectives portfolio  However  Pfizer said that the transaction will not impact its financial guidance for 2016 AstraZeneca  on the other hand  will now be able to concentrate on its three main therapeutic areas   respiratory   autoimmunity  cardiovascular   metabolic diseases  and oncology  backed by a strong portfolio of established products and a deep pipeline Currently  both Pfizer and AstraZeneca carry a Zacks Rank  3  Hold   A couple of better ranked stocks in the health care sector include Actelion Ltd    OTC ALIOF   and ANI Pharmaceuticals  Inc    NASDAQ ANIP    Both the stocks sport a Zacks Rank  1  Strong Buy  Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-08-24,Zacks Investment Research,https://www.investing.com/analysis/pfizer-to-acquire-rights-to-astrazeneca's-antibiotics-business-200149727,200149727
220921,442437,PFE,Fed Jackson Hole Meeting  What Will Friday Bring ,opinion,"Fed Chair Janet Yellen is set to speak at the Federal Reserve Bank of Kansas annual Economic Policy Symposium in Jackson Hole on Friday and there have been ripples of uncertainty in the market  There had been very light trading on the S P500 and DJ30 earlier this week on the run in to the speech  But with the NASDAQ100 and S P500 closing near record highs yesterday due to a housing boost and  14 billion buyout of Biotech by Pfizer  NYSE PFE  on Monday  the markets are gripped and waiting for what s to come 
With Fed Vice Chair Stanley Fischer speaking last weekend and suggesting the idea that the Fed is close to raising rates  along with New York Fed President William Dudley saying the Fed could hike in September  these main members of the Fed could be trying to take the sting out of the market if Yellen does mention a hike 
Does it seem likely to be mentioned on Friday 
With Job growth on the rise but monetary policy not being as effective as hoped  it seems unlikely that rate hikes would do anything but hinder the growth already achieved and possibly be a step in the wrong direction 
The Fed chair discussions at this symposium in other years have provided key signals in terms of interest rates  but with 2016 being a very significant year in American politics  does Yellen really want the Fed to get dragged into the  scare mongering  tactics of what is surely going to be a vicious presidential race  one week before the first debate  Probably not  With consensus being that the Fed will get a rate hike done this year  it would make December a far better candidate 
The discussion topic of this year s symposium is titled   Designing Resilient Monetary Policy Frameworks for the Future   the feeling here is longer term issues will be the topics on the table rather than next month s interest rates release ",2016-08-24,AvaTrade,https://www.investing.com/analysis/fed-jackson-hole-meeting:-what-will-friday-bring-200149723,200149723
220926,442442,PFE,Mergers   Acquisitions In Headlines,opinion,"Futures are down again ahead of the market open this morning  following a Friday that was awash in red until climbing toward unched in the closing minutes of the trading week  The S P 500 is currently at  4 points  the Dow reads  50 and the Nasdaq is currently at  8  These numbers have fluctuated a bit  but have remained negative ahead of the bell 

Mergers and acquisitions  M A  are taking headlines in this sleepy market period a couple weeks prior to the Labor Day holiday  and we re seeing big gains among smaller companies ready to be purchased by much bigger fish 

California based Intersil  has agreed to be bought by Japan s Renesas for  3 billion  and the semiconductor maker is up nearly 28  in today s pre market  Sources say they expect this deal to close by the end of August 

Chinese state owned ChemChina s pursuit of major agribusiness firm Syngenta  has cleared a regulatory hurdle in China  and this panel clearance looks to be green lighting the massive  43 billion buyout of the Swiss company  Syngenta ADRs are up roughly 10 5  at this hour 

Pfizer  NYSE PFE   is putting forth  14 billion to take over biopharma company Medivation   representing  81 50 per share for the company specializing in cancer treatments  Pfizer expects 5 cents per share in synergies from this deal as of the first year of business 

Everything else looks to be taking a break right now   European markets were down overnight  gold prices wallow at two week lows  even WTI and Brent oil prices   while up over the past few weeks overall   remain below  50 per barrel this morning  We ve got some housing data on the calendar later this week  along with Fed Chair Janet Yellen s Jackson Hole speech this Friday  but not much expected to push the needle in either direction ",2016-08-21,Zacks Investment Research,https://www.investing.com/analysis/mergers---acquisitions-in-headlines-200149278,200149278
220927,442443,PFE,Bernie Sanders Just Called Out Pfizer And Medivation On Twitter,opinion,"After much speculation  Pfizer Inc    NYSE PFE   announced today that it will acquire Medivation  Inc    NASDAQ MDVN   in a deal worth about  14 billion  The acquisition is slated to close in the third or fourth quarter  and early predictions suggest that it could boost Pfizer s earnings by up to five cents in the first full year after finalization 
 Also Read   
Deals like this make a lot of people happy  Pfizer investors will be pleased that the company has boosted its cancer treatment portfolio and added earnings potential  while Medivation investors will be pleased with their big payday 
Nevertheless  big blockbuster mergers aren t loved by everyone  One of the biggest critics to emerge shortly after Pfizer and Medivation announced the deal was none other than former Democratic presidential candidate and current U S  Senator from Vermont  Bernie Sanders 
The official Bernie Sanders Twitter account used the announcement as an opportunity to remind its followers about the current state of the pharmaceutical market 
 Today Pfizer announced they are buying Xtandi  a prostate cancer drug that costs Americans  129 000   4 times more than in other countries   Bernie Sanders   SenSanders  A life saving drug does no good if the people who need it cannot afford that drug   Bernie Sanders   SenSanders  My message to Pfizer and the entire pharmaceutical industry is clear  The era of charging unconscionable prices must end   Bernie Sanders   SenSanders  Sanders specifically calls out Medivation s Xtandi drug  a prostate cancer treatment that is the clear prize for Pfizer in this deal  Xtandi generated global sales of about  2 2 billion in the last four quarters  and the drug is currently being evaluated in several studies to further expand its treatment possibilities 
Sanders  tweets remind us of the difficult debate that surrounds business ethics  especially in the medical sector  As investors  it s easy to forget that smart business moves can oftentimes make necessary treatments that much more difficult for sick patients to afford 
While Sanders is not necessarily criticizing today s merger  he is using the news as an opportunity to further advocate for reform in the pharmaceutical industry  Xtandi will now be in the hands of Pfizer  and Pfizer alone will be responsible for its pricing and availability 
If anything  Sanders is trying to show us the human element of a deal like this  As we look towards profits  revenues  and share prices  Sanders reminds us of the importance that these drugs have for the patients who depend on them 
If any reform is to come  it s in the best interest of everyone to ensure a pharmaceutical industry that can create value for its investors while continuing to provide the best care for its patients ",2016-08-22,Zacks Investment Research,https://www.investing.com/analysis/bernie-sanders-just-called-out-pfizer-and-medivation-on-twitter-200149404,200149404
220928,442444,PFE,Pfizer Medivation Close To Signing  14B Acquisition Deal ,opinion,"According to a Financial Times article  Pfizer Inc    NYSE PFE   and Medivation  Inc    NASDAQ MDVN   are close to signing a deal under which Pfizer will acquire Medivation for more than  80 per share  approximately  14 billion  Medivation has been a part of acquisition talks for quite a while with the company first receiving an offer from French drugmaker Sanofi   NYSE SNY    Sanofi had initially approached Medivation with an offer of  52 50 in cash which was rejected by the company Last month  Medivation announced that it is open to acquisition talks and entered into confidentiality agreements with several firms that had expressed an interest in exploring a potential transaction  The company also confirmed that it had rejected a sweetened bid from Sanofi under which Sanofi offered  58 00 per share in cash plus a Contingent Value Right  CVR  for talazoparib sales representing a potential payment in 2022 of up to  3 00 per share Pfizer s rumored offer of more than  80 per share represents a huge premium compared to Sanofi s last offer  Medivation s shares are up 42 3  so far in 2016 
MEDIVATION INC Price   Why Medivation Medivation is a biopharma company that is focused on cancer treatments  The company currently has one marketed product  prostate cancer treatment  Xtandi  Xtandi  a blockbuster drug  has the potential to be approved for several additional indications as well as patient populations Moreover  pipeline candidate talazoparib  an orally available PARP inhibitor  represents significant upside potential  PARP inhibitors are currently being considered to be the next major class of therapeutics in oncology  Interest in this area has increased considerably following the announcement of impressive late stage data on another company s PARP inhibitor  niraparib  in Jun 2016  Top line results from Medivation s first talazoparib registrational study  EMBRACA  in germline BRCA mutated breast cancer are expected in the first half of 2017 According to Medivation  the addressable patient population for talazoparib in the U S  and Europe is about 760k including 10k for the EMBRACA population  while the addressable market opportunity is more than  30 billion The Medivation acquisition  if it goes through  will strengthen Pfizer s cancer franchise which currently consists of products like Ibrance  Xarelto and Sutent  Pfizer is also working on strengthening its immune oncology pipeline and the Medivation acquisition would be a good strategic fit for the company Pfizer is a Zacks Rank  3  Hold  stock while Medivation is a Zacks Rank  5  Strong Sell  stock  Actelion Ltd    OTC ALIOF   is a better ranked stock in the health care sector with a Zacks Rank  1  Strong Buy  
 
PFIZER INC Price  ",2016-08-22,Zacks Investment Research,https://www.investing.com/analysis/pfizer-medivation-close-to-signing-$14b-acquisition-deal-200149211,200149211
220929,442445,PFE,Pfizer Medivation Close To Signing  14B Acquisition Deal   revised ,opinion,"According to a Financial Times article  Pfizer Inc   NYSE PFE     and Medivation  Inc     are close to signing a deal under which Pfizer will acquire Medivation for more than  80 per share  approximately  14 billion  
Medivation has been a part of acquisition talks for quite a while with the company first receiving an offer from French drugmaker Sanofi  PA SASY      Sanofi had initially approached Medivation with an offer of  52 50 in cash which was rejected by the company 
Last month  Medivation announced that it is open to acquisition talks and entered into confidentiality agreements with several firms that had expressed an interest in exploring a potential transaction  The company also confirmed that it had rejected a sweetened bid from Sanofi under which Sanofi offered  58 00 per share in cash plus a Contingent Value Right  CVR  for talazoparib sales representing a potential payment in 2022 of up to  3 00 per share 
Pfizer s rumored offer of more than  80 per share represents a huge premium compared to Sanofi s last offer  Medivation s shares are up 42 3  so far in 2016 
Why Medivation 
Medivation is a biopharma company that is focused on cancer treatments  The company currently has one marketed product  prostate cancer treatment  Xtandi  Xtandi  a blockbuster drug  has the potential to be approved for several additional indications as well as patient populations 
Moreover  pipeline candidate talazoparib  an orally available PARP inhibitor  represents significant upside potential  PARP inhibitors are currently being considered to be the next major class of therapeutics in oncology  Interest in this area has increased considerably following the announcement of impressive late stage data on another company s PARP inhibitor  niraparib  in Jun 2016  Top line results from Medivation s first talazoparib registrational study  EMBRACA  in germline BRCA mutated breast cancer are expected in the first half of 2017 
According to Medivation  the addressable patient population for talazoparib in the U S  and Europe is about 760k including 10k for the EMBRACA population  while the addressable market opportunity is more than  30 billion 
The Medivation acquisition  if it goes through  will strengthen Pfizer s cancer franchise which currently consists of products like Ibrance and Sutent  Pfizer is also working on strengthening its immune oncology pipeline and the Medivation acquisition would be a good strategic fit for the company 
Pfizer is a Zacks Rank  3  Hold  stock while Medivation is a Zacks Rank  5  Strong Sell  stock  Actelion Ltd     is a better ranked stock in the health care sector with a Zacks Rank  1  Strong Buy   We are reissuing this article to correct a mistake  The original article  issued earlier today  August 22  2016  should no longer be relied upon  ",2016-08-22,Zacks Investment Research,https://www.investing.com/analysis/pfizer-medivation-close-to-signing-$14b-acquisition-deal-(revised)-200149400,200149400
220930,442446,PFE,Pfizer  PFE  Bought Medivation  MDVN   But Is It A Good Deal ,opinion,"Today  Pfizer   NYSE PFE   that it will be acquiring Medivation Inc    NASDAQ MDVN   in an all cash offer for  81 50 per share   This comes out to a transaction value of approximately  14 billion   Shares were trading for about  67 per share before the deal was announced  and since then  MDVN stock has shot up by about 20  
Pfizer doesn t expect the transaction to impact its fiscal 2016 guidance   Pfizer CEO Ian Read is especially bullish on the purchase  saying that  The proposed acquisition of Medivation is expected to immediately accelerate revenue growth and drive overall earnings growth potential for Pfizer    Pfizer expects to achieve high long term growth from its oncology pipeline  and by adding Medivation  PFE hopes to boost this portfolio of drugs which treats tumors 
Medivation wouldn t be fetching a high price tag if it weren t for its drug called XTANDI  enzalutamide    XTANDI is an androgen receptor inhibitor that blocks steps in the androgen receptor signaling pathway inside tumor cells   The hormone therapy has an avid following in the US  and over the past four quarters  the drug has generated  2 2 billion in worldwide sales 
The drug was approved by the FDA in 2012  and it was made for the purpose of treating advanced metastatic prostate cancer   XTANDI has treated 64 000 men in America  and the product stands to see immense sales growth if it gains FDA approval for treating other types of cancer   Medivation and Astellas Pharma Inc    OTC ALPMY   entered an agreement in 2009 to jointly develop and commercialize XTANDI  and the companies are conducting two phase 3 studies in non metastatic prostate cancer as well as a phase 3 study in hormone sensitive prostate cancer   Additionally  there are phase 2 studies being conducted for treating advanced breast cancer and hepatocellular carcinoma 
Pfizer believes that the addition of XTANDI will give it a well rounded oncology portfolio   Pfizer s drug IBRANCE treats metastatic breast cancer  so Medivation s product should fit in well and help Pfizer to have products that effectively treat two of the top cancers in annual incidence  in the US  after lung cancer   The cancers impact millions of people  and there are 300 000 and 180 000 new cases expected this year  and respectively   According to   XTANDI has a 51  share in the novel hormone therapy market  and it is on track to becoming the fourth largest oncology drug by 2021  
There is more to Medivation than XTANDI though   The company also has a promising drug candidate known as Talazoparib   The product is in phase 3 studies for treating BRCA mutated breast cancer  and it has the potential to be a highly potent PARP inhibitor that could be effective for treating several other types of tumors as well  
Bottom Line
It should be noted that Sanofi   NYSE SNY   offered to buy Medivation for  52 50 per share in April   Pfizer s offer is about 55  higher than the bid Sanofi put up  so it is clear that the company has strong faith in the value of XTANDI to be used for treating multiple types of cancer   So far  the trials for treating other types of cancer  such as breast cancer  pre and post metastatic castration resistant prostate cancer  and hepatocellular carcinoma  have progressed into mid and later stage trials  so there is strong potential for XTANDI to become an effective form of treatment for various types of tumors  
The high price tag is a gamble  but if XTANDI gets FDA approval for treating other forms of cancer  it will gain increased traction in the oncology market   This will mean a lot for Pfizer  and it could result in the company becoming one of the premier leaders in oncology   Right now  PFE stock is a Zacks Rank  3  Hold  
The Zacks Rank is a truly marvelous trading tool   Our ranking system has beaten the S P 500  yielding an average return of 25  per year for the last 29 years   Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-08-22,Zacks Investment Research,"https://www.investing.com/analysis/pfizer-(pfe)-bought-medivation-(mdvn),-but-is-it-a-good-deal-200149399",200149399
220931,442447,PFE,Market Update   22 08 2016,opinion,"This promises to be an interesting week again with some key data coming out  mainly later in the week  We will start on Tuesday and Wednesday with important German data to start off with  but the main action will be on Friday  with GDP data out of the UK and the US as well as a speech by FED Chair Yellen  We can expect a lot of positioning ahead of this  especially on the backdrop of recent comments from several FED members 

Currencies
EUR USD   is moving down due to the bullish comments coming out of the US from different members of the FED who are saying that they could  and possibly should   raise the interest rate sooner rather than later  Some are saying that the rate could rise at least once more this year  We will also be looking at the German data this week  which as always is important as the German economy is the growth engine of the Eurozone 
USD JPY   is moving up after comments from BOJ Governor Kuroda that the BOJ might expand stimulus at its meeting next month  and perhaps even cut the interest rate further  This is in addition to the general correction we are currently seeing in the USD  after having seen some severe weakening last week  
GBP USD    even though the data out of the UK was better than expected last week  we see the GBP almost unchanged now  as we are heading down once move  This comes due to the strengthening of the USD  but also due to reports that the UK might enact article 50 early next year which will start the process for the UK to leave the EU 
USD CAD   moved up on Friday  not because oil dropped  but rather because of some weak data out of Canada  We see that this is currently continuing as the USD is gaining in strength and also oil is dropping a bit 

Indices
Dollar Index   as always  when gauging the state of the USD  the best way to do this is to look at the Dollar Index  We can clearly see that the USD is strengthening again and is trading more or less back at the levels pre FOMC meeting minutes  We can expect more moves in the USD  as we get GDP data at the end of the week and the anticipated speech by Yellen at the Jackson Hole Symposium 
S P 500   the stronger USD and also the prospects of a rate cut are causing the S P to move down  We shouldn t forget that we have seen an impressive rally over the last few weeks  starting at the end of June  so there is bound to be some profit taking as well  as we are still trading near record highs 

Commodities
Gold   has dropped in recent days as we keep getting more comments that the FED could raise the interest rate already next month  something again stated over the weekend as the job and inflation targets are close to being reached  We are trading at the lowest level in nearly 2 weeks around the support of the 1332 level 
Oil is moving down after having risen over  4 50 last week  While there are not many people who believe that anything will come out of the discussion next month on a production freeze  one can still see how much influence pure expectation can have on the market  Even if an agreement will be reached  at which levels  As Saudi Arabia and also other countries are producing at  near  record levels  the actual effect on curbing the oversupply will be limited  We saw on Friday that the number of active rigs keeps on increasing  something that also signals that production in the US will be increasing further as well  The stronger USD is also helping oil to move lower this morning 
Stocks
Pfizer  NYSE PFE    is reportedly close to acquiring Medivation for an estimated  14 billion  The company previously rejected an offer by Sanofi  PA SASY  which was around  9 billion ",2016-08-22,AvaTrade,https://www.investing.com/analysis/market-update--22-08-2016-200149233,200149233
220933,442449,PFE,RPT FEATURE To the victors  the spoils  a post Lehman scorecard,news,"  With Lehman deals  Barclays and Nomura progress
   Barclays confident it can top bank league tables
   Nomura gains more nuanced  cultural walls remain
 
 By Clara Ferreira Marques and Michael Flaherty
 LONDON HONG KONG  Sept 11  Reuters    For Barclays and
Nomura  the collapse of Lehman Brothers was the opportunity of
the lifetime    a chance to grab a seat at banking s top table
as Wall Street s giants fell 
 A year after their high speed takeovers  Britain s Barclays
is confident it is on course to fulfil long held ambitions now
it has a foothold in U S  equity and mergers and acquisitions
markets  and Lehman has already boosted its bottom line 
 But Japan s Nomura  a conservative brokerage which went for
Lehman in its own bid to become an international investment
bank  is still hobbled by a lack of scale in the United States
and insiders say lingering cultural differences are a burden 
  We knew we were crossing a line and we would never be able
to go back   Barclays Capital President Jerry del Missier told
Reuters  speaking of frenzied negotiations as departing staff 
carried boxes of belongings across news broadcasts 
 Speed was critical for both banks  not least to retain the
talent and customer connections in the businesses they bought 
 Having failed to buy all of Lehman  Barclays days later
acquired its core U S  broker dealer out of Chapter 11
bankruptcy protection  Nomura bought European and Asian assets
the following week 
 A week after Barclays  acquisition  in the throes of the
worst market turbulence in decades  it had named its top team  
Nomura integrated the new structure in 70 days    much faster
than the 100 it had targeted 
  We wanted to send a powerful message to the marketplace
that we were going to get the Lehman businesses up and running  
Del Missier said in an interview   We had clients to worry
about  our own risk positions we needed to manage    and the
environment was incredibly volatile  
 Nomura declined to comment for this article 
 
 LUCRATIVE OPPORTUNITY
 The core of Lehman Brothers has allowed Barclays to go from
a respected debt shop to a comprehensive investment bank  adding
stock underwriting and M A advisory to the business in a swoop 
 Lehman s U S  equities business was key to that deal    U S 
distribution channels are the largest and critical for anyone
selling and underwriting stocks 
 It has proved a lucrative opportunity  helping to double
pre tax profit from Barclays investment banking business in the
first six months 
  With Lehman you had a ship that had been sailing along very
well and one particular thing torpedoed it   said analyst Mike
Trippitt at Oriel Securities   The rest of the business in the
U S  was still buzzing    what Barclays got was a business in
which 80 percent was pretty vibrant  
 Challenges for Barclays include the huge technological
weight of rolling out a single equities platform across the
globe  and the task of climbing up the ranks of investment
banking league tables as more banks fight over fewer deals 
 Since the deal Barclays has taken the number 2 spot in debt
capital markets tables  up one place  but it is still below
Lehman s old positions in both global M A and equity capital
markets  according to Thomson Reuters data 
 
 CULTURE CLASH
 Success has been more measured for Nomura  While areas such
as its Japanese franchise  M A advisory and convertible bonds
have shown strength  the bank suffered early on from costs
associated with the Lehman deal 
  Looking back at Nomura s financial results for the first
quarter  they only managed to show  some  fruit out of Lehman
acquisition   Credit Suisse analyst Azuma Ohno said   To me it
seems they showed they were able to get a fairly good numbers in
a good financial environment  but it was not extremely good  
 Asia s stock market soared in the first months of the year 
with shares in China alone ahead more than 80 percent in early
August 
 The Japanese bank quickly ran into a challenge that had
little to do with speed or execution  Taking on a risk loving
American brokerage proved a tall task 
 While steps such as Western style contracts have been taken
to improve the cultural differences  issues still pop up  
 The U S  press has relished stories of traders singing
company songs or of lessons on serving tea in the Japanese
tradition  while rumours of Lehman only parties have done the
rounds in Nomura Asia 
  There are still internal divisions that just won t go away 
It s an us vs  them mentality and it s a shame   according to a
legacy Nomura banker who did not want to be identified because
he was not authorised to speak to the media about the deal 
 Sharing client networks is an ongoing problem  he said 
 
 PEOPLE POWER
 To keep Lehman bankers through the upheaval  Nomura offered
many of them one  and two year guarantees  based on their 2007
compensation  The full payout of last year s bonus was due on
Sept  1  prompting speculation that another round of Lehman
departures is soon to follow 
 Nomura has defended the timing of its purchase and has shown
it is still willing to hire  even before the markets recovered 
 Nomura  which jumped to 4 400 employees in Europe from 1 500
after the acquisition of Lehman s businesses  has hired 521
people in Europe since January  including eight number
one ranked research teams 
  The fascinating thing is that 18 months ago  no one from
Goldman or Merrill wanted to work at Nomura   an ex Lehman
executive said  referring to the old school Japanese image   Now
they see the opportunity to build something   
 Still  Lehman bankers have felt under represented at the top
of Nomura s management structure  a feeling that intensified
when Lehman s former Asia Pacific CEO Jesse Bhattal said this
summer he would step down from his chairman role at year end 
 Progress is emerging though  Nomura s first quarter this
year    the three months to the end of June    reversed a
year and a half of decline  and teams have cooperated 
  The capital markets team and sales division have worked
well with convertibles in terms of distribution  That s actually
been an astonishing success   said the legacy Nomura banker 
  In a number of parts we re well positioned  We seem to be
missing the boat with some of our businesses  I d say overall 
it s still a work in progress  
 Even if the deal for Barclays was a more rounded success  
it too still has work to do    not least to grow in Asia and
Europe and realise its ambition of taking a top spot in equities
and M A league tables 
 Its role as adviser to Pfizer on its  68 billion takeover of
Wyeth has helped  but Barclays is number 11 in the global M A
tables  below Lehman s old number 9 spot 
  We are still not up and running in Europe and Asia  and
especially in Europe that will have an impact on global league
tables   del Missier said   I am confident you will start to see
the results come through pretty quickly  
  Editing by Douwe Miedema and Sara Ledwith 
  For a multimedia timeline on the year since the collapse of
Lehman Brothers   ",2009-09-11,Reuters,"https://www.investing.com/news/equities-news/rpt-feature-to-the-victors,-the-spoils:-a-post-lehman-scorecard-85822",85822
220934,442450,PFE,FEATURE To the victors  the spoils post Lehman scorecard,news," Corrects paragraph 11 to show Nomura declined an interview
request 
   With Lehman deals  Barclays and Nomura progress
   Barclays confident it can top bank league tables
   Nomura gains more nuanced  cultural walls remain
 By Clara Ferreira Marques and Michael Flaherty
 LONDON HONG KONG  Sept 11  Reuters    For Barclays and
Nomura  the collapse of Lehman Brothers was the opportunity of
a lifetime    a chance to grab a seat at banking s top table as
Wall Street s giants fell 
 A year after their high speed takeovers  Britain s Barclays
is confident it is on course to fulfil long held ambitions now
it has a foothold in U S  equity and mergers and acquisitions
markets  and Lehman has already boosted its bottom line 
 But Japan s Nomura  a conservative brokerage which went for
Lehman in its own bid to become an international investment
bank  is still hobbled by a lack of scale in the United States
and insiders say lingering cultural differences are a burden 
  We knew we were crossing a line and we would never be able
to go back   Barclays Capital President Jerry del Missier told
Reuters  speaking of frenzied negotiations as departing staff
carried boxes of belongings across news broadcasts 
 Speed was critical for both banks  not least to retain the
talent and customer connections in the businesses they bought 
 Having failed to buy all of Lehman  Barclays days later
acquired its core U S  broker dealer out of Chapter 11
bankruptcy protection  Nomura bought European and Asian assets
the following week 
 A week after Barclays  acquisition  in the throes of the
worst market turbulence in decades  it had named its top team 
 Nomura integrated the new structure in 70 days    much
faster than the 100 it had targeted 
  We wanted to send a powerful message to the marketplace
that we were going to get the Lehman businesses up and
running   Del Missier said in an interview 
  We had clients to worry about  our own risk positions we
needed to manage    and the environment was incredibly
volatile  
 Nomura declined a Reuters request for an interview 
 LUCRATIVE OPPORTUNITY
 The core of Lehman Brothers has allowed Barclays to go from
a respected debt shop to a comprehensive investment bank 
adding stock underwriting and M A advisory to the business in a
swoop 
 Lehman s U S  equities business was key to that deal   
U S  distribution channels are the largest and critical for
anyone selling and underwriting stocks 
 It has proved a lucrative opportunity  helping to double
pre tax profit from Barclays investment banking business in the
first six months 
  With Lehman you had a ship that had been sailing along
very well and one particular thing torpedoed it   said analyst
Mike Trippitt at Oriel Securities 
  The rest of the business in the U S  was still buzzing   
what Barclays got was a business in which 80 percent was pretty
vibrant  
 Challenges for Barclays include the huge technological
weight of rolling out a single equities platform across the
globe  and the task of climbing up the ranks of investment
banking league tables as more banks fight over fewer deals 
 Since the deal Barclays has taken the number 2 spot in debt
capital markets tables  up one place  but it is still below
Lehman s old positions in both global M A and equity capital
markets  according to Thomson Reuters data 
 CULTURE CLASH
 Success has been more measured for Nomura  While areas such
as its Japanese franchise  M A advisory and convertible bonds
have shown strength  the bank suffered early on from costs
associated with the Lehman deal 
  Looking back at Nomura s financial results for the first
quarter  they only managed to show  some  fruit out of Lehman
acquisition   Credit Suisse analyst Azuma Ohno said   To me it
seems they showed they were able to get a fairly good numbers
in a good financial environment  but it was not extremely
good  
 Asia s stock market soared in the first months of the year 
with shares in China alone ahead more than 80 percent in early
August 
 The Japanese bank quickly ran into a challenge that had
little to do with speed or execution  Taking on a risk loving
American brokerage proved a tall task 
 While steps such as Western style contracts have been taken
to improve the cultural differences  issues still pop up 
 The U S  press has relished stories of traders singing
company songs or of lessons on serving tea in the Japanese
tradition  while rumours of Lehman only parties have done the
rounds in Nomura Asia 
  There are still internal divisions that just won t go
away  It s an us vs  them mentality and it s a shame  
according to a legacy Nomura banker who did not want to be
identified because he was not authorised to speak to the media
about the deal 
 Sharing client networks is an ongoing problem  he said 
 PEOPLE POWER
 To keep Lehman bankers through the upheaval  Nomura offered
many of them one  and two year guarantees  based on their 2007
compensation  The full payout of last year s bonus was due on
Sept  1  prompting speculation that another round of Lehman
departures is soon to follow 
 Nomura has defended the timing of its purchase and has
shown it is still willing to hire  even before the markets
recovered 
 Nomura  which jumped to 4 400 employees in Europe from
1 500 after the acquisition of Lehman s businesses  has hired
521 people in Europe since January  including eight number
one ranked research teams 
  The fascinating thing is that 18 months ago  no one from
Goldman or Merrill wanted to work at Nomura   an ex Lehman
executive said  referring to the old school Japanese image 
 Now they see the opportunity to build something  
 Still  Lehman bankers have felt under represented at the
top of Nomura s management structure  a feeling that
intensified when Lehman s former Asia Pacific CEO Jesse Bhattal
said this summer he would step down from his chairman role at
year end 
 Progress is emerging though  Nomura s first quarter this
year    the three months to the end of June    reversed a
year and a half of decline  and teams have cooperated 
  The capital markets team and sales division have worked
well with convertibles in terms of distribution  That s
actually been an astonishing success   said the legacy Nomura
banker 
  In a number of parts we re well positioned  We seem to be
missing the boat with some of our businesses  I d say overall 
it s still a work in progress  
 Even if the deal for Barclays was a more rounded success 
it too still has work to do    not least to grow in Asia and
Europe and realise its ambition of taking a top spot in
equities and M A league tables 
 Its role as adviser to Pfizer on its  68 billion takeover
of Wyeth has helped  but Barclays is number 11 in the global
M A tables  below Lehman s old number 9 spot 
  We are still not up and running in Europe and Asia  and
especially in Europe that will have an impact on global league
tables   del Missier said   I am confident you will start to
see the results come through pretty quickly  
  Editing by Douwe Miedema and Sara Ledwith 
  For a multimedia timeline on the year since the collapse of
Lehman Brothers   ",2009-09-14,Reuters,"https://www.investing.com/news/equities-news/feature-to-the-victors,-the-spoils:post-lehman-scorecard-86331",86331
220935,442451,PFE,UPDATE 1 EXCLUSIVE Sanofi sees sales boost from H1N1 vaccine,news,"  CEO sees H1N1 vaccine boosting sales this year and next
   expects to file H1N1 vaccine for EMEA clearance end Oct
   needs to grow U S  research but nothing big in the works
   looking to appoint over the counter drugs head
   share down 1 47 percent

  adds details and quotes 
 By Caroline Jacobs
 PARIS  Sept 24  Reuters    Sanofi Aventis  expects
its H1N1 vaccine that targets the swine flu virus to boost to
its revenues this year and next  the head of the French
drugmaker told Reuters in an interview 
  There s going to be a significant revenue opportunity  both
this year and next year   Chris Viehbacher said on Thursday 
 It s a nice short term boost for sales and cash flow  
 Sanofi Pasteur  the vaccine division of Sanofi Aventis 
earlier this month won an additional order from the U S  health
department for its H1N1 vaccines  taking the total to 75 3
million doses 
 Sanofi Aventis expects to submit its H1N1 vaccine with the
European Medicines Agency  EMEA  by the end of October and
Viehbacher expected approval to take up to six weeks 
 Viehbacher  who took the helm in December 2008  said the
company had no plans to alter it strategy of making acquisitions
of up to 15 billion euros   22 09 billion  in market value while
preferring to avoid big takeveovers 
  I m not going to change a strategy that has been
successful   he said 
  I still remain skeptical about big mergers   he added 
 Sanofi has several blockbuster drugs such as blood thinner
Plavix and cancer treatment Taxotere 
 Sanofi has a market capitalisation of some  100 billion 
which makes it sixth in the world after Johnson   Johnson
  Roche   Novartis   Pfizer  and
GlaxoSmithKline     the former employer of Viehbacher 
 
 AIDS VACCINE
 Viehbacher was speaking ahead of an expert presentation on a
the clinical results of an experimental AIDS vaccine  made from
two older versions  which showed made major progress in finding
an effective way to combat the illness   ID nLO53122 
 Sanofi s pipeline of drugs in development has become leaner
following a rejig that left it with only the most promising
candidates after Viehbacher put a halt to others 
 Partnerships should help expand the pipeline again with a
focus on the United States  the world s biggest drugmarket 
  I think we are underrepresented in research in the U S  
Viehbacher said   Today you want to be able to capture the best
science everywhere  I d certainly like to strengthen our
presence there   he said  adding  nothing major is cooking  
 Sanofi earlier this year bought U S  biotech company BiPar
whose candidate drug BSI 201 which seeks to treat cancers
including breast and ovarian  is seen as a potential
blockbuster 
 Rather than cost savings  Sanofi s takeover strategy focuses
on boosting its revenues as the company is facing a number of
patent expiries on several of its top selling drugs  making it
vulnerable to cheaper copies made by generic drugmakers 
 
 NO MEGA MERGER
 Instead of mega mergers and a focus solely on finding the
next multi billion euro blockbuster drug  Sanofi seeks to grow
its business by expanding its existing platforms  like vaccines 
generics and over the counter drugs  which can be bought without
a prescription 
 It is aiming to turn its OTC business  which includes
Sanofi s best selling drug in France Doliprane paracetamol  into
a division with a head of its own who should be able to double
sales in next five years from 1 3 billion euros in 2008 
  We are in the process of trying to nominate someone  
Viehbacher said 
 In a first move to expand its widespread OTC business 
Sanofi last year bought Australia s Symbion  which also makes
vitamin supplements 
 Sanofi shares were down 1 47 percent at 50 11 euros at 1430
GMT  after a 12 percent rise sofar this year 
 
 For fundamental data about this company  please double click
on 
 
 For a Geneva story on WHO saying drug firms can make H1N1
vaccines for half the planet see  ID nLO127713 ",2009-09-24,Reuters,https://www.investing.com/news/equities-news/update-1-exclusive-sanofi-sees-sales-boost-from-h1n1-vaccine-89527,89527
220938,442454,PFE,M A Boosts Intersil  Syngenta And Medivation In Pre Market,opinion,Monday  August 22  2016Futures are down again ahead of the market open this morning  following a Friday that was awash in red until climbing toward unched in the closing minutes of the trading week  The S P 500 is currently at  4 points  the Dow reads  50 and the Nasdaq is currently at  8  These numbers have fluctuated a bit  but have remained negative ahead of the bell Mergers and acquisitions  M A  are taking headlines in this sleepy market period a couple weeks prior to the Labor Day holiday  and we re seeing big gains among smaller companies ready to be purchased by much bigger fish California based Intersil   NASDAQ ISIL   has agreed to be bought by Japan s Renesas for  3 billion  and the semiconductor maker is up nearly 28  in today s pre market  Sources say they expect this deal to close by the end of August Chinese state owned ChemChina s pursuit of major agribusiness firm Syngenta   NYSE SYT   has cleared a regulatory hurdle in China  and this panel clearance looks to be green lighting the massive  43 billion buyout of the Swiss company  Syngenta ADRs are up roughly 10 5  at this hour Pfizer   NYSE PFE   is putting forth  14 billion to take over biopharma company Medivation   NASDAQ MDVN    representing  81 50 per share for the company specializing in cancer treatments  Pfizer expects 5 cents per share in synergies from this deal as of the first year of business Everything else looks to be taking a break right now   European markets were down overnight  gold prices wallow at two week lows  even WTI and Brent oil prices   while up over the past few weeks overall   remain below  50 per barrel this morning  We ve got some housing data on the calendar later this week  along with Fed Chair Janet Yellen s Jackson Hole speech this Friday  but not much expected to push the needle in either direction Mark VickerySenior Editor,2016-08-21,Zacks Investment Research,"https://www.investing.com/analysis/m-a-boosts-intersil,-syngenta-and-medivation-in-pre-market-200149293",200149293
220940,442456,PFE,ANALYSIS India s ailing drugmakers may seek foreign cure,news,"  More tie ups likely between global  Indian pharma firms
   Pfizer  Merck  Sanofi may be on lookout for deals
   India s Cipla  Aurobindo seen as potential targets
   Global firms seen benefitting from low costs in India
   Indian firms to gain expertise  avoid legal battles
 By Pratish Narayanan
 MUMBAI  Aug 6  Reuters    For Indian generic drugmakers
struggling with cut throat competition  regulatory hurdles and
expensive legal battles  a tie up with a global pharmaceutical
giant may be just what the doctor ordered 
 The world s biggest drugmakers have been on an acquisition
spree over the past year and are eyeing Indian firms to gain
access to emerging markets and cheap production  as well as to
retake some of the business they ve lost to inexpensive copycat
versions of their blockbuster drugs 
 Global heavyweight Pfizer is seen as the most likely suitor
of Indian rivals as it looks to replace revenue lost from the
lapse of key patents  while Merck and Sanofi Aventis may also
seek to shake hands with Indian producers  analysts said 
 Indian drug companies  for their part  are grappling with
regulatory crackdowns that have made it harder to sell their
products in the key U S  market  making a deal with a bigger
and better funded global rival look increasingly attractive 
 Indian generic drug makers including Ranbaxy  Dr Reddy s and
Matrix Laboratories have all linked up with global players over
the past year  More deals are expected 
  The foreign companies can limit research expenses as the
cost of developing a product in India is lower than probably
anywhere else in the world   said R K  Gupta  managing director
of Taurus Mutual Fund in New Delhi 
  While the Indian firm will get access to world class
facilities and need not handle legal issues once the drug is
developed  
 Analysts say India s Cipla  with its vast range of
products  including anti cancer and anti diabetic drugs  and a
market value of  4 5 billion  is attractive to foreign buyers 
 They add that smaller firms Aurobindo Pharma  Orchid
Chemicals and Pharmaceuticals and Dishman Pharmaceuticals could
also be eyed by overseas firms 
  When foreign companies look at India  they consider two
things  the low cost of development and the chance to expand in
emerging markets   said Sarabjit Kour Nangra  a healthcare
analyst at Angel Broking in Mumbai 
  Cipla s valuations are expensive  but the company has a
strong asset base  
 The company s shares trade at more than 20 times forward
earnings  compared with a 17 5 multiple for India s benchmark
BSE index 
 Rivals Sun Pharma  and Aurobindo Pharma trade at 17 9 times
and 7 3 times expected earnings  respectively  Ranbaxy and Sun 
the two biggest Indian drug makers by sales and market cap 
respectively  are the two worst performers in India s roaring
main index this year  with gains of less than 10 percent 
 India currently represents  6 billion of the  550 billion
global pharmaceutical industry and its share is increasing at
10 percent a year  according to consultancy KPMG 
 It is forecast that Indian companies will likely take
around 30 percent of the global generics market from around 22
percent now  KPMG said 
 EMERGING MARKET FOCUS
 Drug sales in emerging markets are expected to grow by
mid teens percentage rates through 2013  against low
single digits for mature markets  according to IMS Health  the
leading tracker of prescription drug data 
 Pfizer may pursue further links in India as it faces sales
declines in coming years from patent expirations  including for
blockbuster cholesterol treatment Lipitor 
 The company wants to add  3 billion in annual sales from
developing markets by 2012  and recently signed a deal with
India s Aurobindo Pharma under which Pfizer will gain rights to
about 60 products in more than 70 emerging markets 
 Other global firms such as Merck and Sanofi Aventis may
also seek deals with Indian firms as efforts to control health
care costs in countries including the United States push global
drugmakers to find cheaper alternatives to branded drugs 
 In June  Dr  Reddy s signed a licensing deal with the UK s
GlaxoSmithKline  and No  3 generics maker Mylan Inc announced a
partnership with India s Biocon 
 FDA TROUBLE
 Developing nations account for just 6 percent of worldwide
trade in medicines  the World Health Organization estimates  By
offering generic drugs that are a cheaper alternative to
branded drugs from big global firms  Indian companies have an
oppportunity to increase their share of this trade  say
analysts 
 But the U S  Food and Drug Administration has recently been
finding fault with Indian firms  manufacturing procedures  A
tie up with one of the bigger players would help them acquire
the know how to better maintain quality standards 
  The FDA has been going no  no  no  no to so many drugs
from Indian firms   said Alex Mathew  head of research at
Geojit BNP Paribas Financial Services 
  A tie up with foreign players will not only give financial
stability  but access to technological upgradation that can
prevent more disapproval  
 In late June  U S  authorities seized drugs made by the
U S  unit of India s Sun Pharma for manufacturing standards
violations  Last year  the FDA found 15 deficiencies at Indian
firm Lupin s manufacturing plant in central India 
 Japanese drugmaker Daiichi Sankyo s  4 2 billion takeover
in 2008 of Ranbaxy  India s top drugmaker by sales 
demonstrates the possibilities but also the potential pitfalls
that global players face when linking up with Indian rivals 
 Ranbaxy shares plummeted late last year after a U S  ban on
some of its products  The FDA in February said Ranbaxy had sold
misbranded or adulterated drugs in the United States  its
largest market  further hurting the company s market value 
 But analysts say Ranbaxy has been helped since being taken
over by Daiichi  which replaced Ranbaxy head Malvinder Singh
with its own executive in a bid to resolve problems 
  Additional reporting by Lewis Krauskopf in New York  Editing
by Tony Munroe and Dhara Ranasinghe ",2009-08-06,Reuters,https://www.investing.com/news/equities-news/analysis-india's-ailing-drugmakers-may-seek-foreign-cure-76902,76902
220941,442457,PFE,Forest to sell Nycomed s lung drug Daxas in U S ,news,"  Forest gets exclusive rights to smoker s lung drug in U S 
   Forest to pay  100 million upfront  more as milestones
reached
   Daxas would be first pill to treat COPD
 
 By Quentin Webb
 LONDON  Aug 10  Reuters    Nycomed  the private Swiss drug
company  picked Forest Laboratories Inc as a U S  partner for
Daxas  its experimental treatment for  smoker s lung   receiving
 100 million upfront in return 
 Forest will have exclusive rights to develop  make and
commercialise Daxas in the United States  utilising its
2 700 strong sales force 
 Forest also agreed to pay further  significant milestones
and royalties  for the drug  which Nycomed recently submitted to
European and U S  regulators for approval  Nycomed said in a
statement on Monday 
 Daxas is the first tablet based treatment for chronic
obstructive pulmonary disease  COPD     the world s
fifth biggest cause of death in 2002  according to the World
Health Organisation  WHO  
 The drug could compete with GlaxoSmithKline s  Advair and
Spiriva  marketed by Pfizer and Boehringer Ingelheim  in the
multibillion dollar a year worldwide COPD market 
 Nycomed  whose biggest owners are private equity firms
Nordic Capital and Credit Suisse s DLJ unit  aims to use junk
bonds and fresh equity from its owners to fund a planned buyout
of Solvay s drugs unit  people familiar with the matter told
Reuters recently 
 Editing by Ben Hirschler ",2009-08-10,Reuters,https://www.investing.com/news/equities-news/forest-to-sell-nycomed's-lung-drug-daxas-in-u.s.-77825,77825
220942,442458,PFE,UPDATE 2 Forest to sell Nycomed s lung drug Daxas in U S ,news,"  Forest gets exclusive rights to smoker s lung drug in U S 
   Forest to pay  100 million upfront  up to  500 million
more later
   Daxas would be first pill to treat COPD
   Nycomed expects U S   European Daxas registration next yr
 
  Adds CEO comment on IPO  pantoprazole  no comment on Solvay 
 By Quentin Webb
 LONDON  Aug 10  Reuters    Forest Laboratories Inc  the U S 
specialty drugmaker whose biggest drug Lexapro is soon to lose
patent protection  paid  100 million upfront for U S  rights to
Nycomed s promising  smoker s lung  drug Daxas 
 Nycomed will also receive up to  500 million in further
payments based on regulatory approvals and commercialisation
milestones  Chief Executive Hakan Bjorklund told Reuters in a
telephone interview on Monday 
 The privately owned Swiss drug company  which is working
towards a multi billion dollar flotation  also stands to receive
royalties that will be  standard  for a product of this size and
development stage  he added 
 Forest will have exclusive rights to develop  make and
commercialise Daxas in the United States  utilising its
2 700 strong sales force 
 Forest is expected to lose patent protection on Lexapro  the
blockbuster antidepressant that is its top selling drug  in
early 2012  It sells Lexapro in conjunction with Danish
drugmaker Lundbeck 
 Nycomed has recently submitted Daxas to European and U S 
regulators for approval  and Bjorklund said it hopes for
registration in both jurisdictions next year 
 Daxas is the first tablet based treatment for chronic
obstructive pulmonary disease  COPD     the world s
fifth biggest cause of death in 2002  according to the World
Health Organisation  WHO  
 
 BLOCKBUSTER POTENTIAL
 The drug could compete with GlaxoSmithKline s Advair and
Spiriva  marketed by Pfizer and Boehringer Ingelheim  in the
multibillion dollar worldwide COPD market 
 Bjorklund said Daxas had  blockbuster potential     meaning
it could ultimately top  1 billion in annual sales 
 He said Nycomed picked Forest from a handful of partnership
candidates  based partly on its big sales force and its track
record of partnering to develop drugs 
 Nycomed  whose biggest owners are private equity firms
Nordic Capital and Credit Suisse s DLJ unit  aims to use junk
bonds and fresh equity from its owners to fund a planned buyout
of Solvay s drugs unit  people familiar with the matter told
Reuters recently 
 Bjorklund declined to comment on Solvay  He said the Daxas
agreement did not immediately affect Nycomed s plans for an
initial public offering  IPO  
  I don t think it has any immediate bearing on when and how
we would do a public listing   he said   But of course it s a
step in the right direction  it strengthens the company  and
it s proof that not only we but other people see a lot of value
in Daxas  
 He added that sales of pantoprazole  the heartburn treatment
that is Nycomed s best selling drug  were holding up  somewhat
better  than expected  months after it lost patent protection in
Europe 
  Editing by Ben Hirschler and Gilbert Kreijger ",2009-08-10,Reuters,https://www.investing.com/news/equities-news/update-2-forest-to-sell-nycomed's-lung-drug-daxas-in-u.s.-77839,77839
220950,442466,PFE,UPDATE 3 Irish strike halts construction projects  brewing,news,"  10 500 striking electricians to call for all out picket
   Major union says it would be in favour of joining them
   Production hit at Diageo s Guinness brewery in Dublin
   Pickets at power plants  output unaffected
 
 Adds fresh comments on impact 
 By Ashley Beston
 DUBLIN  July 6  Reuters    A union representing thousands of
striking electricians in Ireland said on Monday it would call
for an all out picket of over 200 construction sites  escalating
a dispute that also hit the output of Ireland s favourite beer 
  Our members have sent a very clear signal to the employers
by their actions this morning that they will not be rolling over
and meekly accepting cutbacks to bail out developers and
speculators   said Eamon Devoy  general secretary designate of
the Technical Engineering and Electrical Union  TEEU  
  We will now be seeking to consolidate the support we are
already receiving from other workers through an application for
an all out picket   he said in a statement 
 About 10 500 contractors are taking part in the indefinite
strike  the first major industrial action since Ireland went
into recession last year  Pickets have been set up at building
sites at Dublin Airport and at companies such as Intel  Pfizer
and Microsoft 
 A court granted an injunction against TEEU to stop picketing
the St  James s Gate brewery owned by Diageo  one of the world s
biggest alcoholic drinks groups  where a strike by third party
contractors severely affected Guinness production 
 Because of the delicate yeast based brewing process  even a
relatively short stoppage could potentially affect output of
Ireland s favourite stout for weeks  the company said 
 SIPTU  one of Ireland s biggest unions with 200 000 members 
has said it would support an all out strike and if umbrella
group ICTU  which represents most unions in Ireland  agrees to
the electricians  request that could close most of the affected
construction projects 
 ICTU will need to ballot its members before making a final
decision  which could take at least until next week 
 Employers  group IBEC said the strike could force
manufacturers to lay off workers  with some already put on
protective notice in anticipation of further disruption 
 The dispute centres around wage increases of about 11
percent the electricians say they are owed for a number of
years  A contractor currently earns 21 49 euros   30  per hour 
 Employers have said they cannot afford to give them more
money and instead are looking for a wage cut of 10 percent 
  No one could survive on what they are offering us   said
Pat Mooney as he picketed outside Dublin s Lansdowne Road
Stadium  which is being redeveloped 
  Our members are determined to see this through  otherwise
we might as well throw our tool boxes in the  river  Liffey  
 There were pickets at power stations but electricity
generation was not affected by the strike 
 
 NOT A GOOD TIME
 From factory floors to corporate suites  wages and salaries
have been falling in Ireland as businesses adjust to plummeting
demand and try to claw back competitiveness lost during the boom
years of the  Celtic Tiger  economy 
  I d love to know who s advising the guys that it s a good
time to look for an 11 percent pay increase   said Joe Byrne  a
Dublin shopkeeper   I m not denying or debating that they re
entitled to it but it s not a good time 
 Employers have been able to push through wages cuts of 10
percent or more in Ireland as unemployment balloons 
 The government has put the country on a five year austerity
diet after a debt fuelled property boom turned Ireland from
economic star to one of the industrialised world s worst
performers 
 Prime Minister Brian Cowen has vowed to get the budget
deficit under an EU limit of three percent of gross domestic
product by 2013 from a targeted 10 75 percent this year 
 He is under pressure from the International Monetary Fund
and others to cut public sector pay in the budget in December 
 Cowen  a former finance minister  has said he was committed
to taking tough action  
 But his junior coalition partner  the Green Party  and
members of his own party may baulk at further pain after
cutbacks  tax hikes and the imposition of a pension levy
prompted 100 000 people to take to the streets in February 
  Reporting by Carmel Crimmins and Andras Gergely  Editing by
Sophie Hares ",2009-07-06,Reuters,"https://www.investing.com/news/equities-news/update-3-irish-strike-halts-construction-projects,-brewing-68947",68947
220951,442467,PFE,EU actively pursuing some drugmakers  official says,news,"  EU actively pursuing a number of individual cases
   No conclusions at this stage 
   Kroes report to step up scrutiny of generics deals
 
 By Foo Yun Chee
 BRUSSELS  July 7  Reuters    EU regulators are probing some
drug firms over suspected anti competitive practices that
include deals with makers of cheap generics to delay medicines 
market entry  a European Commission official said on Tuesday 
 European Union Competition Commissioner Neelie Kroes will
say in a report on the pharmaceutical industry on Wednesday that
 we are actively pursuing a number of individual cases   the
official  who has seen the 600 page document  said 
  The report will say that there are no final conclusions at
this stage to those cases being pursued   the official said 
adding that the document did not identify any companies 
 Kroes  tasked with ensuring fair play across the 27 country
European Union  will present the final report of her
investigation at 0930 GMT 
 In its preliminary report last November  the EU s executive
arm estimated that delays in getting generics on the market had
cost healthcare providers 3 billion euros   4 2 billion   based
on a sample of medicines that lost patent protection in 17 EU
states between 2000 and 2007 
 The European Commission s final report will pave the way for
increased regulatory scrutiny of settlement agreements in which
brand name companies pay generics makers for not competing with
them or set restrictions on competition  the official said 
  It will look at this on a case by case basis to see if
there is enough evidence that merits further scrutiny   the
official said 
 Kroes kicked off her investigation in January 2008 with a
series of raids on makers of brand name drugs  including
AstraZeneca  GlaxoSmithKline  Pfizer  Merck and Sanofi Aventis 
 There were also raids on generic drugmakers suspected of
colluding to delay the entry of their products  sometimes in
exchange for payments from originator companies 
 Such settlement agreements have also come under fire in the
United States  where the Federal Trade Commission estimated last
month that they were costing consumers  3 5 billion a year 
 Legislation pending in the U S  Congress would ban such
deals 
 Drugmakers blame most of the delays on regulatory and other
bureaucratic issues  rather than deliberate action by companies 
  Editing by Dale Hudson ",2009-07-07,Reuters,"https://www.investing.com/news/equities-news/eu-actively-pursuing-some-drugmakers,-official-says-69438",69438
220952,442468,PFE,Irish unions ask members to back all out picket,news,"  Unions to urge members to join all out picket
   Talks to be held on Wednesday to resolve dispute
 
 DUBLIN  July 7  Reuters    The union representing striking
Irish electricians said on Tuesday that other affiliates of the
Irish Congress of Trade Unions had agreed to hold ballots and
ask their members to support them with an all out picket 
 Employers hope talks with unions on Wednesday will help end
the strike they fear could cripple industries already weakened
by one of the deepest recessions across the developed world 
 But the union representing the 10 500 contractors taking
part in the indefinite strike over wages    the first major
industrial action since Ireland went into recession last year   
remained defiant 
  Our pickets have already made an enormous impact on the
electrical contracting and construction sectors and this will be
multiplied many times over once the all out pickets are put in
place   the Technical Engineering and Electrical Union  TEEU 
said 
 The dispute centres around wage increases of about 11
percent the electricians say they are owed for a number of
years 
 Employers have said they cannot afford to give them more
money and instead are looking for a wage cut of 10 percent 
 At a time when Ireland is struggling to repair damage to its
investor image from twin banking and fiscal crises  the strike
has hit hundreds of construction sites and hurt production at
Irish units of companies such as Intel  Pfizer  Microsoft and
Cadbury 
 Output has been curtailed in many places as workers not
directly involved in the pay dispute did not cross the
electricians  picket lines 
 A court is expected to decide on Wednesday whether to extend
a temporary injunction against TEEU to stop picketing Dublin s
St  James s Gate brewery where Diageo makes Ireland s trademark
Guinness stout for the Irish and British markets 
 SIPTU  one of Ireland s largest unions with 200 000 members 
said it would complete its ballot by the end of next week 
  As by far the largest union in construction our involvement
in the dispute will see a serious escalation   it said 
  Reporting by Andras Gergely  Editing by Matthew Jones ",2009-07-07,Reuters,https://www.investing.com/news/equities-news/irish-unions-ask-members-to-back-all-out-picket-69520,69520
220953,442469,PFE,UPDATE 2 Glaxo Q2 beats consensus  sees flu vaccine boost,news,"  Revenues 6 747 bln stg compared with expected 6 674 bln
   Pre exceptionals EPS 31p compared with expected 29 8p
   Sees improving performance continuing in second half
   Says has swine flu vaccine contracts for 195 mln doses
   Shares reverse losses  now flat
 
  Adds details  background  comment  updated shares 
 By Ben Deighton
 LONDON  July 22  Reuters    GlaxoSmithKline  the world s
second biggest drugmaker  beat expectations with its
second quarter earnings on Wednesday and said momentum in the
second half would pick up on the back of flu vaccine sales 
 Glaxo said growing sales of new products and its portfolio
of flu products should help drive its improving performance into
the second half of the year as the heavy impact of generic
competition to its formerly patented drugs begins to abate 
 Shares in Glaxo  which had been down 1 percent ahead of the
earnings statement  recovered to stand flat by 1156 GMT  The DJ
Stoxx European health care index was up 0 5 percent 
 WestLB analyst Simon Mather said that at first glance the
results were broadly in line with what he expected  but he
pointed out that there were lower than expected restructuring
costs and there was more of a boost from currency effects than
he had first thought 
 Healthcare companies have proven relatively resilient to the
recession as it is typically one of the last areas where
consumers cut spending 
 Glaxo s figures follow upbeat results from U S  rivals Merck
  Co  Schering Plough and Eli Lilly  The world s biggest
drugmaker Pfizer s earnings also just beat forecasts 
 But pharmaceuticals shares have begun to underperform as
cyclical sectors benefit from the first signs of a possible
recovery 
 Roche  Bristol Myers Squibb and Wyeth are all due to report
on Thursday 
 
 WEAKER POUND
 Glaxo has gained substantially from the pound s decline
because it sells the vast majority of its products abroad 
 However  it still faces heavy generic competition for key
drugs  having lost patent protection on a raft of central
nervous system medicines including Lamictal  Imitrex  Wellbutrin
XL and Paxil CR 
 Pretax  pre restructuring profit in the second quarter was
2 25 billion pounds   3 7 billion   equivalent to earnings per
share before major restructuring charges of 31 pence  up 14
percent  on sales up 15 percent at 6 747 billion 
 Analysts had forecast Glaxo EPS of 29 8 pence and sales of
just under 6 7 billion pounds  according to a Reuters poll 
 The company said it had received H1N1 vaccine contracts for
195 million doses and that it was in talks with over 50
governments of both developing and developed countries in
relation to swine flu vaccine  It said some of the talks were at
a  very advanced  stage 
  I therefore expect further significant orders   Chief
Executive Andrew Witty said in a statement   Shipments are
expected in the second half of 2009 and early 2010  
  Writing by Sam Cage  editing by Will Waterman 
   1  6103 Pound ",2009-07-22,Reuters,"https://www.investing.com/news/equities-news/update-2-glaxo-q2-beats-consensus,-sees-flu-vaccine-boost-73756",73756
220957,442473,PFE,Pfizer Publishes Final Data From Atopic Dermatitis Studies,opinion,Pfizer Inc    NYSE PFE   announced findings from two pivotal phase III studies   AD 301 and AD 302   on non steroidal topical anti inflammatory phosphodiesterase 4  PDE 4  inhibitor  crisaborole topical ointment 2   Crisaborole is being developed for the treatment of patients with mild to moderate atopic dermatitis  AD  Detailed data from the studies revealed that crisaborole achieved statistical significance on both primary and secondary endpoints in the treatment of AD in children  aged two years and above  and adults  compared to vehicle ointment alone  Adverse events related to the treatment were infrequent  mild to moderate in severity and similar to vehicle ointment  These findings were published in the online issue of the Journal of the American Academy of Dermatology We note that crisaborole was added to Pfizer s portfolio following its acquisition of Anacor Pharmaceuticals  Inc  in Jun 2016 PFIZER INC Price   Crisaborole is currently under review in the U S  for the treatment of mild to moderate AD  A response from the FDA is expected by Jan 7  2017 According to information provided by the company in its press release  AD affects about 18 25 million people in the U S  including 8 18  of infants and children  In the U S   about 80 90  of all AD patients have mild or moderate disease Since no new therapies have been approved for AD in the last 15 years  crisaborole could gain market share quite rapidly on commercialization Meanwhile  Regeneron Pharmaceuticals  Inc    NASDAQ REGN   and Sanofi   NYSE SNY   are also looking to get their candidate  dupilumab  approved for the treatment of adult patients with inadequately controlled moderate to severe AD  A regulatory application in the U S  is planned for the third quarter of 2016  Dupilumab enjoys Breakthrough Therapy status in the U S  for the treatment of AD Pfizer currently carries a Zacks Rank  2  Buy   Another favorably placed stock in the health care sector is GW Pharmaceuticals plc   NASDAQ GWPH    sporting a Zacks Rank  1  Strong Buy  Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-07-14,Zacks Investment Research,https://www.investing.com/analysis/pfizer-publishes-final-data-from-atopic-dermatitis-studies-200141922,200141922
220958,442474,PFE,Ultragenyx  RARE  Reports Positive Phase III RhGUS Data,opinion,Ultragenyx Pharmaceutical Inc    NASDAQ RARE   announced positive top line data from a pivotal phase III study on recombinant human beta glucuronidase  rhGUS  for the treatment of mucopolysaccharidosis 7  MPS 7   also known as Sly syndrome The study assessed the safety and efficacy of rhGUS in patients  n 12  aged 5 35 years Data demonstrated a rapid and sustained reduction of 64 8  from baseline in urinary GAG  dermatan sulfate  excretion after 24 weeks of treatment  thereby meeting the primary endpoint  It also provided evidence of clinical improvement  Treatment emergent adverse events were generally mild to moderate in severity  Results from the study are being presented at the International Symposium on MPS and Related Diseases Ultragenyx intends to meet regulatory authorities in both the U S  and the EU to discuss plans to submit regulatory filings in the first half of 2017 ULTRAGENYX PHAR Price   We note that MPS 7 represents an underserved market with no approved therapies presently available  A potential approval and successful commercialization of rhGUS will thus be a major boost for the company Drugs currently approved for the treatment of other MPS disorders include Aldurazyme  Elaprase  Vimizim and Naglazyme Meanwhile  Ultragenyx continues to progress on its pipeline  Currently  the company is evaluating aceneuramic acid extended release  Ace ER  in a pivotal phase III study for the treatment of patients with GNE myopathy  Results are expected in 2017 Moreover  the company has filled a marketing application for Ace ER in the EU  based on phase II results for the treatment of adult patients with GNE myopathy  A response from the European Medicines Agency s  EMA  Committee for Orphan Medicinal Products for Human Use  CHMP  is expected in the second half of 2016 We expect investor focus to remain on further pipeline updates from the company Currently  Ultragenyx carries a Zacks Rank  3  Hold   Some better ranked stocks in the health care sector include Merrimack Pharmaceuticals  Inc    NASDAQ MACK    Pfizer Inc    NYSE PFE   and Innoviva  Inc    NASDAQ INVA    Each of these stock sports a Zacks Rank  1  Strong Buy  Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-07-14,Zacks Investment Research,https://www.investing.com/analysis/ultragenyx-(rare)-reports-positive-phase-iii-rhgus-data-200142104,200142104
220959,442475,PFE,Pfizer A Buy  It Was Over 4 Months Ago,opinion,"Pfizer Inc   NYSE PFE  stock closed last week at new multi year highs near 36 71 dollars a share  breaching the previous top of 36 43  Such breakouts could deceive most people to think that just because a stock is obviously in an uptrend  it is a good time to buy it  But in the market environment   obvious things lead to the biggest mistakes  So is Pfizer a  buy  now  Well  it was in March  when we published  Pfizer Obeys the Elliott Wave Rules   The next chart shows what the  was saying about Pfizer over four months ago 
As visible  we were expecting the resumption of the uptrend  because the weakness from 36 43 seemed to be a three wave A B C correction  and  as the theory states  once a correction is over  the larger trend resumes  This chart was all an Elliott Wave analyst needed to identify Pfizer as a  buy  in March  when it was trading below 30 00  The next one  though  is showing a completely different outlook 
Pfizer began recovering almost immediately and took the previous extremes out in a swift fashion  It was a good call  but what to expect from now on  First  a little relabeling seems appropriate  motivated by two other techniques  which often go hand in hand with the Wave Principle  The first one is channeling  which says that  usually develop between the parallel lines of a trend channel  As you can see  the entire rally since 2009 fits into one  while the sub waves of wave III form another  The second thing  supporting the above shown count is the  ratios between the waves  Wave III equals almost exactly 261 8  the length of wave I  while the decline between 36 43 and 28 24 retraces 38 2  of wave III  which makes it a plausible wave IV  According to this scenario  the current advance to 37 17 is supposed to be wave V  If this count is correct  a major three wave pullback should be expected from now on  because every impulse is followed by a three wave correction in the opposite direction  Now let s take a look at wave V from up close  in order to determine what is left of it 
Wave V could already be seen as a complete impulsive wave  In addition  the MACD indicator is showing the typical bearish divergence between waves 3  5 of  3  and  5   It definitely does not look good for Pfizer stock right now  So if the recent bullish breakout make you feel optimistic and willing to buy it  our opinion is you should be very careful  because now might be the worst possible moment to join the bulls  Buying Pfizer  No  thank you ",2016-07-24,EWM Interactive,https://www.investing.com/analysis/pfizer-a-buy-it-was-over-four-months-ago-200143695,200143695
220962,442478,PFE,Drug industry expects final EU probe report July 8,news,"  Preliminary report blasted firms for blocking generics
   Industry hopes for some softening in final version
 By Ben Hirschler
 LONDON  June 17  Reuters    The European Commission looks
set to deliver its final verdict on competition  or lack of it 
in the pharmaceutical sector on July 8  the industry s trade
organisation said on Wednesday 
 Competition Commissioner Neelie Kroes blasted drugmakers
last November when preliminary results of her inquiry concluded
they were delaying or blocking the entry of cheaper generic
medicines 
 Thomas Cueni  who heads a European Federation of
Pharmaceutical Industries and Associations taskforce on the
issue  told Reuters he hoped for a reassessment in the latest
version but acknowledged a radical re write was unlikely 
  The preliminary report was 420 odd pages     it might be up
to 600 pages now  I would be surprised if it was totally
rewritten   he said 
 The Commission  the European Union s executive arm  said
last year that delays in getting generics to market had cost
healthcare providers about 3 billion euros   4 2 billion 
between 2000 and 2007 
 But drugmakers argue most of the delays were down to
regulatory and other bureaucratic issues  rather than deliberate
action by companies    and Cueni is hoping there will be greater
recognition of this in the final version of the report 
 There could also be a couple of positive recommendations  he
added  such as backing for a common European patent  applicable
in all EU countries  and the introduction of a specialised
patent litigation system 
 Kroes kicked off her sector investigation in January 2008
with a series of raids on makers of brand name drugs  including
AstraZeneca  GlaxoSmithKline  Pfizer  Merck and Sanofi Aventis 
 There were also raids on generic drugmakers suspected of
colluding to limit the entry of generics  sometimes in exchange
for payments from originator companies 
 The Commission s findings could open the door to action
against individual companies  with the potential for large fines
down the road 
  Editing by Rupert Winchester ",2009-06-17,Reuters,https://www.investing.com/news/equities-news/drug-industry-expects-final-eu-probe-report-july-8-63620,63620
220963,442479,PFE,UPDATE 1 NicOx shares slump on possible delay to key drug,news,"  naproxcinod talks may not conclude until H1 2010
   NicOx shares close down 7 4 percent
 
  Adds details  updates to close 
 PARIS  June 18  Reuters    Shares in NicOx slumped on
Thursday after the French biotech firm said talks to seal a
partnership to bring anti inflammatory drug naproxcinod to
market may not reach a conclusion until the first half of 2010 
 Shares in NicOx closed down 7 4 percent at 8 88 euros 
compared to a 1 percent rise in France s CAC 40 index 
 Some of NicOx s potential partners prefer to wait until they
see the drug s guidelines  which are being negotiated with
health authorities  before signing a commercial partnership with
NicOx  a spokesman said 
 The main question is whether the U S  Food and Drug
Administration will let NicOx state on the label that the drug
is less likely to increase arterial pressure than other
competing medicines  the spokesman said 
 Negotiations over the medicine s guidelines will take place
during the first half of 2010  he added 
 He confirmed that NicOx is likely to clinch two or three
partnerships depending on the geographical zone  adding that
partners will include global  regional and specialised
pharmaceutical firms 
 The submission for marketing approval will still be sent to
the FDA this summer as expected  the spokesman said  adding that
a proposal will be sent to European health authorities two to
three months after the United States 
 NicOx has high hopes for naproxcinod  which took 10 years to
develop at a cost of around 100 million euros   139 6 million  
It would be its first marketed drug and the only branded rival
to Pfizer s Celebrex  which made  2 5 billion in sales last
year 
   1  7165 Euro 
 Reporting by Juliette Rouillon and Sophie Taylor  editing by
Elaine Hardcastle ",2009-06-18,Reuters,https://www.investing.com/news/equities-news/update-1-nicox-shares-slump-on-possible-delay-to-key-drug-64102,64102
220964,442480,PFE,INTERVIEW Rigel s oral arthritis drug as good as Pfizer s  COO,news,"  Says rheumatoid arthritis drug comparable to Pfizer s
   Sees multi billion dollar potential for drug
   Sees partnering on drug by second half of 2010
   Has enough cash until then
   Says will not pursue psoriasis drug without partner By
Vidya L Nathan BANGALORE  June 25  Reuters    Rigel
Pharmaceuticals Inc s experimental oral treatment for
rheumatoid arthritis would hold its own against a rival drug in
development at Pfizer and has the potential to be a
multi billion dollar business  a top company official said 
 The efficacy between the two products is about the same  We
have a little bit more efficacy in some areas than they do but
it is basically very similar  The two products are comparable  
Chief Operating Officer Raul Rodriguez told Reuters in a
telephone interview 
 Rigel s drug  R788  is currently being studied in mid stage
trials  the results of which are expected mid July  Pfizer
Inc s comparable drug is in late stage studies 
 Rigel s Rodriguez sees the oral compounds being developed
by the two as having an edge over competitors  injections  as
 people generally prefer having an oral pill than having to
undergo injections  
 Existing injectable treatments for the condition include
Abbott Laboratories s Humira  Johnson   Johnson and
Schering Plough s Remicade  and Amgen and Wyeth s Enbrel 
  If we are able to come in before the injectable drugs
during treatment  that gives us a very big market and even if
we share it with Pfizer it still means that R788 has
multi billion dollar potential   Rodriguez said 
 However  R788 future also rests upon the clinical stage
development company finding a licensing partner to fund the
large late stage trials required for the drug 
 Rigel s compound works by blocking white blood cells in
tissues from signaling the body defenses into attacking the
disease area and causing swelling and inflammation 
 Rodriguez said Rigel is also looking to find a partner who is
also interested in the compound s potential benefits in cancer 
for which it is currently being studied in mid stage studies
with funding from the National Institutes of Health 
 In February  Rigel had halted partnership talks on the drug
until after results of the mid stage studies were out  so as to
get a better deal 
 CASH NO BAR
 The South San Francisco  California based company  which
has about  134 5 million cash  had also let go of about 20
percent of its employees and cut some of its pipeline products
in oncology and virology  to conserve resources 
 Rodriguez said Rigel now has enough cash to last through
the first half of 2010  by which time it expects to have found
a partner for R788 
  Our burn would drop dramatically going forward because we
do not have any clinical trials ongoing in the third quarter 
fourth quarter  or early next year  
 Rodriguez also said the company would not be pursue any
further trials of its early stage experimental psoriasis drug
as it was no longer interested in the dermatological
indication  but added that it was open to partnering on it 
 Clinical trials of the remaining compounds in the company s
pipeline    an inhaled asthma product and a cancer drug    are
being funded by existing partners 
  And so that  current  cash number is sufficient to take us
through the middle of next year   the COO said 
  Reporting by Vidya L Nathan in Bangalore  Editing by Anthony
Kurian ",2009-06-25,Reuters,https://www.investing.com/news/equities-news/interview-rigel's-oral-arthritis-drug-as-good-as-pfizer's:-coo-66391,66391
220965,442481,PFE,EU regulator extends review of Pfizer Wyeth deal,news,"BRUSSELS  June 30  Reuters    European Union antitrust
authorities on Tuesday extended the deadline for their review of
U S  drugmaker Pfizer s  68 billion plan to take over rival
Wyeth 
 The European Commission extended the review deadline to July
20 from July 6 to consider remedies offered to address
competition concerns  a daily list of planned mergers being
scrutinised by the EU executive said 
 Double click on the newslinks below for the relevant topics 
  For stories on competition issues
  For stories on state aid  M As
  Reporting by Bate Felix  editing by Dale Hudson ",2009-06-30,Reuters,https://www.investing.com/news/equities-news/eu-regulator-extends-review-of-pfizer-wyeth-deal-67541,67541
220966,442482,PFE,UPDATE 1 Pfizer offers EU remedies over planned Wyeth buy,news,"  EU Commission extends review deadline by 10 working days
   Remedies offered  regulator gives no further details
   Pfizer had said it may have to shed some assets

  Adds background 
 BRUSSELS  June 30  Reuters    U S  drugmaker Pfizer has
offered remedies aimed at tackling concerns that its  68 billion
planned takeover of rival Wyeth may be anti competitive  the
European Commission said on Tuesday 
 The Commission  which polices competition in the 27 country
European Union  said in a daily list of planned mergers under
scrutiny that it had extended the deadline for its review of the
deal to July 20 from July 6  
 It gave no further details 
 Parties in mergers often offer to divest some sectors or
activities to address concerns that their transaction could
infringe EU competition rules 
 A Pfizer executive was quoted in March as saying that the
company may have to shed some of its animal health business so
that it can gain antitrust clearance 
 Pfizer said in April that it had received a request for
additional information from the U S  Federal Trade Commission
regarding the proposed acquisition of Wyeth 
 The company said it still expected to close the deal by the
end of the third quarter or during the fourth quarter of this
year 
  Reporting by Bate Felix  editing by Dale Hudson ",2009-06-30,Reuters,https://www.investing.com/news/equities-news/update-1-pfizer-offers-eu-remedies-over-planned-wyeth-buy-67583,67583
220967,442483,PFE,UPDATE 5 J J buys  1 bln Elan stake  gains Alzheimer s RD,news,"  J J buys 18 4 pct stake in Elan for  1 bln
   U S  group takes over interest in Alzheimer s program
   Relationship with Wyeth to continue
   Elan shares rise 8 6 pct  J J falls 1 9 pct
  Adds J J  analyst comments  updates share prices 
 By Toni Clarke
 BOSTON  July 2  Reuters    Johnson   Johnson  has
agreed to pay  1 billion for an 18 4 percent stake in Irish
drugmaker Elan Corp   and will acquire a major stake in
Elan s portfolio of experimental drugs to treat Alzheimer s
disease 
 The transaction  announced on Thursday  will  among other
things  give J J a 25 percent interest in a closely watched
Alzheimer s drug called bapineuzumab  which Elan is developing
in a 50 50 partnership with Wyeth  Wyeth is being acquired by
Pfizer Inc  
 The agreement caps a lengthy battle between Elan and some
of its largest shareholders  who had called on Elan to shake up
its board  streamline operations and tighten what they
considered lax corporate governance 
 Last month  the company agreed to nominate two dissidents
to its board  including Jack Schuler  a shareholder who
publicly called for the resignation of Elan s chief executive 
Kelly Martin 
 As a potential board member  Schuler declined to discuss
the J J transaction  but another of Elan s previous critics
welcomed it 
  We are encouraged by this deal   said Matt Strobeck 
partner at Westfield Capital Management Co  which holds 18 8
million Elan shares   Now not only is the balance sheet
strengthened but we believe the board has been dramatically
improved  
 Elan said it plans to use the new funds to cut its debt by
70 percent to about  400 million  Moody s Investors Service
said it has placed Elan s ratings under review for a possible
upgrade 
  The transaction is expected to have a very favorable
impact on Elan s capital structure and liquidity profile   said
Moody s Senior Vice President Michael Levesque 
 On the New York Stock Exchange on Thursday  Elan 
closed up 8 6 percent at  7 60 and J J fell 1 9 percent to
 55 98 
 For New Brunswick  New Jersey based J J  the deal
represents a leap into a therapeutic area in which it has only
a limited presence 
 J J sells Reminyl  which is in the same class of medicines
as Pfizer Inc s best selling Aricept treatment for Alzheimer s
disease  But the drugs  which block an enzyme called
acetylcholinesterase  only slightly improve cognition and for a
very brief period 
 Combined U S  sales of all Alzheimer s drugs rose to  3 4
billion last year  according to market research firm IMS
Health  but analysts believe revenue could explode if new
medicines can appreciably slow damage to the brain and memory 
  J J has a much better chance to make bapineuzumab
successful than Elan because it has the resources to conduct
trials and distribute it   said David Katz of asset manager
Matrix Asset Advisors   And from a patient perspective  to have
J J involved is a good thing  
 But the bet on bapineuzumab is risky 
 Some analysts have all but written the drug off after a
mid stage trial showed that while it helped some patients with
a certain genetic profile  it raised the risk of potentially
serious side effects in the brain 
 For J J  which sells an array of products ranging from
Band Aids to arthritis drug Remicade  the potential warrants
the risk 
  The fact that this drug may have potential to delay
disease progression  we believe is significant   said company
spokesman Srikant Ramaswami 
 Elan and Wyeth remain committed to the drug  which is
Elan s most advanced product  But under the transaction with
J J  Elan will receive 25 percent of any profit instead of the
50 percent it would have received previously 
 That is because J J and Elan plan to form a new company 
which will be 50 1 percent owned by J J and 49 9 percent owned
by Elan  J J will contribute an initial  500 million to the
venture  Elan will contribute its Alzheimer s immunotherapy
program 
  Elan loses control of one of its babies but they have a
stake in it once it gets to market so they will get their due
returns for the work they have put in   said Ian Hunter  an
analyst with Dublin based Goodbody Stockbrokers 
 Elan said the new entity will be governed by a seven person
board  Five members will come from J J 
 As many as 5 million Americans are believed to have
Alzheimer s disease  a progressive neurological condition
associated with aging 
 The deal adds to Elan s complicated series of partnerships 
Its main product is the multiple sclerosis drug Tysabri  which
it markets together with U S  biotechnology company Biogen Idec
Inc  
 Elan said it has no intention of selling any part of
Tysabri  Naomi Aoki  a spokeswoman for Biogen  said J J s entry
will make no difference to its partnership with Elan 
 J J said the transaction would dilute its adjusted earnings
in 2009 by between 2 and 3 cents a share 
 Elan said it will update its financial guidance on its next
earnings call  but it expects to be profitable on a pretax
basis by the end of 2010 
  Reporting by Toni Clarke  Additional reporting by Ben
Hirschler  Carmel Crimmins  Lewis Krauskopf  Ransdell Pierson
and Jessica Hall  Editing by Maureen Bavdek  Richard Chang  Tim
Dobbyn ",2009-07-02,Reuters,"https://www.investing.com/news/equities-news/update-5-j-j-buys-$1-bln-elan-stake,-gains-alzheimer's-r-d-68478",68478
220972,442488,PFE,Dovish Indeed,opinion,"DOW   78   17 918SPX   11   2099NAS   36   485910 Y    02   1 38 OIL   1 27   47 87GOLD   7 00   1364 20SILVER    14   20 16
The Federal Reserve released the minutes of the June FOMC meeting  When the central bank met in mid June  an abysmal May jobs report  just 38 000 new jobs in May  had just startled markets  and the upcoming British referendum on European Union membership loomed large   an event that certainly had the Fed worried 
But beyond that  what was the Fed thinking  Were they confident of a recovery and chomping at the bit to hike rates  or were they more concerned that the economy was still too fragile for higher rates 
Turns out  the Fed was mixed  Some of the policymakers thought the weak jobs report was an aberration  others thought  the lower rate of payroll gains could instead be indicative of a broader slowdown in growth of economic activity   Even though retail sales were strong in April and May   a few participants expressed caution  
Some officials thought business investment could pick up  particularly given the  greater optimism  businesses had expressed  including in the Fed s Beige Book  Yet  some participants mentioned that the sluggishness in business investment could portend a broader economic slowdown  
There were similar mixed interpretations on inflation  In the end  the doves prevailed  The decision to leave rates unchanged was unanimous  The June minutes contained no reference to the timing of any future rate rises  Dovish indeed 
Stronger demand for imports boosted the U S  trade deficit by 10  in May  but the rebound in consumer spending suggests the economy regained momentum after a slow start to the year 
The nation s trade gap climbed  41 1 billion   a three month high   from a revised  37 4 billion in April  Imports increased 1 6  in May to a seasonally adjusted  223 5 billion  Exports  meanwhile  slipped 0 2  to  182 4 billion 
Exports have been weak because of a strong dollar that makes American products more expensive as well as slower growth around the world  The U S  exported fewer autos  airplanes and computer accessories in May 
The Institute for Supply Management s service sector index jumped to 56 5  in June  a much stronger reading than expected  The forward looking new orders component jumped 5 7 points to 59 9   and the production index rose to 59 5  Employment increased 3 0 points to 52 7   signaling expansion  The ISM says the report shows a  strong rebound  in economic activity 
The pound sterling dropped to a fresh 31 year trough overnight  sliding as far as  1 2796 to record a more than 14  loss in value since last month s referendum  The 10 year US Treasury note yield hit a new record low of 1 32  in overnight trade  not so much an indication of US strength but of global weakness 
The Stoxx Europe 600 dropped 1 7   with all but the defensive utilities sector losing ground  Among banks  Switzerland s Credit Suisse Group  SIX CSGN  and German lenders Deutsche Bank  DE DBKGn  and Commerzbank  DE CBKG  posted their lowest share price closes on record 
Henderson Global Investors  Columbia Threadneedle Investments and Canada Life suspended trading in at least  7 4 billion of property funds  taking the number of U K  firms curbing redemption to six in the wake of Britain s shock decision to leave the European Union 
Investors pulled money from real estate funds in the lead up to the vote  depleting cash levels  as industry commentators warned that London office values could fall by as much as 20 percent within three years of the country leaving the EU 
Standard Life Investments  LON SL  was the first money manager to halt withdrawals on Monday  followed by Aviva Investors  LON AV  and M G Investments  These are open end funds  It is kind of like a run on a bank  but it is a mutual fund  and it is not as liquid as many investors had hoped 
Deutsche Boerse  DE DB1Gn  has signaled the company to be created from its planned merger with the London Stock Exchange  LON LSE  may be headquartered outside of the U K  following Britain s EU vote  A referendum committee  involving representatives of both partners  will assess all regulatory and commercial goals aimed at getting the transaction approved 
Paris is sending letters to British executives  German politicians have paid for billboards in London to promote Berlin  Dublin is planning an advertising campaign  and Milan wants to be home to Europe s bank regulator  Not 2 weeks after the Brexit vote and cities across the Eurozone are trying to steal away British jobs and lay claim as the new financial hub 
In London s financial district on Tuesday a truck was spotted carrying a billboard with the words  Dear start ups  Keep calm and move to Berlin   French and German politicians have sparred over whether Frankfurt or Paris should take over London s euro clearing business 
And once again they miss the point  instead of trying to poach the UK s financial interests  they should try to think about how they can build a union that is better than what they have and so good that people will want more of it 
Stock in struggling Italian bank Monte dei Paschi di Siena  OTC BMDPY  bounced back after the country s financial market regulator temporarily banned short selling in the bank s shares  The intervention comes after shares in the troubled lender fell by nearly 20  in yesterday s session 
Gold prices extended recent gains to strike a fresh two year high and is now challenging  1400 per ounce  Silver prices topped  20 an ounce  a nearly two year high  gaining over 10  just in the handful of trading days since the Brexit vote 
Analysts at UBS say gold has now entered a  new phase  and is the go to investment for the remainder of 2016  They raised their annual forecast to an average of  1 280 an ounce  up from  1 225 an ounce 
Copper inventories are piling up  Copper inventories at the London Metals Exchange approved warehouses rose 10 525 tons  The jump in inventory made for the biggest copper stockpile in nearly a month 
US cancer drug company Medivation  NASDAQ MDVN  has agreed to open its books and provide confidential information to French pharmaceutical company Sanofi  PA SASY  as part of exploring a sale that would be open to other bidders 
Similar agreements have been signed with Pfizer  NYSE PFE  and Celgene  NASDAQ CELG   which have also expressed interest in an acquisition  As part of negotiations  Sanofi agreed to drop efforts to have Medivation shareholders replace the board  after its  9 3 billion offer for the company was rejected in April 
Sanofi has also formed a partnership with the US Army to expand R D of an experimental Zika vaccine that has shown promise in early laboratory studies and is among a few candidates expected to be tested on humans in the coming months  Researchers and companies are racing to get a vaccine to market as quickly as possible   though they caution it is likely to take three years or more before that happens 
Barcelona s Argentine soccer star Lionel Messi was sentenced on Wednesday to 21 months in prison and fined  2 2 million after being found guilty of three counts of tax fraud  although it is unlikely he will serve time  Another penalty he will miss  Spanish law is such that any sentence under two years for a non violent crime rarely requires a defendant without previous convictions to serve jail time 
The court also found Messi s father guilty  sentencing him to 21 months and fining him 1 5 million euros  Messi and his father were accused of defrauding the Spanish government of 4 2 million euros in taxes between 2007 and 2009  They allegedly evaded taxes on income from Messi s image rights by using a web of shell companies  which were revealed in the Panama Papers expose this spring 
The Pension Benefit Guaranty Corporation  PBGC  is now saying the government is on track to run out of money to prop up the troubled Teamsters Central States Pension Fund in 2024  roughly the same time the fund itself is expected to go bankrupt 
Without congressional action  the confluence of those two events could leave Central States pensioners collecting pennies on the dollars they invested in their retirements  Central States  the largest of the country s troubled pension plans negotiated between single unions and multiple employers  has been operating at deficits of  2 billion a year recently 
The PBGC  which guarantees a minimum benefit to pensioners  expects to spend the better part of  15 billion assisting Central States in the next decade  But the projected rate of assistance to Central States and other ailing pension plans will wipe out the government s multi employer assistance funds by 2024  Should Central States fail and the PBGC emergency fund run dry  all of Central States  407 000 participants could see their payments cut almost to nothing 
The scramble to solve the problem has not been as urgent as the pressure to stop the cuts Central States proposed under the Multi employer Pension Reform Act of 2014  MPRA   That fight involved rallies by angry pensioners  some of whom faced benefit cuts of 40 to 70 percent  The Government Accountability Office said it would investigate investment decisions made by Wall Street firms hired by Central States Pension Fund trustees ",2016-07-07,Marvin Clark,https://www.investing.com/analysis/dovish-indeed-200140436,200140436
220973,442489,PFE,Puma  PBYI  Stock Up  Phase II Data On Neratinib Published,opinion,"Puma Biotechnology  Inc    NYSE PBYI   announced that positive results from a randomized phase II study  I SPY 2   Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2  on neratinib for the neoadjuvant treatment of breast cancer were published in the New England Journal of Medicine  The company s shares were up 5 5  on the news 
The study  a collaborative effort among academic investigators  was conducted in women with newly diagnosed stage 2 or higher  tumor size at least 2 5 cm  breast cancer to evaluate whether adding investigational drugs to standard chemotherapy in the neoadjuvant setting is better than standard chemotherapy  The primary endpoint of the study was pathological complete response  pCR  in the breast and the lymph nodes at the time of surgery 
Results showed that treatment with the neratinib containing regimen  neratinib plus paclitaxel followed by Adriamycin and Cytoxan  in HER2 positive patients  including those who were either hormone receptor positive or negative  resulted in an estimated pCR rate of 39 4  compared with the control arm of 22 8   On the safety front  the most frequently observed severe adverse event in the study was diarrhea PUMA BIOTECHNLG Price   We are encouraged by the phase II study results  Per the company s press release  the I SPY 2 data represents the first clinical data on neratinib in the neoadjuvant treatment of breast cancer and recommends that the combination of paclitaxel plus neratinib holds potent activity for the treatment of HER2 positive breast cancer and a subset of patients with HER2 negative breast cancer 
Puma Biotech expects to report data from its ongoing studies on the candidate through 2016 
We remind investors that Puma Biotech had announced last month that it has submitted a regulatory application in the EU seeking approval for neratinib  The company is looking to get neratinib approved for the extended adjuvant treatment of HER2 positive early stage breast cancer that has previously been treated with Roche Holding  SIX ROG  AG s   OTC RHHBY   Herceptin  trastuzumab  based adjuvant therapy 
Meanwhile  Puma Biotech also plans to seek FDA approval for neratinib shortly 
Given that Puma Biotech has no approved product in its portfolio at the moment and neratinib is its lead pipeline candidate  we expect investor focus to remain on updates pertaining to its development 
Puma Biotech is a Zacks Rank  4  Sell  stock  A couple of better ranked stocks in the health care sector are Innoviva  Inc    NASDAQ INVA   and Pfizer Inc    NYSE PFE    While Innoviva sports a Zacks Rank  1  Strong Buy   Pfizer carries a Zacks Rank  2  Buy  ",2016-07-07,Zacks Investment Research,"https://www.investing.com/analysis/puma-(pbyi)-stock-up,-phase-ii-data-on-neratinib-published-200140823",200140823
220976,442492,PFE,INTERVIEW UPDATE 1 O Shaughnessy AM close to U S  sales deal,news,"  Former Bear Stearns manager to seek sales tie up in Europe
   Plans to launch new global market neutral hedge fund in H1
   Weighing prospect of three year hedge fund lock ups
  Adds details 
 By Claire Milhench
 LONDON  Dec 5  Reuters    United States based quantitative
investment firm O Shaughnessy Asset Management  OSAM  said it is
close to a deal with a  very large  mutual fund distributor in
the U S  as part of a global push to build its sales platform 
 Jim O Shaughnessy  chairman and CEO of OSAM  told Reuters
the agreement will be announced in January  after which he will
spend more time in Europe looking for a similar partner 
 O Shaughnessy is also seeking a sales partner in Australia 
and possibly Asia   If it ends up being just Australia then we
would try to find a strong Japanese or Chinese bank for Asia  
 OSAM already has an deal with Royal Bank of Canada  which
owns 11 percent of OSAM  to sub advise  a suite of mutual funds 
 O Shaughnessy said the top priority was institutional
investors  but he also wanted to reach retail investors in a way
that was not prohibitively expensive   That means partnering
with distributors who are looking for talent on the alpha
generation side   he said 
 The firm  which managed  7 5 billion as of September 30
across a range of strategies  was formed when O Shaughnessy and
his team left Bear Stearns Asset Management in 2007  OSAM  uses
quantitative analysis to pick stocks and seeks to generate
 alpha  returns above the average market return 
 
 HEDGE FUND PLANS
 The firm is also planning to launch a second hedge fund in
the first or second quarter next year  he told Reuters at the
CFA Institute s European conference this week  The first  the
O Shaughnessy Pari Passu fund  launched on September 26 this
year and invests across asset classes  with a net long strategy 
 Acknowledging that it hadn t been the easiest time to
launch  O Shaughnessy said he was exploring the option of three
year lock ups   What we have seen this year is that investors 
however sophisticated  are their own worst enemy  We want
rational partners who truly understand our process  
 The 2009 launch will be a global market neutral fund
investing almost exclusively in equities  he added   We are
trying to develop a robust package of businesses so our hedge
funds won t use more than two or three times leverage  which may
put us with the lower volatility crowd  But that might be of
interest after what s happened   he said 
 Quant investing has attracted heavy criticism in the last 12
months  after performing poorly through the August and November
2007 sell offs  and again in January 2008  But O Shaughnessy
argued that this confused leverage with quant strategies  
  The quants were using too much leverage over too short a
time span   the optimisers they employed moved all the quants to
the same names  and then levered those names   he said   We
don t use optimisers  
 He conceded that this has been an  awful year  for OSAM  but
insisted he would be sticking to his strategy   Times like this
can rattle us as people  but they do nothing to our stock
selection methodology   he said  
 OSAM s Value Opportunities Fund is down 27 42 percent in the
10 months to end October  The Russell 3000 Value benchmark is
down 32 25 percent in the same period 
 O Shaughnessy s model is currently pushing him to overweight
healthcare stocks such as Pfizer and hold certain consumer
discretionary stocks   That may sound surprising  but we are
talking about the deep discount retailers like Costco and
Wal Mart  
 He remains underweight on energy and IT in most portfolios 
saying that these are either too richly valued  don t have
enough momentum  or don t pay a high enough dividend yield ",2008-12-05,Reuters,https://www.investing.com/news/forex-news/interview-update-1-o'shaughnessy-am-close-to-u.s.-sales-deal-11493,11493
220977,442493,PFE,Pfizer eyes deals to raise emerging mkts presence,news,"By John Irish
 DUBAI  June 14  Reuters    Pfizer Inc  the world s largest
drugmaker  is looking to conclude deals in emerging markets over
coming months to raise its share of a market worth an estimated
 80 billion  an executive said on Sunday 
 Pharmaceutical companies are increasingly turning their
attention to developing nations as they face tougher conditions
in more mature markets 
 The drugmaker struck a  68 billion deal in January to
acquire U S  rival Wyeth to help shore up profits and in May
signed licensing agreements with two Indian based companies 
including Aurobindo Pharma Ltd  as it seeks new growth
opportunities in generics and emerging markets 
  We will have other elements in the next few months  
Pfizer s emerging market business unit president Jean Michel
Halfon told Reuters when asked if the firm was eyeing new
acquisitions 
  We see opportunities coming from the financial crisis    
opportunities to build partnerships in emerging markets  
 Halfon declined to give further details 
 Pfizer is seeking to add  3 billion in annual sales by 2012
in developing markets and is targeting China  Brazil  Mexico 
Russia  Turkey  India and to a lesser extent the Middle East to
help lift its 4 percent market share  Halfon said 
  We start in position number three in emerging markets and
we want to be number one  
 The emerging markets pie could increase to  120 billion by
2012 with China providing the greatest growth prospects  Halfon
said 
 The group saw 28 percent growth in sales in the world s most
populous nation in the first quarter  he said 
 Pfizer  which posted  48 billion in revenue last year  faces
severe sales declines in the coming years from patent
expirations to its own products  including its blockbuster
Lipitor cholesterol treatment 
 It has responded with the purchase of Wyeth  which Halfon
said the firm was looking to complete  somewhere in the fourth
quarter   and the restructuring of its operating model around
separate units including generic drugs and emerging markets 
  We are in a very competitive environment and need to make
decisions very fast in this area  so an example of what we re
doing is managing the acquisition of Wyeth     It will add
significant revenues to our organisation in emerging markets by
adding footprint in vaccines  biological medicine     
 Halfon said he expected growth in the Middle East of about
10 12 percent over the next five years as opportunities arise
from sustained economic activity in the world s largest oil
exporting region 
  editing by John Stonestreet ",2009-06-14,Reuters,https://www.investing.com/news/equities-news/pfizer-eyes-deals-to-raise-emerging-mkts-presence-62479,62479
220978,442494,PFE,Boehringer  Vitae ink  242 mln Alzheimer s deal,news,"   42 mln upfront   200 mln pre commercial milestones
   Collaboration covers beta secretase inhibitors 
 
 LONDON  June 15  Reuters    Germany s Boehringer Ingelheim
has signed a deal worth up to  242 million with U S  biotech
company Vitae Pharmaceuticals to research and develop new
Alzheimer s drugs  the companies said on Monday 
 Vitae will get  42 million upfront    consisting of cash  an
equity investment and near term research funding    and will
also be eligible for  200 million in pre commercial milestone
payments  depending on the progress of products in development 
 Vitae may receive additional commercial performance payments
and royalties from Boehringer on potential future sales 
 The partners  both of which are unlisted  will be working to
develop drugs that inhibit beta secretase  an enzyme responsible
for the build up of sticky deposits  or plaques  in the brain 
 The formation of these plaques is thought to play a key role
in the development of Alzheimer s disease and several companies
are working on beta secretase inhibitors to tackle the
degenerative disorder 
 Alzheimer s is a hot area for pharmaceutical research  since
the incidence of the brain disease is rising rapidly as people
live longer  But developing effective treatments has proved
notoriously difficult 
 Existing drugs  such as Aricept from Pfizer and Eisai  can
ease symptoms but do not stop the disease 
  Reporting by Ben Hirschler  editing by Simon Jessop ",2009-06-15,Reuters,"https://www.investing.com/news/equities-news/boehringer,-vitae-ink-$242-mln-alzheimer's-deal-62676",62676
220984,442500,PFE,Buy 5 Attractive Biotechs At Bargain Prices,opinion,In retrospect  we had a roller coaster ride in the first half of this year  2016 started off on a negative note for the U S  markets   The markets rallied back only to be thrown in the storm of uncertainty after a shock Brexit vote during late June  The markets have recuperated the losses and have come back strongly afterward laying aside Brexit fears  The healthcare sector was also turbulent right at the onset of 2016 while the ever volatile biotech sector continues to maintain its negative streak as we stand midway  The NASDAQ Biotechnology Index has declined 19 8  year to date   The biotech sector was hit hard in the second half of 2015 as well due to pricing issues It s anybody s guess how the second half will turn out to be  Yet  we believe it might be a good time for investors to put their bets on the dynamic biotech sector which of late has plunged into a series of mergers   acquisitions  Last month  Shire acquired Baxalta to further strengthen its rare disease portfolio   The company has an important event coming up with a Prescription Drug User Fee Act  PDUFA  date of Jul 22  2016 for ophthalmology lifitegrast  A potential approval of lifitegrast will give a significant boost to Shire s efforts to build an ophthalmology unit   Aegerion Pharmaceuticals and QLT Inc entered into a definitive merger agreement in Jun 2016 to form a new company  Novelion Therapeutics Inc   as both are looking to overcome their existing challenges  Earlier  pharma major Pfizer  NYSE PFE   Inc  acquired Anacor Pharmaceuticals  Meanwhile  Sanofi  PA SASY  is looking to acquire Medivation  Inc Alongside  regular trial updates and approval of new drugs will continue to hold center stage  Amid this recent wave of consolidations  it makes sense to zero in on some low priced biotechs below  10 carrying a Zacks Rank  1  Strong Buy  or Zacks Rank  2  Buy   These stocks look poised to emerge as winners in the second half of 2016 with impressive portfolios healthy pipelines Attractive Biotechs at Bargain PricesCambridge  MA based Merrimack Pharmaceuticals   NASDAQ MACK   primarily focuses on innovative therapies in combination with companion diagnostics for the treatment of cancer  Merrimack gained FDA approval for its first product  Onivyde  in Oct 2015 in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following Gemzar based therapy  The initial uptake of the drug has been encouraging while Merrimack works on expanding its label for other oncology indications  The company also has four candidates in its pipeline  The stock currently carries a Zacks Rank  1 MERRIMACK PHAR Price and Consensus   New York based Anavex Life Sciences Corp    NASDAQ AVXL   is a clinical stage biopharmaceutical company which is focussing on the development of drugs therapies for the treatment of neurodegenerative and neurodevelopmental diseases  The company s efforts to develop its lead candidate  ANAVEX 2 73  for Alzheimer s disease  phase II  and Rett syndrome are encouraging  In Jun 2016  the FDA s Office of Orphan Product Development granted Orphan Drug Designation to ANAVEX 2 73 for the treatment of infantile spasms  The company also enjoys an orphan drug status for Rett syndrome in the U S  The stock currently carries a Zacks Rank  2  Buy  and the 2016 loss per share estimate has narrowed by 18 cents in the last 60 days ANAVEX LIFE SCI Price and Consensus   Cambridge  MA based AVEO Pharmaceuticals  Inc    NASDAQ AVEO   also focuses on therapeutics for oncology and other areas of unmet medical need  The company s lead candidate  tivozanib  is being developed for the treatment renal cell carcinoma  RCC   The company has collaborated with other companies to fund development programs for its other pipeline candidates including AV 380  ficlatuzumab  AV 203  and tivozanib in non oncologic indications along with oncology indications outside North America   The company continues to progress with its pipeline and recently dosed its first patient in a randomized  controlled  multi center  open label study to compare tivozanib to Nexavar in subjects with refractory advanced RCC  The stock currently carries a Zacks Rank  2 and the 2016 loss per share estimate has narrowed by 12 cents over the past 60 days AVEO PHARMACEUT Price and Consensus   Next up on our list of buys is Durham  NC based Argos Therapeutics  Inc    NASDAQ ARGS    a clinical stage company  focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases  which it is developing using its technology platform called Arcelis  The company s lead candidate  AGS 003  is currently being evaluated in phase III for the treatment of metastatic renal cell carcinoma  mRCC   The company is also developing AGS 004  currently in phase II  for the treatment of HIV  The 2016 loss per share estimate for this Zacks Rank  2 stock has narrowed by 48 cents in the last 60 days ARGOS THERAPEUT Price and Consensus   Cambridge  MA based Idera Pharmaceuticals  Inc    NASDAQ IDRA   is a clinical stage company which also focuses on the development of drug candidates for oncology and rare diseases  The company uses two distinct proprietary drug discovery technology platforms to develop drugs   toll like receptor  TLR  targeting technology and third generation antisense  3GA  technology  The company s TLR antagonist candidates include IMO 8400 and IMO 9200  which are both antagonists of TLR7  TLR8 and TLR9  These antagonists can be potentially developed in the immune oncology space  Meanwhile  the 3GA technology has the potential to reduce the immunotoxicity and increase the potency of earlier generation antisense and RNA interference  or RNAi  technologies  The stock currently carries a Zacks Rank  2 IDERA PHARMACT Price and Consensus  ,2016-07-05,Zacks Investment Research,https://www.investing.com/analysis/buy-5-attractive-biotechs-at-bargain-prices-200140090,200140090
220985,442501,PFE,Sanofi Starts Olipudase Alfa Study  Praluent Ok d In Japan,opinion,"Sanofi  PA SASY  s   NYSE SNY   specialty care global business unit  Sanofi Genzyme  announced the dosing of the first adult patient in a pivotal phase II III study  ASCEND  on its experimental enzyme replacement therapy  olipudase alfa  It is being evaluated for the treatment of non neurological manifestations of acid sphingomyelinase deficiency  ASMD   also known as Niemann Pick disease type B  NPD B  
The multi national  multi center  double blinded  placebo controlled study will evaluate the efficacy  safety  pharmacodynamics and pharmacokinetics of olipudase alfa when given intravenously once every 2 weeks for 52 weeks in adults with ASMD  specifically NPD B  In the study  36 patients will be enrolled to assess the effect of the candidate on spleen size  lung function and other important clinical parameters 
Last June  Sanofi Genzyme had announced the initiation of a phase I II study in pediatric patients with ASMD  specifically NPD B 
Sanofi Genzyme s progress with the candidate is encouraging  Given the lack of approved treatments for ASMD  there exists a significant unmet need for drugs addressing this rare and debilitating disease 
We remind investors that olipudase alfa has been granted Breakthrough Therapy status by the FDA  The regulatory agency usually grants Breakthrough Therapy status to expedite the development and review of a candidate that is believed to have the potential to treat serious or life threatening conditions 
PCSK9 Inhibitor Praluent Gains Japanese Approval
Early this week  Sanofi and partner Regeneron Pharmaceuticals  Inc    NASDAQ REGN   announced that the Japanese Ministry of Health  Labour and Welfare has approved Praluent for the treatment of patients with hypercholesterolemia and familial hypercholesterolemia who are at high cardiovascular risk and in whom treatment with statins  HMG CoA reductase inhibitors  is not sufficient 
Per the companies  press release  Praluent 75 mg and 150 mg will be available in Japan as a single dose pre filled pen and syringe  We note that Praluent is already approved both in the U S  and EU  Investor focus is expected to remain on the sales ramp up of Praluent given that the drug s sales are yet to pick up 
Sanofi is a Zacks Rank  3  Hold  stock  A couple of better ranked stocks in the health care sector are Innoviva  Inc    NASDAQ INVA   and Pfizer Inc    NYSE PFE    While Innoviva sports a Zacks Rank  1  Strong Buy   Pfizer carries a Zacks Rank  2  Buy  ",2016-07-06,Zacks Investment Research,"https://www.investing.com/analysis/sanofi-starts-olipudase-alfa-study,-praluent-ok'd-in-japan-200140523",200140523
220999,442515,PFE,Sanofi Inks Deal To Swap Business With Boehringer Ingelheim,opinion,Sanofi  PA SASY    NYSE SNY   announced that it has signed contracts with Boehringer Ingelheim for the strategic transaction initiated in Dec 2015 regarding an exchange of their respective businesses The business swap comprises an exchange of Sanofi s animal health business  Merial  with an enterprise value of  11 4 billion for Boehringer Ingelheim s consumer healthcare  CHC  business worth  6 7 billion  However  the deal does not cover Boehringer Ingelheim s CHC business in China The transaction is expected to close by the year end Benefits for SanofiThe addition of Boehringer Ingelheim s CHC business is expected to strengthen Sanofi s position in several of its categories like Pain Care  Allergy Solutions  Cough   Cold Care  Feminine Care  Digestive Health and Vitamins  and Minerals and Supplements In addition  Boehringer Ingelheim will make a cash payment of  4 7 billion to Sanofi  which is the difference in value of the two businesses  Sales from the CHC business  excluding sales in Venezuela  should amount to approximately  4 9 billion  based on 2015 worldwide sales Considering projected CHC results  share buybacks and potential synergies  Sanofi expects the deal to be neutral to its earnings in 2017 and accretive in subsequent years Notably  Germany will become a key center for Sanofi s CHC business  particularly for the Gastro Intestinal and Cough   Cold categories  These categories are expected to benefit from the strong capabilities of Boehringer Ingelheim s teams Benefits for Boehringer IngelheimBoehringer Ingelheim s animal health business will see its sales more than double to approximately  3 8 billion  based on 2015 worldwide sales The combined portfolios and technology platforms in anti parasitics  vaccines and pharmaceutical specialties will enable the company to enter key growth markets  thereby bringing more value and innovation to customers across the world While Lyon and Toulouse would be key operational centers for Boehringer Ingelheim s animal health business  the company will maintain operations  and R D and manufacturing facilities in Lyon and the production site in Toulouse Considering importance of the U S  market for Merial s business  Boehringer Ingelheim intends to focus on maintaining the momentum of its operations in the country Upon the necessary regulatory clearances  both the companies will become global leaders in two different sectors of the pharmaceutical market Sanofi currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the health care sector are ANI Pharmaceuticals  Inc    NASDAQ ANIP    Retrophin  Inc    NASDAQ RTRX   and Pfizer Inc    NYSE PFE    each sporting a Zacks Rank  1  Strong Buy  Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-06-27,Zacks Investment Research,https://www.investing.com/analysis/sanofi-inks-deal-to-swap-business-with-boehringer-ingelheim-200138472,200138472
221002,442518,PFE,Nymox  NYMX  Stock Up On Positive 7 Year Fexapotide Data ,opinion,Nymox Pharmaceutical Corporation s   NASDAQ NYMX   shares were up 35 2  after the company announced positive results from the seven year  prospective  placebo controlled  double blind study on its lead candidate  fexapotide  NX 1207  The study evaluated fexapotide  in comparison to placebo  in men  n 995  with prostate enlargement  benign prostate hyperplasia BPH  symptoms  Subjects were evaluated thoroughly to exclude any prostate cancer prior to treatment with fexapotide  They were followed for up to seven years  median of five years  after treatment Data from the study demonstrated that men receiving fexapotide revealed a major reduction in the incidence of prostate cancer  compared to placebo  as well as to the known and expected normal incidence of the disease  Data also revealed a statistically significant and very low incidence of 1 3  for prostate cancer We note that Nymox is developing fexapotide in a phase III study for the treatment of BPH and in a phase II study for the treatment of low grade localized prostate cancer We remind investors that earlier this year  the company has announced results from a phase II study   NX03 0040   on fexapotide for the treatment of localized prostate cancer  The study met its pre determined endpoints  There was a significant improvement in cancer progression outcomes in the fexapotide treated patient groups Stocks to Consider Investors interested in the health care sector may consider stocks such as Pfizer Inc    NYSE PFE    ANI Pharmaceuticals  Inc    NASDAQ ANIP   and Retrophin  Inc    NASDAQ RTRX    All these stocks sport a Zacks Rank  1  Strong Buy  Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-06-23,Zacks Investment Research,https://www.investing.com/analysis/nymox-(nymx)-stock-up-on-positive-7-year-fexapotide-data-200137836,200137836
221003,442519,PFE,Retrophin  RTRX  RE 024 Positive In Physician Initiated Study,opinion,Retrophin  Inc    NASDAQ RTRX   announced new data from a physician initiated study on RE 024 for the treatment of pantothenate kinase associated neurodegeneration  PKAN  Data revealed that patients  n 2  treated with RE 024 demonstrated clinically meaningful improvements  followed by stabilization of disease progression over 47 weeks of treatment  The study also showed that patients experienced a gradual improvement in gait and could walk unassisted for short distances within eight weeks of treatment initiation  In addition  RE 024 was found to be safe and well tolerated  Results were presented at the Congress of Parkinson s Disease and Movement Disorders Retrophin is planning to initiate an efficacy study on RE 024 in the second half of 2016 We note that RE 024 enjoys Orphan Drug status in both the U S  and the EU for the treatment of PKAN  The candidate also has Fast Track status for PKAN in the U S PKAN  a rare and life threatening genetic condition  is estimated to affect up to 5 000 individuals around the world  With no treatments approved currently for the disease  the company has significant potential in this area Meanwhile  Retrophin is progressing with other candidates in its pipeline  Currently  the company is conducting a phase II study  DUET  on sparsentan for the treatment of patients with focal segmental glomerulosclerosis  FSGS   Top line data from the DUET study are expected in the third quarter of 2016 Retrophin currently sports a Zacks Rank  1  Strong Buy   Other favorably placed stocks in the health care sector  sharing an equal rank with  Retrophin  include Pfizer Inc    NYSE PFE    ANI Pharmaceuticals  Inc    NASDAQ ANIP   and Bio Blast Pharma Ltd    NASDAQ ORPN   Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-06-24,Zacks Investment Research,https://www.investing.com/analysis/retrophin-(rtrx)-re-024-positive-in-physician-initiated-study-200138017,200138017
221025,442541,PFE,Novartis Reports Positive Data On Biosimilar Candidates,opinion,Novartis AG   NYSE NVS   announced results from two key studies comparing its proposed biosimilar versions of Amgen s  blockbuster drug  Enbrel  etanercept   and Roche s  MabThera  rituximab  to the reference drugs at the Annual European Congress of Rheumatology  EULAR 2016  in London Sandoz  the generic arm of Novartis  reported that both the studies met the primary endpoints of achieving pharmacokinetic  PK  bioequivalence While the biosimilar version of Enbrel demonstrated PK bioequivalence  with no clinically meaningful differences in safety  tolerability and immunogenicity to the reference product in a phase I study  the biosimilar version of MabThera showed PK bioequivalence and similar pharmacodynamics  safety  efficacy and immunogenicity in a phase II study We note that MabThera is approved for the treatment of non Hodgkin s lymphoma  which includes follicular lymphoma and diffuse large B cell lymphoma  chronic lymphocytic leukemia and autoimmune diseases such as rheumatoid arthritis  RA   Sandoz is seeking approval of its biosimilar in all of these indications Meanwhile  Enbrel is approved for moderate to severely active RA  chronic moderate to severe plaque psoriasis in patients who are candidates for systemic therapy or phototherapy  and active psoriatic arthritis  Sandoz is seeking approval for the biosimilar in all of these indications We are impressed by Sandoz s efforts to broaden its biosimilars portfolio  Sandoz currently markets three biosimilars   Omnitrope  a human growth hormone  Binocrit  an erythropoiesis stimulating agent  and Zarxio   in the U S  Backed by its deep pipeline of biosimilars  the company plans to make 10 regulatory filings over the 2015 2017 time frame  of which six applications have already been submitted Sandoz s filing for a biosimilar version of Enbrel was accepted by both the FDA and the EMA for regulatory review in the fourth quarter of 2015   Last month  the EMA accepted Sandoz s Marketing Authorisation Application  MAA  for its proposed biosimilar of MabThera Approval of new drugs  generics and biosimilars  along with the label expansion of existing ones  should bode well for Novartis as it has been facing stiff generic competition for some of its key drugs like Diovan and Gleevec of late  Additionally  its oncology drugs are facing competition from immuno oncology therapies Novartis currently carries a Zacks Rank  4  Sell   Currently  Pfizer  NYSE PFE   is a better ranked stock in the health care sector  with a Zacks Rank  1  Strong Buy  ,2016-06-09,Zacks Investment Research,https://www.investing.com/analysis/novartis-reports-positive-data-on-biosimilar-candidates-200135352,200135352
221026,442542,PFE,Bull Of The Day  Pfizer  PFE ,opinion,"In the current uncertain market environment big pharma stocks like Pfizer  NYSE PFE     are worth a look due to their defensive nature  attractive dividend yields and solid growth opportunities  The company reported excellent results  sending estimates higher and the stock to a Zacks Rank  1  Strong Buy  About the Company
New York based Pfizer  Inc   PFE  is a leading pharmaceutical company in the world  They have a large portfolio of products and medicines that support wellness and prevention  as well as treatment and cures for diseases across a broad range of therapeutic areas  They also have an impressive pipeline of promising new products  Pfizer had two business segments   Innovative Products and Established Products  Strong Q1 Results   Upgraded Guidance
Pfizer  PFE  reported much better than expected results for Q1  They beat both on top and bottom lines and also raised their guidance for the current year   Earnings of  0 67 per share handily beat the Zacks Consensuses Estimate of  0 55 per share  The company has an excellent history of beating estimates  having missed only once in last five years 
Revenues of  13 billion were also ahead of the Zacks Consensus Estimate of  11 9 billion  This was the six consecutive quarter of revenue growth for the company  While some of the newer products did much better than expected  results also benefitted from the easing of currency headwinds 
They now expect EPS in the range of  2 38 to  2 48  above the street consensus of  2 30  Revenue guidance of  51 billion to  53 billion was also better than analysts  estimate of  51 24 billion Betting on Growth
Pfizer had to cancel its proposed deal with Allergan  NYSE AGN pa  that would have created the biggest drug company in the world and significantly lowered the tax rate for the merged entity  in the wake of new rules to restrict US companies merging with overseas firms in order to move their headquarters to low tax countries  They now say they re not planning to pursue another tax inversion merger due to new rules 
But the company continues to look for ways to grow  Last month  they announced plans to acquire Anacor Pharmaceuticals for  5 2 billion  With this acquisition  scheduled to close next quarter  Pfizer will add experimental eczema treatment  crisaborole  to its pipeline 
Last year s acquisition of Hospira has given Pfizer a strong position in the areas of sterile injectable drugs and biosimilars 

The company has also committed a lot of resources towards the development of treatments in the fields of oncology  cardiology  metabolic disorders  neuroscience  immunology  inflammation and vaccines  They believe they can be in leading positions in these areas  
Returning Capital to Shareholders
They continue to reward shareholders through share buybacks and dividends  The current dividend yield is 3 6   The company returned about  13 1 billion to shareholders in the form of dividends and share buybacks in 2015  They executed a new  5 billion accelerated share buyback in March this year 
The Bottom Line 
Pfizer share are currently trading at 14 4 times forward earnings which I think is quite reasonable given their growth potential  In addition to valuation  solid dividend yield and strong growth potential make this stock an excellent pick for long term income focused investors ",2016-06-12,Zacks Investment Research,https://www.investing.com/analysis/bull-of-the-day:-pfizer-(pfe)-200135690,200135690
221031,442547,PFE,ARIAD  ARIA  Presents Phase II Study Data On Cancer Drug,opinion,"ARIAD Pharmaceuticals  Inc    NASDAQ ARIA   presented updated data from a pivotal phase II study  ALTA  on its most advanced pipeline candidate brigatinib  in patients with ALK  non small cell lung cancer  NSCLC  who had experienced disease progression on Pfizer Inc  s   NYSE PFE   Xalkori therapy  Data were presented at the annual meeting of the American Society of Clinical Oncology Results from the study showed that among the patients with a median follow up of 8 3 months  when treated with brigatinib  180 mg   a confirmed objective response  primary endpoint  of 54  was observed  Moreover  the median progression free survival was found to be greater than one year  12 9 months  in the post Xalkori setting  In addition  patients with measurable brain metastases demonstrated a 67  confirmed intracranial objective response rate ARIAD is on track to file a new drug application for brigatinib in the third quarter of 2016  We note that brigatinib has Orphan Drug status in the U S  for the treatment of ALK NSCLC  It also enjoys Breakthrough Therapy status in the U S  for the treatment of patients with ALK NSCLC that is resistant to Xalkori Meanwhile  ARIAD has also initiated the phase III ALTA first line study comparing the efficacy of brigatinib to Xalkori Apart from brigatinib  the only other candidate in the company s pipeline is AP32788  which is in a phase I II study for the treatment of patients with NSCLC with specific mutations in EGFR or HER2 Currently  the only marketed product in ARIAD s portfolio is Iclusig  which is a leukemia drug 
ARIAD is a Zacks Rank  3  Hold  stock  A couple of better ranked stocks in the health care sector are Juniper Pharmaceuticals  Inc    NASDAQ JNP    sporting a Zacks Rank  1  Strong Buy  and Actinium Pharmaceuticals  Inc    NYSE ATNM   carrying a Zacks Rank  2  Buy  ",2016-06-07,Zacks Investment Research,https://www.investing.com/analysis/ariad-(aria)-presents-phase-ii-study-data-on-cancer-drug-200134558,200134558
221048,442564,PFE,Top Stock Picks For The Week Of May 23rd ,opinion,"Pfizer Inc   NYSE PFE   is a research based  global pharmaceutical company that discovers  develops  manufactures  and markets medicines for humans and animals  The Company s diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines  as well as nutritional products and consumer healthcare products  Pfizer s Animal Health business unit discovers  develops and sells products for the prevention and treatment of diseases in livestock and companion animals  It sells its products to wholesalers  distributors  retailers  hospitals  clinics  government agencies  pharmacies  individual provider offices  veterinarians  livestock producers  and grocery and convenience stores  Pfizer Inc  is headquartered in New York  
KB Home  KBH   is a builder of single family homes with domestic operations in several western states  and international operations in France  Domestically  the company builds innovatively designed homes which cater primarily to first time homebuyers  generally in medium sized developments close to major metropolitan areas  Internationally  the company also builds commercial projects and high density residential properties such as condominium complexes ",2016-05-25,Zacks Investment Research,https://www.investing.com/analysis/top-stock-picks-for-the-week-of-may-23rd-200132189,200132189
221056,442572,PFE,The Zacks Analyst Blog Highlights  Medivation  Anacor  Aduro  Trevena And Tetraphase,opinion,"For Immediate Release

	Chicago  IL   May 20  2016   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include   Medivation     Anacor     Aduro     Trevena     and Tetraphase    

	Today  Zacks is promoting its   Buy   stock recommendations    

Here are highlights from Thursday s Analyst Blog  

Biotech Stock Roundup

	Acquisitions and deals continue to make news in the biotech sector  Pfizer  NYSE PFE   which is rumored to be interested in acquiring Medivation     announced that it will be acquiring Anacor     for about  5 2 billion  Meanwhile  Sanofi  PA SASY  remains committed to acquiring Medivation 
	Apart from this  companies like Aduro    and Trevena     came out with disappointing data from mid stage studies Recap of the Week s Most Important Stories
	1  Anacor s shares shot up more than 57  with the company agreeing to be acquired by Pfizer for approximately  5 2 billion  The acquisition is slated to close in the third quarter   Anacor has a late stage eczema treatment currently under FDA review with a response from the agency expected by Jan 7  2017  Read more     
	2  Aduro suffered a setback with the company failing to hit the primary endpoint in a mid stage study being conducted on its experimental pancreatic cancer immunotherapy regimen of CRS 207 and GVAX Pancreas  Read more     
	3  Trevena also came out with disappointing news on the development front with the company saying that TRV027 failed to meet the primary as well as secondary endpoints in a mid stage study for acute heart failure  AHF   The company has decided to shift focus to its lead pipeline candidate  oliceridine  which is currently in late stage development for pain management and earlier stage programs  Read more     
	4  Tetraphase s    shares were down following an update regarding the regulatory path for its lead candidate  eravacycline  an antibiotic  The company said that the FDA has asked it to provide data from an additional phase III study  The company will be conducting two late stage studies  Top line data from the pivotal complicated intra abdominal infections  cIAI  study are expected in the fourth quarter of 2017 assuming the study commences in the fourth quarter of 2016 
	The other study will be conducted in patients with complicated urinary tract infections  cUTI  to support label expansion 
	5  French drugmaker  Sanofi  remains committed to acquiring Medivation  Last week  the company filed for premerger notification regarding its intention to acquire Medivation  Sanofi intends to acquire Medivation for  52 50 per share  approximately  9 3 billion  

	Today  Zacks is promoting its   Buy   stock recommendations   

About Zacks Equity Research

	Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term 

	Continuous coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons 

	Zacks  Profit from the Pros  e mail newsletter provides highlights of the latest analysis from Zacks Equity Research   

About Zacks 

	Zacks com is a property of Zacks Investment Research  Inc   which was formed in 1978  The later formation of the Zacks Rank  a proprietary stock picking system  continues to outperform the market by nearly a 3 to 1 margin  The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter  Profit from the Pros  In short  it s your steady flow of Profitable ideas GUARANTEED to be worth your time   

	Follow us on Twitter  

	Join us on Facebook 

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Media Contact
	Zacks Investment Research

	800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2016-05-19,Zacks Investment Research,"https://www.investing.com/analysis/the-zacks-analyst-blog-highlights:-medivation,-anacor,-aduro,-trevena-and-tetraphase-200131215",200131215
221064,442580,PFE,Anacor Pharmaceuticals Stock Shares Skyrocket On Pfizer Buyout,opinion,"Anacor Pharmaceuticals Inc  NASDAQ ANAC 
Anacor Pharmaceuticals News   Technicals

On Monday morning before the market opened  shares of Anacor Pharmaceutical  ANAC  blasted off on news that they will be acquired by Pfizer Inc   NYSE PFE  in a  5 2 billion cash deal  This equates to an ANAC share value of  92 25 after closing Friday at  64 03  a 44  jump in value  This should add great value to Pfizer s bottom line in the long run and is estimated it will start adding to earnings by 2018 with the deal closing in the third quarter of this year  ANAC is known for their eczema treatment  Crisaborole  which has performed favorably in clinical studies so far with the Food and Drug Administration  Before the buyout news  analysts had an average price target of  38 43 
Looking at the chart you will see that shares have been beaten down over the past year after peaking in the summer of 2015 at  156 93  Shares have since trended lower as shorts were able to reclaim the 200 day moving average in January with share price continuing lower before finding a base at the  60 level  a 61  tumble value  Shares are looking to pop back up around their 200 day moving average that is currently sitting at  97 36 and should stay around that price range as the buy out terms are already being priced in  There probably won t be much opportunity to trade this stock as buyouts tend to hover around the prices determined in the deal but if you re looking for a long term value play then you may want to look at Pfizer as this should help boost their bottom line in the long run which will increase the share price 
Comments Regarding Buyout

 Anacor will be a strong fit with Pfizer s innovative business  further supporting our strategic focus on Inflammation and Immunology  and is expected to enhance near term revenue growth for the innovative business   said Albert Bourla  president of Pfizer s global innovative pharma and vaccines  oncology and consumer healthcare businesses    

ANAC Profile
Anacor Pharmaceuticals  Inc  is a biopharmaceutical company  The Company is focused on discovering  developing and commercializing small molecule therapeutics derived from its boron chemistry platform  Its lead product development candidate is crisaborole topical ointment  approximately 2   a non steroidal topical anti inflammatory phosphodiesterase 4  PDE 4  inhibitor in development for the treatment of mild to moderate atopic dermatitis and psoriasis  Its product  KERYDIN  tavaborole  topical solution  approximately 5   is an oxaborole antifungal approved by the United States Food and Drug Administration  FDA  for the topical treatment of onychomycosis of the toenails  It also has a pipeline of other internally discovered topical and systemic boron based compounds in early stages of research and development  which include AN3365  Its compound  AN5568  SCYX 7158   is licensed to Drugs for Neglected Diseases initiative  DNDi  for the treatment of human African trypanosomiasis    ",2016-05-16,Warrior Trading,https://www.investing.com/analysis/anacor-pharmaceuticals-$anac-stock-shares-skyrocket-on-pfizer-buyout-200130112,200130112
221065,442581,PFE,Anacor Pharmaceuticals Stock Climbs After Acquisition Announcement,opinion,"Anacor Pharmaceuticals Inc  NASDAQ ANAC    Pfizer Inc   NYSE PFE  
Anacor Pharmaceuticals is having an absolutely incredible start to the trading day today  and for good reason  Early this morning  the company announced that it would be acquired by Pfizer  Today  we ll talk about the details of the acquisition  how the market reacted to the news  and what we can expect to see from ANAC moving forward  So  let s get right to it 
ANAC To Be Acquired By PFE
As mentioned above  it was announced early this morning that Anacor Pharmaceuticals will be acquired by Pfizer under a definitive merger agreement that was entered recently  Under the terms of the agreement  the deal will take place as a 100  cash transaction  PFE will be purchasing all outstanding shares of ANAC at a value of  99 25 per share  This brings the total acquisition value to about  5 2 billion  This is great news for both companies  For ANAC  the company will be receiving a heavy premium and on the PFE side  they will gain access to crisaborole  the flagship product at Anacor Pharmaceuticals  In a statement  Albert Bourla  Group President of Pfizer s Global Innovative Pharma and Global Vaccines  Oncology and Consumer Healthcare Businesses had the following to offer   

 We believe the acquisition of Anacor represents an attractive opportunity to address a significant unmet medical need for a large patient population with mild to moderate atopic dermatitis  which currently has few safe topical treatments available    Crisaborole is a differentiated asset with compelling clinical data that  if approved  has the potential to be an important first line treatment option for these patients and the physicians who treat them    Anacor will be a strong fit with Pfizer s innovative business  further supporting our strategic focus on inflammation and immunology  and is expected to enhance near term revenue growth for the innovative business  Our dedicated inflammation and immunology group has strong existing in market franchises with Enbrel and Xeljanz  as well as a robust mid stage pipeline  and this acquisition has the potential to add a near term U S  product launch  We believe we are well positioned to maximize crisaborole s commercial potential through our strong relationships with pediatricians and primary care physicians  

How The Market Reacted To The News
As investors  we know that the news moves the market  Any time there is positive news released with regard to a publicly traded company  we can expect to see gains in the value of the stock associated with the news  Not to mention  few things get investors excited quite as much as mergers and acquisitions  All in all  the news released with regard to ANAC was overwhelmingly positive  As a result  the stock is gaining big in the market today  Currently  10 05   the stock is trading at  98 95 per share after a gain of  34 92 per share or 54 54  thus far today 
What We Can Expect To See Moving Forward
Moving forward  I am expecting to see bullish activity out of both ANAC and PFE  The reality is that the acquisition is overwhelmingly positive for both  Soon  ANAC will be purchased at a rate of  99 25 per share  giving the company s stock a big boost  On the PFE side of the equation  the company will gain access to a treatment that will likely prove to be overwhelmingly profitable  All in all  this is a win win for both parties involved 
What Do You Think 
Is this acquisition good news for ANAC and PFE investors  Let us know your opinion in the comments below ",2016-05-16,Joshua Rodriguez,https://www.investing.com/analysis/anacor-pharmaceuticals-(anac)-stock-climbs-after-acquisition-announcemen-200130121,200130121
221066,442582,PFE,Anacor Pharmaceuticals Stock Rockets Following News Of Pfizer Purchase,opinion,"Anacor Pharmaceuticals Inc  NASDAQ ANAC 
Anacor shares have risen an impressive 56  following news that Pfizer Inc  NYSE PFE N  is buying the company in   to acquire an eczema ointment  Under terms of the deal  Pfizer will pay  99 25 for each outstanding share 
Anacor Pfizer Deal

Anacor stock had fallen 43 percent this year to Friday s close  yet the news of the impending acquisition by Pfizer has produced a remarkable volte face  The swing in direction corresponds to a 60  premium as compared to last Monday s closing price of  62 55 for Anacor s stock  The deal between the drug giant and Anacor should be completed in the third quarter of 2016  Pfizer anticipates the agreement will entail slightly reduced adjusted earnings per share in 2017  yet should add to adjusted EPS in 2018  The Boards of Directors of both companies have unanimously approved the transaction  The equity value of the Anacor deal is  4 45 billion  based on the company s outstanding fully diluted shares as of March 31  Pfizer said it believed crisaborole had the potential to reach or exceed peak sales of  2 billion 
 We believe the acquisition of Anacor represents an attractive opportunity to address a significant unmet medical need for a large patient population with mild to moderate atopic dermatitis  which currently has few safe topical treatments available   said Albert Bourla  president of Pfizer s global innovative pharma and vaccines  oncology and consumer healthcare businesses  Mr  Bourla added that  Anacor will be a strong fit with Pfizer s innovative business  further supporting our strategic focus on Inflammation and Immunology  
Innovative Eczema Unguent
The treatment Pfizer was so zealous to obtain is an eczema treatment  crisaborole  which has achieved statistically significant results in late stage studies with the Food and Drug Administration  In the past 15 years  there have been no new molecules approved for eczema   or atopic dermatitis   a common  relapsing  inflammatory skin disorder that affects 18 25 million people in the United States alone   topical ointment  is a non steroidal topical anti inflammatory PDE 4 inhibitor for the potential treatment of mild to moderate atopic dermatitis  Crisaborole is to reduce the production of pro inflammatory cytokines thought to cause the signs and symptoms of atopic dermatitis  In a long term safety study  crisaborole was found to be well tolerated  In March 2016  the FDA accepted Anacor s New Drug Application for review  The Prescription Drug User Fee Act goal date for the completion of the FDA s review is January 7  2017 
About ANACOR
Anacor Pharmaceuticals is a biopharmaceutical company focused on discovering  developing and commercializing novel small molecule therapeutics  Anacor s first approved product  KERYDIN   tavaborole  topical solution  5   is an oxaborole antifungal approved by the U S  FDA in July 2014 for the topical treatment of onychomycosis of the toenails  Sandoz Inc   a Novartis company  currently distributes and commercializes KERYDIN in the United States  Beyond KERYDIN and crisaborole  Anacor has discovered three investigational compounds that it has out licensed for further development  Anacor also has a pipeline of other internally discovered topical and systemic boron based compounds in early stages of research and development ",2016-05-17,Warrior Trading,https://www.investing.com/analysis/anacor-pharmaceuticals-$anac-stock-stock-rockets-following-news-of-p-200130398,200130398
221081,442597,PFE,Pfizer  PFE  Beats On Q1 Earnings And Revenues,opinion,Pfizer Inc    NYSE PFE   is one of the most well known names in the pharmaceutical sector not just for its medicines and vaccines but also for its consumer healthcare products  This New York based company is well known for products like Prevnar  Lyrica  Lipitor and Celebrex among others However  like many of its peers  PFE is facing generic competition and pricing pressure for several products like Lipitor  Norvasc  Protonix  Camptosar  Celebrex and Zoloft  The influx of generic competition will not only put downward pressure on the company s pricing  it will also result in gross margins contracting In this scenario  investor focus remains on late stage pipeline candidates and their commercial potential and performance of new products apart from the usual top and bottom line numbers  Pfizer is also looking to strengthen its portfolio through the acquisition of Hospira  NYSE HSP  PFE has a pretty good earnings track record with the company delivering positive earnings surprises in each of the last four quarters with an average surprise of 7 84  Currently  PFE has a Zacks Rank  3  Hold   but that could definitely change following the company s earnings report which was just released  We have highlighted some of the key stats from this just revealed announcement below Earnings Beat  PFE beat on first quarter earnings which came in at 67 cents while our consensus called for EPS of 55 cents Revenue Beat  Revenues were also well above expectations  Pfizer posted revenues of  13 005 billion  compared to our consensus estimate of  11 971 billion  Hospira boosted first quarter revenues by  1 199 billion  Unfavorable currency movement cut Pfizer s first quarter revenues by 7    729 million  Raises Guidance  Pfizer now expects to earn  2 38    2 48 per share on revenues of  51 billion    53 billion  The company had previously guided towards earnings of  2 20    2 30 per share on revenues of  49 billion    51 billion in 2016 The Zacks Consensus Estimate for earnings and revenues are currently  2 29 per share and  51 260 billion  respectively Pre Market Trading  Pfizer s shares were up 3 05  in pre market trading on the better than expected results and raised outlook Check back later for our full write up on this PFE earnings report Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-05-03,Zacks Investment Research,https://www.investing.com/analysis/pfizer-(pfe)-beats-on-q1-earnings-and-revenues-200127563,200127563
221086,442602,PFE,Will The Allergan Fallout Impact Pfizer s Earnings ,opinion,"Pfizer Inc   NYSE PFE  Health Care   Pharmaceuticals   Reports May 3  Before Market Opens
Key Takeaways
The Estimize consensus is calling for earnings per share of  0 56 on  11 99 billion in revenue  1 cent higher than Wall Street on the bottom line and right in line on top
The biggest news from Pfizer this quarter has been the scrapped deal with Allergan  NYSE AGN pa  
Pfizer faces meaningful short term threats from mass genericization of key products and ongoing currency headwinds
What are you expecting for PFE  
Just weeks after the collapse of the largest deal in American history  Pfizer  PFE  is scheduled to report first quarter earnings  The deal between Pfizer and Allergan was recently scratched after new tax reforms made the takeover no longer beneficial  The fallout of the merger should have no bearing on earnings this quarter but disturbs future guidance and the psyche of investors 
For Q1  the Estimize consensus is calling for earnings per share of  0 56 on  11 99 billion in revenue  1 cent higher than Wall Street on the bottom line and right in line on top  Compared to a year earlier  profits are predicted to increase 9  while sales could rise 11   Expected growth this quarter is largely consistent with the past few quarters in which Pfizer topped expectations in 4 consecutive quarters 
Unfortunately the stock has only recently begun to trend positively  Shares are now up 8  over the last 3 months and nearly 9  in the last 30 days  During earnings season however  the stock tends to remain relatively flat 

Clearly the biggest news from Pfizer this quarter has been the scrapped deal with Allergan  The deal which was valued at over  150 billion was intended to give Pfizer a home in tax friendly Ireland but also expand its already extensive pipeline of branded products  Despite the flopped deal  Pfizer should be just fine moving forward  The company has aggressively cut costs  expanded its pipeline and signed new licensing deals to meet or beat expectations 
Within its current product suite  Lyrica has seen the most robust growth with no signs of waning  Meanwhile  Pfizer has a deep pipeline of products pending FDA approval or on the verge of hitting the market  Last quarter  the company reported 30 phase III projects to meet the needs of various conditions 
Due to the nature of pharmaceuticals  Pfizer is constantly facing threats from all sides  Genericization and currency headwinds continue to pose a risk to top line growth  Pfizer expects both of these issues to impact revenue by nearly  5 billion in fiscal 2016  Genericization has lost the company exclusive rights to key products including Liptor and Zoloft  Any pipeline setbacks would be a huge blow moving forward  That said  the most important thing to watch this Tuesday will be future guidance  and any mention of the impact of the failed Allergan deal 
Do you think PFE can beat estimates ",2016-05-03,Estimize,https://www.investing.com/analysis/will-the-allergan-fallout-impact-pfizers-earnings-this-quarter-200127414,200127414
221091,442607,PFE,XOMA  Here s Why We re Seeing Gains,opinion,"XOMA Corporation  NASDAQ XOMA  is having an incredibly strong day in the market after reporting exceptional earnings after the closing bell yesterday  Here s what we saw from the report   
Earnings Per Share   In terms of earnings per share  XOMA produced well ahead of expectations  In the fourth quarter analysts expected that the company would produce earnings in the amount of  0 15 per share  However  they actually reported revenue in the amount of  0 21 per share  well ahead of analyst expectations 
Revenue   While earnings was overwhelmingly positive  XOMA posted one of the strongest revenue beats I ve seen ever  According to The Street  the company was expected to produce revenue in the amount of  4 01 million  However  in the quarter  the company actually produced revenue in the amount of  48 18 million  more than 12 times expectations 
As you can see from the data above  the earnings release was overwhelmingly positive  In a statement  the company had the following to say with regard to the incredible results from the quarter 

The increase in full year and fourth quarter 2015 revenues was due primarily to our licensing activity in the fourth quarter  including a  37 million upfront payment from Novartis  a  5 million upfront payment from Novo Nordisk  CO NOVOb  and a  3 8 million payment from Pfizer  NYSE PFE  

The CEO of XOMA  John Varian followed up with the statement below 

The transformation we initiated in the third quarter of last year   and now have completed in less than six months   was considerable in its scale and complexity  but essential to position XOMA to deliver our promising portfolio of endocrine assets   

How The Market Reacted To The News
As investors  we know that the news moves the market  So  it s no surprise that news of an overwhelmingly positive earnings report from XOMA would move the needle for the stock in a big way  Currently  11 12   the stock is trading at  0 93 per share after a gain of  0 04 per share or 5 06  thus far today 
What We Can Expect To See Moving Forward
Overall  I have a relatively bullish opinion of what we can expect to see from XOMA moving forward  First and foremost  I m incredibly impressed with the partners the company has been able to bring on board over the past few months  Bringing in some of the largest players on the biotechnology field will likely lead to incredible improvements in XOMA s business as a whole  On top of that  I like what I m seeing with regard to the pipeline the company currently has  At the moment  they have 3 preclinical candidates as well as one candidate in the end of Phase 1 and one candidate in the midst of Phase 2 testing  While I am a bit concerned about the company s cash flow  I believe that the positive aspects of the stock largely outweigh anything negative there is to say ",2016-03-10,Joshua Rodriguez,https://www.investing.com/analysis/xoma-corp-(xoma)-stock:-heres-why-were-seeing-gains!-200121160,200121160
221092,442608,PFE,Chinese Data Lifts Europe Oil Rebounds While FOMC Under Focus Pfizer,opinion,"European markets are higher today despite the fact that Greece is dragged back in the headlines by the IMF  Investors are optimistic this morning and willing to move on after a heavy sell off  which took place last night over on Wall Street  Thanks to the Chinese Caxin services PMI number  it has assured the markets that there is hope that the Chinese economy will bounce back  The number came in ahead of expectations with a reading of 52 2 compared to a forecast of 51 4  Although  over in Japan  the expectations are building up that the Bank of Japan is not going to sit tight and let the strength of the Japanese currency undo all of their easing efforts  It is expected that the bank will intervene if we do fall below the 110 mark for the USD JPY pair 
Warnings have started to creep in about global economic growth with Christine Laggard  IMF chief  warning yesterday that she is not pleased with the reform work carried out by various countries  Reforms have been the cornerstone of her agenda and she has echoed this message over and over  However  it is the most arduous strategy to adopt for politicians  seeing that it cuts into their own flesh with respect to their political party s popularity 
The economic data out of Europe clearly highlights how meagre the performance has been in relation to reforms  especially in countries such as France and Italy  The services PMI fell back into contraction territory in France  and the adverse factory order data for Germany occupied attitudes yesterday  Expectations are not sky high today for Germany when its industrial production will hit the wire  The forecast number of  1 8  is well below the previous reading of 3 3   It may get ugly if the actual number falls below the forecast and it could deflate the euro s rally even further 
After another negative day  oil prices are looking a little firmer today as traders are willing to believe somewhat the comments coming from Kuwait  The country issued a statement which wasn t popular initially  but in bad times any good news is appreciated  Kuwait anticipates that a production freeze could take place when OPEC members meet and this is helping oil prices today  Although  oil buyers will not want to rely on such comments if purchasing over the coming days  The biggest producer within the OPEC cartel  Saudi Arabia  has clearly stated their position with respect to a production freeze  The Saudis are not willing to freeze oil production unless Iran follows suit and adopts a similar strategy 
Back in the US  it is all about the FOMC  with everyone eagerly awaiting for what they have to say  The FOMC members need to put on a united front with a clear message that confirms that they are on the same page  It is bizarre for the FOMC members not to parade their solidarity  Showing a distorted front and issuing their own agenda will only make for a muddy message 
Traders will benchmark the statement with respect to when the next rate hike could be and if the tone amid Fed members is still dovish  Certainly the Fed chair  Janet Yellen  is in no rush to make any hasty decree now  for that could result in her paying the price later  But some members on her committee do not agree with her state of mind 
In terms of stock news  Pfizer  NYSE PFE  is calling it a day with respect to their merger with Allergan  NYSE AGN pa   Allergan shareholders must be very bitter today when they were being offered the price which was substantially higher than their current market price  Nonetheless  for Pfizer the benefits audibly outweigh costs under the new law 
In terms of stock news  Pfizer is calling it a day with respect to their merger with Allergan  Allergan shareholders must be very bitter today when they were being offered the price which was substantially higher than their current market price  Nonetheless  for Pfizer the benefits audibly outweigh costs under the new law 
This is another victory for the Obama administration to stop the firms use the Smart Gates for tax avoidance  The fail merger is also a wake up call for new firms who were envisaging of using the similar strategy to fly to the tax heaven country  The new rules created by the Treasury are also going to make an impact on the banks which used to secure large sums of fees under these merger strategies  Shares for both firms have another day of volatile session ahead of them as investors will digest this news 
by Naeem Aslam",2016-04-06,AvaTrade,https://www.investing.com/analysis/chinese-data-lifts-europe-oil-rebounds-while-fomc-under-focus-pfizer-200124132,200124132
221093,442609,PFE,Yen Bull Eyes  105,opinion,"Wednesday April 6  Five things the markets are talking about
Yesterday  global equities came under renewed pressure with investors having a plethora of reasons why to choose from  ranging from an overbought stock market  suspect earnings reports  weakening oil prices  U S  treasury department stunning the Street with new inversion rules  weaker German factory orders  a strengthening yen and an IMF Chief insisting that more government action is required to combat global  sluggishness  
Nevertheless  today the market will want to be taking its cue from the Federal Open Market Committee  FOMC  minutes  The fixed income market will be hoping to get a better idea on the timing of the next Fed rate hike  While the rest of us want a clearer understanding of what prompted the Fed to reduce the number of forecasted  dot plot  rate hikes this year from 4 to 2 in a matter of months 
1  Japanese officials clash over state of economy
With a matter weeks to go to the expected decision on second round of consumption tax hike  Japan s government continue to debate just how bad domestic current conditions are to justify postponing the increase 
Last week PM Abe indicated that his government would raise the tax rate  unless there is a Lehman type event   Overnight  opposition speakers suggest that current consumption is at its  worst level since the Lehman crisis  
The rest of the market continues to focus on the strength of the yen  outright  trading atop its November 2014 highs  110 34  and wondering how aggressive the BoJ is expected to be 
The market has been record short yen futures  and the latest dollar move has many speculating some form of intervention by the Government or BoJ  Technical analysts have eyed  110 as that breaking point 
However  according to Mr   Yen   former Minister of Finance Eisuke Sakakibara  was in charge of currency intervention   he remains more bullish on his own currency  seeing it rallying to  105 in H2 as the outlook for the world economy worsens  He said that  a climb to  105 only then is likely to prompt Japanese officials to intervene verbally to try and talk it down  while gains past  100 could see physical intervention to weaken it  

2  Global yields plummet as flight to quality dominates
Rising demand for haven assets yesterday again pushed down government debt yields 
German Bund fell to their lowest yield level in a year  trading atop of zero interest   0 09    U S  10 s reached their weakest return in two months at  1 72   while U K gilt benchmark 10 years yielded  1 34  
Downbeat German factory orders coupled with U K s Brexit referendum concerns has investors seeking sanctuary in the  big  dollar and like minded stateside assets  Other safe haven instruments  particularly gold   1 226  and yen   110 34   have also found favour with investors who are trying to preserve capital 
Government bond yields have naturally fallen sharply this year as investors continue to struggle with a world of low growth  subdued inflation  falling productivity and a high level of debt globally  The ECB and BoJ have already generated a growing pool of negative yield government bonds  intensifying investors  struggle to obtain income  JGB s continue to trade below zero   Even the Fed s cautious stance towards rate normalization has reduced the risk of U S  bond yields backing up aggressively any time soon 

3  Inversion rules stun Wall Street
The U S Treasury implemented tough new rules in Q4 to curb inversion deals   a U S company  reincorporates  overseas following the purchase of a foreign company in an attempt to benefit from lower overseas tax rates 
This week  the U S Treasury has released another set of regulations aimed at  tax inversions  that look to prevent foreign companies from acquiring multiple U S companies over a short period of time  The new rules suggest there now will be a three year limit on foreign companies acquiring U S assets to avoid ownership requirements for a later inversions deal 
Yesterday s announcement has managed to scuttle the world s largest ever health care acquisition   U S pharma giant Pfizer  NYSE PFE   160b agreement to acquire  59  of Irish firm Allergan  NYSE AGN pa  in an inversion deal  The deal would have given the New York based company a foreign address and a lower tax rate 
The break up of the deal will cost Pfizer a supposed cool   400m 

4  Equities suspend slide on oil inventory surprise
A rebound in world crude prices overnight  WTI  37 03  Brent  38 79  is helping to slow down this months global equity slide  Energy markets remain cautious after yesterday s API inventories recorded the first draw down   4 3m vs   2 6m prior  in nearly two months  Also aiding oil prices is Ecuador s President indicating that Latin America oil producers will meet on Apr 8th to discuss an oil output freeze 
To date  crude bulls have been focusing most of their attention on the April 17 Doha production meeting  Kuwait continues to express their confidence that global producers may agree to limit crude output and this despite tensions between Iran and Saudi Arabia 
Data on U S  oil stocks will be closely watched this morning   Official EIA data is due at 10 30 EDT 

5  Federal Open Market Committee  FOMC  minutes
The release of the March FOMC minutes at 02 00pm EDT today could renew pressure on the  mighty  dollar  The market is hoping to get a better idea on U S rate normalization timing   last week investors were sideswiped by Fed Chair s Yellen s overtly  dovish  comments 
Expect fixed income dealers to be seeking out the comments from Fed Kansas City President Esther George   she was the only dissenter on the vote to hold interest rates unchanged ",2016-04-06,Dean Popplewell,https://www.investing.com/analysis/yen-bull-eyes-105-200124166,200124166
221094,442610,PFE,iFOREX Daily Analysis   April 07  2016,opinion,"The dollar fell against most major currencies on Wednesday  pressured by minutes of the U S  Federal Reserve s meeting last month that urged for caution about future interest rate hikes  Minutes from the Fed s March policy meeting suggested that the central bank appears unlikely to raise interest rates before June due to concerns over the limited ability to tackle a global economic slowdown  The minutes showed debate over whether they might increase rates in April with  a number  of policymakers arguing that headwinds to growth would probably persist  and many urging caution about raising rates  At the meeting  the FOMC voted 9 1 to hold its benchmark Federal Funds Rate at a targeted range between 0 25 and 0 50   In contrast with the Fed  Bank of Japan policymakers will likely debate the possibility of easing further at their April 27 28 meeting  as recently downbeat economic data has failed to reinforce their expectations that a moderate economic recovery would lift inflation towards their 2 percent target  Today  The U K  is to release data on house price inflation  the European Central Bank is to publish the minutes of its latest meeting and the U S  is to publish the weekly report on initial jobless claims 
EUR USD
The euro posted a slight increase against the dollar on Wednesday after the minutes from the Federal Reserve s March meeting on Wednesday afternoon which showed that the U S  central bank  was divided on whether it will be appropriate to raise short term interest rates at the end of this month  The currency pair traded in a tight range between 1 1327 and 1 1431  before settling 0 14  higher for the session  When the Federal Open Market Committee last met in mid March  several members wanted to consider the possibility of raising interest rates at the meeting  while leaving a potential rate hike on the table when they meet again on April 26 27  The majority of the members expressed caution at raising rates prematurely due to concerns that global economic headwinds will only subside slowly in the near future  Today  the European Central Bank is to publish the minutes of its latest meeting and the U S  is to publish the weekly report on initial jobless claims 
Pivot  1 1365Support  1 1365 1 1325 1 131Resistance  1 1435 1 146 1 148Scenario 1  long positions above 1 1365 with targets   1 1435   1 1460 in extension Scenario 2  below 1 1365 look for further downside with 1 1325   1 1310 as targets Comment  the RSI is mixed to bullish 
Gold
Gold posted a slight drop yesterday  erasing some of its gains from the previous session s rise  as investors traded cautiously  Gold is coming off its strongest quarter in three decades  where it gained 15  as investors shifted their attention into the safe haven asset due to rising concerns of a China driven global economic slowdown  In its last meeting  the FOMC lowered its long term interest rate and inflation forecasts reducing the number of projected rate hikes this year from four to two thus providing some support to the metal  In the last FOMC meeting  members voted 9 1 to hold interest rates at a targeted range between 0 25 and 0 50   For today  the focus is shifted on the jobless claims report from the U S 
Pivot  1232Support  1218 5 1214 5 1208 5Resistance  1232 1238 1243Scenario 1  short positions below 1232 00 with targets   1218 50   1214 50 in extension Scenario 2  above 1232 00 look for further upside with 1238 50   1243 00 as targets Comment  the upward potential is likely to be limited by the resistance at 1232 00 
WTI Oil
Crude oil prices gained by more than 5  on Wednesday  rebounding from 1 month lows  as inventories posted their biggest weekly decline last week since January  temporarily easing concerns related to the excessive supply glut on domestic energy markets  On Wednesday morning  the U S  Energy Department s Energy Information Administration  EIA  said in its Weekly Petroleum Status Report that crude inventories nationwide decreased by 4 94 million barrels for the week ending on April 1  falling sharply below consensus estimates of a build of 2 85 million barrels  However  at 529 9 million barrels  U S  crude oil inventories are still at historically high levels for this time of year  Oil prices are expected to remain in a holding pattern heading into a highly anticipated meeting in Doha on April 17  when Russia  Saudi Arabia and two other OPEC producers could freeze production at their respective levels from January 
Pivot  37 16Support  37 16 36 5 35 88Resistance  38 39 39 39 85Scenario 1  long positions above 37 16 with targets   38 39   39 00 in extension Scenario 2  below 37 16 look for further downside with 36 50   35 88 as targets Comment  the RSI is mixed with a bullish bias 
US 500
U S  stocks jumped on Wednesday  supported by gains in healthcare shares after the collapse of the  160 billion merger of Pfizer and Allergan  NYSE AGN pa  and by a rise in energy shares  Further support came from the minutes from the most recent Federal Reserve meeting which suggested that the Fed was unlikely to raise interest rates before June  U S  drugmaker Pfizer Inc  NYSE PFE  and Ireland based Allergan Plc called off their merger after new U S  Treasury rules aimed at curbing tax cutting inversion deals  The Dow Jones industrial average was up 0 64 percent  the S P 500 gained 1 05 percent and the Nasdaq Composite added 1 59 percent  The S P had rallied 13 percent in the previous seven weeks  thanks to stabilizing oil prices and reduced concerns about China s economy  Investors will soon turn their attention to first quarter S P 500 earnings  which are estimated to be down 7 4 percent from a year ago  according to Thomson Reuters data 
    Pivot  2020  Support  2020 1970 1950  Resistance  2080 2100 2130    Scenario 1  long positions above 2020 00 with targets   2080 00   2100 00 in extension   Scenario 2  below 2020 00 look for further downside with 1970 00   1950 00 as targets   Comment  the RSI has struck against a major resistance around 70  and is reversing down  But the 20 day simple moving average is trending higher and plays a suppport role ",2016-04-07,iFOREX,"https://www.investing.com/analysis/iforex-daily-analysis-:-april-07,-2016-200124283",200124283
221095,442611,PFE,Oil Gains  FTSE Oscillates 6200,opinion,"The FOMC minutes revealed some hawkish opposition among the members  but the majority preferred to sit on the safe  dovish side of the bench  This was not the case for Bullard  who insisted that the FOMC has reserved rights to move at any meeting  On the flip side  the majority of officials wanted to avoid sending wrong messages to the market  The dominant force in the Fed s policy making is volatility and global risks against the domestic risks of inflation and employment  In this context  the market gives nearly no probability for an April action from the Fed and thus the market now looks to sell the greenback for now 
Other drivers abound in the FX space  the pound is vulnerable to rising Brexit shenanigans but remains for now above the  1 40 level  Against the euro  it looks even more shaky with the 0 81 level already breached 
Bloomberg reported that if Britain decides to leave the European Union   a corner of the credit market may depart with it and European banks could be left having to replace as much as 108 billion euros   123 billion  of securities   JP Morgan CEO Dimon warned against the pending risks  saying that even in the best case scenario  years of uncertainty could be ahead of us 
The focus later this afternoon will be trained on Mario Draghi  Monetary policy has driven yields on government to record lows but inflation remains an issue  Likewise the recent volatility in equity markets has unnerved investors and the expected spill over effects of QE has not benefited European indices all that much 
A divided Fed for sure but investors seem to have taken the minutes as positive for risk assets  The big 4 5m barrel draws in oil inventory data from both the API and EIA yesterday was the real precursor to upside action though  As stated many times this year  equities are at the mercy of oil prices so any positive sign that the supply glut is diminishing is taken as a beacon of light  We still have the April meeting in Doha to contend with so we can still expect a degree of choppiness in the oil market in the run up that will no doubt make its mark on risk sentiment 
Oil companies are clearly benefiting from this short term change of fortunes 
Shell  LON RDSa    1 26  
BP  LON BP    0 84  
A number of companies trade ex div this morning  Lloyds  LON LLOY    1 97    Aviva  LON AV    1 92    Pearson  LON PSON    6 62    GKN  LON GKN    0 74    St  James s Place PLC  LON SJP    0 66    Rexam PLC  LON REX    1 57   and Taylor Wimpey  LON TW    0 67    This drags 8 points from the index 
Mining stocks are benefitting from the lift higher in commodity prices  The FTSE has challenged the 6200 level already but seems reluctant to push higher for now 
Astrazeneca  LON AZN   2 51   the M A watch continues and now with the Allergan  NYSE AGN pa  deal off the table  many will speculate as to what Pfizer  NYSE PFE  might do next  A possible interest in Astrazeneca or GSK is now front and centre for those wanting to front run any approach  The thing is  Pfizer already tried to approach Astra a couple of years ago to no avail 
Marks and Spencer Group PLC  LON MKS    1 81   Sales in the clothing and home arm fell by 2 7  on a like for like basis in the 13 weeks to 26 March  On food  M S said that like for like sales were unchanged  but that thanks to the opening of 80 new stores during the year it had seen its market share grow to 4 3  
J Sainsbury PLC  LON SBRY    1 64   raised to outperform at Credit Suisse  SIX CSGN  
We call the Dow 30 points lower to 17685 ",2016-04-07,Ipek Ozkardeskaya,https://www.investing.com/analysis/oil-gains.-ftse-oscillates-6200-200124307,200124307
221102,442618,PFE,How Are S P 500 Earnings Looking For Full Year 2016  ,opinion,"Meant to publish this earlier this week 
Which sectors have improved in terms of Q4  15 earnings growth since Jan 1  16  
 First column is expected Q4  15 earnings growth as of Feb 9  the second data set is expected Q4  15 earnings growth as of Jan 1  16  
Data courtesy of Thomson Reuters 
Cons Disc   9 6    8 5 
Cons Spls   1 3    2 1 
Energy   75 3   67 7 
Financials   2    10 9 
Health Care   8 5    4 3 
Industrials   1 8    1 8 
Basic Mat   18 3    23 7 
Technology   0 3    4 
Telco   18 9    18 1 
Utilities   9 3    6 3 
SP 500   4 1    3 7 
The biggest improvement is Technology  albeit off low expectations  Health care is solid too  showing a 100  increase in actual versus expected  but it is clear the political climate is spooking investors  Look at Pfizer  N PFE  and large cap pharma for a safer way to play Health Care in 2016 s market  Biotech is finally getting interesting from a technical perspective  the O IBB is down 35  from its  400 peak in July  15  The 200 week moving average is  235 
S P 500 Sectors ranked best to worst growth for Q4  16  
Telco   18 9 
Cons Disc   9 6 
HealthCare   8 5 
Fincl s  2 
Technology   0 3 
Cons Spls   1 3 
Industrials   1 8 
Utilities   9 3 
Basic Mat   18 3 
Energy   75 3 
Q1 16 sector growth rate change from Jan 1  16   Note Energy   wow  
Cons Disc   15 3    18 3 
Cons Spls   1 3    2 3 
Energy   87 2    41 4   far worse than the rate of decline from last year   hard to believe how this gets worse 
Fincl s   0 9    2 4 
HlthCare   6 4    7 4 
Industrials   3 1    3 1 
Basic Mat   14 1    1 1 
Technology   5 5    1 7 
Telco   4 7    5 8 
Utilities   1 8    1 2 
SP 500   4 2    2 3 
For the current quarter  expected growth for Consumer Discretionary  HealthCare and Telco again top the list for the sectors with the best expected growth
2016 estimated earnings growth  full year  
Cons Disc   12 9    15 2 
Cons Spls   4 1    6 3 
Energy   50 6    10 1 
Fincl s   8 4    8 8 
HlthCare   8 1    9 6 
Industrials   4    5 4 
Basic Mat   1 5    11 6 
Technology   3 1    7 4 
Telecom   2 6    2 3 
Utilities   4 1    3 7 
SP 500   3 9    7 6 
Analysis   commentary  The decline in Energy estimates continues to be nothing short of tragic  I was having lunch with a client last week  who works at a large bank  and the regulators came through the bank and told the institution to write their energy loans down  whether they were performing or not  Shades of 2008 i e   you will take this equity whether you want it or not  
For full year 2016  HealthCare and Consumer Discretionary  still show the best growth  but the Financial sector for the next 11 months looks far better than the rapid drop for Q4  16 
There are places to hide in this market and it may be last year s losers 
I still think the US dollar weakening will help take some immediate pressure off the SP 500  Today  the US dollar index dropped again  Technology and Industrial s should be the immediate beneficiaries of a weaker dollar 
The 4 sectors or asset classes that have been thoroughly trashed since last summer and have suffered the biggest declines are biotech s  Transports  small cap s  Russell 2000   and Emerging Markets  The Transports look to be bottoming  Emerging Markets are range bound ",2016-02-10,Brian Gilmartin,https://www.investing.com/analysis/how-are-sp-500-earnings-looking-for-full-year-2016--(energy-is-beyond-384126,384126
221103,442619,PFE,Pfizer Obeys The Elliott Wave Rules,opinion,"Do you remember  Black Monday   It was August 24th  2015  when most stocks  including Pfizer Inc   N PFE   saw their worst sell off in four years  And while the majority of traders and investors were caught completely off guard by this swift and sharp decline  to Elliott Wave analysts there was nothing surprising about it  as  proves  However  the purpose of this article  published on October 4th  2015  was not only to demonstrate the Elliott Wave Principle s ability to warn you about an upcoming market crash  but also to make another prediction about Pfizer Inc  s stock prices  See it on the chart below 
According to the theory  markets moves in repetitive patterns  called  waves   Five waves in the direction of the larger trend are followed by three waves against it  The five wave sequence forms a larger pattern  knows as an  impulse   while the three wave move is a correction  usually marked with A B C  As the chart above shows  Pfizer s impulse was over at  36 43  That is the starting point of the corrective phase of the 5 3 cycle  So  through the perspective of the Wave Principle  the so called  Black Monday  was nothing more than a natural wave A  part of a larger A B C corrective pull back  In other words  waves B up and C down were still left  so more weakness could have been expected in Pfizer  The next chart shows how the stock looks like today 

The deceptive wave B has probably caused a lot of optimism within the lines of the bulls  It almost reached the top of wave V of the impulse  climbing as high as  36 04  Despite wave B s false strength  wave C was still supposed to take prices below the bottom of wave A  Which it did on February 8th  2016  when the stock fell to as low as  28 23  24 cents per share lower than the bottom of wave A at  28 47  The only thing we could not predict was the time factor  We did not expect Pfizer s A B C correction to develop that fast  But in technical analysis  where  prices are headed is far more important than  when  are they going to get there 
From now on  it appears wave C still has some room to evolve  It may force Pfizer below the  28 mark  but the support of wave IV is supposed to put the bears  ambitions to rest  Once wave C is over  the requirement for a pull back of minimum three legs would be fulfilled and a new recovery could be anticipated ",2016-03-01,EWM Interactive,https://www.investing.com/analysis/pfizer-obeys-the-elliott-wave-rules-200119967,200119967
221113,442629,PFE,The Closing Of The Global Economy,opinion,"I don t often write about global geopolitics because I think  in general  investors spend too much time worrying about things they can t control or aren t going to happen or wouldn t matter much if they did  The best example is the Middle East which has been a mess my entire life and long before it for that matter  Changing your investments based on the latest threat in or from the Levant is a recipe for constant chaos  The only accurate prediction about the Middle East will always be that the various factions that have been fighting for centuries will continue to fight  And that no matter who is in charge they will have to sell oil to make ends meet  And make no mistake oil is the only economic reason we care about the region 
The recent Paris attacks  though  have me thinking more about how global geopolitics is affecting the global economy  The terrorist attacks Europe has experienced in Madrid  London  Paris and other locales are raising old barriers across the continent  Borders where goods  people and capital have crossed freely for the last few decades are now manned and monitored again  Capital largely continues to flow freely but people and goods are starting to be restricted  you can t restrict the flow of people without also obstructing the flow of goods  For now  the people and goods continue to flow  just more slowly  One can t help but think though that if the borders become literal barriers again it won t be long before the metaphoric ones   protectionist policies   return as well 
If one also considers the antipathy toward Germany that permeates most of Europe and the perception   and reality to some degree   that the EU and especially the EMU are much more favorable for the Teutonic members than the Latin ones  then one begins to see how the fragile union might devolve into its former squabbling  fractured self  The feared break up of Europe and the Euro has until now been based on economic considerations but physical security would seem a larger concern at this point  If the EU can t guarantee physical security and has already failed at providing economic security  it s raison d etre is  what exactly  To provide employment for feckless bureaucrats 
The desire for physical security isn t confined to Europe obviously  the Paris attacks have amped up the political debate in the US over immigration  with Syrian refugees and physical security now replacing Latin Americans and economic security as the targets  The emergence of Donald Trump as a right wing populist to challenge the near universally populist Democrats means that both parties are now pandering to the population s baser instincts of fear and greed  That isn t to say that their fears aren t real or legitimate just that the solutions offered by populist politicians are simplistic and unlikely to achieve the intended results  Indeed  history says that walling ourselves off from the world is more likely to create less security  physical and economic  rather than more 
The demonization of foreigners  this emerging isolationist consensus   a natural response in many ways to the jingoism of the last decade s Western governments   is not confined to the debate over national defense or immigration  It is also a part of the economic debate  Politicians exploit our economic insecurities  laying blame on foreigners   the Chinese are the most often cited bogeymen   for problems created by our own policies  Donald Trump says he will be a tougher negotiator and get better trade deals but doing so will require threatening consequences   trade restrictions   that would please Smoot and Hawley and potentially repeat the mistakes that led to the Great Depression  Jack Lew decries corporate inversions and announces new rules designed to prevent US companies from doing what our corporate tax code incentivizes them to do  Meanwhile  Pfizer Inc  N PFE  and Allergan  N AGN pa  look to structure a deal that has Allergan   an Irish corporation with a low tax rate and the smaller of the two companies   playing the role of acquirer to avoid the new rules  Will the current administration or future ones regularly reject takeovers of US corporations unless they are carried out by other US corporations  Will other countries follow suit 
The inequality debate is rooted too in the discussion over trade policy  globalization and outsourcing  The decline of the American middle class  the rise of the so called creative class and the consequences of the financialization of the US economy are all part of the same populist  isolationist rhetoric  Foreigners are demonized as stealing American manufacturing jobs  polarizing the US between the haves  largely in the coastal cities  who benefit from free trade and the have nots  largely in the interior of the country  who don t  It mostly isn t true   productivity has reduced manufacturing employment much more than free trade   but it has enough of a whiff of truth that it works as a political strategy even if it would fail miserably as an economic one  Monetary policy has attempted to assuage the middle class angst with expanded credit but that has exacerbated the divide as financial engineers have been rewarded at the expense of real ones 
We see this nationalistic impulse in the so called currency wars  the devaluations intended to steal some of what is left of global growth for one s own country  Rather than pursue domestic policies that would improve growth  politicians are happy to leave it to central banks to try and gain a trade advantage by weakening the national currency  seeking to enrich through impoverishment  a policy doomed to failure  The unintended consequences are reflected in money markets where conditions once thought impossible or at least illogical have become commonplace  In the process of trying to recover from the last crisis we are creating the conditions for the next 
Meanwhile  global trade is contracting  down for three years in a row and a major reason for the weak recovery from the last recession  The growth and falling inflation of the 90s was  in a lot of ways  driven by the expansion of trade  the liberalization of the global economy as former communist nations adopted more liberal  free market economic policies and joined the world trade order  That expansion appears to now be reversing in a cacophony of nativist rhetoric  a global phenomenon that encompasses  unites and animates the far left and the far right  As I said in my 

The political left is happy to see people cross borders but would gladly restrict the flow of capital and goods  The political right is happy to see capital and goods cross borders but would gladly build a fence to restrict the flow of people  I m afraid that the compromise might be to restrict people  capital and goods 

This political pandering has consequences for our society and economy that are hard to predict  The recent college campus protests would appear to be another manifestation of this growing desire for security over all else  Students want to create  safe spaces  where they are free to extend their childhood  protected from harm both real and imagined  With the random violence and economic upheaval that has marked their lives  from 9 11 to Madrid to London to Paris to the dot com bust to the Great Recession  is it any wonder that our young adults seek to be protected from the real world  The intolerance practiced by our leaders is reflected in the intolerance of the students who shout down anyone who doesn t toe the politically correct line  a feat that becomes harder by the day  We have lost the ability to take a joke  to distinguish between satire and seriousness  In the process  we divide rather than unite  for fear of offending and being subjected to the modern day pillory of social media 
As I said at the beginning  I don t generally spend a lot of time thinking about geopolitics as it relates to investing because it isn t generally profitable  This closing of the global economy  this emerging trend toward protectionism in the form of currency devaluation and populist politics is already impacting the global economy but in the short term probably shouldn t impact our investment approach  We don t know yet how far this will be taken  if the rhetoric will turn into actual economy damaging policies  For now  the most obvious impact has been the rising dollar and falling inflation expectations with  so far  little impact on real growth expectations here in the US  But the direction is disturbing especially with the US coming into an election year when the rhetoric may have more impact on market outcomes 
As investors we have more immediate concerns  Growth remains stuck at the secular stagnation  new normal pace of 2 to 2 5  growth  The economic data continues to point to weakness even as the Fed prepares to enter a tightening cycle  Inventories are building as sales and investment stagnate  The energy industry  responsible for an historically large proportion of investment since the crisis  is in deep trouble as the dollar rises and oil prices sink  Earnings are falling and margins appear to have peaked  Stock market valuations are extreme and market technicals are unhealthy with a small number of stocks leading the averages higher even as most stocks head south  Investors have plenty to worry about that is real and now without delving into what is speculative and possibly far in the future 
The closing of the global economy  the reversal to some unknown degree of the globalization process  has negative consequences for the lives to which we ve become accustomed  Much of the disinflation since the early 90s is a direct result of increased trade and reversing the process will in time mean less choice and higher prices for Americans  And no  it won t  despite what the protectionist populists would have you believe  bring back high wage manufacturing jobs  The giant sucking sound Ross Perot warned about isn t coming from Mexico but rather from Silicon Valley and we should be thankful for it not ruing it  We should be preparing our young adults for the real world and the jobs of this century rather than coddling them and trying to bring back the jobs of the last one  The closing of the global economy is not a fait accompli  But we will have to resist with all our might the siren song of the politicians who tell us what we want rather than need to hear and push back against the monetary policies that are a poor substitute for better fiscal and regulatory policies ",2015-11-23,"Alhambra Investment Partners, LLC",https://www.investing.com/analysis/the-closing-of-the-global-economy-272171,272171
221114,442630,PFE,Markets Decline Worldwide ,opinion,"U S   Asian and European shares moved lower on Monday after the highly controversial merger between Pfizer Inc  N PFE  and Allergan  N AGN pa   The dollar moved lower against its major rivals as the market weighs in on the Federal Reserve s likely December  interest rate hike 
U S  stocks erased more gains made last week when major benchmarks saw some of their best weekly results in months  Trading volume was relatively low  possibly reflecting the holiday atmosphere ahead of Thanksgiving Day  during which markets will be closed  The S P 500 shed 2 58 points  or 0 12   to trade at 2 086 59 as six of its ten main sector finish in the red  Consumer and energy sectors led the gainers  although they were eclipsed by heavy declines in the telecom  utilities and tech sectors  The Dow Jones Industrial Average declined 31 13 points  or 0 17   to trade at 17 792 68 as more than two thirds of its components closed the day lower  The Nasdaq Composite declined 2 44 points  or 0 05   to close Monday s trading session at 5 102 48  Historically  Thanksgiving week trading tends to have low trading volume despite the release of key economic data this week  with pace picking up in December  Despite expectations  the  155 billion merger between Pfizer Inc  N PFE   and Allergan PLC failed to lift the markets  despite the creation of worlds largest drug maker  Both companies saw their shares decline following the announcement as criticism was pointed at some of the specifics of the deal  which could be viewed as an attempt to evade U S  taxation by moving operations to Ireland 
Asian shares followed Wall Street s lead  posting declines during early trade  MSCI s broadest index of Asia Pacific shares outside Japan moved between positive and negative territory  and was up 0 2  as of this writing  The Japanese Nikkei 225 dipped about 0 1 percent after a long holiday weekend but recovered to a 0 3  gain over the session  Chinese shares also moved lower  as the blue chip CSI 300 index of the largest listed companies in Shanghai and Shenzhen was last seen 1 2  lower  The Shanghai Composite Index was last seen down around 0 4   The focus in Japan is moving away from earnings reports and towards China  The second largest economy in the world has recently taken some drastic steps in order to secure economic growth  though August s sudden devaluation of the yuan resulted in considerable volatility worldwide  Asian markets are also focused on the U S  Federal Reserve and its likely interest rate hike next month 
This week s major economic data releases continue today with the release of German GDP and business climate data and will continue with U S  GDP and consumer confidence data  U S  personal spending  employment  durable goods orders and oil stock data will be released on Wednesday  U S  trade will be closed for Thanksgiving Day on Thursday ",2015-11-24,OptionsClick,https://www.investing.com/analysis/markets-decline-worldwide-272334,272334
221115,442631,PFE,Weekly Snapshot  PFE And AGN Agree To Merge  Manufacturing Still Weak,opinion,"Top News Headlines
Turkey and Russia spar over airspace  Russian promises retaliation for fighter shoot down 
Brussels shuts down for days in terrorist hunt 
Chicago policeman charged with murder 
Stocks little changed on the week  no follow through from last week s rally 
Pfizer  N PFE   Allergan  N AGN pa  agree to merge for tax benefits  politicians posture  threaten 
Economic News
Japan unveils new stimulus measures 
US corporate profits decline nearly 5  year over year  most since recession 
Spain economy grows 3 4  year over year  no one notices 
Durable goods orders rebound for the month but ex transportation still down year over year 
Consumer confidence tanks as expectations fall 
Manufacturing data still weak  Flash PMI  CFNAI  Richmond Fed all less than expected 
Income up  spending up 0 1   savings rate rises 
Chart Of The Week
Corporate profits rarely fall outside of recession as they are now  That s not a prediction but one probably ought to factor it into one s outlook 

Broad Market Top 10   3 Month Returns

MOMENTUM ASSET ALLOCATION MODEL SPDR Sector Returns   3 Month Returns

SPDR SECTOR ROTATION MODEL Country Returns Top 10   3 Month Returns

Commodity Returns Top 10   3 Month Returns

Bond Returns Top 10   3 Month Returns

Stock Valuation Update",2015-11-29,"Alhambra Investment Partners, LLC",https://www.investing.com/analysis/the-weekly-snapshot-272777,272777
221116,442632,PFE,Of Rotten Apples And Rotten Systems,opinion,"Martin Shkreli  the former hedge fund manager turned pharmaceutical CEO who was arrested last week  has been described as a sociopath and worse 
In reality  he s a brasher and larger version of what others in finance and corporate suites do all the time 
Federal prosecutors are charging him with conning wealthy investors 
Lying to investors is illegal  of course  but it s perfectly normal to use hype to lure rich investors into hedge funds  And the line between the two isn t always distinct 
Hedge funds are lightly regulated on the assumption that investors are sophisticated and can take care of themselves 
 prosecutors went after Shkreli because they couldn t nail him for his escapades as a pharmaceutical executive  which were completely legal   although vile 
Shkreli took over a company with the rights to a 62 year old drug used to treat toxoplasmosis  a devastating parasitic infection that can cause brain damage in babies and people with AIDS  He then promptly raised its price from  13 50 to  750 a pill 
When the media and politicians went after him  Shkreli was defiant  saying  our shareholders expect us to make as much as money as possible   He said he wished he had raised the price even higher 
That was too much even for the Pharmaceutical Research and Manufacturers of America  Big Pharma s trade group  which complained indignantly that Shkreli s company was just an investment vehicle  masquerading  as a pharmaceutical company 
Maybe Big Pharma doesn t want to admit most pharmaceutical companies have become investment vehicles  If they didn t deliver for their investors they d be taken over by  activist  investors and private equity partners who would 
The hypocrisy is stunning  Just three years ago  Forbes Magazine Shkreli as one of its  30 under 30 in Finance  who was  battling billionaires and entrenched drug industry executives  
Last month  Shkreli got control of a company with rights to a cheap drug used for decades to treat  in Latin America  His aim was to get the drug approved in the United States and charge tens of thousands of dollars for a course of treatment 
Investors who backed Shkreli in this venture did well  The company s share price initially shot up from under  2 to more than  40 
While other pharmaceutical companies don t raise their drug prices fiftyfold in one fell swoop  as did Shkreli  they would if they thought it would lead to fat profits 
Most have been increasing their prices more than 10 percent a year   still far faster than inflation   on drugs used on common diseases like cancer  high cholesterol  and diabetes 
This has imposed a far bigger burden on health spending than Shkreli s escapades  making it much harder for Americans to pay for drugs they need  Even if they re insured  most people are paying out big sums in co payments and deductibles 
Not to mention the impact on private insurers  Medicare  state Medicaid  prisons and the Veterans Health Administration 
And the prices of new drugs are sky high  Pfizer s  N PFE  new one to treat advanced breast cancer costs  9 850 a month 
According to an analysis by the Wall Street Journal  that price isn t based on manufacturing or research costs 
Instead  Pfizer set the price as high as possible without pushing doctors and insurers toward alternative drugs 
But don t all profit maximizing firms set prices as high as they can without pushing customers toward alternatives 
Unlike most other countries  the United States doesn t control drug prices  It leaves pricing up to the market 
Which enables drug companies to charge as much as the market will bear 
So what  exactly  did Martin Shkreli do wrong  by the standards of today s capitalism 
He played the same game many others are playing on Wall Street and in corporate suites  He was just more audacious about it 
It s easy to go after bad guys  much harder to go after bad systems 
Hedge fund managers  for example  make big gains from trading on insider information  That robs small investors who aren t privy to the information 
But it s not illegal unless a trader knows the leaker was compensated   a looser standard than in any other advanced country 
Meanwhile  the pharmaceutical industry is making a fortune off average Americans  who are paying more for the drugs they need than the citizens of any other advanced country 
That s largely because Big Pharma has wielded its political influence to avoid cost controls  to ban Medicare from using its bargaining clout to negotiate lower prices  and to allow drug companies to pay the makers of generic drugs to delay their cheaper versions 
Shkreli may be a rotten apple  But hedge funds and the pharmaceutical industry are two rotten systems that are costing Americans a bundle ",2015-12-22,Robert B. Reich,https://www.investing.com/analysis/of-rotten-apples-and-rotten-systems-376606,376606
221125,442641,PFE,Uptrend Line Support At Current Levels For Pfizer Inc,opinion,"There is uptrend line support at current levels for Pfizer Inc  NYSE PFE  shares  A rebound will help them register a new decade high  Breaking below the trendline will drive price towards filling the gap    32  In such a case buy the dips  Bullish outlook 
PFE stock price  8 months ",2015-05-04,Petros Steriotis,"https://www.investing.com/analysis/pfizer-(pfe)-may-4,-2015-preview-250478",250478
221128,442644,PFE,Oppenheimer Weighs In On Biotech Stocks  OPK  OVAS,opinion,"of Oppenheimer rates stocks in the biotechnology sector and is one of the top 25 analysts rated on TipRanks  Yesterday  Vanjani made two news ratings for Opko Health Inc  NYSE OPK  and Ovascience Inc  NASDAQ OVAS  
Vanjani maintained a Perform rating on Opko Health Inc though he did not provide a price target  The pharmaceutical and diagnostic company posted first quarter earnings on May 11  reporting consolidated revenue of  30 1 million  higher than Vanjani s estimate of  20 4 million  However  Opko reported a net loss of  117 1 million for the quarter compared to a net loss of  44 6 million in the same quarter of last year  The company also posted a loss of   0 26  per share  compared to   0 11  in the same quarter of last year 
Opko beat Vanjani s revenue estimate thanks to a collaboration deal with Pfizer Inc  NYSE PFE   which resulted in a  295 million upfront payment  Vanjani commented   Shares of OPKO have traded flattish in the current quarter  We believe the recent EirGen acquisition was incrementally positive and could provide a small catalyst   referring to Opko s acquisition of the specialty pharmaceutical company  The analyst continued   OPKO paid roughly  135M in cash and stock for an asset that potentially provides manufacturing capabilities for vertical integration  tax incentives  existing revenue and cash flow  as well as pipeline products  We should begin to see the benefit of EirGen in the revenue line beginning in 2Q15  
Rohit Vanjani has rated Opko health 10 times since May 2014  earning a 100  success rate recommending the stock with a  69 2  average return per OPK rating 
The analyst also provided a rating on OvaScience yesterday after the biopharmaceutical company released first quarter earnings on May 11 
Vanjani maintained an Outperform rating on the stock with a  60 price target  
The fertility company was happy to announce that the first baby had been born using the Augment treatment  Augment is OvaScience s therapy to improve the health of eggs in women undergoing in vitro fertilization 
OvaScience posted a net loss for the quarter of  17 2 million  or   0 65  per share compared to a net loss of  7 8 million and   0 41  in the same quarter a year prior  Aside from revenue  Vanjani believes it is more important to focus on the future of Augment  He explained   OvaScience maintained its guidance for 1 000 cycles in 2015  which we view as positive  
Although Vanjani usually makes cunning recommendations in the biotechnology sector  he is not always accurate rating OvaScience  Vanjani has rated OvaScience 14 times since May 2014  earning only a 20  success rate earning the stock with an average loss of  6 2  per rating  However  most analysts agree with this latest rating as the top analyst consensus for OvaScience on TipRanks is Strong Buy Overall  Vanjani has a 73  success rate recommending stocks with a  35 2  average return per rating ",2015-05-13,Sarah Roden,"https://www.investing.com/analysis/oppenheimer-weighs-in-on-biotech-stocks:-opko-health-inc.-(opk),-ovascie-251663",251663
221129,442645,PFE,Delivering Alpha Highlights  Part 2,opinion,"Surely John Paulson s discussion of merger arb with Melissa Lee counts as one of the highlights of this year s Delivering Alpha conference 
In part  it became a highlight through the luck of timing  that is  breaking news on the subject  21st Century Fox had just offered to take over Time Warner  NYSE TWX   bidding  80 billion  Time Warner has also immediately rejected the offer  but in the view of the market  the fact of such an offer puts the company in play 
A common pattern in such cases is that the offerer s equity falls in value in the wake of the offer  and the target s equity rises  That isn t what happened in this instance  exactly  Yes  on the side of the target matters played according to Hoyle  TWX spent the day Wednesday  the 15  climbing from  90 06 to  90 60  then it leaped above  91 overnight 
Meanwhile  though  FOX  TA FOX  opened Wednesday at  33 12  and  after a day of wild hour by hour swings  settled down at the same place at end of day  Thursday  though  was when it discovered what the market thought of the idea of its acquisition of Time Warner   it spent most of the day above  33 40 
At the conference  Melissa Lee began the interview by congratulating Paulson on the 20th anniversary of Paulson   Co  She observed that it  started off as an arb shop  though it has since expanded its scope 
Drivers of Activity
Paulson accepted the congratulations  and launched into a discussion of the three factors driving mergers and acquisitions activity today  low interest rates  record equity valuations  these two factors together mean that companies can use either stock swaps or borrowed cash or a combination of the two  in acquiring one another   and  finally  the degree to which acquisitions have become necessary for executives in their own self defense  the executives of a company that isn t business making deals will find that  they themselves have become a takeover target   Paulson called this the  accretive  nature of takeovers 
As to the Fox deal  Paulson didn t want to predict how matters will play out  He spoke in general terms  though  about how he and his associates analyze such a deal  especially when the initial bid is rebuffed and the prospect of a hostile takeover fight has arisen 
There are of course risks  Any piker can say  aha  This will cause a rise in the value of the target  and rush in to try to ride that  But the pikers might get in only after most of the spike has happened already  ad just in time to take the other side of the roller coaster ride  the one that gets scary when the initial bidder backs away 
Paulson alluded to the Pfizer  NYSE PFE  bid for AstraZeneca  NYSE AZN  a little more than a year ago  Speculators who bought in before Pfizer backed away lost money  On Friday  May 16  2014  AZN stock closed at  80 28  after an intraday high of  81 19   the next business day s close   70 64  That s a one day loss of 12  
In the hope of avoiding such a loss  Paulson assured Lee  he will look closely at the 21st Century Time Warner deal 
One consideration is that this bid doesn t lend itself to the prospect of a rapid fire auction  such as one can get where two very larger bidders emerge for a single company that is of strategic value to both of them but has a low capitalization before put in play  The this case  the bidder and the target are roughly the same size  so on the one hand  there s a limit to how much cash you can pay  and on the other  there s also a limit to how much stock you  21st Century  can provide before it becomes diluted   
Valeant Allergan
On the Valeant Allergan matter  Paulson   Co  has a stake in Allergan  NYSE AGN pa   which is almost inevitably identified as  the maker of Botox   It should be noted  Allergan has other products as well  some well known  such as Restasis  a treatment for dry eye syndrome  and Juv derm  an injectable anti wrinkle gel   Still  Botox is the blockbuster  Heck  the late Joan Rivers  comedy legend  titled a chapter in her memoir   Botox  Baby  
Paulson   Co  has a stake in Allergan so it has obviously not escaped John Paulson s attention that Valeant wants to buy it 
Ms  Lee observed that a traditional merger arb play aims at making the spread  then exiting the position once is deal is completed  Paulson suggested that that wasn t what he was aiming at here   In many situations today you can make far more than the spread by holding on to the acquirer s stock after the transaction is completed   Valeant Allergan is a case in point  because Valeant  is a very serious acquirer Mike Pearson  LONDON PSON  is very cost conscious  
What Paulson expects is that Valeant will acquire Allergan and reduce costs to such a point that it will be 25  accretive to Valeant s EPS  If one presumes that Valeant s stock will rise by the same amount  then Allergan  prior to an acquisition by a stock and cash offer is worth  as much as  2 20 a share  
If Paulson were aiming for the spread in this situation  he d be aiming for a gain of  1 72 a share  But since his best is on Valeant s ability to attain cost synergies  his goal is as much as  2 22 per share ",2015-07-21,AllAboutAlpha,https://www.investing.com/analysis/delivering-alpha-highlights:-part-two-258924,258924
221134,442650,PFE,Should Investors Trust Pfizer ,opinion,It has been more than a year since we last wrote about Pfizer Inc  NYSE PFE   On March 28th 2014  the stock was trading around 32 40  but the  was warning us about a probable reversal to the downside  The chart below shows how things looked like  when we published   Our bearish outlook was supported by two consecutive patterns  A  in the position of wave  4  and an  for wave  5   So  despite Pfizer s multi year advance  we decided to stick to the wave analysis  Was this the right thing to do  Find the answer on the next chart  Yes  it was  The price of Pfizer s shares fell from 32 66 to 27 50 in less than seven months  In October 2014  the bears got tired and the rally resumed  Last week  Pfizer Inc  stock reached 35 40  But is it going to get even more expensive  Is this the right time to invest in Pfizer  In our opinion  the answer to both questions is  no   The following chart explains why  As visible  Pfizer has drawn a nicely looking five wave impulse to the upside  starting from the bottom in 2009  According to the theory  every impulse is followed by a three wave correction in the opposite direction  This means we should expect a significant decline  once wave V is over  If this is the correct count  now could be the worst possible moment for an investment in Pfizer stock ,2015-04-02,EWM Interactive,https://www.investing.com/analysis/should-investors-trust-pfizer-247137,247137
221137,442653,PFE,Dow Jones Analysis  February 06  2015,opinion,Dow Jones U S  stocks climbed on Thursday as energy shares bounced with oil prices  while news Pfizer  NYSE PFE  would buy Hospira in a massive deal also lifted investor sentiment  Adding to the upbeat tone  weekly jobless claims rose less than expected last week  The report comes on the heels of a private payrolls report that fell short of expectations on Wednesday and ahead of a monthly employment report on Friday ,2015-02-06,ICM Brokers,"https://www.investing.com/analysis/dow-jones-analysis:-february-06,-2015-241054",241054
221138,442654,PFE,The United States Decouples From A Deflationary World,opinion,"With the investment community totally convinced the world is falling into a deflationary spiral  the monthly jobs report became a focal point for corroboration the United States is afflicted with a similar condition  Shock of shock  when the number came in at 257k  above expectations of nearly 230k  plenty of skeptics probably are reconsidering their investment thesis  The week saw plenty of volatility with Crude Oil prices as well  only this time  the loveable black substance rose 13   It seems Libya has cut back dramatically on production because of dangerous conditions in that country  You could say the same thing about nearly every vacation paradise that is the Middle East  Another group sure to bring a smile to investor s faces is Greece  which is trying to renegotiate it s obligations to the rest of the European Union  It s sugar daddy  along with the rest of Europe  Germany  is not real pleased with the request but will try to do the best it can to accommodate the hard working Greeks  More importantly  it wants to save itself and the rest of Europe from beginning down the path of a potential currency blowup  Interesting how self preservation takes full precedence in most cases  eh 





In conjunction with the volatility in the oil pits  the ten year treasury actually budged a bit higher to yield an earth shattering 1 94   The large money center banks are helped by the slight increase in the slope of the yield curve  so investors began to nibble on this long dormant group  If our loveable Fed head ever becomes joltin Janet by announcing an increase in rates sooner than expected  the big boy lenders will see more than just token interest 




In tech world  where the biggest bubbles don t reside in public markets  but instead lie in the market prices of yet to be launched IPO s  think Uber  Pinterest  and AirBnB   there was plenty of action as well  LinkedIn continued to grow its user base and revenue total and was viewed as the biggest victor of the week  Twitter posted a very good revenue number and improved monetization metrics  although the number of tweeters twitting truly tumbled  GoPro also showed that plenty of people want their product  probably to be placed in crevices we don t even know exist  Still  the street was not impressed  but some of that has to because of it s  shall we say  interesting valuation 



Showing there is always something going on with big pharma  Pfizer Inc  NYSE PFE  bought Hospira for  17 billion to gain more access to the injectable and biosimilar markets  In the media world  Sirius XM Holding Inc  NASDAQ SIRI  impressed with good subscriber numbers  Pandora  NYSE P   the free music and subscription entertainment offering  was roundly seen as being in a world of hurt because of  who would have thought  competiton from other free services  can you say Spotify    A few cable companies saw their number of users increase as the idea they are going anywhere because of over the top services remains strictly an idea  Finally  in the quick service restaurant sector  Dunkin Donuts was seen as having a poor result as apparently their new swill is pretty much the same as the old stuff 

In the political universe  the leader of Jordan showed there is politician in the world who has the will to take on Isis  As he so eloquently stated  the real question is will other countries  hint  hint  have the courage to be all in as well  

Y H   C Investments  Yale Bock  and the family of Yale Bock own positions in securities mentioned in the blog post  Investing in stocks can lead to the complete loss of your capital  As always  on any company mentioned here  past performance is not a guarantee of future returns  Investing involves risk of losses on invested capital  One should research any investment and make sure it is suitable with your objectives  risk tolerance  risk profile liquidity considerations  tax situation  and anything else pertinent to your financial situation  Also  the CFA credential in no way implies investment returns will be superior for any charter holder ",2015-02-08,Yale Bock,https://www.investing.com/analysis/the-united-states-decouples-from-a-deflationary-world-241188,241188
221156,442672,PFE,Pfizer Inc  5 Bonus Trade Ideas,opinion,"Pfizer Inc  NYSE PFE 

Pfizer has been pulling back since a top in early March  The last few legs suggest a bounce higher may be in the process now that could take it to 30 30  A shorter perspective sees a bull flag consolidation that could target 29 90 in short order on a move higher  Either way  with the RSI rising and the MACD following suit higher as well  the bias is to the upside  There is resistance at 29 and 29 80 before 30 60 and 31  Support lower comes at 28 70 and 28 
The target move higher may not seem like much but using options you can look for a possible 100  gain or more by next week 
Trade Idea 1  Buy the stock on a move over 29 with a stop at 28 70 
Trade Idea 2  Buy the September 5 Expiry 29 Calls  offered at 23 cents late Friday  
Trade Idea 3  Buy the August 29 Expiry 28 5 29 Call Spread  36 cents  
Trade Idea 4  Buy the September 5 Expiry 28 5 29 Call Spread and sell the September 5 Expiry 28 5 Put  25 cents  
Trade Idea 5  Buy the September 5 Expiry 28 5 29 bullish Risk Reversal  13 cents  
Disclaimer  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ",2014-08-26,Gregory W. Harmon,https://www.investing.com/analysis/pfizer-inc:-5-bonus-trade-ideas-223738,223738
221161,442677,PFE,Europe Trading Higher  Astrazeneca And Deutsche In Foucs,opinion,"European markets are trading higher this morning  despite having a very volatile week last week  There is no doubt that the DAX IIndex and the FTSE 100 were able to record their highs last week  but the sentiment remained on the seesaw on the back of the mixed economic data released last week  We do know that the economy in the euro region has started facing serious challenges as per the GDP report and this will remain the main headwind for the bull investors  The CAC 40 slipped sharply lower while the FTSE MIB stayed near the 2 month low and if the equity markets does not pick up its momentum together in the upward direction  we may experience the bond yields go even lower for these countries as investors may prefer to invest in bonds rather than in the equity market Back in the UK  the main focus will remain on the pharmaceutical sector and on the bank sector  especially after the stocks such as Astrazeneca Plc  NYSE AZN  and Deutsche Bank  NYSE DB  are back in the spotlight  Let s talk about the AstraZeneca first  who has rejected the Pfizer Inc s  NYSE PFE  new offer once again  which is a good decision from the shareholder  because Pfizer is certainly undervaluing the firm and we do not think they are offering what the company really worth  Moreover  there is strong possibility that after the merger the company will spin off some of the business in AstraZeneca and sell them off separately  What we do need is a decent offer from Pfizer  which does not undervalue the performance and number of new drugs in the pipeline The Deutsche Bank has announced that is going to raise more capital ahead of the stress test  Obviously  the bank wants to make its balance sheet more stronger and with Qatari investment coming on board as a major shareholder  the bank s position could become much stronger as compared to its peers 

Disclaimer  The above is for informational purposes only and NOT to be construed as specific trading advice  responsibility for trade decisions is solely with the reader ",2014-05-19,AvaTrade,https://www.investing.com/analysis/europe-trading-higher;-astrazeneca-and-deutsche-in-foucs-213279,213279
221162,442678,PFE,Maybe Pfizer s Third Offer Won t Be Their Last ,opinion,"Last month  analysts predicted that Pfizer Inc  NYSE PFE  had to beat  100 billion if it wanted to get its hands on Britain s Astrazeneca  ST AZN   Well  its second proposal was turned down  As of April 30  the markets responded well to Pfizer  as it reigned as one of the S P 500 s best performers  At that point  AstraZeneca s U K  listed shares had jumped nearly 15  since Pfizer s interest made headlines 
Now  fast forwarding to PFE s most recent  third  proposal  On May 19  AZN rejected the  117 billion offer  as well  claiming that it still fell short of the company s value  That day  the company s shares fell as much as 15  intraday in London trading 
They say that  third time s the charm   Well  I guess in this case  Pfizer is all out of luck 

No Coming Back
What would have merged into the world s largest drugs company is now nothing more than an evaporating thought  Pfizer has officially given up on buying AZN  no last minute offers  no nothing 
Just a cooling off period  required by British rules  At the end of the day  the deal was politically charged  Pfizer was already given the courtesy of a conveniently reduced tax bill  But  you see  the numbers just didn t add up  Pfizer spent over  250 billion on takeovers  over the past 10 years   Yet  it s now worth  185 billion  So  AstraZeneca probably kept its shareholders  best long term interests in mind  according to CMC s Michael Hewson 
After this cooling off period  there s a slight  and we mean slight  possibility that  after three months  AZN could contact PFE  or vice versa  after six months   AstraZeneca s shares fell 2  as markets opened this morning  This share drop  coupled with shareholder pushback  could be enough to persuade AZN s mind over the next three months  Jeremy Batstone Carr of Charles Stanley argues that it ll be  a big issue now  I think  for AstraZeneca to convince shareholders that  55 per share was undervaluing their business  

The Bottom Line
It s apparent that Pfizer and AstraZeneca wanted different things  While PFE had its eye on many cancer medicines  AZN wanted to focus solely on growth as an independent company  Some say politicians in Britain  the United States and Sweden opposed the transaction  afraid that thousands would lose their jobs 
But in all honesty  the deal fell through because of the bottom line dollar  AstraZeneca wanted  at minimum   58 per share  And the  55 offer didn t cut it 
For now  Swiss firm  Novartis N  NYSE NVS   reigns as the world s largest drugmaker   that s only if AZN refuses to budge in the next three or six months ",2014-05-28,Louis Basenese,https://www.investing.com/analysis/maybe-pfizers-third-offer-wont-be-their-last-214210,214210
221163,442679,PFE,Dollar Mostly Bid  Sterling and Kiwi Offered,opinion,"The US dollar remains firm against most of the major and active emerging market currencies  The euro and yen have thus far remained confined to yesterday s ranges  while sterling saw yesterday s losses extended  following yesterday s reversal  US 10 year Treasury yields have pushed back below 2 5   which seems to cap the dollar near JPY102  Better than expected Norwegian retail sales  0 5  vs  0 3  consensus  helped the krone resist the dollar bid 
 
The most important data  however  was the euro area money supply figures  M3 grew by less than 1  in April  0 8    which is the slowest since September 2010  The March pace was revised to 1 0  from 1 1   The consensus was for an unchanged reading  Credit to the private sector continued to contract as it has for the past two years  The pace moderated however  to  1 8  from  2 2   The report is not going to change anyone s view about the outcome of next week s ECB meeting 
 
Separately  there were three other pieces of the macroeconomic picture that the market received today  and they were all unexpected  First  German unemployment rose by 24k in May  The consensus was for a 15k decline  Second  it was reported that household consumption fell 0 3  in April  The Bloomberg consensus was for a 0 5  gain  The March data was revised a bit higher  0 6  from 0 4    but not enough to take the sting out of the disappointment  And third   
 
Third  Spain s positive data stream continued with April retail sales jumping 0 7  year over year  The market had a flat report after a  0 5  reading in March  Separately  Spain reported mortgage lending was up 16  in March year over year  a reversal from the 11 6  contraction in February and the highest reading since early 2007 
 
Taken together  the picture is fairly consistent with what investors have already come to appreciate  The German economic engine has begun moderating after a strong Q1  The French economy continues to struggle to sustain any meaningful momentum  The Spanish economy is leading the periphery 
 
Spain and Italy s bond and stock markets are performing well  extending recent gains  Over the past five sessions  Spain s 10 year yield is off 17 bp and Italy s is off 23 bp  with both pushing below the 3  threshold  Italian and Spanish shares are the strongest of the major bourses in Europe  Over the past five sessions  those bourses are up 4 6  and 2 0  respectively  Yet the euro itself is not finding much traction  as speculators appear to be moving to the sidelines ahead of the ECB meeting  where great uncertainty continues shroud next week s big event  The  1 3640 area is now resistance  Support is seen  1 3600 10  A break of that would target the  1 3520 45 band 
 
Sterling has underperformed in recent days  The Pfizer  NYSE PFE  Astrazeneca  NYSE AZN  cooling off period  GBP60 bln deal   may have weighed on sentiment  and there is some talk of euro demand against sterling related to month end  Sterling was already on its back foot when the CBI disappointed with a distributive trades  retail sales  report showing a  16 balance in May after  30 in April  The consensus had looked for improvement  The forward looking indicators also softened  With the  1 6770 level now violated  the next target is  1 6720  Euro resistance against sterling is seen near GBP0 8160 
 
 
The New Zealand dollar is the weakest of the majors  off about 0 75   sterling is second with a loss of about 0 25  near midday in London  The Kiwi initially firmed in response to the Fonterra auction  which set a payout of NZD 7 0  per kilo  for 2014 15 and cut the payout for the current period by 25 cents to NZD 8 40  New Zealand appears to be producing more milk than can be absorbed presently  and this appears to be the main reason for the 23  slide in whole milk powder prices over the 3 5 months  The market consensus is for the RBNZ to continue its tightening cycle with a hike in June  Indicative prices suggest another hike in July is largely anticipated  but there is where we think the market may be a bit ahead of itself 
 
 
There are no US economic reports of consequence today  and no Fed officials scheduled to speak  Tomorrow the US reports its second estimate of Q1 GDP  It is widely expected to be revised lower from the initial 0 1  pace  The Bloomberg consensus is for a 0 5  contraction  but risk is to the downside  It may not matter much for investors  as the news is old and the more recent news is that the US economy is recovering smartly in the current quarter   3 0    However  when the Fed updates its forecasts next month  the poor performance in Q1 will likely see officials revise down their 2014 forecasts  This is likely to be a simple accounting function rather than a less optimistic outlook ",2014-05-28,Marc Chandler,"https://www.investing.com/analysis/dollar-mostly-bid,-sterling-and-kiwi-offered-214221",214221
221164,442680,PFE,AcelRx Likley To Receive FDA Approval Shortly,opinion,"Summary
AcelRx develops Zalviso to treat acute and breakthrough pain 
We believe there is a 90  chance the company receives FDA approval on July 27 
Zalviso has several advantages over intravenous delivery methods 
Obamacare and favorable product pricing should benefit the company in the long term 
Written by Kyle Dennis  AcelRx  NASDAQ ACRX  has been one of our favorite companies over the last two years  which we have written on a few times during that period  AcelRx develops therapies for acute and breakthrough pain that help solve the problems patients have with intravenous delivery systems  The 2H of 2014 should be an inflection point for the company as its product Zalviso is expecting an approval decision from the Food and Drug Administration  FDA  July 27 
Technology  ZALVISO Sublingual Sufentanil Nanotab System
AcelRx is developing Zalviso  which is designed to address intravenous patient controlled analgesia  IV PCA  problems  which can cause harm following surgery  Zalviso uses an already approved generic FDA pain medication called sufentanil  Usually sufentanil is delivered intravenously with infusion pumps  which can cause infections  dosing errors  and irregular gaps in treatment  Zalviso uses NanoTab technology to deliver a high dosage of sufentanil underneath the tongue  This delivery method eliminates the complications of an IV  increases the drug s efficacy  and provides patients and doctors with a safer treatment  Top line data from the final pivotal trial treating pain after knee or hip surgery was  of 2013 and highlighted many benefits  Some Doctor and Patient Benefits 
Patients experienced better  longer lasting  and more complete pain relief after orthopedic surgery 
Nurses reported that it was much easier to use the Nanotab system 
Traditional IV PCA is known for its confusing administering program and Zalviso avoids this problem 
Increased mobility in the hospital 
Decreased chance of IV related infections 
Political pressure and the opioid market
The FDA has been under pressure recently because opioid abuse is becoming a growing problem   the Centers for Disease Control and Prevention  CDC  declared prescription drug abuse to be an epidemic   of this year  the FDA announced stronger warning labels for all extended released opioids  The continued social pressure has negatively affected several small cap companies  while leaving others with opportunity  Because of this pressure  the FDA has been more apt to approve drugs that tackle this issue head on  AcelRx should benefit from this because it is improving the delivery system of approved drugs Zalviso should provide a safer  more effective  and a more cost effective solution with higher quality of care  BioDelivery Sciences International  NASDAQ BDSI  is a company that recently benefitted from the recent trends  BioDelivery develops several drugs that are in late stages of clinical trials in the pain and opioid dependence marketplace  The company recently received FDA approval for Bunavail  which delivers Subxone  buprenorphine naloxone sublingual film  as a therapy for opioid dependence  Subxone was approved by the FDA in 2002 and has been very successful  generating  1 4B in sales in 2013  BioDelivery is hoping to gain a share of that market using its BEMA  BioErodible MucoAdhesive  technology  BEMA technology delivers drugs using a bio erodible film across a mucous membrane  The film adheres to an oral mucosa membrane in about five seconds and takes fifteen to thirty minutes to dissolve  The BEMA platform has been proven to work  since the company already has received approval for its other product  Onsolis  BioDelivery recently  on June 6  BioDelivery s platform has been shown to be safer and more effective which is certainly what Obamacare aims for in part  BioDelivery is similar to AcelRx in that both companies are improving the delivery method for drugs that have been approved by the FDA and have a strong safety profile  Recently  Zogenix  NASDAQ ZGNX  has been in the news regarding its FDA approved drug Zohydro  Since the drug s approval last October  Zohydro has been under scrutiny by many physicians  as some are calling Zohydro    because it is a pure hydrocodone  and not a mix of Tylenol 3 and hydrocodone  Subsequently  some physicians have been encouraging the FDA to rescind its approval  Additionally  there were bills drawn by the House and the Senate to recommending the FDA reverse its decision  However  proponents of the drug agree with the FDA and believe Zohydro serves a great purpose for a subset of pain patients who suffer from unbearable pain that the currently available opioids cannot effectively treat  We tend to agree with Zohydro proponents and feel the FDA was correct in approving Zohydro  Additionally Durect Coproration  NASDAQ DRRX  and Pain Therapeutics  NASDAQ PTIE  are two partnered companies that have also been in the news regarding its chronic pain drug  The companies are developing Remoxy  which is a sustained release oral gel cap of oxycodone  The companies are also partnered with Pfizer  NYSE PFE   who is handling most of the development  The FDA has rejected Remoxy multiple times to date  and the organization is now asking for additional studies to be conducted before the companies can resubmit the NDA  As a result  the companies are currently conducting a Phase I safety study on the potential abuse factor  The FDA did not require any additional efficacy studies  but obviously was concerned with identifying any other potential safety issues with the drug 
Catalyst  Drug Approval Decision on July 27  2014
AcelRx  in December 2013 that the FDA accepted the NDA for Zalviso and set a   PDUFA  date for July 27  2014  This date is extremely important for the company because it will be its first approved product and the first revenue generator for the company  We believe there is a high chance that Zalviso receives approval because of the strong Phase III trial results  Since AcelRx is using an already approved drug  this significantly de risks the event  Additionally  the FDA has been highly focused on approving treatments that improve patient safety  From the Phase III trial results we can see that patients experienced better safety and better efficacy profiles  We give a 90  chance for approval  with the only wild card being a CRL for manufacturing  However  given that the company has experienced management and board members  we think this chance is relatively low  The company began partnering and preparing to commercialize Zalviso worldwide over 7 months ago  Recently   to prepare for commercialization  Although there is never a guarantee for approval  these signs are very positive and show the company is well prepared to market Zalviso  unlike many developmental companies who prepare poorly by not hiring the needed personal 
Zalviso Economics and Obamacare
When it comes down to it  the most important aspect of a biotechnology company is the profits  Zalviso is poised to take a significant share of the acute pain market because it is not only safer  but also more cost effective  The company recently published a   The study concluded that it would cost between  200  240 for two days of post surgical IV PCA s  Zalviso has been projected as low as  140  Additionally  Zalviso avoids the high cost of IV infections or other complications  Since  Obamacare  is beginning to further subsidize the healthcare system  the FDA and insurance companies favor more cost effective treatments  This bodes well not only for approval  but also for its long term commercial success  Cost effectiveness and quality of care are important as Obamacare seeks to cut down on the volume of patients in hospitals  Zalviso is certainly a product that can help hospitals achieve this goal  Hospitals that comply by cutting down on patient volume and improve patient satisfaction are eligible to  under Obamacare 
Chart

Based on the chart above  we think the stock price has a good chance here to see the mid  12 range  We have marked on the top of the chart in white a cup and handle formation in the chart  that is normally a very bullish sign  Additionally  we have also marked with the bottom white line a double bottom type pattern that shows up as a  W  in the chart  also bullish  Also  when considering the risk on market condition  with markets exceeding all time highs  along with Zalviso having a strong chance at approval  we think the 52 week high of  13 64 is possible here 
Conclusion
We believe July 27 is an inflection point for the company and that Zalviso will be approved that day  Given the strong trial results and political situation  we think the chances of approval are very high  On the rare chance the FDA rejected Zalviso  the stock price would likely be cut in half  We are also bullish on AcelRx management and are confident in the company s ability to market the product  Zalviso may not be a blockbuster drug or a revolutionary treatment  but it is a drug that should help provide significant revenue to grow this small cap company  We believe AcelRx can reach 52 week highs in the near term  and could see its valuation much higher in the longer term considering the advantages a product like Zalviso can enjoy under the new healthcare changes that Obamacare implements       This article is intended for informational and entertainment use only  and should not be construed as professional investment advice  They are my opinions only  Trading stocks is risky   always be sure to know and understand your risk tolerance  You can incur substantial financial losses in any trade or investment  Always do your own due diligence before buying and selling any stock  and or consult with a licensed financial adviser ",2014-07-02,Scott Matusow,https://www.investing.com/analysis/acelrx-likley-to-receive-fda-approval-shortly-218126,218126
221173,442689,PFE,Will FX Volatility Finally Pick Up This Week   ,opinion,"Market Drivers for April 28  2014

Cable at fresh yearly highs as Pfizer AZTA talks confirmed
JPY Retail Sales up 11 ahead of tax increase
Nikkei  0 99  Europe 0 46 
Oil  101 bbl
Gold  1303 oz 

Europe and AsiaJPY  Retail Sales 11 0  vs  10 9 EUR  GE Import Prices  0 6 North AmericaUSD  Pending Home Sales 10 00 AM AMThe dollar was weaker across the board with the exception of the yen on the first trading day of the week  as investors put aside the growing tensions in east Ukraine and focused instead on a string of M A activity in Europe that helped to lift European equities higher in morning Frankfurt trade Pfizer  NYSE PFE  confirmed last week s rumors of its interest in AstraZeneca Plc  AZN L  a deal that is reported to be near the  100 Billion mark  The news helped push cable to fresh yearly highs as the pair finally cleared the 1 6850 level on the assumption that M A flows from the transaction could prove to be enormous The euro also kept pace but the reason for its rise was less clear  The pair hit a high of 1 3876 on reports that Russian banks were heavy buyers  It is unclear whether buying was simply end of the month flows or whether there was continued capital flight in Russia as a result of a new round of sanction set to be announced by President Obama Mr  Obama is expected to issue new sanctions that will target individuals and companies and will target some high tech exports in Russia  This is another gradual move to punish Russia economically  but US has refrained from issuing full sectoral bans against banking or defense companies  although it reserved the right to do so in the future The conflict in Ukraine remains at a slow boil  as neither side is backing down and the prospect of further violence remains very real as Russian separatists have refused to surrender their positions  Any military move by Ukraine that results in casualties of Russian separatists could prompt a full incursion by Russian armed forces  but for now the markets remain non plussed by the events as consensus view continues to believe that the issue will be solved diplomatically In North America today  the eco calendar is nearly barren with only Pending Homes on the docket  Given the recent weakness in all the housing indicators the prospects of a downside miss are quite possible although the news is unlikely to have much impact on the market  USD JPY continues to hover in a 102 00 102 50 zone as it awaits a slew of economic data later this week After historically low volatility over the past two weeks  the currency markets appear to have finally come alive today and given the large amount of economic data along with the ever present geo political risks G 10 currencies look like they are finally ready to wake from their slumber ",2014-04-28,Boris Schlossberg,https://www.investing.com/analysis/will-fx-volatility-finally-pick-up-this-week-210916,210916
221174,442690,PFE, Dollar Heavy To Start The Week,opinion,The US dollar is heavy to start the week  Its gains are concentrated against the European currencies  whereas the yen weakness is a notable exception  Sterling has been lifted to new multi year highs  with the help of more M A reports  Pfizer  NYSE PFE  and Astrazeneca Plc  AZN   and ahead of Q1 GDP data tomorrow that is expected to show a modest acceleration in the economy over Q4 13 The euro shot up in European activity  seemingly led by sterling s advance  reaching  1 3880  an eleven day high  Fitch s upgrade of Spain before the weekend  BBB  from BBB  and the firm EONIA may be encouraging some buying of the euro  We note EONIA was fixed above the repo rate last Thursday and Friday  Barring month end squeezes  last Friday s fix of 33 bp was the highest in a few months  Spanish 10 Year bonds are bucking the heavier tone in the European bond market today  Robust gains in European equities may be sapping some strength from the bond market  German and Italian shares are leading the way higher  and the Dow Jones STOXX 600 is up 0 6   led by healthcare and financials The Swedish krone though is the strongest of the major currencies today  The surge in March retail sales  1 1  vs  Bloomberg consensus of 0 2   has given participants second thoughts about the prospects for a rate cut  which had been spurred by deflation  March CPI  0 6  year over year   Owing to a decision to reduce the number of meetings years  the Riksbank will not meet again until July The pendulum of sentiment will likely swing back and forth  but we suspect the key variable that the central bank s decision turns on is likely inflation deflation  not the real sector  The next CPI report is due out May 13  Nearby support for the euro against the krona comes in near SEK9 0440  last week s low and break could spur a quick move toward SEK9 0 The dollar briefly dipped below JPY102 before the weekend  It has traded in a narrow trading range in the third of a yen range above JPY102  We suspect that offers will be found in the JPY102 50 60 area today that may prove sufficient to cap the greenback  The somewhat stronger than expected March retail sales report  11 0  rise vs  consensus 10 8  and 3 6  in February  failed impress the foreign exchange market  The retail sales tax increases changes everything  The economic performance after the tax  and specifically  after the initial hit  is the key  The BOJ meets tomorrow  but this is a non event  The labor cash earnings report tomorrow may be more significant  Cash earnings contracted on a year over year basis in seven months last year and have begun off this year by contracting in both January and February  Lastly  we note the Shanghai Composite fell for the fourth session today and by the most in seven weeks   with a 1 6  drop  Reports suggesting that the China Securities Regulatory Commission will approve at least four new IPOs at midweek may have weighed on sentiment  In addition  the country s largest life insurers reported a drop in profits  There are also reports that regulators are clamping down on lending to the steel industry  a sector that has been identified by officials as suffering from excess capacity  This seemed to have been behind the 5  slide Chinese iron ore futures prices today  Meanwhile  the PBOC lifted the yuan s reference rate by 0 02  today to CNY6 1565  the highest since April 14 ,2014-04-28,Marc Chandler,https://www.investing.com/analysis/dollar-heavy-to-start-the-week-210926,210926
221175,442691,PFE,Euro And Sterling On The Move,opinion,"After last week s painfully tight forex trading ranges  and an historic seven year low in volatility  it seems that dealers and investors are beginning this week on the  front  foot  Both the Euro and the pound are on the move  Potential M A activity  Astrazeneca     Pfizer   seems to helping GBP on the margins   pushing it to print a fresh 4 year high above  1 6843  Regarding the 18 member single currency the EUR  there is no obvious reason for this morning s strength  There has been reasonable retail demand and combined with market chatter that Russian Banks have entered the fray has managed to push the EUR above its two week high   1 3873   The Central Bank of Russia s recent comments that they would sell their dollar holdings has also the market  front  running the Central Bank s requirement of reserve diversification into the EUR 

It may not just be  reserve diversification  talk that s supporting the EUR  Some of the blame should also be passed off to the ECB s excess liquidity managing to hit a multi year low and the EONIA  overnight interest rates  at their second highest level this year  Higher rates combined with greater Euro money market liquidity would suggest that  markets are healing and segmentation abating   This would obviously dampen the prospect for any immediate ECB action  and keep the single currency somewhat supported across the board  It will be difficult for Draghi s and his fellow cohorts at the ECB to have a lasting impact unless they provide more explicit signals to help clear market uncertainty over whether they will act in May or June  The market is leaning predominately towards June  but no one can rule out any liquidity enhancing measures being introduced next month 

The market has little fundamental data to chew on today  but there have been a few ECB speakers already on tap during the Euro session  The ECB s Constancio is worried about disorderly increases in bond yields and stated that the central bank would act if it saw the need to do so  While Noyer  speaking in Frankfurt  commented that the EUR s rise is equivalent to  unwarranted monetary policy tightening   The market is interpreting his comments as  sufficient to support the prospect of a negative deposit rate   However  with the market already expecting negative deposit rates his comments have had little impact  The ECB is required to  walk the walk  rather than repeating their  desire to act  

A squeeze in money market rates and reserve diversification is the likely EUR driver as the market heads stateside  With so little actually going on this month  this rally has more to do with a  positional  squeeze rather than a fundamental one  The EUR bear got short of the currency on expectations that Draghi and company would be dovish and on the back of some stronger US data  However  the single currency has remained resilient to both  and coupled with the major event risks this week is pressurizing most of those weaker  short  positions  The tech traders believe that the  1 3910 threshold will provide strong resistance in the first time of asking  especially ahead of German state CPI s tomorrow and the Euro zone s CPI and FOMC meeting on Wednesday  If the April figure fails to improve the ECB would come under further pressure to take incremental monetary actions 

Regarding the pound  there was a modest cable dip to  1 6837 after the AstraZeneca statement stating that they were confident in their own strategy and rejected Pfizer talks  However  there is solid support at this morning s sessions low between  1 6777 1 6787  with laddered sterling bids all the way above the psychological  1 6800 handle  Now with a new multi year high print   1 6855  it certainly exposes  1 6900 in the shorter term 
Both the FOMC and BoJ meet this week  The Fed meet finishes Wednesday and is almost certain to taper their asset buying program by another  10B  The accompanying statement  no press conference scheduled  should indicate that the Fed intends to keep rates  lower for longer   The BoJ meeting finishes the same day  and so far market consensus does not expect any immediate action from Governor Kuroda and company  However  it should not be ruled out  but the general feeling is that the BoJ will stay on hold  believing it s too soon to gage total effect of the introduction of the sales tax  April 1st   Governor Kuroda s press conference will be key   expect it to shape the timing for when the BoJ will next take action ",2014-04-28,Dean Popplewell,https://www.investing.com/analysis/euro-and-sterling-on-the-move-210938,210938
221176,442692,PFE,Global FX  ECB Comments Lift Euro,opinion,"EUR USDComments from ECB s Knot over the weekend saying that he holds reserves on the effectiveness of QE  despite the general pro QE sentiment coming from the ECB  lifted money market rates and consequently the EUR  The EUR USD pair saw a sharp upturn early in the European session as the ECB announced that liquidity in the Eurozone had fallen again holding below the EUR 100bln level to EUR 86 6bln  marking multiyear lows  This comes after the ECB balance sheet contracted following the large 3y LTRO repayment on Friday  The pair then traded relatively range bound throughout the session with no scheduled tier 1 data releases  The remainder of the session has no scheduled risk events as markets will now look towards German regional and national CPIs tomorrow  
GBP USDGBP also saw a sharp upturn in the early European session  adding to USD weakness  as Pfizer Inc  NYSE PFE  confirmed interest in purchasing Astrazeneca Plc  AZN  in a deal worth an estimated GBP 58bln  This move saw GBP USD at the highest levels since November 2009  The pair then traded horizontally through the majority of the session before later paring much of the gains  reducing them to only 20 pips  as markets correct for the earlier up tick  The markets look ahead to UK GDP due tomorrow at 0930BST  
USD JPYDespite USD weakness from the get go  due to M A talk in the UK and the contracting liquidity in Europe  USD JPY has been pushing upward today  The JPY softened as the US unveiled its latest sanctions on individuals and companies in Russia which were less imposing than feared  The pair was then lifted further as US pending home sales beat expectations at 3 4  vs  Exp  1 0   This helped to relieve some of the poor sentiment from last week s disappointing existing homes sales data  helping push USD JPY above 102 50  Markets in Japan will be closed tomorrow marking Showa day and the start to the Golden Week holiday ",2014-04-28,Talking Forex,https://www.investing.com/analysis/global-fx:-ecb-comments-lift-euro-210959,210959
221177,442693,PFE,Euro Higher On Draghi QE Dismissal Reports,opinion,Euro continues to sit closer to the 1 40 level in EUR USD than the European Central Bank would have wanted  The single currency moved higher after Obama threatened further sanctions on Russia  The EUR USD move is obviously a reaction to Russian banks  efforts to diversify away from the USD  a currency that may not be as easy to get in Russia in a few weeks  The weakness of these additional sanctions   on 17 companies and 7  inner circle  individuals   allowed Russian assets to recover some of their losses The remainder of the euro strength has come from a report in which the ECB President Mario Draghi has told German politicians that a QE programme is not likely at the moment  This would match up with the rhetoric from the European Central Bank in the previous weeks  a bank that believes in a period of low inflation but little risk of outright deflation GBP also moved higher yesterday morning as traders began to price in the mega merger in the pharmaceutical industry  AstraZeneca  AZN LONDON  may be worth  100bn to Pfizer  NYSE PFE  but that is a heck of a lot of cable to shift even in a very liquid cross  GBP USD was unable to stay as well bid as EURUSD given the strong buying of euro by Russian banks in the European session Q1 s GDP numbers from the UK are due this morning   albeit the volatile provisional release   and should confirm that the UK s recovery is continuing at a fair old clip  Manufacturing  construction and services output numbers have all been healthy throughout the quarter despite the softening of PMI measures comparatively from Q4 All in all  we are expecting growth to increase by 0 8  in Q1 and around 3 2  on a year on year basis  It is a matter of time until these strong figures start to see some form of dissent by the more hawkish of Bank of England members  although we maintain the view that the PMI numbers later this week are more useful in gauging the strength of the UK s corporate sector The number is due at 09 30 with the more bullish of estimates at 1 0   consensus at 0 9  and the low at 0 6   Elsewhere  the story of falling volatility in currency markets continued with overall volumes falling to a 7 year low  Yesterday s slip was a continuation of the low rate trend that we have been seeing for years now  but emphasised by an Interfax report that some Russian troops had returned to base overnight from positions close to the Ukraine border  We have seen AUD and NZD come lower overnight as investors continue to shift price out some fairly aggressive rate rise expectations  Overnight swaps markets have lost 40bps of increases in the past 2 weeks   a sign that the 125bps of increases the RBNZ wanted through the year was a bit too rich German CPI will give us a fair sign of where tomorrow s Eurozone CPI number will be tracking  Once again  consensus estimates put Eurozone CPI at 0 8  through the past month  0 3  higher than March s and  although still a fair way away from the ECB s 2  inflation target  a lot healthier  Anything higher and the market will be looking to take EURUSD to the 1 40 level and GBP EUR back towards 1 20  The German measure is due at 13 00 with releases from individual states due throughout the morning ,2014-04-29,Jeremy Cook,https://www.investing.com/analysis/euro-higher-on-draghi-qe-dismissal-reports-211055,211055
221178,442694,PFE,What to Expect From Pfizer s Earnings,opinion,"Pfizer Inc  NYSE PFE  is set to report FQ1 2014 earnings before the market opens on Monday  May 5th  Pfizer is one of the world s largest pharmaceutical companies and is currently attempting to buy British Swedish pharmaceutical giant AstraZeneca for up to  106 billion  The pharmaceutical industry has a very high cost structure and right now we are seeing several potential consolidation deals to drive those costs down so the firms can benefit from a larger scale of operation  This quarter Wall Street expects Pfizer s earnings to increase marginally compared to FQ1 of last year and for sales to fall by over  1 billion  Here s what investors are expecting from Pfizer on Monday 
The information below is derived from data submitted to the Estimize com platform by a set of Buy Side and Independent analyst contributors 

The current Wall Street consensus expectation is for Pfizer to report 55c EPS and  12 016B revenue while the current Estimize com consensus from 13 Buy Side and Independent contributing analysts is 57c EPS and  12 265B in revenue  This quarter the buy side as represented by the Estimize com community is expecting Pfizer to beat EPS estimates from Wall Street by 2c per share and  249 million in revenue 
Over the past 6 quarters the consensus from Estimize com has been more accurate than Wall Street in forecasting Pfizer s EPS and revenue 4 and 3 times respectively  By tapping into a wider range of contributors including hedge fund analysts  asset managers  independent research shops  students  and non professional investors Estimize has created a data set that is more accurate than Wall Street up to 69 5  of the time  but more importantly it does a better job of representing the market s actual expectations  It has been confirmed by Deutsche Bank Quant  Research and an independent academic study from Rice University that stock prices tend to react with a more strongly associated degree to the expectation benchmark from Estimize than from the Wall Street consensus 
The magnitude of the difference between the Wall Street and Estimize consensus numbers often identifies opportunities to take advantage of expectations that may not have been priced into the market  In this case we are seeing a larger than usual differential between the expectations from Estimize and Wall Street 

The distribution of estimates published by analysts on the Estimize com platform range from 56c to 58c EPS and from  11 779B to  12 537B in revenues  This quarter we re seeing a narrower range of estimates on Pfizer than usual 
The size of the distribution of estimates relative to previous quarters often signals whether or not the market is confident that it has priced in the expected earnings already  A narrow distribution of EPS estimates signals more agreement in the market  which could mean less volatility post earnings 

Throughout the quarter the Wall Street EPS consensus fell from 57c to 55c while the Estimize consensus also dropped 2c from 59c to 57c  Meanwhile the Wall Street revenue consensus remained relatively flat and ended the period at  12 016B while the Estimize consensus decreased from  12 644B to  12 265B   Timeliness is correlated with accuracy and downward analyst revisions going into an earnings report are often a bearish indicator 

The analyst with the highest estimate confidence rating this quarter is bonefishr who projects 58c EPS and  12 537B in revenue  bonefishr is ranked 515th overall among over 4 400 contributing analysts  Over the past 2 years bonefishr has been more accurate than Wall Street in forecasting EPS and revenue 71  and 43  of the time respectively throughout 7 estimates  Estimate confidence ratings are calculated through algorithms developed by deep quantitative research which looks at correlations between analyst track records and tendencies as they relate to future accuracy  In this case bonefishr is making a bullish call and also submitted an optional analysis citing a recent study showing efficacy in the Prevenar 13 preventative pneumonia drug for the elderly 
This quarter the Estimize community expects Pfizer to come in ahead of Wall Street s expectations by a considerable amount on both the top and bottom line  However revenue is expected to fall by over  1 billion compared to last year and Pfizer is picking up the pace on its efforts to acquire AstraZeneca for over  100 billion  For more speculation about the AstraZeneca deal and to see other merger and acquisition predicts  head over to our corporate actions platform at  
Get access to estimates for Pfizer published by your Buy Side and Independent analyst peers and follow the rest of earnings season by heading over to Estimize com  Register for free to create your own estimates and see how you stack up to Wall Street ",2014-05-05,Estimize,https://www.investing.com/analysis/what-to-expect-from-pfizers-earnings-211690,211690
221180,442696,PFE,Halozyme Therapeutics  PEGPH20 The Next Major Value Driver ,opinion,Investment summary  Halo effectWith a positive CHMP opinion received for Herceptin SC  Halozyme  HALO  is moved a step closer to being able to reap the full commercial potential of its rHuPH20 platform  which is being used to develop subcutaneous  sc  formulations of leading IV drugs for Roche and other partners  This opportunity currently drives Halozyme s valuation  but we contend that the market is ignoring certain key pipeline assets  notably PEGPH20  which is in a Phase II study in pancreatic cancer rHuPH20 on its way to the marketHalozyme s recombinant human hyaluronidase  rHuPH20  technology enables sc delivery of biologic drugs that can otherwise only be given by IV infusion  The positive opinion from the Committee for Medicinal Products for Human Use  CHMP  for Herceptin  trastuzumab  SC for HER2 positive breast cancer  one of Herceptin s two approved indications  is a major event and will pave the way for its approval and commercialisation over the next one to two quarters  Herceptin  IV  recorded sales of CHF5 9bn in 2012  of which c 36  was in Europe  Halozyme will receive a c 5  royalty on sales of the sc product  We believe Roche will drive physicians to adopt given the potential approval of biosimilars PEGPH20 the next major value driverA major event on the horizon is data from a 124 patient Phase II trial of Abraxane  nab paclitaxel  gemcitabine   PEGPH20 for pancreatic cancer  This study has the potential to show added clinical benefit to this new standard of care  Data from a single arm Phase II study presented at ASCO 2012 showed that PEGPH20  a pegylated version of rHuPH20  given with gemcitabine produced an overall response rate of 42   rising to 67  in patients with higher levels of hyaluronan  the target of rHuPH20  This compares favourably to historic data for gemcitabine  which indicates an ORR in the 5 10  range  The nab pac gem combination showed an ORR of 48  in a Phase I II and a 29  in the MPACT Phase III trial Valuation  New data would add valueHalozyme s EV of c  820m can in our view be accounted for by its future rHuPH20 based royalty streams from partners including Roche  Pfizer  Baxter and ViroPharma  while the value of its pipeline drugs  including Hylenex  PEGPH20 and HTI 501  recombinant human cathepsin L   is largely ignored by the market  Thus  future clinical data  if positive  could catalyse a significant increase in value To Read the Entire Report Please Click on the pdf File Below ,2013-07-05,Edison,https://www.investing.com/analysis/halozyme-therapeutics:-pegph20-the-next-major-value-driver-174335,174335
221186,442702,PFE,Big Cap Pharma Is Turning Up,opinion,Tuesday morning I wrote about how Healthcare was ready to take some leadership again  and it is moving a bit  although everything is   But lets talk specifics  Here are 3 stocks that all are reversing back higher on the weekly timeframe  Eli Lilly  LLYEli Lilly  LLY  is bouncing off of the 20 week Simple Moving Average  nearly equivalent to the 100 day SMA  after a short pullback  this pullback reset the Relative Strength Index  RSI  back below the technically over bought level and pulled down the Moving Average Convergence Divergence indicator  MACD  from its recent new high on the signal line  The Measured Move higher takes it to 67 50  Merck  MRKMerck  MRK  pulled back from its recent high on the earnings report  and is now heading back higher  The RSI is also moving back higher after resting off the technically overbought level  and the MACD is leveling  The Measured Move higher on this one takes it to 53  Pfizer  PFEPfizer  PFE  is doing the same thing  settling after pulling back and now reversing higher  The RSI is back rising and the MACD has pulled back a bit and is stabilizing  The Measured Move higher in this name takes it to about 35  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ,2013-05-14,Gregory W. Harmon,https://www.investing.com/analysis/big-cap-pharma-is-turning-up-166951,166951
221187,442703,PFE,Clovis Oncology Skyrockets After ASCO Presentations,opinion,Clovis  CLVS  is an acquisition focused biopharmaceutical company that stayed under the radar after its NASDAQ IPO in November 2011  With two notable early stage oncology compounds in its pipeline  Clovis didn t really attract much interest from the market until yesterday  June 3rd  2013    when the company reported results from ongoing Phase I II trials for both CO 1686 and Rucaparib  CO 1686 was originally designed by a biotech company named Avila Therapeutics  a covalent drug focused entity that was acquired by Celgene on March 7th  2012 in a  925 M deal  The compound was introduced to the Clovis pipeline in a  209 M partnership made in 2010 between Avila and Clovis  and the IND application was accepted not long before the company held its IPO on April 3rd  2012  The molecule is a covalent drug that irreversibly inhibits epidermal growth factor receptor  EGFR   which aids cancer cells in proliferation  Clovis is specifically developing it as a non small cell lung cancer  NSCLC  treatment  since it can bypass certain obstacles in NSCLC cells that other EGFR inhibitors cannot  Lung cancers that are caused by EGFR are initially responsive to tyrosine kinase inhibitors that can inhibit their catalytic activity  although mutations in the lung cancer cells  like the T790M resistance mutation  can ultimately shut down the viability of TKI based mechanisms of action for drugs like gefitinib  Iressa  and erlotinib  Tarceva   Unlike other EGFR inhibitors  CO 1686 is designed to irreversibly inhibit mutated versions of EGFR  including T790M  while ignoring wild type  normal  EGFR  This is a particularly desirable trait  since a molecule with potent and irreversible EGFR inhibition would be highly toxic to patients  Because of this particular trait the strong safety data that Clovis reported at ASCO 2013 was particularly exciting to Wall Street  The stock moved up 104  on the Monday following the presentation  and the market capitalization of the company hovered around  2 B for the first time since Clovis  IPO in late 2011  Also important to the rally was the strong data that company presented for the drug Rucaparib  which is a potent PARP inhibitor   or a Poly ADP ribose  polymerase inhibitor being developed for breast ovarian cancer indications  This compound was originally one of Pfizer s oncology drugs and was named  PF 01367338  during its tenure as drug for solid tumors  although the development was handed over to Clovis in a deal announced in 2011 that gave Clovis full responsibility over the development and commercialization of the compound in exchange for an upfront payment and milestone payments of up to  255 M  This is an unusual move for an early stage pharmaceutical company  although Clovis was  and is  better funded than most companies in the sector  What was so exciting about the CO 1686 and Rucaparib data was that both drugs demonstrated efficacy in their respective early stage trials without reaching MTD  maximum tolerated dose   The implication is that the efficacy of these drugs may be significantly boosted in Phase II trials  which bodes well for the company s hopes for expedited approval for its oncology pipeline  CO 1686 was probably the more exciting of the two candidates after the results it demonstrated in non small cell lung cancer  although optimal dosing has not been established yet  Although the drug was extremely well tolerated  the safety profile should improve as the company switches from a capsule to a tablet formulation  a move which will triple the plasma concentration of CO 1686 per dose   This may allow the company to significantly increase the already promising efficacy  From the company s ASCO related  for CO 1686  One patient with a del19 T790M  tumor had progressed on erlotinib immediately before beginning CO 1686 therapy  The patient  enrolled in the 300 mg BID cohort  is currently in cycle 6 of CO 1686 therapy  with a confirmed PROne patient with an L858R T790M  tumor had received six previous lines of therapy  including two previous TKIs  dacomitinib and erlotinib  and had most recently progressed on a combination of erlotinib and gemcitibine immediately before beginning CO 1686 therapy  This patient has demonstrated tumor shrinkage in brain metastases  present at baseline   as well as lung and liver tumors  The patient  enrolled in the 900mg BID cohort  exhibited a PR in cycle 4 of CO 1686 therapy  treatment is ongoingOne patient with a del19 T790M  tumor had received two previous lines of therapy  This patient exhibited a PR in cycle 2 and is currently being dosed in cycle 3 at 900mg BIDOne patient with a del19 T790M  tumor had received two lines of prior cytotoxic chemotherapy and had also progressed on erlotinib treatment  This patient exhibited a PR in cycle 2 and is currently in cycle 3  receiving 900mg BIDTwo additional T790M  patients have achieved greater than 20 percent target lesion shrinkage with stable non target lesionsRucaparib  which also drew major interest  presented 89  clinical benefit rate in ovarian cancer patients across all the dosage arms  and was well tolerated with objective responses in BRCA mutant ovarian  breast  and pancreatic cancer patients as a monotherapy  This helps to build the case that this could become a popular breast ovarian cancer therapy that can be combined with a chemotherapeutic agent in a first line regimen ,2013-06-05,Myriad Equity,https://www.investing.com/analysis/clovis-oncology-skyrockets-after-asco-presentations-169854,169854
221191,442707,PFE,Athersys QuickView ,opinion,Investment Summary  Gathering MomentumAthersys  stock has gained 25  in the last month to trade at an 18 month high  We believe positive biotech sentiment in general  and burgeoning interest in stem cells and regenerative medicine in particular  are contributory factors  For Athersys  the key near term catalyst is headline data in Q413 from a Phase II study of its MultiStem product  allogeneic stem cells from adult bone marrow  for ulcerative colitis  UC   conducted by partner Pfizer  Positive results would provide important clinical validation of MultiStem and help to de risk other opportunities A Significant Market Opportunity  UCDecision Resources predicts the drug market for UC will double to  3 7bn by 2021  driven by the use of current  Remicade Humira  and prospective  Simponi  anti TNFs  and newer agents such as vedolizumab and tofacitinib  Yet these numbers do not project the potential impact of cell based therapies  which could be significant for patients intolerant of  or failing to respond to  these treatments Robust Trial DesignIn February 2011  Pfizer and Athersys initiated the Phase II study in up to 126 patients with moderate to severe UC  Mayo score  6   who are intolerant   unresponsive to multiple current treatments  including anti TNFs  Low and high doses of MultiStem are being tested in the 16 week safety efficacy study and primary endpoints include  incidence severity of adverse events  up to one year   changes in endoscopic valuation  Baron score   and the Mayo rectal bleeding sub score  In a mouse model of graft vs host disease  MultiStem cell treatment resulted in almost complete reversal of gastrointestinal pathology  similar to UC pathology  Clinical Validation OpportunityResults in UC will be the first Phase II data for the MultiStem technology  a significant milestone for Athersys and potential trigger for Pfizer to advance MultiStem into pivotal studies in UC and or Crohn s disease  The 2009 Pfizer deal provides for up to  105m in milestones and royalties on sales Valuation   98m EV And RisingWith an estimated  21m in cash at end Q113  Athersys  EV is now  98m and we see this rising further on positive UC data  Results in H114 from a Phase II study of MultiStem in ischaemic stroke  a high risk but high reward indication  is a potentially transformational event for Athersys To Read the Entire Report Please Click on the pdf File Below ,2013-05-08,Edison,https://www.investing.com/analysis/athersys-quickview-166143,166143
221196,442712,PFE,Athersys  A Quick View ,opinion,Investment Summary Multi tasking Stem CellsAthersys is lining up a number of catalysts over the next 12 months that could transform the investment case for the stem cell specialist  The key event in 2013 is headline data in Q3 from a Phase II study of its MultiStem product  allogeneic stem cells from adult bone marrow  for ulcerative colitis  UC   conducted by partner Pfizer  Further 2013 catalysts include  FDA authorisation of a Phase II III trial of MultiStem in graft versus host disease  GvHD   and partnership s  for the preclinical 5HT2c agonist programme in obesity schizophrenia  In H114  Phase II data for MultiStem in ischaemic stroke could be a breakthrough event for Athersys Inflammatory Bowel Disease  IBD  PotentialA partner since 2009 for potential IBD applications of MultiStem  Pfizer is running a  Phase II study in moderate to severe UC  Mayo score  6    adverse events  endoscopic valuation  Baron score  and the Mayo rectal bleeding sub score are the primary endpoints  Positive data in H213 would provide important validation of the MultiStem approach  first ever Phase II data  and encourage Pfizer to conduct pivotal studies in UC and or Crohn s disease  deal    105m milestones   royalties  Multiple Shots On GoalAthersys has successfully completed Phase I studies of MultiStem in acute myocardial infarction  AMI  and GvHD  with a design for a Phase II III study in GvHD currently under FDA review  The 36 patient Phase I data in GvHD showed a positive impact on GvHD incidence  in a high risk patient group  and other clinical measures  eg relapse free survival and infection rates   Meanwhile  a  Phase II study in ischaemic stroke is ongoing   results in H114  adverse events and portion of patients with a modified Rankin Scale  mRS  score  2  could be transformational Partners Sought For Obesity ProgramThe FDA approval in 2012 of Arena s obesity drug Belviq  lorcaserin  has renewed partnering optimism for Athersys  small molecule 5HT2c agonist programme  for obesity and or schizophrenia  Highly selective to 5HT2c  i e  inactive on side effect linked  off target 5HT2a b   a partnership may be secured in H113 Valuation   57 5m EVWith  25 5m in cash at end 2012  Athersys has an EV of  57 5m  We note some of its more advanced stem cell peers  Cytori and Pluristem  have respective EVs of  155m and  132m  Positive Phase II data for MultiStem in UC and ischaemic stroke should help Athersys narrow this valuation gap To Read the Entire Report Please Click on the pdf File Below ,2013-03-13,Edison,https://www.investing.com/analysis/athersys:-a-quick-view-158865,158865
221199,442715,PFE,Strong Performance From US Stocks  All Eyes on The Fed ,opinion,US stocks continue strong performance despite weak US consumer confidence Asian stocks rise on strong Korean production and positive sentiment All eyes on the Fed today  We expect a continued soft tone in the statement Markets Overnight  Risk appetite continued to be strong yesterday despite weak data on US consumer confidence and technically overbought markets  The Dow Jones Index reached a new 5  year high and is now up 6 5  so far this year  Equity markets continue to be underpinned by earnings reports as around 70  of companies reported so far have beaten expectations  Yesterday Pfizer led blue chip stocks higher after reporting Q4 earnings that beat estimates  Shares are technically overbought on short term measures but so far better earnings and a strong investor flow into equities have supported the strong performance   A weak report on US consumer confidence was not able to ruin the positive market sentiment  Confidence among US consumers fell more than expected in January from 66 7 to 58 6   most likely related to the increase in the payrolls tax on 1 January   In Asian markets the positive sentiment was underpinned by strong data on Korean industrial production adding to the picture of a decent recovery in Asia  Industrial production rose 1 0  m m in December  consensus  1 5  m m  and has increased at the fastest pace over a three month period since February 2011   All eyes now turn to the Fed meeting tonight where markets look for a continued soft statement from FOMC  We do not expect any big changes in the statement as the Fed is likely to stick to the easing bias given the mixed data at the beginning of the new year   see FOMC Preview  Too early for the Fed to change bias  January 28  The US economic surprise index has fallen from fairly high levels to below zero over the past month showing that on balance key figures have been weaker than expected lately   The rise in risk appetite pushed the 10 year yield in the US higher overnight  above 2   whereas 2 year yields have been broadly stable in anticipation of a continued soft statement from the Fed today   In the FX markets EUR USD climbed higher again yesterday but has stayed unchanged overnight just below 1 35  USD JPY is up in Asian trading to just below 91  EUR SEK fell below 8 60 in late afternoon and has stayed there overnight  To Read the Entire Report Please Click on the pdf File Below ,2013-01-30,Danske Markets,"https://www.investing.com/analysis/strong-performance-from-us-stocks,-all-eyes-on-the-fed-153124",153124
221200,442716,PFE,Cytos Biotechnology   Musical Chairs ,opinion,Musical chairsNovartis  NVS  has returned NIC002  a smoking cessation vaccine  to Cytos Biotechnology  CYTN  but Pfizer  PFE  has started a Phase I study with VLP IgE  The investment case is barely altered by these changes and still largely hinges solely on how its main asset  CYT003  progresses through a key Phase IIb trial in allergic asthma  The study is due to report early data in H114  with full results by end 2014  A positive outcome should mean that debt  due for repayment in February 2015  will be converted or repaid without difficulty  and that Cytos will have sufficient time to out license CYT003 Novartis returns rights for NIC002   Novartis has terminated development of NIC002  a therapeutic vaccine candidate for the treatment of nicotine addiction  This follows from a disappointing Phase II study  submitted in October 2009  which failed to meet the primary endpoint of increased smoking cessation  The other Novartis collaboration involves CAD106 for Alzheimer s disease and is in Phase II development     but Pfizer moves IgE programme into Phase IPfizer has started a Phase I trial with the anti IgE vaccine with two different adjuvants in patients with perennial allergic rhinitis  The vaccine is based on Cytos s virus like particle  VLP  platform  The 189 patient trial is expected to be completed by the end of 2014  Novartis and Roche sell the anti IgE antibody omalizumab  Xolair  for the treatment of allergic asthma Key CYT003 trial to report early data in H114The investment case for Cytos Biotechnology is still largely dependent on how its main asset  CYT003  progresses through a critical Phase IIb trial in allergic asthma  Full data from this study is expected by end 2014  if the trial is positive  we believe that current financing structures should mean that debt will be converted or repaid without difficulty  and that Cytos will have sufficient time to out license Valuation  Upside dependent on CYTOO3 trial successOur valuation falls by CHF4m to CHF94m or CHF4 19 per share following the removal of NIC002 and addition of VLP IgE on our model  If CYT003  currently worth CHF75m  is successful in the key Phase IIb trial  the value per share would rise to between CHF5 31 and CHF5 92 per share at FY14  assuming that the conversion of loan notes and exercising of outstanding warrants occurs as expected To Read the Entire Report Please Click on the pdf File Below ,2013-02-11,Edison,https://www.investing.com/analysis/cytos-biotechnology---musical-chairs-154789,154789
221201,442717,PFE,Oxford BioMedica  Financed Through To Early 2014 ,opinion,Look no further   Oxford BioMedica s  OXB L  investment case is geared to the striking of worthwhile commercial partnerships for its late stage clinical assets  The next key inflection point is whether Sanofi decides to opt in for the further development of RetinoStat  a gene based treatment for  wet  AMD  age related macular degeneration   A positive outcome would help validate the LentiVector platform and could kick start additional collaborations  We currently value the company at  58 5m  down from  62 5m  RetinoStat opt in by Sanofi is keenly awaitedOxford BioMedica is essentially a bet on the merits of gene therapy in general and the LentiVector delivery platform in particular  The approach is promising  particularly in ophthalmology indications where a single administration could safely provide a sustained  or even permanent  effect  Having opted in for two smaller ocular projects  Sanofi s decision on RetinoStat could be the defining moment for Oxford BioMedica Collaborations have been slowOxford BioMedica has endured a difficult period  especially as collaboration discussions failed to conclude  yet gene based medicines offer the prospect of dramatically altering the outcomes of a number of devastating diseases  The recent  November 2012  European approval of UniQure s Glybera marks a pivotal point for gene therapy  effectively mapping a regulatory pathway  Meanwhile  Oxford BioMedica has successfully de risked several critical aspects of the process  especially production Currently financed through to early 2014Net cash was reported as  14 1m at the end 2012  which with forecast FY13 R D  net  spend of  11 3m and underlying G A expenditure of  3 3m  suggests the current cash runway extends through to early 2014  Were Sanofi to opt in to RetinoStat  a decision is expected before Q114   we estimate a  20m milestone payment would be triggered  so extending the runway to around mid 2015  Further income could arise from manufacturing revenues and other partnering milestones  eg around  1 2m from Pfizer for the clinical start for the anti 5T4 antibody project  Valuation  Pipeline alone supports a  58 5m valueClearly much depends of the successful development of the ocular programmes  in collaboration with Sanofi   Our valuation of  58 5m  down from our previous  62 5m  is based on an rNPV model of the late stage pipeline alone  We have conservatively chosen not to include the value of other less visible  but arguably just as important  assets such as the manufacturing facility and intellectual property estate To Read the Entire Report Please Click on the pdf File Below ,2013-03-05,Edison,https://www.investing.com/analysis/oxford-biomedica:-financed-through-to-early-2014-157768,157768
221206,442722,PFE,Halozyme s Newfound Credibility  Pfizer,opinion,For the most part  2012 was not a very good year for Halozyme Therapeutics  HALO  Investors  eagerly anticipating FDA approval of Baxter s  BAX  immune globulin infusion HyQ  were met with a press release on April 16  which announced that the FDA wanted more information on HyQ  which drew immediate concern for the status of the biologic s BLA Bumps In The RoadHALO and BAX shareholders  worst fears were confirmed on August 1 when we learned that the FDA issued a complete response letter  saying there was not enough pre clinical data to support the BLA  Other specific issues were brought up  like the generation of antibodies through usage of HyQ that could potentially have adverse effects on patients in terms of reproduction  development  and fertility  Halozyme doesn t seem to believe that the antibody in question  anti rHuPH20  is associated with adverse events  even in large amounts  That is a fairly important stance to take  since Halozyme s entire Enhanze biologics platform is based on the patented rHuPH20 enzyme Due to the failure of HyQ s BLA last year  HALO lost about half its value by mid December 2012  BAX  being a much larger company with less dependency on the potential revenues of HyQ  shrugged off the damage  Things could have gotten worse for Halozyme had they not announced a partnership with Pfizer  PFE  on December 21  which sent the stock soaring about 25  higher The Pfizer EffectWhile the market is still quite skeptical about Halozyme s Enhanze platform due to the FDA s concern with the safety of rHuPH20  a good number of people changed their mind after the announced collaboration with Pfizer  Not only did this give Halozyme new opportunity in the future  but it also suggested that Pfizer s own research indicated that there was nothing wrong with rHuPH20 or the Enhanze platform at all Another great aspect of the arrangement is that EPS negative Halozyme will receive milestone payments from Pfizer  Considering that the company has just  100 million of cash  with an expected cash burn rate of  45  50 million in 2013  it s clear that the company would have had to hold a public offering or secured a private line of financing to sustain operations after 2014  Pfizer s milestone payments could turn out to be extremely useful as Halozyme as it sustains three of its own drug development programs It s hard to say how high HALO can move on the Pfizer deal alone  HALO isn t exactly cheap with a market capitalization of  780 million and a lack of a steady revenue stream  although the Pfizer deal could yield as much as  518 million in milestone payments  This is encouraging for investors who are interested in waiting for the full development of the aforementioned drugs that Halozyme is developing  Analog Insulin PH20 for diabetes  PEGPH20 for cancer  and the dermatology treatment HTI 501 are all in phase II trials and could generate substantial interest in Halozyme with their own prospects in the market  It s true that Halozyme s pipeline is also tied to rHuPH20  the diabetes drug uses it directly   which is why there is still major concern over the FDA s complete response letter in 2012  but Halozyme should be able to address all the issues well before another BLA is submitted ConclusionI think HALO is undergoing a recovery rally due to the hype about the collaboration with Pfizer  and could see  8 share or more as we head into a new year  Those who are interested in HALO for the long haul should carefully watch developments surrounding the safety profile of rHuPH20  which could make or break Halozyme s own pipeline  The market seems to think that rHuPH20 is fine  since the FDA s complete response letter seemed a bit too cautious  Also note that Pfizer s research indicated that Enhanze was a safe enough biologics development platform to partner with  HALO investors should also keep tabs on the company s financials  which are stable for the time being but could become an issue if Pfizer s milestone payments don t bring in as much income for Halozyme as we are expecting ,2013-01-15,Myriad Equity,https://www.investing.com/analysis/halozymes-newfound-credibility:-pfizer-150940,150940
221208,442724,PFE,Adventrx Pharmaceuticals Progress With Phase III Plans ,opinion,ANX 188 Poised For Pivotal RoleAdventrx is on the verge of initiating its all important pivotal Phase III study of ANX 188  a product that has the potential to become the standard of care to treat severely painful  crisis  episodes in patients with sickle cell disease  The key requirements are now in place   manufacturing and CRO contracts have been secured   and assuming the FDA has no objections to the trial design  the study should start by end 2012  Advancing ANX 188 into Phase III  and clarity on the study design  represents a significant milestone and potential catalyst that could lead to a re rating Pieces In PlaceAdventrx has secured manufacturing agreements with Pierre Fabre to produce the active ingredient in ANX 188  purified poloxamer 188   and Patheon to formulate  fill and finish the product for use in the pivotal study  Adventrx has also engaged Theradex Systems  a contract research organisation  CRO  with experience of conducting studies in patients with sickle cell disease  to manage the pivotal trial Burgeoning Interest In SCDIn the 12 months since Pfizer licensed GlycoMimetics  Phase II sickle cell candidate for up to  340m  we note that  163m has been invested in companies  public and private  developing novel therapies for sickle cell disease  This points to growing interest and investment in the field  highlighted by Novartis obtaining an option to acquire Selexys Pharmaceuticals for up to  665m  We recently participated in the first Annual Sickle Cell Disease Therapeutics Conference  where presentations from leading experts and companies to over 100 attendees  investors  physicians  analysts  patients  highlighted the extent of the unmet medical need and market opportunity Expanding The ANX 188 FranchiseTo broaden the potential of ANX 188  Adventrx has guided to announcing plans by year end to develop the product for an additional indication   a Phase II study could begin in H113  This represents another potential catalyst and we note previously reported encouraging pre clinical data for ANX 188 in haemorrhagic shock Valuation   80m With Near Term Re Rating PotentialWe maintain our value of Adventrx at  80m  or  1 46 per share  based on a sum of the parts DCF valuation  However  the start of the Phase III study for ANX 188 could boost our valuation in excess of  2 50  dependant on trial design specifics  Estimated Q312 cash of  39m is sufficient for 18 months to cover the launch of ANX 188 trials To Read the Entire Report Please Click on the pdf File Below ,2012-10-12,Edison,https://www.investing.com/analysis/adventrx-pharmaceuticals-progress-with-phase-iii-plans-139625,139625
221209,442725,PFE,Benitec Biopharma  QuickView ,opinion,Investment Summary  Deal Focused On HCVBenitec s acquisition of its US based technology licensee  Tacere Therapeutics  allows the Australian RNAi specialist to bring in house a Phase I ready drug candidate for Hepatitis C virus  HCV  infection  The transaction  of 102m shares  plus a potential cash royalty based on future licensing revenue  values Tacere at US 1 5m  hence it would appear to be a very attractive price TT 034 To Enter Phase I II trials In Mid 2013Tacere s principal asset is TT 034  a Phase I ready RNAi therapeutic for HCV infection  This  as PF 05095808  was previously the subject of a collaboration with Pfizer  which was discontinued in 2011 following a strategic review  Benitec plans to submit an IND in 2013 pending a meeting with the Recombinant DNA Advisory Committee  although in our view it would need new funding or a partner to conduct any studies Lower Admin Frequency Could Be Key Differentiation vs  All OralsTT 034 contains three separate RNAi elements targeted against conserved regions of HCV  which are encapsidated in an adeno associated virus protein coat  Preclinical studies in non human primates showed high penetration of hepatocytes  following a single IV administration  This offers a potential dose frequency advantage versus putative all oral anti HCV approaches  which are currently under development and all expected to be given over 24 weeks  or more  Cancer Pain Is The Candidate Next In LineBenitec s development pipeline  albeit wholly preclinical  is well diversified  Its programme in cancer pain is next in line to enter the clinic in late 2013  Tacere also adds an advanced preclinical programme for macular degeneration Valuation  EV of A 12 5mBenitec has cash of A 3m  suggesting its EV is c A 12 5m  Given the current heightened investor interest in the HCV space  this could offer an attractive entry point for a company with a relatively near term value inflection point in the form of proof of concept Phase II data for TT 034 To Read the Entire Report Please Click on the pdf File Below ,2012-10-16,Edison,https://www.investing.com/analysis/benitec-biopharma:-quickview-140018,140018
221210,442726,PFE,Mid Morning Trading On The FTSE Slips Lower,opinion,In mid morning trading the FTSE has slipped lower  down around 30 points  as a result of economic worries and lacklustre corporate earnings Third quarter earnings have not provided the real boost that some might have looked for  and markets have found it difficult to make real headway as a result  In some ways  the summer lull has never really gone away  with even the eurozone crisis failing to provide much in the way of excitement  At least there is some merger activity this morning  as publishers Pearson and Bertelsmann announce that they will combine their two publishing divisions  although sadly those hoping that the combined entity would be called  Random Penguin  have been disappointed  After starting higher this morning  Pearson shares have slipped lower  now down around 0 8  The impending arrival of Hurricane Sandy has meant that exchanges in New York will be closed today and possibly tomorrow as well  As a result  markets are much quieter as US traders stay away from their desks  There will be a degree of disruption to earnings season as well  as some firms  including pharmaceuticals giant Pfizer  delay their earnings until later in the week ,2012-10-30,IG,https://www.investing.com/analysis/mid-morning-trading-on-the-ftse-slips-lower-141614,141614
221211,442727,PFE,Navidea  Unjustly Damaged By Misleading Article,opinion,On December 19th  2012 The GeoTeam  on Navidea Biopharmaceuticals  NAVB  that contained a number of misleading statements and outright inaccuracies that prompted this reactionary piece  Most of the truly egregious statements are listed and addressed below  Note  Each statement is taken directly out of The GeoTeam s  Statement 1   Platinum Montaur Life Sciences  LLC  a firm that provided a credit facility to Navidea  may be losing faith in the company  The group has sold approximately 3 8 million shares  or approximately 50  of its public equity ownership stake in NAVB since September 4  2012   Platinum Montaur Life Sciences  a firm that provided a credit facility to Navidea  is not losing faith in the company at all  The GeoTeam really can t seem to get the facts straight  Montaur  Navidea s largest shareholder and supporter of the company  did NOT sell 3 million shares  Instead  Montaur converted 3 million of its preferred shares into common shares in order to exercise warrants  creating a net long position for the fund  With respect to NAV5001 and Alseres Pharmaceuticals  ALSE PK   the only thing we know for sure is that the shares have been registered for resale  not that they have been sold  A 300 000 share position is not material for reporting for SEC purposes  Alseres is no longer a diagnostic company  If they were to sell shares  it would be to satisfy their capital needs and not as a vote of no confidence in the Parkinson s diagnostic agent they licensed to Navidea  In fact  the Alseres agreement is largely back end loaded  signaling that Alseres has a confident outlook for this product  with contingent milestone payments to Alseres of up to  2 900 000  and the issuance of up to an additional 1 150 000 shares of the Company s common stock  In addition  the terms of the Sublicense Agreement anticipate royalties on annual net sales of products based on the agent  Alseres would not have accepted a back end loaded structure where they get paid upon success of the product if they didn t believe in the agent or Navidea  Statement 1   Platinum Montaur Life Sciences  LLC  a firm that provided a credit facility to Navidea  may be losing faith in the company  The group has sold approximately 3 8 million shares  or approximately 50  of its public equity ownership stake in NAVB since September 4  2012   Platinum Montaur Life Sciences  a firm that provided a credit facility to Navidea  is not losing faith in the company at all  The GeoTeam really can t seem to get the facts straight  Montaur  Navidea s largest shareholder and supporter of the company  did NOT sell 3 million shares  Instead  Montaur converted 3 million of its preferred shares into common shares in order to exercise warrants  creating a net long position for the fund  With respect to NAV5001 and Alseres Pharmaceuticals  ALSE PK   the only thing we know for sure is that the shares have been registered for resale  not that they have been sold  A 300 000 share position is not material for reporting for SEC purposes  Alseres is no longer a diagnostic company  If they were to sell shares  it would be to satisfy their capital needs and not as a vote of no confidence in the Parkinson s diagnostic agent they licensed to Navidea  In fact  the Alseres agreement is largely back end loaded  signaling that Alseres has a confident outlook for this product  with contingent milestone payments to Alseres of up to  2 900 000  and the issuance of up to an additional 1 150 000 shares of the Company s common stock  In addition  the terms of the Sublicense Agreement anticipate royalties on annual net sales of products based on the agent  Alseres would not have accepted a back end loaded structure where they get paid upon success of the product if they didn t believe in the agent or Navidea  Statement 2   Lymphoseek has now been in the approval process for 10 years  with at least another year before the possibility of approval   This is a completely inaccurate statement  given that Lymposeek has an PDUFA action date of April 30th  2013 for their flagship diagnostic compound Lymphoseek  It s also worth noting that the product could be approved before that date as well  Statement 3   Navidea has had chemistry  manufacturing  and controls   CMC   issues with its main product  Lymphoseek  since 2006 and is still having CMC issues today   I am perplexed as to where they got that information  The CMC issues became known when the company received a CRL  complete response letter  in September 2012  which pinpointed an issue that has now been resolved  Statement 4   Navidea has  16 million in cash and while it has a  50 million revolver  it can currently only draw down  15 million of that revolver for its cash needs  On December 11  2012  the company drew  2 million from this facility  It needs approval of Lymphoseek in order to get any more than the initial  15 million  This means NAVB could run out of cash within 18 months  if not sooner  if it is unable to secure additional financing or if it is not granted FDA approval for Lymphoseek   Navidea s liquidity issues are actually less significant than what is implied above  The company is currently eligible to draw  15 million from Montaur prior to approval and  20 million after approval  Statement 5   Management s track record over the past 16 years with other drugs has thus far been very unimpressive  All three of NAVB s drugs have not gained FDA approval  calling into question management s ability to get drugs approved   The GeoTeam criticized the management team s track record over the last 16 years  while it is widely known that many have joined the company within the last two years  We ve recently seen Navidea complete clinical studies for Lymphoseek  followed with an NDA and MAA submission for the FDA and EMA  European Medicines Agency  respectively  It s difficult to understand The GeoTeam s argument here  because the new management team is quite competent  Statement 6    Lymphoseek approval from the FDA for both breast cancer and melanoma  for a total of 300 000 cases in the United States   This statement was regarding the NEO3 06 phase III trial  which could expand the label for Lymphoseek to the  sentinel lymph node biopsy  claim which actually brings its target population to 1 3 million in the United States alone  This is over four times what The GeoTeam cited in their analysis  Statement 7   NAVB has expressed its intent to pursue the approval of treatments for melanoma and breast cancer in Europe  We feel this is highly unlikely to occur   This statement is completely wrong  Navidea filed their MAA with the EMA on December 18th  and fully intends to pursue the European market for lymphatic mapping  It s also worth noting that The GeoTeam claimed that this was a market of about 300 to 400 thousand patients  while it s closer to 2 5 million in reality  Statement 8   Navidea has two products other than Lymphoseek that we believe will not have any positive impact on the company s operations  AZD4694  a phase 2 product for which comparables from other companies have failed to be approved  and Rigscan  which has been in phase 3 since 1998   Not only is AZD4694 a phase III drug  but it is very dissimilar from the compounds that The GeoTeam wants to compare it to   specifically Lilly s solanezumab and Pfizer s bapineuzumab  Conclusion  The large number of mistakes and misleading statements that were made to build the bearish case on Navidea Pharmaceuticals in The GeoTeam s article should be enough to discredit them as a source of reliable information for NAVB  The slam piece actually made a dent in the stock after its release  which leads me to believe that there may have been an agenda associated with their publication  Hopefully  this article has established some clarity on Navidea s actual prospects  Investors who have a stake in NAVB should be watching for the PDUFA action date of April 30  2013 ,2012-12-23,Myriad Equity,https://www.investing.com/analysis/navidea:-unjustly-damaged-by-misleading-article-148706,148706
221212,442728,PFE,Upcoming FDA Decision for AVEO s Tivozanib Builds Speculation,opinion,We ve seen a lot of choppy trading in shares of in the oncology drug developer AVEO Pharmaceuticals  AVEO   which has been struggling ever since August 2nd when it released some data from a phase III trial called  TIVO 1  that compared their flagship drug tivozanib with Onyx Pharmaceuticals   ONXX  Nexavar sorafenib in the treatment of renal cell carcinoma  RCC    In terms of raw survival after one year  it was seen that 77  of the patients treated with tivozanib survived while 81  of sorafenib treated patients survived RCC   As a result  AVEO dropped sharply from  13 30 share to  9 75 share on August 2nd and has remained troubled ever since  The question now is whether or not these preliminary phase III results actually mean that tivozanib is inferior to sorafenib  and whether this will result in a complete response letter to the NDA that AVEO recently submitted   The company thinks that the 1 year survival data could be misleading  due to their claim that a large number of the patients who were assigned Onyx s sorafenib  just over half of them  were moved onto other therapies tivozanib when their condition worsened while only 17  of tivozanib patients were given other treatments  This presents a problem when you try to evaluate the relative overall survival between both arms  since it s very possible that the sorafenib arm benefitted from tivozanib s efficacy as a second line treatment for RCC   It s also worth noting that the study s primary endpoint  progression free survival  PFS   showed statistically significant improvements in the tivozanib arm versus the sorafenib arm  The median PFS measurements were 11 9 months and 9 1 months for AVEO and Onyx s drug  respectively  The bulk of the patient population  70   were na ve for advanced RCC  and responded even better to tivozanib with media PFS of 12 7 months versus 9 1 months   So  while the FDA has  expressed concern  about the implications of the weak overall survival  OS  data for tivozanib versus sorafenib the progression free survival argument is still quite intact  It is also very well tolerated amongst patients  which significantly reduces its risk and increases its chances of approval  Judging by the movements in shares of AVEO in the last few months  I think the market might be a little too pessimistic about tivozanib s approval chances   The market that is being targeted by tivozanib is quite large  at over  2 4 billion  Onyx s sorafenib was FDA approved for RCC in 2005  and is marketed by Bayer  BAYRY  under the name Nexavar and brought the company  199 million in Q3 2011  although it s worth mentioning that Bayer Onyx have expanded its indication to other types of cancer since 2005   Sutent  one of Pfizer s  PFE  most profitable drugs  also treats RCC and brought the company  294 million in Q3 2012   AVEO also saw some major insider buying this month  The first significant purchase was made by one of AVEO s directors Raju Kucherlapati  who bought 15 000 shares  equating to  101 thousand  throughout the first week of the month  A much bigger buy was made by president and CEO Tuan Ha Ngoc throughout the following week  He accumulated 75 000 shares which cost  499 thousand  This implies that there is substantial confidence in the success of tivozanib going forward   It s worth mentioning that AVEO intends to expand the tivozanib indication to other types of cancer  including colorectal and breast cancer  following in the footsteps of their competitor sorafenib   The company also has two other compounds in its pipeline that could prove very interesting  including ficlatuzumab for non small cell lung cancer  NSCLC  and AV 203 for solid tumors  These two other compounds are in phase II and phase I trials respectively  Still  I don t think the market will pay any attention to these drugs while the speculation over tivozanib s NDA submission builds   The PDUFA action date for tivozanib s NDA is July 28  2013  There will probably be an advisory committee that will vote on the drug s chances of approval prior to the actual decision date  but AVEO shareholders have little to do but wait for more developments at this point ,2012-12-23,Myriad Equity,https://www.investing.com/analysis/upcoming-fda-decision-for-aveos-tivozanib-builds-speculation-148707,148707
221215,442731,PFE,Cytos Biotechnology   QuickView ,opinion,Investment summary  Restructuring and refinancing completedCytos has been transformed  having faced a funding crunch  It now has cash of  37m  sufficient to fund a large Phase IIb trial on CYT003 in asthma  and has until February 2015 to repay outstanding convertible bonds  previously due February 2012   Phase IIa results on CYT003 are due to be published in a peer review journal later this year  We will initiate full coverage on Cytos shortly Focus on CYT003Results from a 60 patient Phase IIa trial on CYT003 in asthma showed a significant improvement in symptoms already at two weeks  plus longer term improvement in lung function and asthma control  A 360 patient Phase IIb global placebo controlled is planned for Q412 with results due Q214  funded by the recent capital raising Strengthened balance sheetCytos was restructured and refinanced between August 2011 and May 2012  reducing workforce from 80 to 15  and closing R D and production  The company has raised CHF23 75m in equity  CHF13 5m in convertible loan notes  half due on milestones being reached the in the phase IIb trial  and CHF3 2m via a rights issue  Issued warrants could also yield CHF28 5m within four years if exercised Confidence from investorsKey stakeholders now include Amgen  venBio  Abingworth Bioventures and Aisling Capital  In addition Cytos has two compounds partnered with Novartis  in smoking cessation and Alzheimer s disease  plus one in allergic disease with Pfizer Valuation  Minimal technology valueGiven the crisis over funding in the past year  the market is assigning little value  CHF23m  to Cytos s technology  Phase IIa results on CYT003 in asthma have been enough to encourage an impressive array of financial investors plus Amgen  Publication of CYT003 data and further positive trial results should focus investors  attention back on to the science within Cytos and away from the financing troubles To Read the Entire Report Please Click on the pdf File Below ,2012-08-14,Edison,https://www.investing.com/analysis/cytos-biotechnology--quickview-132964,132964
221216,442732,PFE,Exonhit Update  changing Alzheimer s Disease Landscape ,opinion,Prodromal attackThe recent failure of two high profile  late stage clinical candidates for Alzheimer s disease  AD  has highlighted the need to target future therapeutic interventions earlier in the course of this disease  This strengthens the case for using diagnostic tools such as Exonhit s  ALEHT PA  AclarusDx  both in trials  and if the products are ultimately successful  in clinical practice  Exonhit s investment case is largely based on the commercial potential of AclarusDx  its blood based aid for the diagnosis of AD  although it also has an interest in the Phase II trial stage neuropathic pain programme  EHT AGN 0001  which is partnered with Allergan and Bristol Myers Squibb AclarusDx is competitive in a changing AD landscapePfizer J J s bapineuzumab and Lilly s solanezumab both recently failed to meet their primary endpoints in multiple large Phase III trials in mild to moderate AD  However  exploratory analyses of the data suggested that these anti   amyloid products may be effective if given earlier in the prodromal phase  Future AD studies are  therefore  more likely to use biomarkers to identify potential responder groups  a trend that we believe should considerably enhance AclarusDx s commercial potential Enrolment completed in AD studiesPatient enrolment was completed ahead of schedule in July for both the French and US observational studies of AclarusDx  The French real life observational study DIALOG  Diagnosis ALzheimer cOGnitive  evaluates AclarusDx s performance in 600 cognitively impaired patients attending a memory centre for the first time  Patients will be followed up for one year and results are expected in Q413  A US pilot clinical study evaluates AclarusDx s performance in 160 patients newly referred to a Reference Memory Centre for an AD diagnostic assessment  Results are expected in H113 Financials funded to H113Exonhit ended the half year with cash of  11 2m  which should provide a sufficient runway to conduct the AclarusDx clinical studies and target French neurologists Valuation  Risk adjusted NPV of  88mWe value Exonhit based on a risk adjusted NPV at  88m  based on assumptions of its four main products  probability of success  launch date  pricing and market penetration  Exonhit currently has an EV of  27m  based on its market cap of  38m and cash of  11 2m To Read the Entire Report Please Click on the pdf File Below ,2012-10-09,Edison,https://www.investing.com/analysis/exonhit-update:-changing-alzheimers-disease-landscape-139133,139133
221217,442733,PFE,Vectura Inhaler Now Approved In Europe And Japan ,opinion,Seebri approved in key marketsNovartis Vectura s COPD inhaler  Seebri  is now approved in two key respiratory markets  Europe  Japan  and is expected to launch by end 2012  This triggers milestones of  12 5m and a new royalty stream from Novartis  Clever market positioning should support Seebri uptake in the face of incumbent Spiriva  and paves the way for potential approval of the QVA149 combination in late 2013 Seebri to launch in EU and Japan by end 2012Following European and Japanese approvals for Seebri  formerly NVA237  for COPD  Novartis is on track to launch in two key respiratory markets by year end 2012  Seebri now becomes the second once daily LAMA to market behind Boehringer Pfizer s Spiriva  The approvals validate Seebri s once daily profile  trigger milestones of  12 5m to Vectura  VEC L   and should generate first royalties  mid single digit  in FY13  The first meaningful indication of Seebri sales is likely to be Novartis s Q113 results in April Promotion via established sales forceNovartis will promote Seebri via the same respiratory sales force that sells the LABA inhaler Onbrez  with initial launches likely in the UK and Germany  then other territories once pricing reimbursement discussions are completed  Given Seebri s strong clinical data package and competitive profile vs Spiriva  we expect these discussions to be relatively straightforward  We project ex US Seebri peak sales of c  230m Clever positioning should support uptakeHead to head studies showed that Seebri is a credible competitor to Spiriva  We expect Novartis to leverage Seebri s differentiating features  faster onset  better sideeffect profile  to promote market uptake vs the incumbent  Results of ongoing studies of Seebri in combination with Advair in moderate severe COPD could provide even further differentiation  Finally  we see Seebri being positioned for use alongside Onbrez  with physicians becoming comfortable with prescribing the combination ahead of QVA149 approval  With all the components of QVA149 now approved in Europe and Japan  this de risks potential approval of the combination in H213 Valuation  Risk adjusted NPV of  416m  125p share We maintain our  416m Vectura valuation  but expect to increase this after Europe and Japan launch timings for Seebri are clarified  and on EU filing of QVA149  expected by the year end   Upside could come from regulatory and clinical progress  more regulatory clarity or further technology licences To Read the Entire Report Please Click on the pdf File Below ,2012-10-10,Edison,https://www.investing.com/analysis/vectura-inhaler-now-approved-in-europe-and-japan-139350,139350
221225,442741,PFE,Political Uncertainty In Europe Weighs On Risk Appetite  Major European PMI Data Disappoints  April 23  2012,opinion,Economic Data EU  ECB   311M borrowed in overnight loan facility v  335M prior   775 7B parked in deposit facility v  746 5B prior  FR  France Apr Business Confidence  95 v 96e  Production Outlook   14 v  15 prior  Own Company Production Outlook   4 v  8 prior  FR  France Apr Preliminary PMI Manufacturing  47 3 v 47 4e  PMI Services  46 4 v 50 1e  CH  Swiss M3 Money Supply Y Y  6 6 v 6 4  prior  CH  Swiss Q1 Real Estate Index Family Homes  410 4 v 404 6 prior  NL  Netherlands Apr Producer Confidence   3 3 v  2 6 prior  DE  Germany Apr Advanced PMI Manufacturing  46 3 v 49 0e  PMI Services  52 6 v 52 3e  EU  Eurozone Apr Advanced PMI Manufacturing  46 0 v 48 1e  PMI Services  47 9 v 49 3e  PMI Composite  47 4 v 49 3e  IT  Italy Apr Consumer Confidence  89 0 v 96 5e  TW  Taiwan Mar Industrial Production Y Y   3 4  v  6 5 e v  8 4  prior  Commercial Sales Y Y   1 1  v  0 5 e  TW  Taiwan Mar Unemployment Rate  4 1  v 4 2 e  HK  Hong Kong Mar CPI Composite Index Y Y  4 9  v 4 9 e  EU  Eurozone 2011 Govt Debt GDP Ratio  87 2  v 85 3  prior  IT  Italy March Non EU Foreign Trade Balance    495M v   3 1B y y Fixed Income SL  Slovakia Debt Agency  ARDAL  sold  125 8M in 12 month Bills  Yield 1 0602  v 0 9798  prior  bid to cover  2 33x vs  2 08x prior  DE  Germany sold  1 96B in 12 Month BuBills  Avg Yield 0 0765  v 0 0765  prior  Bid to cover  2 3x v 1 4x prior Notes ObservationsChina HSBC Apr Flash PMI rises to 49 1 but remains below the key 50 level for the 6th straight month Netherlands budget talks collapse putting its AAA sovereign rating at risk France presidential candidate Hollande wins 1st round over Sarkozy  as expected   Run off set for May 6th  Far Right party  led by Le Pen  posts strong 3rd place Lots of central bank meetings during the week with FOMC decision on Wed and BOJ on Friday ECB says it was not pressured at IMF meeting to lower interest rates Major European Advanced PMI data disappoint German PMI data at odds with recent IFO and ZEW readings EquitiesIndices  FTSE 100  1 7  at 5674  DAX  2 7  at 6568  CAC 40  1 9  at 3128  IBEX 35  3 1  at 6830  FTSE MIB  3  at 13 966  SMI  1 7  at 6130 European equity indices opened the session lower and most indices have continued to trade lower by more than 1   In Spain  the IBEX 35 has once again hit fresh 3 yr lows  with some dealers eying the 6 702 area  Banks are trading lower across the board  amid the rise in peripheral bond yields  Factors weighing on the indices include  PMI data out of China and Germany  political concerns related to France and the Netherlands and higher peripheral yields  Additionally  there have been some concerns that the IMF could face delays in deploying its newly expanded resources In Germany  automakers are trading lower across the board  BMW  BMW DE  has declined by more than 2   as the company said that it saw Chinese sales slowing in the coming months  BMW also noted that Europe continues to be challenging  Lufthansa  LHA DE  is lower by more than 2  on speculation that the firm is planning to implement approx   1B in cost cutting measures  while Man SE  MAN DE  has lost over 3   as the company is trading ex dividend  Philips  PHIA NL  is higher by over 4   after reporting better than expected Q1 results Also  TomTom  TOM2 NL  has lost over 5   after the company gained more than 10  on Friday s session on speculation that it could pursue a delisting  Italian names Fiat  F IT  and Fiat Industrial  FI IT  are both lower as the companies are trading ex dividend  Cable   Wireless Worldwide  CW UK  has gained over 16   after receiving a bid worth more than  1B from Vodafone  VOD UK   In Switzerland  Nestle  NESN CH  is lower by approximately 3   after confirming plans to acquire Pfizer s infant nutrition unit for  11 85B in cash ,2012-04-23,Trade The News,"https://www.investing.com/analysis/political-uncertainty-in-europe-weighs-on-risk-appetite;-major-european-pmi-data-disappoints:-april-23,-2012-121027",121027
221226,442742,PFE,Stock Indexes  ETFs Back To Resistance  Big Week Ahead,opinion,Major U S  stock indexes and ETFs climbed back to the ceiling this past week but failed to break higher    Shrugging off weak economic reports and focusing on overall strong U S earnings reports  U S  stock indexes and ETFs climbed back to and stopped at recent resistance levels    On My Wall Street Radar  In the chart of the S P 500  NYSEARCA SPY  above we can see how this major index has climbed back into serious resistance levels  Relative strength  RSI  is above 50 and climbing  which is bullish  and short term momentum as represented by MACD has recently generated a  buy  signal and all of this comes within the context of an ongoing uptrend with the S P 500  NYSEARCA SPY  above both its 50 and 200 day moving averages    However  we now find ourselves in the most frustrating of all conditions  a long  sideways channel or trading range  this one being between resistance at 1400 1420 and support at 1360  A break above 1400 1420 would indicate the end of the channel and the resumption of  the current trend upwards while a reversal below 1360 would indicate a correction could be underway    The Economic View From 35 000 Feet   For the week  the major indexes were positive with the Dow Jones Industrial Average  NYSEARCA DIA  gaining 1 5   the Nasdaq 100  NYSEARCA QQQ  adding 2 3  and the Russell 2000  NYSEARCA IWM  climbing 2 7   The gains came in the face of some rather dismal economic reports  with just a ray or two of sunshine  while earnings reports in the United States continued to support bullish optimism On the positive side of the economic ledger  we saw pending home sales for March vastly beat expectations by climbing 4 1  and new home sales improving  as well  The University of Michigan Confidence Index came in at 76 4 compared to 75 7 previously  and overseas  Spain and Italy stayed afloat with successful bond auctions On the downside  the biggest shocker was the GDP estimate on Friday which indicated that Q1 GDP expanded by a mediocre 2 2  compared to 2 7  expected and the previously reported 3 0   Final sales were dismal and durable goods orders were weak  while weekly unemployment claims clung stubbornly above 380 000 missing estimates for the week Overseas the big news came from Britain where the country entered a double dip recession  joining Spain  Italy and Netherlands whose government fell over national dissatisfaction with planned austerity programs  The French election puts another twist in eurozone politics while German and Italian consumer and business confidence fell On the upside for the week were U S  earnings reports  particularly in the tech sector  with Amazon  AMZN  and Apple  AAPL  blazing higher as U S  companies continued to find ways to make money in a slowing global environment  However  the GDP report points to some significant structural weaknesses as much of it came from inventory buildup and not from final sales  In either case  this type of action cannot continue for the long term which can only be bad news for spending and earnings somewhere down the road Finally  the FOMC says they re going to keep interest rates near zero for as far as the eye can see because they still see significant downside risks to the economy and unemployment isn t improving as rapidly as they d like  Dr  Bernanke s press conference was interesting  as always  as market participants are counting on the Fed to keep things going with more easing as Dr  Bernanke promises he s ready  willing and able to do This coming week brings earnings reports from the likes of Merck  MRK   Office Depot  ODP   Pfizer  PFE   Mastercard  MA   Clorox  CLX  and UBS  UBS  but the big news will be in economic reports which come hot and heavy all week  Monday brings income  spending and Chicago PMI  Tuesday sees the widely watched ISM report  construction spending and car sales  Wednesday finds ADP Employment and factory orders  Thursday brings the weekly jobs report and ISM non manufacturing  and Friday brings the grandaddy of all economic reports  the monthly Non Farm Payrolls and Unemployment Reports  It s going to be a big week Bottom line   Having made three tries to scale new highs  the major U S  indexes appear ready to give it another try  We remain in  bear alert  mode from April 16th  and this coming week s action will be significant as we move into the seasonally weak period of May through October Disclaimer  Wall Street Sector Selector trades a wide range of exchange traded funds and positions can change at any time ,2012-04-30,John Nyaradi,"https://www.investing.com/analysis/stock-indexes,-etfs-back-to-resistance.-big-week-ahead-121627",121627
221227,442743,PFE,Medicinova  Developmental Pharma With Massive Long Term Potential,opinion,Primary ticker  MNOV  Secondary tickers include  AZN  GSK  MRK  PFE   I previously released an article referencing MediciNova  MNOV   which engages in the acquisition and development of small molecule therapeutics for the treatment of serious diseases for the United States market  This is an up and coming company who has incredible potential as an investment because of its strong pipeline of six clinical stage compounds and tiny market capitalization  As of the end of the trading day on May 1st  this value was around  48 million  I have seen companies that look far less appealing selling in a price range that reflects a 150 200 million dollar market cap  Even if MNOV could achieve the bottom end of this range  that would put it around  9 share compared to the  2 83 price it currently sits at  Let s take a look  Although this pipeline taken directly from MNOV s website contains numerous clinical pipelined drugs  I want to focus on the most advanced clinical drug to date    The drug candidate that I feel is not giving MNOV appropriate visibility is their MN 221 drug for Acute Exacerbations of Asthma  more commonly referred to as an asthma attack  Why is this drug important  For starters  asthma affects one in twelve people or about 25 million in the United States alone    Secondly  approximately two million emergency room visits per year are due to asthma attacks  Of those  about 500 000 lead to hospital stays  MediciNova is looking to prevent these people from needing that expensive hospital stay by filling an unmet need for those not responding to the typical treatments  The reason is pretty simple for people s tendency to go to a hospital for asthma  breathing is the most critical necessity of life    MediciNova has completed 2 phase II clinical studies for MN 221  with important data from one of the studies due out before the end of this month  the other at the beginning of June  Positive results from these studies could lead to a possible pivotal trial if the trials confirm the success of the prior phase 1 studies  which should lead to a partnership with a large pharma    Patients suffering from acute exacerbations of asthma in the emergency room who were not promptly responding to standard pharmacotherapy were enrolled in the study  MediciNova is currently in the process of auditing and organizing the data and preparing to lock the database for a complete analysis    In prior double blind studies  MN 221 was given to patients from an IV  Once in the bloodstream  scientists believe MN 221 may directly enter the lungs and migrate to the irritated bronchial tubes  eventually relaxing the muscles which may result in an open airway  Most of the time when people go to the ER for an asthma attack  they are given the same types of things they take at home just in higher doses combined with medical therapy  It s clear to me that these advancements have not gone far enough to help people with a symptom as scary as not being able to breathe  MediciNova is looking to fill an unmet need whose end result is 500 000 people not responding well to common treatments    In modeling the market potential of MN 221  Chief Business Officer Michael Coffee  that if the company can demonstrate a reduction in hospital admissions  he believes that insurance payers would feel comfortable with an attractive branded price  In an earlier Phase 2a trial  the company generated data showing a 54  reduction in potential hospital admissions     Given that  we ve extrapolated to show that acute asthma and COPD exacerbations represent a combined annual worldwide sales potential in excess of  1 billion   he adds    Let s look at the current environment for treating asthma  The most commonly prescribed asthma drug is GlaxoSmithKline s  GSK  Advair  with projected sales of  7 4 billion Another popular drug is Merck   Co s  MRK  Singulair  which helps to block genetic signals that trigger airway constrictionAstraZeneca  AZN    Symbicort is an asthma drug that launched in the US in mid 2007  with 2007 sales of  1 6 billion  It belongs to the same drug family as Advair  ICS LABA   but with slightly faster action Spiriva  co marketed by Pfizer  PFE  and the privately held Boehringer Ingelheim  is already used for chronic obstructive pulmonary disease and works by blocking the nerves that can tighten the muscles surrounding the airways to the lungs These drugs are not for asthma attacks but rather less severe symptoms  Again  GlaxoSmithKline sells 7 4 billion dollars  worth of their drug and it does not cover the most severe issues that asthma brings    To me  it seems like an incredible fit for one of these big players to partner with MediciNova  if not flat out buy the company    I Look at it this way  Glaxo could fire away 200 Million dollars at MNOV and it would be a tiny 2 7  of the sales it did for one asthma drug of theirs  This would then enable a company like Glaxo to treat not only the regular mild form of asthma  but also the more serious  life threatening variety  Here is where the extremely small market cap again comes into play regarding MNOV  What would this relatively tiny investment from GSK translate for MNOV shareholders  Approximately  12 share    The second most advanced product that MediciNova is working on is their MN 166  Ibudilast   This has been approved for dizziness after stroke and asthma in Japan and South Korea  and has treated more than three million patients   But it was our scientists who determined that ibudilast had a potential clinical utility in central nervous system disorders   Mr  Coffee points out    The company has conducted successful early stage testing to determine safety and tolerability of higher doses of ibudilast in three clinical areas  progressive Multiple Sclerosis  neuropathic pain  and drug addiction    In progressive MS  Mr  Coffee says the company is organizing a Phase 2b trial with MN 166 and anticipates announcing in the second half of this year the company s plans for conducting this trial    In preclinical in vivo and in vitro studies  MN 166 inhibited leukotriene activity  phosphodiesterases and nitric oxide synthase  all of which are inflammatory mechanisms known to be involved in Multiple Sclerosis  These studies also suggested that MN 166 may suppress the production of pro inflammatory cytokines  IL 1   TNF a  and enhance the production of the anti inflammatory cytokines  IL 4  IL 10   Based on the potential mechanisms of action of MN 166  its clinical safety history in Japan  the results of pilot studies conducted by Kyorin Pharmaceutical in MS patients  and the issuance of a U S  patent covering the method of using MN 166 to treat the disease  MediciNova decided to pursue development of MN 166 as a novel oral agent for the treatment of MS    MediciNova also has non core programs in asthma  interstitial cystitis  generalized anxiety disorder  thrombosis and overactive bladder that are in various stages of development  The company is seeking to monetize these non core programs through licensing partnerships    Let s take a look at the MNOV chart   A nice symmetrical continuation triangle has formed also creating a nice wedge pattern  The MACD and signal are trending upwards  The volume has begun to pick up  and this chart looks to be setting up a bullish short term pop to a price over 3 50 a share in my opinion  possibly higher    If the data from MN 221 turns out to be good  and if phase 2 follows phase 1 and confirms  expect MNOV to partner up with a large pharma  and expect the stock price to move over  4 a share  MN 221 faces a multi billion dollar market With MNOV being a very small cap coming in at around  49M  savvy investors will see the huge value in this company moving forward in my strong opinion    It is my opinion that MNOV is a strong speculative buy and worth taking a gamble on for a long term hold  As I mentioned in    I expect a run up to start within the next 2 weeks before the data on MN 221 is revealed  At  3 02 a share  no debt on the books  and a market cap under 50 million  MNOV is highly undervalued  and should be selling for near  4 a share  I would not be surprised to see a  4 a share price after the data on MN 221 is released    My price target opinion   3 50 a share short term   4 25 midterm  and an  8 one year target price    Disclosure  I am long MNOV    Disclaimer  This article is intended for informational and entertainment use only and should not be construed as professional investment advice  but rather my opinions as a writer only  Always do you own complete due diligence before buying and selling any stock ,2012-05-03,Scott Matusow,https://www.investing.com/analysis/medicinova:-developmental-pharma-with-massive-long-term-potential-122067,122067
221228,442744,PFE,Adventrx Pharmaceuticals  Its Orphan Drug Could Attract Partners ,opinion,Investment summary for Adventrx Pharmaceuticals  ANX   Sickle cell potentialFundamental to Adventrx s investment case is the successful development and commercialisation of ANX 188  a product that has the potential to become the standard of care for the treatment of severely painful  crisis  episodes in patients with sickle cell anaemia  A two year pivotal Phase III trial is scheduled to start by the end of 2012  the design of which will draw on the experiences of a previous pivotal study that showed a clear benefit in reducing the duration of crisis in paediatric patients FDA negotiations ongoingANX 188 is the lead candidate in a limited development field to become the first approved therapy to reduce the duration of crisis episodes  which typically require hospitalisation for six to seven days  Discussions are ongoing with the FDA over the design of the pivotal study and reaching agreement  which Adventrx expects in H212  presents an important milestone and potential catalyst Drawing on experiencesThe prior 250 patient Phase III trial missed its primary endpoint across all patients but showed a statistically significant benefit in children  15 years old who have less confounding factors that may obscure treatment effects in older patients  ANX 188 also provides Adventrx with an opportunity to move on from disappointing outcomes from its prior strategy focused on reformulations of cancer drugs Orphan drug sweet spot could attract partnersWe assume Adventrx will commercialise ANX 188 itself in the US  achievable given the condensed nature of the market  but a partner could be secured  GlycoMimetics licensed its Phase II candidate to Pfizer for up to  340m milestones Valuation   80m until ANX 188 progressesWe value Adventrx at  80m  or  1 46 per share  based on a sum of the parts DCF valuation  using a standard 12 5  discount rate  Our valuation is currently restricted to the potential use of ANX 188 in children in the US market  based on market launch in 2016 and peak sales of  85m  An FDA agreement and clarity on the pivotal study design is crucial and could lead to a re rating  Cash of  46m is sufficient for two years  assuming the trial starts by year end To Read the Entire Report Please Click on the pdf File Below ,2012-05-28,Edison,https://www.investing.com/analysis/adventrx-pharmaceuticals:-its-orphan-drug-could-attract-partners-124616,124616
221229,442745,PFE,Durata Therapeutics  DRTX  Pre IPO Report,opinion,Based in Morristown  NJ  Durata Therapeutics  DRTX  scheduled a  75 million IPO with a market capitalization of  192 at a price range mid point of  12 for Thursday  July 19  2012  RECOMMENDATION DRTX wants to IPO at a price to book discount to CEMP and RIBX  However  we are concerned about DRTX s lack of intellectual property protection and would avoid the DRTX IPO  DRTX  S 1  filed July 9  2012 UNDERWRITERS Manager  Joint Managers  BofA Merrill Lynch  Credit Suisse Co Managers  RBC Capital Markets  Wedbush PacGrow Life Sciences SUMMARY DRTX is pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses  DRTX is owned 98  by venture capital firms pre IPO  and expects to IPO at 2x book  which is low for a pharmaceutical company The core business was acquired from Pfizer in 2009  It looks like DRTX is not protected very much by patents  see INTELLECUAL PROPERTY below  BUSINESS DRTX is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses  DRTX is currently enrolling and dosing patients in two global Phase 3 clinical trials with the lead product candidate  dalbavancin  for the treatment of patients with acute bacterial skin and skin structure infections  or abSSSI  Dalbavancin is an intravenous antibiotic product candidate designed for once weekly dosing  which DRTX believes will facilitate the treatment of patients with abSSSI in both the in patient and out patient settings by reducing the length of a patient s hospital stay or avoiding hospital admission altogether and  ultimately  lowering the overall cost of care for these patients  DRTX is conducting each of these Phase 3 clinical trials pursuant to special protocol agreements  or SPAs  with the U S  Food and Drug Administration  or FDA  based on draft guidance issued by the FDA in 2010 for the development of drugs to treat abSSSI  DRTX also designed these trials based on scientific advice that we received from the European Medicines Agency  or EMA  in December 2010 to meet the regulatory filing requirements in the European Union  PHASE 3 DRTX expects to complete these Phase 3 clinical trials and have initial  top line data available in the beginning of 2013  If DRTX s ongoing Phase 3 clinical trials are successful  DRTX plans to submit a New Drug Application  or NDA  to the FDA in the first half of 2013 and a marketing authorization application  or MAA  to the EMA in the second half of 2013  If approved  DRTX intends to directly commercialize dalbavancin in the United States and Western Europe with a targeted hospital sales force and to utilize a variety of types of collaboration arrangements for commercialization in other markets  ACQUISITION OF VICRON FROM PFIZER In December 2009  DRTX acquired all of the outstanding shares of capital stock of Vicuron from Pfizer  PFE   DRTX paid total upfront consideration of  10 million for the Vicuron shares and dalbavancin inventory that DRTX acquired pursuant to a separate inventory transfer agreement with Pfizer Overseas LLC  In March 2011  Pfizer refunded  6 million of the initial purchase price under the terms of the stock purchase agreement  based on documentation DRTX provided that supported the position that marketing approval for dalbavancin required more than one new Phase 3 clinical trial  Following the first commercial sale of dalbavancin for the treatment of abSSSI in the United States  the United Kingdom  Germany  Italy  Spain or France  DRTX is obligated to pay Pfizer an additional milestone payment of  25 million  However  DRTX s sole discretion  DRTX may elect to defer the milestone payment for a period of up to five years if DRTX delivers to Pfizer a promissory note for the full amount of such milestone payment  INTELLECTUAL PROPERTY Dalbavancin is protected by four issued U S  patents consisting of two method of treatment patents  a dosage form patent and a formulation patent  patent protection is not available for composition of matter claims that only recite the active pharmaceutical ingredient for dalbavancin  Because dalbavancin lacks composition of matter protection for its active pharmaceutical ingredient  competitors will be able to offer and sell products with the same active pharmaceutical ingredient so long as these competitors do not infringe any other patents covering this drug  COMPETITION There are also a number of products in clinical development by third parties to treat abSSSI  These companies include pharmaceutical companies  biotechnology companies  and specialty pharmaceutical and generic drug companies of various sizes  such as  The Medicines Company  Trius Therapeutics  Inc   Cempra  Inc   Rib X Pharmaceuticals  Inc   Paratek Pharmaceuticals  Inc   Nabriva Therapeutrics AG  Tetraphase Pharmaceuticals  Inc  and Furiex Pharmaceuticals  Inc  VENTURE CAPITAL 98  owned by Venture Capital  Pre IPO Domain Associates  23  New Leaf Ventures II  L P   23  Aisling Capital III  LP   21  Sofinnova Venture Partners VII  L P   17  Canaan VIII L P   14  EMPLOYEES As of June 30  2012  DRTX had 22 employees  All of employees are engaged in administration  finance  clinical  regulatory and business development functions  USE OF PROCEEDS DRTX expects to receive  69 million IPO proceeds  As of March 31  2012  DRTX had cash and cash equivalents of  25 3 million  DRTX currently estimates that it will use the net proceeds from this offering  together with cash and cash equivalents  as follows   13 million to complete the clinical development of and seek marketing approval in the United States and the European Union for dalbavancin for the treatment of patients with abSSSI   20 million to fund commercial activities for dalbavancin in the United States and Western Europe  if it is approved for the treatment of patients with abSSSI   15 million to fund the scale up of the manufacturing of dalbavancin in preparation for commercial launch   10 million to pursue the development of dalbavancin in additional indications  and Remainder for working capital and other general corporate purposes  which may include the in licensing or acquisition of other products or technologies ,2012-07-19,Francis Gaskins,https://www.investing.com/analysis/durata-therapeutics-(drtx)-pre-ipo-report-130084,130084
221236,442752,PFE,RadioShack  Stock Tumbles  Vol Explodes on Pre Announcement,opinion,RadioShack Corporation  RSH  is engaged in the retail sale of consumer electronics goods and services through its RadioShack store chain The stock is down substantially on a pre announcement which obviously wasn t very good news  Here s a quick snippet to summarize the report  RadioShack Corp  shares plummeted 29 percent morning trading  The company announced it beat fourth quarter revenue expectations  but will miss profit estimates due to selling smartphones at lower prices  The Shack explained   The Company s results for the fourth quarter are due in large part to the underperformance of the Sprint postpaid wireless business and reflect further unanticipated changes in Sprint s customer and credit models   CEO Jim Gooch said the company is moving towards more profitable sales from Verizon and AT T  Source  WALL ST  CHEAT SHEET via Yahoo  Finance    12 Super Hot Stocks  RadioShack Drops 30   Mattel Pops 5  and Pfizer Holds Steady  written by Eric McWhinnie Icky   Let s look to the Charts Tab  six months   below  The top portion is the stock price  the bottom is the vol  IV30    red vs HV20    blue vs HV180    pink  On the stock side  we can see that single data point down to the  7 level on the news today  On the vol side  we can see the 50  pop in the implied  What s interesting here is that while the news was unexpected  it s now out  Normally  No matter what the news on earnings  i e  good or bad   the vol dips as the event is over and digested in the underlying  It s that elevated vol that caught my attention Let s turn to the Skew Tab We can the front is elevated while the skew shapes are all similar  According to the RSH investor relations website  the next actual earnings report is due out on 2 21 2012  which is after Feb expiry and in Mar  Tricky Finally  let s turn to the Options Tab I wrote about this one for TheStreet  OptionsProfits   so no specific trade analysis here  We can see the vols across the top per expiry  73 45   63 70  and 57 92  for Feb  Mar and Apr  respectively  Again  earnings are in the Mar expiry  The 52 wk range in IV30   31 30   72 91    so the level today is fast approaching the annual high   it s in the 86th percentile  The Feb sigma is actually above the annual high in IV30  This is trade analysis  not a recommendation ,2012-02-01,Ophir Gottlieb,"https://www.investing.com/analysis/radioshack:-stock-tumbles,-vol-explodes-on-pre-announcement-112711",112711
221237,442753,PFE,Watson Pharmaceuticals   Low Vol  Pharma Shows Vol Explosion on Deal News,opinion,Watson Pharmaceuticals  Inc   WPI  is an integrated global pharmaceutical company engaged in the development  manufacturing  marketing  sale and distribution of generic and brand pharmaceutical products WPI is a cool company in that it s a pharma with a vol normally in the 20 s  This  however  is a vol note as the stock and vol are popping on news  Let s start with the story Watson Pharmaceuticals Inc   WPI  is in talks to buy Actavis Group hf  a Swiss maker of generic drugs  a person with knowledge of the matter said Watson made an unsolicited approach to Actavis  said the person  who declined to be identified because the discussions are confidential  There are no other suitors at the moment and a deal may be weeks away  the person said  Reuters  which reported the discussions earlier today  said Watson may pay 5 billion euros   6 6 billion  to 5 5 billion euros Watson Chief Executive Officer Paul Bisaro said in January the Parsippany  New Jersey based company was interested in buying either a generic or brand name drugmaker   Our appetite for a larger transaction  it s there   Bisaro said at the JPMorgan Chase   Co  health care conference in San Francisco Charlie Mayr  a Watson spokesman  said the company doesn t comment on speculation  Frank Staud  a spokesman for Zug based Actavis  also declined to comment Watson  the maker of the authorized copy of Pfizer Inc  s cholesterol pill Lipitor  is looking to expand its international reach as well as the company s portfolio of brand name drugs Source  Bloomberg via Yahoo  Finance    Watson Said to Be in Talks to Buy Swiss Drugmaker Actavis  written by Aaron Kirchfeld and Naomi Kresge Tricky    A vol and stock rise as the potential acquirer  The  appetite  part feels a little scary coming from the CEO  but it makes for some cool vol analysis The news has driven some order flow as over 18 000 contracts have traded on total daily average volume of just 2 464  Calls have traded on a 3 8 1 ratio to puts with the action in the May 65 and Apr 65 calls  The Stats Tab and day s biggest trades snap are included below The Options Tab  below  demonstrates that the Apr 65 calls are mostly opening  compare trade size to OI   The May 65 calls are more ambiguous  The color I got on the May 65 calls was that the 4 588 lot was a purchase without stock  The Apr 65 calls are hard to tell    look two sided  although the vol rise is circumstantial evidence of purchases Let s turn to the Skew Tab It s interesting that the May options are priced to higher vol than Apr given that the news feels  pending   It s also noteworthy that the Aug options show a  normal  skew in that the OTM calls are priced to lower vol than the ATM options  That is not the case for Apr and May where the skew is flattish or even bent up to the upside  The next earnings release should be in the May expiry  but outside of Apr Finally  let s turn to the Charts Tab  six months   below  The top portion is the stock price  the bottom is the vol  IV30    red vs HV20    blue vs HV180    pink  This was actually a stock trading over  70 as recently as September  It hit as low as  55 89  closing  in Jan  We can see the stock spike today On the vol side we can see a bumpy ride in between  20  and  40  in the implied  Before today  IV30  closed at 22 60   It s up 28 8  today  The 52 wk range in IV30  is  19 84   41 25   putting vol in the 45th percentile  annual   As of yesterday s close  IV30  was in the 6th percentile  My curiosity here lies in whether the upside really has any more legs    and on the flip side    if the downside is still a legitimate risk if this  deal  falls apart This is trade analysis  not a recommendation ,2012-03-22,Ophir Gottlieb,"https://www.investing.com/analysis/watson-pharmaceuticals:-""low-vol""-pharma-shows-vol-explosion-on-deal-news-117835",117835
221239,442755,PFE,Antares Pharma  A Lower Risk Small Cap With Larger Cap Potential,opinion,In this article  I would like to talk about a company I own a substantial amount of shares in  The company s name is Antares Pharma    and is listed on The AMEX exchange  It s current closing price as of 4 10 12 is  2 98 a share  with a market cap of  309 01M  At first glance  Antares appears to be over valued  but in this article  I will give my opinion why I believe the stock is actually grossly undervalued  considering its strong potential moving forward  to be an eventual larger cap company    First off  if we valuate Antares on what the company earns now  the stock would certainly appear to be again  over valued  Antares will likely bring in around  25 million dollars in revenue this year  with most of this revenue as profit  These revenues will primarily come from royalty deals the company has made in the last few years with larger pharmas such as Watson Pharma     Teva     and Pfizer     Antares does not have much capital expenditures in these deals  so again  the company will see mostly profit from the  25 million number    Antares focuses on self injection pharmaceutical products and technologies  and topical gel based products  It offers injection devices  which include Zomajet 2 Vision  Zomajet Vision X  Twin Jector EZ II  and Tjet for human growth hormone  Medi Jector Vision for insulin  Vibex disposable pressure assisted auto injectors that enables a controlled pressure delivery of drugs into the body utilizing a spring power source  and disposable pen injectors  which are needle based devices designed to deliver multiple injections from multi dose drug cartridges    Antares also is in a strong position to take advantage of the eventual emergence of the  and  market  Rather than me going on about every specific detail about what Antares offers in specific detail  I encourage readers to visit its company website and download    What excites me about Antares are the recent comments the company s CEO  Paul Wotton made at a  He flatly stated that Antares will not be engaging in anymore royalty deals  He went on to state that Antares is looking for partnerships along the lines of a 50 50 split  notwithstanding that the company plans to market and commercialize most of their top line products in the future    You can find Wotton s remark concerning Antares no longer seeking royalty deals  but full partnerships at the 25 19 mark on the recording of The Roth Capital investor s conference linked above    One such product Antares plans to  go it alone  is  a self injector that will be pre filled with doctor prescribed doses of   Clicking on the VIBEX MTX link will bring you to a prior article of mine where I lay out some revenue projections for VIBEX MTX    In collaboration with a fellow Antares investor  our Vibex MTX U S  market earnings formula is as follows 2 Million patients in U S  10 15  market share   50 per injection  52 weeks  52  margin  May 2014 commercial launch  possibly earlier  Our equation produced the following high low MTX earnings projections for 2014 and 2015    2014    203M   1 70 eps   135M   1 13 eps  2015    405M   3 24 eps   270M   2 16 eps    Now  when we look at the total projected revenue for all Antares product sales in 2015  we come up with the following numbers   12 5M HgH global royalties and margin from device and component sales 8 1M EpiPen U S  royalties and margin from device sales 10M Vibex2 U S  royalties and margin from device sales 6M Pen1 royalties and margin from device sales  EU only in 2015  12 5M Pen2 U S    EU royalties and margin from device sales 9M Gelnique Anturol global royalties 1 5M Elestrin royalties 277M Vibex MTX U S  sales and EU royalties and margin from device sales 140M VIBEX QS1 U S  sales and EU royalties and margin from device salesPfizer deal unknown  Guess is  7MNestraGel  the wild card factor I will comment more on later in this article  476 6M     Total Revenues 2015   Nearly  500M in revenues is what we believe Antares will bring to the table in 2015  placing the fair value low end estimate of Antares Stock at around  20 a share  in roughly 3 years from now    All of this would not mean a lot if management does not execute  The number one factor for me to take a risk on a small cap is confidence in competent management  When Dendrean gained approval a couple of years ago for its Prostate cancer drug Provenge  the stock went from  10 all the way up to over  57 before crashing back down to under  8  This happened because management failed to inform insurance companies of the cost for the drug  This is a case of a good product  but poor management execution  In fact  most all small cap companies that fail  do so because of poor management execution  money mismanagement  and other various issues involving incompetence    I encourage those interested in Antares to do due diligence on Dr  Paul Wotton  The Antares CEO  I find him conservative  smart and very focused  without offering B S hype in conference calls  On The Antares website  you can listen to the company s conference calls and investor conference presentations    Antares expects to file an NDA for VIBEX MTX in 2012 and is seeking a licensing partner for territories outside of the U S  and Canada  Antares will go it alone without a partner for the U S  market  This product has a high profit margin rate with reasonable capital expenditures    Nestragel  The true wild card factor that deal for it this year can potentially double the Antares stock overnight  Paul Wotton can be heard commenting on Nestragel at the 23 20 mark of The Roth Capital California investor s conference    As I remarked earlier  CEO Wotton has stated Antares is not interested in royalty deals anymore  but partnerships  Nestragel is rub on Female contraception  which I project will be a massive money maker in 5 years  potentially bringing Antares up to  500M A year in revenues  if the deal involves a true partnership and not a royalty licensing deal    Wotton remarked that talks are ongoing for a partnership for Nestragel  Nestragel has been thru phase 1 and phase 2 clinical  and now is ready for Phase 3 clinical  My  I wrote for Seeking Alpha covered Nestragel s market potential and various other factors involved in the female contraception market  Being my first article for Seeking Alpha  it reads a little bit like an infomercial  so it can be a little funky to read    Many investors have been wondering why there has not been a deal yet for this product  I believe the answer for this is contained once again  in Paul Wotton s comments from Antares s last investor conference presentation  It is also my belief that Pfizer is the main suitor for Nestragel  and originally contacted Antares for it    I believe this because the undisclosed deal with Pfizer appears to be for an insignificant product that Pfizer  according to Wotton s comments in the investor conference    had this product in their inventory for some time   This indicates to me that Pfizer did not originally contact Antares for this undisclosed over the counter product that was shelved away in Pfizer s inventory  Why would Pfizer seek out Antares for a small over the counter product that has been sitting on the shelf for some time    Antares and Pfizer were talking about something else in my opinion  and I believe that something else was Nestragel  I also believe Pfizer may have interest in acquiring Antares at some point  and this undisclosed deal is a kind of  feeler  Pfizer has laid out  When I consider this along with the new hiring of Jack Howarth  I start to sniff out a possible buy out offer coming  Taking a look at Howarth s employment history shows a clear pattern to me  Oct 2007 Alphapharma hires Howarth VP of Investor RelationsNov 2008 King acquires AlphapharmaJune 2009 King hires Howarth VP of Investor RelationsOct 2010 Pfizer acquires KingFeb 2011 Antares hires Howarth VP of Investor RelationsHowarth was hired by Antares at the same time it made a deal with Pfizer for the undisclosed product I mentioned above  coincidence or something more  I do not believe the Howarth hire is a coincidence when factoring in what I mentioned above  A shorter term cup and handle formation occurred beginning in January  then a continuation of a symmetrical triangle  We can see the confirmation of this as the stock had a decent break out occur after the handle was confirmed as I crudely mark above in black  I made a mark on where I feel is a key MACD point from January in conjunction with the beginning of the last cup and handle  and make the same mark on the MACD at the end of March  I see the beginning of the same cup and handle and continuation of a symmetrical triangle forming again  The recent pull back in the pps I feel has been in conjunction with the recent overall market correction that I feel is near or finished with its correction    I strongly encourage fund managers reading this article to do hard due diligence on all of the factors I mention herein  I consider Antares to be the best long term small cap investment around because the risk is very low for a small cap  and the reward very high  Again  I want to point out  because the company carries less risk  do not expect an explosive move upwards overnight  However  a deal for Nestragel would likely double the stock price overnight  if the deal is a major one    I also wrote an article for Seeking Alpha the mentions The recent FDA directive received from The Obama Administration  I feel what I wrote about in that article is a major factor that should help Antares be in a good position to capitalize on  the article can be found    I bought Antares because I believe in the long term prospects  fundamentals  and management of this company  I believe once any savvy investor does the deeper DD on Antares  they will agree with me and buy and hold it for the long term  I have written other articles on Antares for your consideration  Article about Nestragel  Female gel contraceptive  is Article about Teva and AIS is Another article is Key points of interest Management growth plan on target   I am expecting Q1 2012 earnings to be Antares  first profitable quarter ever  I estimate 2 to 4 cents a share profit  The company has no debt  and around  32 million in cash and investment Antares has strong insider and institutional ownership   For a stock that has not been over  5 a share since 1999  40  institutional ownership is very unusual  See my article  on these two potential pps drivers Potential negatives Lack of market acceptance for VIBEX MTX Over all weak stock market means risk off trading and safer investments  namely Treasuries A buy out offer accepted that is too low per the potential market value of The Antares product line Management changes course and gets too aggressive  too quickly While I certainly do not feel any of the negatives above will occur with Antares  they are always possible to occur as we are dealing in factors that are never certain    Good things come to those who wait  or so we are told  Antares Pharma is definitely a good thing  and buying it around its current price range now will yield a huge long term reward in my strong opinion  As of 4 10 12  Antares sells for  2 98 a share  If the company is not acquired  I believe the stock price on 4 10 15 will be north of  20 00 a share   Disclosure  I am long   Additional disclosure  DISCLAIMER  This article is intended for informational and entertainment use only and should not be construed as professional investment advice  but rather my opinions as a writer only  Always do you own complete due diligence before buying and selling any stock ,2012-04-11,Scott Matusow,https://www.investing.com/analysis/antares-pharma:-a-lower-risk-small-cap-with-larger-cap-potential-119754,119754
221240,442756,PFE,Smart Investors Need to Dump This,opinion,As Warren Buffett  George Soros and so many others have said  you need to swim against the tide  finding values where others miss and shunning stocks that are loved by all    Back in the summer of 2010  agriculture firm Monsanto  NYSE    was simply loathed  Low cost Chinese competitors were eating into its Round Up herbicide franchise  farmers were up in arms over a restrictive seed usage policy  which made its way to a story on 60 Minutes   the company was headed for a 10  drop in annual sales and analysts were uniformly tepid on the stock s prospects    As I noted back then  Monsanto s  1 billion in annual research and development spending would soon make the company relevant once again  Indeed  in the subsequent fiscal year  ended August 2011   Monsanto s sales rose 13  to  11 8 billion and earnings per share  EPS  shot up a heady 49  to  2 96  Yet as you dig into just released quarterly results and start to look at where Monsanto may be headed next  you may find reasons to sell  The stock s impressive rebound has set up a clear disconnect between a fairly high valuation and slowing growth  That s what happened to major drug stocks a decade ago and may be happening to Monsanto soon    Another good quarter Monsanto just announced fiscal second quarter results that once again topped forecasts  this time with an  of  2 28  roughly 7  ahead of projections   Almost all of the upside was attributed to stronger than expected demand for corn seeds  as farmers got an early start thanks to very balmy weather this winter  Some of that strength may also extend into the current quarter as spring plantings are underway  but many analysts decided to leave their full year forecasts intact    The pull in for the planting season is expected draw demand from the summer quarter  Despite beating second quarter estimates by  0 16  analysts have boosted their fiscal  August  2012 full year estimates by just three cents to  3 54    It s the view beyond 2012 that becomes more concerning  The company is now so large  and the field so saturated  that unless Monsanto can take market share from Syngenta  NYSE     DuPont s  NYSE    Pioneer Hi Bred division or other emerging global rivals  then investors need to brace for slowing growth  The company has likely squeezed out all it can from the  ethanol play     ethanol as a fuel mandates  which led to major corn planting  are set to expire in coming years    After a good 20  growth in fiscal 2012  analysts at UBS  which rates the stock as a  neutral   recently wrote that  we expect only 13  growth in F13  then we expect less than 10  growth in F14     It s important to note that after a strong two year run  shares of Monsanto now trade for more than 20 times forward earnings  Recall that major drug companies finally stopped growing as their drug pipelines matured and new drugs failed to outpace older drugs that lost patent protection  Will that multiple compress  as UBS suggests  until Monsanto looks more like Merck  NYSE    or Pfizer  NYSE     With the exception of 2009 and 2010  when Merck completed a pair of large acquisitions  sales have not grown more than 5  at any point in the last decade  EPS in 2011 was roughly 30  lower than it was a decade ago  As a result  Merck s stock started to garner an ever lower price to earnings  P E  ratio  There s one clear connection between Monsanto and Merck  Each once spoke of a blockbuster product or two that could fuel tremendous growth  but each eventually has come to rely on a series of smaller hits to keep that ball rolling  As UBS  Andrew Cash recently noted  Monsanto s CEO is  increasingly spending more time discussing its multiple sources of future earnings  including integrated farming systems  and almost no time on new blockbuster product introductions  We believe this is code for slowing overall EPS     You can see that slowing growth by walking through updated projections provided by Merrill Lynch  After boosting EBITDA 22   to  3 05 billion  in 2011  they see EBITDA rising 19  this year  11  in fiscal 2013 and 5  in fiscal 2014    When  neutral  is a  sell  Here s the tricky thing  Nobody on Wall Street will tell you this stock is going to go down    Indeed  this is a stock that has made bullish analysts look smart in front of their clients  and they need a reason to keep getting in front of those clients if they are to secure a meeting at all  Sadly  that s what more than 10 years of working on Wall Street taught me    UBS  in laying out its concerns  only has a  neutral  rating  lest the firm s analysts end up in the doghouse with Monsanto s management  Goldman Sachs also recently lost its appetite for this stock  removing it from the firm s  Conviction List   But they still suggest the stock deserves to trade at 20 times projected fiscal 2013 EPS of  4 38  Yet as noted earlier  slowing growth more likely argues for a slowly falling multiple  Monsanto s projected rates of growth are unlikely to support an EPS  and thus  a P E ratio  that high    Risks to Consider  Monsanto still spends huge sums on R D  and those efforts may still yield another blockbuster product to bolster future sales    Action to Take     Note the phrase  slowly falling multiple   There s no reason to expect this stock to fall out of bed quickly  but it appears to have peaked after a solid two year run  A high multiple and slowing growth is never the recipe for further upside  By David Sterman,2012-04-12,StreetAuthority,https://www.investing.com/analysis/smart-investors-need-to-dump-this-119959,119959
221241,442757,PFE,PSivida  Small Cap BioTech Positioned For Long Term Growth,opinion,The following small cap company I find very interesting for a long term speculative buy  I actually have been able to ask the CEO of the company some questions that is part of my standard due diligence for me to make a determination whether a small cap company is worth writing about and or investing in  Later on in this article  you will find a question and answer session between me and The CEO  Dr  Paul Ashton    pSivida  PSDV  develops drug delivery products for treatment of back of the eye diseases that are administered by implantation  injection  or insertion  The company s lead product candidate includes Iluvien  licensed to Alimera Sciences  ALIM   Iluvien is an drug that is inserted into the back of the eye that delivers fluocinolone acetonide  FA  for the treatment of diabetic macular edema  DME   a cause of vision loss  Alimera received its second CRL for the drug in November 2011  so Iluvien is not approved in the US  It is uncertain whether Alimera will pursue the clinical trials that the FDA would require for resubmission  However  Iluvien has been deemed  approvable  by the seven European countries where Alimera submitted its applications  Individual approvals are expected to be received in the coming months and will enable Alimera to commence marketing of Iluvien    Alimera is also conducting Phase II clinical trials with Ilu for the treatment of wet and dry form of age related macular degeneration  and retinal vein occlusion  These trials fall under the license agreement that pSivida has with Alimera    pSivida s already FDA approved products include Retisert for the treatment of posterior uveitis  an autoimmune condition characterized by inflammation of the posterior of the eye that can cause sudden or gradual vision loss  and Vitrasert for cytomegalovirus retinitis  a blinding eye disease that occurs in individuals with advanced AIDS  Both of these are licensed to Bausch   Lomb    It is developing a Latanoprost product  an injectable  bioerodible drug delivery implant in Phase I II dose escalating study for the treatment of glaucoma and ocular hypertension  a Posterior Uveitis product candidate expected to start pivotal clinical trials shortly  its BioSilicon technology system  which is nano structured porous silicon designed for use as a drug delivery platform and can deliver smaller molecules  and Tethadur  which utilizes BioSilicon to deliver biologic molecules  including peptides and proteins  It has strategic collaborations with Bausch   Lomb Incorporated  Alimera Sciences   and Pfizer  PFE    PSDV s lead implant treatment is ILUVIEN  which is licensed to Alimera  The deal with Alimera in terms of outside The United States includes 20  net profits on a country by country basis and pSivida has full audit rights  If Alimera decides to partner out the European commercialization then PSDV is entitled to 33 percent of any upfront and or milestone payments and 20 percent of whatever Alimera gets in royalties    I wrote an  that covered the EU approval catalyst that was supposed to occur at the end of Q2  2012  However  Alimera has now reported a delay in this process and does not expect approval to be gained to at least until later Q3  This certainly helped to throw off my projected short term price target opinion for Alimera    It seems to me PSDV may have more to gain from the European approval  PSDV might get the bigger stock price percentage gain on the European approval news than Alimera may receive    As referenced in my Alimera article  the FDA rejected ILUVIEN on its first attempt to gain approval  and issued a complete response letter  CRL  to Alimera    After further research into PSDV  I have discovered that ILUVIEN is the not the product to be most optimistic about that PSDV is offering  Tethadur could be the company s most valuable technology according to Dr  Paul Ashton  with its potential to deliver proteins peptides and other small molecules  particularly interesting for biosimilars and biobetters  Small molecule based procedures are more cost effective thancostlier biologic methods    pSivida s Tethadur Technology is a platform drug delivery system that relies on nanostructuring to achieve optimal drug delivery  It can be used alone or in combination with pSivida s other technologies  Tethadur has  Ability to provide long term delivery of anti bodies and other proteinsHigh efficiency capacity of drug loadingControlled nanostructuring can vary nanosized pores to accommodate different molecule sizesFully bioerodible over range of time periodsUnlike most polymer based drug delivery systems  the manufacture of Tethadur does not require complex chemistry and the final product is pure silicon irrespective of the delivery characteristics imparted by the nanostructuring process    Tethadur distinguishes itself from other delivery systems by its heat and radiation stability  simplifying the manufacturing and sterilization process    pSivida is the kind of small cap bio I look for  grossly undervalued based on its technology platform and competent management    The current management team eliminated  20 million in toxic debt inherited from the Australian management predecessors  I stress this over and over  The most important factor on success and or failure of a small cap company is its management s ability to execute  Hype aside  good products mean nothing if management cannot execute correct business practices    Money management  deal making  position leverage  communication with insurance companies  and other factors can and will determine a great deal of the company s success or lack thereof  I have given the prior example of Dendreon s  DNDN  Provenge  an effective treatment for prostrate cancer  yet insurance companies were not in an effective loop to fully understand the cost of the drug  Dendreon stock went on a wild ride all over the place  from  5 a share all the way up to  57  a share  only to fall back below  8  mainly because of management s lack of proper communication  Most unfortunate  because Dendreon posesses great technology to make a real difference in the lives of many patients not only suffering from prostate cancer  but other forms of cancer as well  It does appear that Dendreon management has gotten its act together lately  but the damage was already done    Should pSivida be selling for a price of around  2 a share currently  Let s take a look at its deep pipeline of treatments and find out  With a market cap of  40 56M  pSivida is one of the most undervalued companies I have ever seen  Nothwithstanding  the Alimera partnership  and its potential partnership with Pfizer values the company at least an  80M market cap in my strong opinion  The following sums up the Pfizer agreement    In terms of the Pfizer agreement  at the moment Pfizer has no commitment to pSivida other than working with pSivida in terms of the phase I II trials using the latanaprost in the insert  At the end of the Phase II trial  Pfizer has an option to pick up the product  If Pfizer exercises that option  then they would pay pSivida  20 million and Pfizer would take the product through Phase 3  and there would be performance milestone payments and a double digit royalty rate over 10   Pfizer would then own the product  If Pfizer decides not to exercise its option  pSivida retains the right to develop and commercialize the glaucoma product on its own or with a partner  pSivida would also have royalty free use of latanaprost  Pfizer s billion dollar drug that went off patent last year  as well    Dr  Paul Ashton  CEO of pSivida  has a very solid resume of leadership as noted from his bio referenced from    Dr  Ashton was named pSivida s President and Chief Executive Officer in January 2009 and previously served as the company s Managing Director from January 2007 to January 2009 and Executive Director of Strategy from December 2005 to January 2007  From 1996 until its acquisition by pSivida in December 2005  Dr  Ashton was the President and Chief Executive Officer of Control Delivery Systems  Inc   CDS   a drug delivery company that he co founded in 1991 and that developed pSivida s Durasert technology system  Dr  Ashton previously was a joint faculty member in the Departments of Ophthalmology and Surgery at the University of Kentucky  served on the faculty of Tufts University and worked as a pharmaceutical scientist at Hoffman La Roche  Dr  Ashton s long history of leadership and strategic oversight of pSivida and CDS  his role in developing and extensive knowledge of pSivida s core technology platforms  products and product candidates  his scientific expertise including his PhD in pharmacology and strong knowledge of research and development uniquely position him to lead pSivida in the execution of its long term strategy    The following below is a question and answer session with Dr  Paul Ashton  I asked the standard questions I normally do when I am considering making an investment in a small cap growth company    Scott  Hello Dr  Ashton  thank you for taking the time to answer my questions for Seeking Alpha readers  Dr  Ashton  You are welcome Scott     1  Where do you feel the true value in your company is where Investors should focus on  2  I notice you have established a nice royalty base  do you plan to use this revenue to reinvest into the future of the company  3  What do you find is the toughest challenge for a small company like yours to overcome  4  While we know predicting the future is hard and many factors are uncertain  but where would you like to see the company in say  5 years from now  What is the mission goal of the company in that time frame  5  Do you feel your company has what it takes to eventually market your top line products on your own  is that your ultimate goal  using royalty revenue to eventually attempt to become a top line company    Dr  Ashton s answers below in sequential order    1  I think there is a lot of focus on Iluvien for Diabetic macular edema and appropriately so  however people may be overlooking the real upside  1a  Our program in posterior uveitis  3rd largest cause of blindness in the US   In uveitis we are planning to develop an injectable implant delivering the steroid Fluocinolone acetonide  This is the exact same implant already successfully reviewed by the EU regulators for DME but rejected by the FDA  Why are we so confident  This insert delivers the exact same drug as Retisert  already approved by the FDA   the new inserts are injectable while Retisert is surgically inserted and the side effect profile of the new inserts is significantly better than that of Retisert  Also we can develop this product ourselves  Also based on our discussions with the FDA we believe we can proceed directly to phase iii clinical trials with these devices  referencing all the data from the DME application  a BIG time money saver   1b  The glaucoma program hasn t received any attention  This is another low risk  high reward opportunity  We are using a bio erodible version of the Durasert technology  that underlies the Iluvien device  to deliver latanoprost  Pfizer s billion dollar glaucoma drug until the patent expired  So  it s an effective drug with a proven delivery system going after a very large market opportunity  It s in early clinical trials but as clinical data emerges I think it will get more attention    1c  It s becoming increasingly apparent  see Alcon s  ACL  recent failure of a topical drug for geographic atrophy  a form of dry AMD  Allergan s  AGN  failure of an oral for glaucoma   that a drug delivery system is needed to treat back of the eye diseases  We are the only company with a proven back of the eye delivery technology   Dr  Ashton  Sorry that s a long answer  but we have a lot going on    Scott  Understandable  I think as much detail as possible for investors to consider is a good thing    2  Yes  historically we have used our royalties and cash from license fees etc to minimize our cash burn  3  One of the biggest challenges we have is getting on the radar screen of investors  We have a couple of approved products earning royalties  a product pending marketing authorization in EU  we expect to have phase 3 ready product for uveitis very shortly and a glaucoma product already in the clinic  That seems pretty compelling to me  certainly better than many companies with a much higher market cap  I ve been told many times  if your market cap was higher you would be worth more   4  We are planning to evolve into a specialty pharma focused on ophthalmology  We plan to develop some of our own products  like for uveitis  and work with partners to develop others    Dr  Ashton  We plan to out license non ophthalmic applications of our technologies    5  We have the best technology and we are fortunate in that we are going after a new area  diseases of the back of the eye  where none of the big guys has a dominant position in the market  Also the back of the eye space can be addressed with a small sales force  there are only 1 500 retina specialists in the US  However this space now has the attention of a lot of the big players  Merck  MRK   Roche  RHHBY PK  Glaxo Smith Kline  GSK  etc  and there is a lot of consolidation  so I d imagine that we d likely be acquired before we get there  We are not planning this  but it seems to be the way things sometimes work    Scott  Thank you Dr  Ashton for taking the time to answer my questions    Dr Ashton  You are welcome Scott    We can see from the chart above  the massive move down when the FDA issued a CRL to Alimera concerning ILUVIEN  Using crude black lines  I show where the stock channel connects up  There was a catalyst run up concerning the EU approval of ILUVIEN  but that was delayed for another quarter and the stock sold off in March  Another gap up occured and has since been filled  Now it appears a tighter wedge is forming  indicating to me a move to near 2 50 is coming very soon  We see high lowers and lower highs representing the tighter wedge  The MACD has been somewhat flat  but the signal appears to be turning up  To me this seems stock holders are not willing to part with their shares at the current stock price level    Key points in my opinion why pSivida has a legit shot to become a larger cap company over time  Very low cash burn rate  about two million a Quarter  The company tries to have agreements  evaluation agreements and license agreements  basically cover their costs on their programs Nice capital structure  only about 20 million shares outstanding with an additional 5 million warrants and those are going down as groups of them expire  No debt  Cash that takes them with present programs through 2013 Opthalmology is a big area of interest as the population ages  take into account the success of Lucentis  which was developed by Genentech and is marketed in the United States by Genentech and elsewhere by Novartis  NVS   Also Regeneron s  REGN  eElea is having great success Technologies that while obviously are for opthalmology now are adaptable for other parts of the body   there is currently an evaluation agreement with the Hospital for Special Surgery in NYC for example  and their focus is orthopaedics   The uveitis program and the bioerodible version of the underlying technology of Iluvien for glaucoma with Pfizer  Pfizer is the second largest shareholder with about eight percent and have held the shares since 2007  Since Pfizer already owns around 7  of the company s stock  pSivida is an acquisition target for them in my opinion  How strong of an acquisition target I really do not know    Final opinion and price target opinions    I see a short term move to near  2 50 setting up as the overall market appears to corrected itself  and the overall macro economic condition appears to have become more stable  at least in the short term  This should translate into more of a risk on trade appearing in the market again  I also see a catalyst run up occurring as Alimera gets closer to EU approval for ILUVIEN  I am not sure when this will begin or if it has already begun  A move to  5 a share by the end of the year is not out of the question  Where the price goes from there will be dependent on many factors including what Pfizer decides to do with its arrangement with pSivida  I like the CEO here as his team wiped off all the toxic financing the prior management left for them  Dr  Ashton is straight forward and to the point  Again  having top management in a small cap company is the number   one key in determining future success of the company  It is my opinion pSivida is a strong long term buy and hold for investors who wish to be patient and wait for large long term gains    Disclosure  I have no positions in any stocks mentioned  and no plans to initiate any positions within the next 72 hours    DISCLAIMER  This article is intended for informational and entertainment use only and should not be construed as professional investment advice  but rather my opinions as a writer only  Always do you own complete due diligence before buying and selling any stock ,2012-04-18,Scott Matusow,https://www.investing.com/analysis/psivida:-small-cap-biotech-positioned-for-long-term-growth-120599,120599
221246,442762,PFE,Cheap Is Not Always Good And Stocks As Sweaters ,opinion,Cheap Is Not Always GoodThere are many investors who hold low P E ratios as sacrosanct  To them  any stock with a high P E ratio is off limits  While some stock certainly are overvalued  like Netflix at  300  or Green Mountain at  100  many stocks with high P E ratios deserve them  Alexion Pharmaceuticals sports a P E ratio of 80  while Pfizer  the king of the pharmaceutical industry  sports a P E ratio of just under 16  Yet  over the past 5 years  Pfizer stock has not simply stagnated  it has dropped by over 22   all while Alexion rose by over 466   Investors who pounded the table saying Pfizer was cheap rode it all the way down to  20  While it is true that some stocks are simply too cheap  such as Apple or EMC  investors must always ask WHY a stock has a low P E ratio  Often  there is a reason for that  Microsoft is cheap not because it is ignored by Wall Street  but because after close scrutiny  Wall Street did not like what it saw  There is so much more to investing than P E ratios  That is merely one piece of the puzzle  And investors would do well to remember that  cheap  and  expensive  are simply matters of opinion  To truly gauge a company s suitability as an investment  one must always look beneath the surface and closely examine the company s future prospects Sentiment as a Contrarian IndicatorHistory has shown us that some of the most profitable investments are those made with a contrarian outlook  No one thought Apple would survive past 1997  but investors that ought in at that time doubled their money again and again  Buying financial stocks in March 2009 was a wonderful investment  Buffet s avoiding of dot com stocks was a great way to avoid losses  Sentiment is a great indicator of where a stock could go  but in the opposite direction  There s a rule in investing that says when retail investors pull huge sums of money out  that is the time to get in  Just as when retail investors are pouring money into the market  it is time to get out When sentiment in any one company turns extreme  we think it is time to go against the grain  A prime example of this is Netflix  For years  sentiment was extremely bullish on Netflix  and investors made huge sums of money on the stock  And if you got out in time  you made large sums of money too  But now  the sentiment surrounding Netflix is exactly the opposite  Everyone is predicting doom for the company  We see that as a contrarian buy signal  as long as you believe the company will survive  The bulls have had their success with Netflix  So have the bears  Now  we believe it is time for the bulls to be in the drivers seat once again Stocks as SweatersFor all the complexities in the stock market  sometimes simple analogies can provide us with clarification  Investors would do well to think of stocks as sweaters  You wouldn t buy a sweater if it was too expensive right  If the quality matched the price  then perhaps you would  That is the case with companies such as Chipotle  or lululemon  They may be expensive  but these  sweaters  are worth it  Then  there are sweaters you want to buy  but they re simply too expensive  Companies like Alexion or salesforce may be good  but the  sweaters  are simply not worth the price  Then there are sweaters that have gotten too cheap to ignore  Companies like Akamai  Akamai used to be overpriced  but now it is simply undervalued  pricing in a doomsday scenario  However  some  sweaters  should be avoided  no matter how far in the clearance aisle they are in  Companies like RIM and Microsoft may be cheap  but they are cheap for a reason  You don t want to be seen wearing rags do you  Just as you don t want to be seen as getting ripped off buying some overpriced sweater  But  if its a luxurious sweater  than you will be the talk of the town  The lesson is  know your price  know the most that you are willing to pay for a stock  and know when to hand that sweater off to someone else ,2011-11-23,Helix Investment Management,https://www.investing.com/analysis/cheap-is-not-always-good-and-stocks-as-sweaters-106549,106549
221247,442763,PFE,PROLOR Biotech  A Top Takeover Candidate,opinion,Billionaire Phillip Frost is an esteemed entrepreneur and philanthropist who built his fortune from pharmaceuticals  His success in the field  in my view  is unrivaled  his story  a classic  Fortunately for investors  Frost is still active in healthcare companies  He currently chairs PROLOR Biotech  an emerging biopharmaceutical firm that is trading significantly below intrinsic value with favorable risk reward  as evidenced by comparable past buyout multiples  PROLOR is engaged in the biosimilars and biobetters space  developing new forms of perviously approved biologic therapeutics  Since products are not coming from scratch  valuing a business like PROLOR is much less speculative than it is for other biotech companies  At the same time  the firm s products have relatively minimal time to commercialization  since clinical trials use short term biological parameter readouts and are not dependent on primary endpoints from outcome measures The company employs Carboxyl Terminal Peptide  CTP  technology to develop new forms of previously approved biologic therapeutics  CTP  a small peptide that is naturally found in hCG  is attached to other proteins to significantly increase longevity with minimal risk  Further limiting downside  this technology is being leveraged for diverse solutions  thus providing the kind of safety and breadth that is heavily demanded by large biopharmaceutical companies  In particular  I see Merck   Co   MRK  and Pfizer  PFE  as possible suitors  Merck  for example  has licenses for 4 fertility focused proteins while PROLOR has licenses for all other human therapeutics of natural or non natural sequence  Pfizer  on the other hand  has a weak pipeline among pharmaceuticals and buying out PROLOR would yield substantial revenues synergies by opening the target s products to sizable patient populations Perhaps one of the most important factors to consider when investing in biotechnology is market potential and diversity in the portfolio  A winner in both concerns  PROLOR has major developments in hemophilia  weight loss  multiple sclerosis  and human growth hormone  Accordingly  the firm has a very  strong buy  rating on the Street and Morgan Joseph places the price target at  16  representing a 280  premium Consider  for example  that PROLOR is developing the first FDA approved long acting hGH  hGH CTP has a market potential of  3B annually and has already indicated safety advantages and strong efficacy  Phase II clinical trials indicated that hGH CTP could produce results with much fewer injections than what is currently marketed  ie  weekly  possibly even twice monthly  versus daily   Patients in all three cohorts showed average IGF 1 levels returning to normal range on all of the days when there was an assessment  In addition  hGH CTP has indicated a very strong pharmacokinetic profile  which contributes to safety and ease in dosing  Having aggressively secured patents around everything from the composition of hGH CTP to production and manufacturing  PROLOR has the solid IP protection that will be attractive to a larger biopharmaceutical company weary about risk  The hGH CTP program is scheduled to enter Phase III trials in 2012 Now consider that Roche earlier acquired Marcadia Biotech for  287M upfront in cash and  250M more if the target s diabetes drugs meet certain milestones  PROLOR is trading at nearly a quarter of this potential value while offering a substitute   long acting oxyntomulin MOD 6030   in addition to a variety of high growth versions of therapeutic proteins  Factor VIIa CTP and Factor IX CTP  for example  have a cumulative potential market of  2B  growing 14  annually  These hemophilia solutions have already indicated superior longer acting and clotting activity in preclinical trills  The market has yet to fully rationalize such a favorable context In conclusion  I find myself in agreement with the Street that the company represents a very attractive value play  While solid IP protection and a diverse biosimilar   biobetter market provide meaningful safety  undervaluation of the parts compared to past buyouts provide significant upside  2012 is likely to be a favorable inflection point for PROLOR and opening a long position is recommended sooner rather than later Disclosure  I may open a long position in PBTH  Writing is paid  but research is independent  All views expressed herein are my own ,2011-12-06,Takeover Analyst,https://www.investing.com/analysis/prolor-biotech:-a-top-takeover-candidate-107900,107900
221248,442764,PFE,2 Defensive Dividend Stocks Outperforming The SP,opinion,Looking to play defense in the market  As the market has vacillated between up and down months since July  income investors are seeking dividend paying stocks with less correlation i e   dividend stocks which are defensive during pullbacks  but still share in rallies  It has become more challenging to find such an animal  but they are out there  However  defensive stocks aren t always the best stocks to buy for growth   These two giant Healthcare dividend stocks  Lilly and Pfizer  have both outperformed the S P in 2011  in both up and down markets Performance wise  LLY and PFE flip flopped in the Sept  and Nov  pullbacks and the Oct  rally  Lilly just got a nice boost recently  after an analyst said that LLY s anti Alzheimer drug could double the share price  if proven to be effective  which he thought it had a 10 20  chance of Dividends  Financials  Lilly  metrics outshine Pfizer s  and also its Big Pharma peers Options  The put and call options trades listed in this article expire in April for LLY  and March for PFE Covered Calls  Although Lilly and Pfizer s don t have high option yields when compared to other stocks we ve covered recently  such as CAT or CMI  both of the options trading strategies listed here give you a chance to significantly improve upon these stocks  dividend yields over this 4 5 month period Cash Secured Puts   LLY s put options offer more yield than PFE s   Since PFE and LLY have made 17  to 20  plus gains year to date   selling cash secured puts below the current stock prices might be the most conservative approach you could take in potentially accumulating shares   Note  Put sellers don t receive dividends  EPS Valuations  Due to issues with patent expirations  the future sales forecasts are sub par for LLY and nearly flat for PFE  As we mentioned earlier though  there s a trade off between growth and defense in these stocks Disclosure  Author has no positions in LLY or PFE at the time of publication Disclaimer  This article is written for informational purposes only and isn t intended as investment advice ,2011-12-19,Double Dividend Stocks,https://www.investing.com/analysis/2-defensive-dividend-stocks-outperforming-the-s-p-109101,109101
221249,442765,PFE,PROLOR  An Upside Story,opinion,PROLOR Biotech is one of the hottest stocks on the Street with significant upside  limited downside  and a well deserved  strong buy  rating from equity analysts  According to Raghuram Selvaraju  Ph D   of Morgan Joseph  2012 should be a transformational year for PROLOR  in our view  with one Phase 3 project  two Phase 2 candidates  and one Phase 1 candidate all moving forward simultaneously   PROLOR has solid liquidity with a current ratio of 9 5 and a net cash position of  17 6M  which represents 7 6  of market value  Add in innovative platform technologies  relatively short and safe clinical trials  a stellar pipeline  multi billion dollar market potential  and backing from the industry s most successful investor   PROLOR is simply trading well below intrinsic value  I find that  based on industry standard numbers  the hGH CTP and MOD 6030 blockbuster products alone indicate 420  upside for the emerging biotech company  Let s review hGH CTPThis product will be the first FDA approved long acting version of human growth hormone and target a  3B market that is growing 7  annually  In the Phase II study  hGH CTP demonstrated a strong pharmacokinetic profile and that it could be injected just weekly to return patients  average IGF 1 levels to normal range  This is stunning in light of the backdrop that all of the available products require daily injection  Pfizer  PFE   Eli Lilly   Co   LLY   Roche  RHHBY   Merck Serono  and Novo Nordisk  NVO  are behind in this development and  in my view  will inevitably   and aggressively   seek a partnership with PROLOR  Thankfully  the company has solid IP protection as it has secured hGH CTP with patents to everything from the product s composition to its manufacturing  2012 is likely to be an inflection point for PROLOR as Phase III begins DCF Analysis  Considering the standard average for Phase III partnership deals is around 20  in royalties and assuming 35  penetration into the  3B market  PROLOR s take is  200M for the immediate 12 months forward  This will further compound 7  annually from market growth  to say nothing about other business deals  Discounting the stream of free cash flow backwards using the capital asset pricing model and accounting for risks yields a net present value of around  1B for hGH CTP  This matches the valuation derived from assuming 5x sales   too low  if anything  considering the growth potential  Put differently  the hGH CTP product warrants PROLOR being worth at least  18 50 per share MOD 6030This diabetes type II drug is a long acting version of oxyntomodulin and similarly would be heavily demanded in a buyout  According to the American Diabetes Association  8 3  of individuals in the United States have diabetes  The World Health Organization estimates that 346M people worldwide are affected   more than 5  of the population  Having demonstrated superiority to oxyntomodulin in weight loss and reduction of food intake  MOD 6030 is yet another under appreciated asset of the rising biotech firm Analysis  One can only assume that if a drug has better efficacy and safety than its analogues  it is only fair that it be worth more  Two improvements on oxyntomodulin have had deals that indicate the undervaluation of MOD 6030  In 2010  Roche acquired Marcadia Biotech for an implied value of  537M in order to gain rights to the lead compound  preclinical GLP 1 Glucagon dual receptor agonist  Then in 2011  Zealand Pharma reached an agreement with Boehringer Ingelheim over another preclinical version of oxyntomodulin  This deal was worth  57M in payments for the first 2 years and  480M more in milestones  Thus  improved oxyntomodulin variants are priced at a minimum of  200M for preclinical versions  Accordingly  PROLOR s MOD 6030 is worth at least  3 70 per share Still more Based on just MOD 6030 and hGH CTP  the stock should be valued at  22 20   significantly above the present market price  But investors should consider PROLOR s other strengths  Factor VIIa CTP and Factor IX CTP are two hemophilia treatments that target a market of  2B   one that is compounding 14  annually  Preclinical trials have already indicated superior length and clotting activity  As hemophilia is an orphan disease  these variants will offer premium pricing and smoothly transition to the market PROLOR also employs Carboxyl Terminal Peptide technology to develop biosimilars  Merck has licenses for 4 fertility focused proteins while PROLOR has licenses for all other human therapeutics of natural or non natural sequence  CTP technology is being leveraged in diverse applications and is heavily demanded by larger biopharmaceutical companies in need of pipeline innovation  Investors should further be mindful about the limited risk that PROLOR offers  Whereas novel drugs are often a hit or a miss  biosimilars and biobetters face more certainty in terms of returns  PROLOR operates in the latter universe  which enables products to have minimal time to commercialization with clinical trials not being dependent on primary endpoints from outcome measures Finally  in light of the favorable risk reward highlighted above  it is important to stress that a lack of news flow and behavioral anomalies are the main reasons for the company s undervaluation  It is only a matter of time   in my view and those of other analysts   before the fundamentals shift the stock price skyward to its rightful place  In closing  I would like to reiterate Morgan Joseph s comment in their November 29  2011  buy  call  which still holds true  We advise investors to take advantage of recent weakness to aggressively accumulate shares   Disclosure,2012-01-02,Takeover Analyst,https://www.investing.com/analysis/prolor:-an-upside-story-110143,110143
